FN Thomson Reuters Web of Science™ VR 1.0 PT J AU O'Hare, AM Newman, AB Katz, R Fried, LF Stehman-Breen, CO Seliger, SL Siscovick, DS Shlipak, MG AF O'Hare, AM Newman, AB Katz, R Fried, LF Stehman-Breen, CO Seliger, SL Siscovick, DS Shlipak, MG TI Cystatin C and incident peripheral arterial disease events in the elderly - Results from the cardiovascular health study SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; RENAL-INSUFFICIENCY; HEART-FAILURE; RISK; MORTALITY; PREVALENCE; MARKER; IMPACT; INDIVIDUALS; CREATININE AB Background: The association of cystatin C, a novel marker of renal function, with risk for developing complications related to peripheral arterial disease (PAD) has not been examined. Methods: We evaluated the hypothesis that a high cystatin C concentration is independently associated with future PAD events among 4025 participants in the Cardiovascular Health Study who underwent serum cystatin C measurement at the 1992-1993 visit and who did not have PAD at baseline. The association of cystatin C quintiles with time to first lower-extremity PAD procedure (bypass surgery, angioplasty, or amputation) was evaluated using multivariable proportional hazards models. Secondary analyses were conducted using quintiles of serum creatinine level and estimated glomerular filtration rate (eGFR). Results: The annualized risk of undergoing a procedure for PAD was 0.43% per year among participants in the highest cystatin C quintile (> 1.27 mg/L) compared with 0.21% per year or less in all other quintiles. After multivariable adjustment for known risk factors for PAD, elevated cystatin C levels remained associated with the outcome (hazard ratio, 2.5 for highest vs lowest quintile of cystatin C, 95% confidence interval, 1.2-5.1). The highest quintiles of serum creatinine level and eGFR were not associated with future PAD events in either unadjusted or adjusted analyses. Conclusion: Elevated concentrations of cystatin C were independently predictive of incident PAD events among community-dwelling elderly patients. C1 Vet Affairs Med Ctr, Div Nephrol, Dept Med, San Francisco, CA 94121 USA. Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Med Epidemiol & Hlth Serv, Seattle, WA 98195 USA. RP O'Hare, AM (reprint author), Vet Affairs Med Ctr, Div Nephrol, Dept Med, Box 111J,4150 Clement St, San Francisco, CA 94121 USA. EM Ann.O'Hare@med.va.gov RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [R01 HL 073208-01, N01 HC 15103, N01 HC 35129, N01 HC 85079, N01 HC 85080, N01 HC 85081, N01 HC 85082, N01 HC 85083, N01 HC 85084, N01 HC 85085, N01 HC 85086] NR 25 TC 57 Z9 58 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD DEC 12 PY 2005 VL 165 IS 22 BP 2666 EP 2670 DI 10.1001/archinte.165.22.2666 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 992KW UT WOS:000233883800020 PM 16344426 ER PT J AU Becker, MA Schumacher, HR Wortmann, RL MacDonald, PA Eustace, D Palo, WA Streit, J Joseph-Ridge, N AF Becker, MA Schumacher, HR Wortmann, RL MacDonald, PA Eustace, D Palo, WA Streit, J Joseph-Ridge, N TI Febuxostat compared with allopurinol in patients with hyperuricemia and gout SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID XANTHINE OXIDASE/XANTHINE DEHYDROGENASE; MONOSODIUM URATE; SERUM URATE; NON-PURINE; SELECTIVE INHIBITOR; ARTHRITIS; THERAPY; OXIDASE; CRYSTALLIZATION; SOLUBILITY AB BACKGROUND: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. METHODS: We randomly assigned 762 patients with gout and with serum urate concentrations of at least 8.0 mg per deciliter (480 micromol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once daily for 52 weeks; 760 received the study drug. Prophylaxis against gout flares with naproxen or colchicine was provided during weeks 1 through 8. The primary end point was a serum urate concentration of less than 6.0 mg per deciliter (360 micromol per liter) at the last three monthly measurements. The secondary end points included reduction in the incidence of gout flares and in tophus area. RESULTS: The primary end point was reached in 53 percent of patients receiving 80 mg of febuxostat, 62 percent of those receiving 120 mg of febuxostat, and 21 percent of those receiving allopurinol (P<0.001 for the comparison of each febuxostat group with the allopurinol group). Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in all groups: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those receiving allopurinol (P=0.99 for 80 mg of febuxostat vs. allopurinol; P=0.23 for 120 mg of febuxostat vs. allopurinol). The median reduction in tophus area was 83 percent in patients receiving 80 mg of febuxostat and 66 percent in those receiving 120 mg of febuxostat, as compared with 50 percent in those receiving allopurinol (P=0.08 for 80 mg of febuxostat vs. allopurinol; P=0.16 for 120 mg of febuxostat vs. allopurinol). More patients in the high-dose febuxostat group than in the allopurinol group (P=0.003) or the low-dose febuxostat group discontinued the study. Four of the 507 patients in the two febuxostat groups (0.8 percent) and none of the 253 patients in the allopurinol group died; all deaths were from causes that the investigators (while still blinded to treatment) judged to be unrelated to the study drugs (P=0.31 for the comparison between the combined febuxostat groups and the allopurinol group). CONCLUSIONS: Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate. Similar reductions in gout flares and tophus area occurred in all treatment groups. C1 Univ Chicago, Pritzker Sch Med, Med Ctr, Chicago, IL 60637 USA. Univ Penn, Sch Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Oklahoma, Dept Med, Tulsa, OK USA. TAP Pharmaceut Prod, Res & Dev, Lake Forest, IL USA. RP Becker, MA (reprint author), Univ Chicago, Pritzker Sch Med, Med Ctr, MC0930,5841 S Maryland Ave, Chicago, IL 60637 USA. EM mbecker@medicine.bsd.uchicago.edu NR 37 TC 479 Z9 521 U1 5 U2 54 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 8 PY 2005 VL 353 IS 23 BP 2450 EP 2461 DI 10.1056/NEJMoa050373 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 990OZ UT WOS:000233754400007 PM 16339094 ER PT J AU Mangione, CM Washington, DL Woolf, P AF Mangione, CM Washington, DL Woolf, P TI Management of menopause-related symptoms - In response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; PREVENTION; TRIAL C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Crozer Chester Med Ctr, Upland, PA 19013 USA. RP Mangione, CM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 6 PY 2005 VL 143 IS 11 BP 846 EP 846 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 992LH UT WOS:000233884900024 ER PT J AU Dobscha, SK Snyder, KM Corson, K Ganzini, L AF Dobscha, SK Snyder, KM Corson, K Ganzini, L TI Psychiatry resident graduate comfort with general medical issues: Impact of an integrated psychiatry-primary medical care training track SO ACADEMIC PSYCHIATRY LA English DT Article ID MORTALITY AB Objective: To determine if a psychiatry-primary medical care ( PPMC) training track impacts comfort and behaviors related to addressing general medical issues after residency. Method: Thirty five psychiatry resident graduates completed mailed surveys; nine of them had completed the PPMC track. Results: Compared to non-PPMC participants, PPMC participants felt better prepared to address medical issues and tended to perform more consultations and feel more comfortable referring patients to general medical providers. They were not more likely to perform routine health screenings. Conclusion: Integrated training tracks may impact resident preparedness and career choice but may be insufficient to influence practice behaviors related to delivering general medical care. C1 Portland VA Med Ctr, Behavior Hlth & Clin Neurosci Div, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Portland, OR USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Behavior Hlth & Clin Neurosci Div, POB 1034 P3MHDC, Portland, OR 97207 USA. EM steven.dobscha@med.va.gov NR 9 TC 7 Z9 7 U1 1 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1042-9670 J9 ACAD PSYCHIATR JI Acad. Psych. PD DEC PY 2005 VL 29 IS 5 BP 448 EP 451 DI 10.1176/appi.ap.29.5.448 PG 4 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA 998EK UT WOS:000234301200008 PM 16387968 ER PT J AU Shlipak, M AF Shlipak, M TI Diabetic nephropathy SO AMERICAN FAMILY PHYSICIAN LA English DT Editorial Material ID RENAL-DISEASE; MELLITUS; PROGRESSION; PROTEINURIA; MORTALITY C1 San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Shlipak, M (reprint author), San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. NR 18 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD FAMILY PHYSICIANS PI KANSAS CITY PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA SN 0002-838X J9 AM FAM PHYSICIAN JI Am. Fam. Physician PD DEC 1 PY 2005 VL 72 IS 11 BP 2299 EP 2302 PG 4 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 990ZC UT WOS:000233780900016 ER PT J AU Bozkurt, B Deswal, A AF Bozkurt, B Deswal, A TI Obesity as a prognostic factor in chronic symptomatic heart failure SO AMERICAN HEART JOURNAL LA English DT Article ID LEFT-VENTRICULAR MASS; MORBID-OBESITY; WEIGHT-LOSS; RISK FACTOR; FOLLOW-UP; DISEASE AB Background Obesity is considered as an independent risk factor for development of heart failure (HF); however, its role in the progression of HF independent of atherosclerotic heart disease, hypertension, and diabetes is not well described. Methods To identify the role of obesity in HF outcomes, we analyzed the Digitalis Investigation, Group database with 7788 patients with chronic stable HF. Subjects with body mass index of >= 18.5 and <25 kg/m(2) were categorized as normal weight, >= 25.0 and <30 kg/m2 as overweight, and >= 30.0 kg/m2 as obese. Results Compared with normal weight,, overweight or obese patients had lower all-cause mortality (37.8%, 32.4%, and 28.5%, P < .0001) and lower HF mortality (38.7%, 31.2%, and 33.6%, P = .01). After adjustment for differences in baseline characteristics, the overweight (HR 0.87, 95% CI 0.79-0.95, P = .002) and the obese (HR 0.82, 95% CI 0.73-0.92, P = .0005) had better survival rates compared with normal-weight groups. Similarly, the overweight (HR 0.76, 95% CI 0.65-0.88, P = .0003) or the obese (HR 0.79, 95% CI 0.63-0.88, P = .005) patients had better HF survival rates. After adjustment for baseline differences, the rate of hospitalizations was similar in the 3 groups. Conclusions in patients with chronic symptomatic HF, obesity or overweight status was associated with a lower risk for mortality but a similar risk for hospitalization compared with normal weight status. Prospective studies evaluating the risks and benefits of sustenance of obesity or weight loss are needed in this population. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Cardiol Sect, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. RP Bozkurt, B (reprint author), Vet Affairs Med Ctr, 111 MCL 4C-211,2002 Holcombe Blvd, Houston, TX 77030 USA. EM bbozkurt@bcm.tmc.edu NR 16 TC 46 Z9 46 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD DEC PY 2005 VL 150 IS 6 BP 1233 EP 1238 DI 10.1016/j.ahj.2005.02.004 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 000TJ UT WOS:000234485000020 PM 16338264 ER PT J AU Ahmad, NA Kochman, ML Ginsberg, GG AF Ahmad, NA Kochman, ML Ginsberg, GG TI Practice patterns and attitudes toward the role of endoscopic ultrasound in staging of gastrointestinal malignancies: A survey of physicians and surgeons SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT Digestive Disease Week/105th Annual Meeting of the American-Gastroenterological-Association CY MAY 16-20, 2004 CL New Orleans, LA SP Amer Gastroenterol Assoc ID ESOPHAGEAL-CARCINOMA; ULTRASONOGRAPHY; CANCER; EUS; CT AB BACKGROUND AND AIMS: It is unknown how physician specialties other than gastroenterologists that manage gastrointestinal (GI) malignancies utilize endoscopic ultrasound (EUS) in their practices. The aim of this study was to (i) assess the proportion of gastroenterologists, oncologists, and surgeons that utilize EUS for staging of GI malignancies; (ii) assess the general availability of EUS; and (iii) determine which factors are associated with the use and availability of EUS. METHODS: A self-administered questionnaire was mailed out to 1,200 randomly selected gastroenterologists, oncologists, and surgeons throughout the United States. RESULTS: The data was analyzed from 521 (43%) responses. There were 60% respondents who had EUS available within their practices. There was greater availability of EUS within the practices of surgeons (81%; p < 0.001), within academic practices (87%; p= < 0.001), and in practices that serve a population > 500,000 (p < 0.001). The majority of respondents (71%) utilized EUS in their practices. There was a similar utilization of EUS across specialties (p= NS). There was greater utilization of EUS in academic centers (82%; p < 0.001), in practices that served a community of > 500,000 (p= 0.003), and among respondents who had been in practice for less than 5 yr (p= 0.005). Employing logistic regression models for utilization of EUS, lesser number of years in practice, and availability of EUS were found to be the only significant predictors of utilization. CONCLUSIONS: The majority of practitioners utilized EUS in management of GI malignancies. There was similar utilization of EUS across specialties. EUS is available to the majority of practitioners who manage GI malignancies. C1 Hosp Univ Penn, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Dept Med, Div Gastroenterol, Philadelphia, PA USA. RP Ahmad, NA (reprint author), Hosp Univ Penn, Div Gastroenterol, Dept Med, 3rd Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. NR 11 TC 15 Z9 15 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2005 VL 100 IS 12 BP 2662 EP 2668 DI 10.1111/j.1572-0241.2005.00281.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 988UV UT WOS:000233627400011 PM 16393217 ER PT J AU Lieberman, D AF Lieberman, D TI Race, gender, and colorectal cancer screening SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID AVERAGE-RISK; GUIDELINES; ADULTS; WOMEN AB Colorectal cancer (CRC) screening in asymptomatic, average-risk populations can reduce mortality and incidence of CRC. The United States Preventive Services Task Force, the American Cancer Society, and the Multi-Society Task Force all recommend initiation of screening at the age of 50 yr for men and women of all races, with an identical menu of screening options. However, there are important differences in risk based on gender, race, and ethnicity. These differences could influence the timing of initiation of screening, and the most optimal form of screening test. This commentary discusses the basis for these differences, and proposes that we should consider customization of screening based on gender, race, and ethnicity. C1 Oregon Hlth Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. RP Lieberman, D (reprint author), Oregon Hlth Sci Univ, Portland VA Med Ctr, Div Gastroenterol, P3-GI 1037 SW Vet Hosp Rd, Portland, OR 97201 USA. NR 10 TC 33 Z9 33 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2005 VL 100 IS 12 BP 2756 EP 2758 DI 10.1111/j.1572-0241.2005.00352.x PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 988UV UT WOS:000233627400025 PM 16393231 ER PT J AU Schreiber, ZA Brau, N AF Schreiber, ZA Brau, N TI Acquired factor VIII inhibitor in patients with hepatitis C virus infection and the role of interferon-alpha: A case report SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article DE acquired factor VIII inhibitor; hepatitis C; interferon-alpha; human immunodeficiency virus ID CHRONIC MYELOGENOUS LEUKEMIA; THERAPY; ANTIBODIES; DISEASE AB A patient with HIV and hepatitis C virus (HCV) co-infection developed an autoantibody to factor VIII after 8.7 months of treatment with pegylated interferon-a and ribavirin. Three previous cases of the development of factor VIII autoantibody in patients infected with the hepatitis C virus have been reported. Only one of these patients was treated with interferon-alpha, and this patient had hemophilia A, a condition prone to development of factor VIII autoantibody, even without interferon treatment. It is possible that chronic HCV infection itself, which has been associated with immunological disorders, is responsible for this phenomenon, but the immunomodulatory properties of interferon-alpha may also contribute to this rare occurrence. No previous case of factor VIII inhibitor in a patient infected with HIV has been reported. C1 Bronx Lebanon Hosp Ctr, Bronx, NY 10456 USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. Bronx Vet Adm Med Ctr, Viral Hepatitis Program, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. RP Schreiber, ZA (reprint author), Bronx Lebanon Hosp Ctr, Bronx, NY 10456 USA. NR 17 TC 11 Z9 12 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD DEC PY 2005 VL 80 IS 4 BP 295 EP 298 DI 10.1002/ajh.20405 PG 4 WC Hematology SC Hematology GA 989TM UT WOS:000233696800008 PM 16315253 ER PT J AU Pogach, L Xie, MG Yue, ST Tseng, CL Maney, M Rajan, M Tiwari, A Kolassa, J Helmer, D Crystal, S Safford, M AF Pogach, L Xie, MG Yue, ST Tseng, CL Maney, M Rajan, M Tiwari, A Kolassa, J Helmer, D Crystal, S Safford, M TI Diabetes healthcare quality report cards: How accurate are the grades? SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID OF-CARE; PERFORMANCE-MEASUREMENT; SYSTEM; RISK; TRANSFORMATION; INFORMATION; MANAGEMENT; FACILITIES; MORTALITY; PROVIDERS AB Objective: To evaluate the accuracy and precision of random sampling in identifying healthcare system outliers in diabetes performance measures. Study Design: Cross-sectional analysis of 79 Veterans Health Administration facilities serving 250317 patients with diabetes mellitus between October 1, 1999, and September 30, 2000. Methods: Primary outcome measures were poor glycosylated hemoglobin (A1C) control and good low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) control. Facility performance for each measure was calculated using 150 separate random samples and was compared with results using the bootstrap method as the criterion standard for determining outlier status (defined as a >= 5% difference from the mean, within the 10th or 90th percentile, or >= 2 SlDs from the mean). Results: The study population was largely male (97.4%), with 54.0% of subjects being 65 years or older. The facility-level mean performances were 22.8% for poor A1C control, 53.1 % for good LDL-C control, and 55.3% for good BP control. Comparing the random sampling method with the bootstrap method, the sensitivity ranged between 0.64 and 0.83 for the 3 outcome measures, positive predictive values ranged between 0.55 and 0.88, and specificity and negative predictive values ranged between 0.88 and 0.99. Conclusions: The specificity and negative predictive value of the random sampling method in identifying nonoutliers in performance were generally high, while its sensitivity and positive predictive value were moderate. The use of random sampling to determine performance for individual outcome measures may be most appropriate for internal quality improvement rather than for public reporting. C1 VA New Jersey Hlth Care Syst, Ctr Healthcare Knowledge Management, E Orange, NJ 07018 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. Rutgers State Univ, New Brunswick, NJ 08903 USA. Birmingham VA Med Ctr, Deep S Ctr Effectivenss, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. RP Pogach, L (reprint author), VA New Jersey Hlth Care Syst, Ctr Healthcare Knowledge Management, 385 Tremont Ave,111 Med, E Orange, NJ 07018 USA. EM leonaid.pogach@med.va.gov NR 36 TC 1 Z9 1 U1 0 U2 1 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD DEC PY 2005 VL 11 IS 12 BP 797 EP 804 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 994GD UT WOS:000234018300006 PM 16336064 ER PT J AU Grady, D Sawaya, GF AF Grady, D Sawaya, GF TI Discontinuation of postmenopausal hormone therapy SO AMERICAN JOURNAL OF MEDICINE LA English DT Meeting Abstract CT NIH Scientific Workshop on Menopausal Hormone Therapy CY OCT, 2002 CL Bethesda, MD SP Natl Inst Hlth C1 Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD DEC PY 2005 VL 118 IS 12 BP 1411 EP 1411 DI 10.1016/j.amjmed.2005.10.028 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 996ER UT WOS:000234157700041 ER PT J AU Howson, KM Aplin, AC Gelati, M Alessandri, G Parati, EA Nicosia, RF AF Howson, KM Aplin, AC Gelati, M Alessandri, G Parati, EA Nicosia, RF TI The postnatal rat aorta contains pericyte progenitor cells that form spheroidal colonies in suspension culture SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE angiogenesis; stem cells; smooth muscle; mural cells; collagen ID ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; SERUM RESPONSE FACTOR; STEM-CELLS; NG2 PROTEOGLYCAN; EX-VIVO; NEURONAL DIFFERENTIATION; COLLAGEN GEL; PDGF-B; ANGIOGENESIS AB Pericytes play an important role in modulating angiogenesis, but the origin of these cells is poorly understood. To evaluate whether the mature vessel wall contains pericyte progenitor cells, nonendothelial mesenchymal cells isolated from the rat aorta were cultured in a serum-free medium optimized for stem cells. This method led to the isolation of anchorage-independent cells that proliferated slowly in suspension, forming spheroidal colonies. This process required basic fibroblast growth factor (bFGF) in the culture medium, because bFGF withdrawal caused the cells to attach to the culture dish and irreversibly lose their capacity to grow in suspension. Immunocytochemistry and RT-PCR analysis revealed the expression of the precursor cell markers CD34 and Tie-2 and the absence of endothelial cell markers (CD31 and endothelial nitric oxide synthase, eNOS) and smooth muscle cell markers (alpha-smooth muscle actin, alpha-SMA). In addition, spheroid-forming cells were positive for NG2, nestin, PDGF receptor (PDGFR)-alpha, and PDGFR-beta. Upon exposure to serum, these cells lost CD34 expression, acquired alpha-SMA, and attached to the culture dish. Returning these cells to serum-free medium failed to restore their original spheroid phenotype, suggesting terminal differentiation. When embedded in collagen gels, spheroid-forming cells rapidly migrated in response to PDGF-BB and became dendritic. Spheroid-forming cells cocultured in collagen with angiogenic outgrowths of rat aorta or isolated endothelial cells transformed into pericytes. These results demonstrate that the rat aorta contains primitive mesenchymal cells capable of pericyte differentiation. These immature cells may represent an important source of pericytes during angiogenesis in physiological and pathological processes. They may also provide a convenient supply of mural cells for vascular bioengineering applications. C1 Vet Adm Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Seattle, WA USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. Carlo Besta Inst, Lab Neurobiol & Neuroregenerat Therapy, Milan, Italy. RP Nicosia, RF (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Pathol & Lab Med, S-113-Lab,1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@med.va.gov RI Parati, Eugenio/G-8765-2011; Gelati, Maurizio/H-2110-2016 OI Gelati, Maurizio/0000-0002-4828-9849 FU NHLBI NIH HHS [HL-52585] NR 59 TC 76 Z9 80 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD DEC PY 2005 VL 289 IS 6 BP C1396 EP C1407 DI 10.1152/ajpcell.00168.2005 PG 12 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 981RD UT WOS:000233104800006 PM 16079185 ER PT J AU Edderkaoui, M Hong, P Vaquero, EC Lee, JK Fischer, L Friess, H Buchler, MW Lerch, MM Pandol, SJ Gukovskaya, AS AF Edderkaoui, M Hong, P Vaquero, EC Lee, JK Fischer, L Friess, H Buchler, MW Lerch, MM Pandol, SJ Gukovskaya, AS TI Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE pancreas ID CYTOSOLIC PHOSPHOLIPASE A(2); NF-KAPPA-B; NAD(P)H OXIDASE; LIPOXYGENASE INHIBITORS; SIGNAL-TRANSDUCTION; REDOX-REGULATION; LEUKOTRIENE B-4; EXPRESSION; APOPTOSIS; MITOCHONDRIAL AB The extracellular matrix (ECM) facilitates pancreatic cancer cells survival, which is of central importance for pancreatic adenocarcinoma that is highly fibrotic. Here, we show that reactive oxygen species (ROS) mediate the prosurvival effect of ECM in human pancreatic cancer cells. Fibronectin and laminin stimulated ROS production and NADPH oxidase activation in pancreatic cancer cells. Both pharmacological and molecular approaches show that fibronectin stimulated ROS production through activation of NADPH oxidase and NADPH oxidase-independent pathways and that 5-lipoxygenase (5-LO) mediates both these pathways. Analyses of the mechanisms of ROS production by ECM proteins and growth factors indicate that activation of NADPH oxidase (Nox4) is a common mechanism employed both by ECM proteins and growth factors to increase ROS in pancreatic cancer cells. We also found that Nox4 is present in human pancreatic adenocarcinoma tissues and that these tissues display membrane NADPH oxidase activity. ECM proteins and growth factors activate NADPH oxidase through different mechanisms; in contrast to ECM proteins, growth factors activate NADPH oxidase through 5-LO-independent mechanisms. Inhibition of 5-LO or NADPH oxidase with pharmacological inhibitors of these enzymes and with Nox4 or 5-LO antisense oligonucleotides markedly stimulated apoptosis in cancer cells cultured on fibronectin. Our results indicate that ROS generation via 5-LO and downstream NADPH oxidase mediates the prosurvival effect of ECM in pancreatic cancer cells. These mechanisms may play an important role in pancreatic cancer resistance to treatments and thus represent novel therapeutic targets. C1 VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Univ Greifswald, Dept Gastroenterol Endocrinol & Nutr, Greifswald, Germany. Univ Heidelberg, Dept Gen Surg, Heidelberg, Germany. RP Gukovskaya, AS (reprint author), VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Dept Med, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu RI Lerch, Markus M./E-2206-2016 OI Lerch, Markus M./0000-0002-9643-8263 FU NIDDK NIH HHS [DK-59926] NR 55 TC 72 Z9 73 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD DEC PY 2005 VL 289 IS 6 BP G1137 EP G1147 DI 10.1152/ajpgi.00197.2005 PG 11 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 983ZI UT WOS:000233270500021 PM 16037546 ER PT J AU Wynn, JK Light, GA Breitmeyer, B Nuechterlein, KH Green, MF AF Wynn, JK Light, GA Breitmeyer, B Nuechterlein, KH Green, MF TI Event-related gamma activity in schizophrenia patients during a visual backward-masking task SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT 19th Annual Meeting of the Society-for-Research-in-Psychopathology CY OCT 07-10, 2004 CL St Louis, MO SP Soc Res Psychopathol ID HEMISPHERIC-ASYMMETRY; FAST OSCILLATIONS; BAND RESPONSE; SUPPRESSION; DISORDERS; MECHANISM; CORTEX AB Objective: Schizophrenia patients experience deficits in many aspects of cognition and perception. Abnormalities in gamma activity may underlie some of these deficits, including rapid processing of visual stimuli. This study examined event-related gamma range activity during a visual backward-masking task in schizophrenia patients and normal comparison subjects. Method: Event-related gamma activity was recorded in 15 normal comparison subjects and 32 schizophrenia patients. Participants had event-related gamma activity recorded while viewing 60 unmasked visual targets and 240 trials of visual backward masking. Effects of group, accuracy (correct versus incorrect), stimulus-onset asynchrony, and regional activity (left versus right hemisphere, anterior versus posterior regions) were assessed. Results: Schizophrenia patients had significantly reduced gamma activity in relation to comparison subjects during the backward-masking task. Normal comparison subjects showed significantly greater gamma activity in the right hemisphere, whereas schizophrenia patients did not show this pattern of lateralization. For the unmasked target, there was no group effect and no significant interactions in gamma-band responses. Conclusions: These results extend previous findings of abnormal gamma range activity in schizophrenia patients. Patients showed overall less gamma activity and failed to show lateralization of activity to the right hemisphere during masking, but they showed comparable levels of gamma activity to unmasked stimuli. Schizophrenia patients' poorer performance during a masking task may be partly influenced by this abnormal level and the distribution of gamma activity. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. Univ Houston, Dept Psychol, Houston, TX 77004 USA. RP Wynn, JK (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,MIRECC 210A,Bldg 210, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NIMH NIH HHS [MH-14584, MH-43292, MH-65707] NR 33 TC 51 Z9 54 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD DEC PY 2005 VL 162 IS 12 BP 2330 EP 2336 DI 10.1176/appi.ajp.162.12.2330 PG 7 WC Psychiatry SC Psychiatry GA 990OX UT WOS:000233754200017 PM 16330598 ER PT J AU Fine, MJ AF Fine, MJ TI Bridging the gaps between race and genetics SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Fine, MJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2005 VL 95 IS 12 BP 2124 EP 2124 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 989EP UT WOS:000233656000009 ER PT J AU Fine, MJ Ibrahim, SA Thomas, SB AF Fine, MJ Ibrahim, SA Thomas, SB TI The role of race and genetics in health disparities research SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID FACTOR-V-LEIDEN; CARE C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Minority Hlth, Pittsburgh, PA USA. RP Fine, MJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C,Bldg 28, Pittsburgh, PA 15240 USA. EM michael.fine@med.va.gov FU NIAID NIH HHS [5K24AI001769-05, K24 AI001769]; NIMHD NIH HHS [5P60 MD00207-04, P60 MD000207] NR 23 TC 34 Z9 35 U1 0 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2005 VL 95 IS 12 BP 2125 EP 2128 DI 10.2105/AJPH.2005.076588 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 989EP UT WOS:000233656000010 PM 16257933 ER PT J AU Washington, DL Villa, V Brown, A Damron-Rodriguez, J Harada, N AF Washington, DL Villa, V Brown, A Damron-Rodriguez, J Harada, N TI Racial/ethnic variations in veterans' ambulatory care use SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID INVASIVE CARDIOVASCULAR PROCEDURES; ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES; MEDICAL-CARE; ACCESS; SYSTEM; DISPARITIES AB Objectives: We assessed racial/ethnic variations in patterns of ambulatory care use among Department of Veterans Affairs (VA) health care-eligible veterans to determine if racial/ethnic differences in health care use persist in equal-access systems. Methods: We surveyed 3227 male veterans about their health and ambulatory care use. Results: Thirty-eight percent of respondents had not had a health care visit in the previous 12 months. Black (odds ratio [OR] = 0.5), Hispanic (OR = 0.4), and Asian/Pacific Islander veterans (OR = 0.4) were less likely than White veterans to report any ambulatory care use. Alternately, Whites (OR = 2.2) were more likely than other groups to report ambulatory care use. Being White was a greater predictor of health care use than was having fair or poor health (OR = 1.4) or functional limitations (OR = 1.5). In non-VA settings, racial/ethnic minorities were less likely to have a usual provider of health care. There was no VA racial/ethnic variation in this parameter. Conclusions: Racial/ethnic disparities in health and health care use are present among VA health care-eligible veterans. Although the VA plays an important role in health care delivery to ethnic minority veterans, barriers to VA ambulatory care use and additional facilitators for reducing unmet need still need to be investigated. C1 VA Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth & Geriatr Res, Los Angeles, CA 90024 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM donna.washington@med.va.gov NR 26 TC 18 Z9 18 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2005 VL 95 IS 12 BP 2231 EP 2237 DI 10.2105/AJPH.2004.043570 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 989EP UT WOS:000233656000027 PM 16257951 ER PT J AU Long, JA Polsky, D Metlay, JP AF Long, JA Polsky, D Metlay, JP TI Changes in veterans' use of outpatient care from 1992 to 2000 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID QUALITY-OF-CARE; PREVENTION SERVICES; HEALTH-SERVICES; OLDER-ADULTS; MORTALITY; VA; FACILITIES; SURVIVAL; NETWORKS; PROGRAM AB Objectives: During the mid-1990s, the Veterans Health Administration (VHA) reorganized and placed greater emphasis on high-quality primary care. To determine whether the reorganization was associated with changes in patterns of outpatient VHA use, we sought to evaluate changes in characteristics of veterans who use VHA outpatient services between 1992 and 2000. Methods: We merged 2 waves of the National Survey of Veterans to determine changes in patterns of outpatient care use. We evaluated the extent to which veterans who received outpatient care received that care from the VHA. Results: The odds ratio for VHA-only outpatient care relative to non-VHA-only care in 2000 relative to 1992 was 1.75 (95% confidence interval [CI] = 1.51, 2.04), and the odds ratio for dual relative to non-VHA-only care was 1.22 (95% CI = 1.08, 1.37). Veterans who were older, had low incomes, and had no additional health insurance coverage were most likely to increase their use of VHA outpatient care. Conclusions: Our results suggest that the VHA is increasingly serving veterans who have trouble accessing the private health care system. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Long, JA (reprint author), Univ Penn, Sch Med, Dept Med, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jalong@mail.med.upenn.edu NR 27 TC 19 Z9 20 U1 1 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2005 VL 95 IS 12 BP 2246 EP 2251 DI 10.2105/AJPH.2004.061127 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 989EP UT WOS:000233656000029 PM 16257943 ER PT J AU Hathout, GM Bhidayasiri, R AF Hathout, GM Bhidayasiri, R TI Midbrain ataxia - Reply SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Letter ID PEDUNCULOPONTINE NUCLEUS C1 Univ Calif Los Angeles, Med Ctr, Geffen Sch Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Hathout, GM (reprint author), Univ Calif Los Angeles, Med Ctr, Geffen Sch Med, Los Angeles, CA 90095 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD DEC PY 2005 VL 185 IS 6 BP 1651 EP 1651 DI 10.2214/AJR.05.51561 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 987IC UT WOS:000233510600044 ER PT J AU Lin, PH Bush, RL Peden, EK Zhou, W Guerrero, M Henao, EA Kougias, P Mohiuddin, I Lumsden, AB AF Lin, PH Bush, RL Peden, EK Zhou, W Guerrero, M Henao, EA Kougias, P Mohiuddin, I Lumsden, AB TI Carotid artery stenting with neuroprotection: assessing the learning curve and treatment outcome SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 57th Annual Southwestern Surgical Congress CY APR 10-12, 2005 CL San Antonio, TX DE carotid artery stenting; learning curve; complications; neuroprotection; carotid angioplasty ID MULTISPECIALTY CONSENSUS RECOMMENDATIONS; CLINICAL COMPETENCE STATEMENT; HIGH-RISK PATIENTS; RANDOMIZED-TRIAL; COMPUTER-SIMULATION; ENDARTERECTOMY; ANGIOPLASTY; STENOSIS; BIVALIRUDIN; EXPERIENCE AB Purpose: Carotid artery stenting (CAS) has emerged as an acceptable treatment alternative in high-risk patients with carotid stenosis. The purpose of this study was to assess the effect of the learning curve oil treatment complications and the clinical outcomes of CAS. Methods: Clinical variables and treatment outcomes of 200 consecutive CAS procedures in 182 patients (mean age 72 years) with carotid stenosis >= 70% during a 40-month period were analyzed. Four sequential groups (groups I, II, III, and TV) of 50 consecutive interventions were compared with regard to technical Success, periprocedural complications, and treatment Outcomes. Results: Treatment indications and relevant risk factors were similar among the 4 groups. The overall technical success and combined 30-day stroke and death rates were 98% and 2.5%, respectively. An increase in the technical success rate was noted in the latter 3 groups compared with group I (P < .05). Total procedural time and contrast volume were significantly higher in group I compared with the latter 3 groups (P < .05). The intraoperative anticoagulation regimen was changed from intravenous heparin combination to bivalirudin after the first 54 patients, which resulted in decreased bleeding, complications in groups III and IV (P = 0.03) compared with the first group. The 30-day stroke and death rate in groups I and II were 8% and 2%, respectively, and was decreased significantly in groups III and IV (0% and 0%, respectively, P < .05). A Cox regression model identified procedural volume (P = .03) as a predictor of decreased complication rate. Conclusions: CAS with neuroprotection can provide excellent treatment Outcomes. Our experience demonstrates a procedure-associated learning curve as evidenced by decreased procedure-related complications, fluoroscopic time, and contrast volume occurring with increased physician experience. Procedural success was also enhanced partly by endovascular device refinement and ail improved anticoagulation regimen. Successful CAS Outcomes can be achieved once physicians overcome the initial procedure-related learning curve. (c) 2005 Excerpta Medica Inc. All rights reserved. C1 Baylor Coll Med, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston Vet Adm Med Ctr, Houston, TX 77030 USA. RP Lin, PH (reprint author), Baylor Coll Med, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston Vet Adm Med Ctr, 2002 Holcomb Blvd, Houston, TX 77030 USA. EM plin@bcm.tmc.edu NR 31 TC 60 Z9 60 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD DEC PY 2005 VL 190 IS 6 BP 850 EP 857 DI 10.1016/j.amsjurg.2005.08.008 PG 8 WC Surgery SC Surgery GA 990RB UT WOS:000233759800006 PM 16307933 ER PT J AU Peyton, DH Burgess, SJ Andrews, S Liebman, K Kelly, JX Riscoe, M AF Peyton, David H. Burgess, Steven J. Andrews, Simeon Liebman, Katherine Kelly, Jane Xu Riscoe, Michael TI Reversed chloroquines: Molecules designed to reverse the resistance to CQ found in Plasmodium falciparum malaria SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Peyton, David H.; Burgess, Steven J.; Andrews, Simeon; Liebman, Katherine] Portland State Univ, Portland, OR 97207 USA. [Kelly, Jane Xu; Riscoe, Michael] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 92 BP 31 EP 31 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990000093 ER PT J AU Esparza, EYO Bonilla, DL Melby, PC Travi, BL AF Osorio Esparza, Elvia Y. Bonilla, Diana L. Melby, Peter C. Travi, Bruno L. TI Estrogen-mediated nitric oxide production is associated with a favorable clinical and parasitological response to Leishmania during pregnancy SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Osorio Esparza, Elvia Y.; Bonilla, Diana L.] CIDEIM, Cali Valle Del Cauca, Colombia. [Melby, Peter C.; Travi, Bruno L.] Dept Vet Affairs Med Ctr, Med Serv, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 310 BP 102 EP 103 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990000309 ER PT J AU Bonilla, DL Travi, BL Esparza, EYO AF Bonilla, Diana L. Travi, Bruno L. Osorio Esparza, Elvia Y. TI The role of neutrophils in American Cutaneous Leishmaniasis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Bonilla, Diana L.; Osorio Esparza, Elvia Y.] CIDEIM, Cali Valle Del Cauca, Colombia. [Travi, Bruno L.] S Texas Vet Hlth Care Syst, Dept Vet Affairs Med Ctr, Med Serv, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 312 BP 103 EP 103 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990000311 ER PT J AU Esparza, EYO Bonilla, DL Peniche, AG Travi, BL AF Osorio Esparza, Elvia Y. Bonilla, Diana L. Peniche, Alex G. Travi, Bruno L. TI Congenital transmission in experimental leishmaniasis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Osorio Esparza, Elvia Y.; Bonilla, Diana L.; Peniche, Alex G.] CIDEIM, Cali Valle Del Cauca, Colombia. [Travi, Bruno L.] S Texas Vet Hlth Care Syst, Dept Vet Affairs Med Ctr, Med Serv, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 311 BP 103 EP 103 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990000310 ER PT J AU Andrews, SS Burgess, SJ Selzer, A Kelly, JX Riscoe, M Peyton, DH AF Andrews, Simeon S. Burgess, Steven J. Selzer, Audrey Kelly, Jane Xu Riscoe, Michael Peyton, David H. TI Synthesis and evaluation of antimalarials formed by linking chloroquine to dibenzylamines SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Andrews, Simeon S.; Burgess, Steven J.; Selzer, Audrey; Peyton, David H.] Portland State Univ, Portland, OR 97207 USA. [Kelly, Jane Xu; Riscoe, Michael] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 342 BP 113 EP 113 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990000341 ER PT J AU Burgess, SJ Andrews, SS Selzer, A Kelly, JX Riscoe, M Peyton, DH AF Burgess, Steven J. Andrews, Simeon S. Selzer, Audrey Kelly, Jane Xu Riscoe, Michael Peyton, David H. TI Diphenylamino-modified Chloroquines that are effective against Chloroquine resistant malaria SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Burgess, Steven J.; Andrews, Simeon S.; Selzer, Audrey; Peyton, David H.] Portland State Univ, Portland, OR 97207 USA. [Kelly, Jane Xu; Riscoe, Michael] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 341 BP 113 EP 113 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990000340 ER PT J AU Smilkstein, MJ Riscoe, M AF Smilkstein, Martin J. Riscoe, Michael TI Antimalarial drug resistance testing with affordable, field-feasible technology SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Smilkstein, Martin J.; Riscoe, Michael] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 366 BP 121 EP 121 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990000365 ER PT J AU Kelly, JX Cooper, R Johnson, R Janowsky, A Smilkstein, M Winter, R Riscoel, M AF Kelly, Jane X. Cooper, Roland Johnson, Robert Janowsky, Aaron Smilkstein, Martin Winter, Rolf Riscoel, Mike TI Unique features of acridone derivatives as quinoline-resistance reversal agents against Plasmodium falciparum SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Kelly, Jane X.; Johnson, Robert; Janowsky, Aaron; Smilkstein, Martin; Winter, Rolf; Riscoel, Mike] Portland VA Med Ctr, Portland, OR USA. [Cooper, Roland] Old Dominion Univ, Dept Biol Sci, Norfolk, VA 23529 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 809 BP 266 EP 266 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990001232 ER PT J AU Lane, KD Kell, JX Smilkstein, M Riscoe, M Cooper, RA AF Lane, Kristin D. Kell, Jane Xu Smilkstein, Martin Riscoe, Michael Cooper, Roland A. TI The PFCRT protein has a direct role in the activity of quinoline-resistance reversal agents against Plasmodium falciparum SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Lane, Kristin D.; Cooper, Roland A.] Old Dominion Univ, Norfolk, VA USA. [Kell, Jane Xu; Smilkstein, Martin; Riscoe, Michael] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 815 BP 268 EP 268 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990001238 ER PT J AU Smilkstein, MJ Kelly, JX Winter, R Kyle, DE Riscoe, M AF Smilkstein, Martin J. Kelly, Jane X. Winter, Rolf Kyle, Dennis E. Riscoe, Michael TI Orphenadrine as a chemosensitizer against quinoline-resistant malaria SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 [Smilkstein, Martin J.; Kelly, Jane X.; Winter, Rolf; Riscoe, Michael] Portland VA Med Ctr, Portland, OR USA. [Kyle, Dennis E.] Walter Reed Army Inst Res, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2005 VL 73 IS 6 SU S MA 832 BP 274 EP 274 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA V44GA UT WOS:000202990001255 ER PT J AU Yu, J Kindy, MS Ellis, BC Baatz, JE Peden-Adams, M Ellingham, TJ Wolff, DJ Fair, PA Gattoni-Celli, S AF Yu, J Kindy, MS Ellis, BC Baatz, JE Peden-Adams, M Ellingham, TJ Wolff, DJ Fair, PA Gattoni-Celli, S TI Establishment of epidermal cell lines derived from the skin of the Atlantic bottlenose dolphin (Tursiops truncatus) SO ANATOMICAL RECORD PART A-DISCOVERIES IN MOLECULAR CELLULAR AND EVOLUTIONARY BIOLOGY LA English DT Article DE Tursiops truncatus; bottlenose dolphin; skin; cell lines; cytokeratin ID MARINE MAMMALS; BELUGA WHALE; DELPHINAPTERUS-LEUCAS; IN-VITRO; SUSCEPTIBILITY; ORGANOCHLORINES; GENERATION AB The Atlantic bottlenose dolphin (Tursiops truncatus), a marine mammal found off the Atlantic coast, has become the focus of considerable attention because of an increasing number of mortality events witnessed in this species over the last several years along the southeastern United States. Assessment of the impact of environmental stressors on bottlenose dolphins (BND) has been difficult because of the protected status of these marine mammals. The studies presented herein focused on establishing epidermal cell cultures and cell lines as tools for the in vitro evaluation of environmental stressors on BND skin. Epidermal cell cultures were established from skin samples obtained from Atlantic BND and subjected to karyotype analysis. These cultures were further characterized using immunohistochemical methods demonstrating expression of cytokeratins. By two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), we observed that the proteomic profile of BND skin tissue samples shared distinct similarities with that of skin-derived cultures. Epidermal cell cultures were transfected with a plasmid encoding the SV40 small t- and large T-antigens, as well as the neomycin-resistance gene. Five neomycin-resistant clones were isolated and expanded, and all of them proliferated at a faster rate than nontransfected BND epidermal cultures, which exhibited signs of senescence. Cell lysates prepared from two transfected clones were shown to express, by Western blot analysis, both SV40 tumor antigens. These experimental results are consistent with the concept that transfected clones expressing SV40 tumor antigens represent immortalized BND cell lines. Epidermal cell lines derived from Tursiops truncatus will provide a unique tool for studying key features of the interaction occurring between dolphins and the environment in which they live at their most crucial interface: the skin. (c) 2005 Wiley-Liss, Inc. C1 Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. Med Univ S Carolina, Inst Neurosci, Charleston, SC 29425 USA. Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. NOAA, Natl Ocean Serv, Ctr Coastal Environm Hlth & Biomol Res, Charleston, SC USA. RP Gattoni-Celli, S (reprint author), Med Univ S Carolina, Dept Radiat Oncol, Strom Thurmond Biomed Res Bldg,Room 338C,114 Doug, Charleston, SC 29403 USA. EM gattonis@musc.edu OI Baatz, John/0000-0001-5870-1000 NR 24 TC 11 Z9 11 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4884 J9 ANAT REC PART A JI Anat. Rec. Part A PD DEC PY 2005 VL 287A IS 2 BP 1246 EP 1255 DI 10.1002/ar.a.20266 PG 10 WC Anatomy & Morphology SC Anatomy & Morphology GA 989VJ UT WOS:000233701700010 PM 16281302 ER PT J AU Abadie, JM Blassingame, CL Bankson, DD AF Abadie, JM Blassingame, CL Bankson, DD TI Albumin Cobalt Binding assay to rule out acute coronary syndrome SO ANNALS OF CLINICAL AND LABORATORY SCIENCE LA English DT Article DE ischemia modified albumin; cobalt binding assay; acute coronary syndrome ID ACUTE MYOCARDIAL-INFARCTION; ISCHEMIA-MODIFIED ALBUMIN; EMERGENCY ROOM PATIENTS; HUMAN SERUM-ALBUMIN; CREATINE-KINASE-MB; CHEST-PAIN; MISSED DIAGNOSES; CARE; MULTICENTER; MARKER AB The purpose of this study was to validate the Albumin Cobalt Binding (ACB((R))) assay at the Seattle Veterans Affairs (VA) Hospital to determine if it would provide an earlier rule-out of acute coronary syndrome (ACS) in patients, compared to current use of cardiac injury markers. This study compares the distribution of ischemia modified albumin (IMA) values of our patient population to those provided by the kit manufacturer. IMA values were determined photometrically on a Roche Modular Analytical System on 200 subjects: 69 subjects not experiencing chest pain (normals), 78 subjects presenting to the emergency room (ER) with chest pain whose initial and subsequent troponin results were negative (non-converters), and 53 subjects presenting to the ER with chest pain whose initial troponin result was negative but subsequent troponin results were positive (converters). Based on the relationships between IMA values in the initial samples from the non-converters and converters, we constructed a ROC curve to identify an optimum IMA rule-out value. The IMA values (mean +/- SD) for the normals, non-converters, and converters were 89 +/- 7.1, 100 +/- 13.9, and 126 +/- 14.1 U/ml, respectively, and each mean was statistically different from the means of the other groups. The ROC curve comparing converters and non-converters showed an area of 0.89 (p < 0.001) compared to the line of identity. An IMA cut-off of 97 U/ml gives a 98% sensitivity and 45% specificity and may be the best decision point to differentiate between these groups in our population. Nine of 78 non-converters were classified as having unstable angina. In conclusion, the ACB assay has a strong negative predictive value and sensitivity in our population for predicting the troponin results at 6 to 24 hr post-presentation. Because ACB results may be facility- and instrument-dependent, each facility should conduct an independent ROC analysis to determine the optimal IMA rule-out level. The ACB assay, when used in conjunction with cardiac injury markers and assessment of unstable angina, holds promise in reducing inappropriate low-risk hospital admissions and improving the clinical management of patients with chest pain. C1 Univ Washington, Med Ctr, Dept Lab Med, Seattle, WA 98105 USA. Vet Affairs Puget Sound Hlth Care Syst, Pathol & Lab Med Serv, Seattle, WA USA. RP Abadie, JM (reprint author), Univ Washington, Med Ctr, Dept Lab Med, NW 120, Seattle, WA 98105 USA. EM judeabadie@medscape.com NR 33 TC 19 Z9 30 U1 0 U2 2 PU INST CLINICAL SCIENCE INC PI PHILADELPHIA PA 1833 DELANCEY PLACE, PHILADELPHIA, PA 19103 USA SN 0091-7370 J9 ANN CLIN LAB SCI JI Ann. Clin. Lab. Sci. PD WIN PY 2005 VL 35 IS 1 BP 66 EP 72 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 906PS UT WOS:000227654800009 PM 15830711 ER PT J AU Markus, TM Tsai, SY Bollnow, MR Farrer, RG O'Brien, TE Kindler-Baumann, DR Rausch, M Rudin, M Wiessner, C Mir, AK Schwab, ME Kartje, GL AF Markus, TM Tsai, SY Bollnow, MR Farrer, RG O'Brien, TE Kindler-Baumann, DR Rausch, M Rudin, M Wiessner, C Mir, AK Schwab, ME Kartje, GL TI Recovery and brain reorganization after stroke in adult and aged rats SO ANNALS OF NEUROLOGY LA English DT Article ID MONOCLONAL-ANTIBODY IN-1; NOGO-A; FUNCTIONAL RECOVERY; CORTICAL LESION; MOTOR CORTEX; PLASTICITY AB Stroke is a prevalent and devastating disorder, and no treatment is currently available to restore lost neuronal function after stroke. One unique therapy that improves recovery after stroke is neutralization of the neurite inhibitory protein Nogo-A. Here, we show, in a clinically relevant model, improved functional recovery and brain reorganization in the aged and adult rat when delayed anti-Nogo-A therapy is given after ischemic injury. These results support the efficacy of Nogo-A neutralization as treatment for ischemic stroke, even in the aged animal and after a 1-week delay, and implicate neuronal plasticity from unlesioned areas of the central nervous system as a mechanism for recovery. C1 Loyola Univ, Neurosci & Aging Inst, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol & Res Serv, Hines, IL 60141 USA. Loyola Univ, Ctr Stat Consulting, Dept Math & Stat, Chicago, IL 60611 USA. Novartis Pharma AG, Nervous Syst Res, Neuroregenerat Unit, Basel, Switzerland. Univ Zurich, Brain Res Inst, Zurich, Switzerland. Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland. Loyola Univ, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA. RP Kartje, GL (reprint author), Edward Hines Jr Vet Adm Hosp, Neurol Serv 127, Bldg 1,Room F201,5th Ave & Roosevelt Rd, Hines, IL 60141 USA. EM wendy.kartje@med.va.gov RI Rudin, Markus/F-2417-2010; Schwab, Martin/B-6818-2016 FU NINDS NIH HHS [NS 40960, R56 NS040960]; RRD VA [I01 RX000828] NR 20 TC 84 Z9 88 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD DEC PY 2005 VL 58 IS 6 BP 950 EP 953 DI 10.1002/ana.20676 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 989WE UT WOS:000233703900018 PM 16315284 ER PT J AU O'Brien, PKH Kucharczuk, JC Marshall, MB Friedberg, JS Chen, Z Kaiser, LR Shrager, JB AF O'Brien, PKH Kucharczuk, JC Marshall, MB Friedberg, JS Chen, Z Kaiser, LR Shrager, JB TI Comparative study of subxiphoid versus video-thoracoscopic pericardial "'window" SO ANNALS OF THORACIC SURGERY LA English DT Article ID PERCUTANEOUS CATHETER DRAINAGE; SURGICAL-MANAGEMENT; CARDIAC-TAMPONADE; EFFUSION; DIAGNOSIS; DISEASE; RESECTION; MALIGNANCY AB Background. It remains undefined whether surgical subxiphoid drainage or thoracoscopic pericardial "window" is the optimal operative approach to pericardial effusion. We hypothesized that the true window into the pleural space created by the latter might improve the duration of freedom from recurrent effusion. Methods. We conducted a retrospective chart review of indications, preoperative and intraoperative variables, morbidity, recurrence, and survival. Results. Fifty-six patients underwent the subxiphoid procedure and 15 underwent the thoracoscopic procedure. Echocardiographic evidence of tamponade was present before 8 of 10 thoracoscopic procedures (80%) and 43 of 56 subxiphoid procedures (81%) for which descriptions of hemodynamics were available. In addition, non-pericardial procedures were performed in 10 (67%) and 18 (32%) patients, respectively (p = 0.020). Anesthesia time was longer at thoracoscopy (117.1 +/- 32.4 vs 81.1 +/- 25.5 minutes; p < 0.001). Procedural morbidity was higher after thoracoscopy (4 [27%] vs 1 [2%]; p = 0.006), but was generally minor. Hospital mortality tended to be higher after the subxiphoid procedure (7 [13%] vs 0 [0%]; P = 0.332), but none of the deaths was procedure-related. Follow-up was complete for 65 patients (92%). Recurrence occurred in 1 thoracoscopy patient (8%) and 5 subxiphoid patients (10%) (p = 1.000). Mean time to recurrence by Kaplan-Meier analysis trends were longer after thoracoscopy (36.1 vs 11.4 months; p = 0.16), and multivariate analysis identified the thoracoscopic approach as an independent predictor of freedom from recurrence (relative risk, 0.41; p = 0.014). Conclusions. Operative time and minor procedural morbidity are higher with thoracoscopic pericardial window, but long-term control of effusion seemed to be better than after subxiphoid surgical drainage. C1 Univ Penn, Sch Med, Sect Gen Thorac Surg, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Dept Surg, Philadelphia, PA USA. RP Shrager, JB (reprint author), Hosp Univ Penn, Silverstein 6,3400 Spruce St, Philadelphia, PA 19104 USA. EM joseph.shrager@uphs.upenn.edu NR 27 TC 19 Z9 22 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD DEC PY 2005 VL 80 IS 6 BP 2013 EP 2019 DI 10.1016/j.athoracsur.2005.05.059 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 993BD UT WOS:000233926800006 PM 16305836 ER PT J AU Barchiesi, F Spreghini, E Santinelli, A Fothergill, AW Fallani, S Manso, E Pisa, E Giannini, D Novelli, A Cassetta, MI Mazzei, T Rinaldi, MG Scalise, G AF Barchiesi, F Spreghini, E Santinelli, A Fothergill, AW Fallani, S Manso, E Pisa, E Giannini, D Novelli, A Cassetta, MI Mazzei, T Rinaldi, MG Scalise, G TI Efficacy of caspofungin against Aspergillus terreus SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PULMONARY ASPERGILLOSIS; INVASIVE ASPERGILLOSIS; ANTIFUNGAL THERAPY; AMPHOTERICIN-B; INFECTION; AGENT AB We investigated the in vitro and in vivo activities of caspofungin against Aspergillus terreus. The drug increased survival and reduced tissue fungal burden in neutropenic mice. Therefore, our data support the role of caspofungin in treating systemic infections due to this emerging pathogen. C1 Univ Policlin Marche, Ist Malattie Infett & Med Pubbl, Azienda Osped Univ, Osped Riuniti Umberto I Lancisi Salesi, I-60020 Ancona, Italy. Univ Policlin Marche, Ist Anat Patol, I-60020 Ancona, Italy. Univ Policlin Marche, Ctr Gest Presidenza Med & Chirurg, I-60020 Ancona, Italy. Univ Osped Riuniti Umberto I Lancisi Salesi, Microbiol Lab, Ancona, Italy. Univ Florence, Ist Farmacol Preclin & Clin, Florence, Italy. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Barchiesi, F (reprint author), Univ Policlin Marche, Ist Malattie Infett & Med Pubbl, Azienda Osped Univ, Osped Riuniti Umberto I Lancisi Salesi, Via Conca, I-60020 Ancona, Italy. EM l.infettive@ao-umbertoprimo.marche.it RI Spreghini, Elisabetta/G-9378-2012 NR 13 TC 11 Z9 11 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD DEC PY 2005 VL 49 IS 12 BP 5133 EP 5135 DI 10.1128/AAC.49.12.5133-5135.2005 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 989RS UT WOS:000233692100044 PM 16304185 ER PT J AU Hilsabeck, RC Gouvier, WD AF Hilsabeck, RC Gouvier, WD TI Detecting simulated memory impairment: Further validation of the Word Completion Memory Test (WCMT) SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article; Proceedings Paper CT 18th Annual Meeting of the National-Academy-of-Neuropsychology CY NOV, 1998 CL WASHINGTON, D.C. SP Natl Acad Neuropsychol DE malingering; cognitive; neuropsychological; faking bad; implicit memory ID TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; REY 15-ITEM TEST; SUSPECT EFFORT; FIGURE TEST; VALIDITY; DEFICITS; MMPI-2; IMPLICIT AB The Word Completion Memory Test (WCMT) was developed to detect sophisticated attempts at simulating memory impairment. The primary purpose of the present study was to provide additional validity and reliability information about the WCMT. Seventy-one participants were recruited for this study: 30 normal volunteers and 11 memory-disordered patients instructed to perform their best, and 30 normal volunteers instructed to fake memory impairment. Normal volunteers were administered five tests of neuropsychological functioning and five tests of simulation to explore the convergent and divergent validity of the WCMT. Two weeks later, these participants completed all 10 measures a second time. Memory-disordered patients were administered the WCMT and two additional simulation measures as part of a comprehensive neuropsychological evaluation. The WCMT successfully discriminated simulators from nonsimulators with an overall classification accuracy of 97% and demonstrated good psychometric properties. In conclusion, the WCMT continues to show promise as a measure of simulated memory impairment. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved. C1 Louisiana State Univ, Baton Rouge, LA 70803 USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM robin.hilsabeck@med.va.gov NR 58 TC 6 Z9 6 U1 14 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD DEC PY 2005 VL 20 IS 8 BP 1025 EP 1041 DI 10.1016/j.acn.2005.05.003 PG 17 WC Psychology, Clinical; Psychology SC Psychology GA 992LD UT WOS:000233884500006 PM 16099137 ER PT J AU Hussein, MR Haemel, AK Albert, DM Wood, GS AF Hussein, MR Haemel, AK Albert, DM Wood, GS TI Microsatellite instability and alterations of mismatch repair protein expression in choroidal melanomas SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID CUTANEOUS MALIGNANT MELANOMAS; POSTERIOR UVEAL MELANOMA; CYTOGENETIC FINDINGS; ALTERED EXPRESSION; COLORECTAL-CANCER; HMLH1 EXPRESSION; MELANOCYTIC NEVI; DYSPLASTIC NEVI; FAMILY-HISTORY; HMSH2 AB Objectives: To examine choroidal melanomas for genomic instability, manifested by microsatellite instability (MSI) and mismatch repair (MMR) protein alterations, and to determine the association of these alterations with selected clinicopathological features of the tumors. Methods: Polymerase chain reaction-based microsatellite assays were applied to analyze 57 cases of choroidal melanomas using 11 microsatellite markers at 5 chromosomal regions: 1p, 2p, 4q, 9p, and 17p. Immunoperoxidase staining methods and mouse monoclonal antibodies were used to investigate the expression patterns of MMR proteins. Results: Microsatellite instability was found at the 1p, 9p, and 17p regions in these lesions with an overall prevalence of 35% (20/57). The frequency of MST ranged from 9% (1/11) to 27% (3/11), ie, low-level MSI (MSI-L). The instability was most commonly found at the 1p region (D1S2734, 55%; D1S2832, 40%; and D1S233, 20%). Two MST banding patterns, band shifts and the appearance of additional bands, were found in 10% and 90% of the unstable lesions, respectively. The average percentages of hMLH1 and hMSH2 positively stained cells were insignificantly reduced in the unstable lesions (81.7 +/- 9.3 and 76.7 +/- 16.7) as compared with the stable lesions (84.1 +/- 15.5 and 78.6 +/- 19.6; P = .62 and 0.74 for hMLH1 and hMSH2, respectively). There was no significant difference in survival between the 2 groups; however, relative to the stable subset, the unstable tumors showed a trend (P < .10) toward occurring at a younger age and having tumor cells in vascular lakes. Conclusions: The presence of MSI-L in some choroidal melanomas defines a novel genetic subset of these tumors and suggests that MSI (genomic instability) may play a role in their molecular pathogenesis. Elucidation of the underlying mechanisms for MSI will require further investigation. Clinical Relevance: Detection of the MSI-L pattern might prove to be useful as an adjunct to the conventional diagnosis of choroidal melanomas. Larger series are needed to determine whether any of the correlative trends noted in this study will achieve statistical significance. To the best of our knowledge, this study is the first to define both the MST and MMR protein expression features of choroidal melanomas. Conclusions: The presence of MSI-L in some choroidal melanomas defines a novel genetic subset of these tumors and suggests that MST (genomic instability) may play a role in their molecular pathogenesis. Elucidation of the underlying mechanisms for MST will require further investigation. C1 Univ Wisconsin, Dept Dermatol, Madison, WI 53715 USA. Assiut Univ Hosp, Fac Med, Dept Pathol, Assiut, Egypt. Brown Med Sch, Providence, RI USA. Univ Wisconsin, Dept Ophthalmol, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Wood, GS (reprint author), Univ Wisconsin, Dept Dermatol, 1 S Pk,7th Floor, Madison, WI 53715 USA. EM gwood@dermatology.wisc.edu FU NIAMS NIH HHS [AR02136] NR 37 TC 8 Z9 8 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD DEC PY 2005 VL 123 IS 12 BP 1705 EP 1711 DI 10.1001/archopht.123.12.1705 PG 7 WC Ophthalmology SC Ophthalmology GA 991BS UT WOS:000233787800011 PM 16344443 ER PT J AU Shrank, W Ettner, SL Slavin, PH Kaplan, HJ AF Shrank, W Ettner, SL Slavin, PH Kaplan, HJ TI Effect of physician reimbursement methodology on the rate and cost of cataract surgery SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID FEE-FOR-SERVICE; FINANCIAL INCENTIVES; VISUAL FUNCTION; CARE; OUTCOMES; PAYMENT; ORGANIZATIONS; PERFORMANCE; EXTRACTION; MORTALITY AB Objectives: To compare the effects of 2 reimbursement methodologies, fee-for-service and contact capitation, on cataract extraction rates and costs in a stable physician population with little potential for the influence of patient selection. Previous research evaluating the relationship between physician reimbursement incentives and cataract surgical rates has been limited by physician and patient selection bias. Methods: A pre-post analysis of claims and encounter data for an average of 91473 commercial beneficiaries and 14 084 Medicare beneficiaries receiving eye care from a network of ophthalmologists and optometrists in St Louis, Mo, between 1997 and 1998. The rate of cataract extractions per 1000 beneficiaries, the costs of cataract procedures, the rates of noncataract procedures, and the level of professional reimbursement for providers were compared during the final 6 months of fee-for-service physician reimbursement and the first 6 months of contact capitation. Results: Both commercial and Medicare beneficiaries were approximately one half as likely to have cataract extraction (P < .001) under contact capitation as compared with fee-for-service. Professional reimbursement increased by 8% whereas facility fees for cataract procedures decreased by approximately 45%. Cataract surgical rates were disproportionately affected when compared with other ophthalmologic procedures. During the study period, cataract surgical rates were stable in the national and Missouri traditional fee-for-service Medicare population. Conclusions: The stability of the physician and patient populations allowed us to isolate the effects of physician reimbursement methodology on practice patterns. Compared with fee-for-service, contact capitation reimbursement was associated with significant decreases in cataract extraction rates and costs. The frequency of the cataract extraction surgery, the most common major elective procedure in ophthalmology, was more responsive to physician financial incentives than other ophthalmologic procedures were. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, Div Gen Internal Med, Los Angeles, CA USA. Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. Barnes Eyecare Network, St Louis, MO USA. Univ Louisville, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40292 USA. RP Shrank, W (reprint author), Harvard Univ, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Brigham & Womens Hosp, 1620 Tremont St, Boston, MA 02120 USA. EM wshrank@partners.org NR 25 TC 23 Z9 23 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD DEC PY 2005 VL 123 IS 12 BP 1733 EP 1738 DI 10.1001/archopht.123.12.1733 PG 6 WC Ophthalmology SC Ophthalmology GA 991BS UT WOS:000233787800015 PM 16344447 ER PT J AU Truong, LD Krishnan, B Shen, SS AF Truong, LD Krishnan, B Shen, SS TI Intraoperative pathology consultation for kidney and urinary bladder specimens SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID RENAL-CELL CARCINOMA; VONHIPPEL-LINDAU-DISEASE; NEPHRON-SPARING SURGERY; FINE-NEEDLE ASPIRATION; XANTHOGRANULOMATOUS PYELONEPHRITIS; PROSTATIC ADENOCARCINOMA; FROZEN-SECTIONS; ANGIOMYOLIPOMA; TUMORS; ONCOCYTOMA AB Context.-Intraoperative pathology consultation for kidney and urinary bladder specimens is relatively infrequent. Scant literature is devoted to this topic. Objective.-The clinical indications and diagnostic usefulness and pitfalls of intraoperative pathology consultation of kidney and urinary bladder specimens will be reviewed, based on literature and personally encountered cases. Data Sources.-The indications for intraoperative pathology consultation for renal lesions included (1) surgical margins in partial nephrectomy specimens, (2) solid renal mass in unusual clinical or radiologic settings, (3) synchronous renal and extrarenal masses, (4) cystic renal lesions, (5) ureteral surgical margin for transitional cell carcinoma, (6) multiple renal masses, (7) solid mass in a diffusely cystic kidney, and (8) evaluation of renal injury. The indications for urinary bladder included (1) status of the surgical margins, (2) diagnosis of bladder tumor biopsy, (3) diagnosis of extravesical tumors with vesical extension, (4) diagnosis of extravesical mass, including pelvic lymph nodes encountered during cystectomy, and (5) status of bladder neck margin during radical prostatectomy for cancer. The frequent problematic areas for the kidney included misdiagnosis or incorrect classification of cystic tumors or spindle cell tumors, and confusion of clear cell renal cell carcinoma with inflammatory lesions. The problematic areas for urinary bladder included the differential diagnoses of high-grade dysplasia/carcinoma in situ with reactive changes at the ureteral or urethral surgical margins. Conclusions.-Distinctive indications and diagnostic pitfalls are recognized for intraoperative consultation of renal or urinary bladder lesions. Awareness of the pertinent problems should improve diagnostic accuracy and facilitate the proper management of these lesions. C1 Baylor Coll Med, Methodist Hosp, Dept Pathol, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. Cornell Univ, Weill Med Coll, New York, NY USA. RP Truong, LD (reprint author), Baylor Coll Med, Methodist Hosp, Dept Pathol, MS 205,6565 Fannin St, Houston, TX 77030 USA. EM ltruong@tmh.tmc.edu NR 58 TC 15 Z9 16 U1 0 U2 2 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD DEC PY 2005 VL 129 IS 12 BP 1585 EP 1601 PG 17 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 990FT UT WOS:000233729300014 PM 16329731 ER PT J AU Cully, JA Gfeller, JD Heise, RA Ross, MJ Teal, CR Kunik, ME AF Cully, JA Gfeller, JD Heise, RA Ross, MJ Teal, CR Kunik, ME TI Geriatric depression, medical diagnosis, and functional recovery during acute rehabilitation SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE cerebrovascular accident; depression; geriatrics; geriatric assessment; rehabilitation ID POSTSTROKE DEPRESSION; INDEPENDENCE MEASURE; SCREENING SCALE; PRIMARY-CARE; LATE-LIFE; STROKE; PREVALENCE; INPATIENTS AB Objective: To examine and compare the prevalence and functional impact of depressive symptoms for older adult stroke and nonstroke rehabilitation inpatients. Design: Case-control study examining functional outcome using a 2 (stroke, nonstroke) by 2 (depression, no depression) design. Setting: Urban hospital rehabilitation unit. Participants: A total of 509 rehabilitation inpatients (age, >= 60y) were included and grouped by diagnosis of stroke (n = 207) and nonstroke (n = 302). Interventions: Not applicable. Main Outcome Measures: Geriatric Depression Scale and FIM instrument. Analysis of covariance procedures examined the impact of depressive symptoms on discharge functional ability controlling for age, sex, admission functional ability, and hospital length of stay. Results: Prevalence of depressive symptoms was similar for stroke (31.8%) and nonstroke (31.5%) and negatively associated with functional ability at discharge for both groups. Overall, the stroke and nonstroke groups did not differ significantly with respect to functional recovery. Conclusions: Depression, and its impact on acute rehabilitation, is significantly related to functional recovery but does not differ in its frequency or impact for stroke patients. Because depressive symptoms do not appear to discriminate across diagnostic groups, routine screening for depression is recommended for all rehabilitation inpatients. C1 Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Vet Affairs HSR&D Ctr Excellence, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. St Louis Univ, Vet Affairs S Cent Mental Illness Res Educ & Clin, Dept Psychol, St Louis, MO 63103 USA. SSM Rehab, Dept Neuropsychol, St Louis, MO USA. RP Cully, JA (reprint author), 2002 Holcombe 152, Houston, TX 77030 USA. EM jcully@bcm.tmc.edu NR 27 TC 26 Z9 27 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD DEC PY 2005 VL 86 IS 12 BP 2256 EP 2260 DI 10.1016/j.apmr.2005.07.292 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 995VE UT WOS:000234131700004 PM 16344020 ER PT J AU Pearlman, JL Cooper, RA Karnawat, J Cooper, R Boninger, ML AF Pearlman, JL Cooper, RA Karnawat, J Cooper, R Boninger, ML TI Evaluation of the safety and durability of low-cost nonprogrammable electric powered wheelchairs SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE reference standards; rehabilitation; safety; wheelchairs ID ANSI/RESNA STANDARDS; MANUAL WHEELCHAIRS; LIFE AB Objective: To evaluate whether a selection of low-cost, nonprogrammable electric-powered wheelchairs (EPWs) meets the American National Standards Institute (ANSI)/Rehabilitation Engineering and Assistive Technology Society of North America (RESNA) Wheelchair Standards requirements. Design: Objective comparison tests of various aspects of power wheelchair design and performance of 4 EPW types. Specimens: Three of each of the following EPWs: Pride Mobility Jet 10 (Pride), Invacare Pronto M50 (Invacare), Electric Mobility Rascal 250PC (Electric Mobility), and the Golden Technologies Alante GP-201-F (Golden). Setting: Rehabilitation engineering research center. Interventions: Not applicable. Main Outcome Measures: Static tipping angle; dynamic tipping score; braking distanced energy consumption, climatic conditionings power and control systems integrity and safety and static, impact, and fatigue life (equivalent cycles). Results: Static tipping angle and dynamic tipping score were significantly different across manufacturers for each tipping direction (range, 6.6 degrees-35.6 degrees). Braking distances were significantly different across manufacturers (range, 7.4-117.3cm). Significant differences among groups were found with analysis of variance (ANOVA). Energy consumption results show that all EPWs can travel over 17km before the battery is expected to be exhausted under idealized conditions (range, 18.2-32.0km). Significant differences among groups were found with ANOVA. All EPWs passed the climatic conditioning tests. Several adverse responses were found during the power and control systems testing, including motors smoking during the stalling condition (Electric Mobility), charger safety issues (Electric Mobility, Invacare), and controller failures (Golden). All EPWs passed static and impact test-ing; 9 of 12 failed fatigue testing (3 Invacare, 3 Golden, 1 Electric Mobility, 2 Pride). Equivalent cycles did not differ statistically across manufacturers (range, 9759-824,628 cycles). Conclusions: Large variability in the results, especially with respect to static tipping, power and control system failures, and fatigue life suggest design improvements must be made to make these low-cost, nonprogrammable EPWs safe and reliable for the consumer. Based on our results, these EPWs do not, in general, meet the ANSI/RESNA Wheelchair Standards requirements. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, 151-R1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136; Boninger, Michael/0000-0001-6966-919X NR 16 TC 14 Z9 14 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD DEC PY 2005 VL 86 IS 12 BP 2361 EP 2370 DI 10.1016/j.apmr.2005.07.294 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 995VE UT WOS:000234131700020 PM 16344036 ER PT J AU Jiang, XH Yang, F Tan, HM Liao, D Bryan, RM Randhawa, JK Rumbaut, RE Durante, W Schafer, AI Yang, XF Wang, H AF Jiang, XH Yang, F Tan, HM Liao, D Bryan, RM Randhawa, JK Rumbaut, RE Durante, W Schafer, AI Yang, XF Wang, H TI Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE homocysteine; endothelial function; eNOS; protein kinase C ID CYSTATHIONINE BETA-SYNTHASE; ACCELERATES ATHEROSCLEROSIS; DEFICIENT MICE; MURINE MODEL; L-ARGININE; DYSFUNCTION; HOMOCYSTEINE; MILD; HYPERHOMOCYST(E)INEMIA; INHIBITION AB Objective-A risk factor for cardiovascular disease, hyperhomocystinemia (HHcy), is associated with endothelial dysfunction. In this study, we examined the mechanistic role of HHcy in endothelial dysfunction. Methods and Results-Through the use of 2 functional models, aortic rings and intravital video microscopy of the cremaster, we found that arterial relaxation in response to the endothelium-dependent vessel relaxant, acetylcholine or the nitric oxide synthase ( NOS) activator (A23187), was significantly impaired in cystathionine beta-synthase null (CBS-/-) mice. However, the vascular smooth muscle cell (VSMC) response to the nitric oxide (NO) donor (SNAP) was preserved in CBS-/- mice. In addition, superoxide dismutase and catalase failed to restore endothelium-dependent vasodilatation. Endothelial nitric oxide synthase (eNOS) activity was significantly reduced in mouse aortic endothelial cells (MAECs) of CBS-/- mice, as well as in Hcy-treated mouse and human aortic endothelial cells (HAECs). Hcy-mediated eNOS inhibition-which was not rescued by adenoviral transduction of superoxide dismutase and glutathione peroxidase, or by tetrahydrobiopterin, sepiapterin, and arginine supplementations in MAEC-was associated with decreased protein expression and increased threonine 495 phosphorylation of eNOS in HAECs. Ultimately, a protein kinase C (PKC) inhibitor, GF109203X (GFX), reversed Hcy-mediated eNOS inactivation and threonine 495 phosphorylation in HAECs. Conclusions-These data suggest that HHcy impairs endothelial function and eNOS activity, primarily through PKC activation. C1 Baylor Coll Med, VA Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. Michael E DeBakey VA Med Ctr, Houston, TX USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Wang, H (reprint author), Baylor Coll Med, VA Med Ctr, Dept Med, 2002 Holcombe Blvd 109-129, Houston, TX 77030 USA. EM hongw@bcm.tmc.edu FU NHLBI NIH HHS [R01 HL036045, HL36045, HL59976, HL64721, HL67033, HL74925, HL77288, K02 HL074925, R01 HL059976, R01 HL064721, R01 HL067033, R01 HL077288] NR 33 TC 83 Z9 89 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD DEC PY 2005 VL 25 IS 12 BP 2515 EP 2521 DI 10.1161/01.ATV.0000189559.87328.e4 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 986PF UT WOS:000233461500015 PM 16210565 ER PT J AU Carter, RH Zhao, H Liu, XM Pelletier, M Chatham, W Kimberly, R Zhou, T AF Carter, RH Zhao, H Liu, XM Pelletier, M Chatham, W Kimberly, R Zhou, T TI Expression and occupancy systemic lupus of BAFF-R on B cells in erythematosus SO ARTHRITIS AND RHEUMATISM LA English DT Article ID NECROSIS-FACTOR FAMILY; LYMPHOCYTE STIMULATOR; AUTOIMMUNE-DISEASE; TNF RECEPTOR; MATURATION ANTIGEN; SJOGRENS-SYNDROME; PERIPHERAL-BLOOD; HUMORAL IMMUNITY; MARGINAL ZONE; HIGH-AFFINITY AB Objective. To determine whether receptors for B lymphocyte stimulator (BLyS) are altered on B cells of patients with systemic lupus erythematosus (SLE). Methods. Total available receptors for BLyS were measured by analysis of binding of recombinant soluble BLyS to peripheral blood B cells in 36 SLE patients, 29 healthy controls, and 10 disease controls. Antibodies to the receptors BAFF-R, BCMA, and TACI were used to define expression of the individual BLyS receptors on subsets of B cells in blood, spleen, and tonsils. Two different antibodies to BAFF-R, which were differentially sensitive to BAFF-R occupancy, were used to compare BAFF-R on B cells in an additional 20 healthy subjects and 25 SLE patients. Assays of B cell survival after stimulation in vitro were used to determine the sensitivity of B cells to exogenous BLyS. Results. Total available receptors for BLyS were decreased in patients with SLE, independent of changes of subsets in the blood in these patients. The decrease correlated with changes in disease activity. Although total surface BAFF-R was not significantly different between healthy controls and SLE patients, BAFF-R was occupied in SLE patients. B cells from these patients were less responsive to exogenous BLyS. Conclusion. BAFF-R is consistently occupied on blood B cells in SLE. Occupancy of BAFF-R on blood B cells is likely to contribute to disease mechanisms in SLE and could serve as a biomarker of disease activity. Targeting BLyS as a therapeutic strategy will require overcoming the persistent binding of BLyS to BAFF-R. C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. BiogenIdec, Cambridge, MA USA. RP Carter, RH (reprint author), 409 LHRB,701 S 19th St, Birmingham, AL 35294 USA. EM rcarter@uab.edu NR 48 TC 68 Z9 76 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2005 VL 52 IS 12 BP 3943 EP 3954 DI 10.1002/art.21489 PG 12 WC Rheumatology SC Rheumatology GA 995VC UT WOS:000234131500033 PM 16320342 ER PT J AU Lee, YH Witte, T Momot, T Schmidt, RE Kaufman, KM Harley, JB Sestak, AL AF Lee, YH Witte, T Momot, T Schmidt, RE Kaufman, KM Harley, JB Sestak, AL TI The Mannose-binding lectin gene polymorphisms and systemic lupus erythematosus - Two case-control studies and a meta-analysis SO ARTHRITIS AND RHEUMATISM LA English DT Article ID PROTEIN GENE; RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; INNATE IMMUNITY; ASSOCIATION; MBL; POPULATION; COMPLEMENT; DEFICIENCY; DISEASE AB Objective. Mannose-binding lectin (MBL) enhances opsonization and activates complement. Dysfunctional alleles of MBL have been associated with low plasma concentrations of MBL and increased risk of systemic lupus erythematosus (SLE), but genotyping studies have shown inconsistent results. We performed case-control studies of the MBL polymorphisms in 2 Caucasian cohorts and a meta-analysis incorporating all published results of MBL genotyping in SLE to explore whether the MBL functional variants are associated with SLE. Methods. MBL genotypes at 7 single-nucleotide polymorphisms were sequenced in 96 European American patients with SLE and 96 age-, race-, and sex-matched controls. MBL codons 52, 54, and 57 were genotyped in 285 German patients with SLE and 200 race-matched controls. Allele frequencies of all known variants were tallied for meta-analysis. Results. Although there was a trend toward association with MBL polymorphisms in both patient cohorts evaluated, none of them was significantly associated with SLE on its own. Seventeen comparisons from 15 studies were included in the meta-analysis. Publication bias was excluded by Egger's regression test (P = 0.14). The overall odds ratio for MBL codon 54 variant B was 1.406 (95% confidence interval 1.221-1.608; P < 0.001). Stratification by ethnicity showed significantly increased odds ratios for association of the MBL codon 54B variant with SLE in African, Asian, and Caucasian cohorts. Conclusion. Meta-analysis of all available studies on MBL polymorphisms and SLE shows that MBL variant alleles such as MBL exon 1 codon 54 B, promoter -550 L, and promoter -221 X are SLE risk factors. This association is robust and persists after incorporation of data from our 2 cohorts in which the association failed to reach significance. C1 Oklahoma Med Res Fdn, Arthrit & Immunol Res Program, Oklahoma City, OK 73104 USA. Korea Univ, Seoul 136701, South Korea. Hannover Med Sch, Hannover, Germany. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. RP Sestak, AL (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM andrea-sestak@omrf.ouhsc.edu RI Witte, Torsten/B-5783-2016 FU NCRR NIH HHS [RR-020143]; NIAID NIH HHS [AI-24717, AI-31584]; NIAMS NIH HHS [AR-12253, AR-42460, AR-48940, AR-49272]; NIDCR NIH HHS [DE-015223] NR 49 TC 131 Z9 132 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2005 VL 52 IS 12 BP 3966 EP 3974 DI 10.1002/art.21484 PG 9 WC Rheumatology SC Rheumatology GA 995VC UT WOS:000234131500035 PM 16320344 ER PT J AU Pessler, F Dai, L Chen, LX Schumacher, HP AF Pessler, F Dai, L Chen, LX Schumacher, HP TI Expression of calcineurin in synovium. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Sun Yat Sen Univ, Guangzhou, Peoples R China. Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2005 VL 52 IS 12 BP 4070 EP 4070 PG 1 WC Rheumatology SC Rheumatology GA 995VC UT WOS:000234131500092 ER PT J AU Jung, SM Schumacher, HR Lee, SH Kim, HC Chen, LX Pessler, F AF Jung, SM Schumacher, HR Lee, SH Kim, HC Chen, LX Pessler, F TI Anti-inflammatory properties of a mixture of traditional oriental medicinal herbs in acute urate crystal imflammation. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Kyung Hee Univ, Sch Oreintal Med, Seoul, South Korea. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Philadelphia, PA USA. Childrens Hosp, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2005 VL 52 IS 12 BP 4072 EP 4072 PG 1 WC Rheumatology SC Rheumatology GA 995VC UT WOS:000234131500097 ER PT J AU Pessler, F Dai, L Einhorn, E Cron, RQ Schumacher, HR AF Pessler, F Dai, L Einhorn, E Cron, RQ Schumacher, HR TI Expression of nuclear factor of activated T cells (NFAT) transcription factors in the synovial subintima distinguishes RA from OA. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Sun Yat Sen Univ, Guangzhou, Peoples R China. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2005 VL 52 IS 12 BP 4073 EP 4073 PG 1 WC Rheumatology SC Rheumatology GA 995VC UT WOS:000234131500100 ER PT J AU Lainer, DT Park, GS Paulus, HE Khanna, D Keystone, EC Furst, DE AF Lainer, DT Park, GS Paulus, HE Khanna, D Keystone, EC Furst, DE CA Western Constorium Practicing TI Association of regional baseline joint tenderness and joint wwelling with regional functional outcomes in early rheumatoid arthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Calif Los Angeles, Med Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA. W Los Angeles VAMC, Los Angeles, CA USA. Univ Cincinnati, Cincinnati, OH 45221 USA. Inst Study Hlth, Cincinnati, OH USA. Univ Toronto, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2005 VL 52 IS 12 BP 4096 EP 4096 PG 1 WC Rheumatology SC Rheumatology GA 995VC UT WOS:000234131500155 ER PT J AU Lainer, DT Park, GS Paulus, HE Khanna, D Keystone, EC Furst, DE AF Lainer, DT Park, GS Paulus, HE Khanna, D Keystone, EC Furst, DE CA Western Constorium Practicing TI Association of baseline tenderness and swelling with 2-year radiographic outcomes of individual joints in early seropositive rheumatoid arthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Calif Los Angeles, Med Ctr, David Geffen Sch Med, Los Angeles, CA USA. W Los Angeles VAMC, Los Angeles, CA USA. Univ Cincinnati, VAMC, Cincinnati, OH 45221 USA. Inst Study Hlth, Cincinnati, OH USA. Univ Toronto, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2005 VL 52 IS 12 BP 4097 EP 4098 PG 2 WC Rheumatology SC Rheumatology GA 995VC UT WOS:000234131500158 ER PT J AU Glahn, DC Bearden, CE Caetano, S Fonseca, M Najt, P Hunter, K Pliszka, SR Olvera, RL Soares, JC AF Glahn, DC Bearden, CE Caetano, S Fonseca, M Najt, P Hunter, K Pliszka, SR Olvera, RL Soares, JC TI Declarative memory impairment in pediatric bipolar disorder SO BIPOLAR DISORDERS LA English DT Article DE cognition; declarative memory; development; juvenile mania; pediatric bipolar disorder ID NEUROCOGNITIVE FUNCTION; PREFRONTAL CORTEX; RATING-SCALE; MANIA; CHILDREN; SCHIZOPHRENIA; ADOLESCENTS; PHENOTYPE; VALIDITY; RELIABILITY AB Objectives: Impaired verbal declarative memory has been proposed as a trait marker for adult bipolar disorder. However, similar impairments in juvenile-onset bipolar disorder have not been yet documented. Here, we assessed declarative memory in a large sample of clinically well-characterized children with bipolar disorder. Methods: Forty-one children and adolescents with bipolar disorder [21 bipolar I disorder (BP-I), 10 bipolar II disorder (BP-II), and 10 bipolar disorder, not otherwise specified (BP-NOS)] and 17 demographically matched healthy participants completed a standardized learning and memory test. Results: BP-I children recalled and recognized significantly fewer words than healthy subjects, whereas children with BP-II and BP-NOS did not differ from controls. However, individuals with BP-NOS made more perseverative errors and intrusions than the other groups. Severity of mood symptomatology was not associated with memory performance in any bipolar subtype. Conclusions: Findings suggest that declarative memory impairments in juvenile BP-I are similar to those seen in the adult form of the illness. These impairments do not appear to be secondary to clinical state; rather, they may reflect trait-related impairments. Distinct performance patterns in BP-I, BP-II, and BP-NOS suggest that the broadly defined phenotype is significantly heterogeneous, and may not be informative for pathogenetic investigations of bipolar disorder. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Fed Rio Grande Sul, Sch Med, Psychiat Res Unit, Porto Alegre, RS, Brazil. RP Glahn, DC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Mail Code 7792,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM glahn@uthscsa.edu RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 FU NCRR NIH HHS [M01 RR 01346]; NIMH NIH HHS [MH 01736, MH 068662] NR 43 TC 46 Z9 48 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD DEC PY 2005 VL 7 IS 6 BP 546 EP 554 DI 10.1111/j.1399-5618.2005.00267.x PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 991MO UT WOS:000233818300008 PM 16403180 ER PT J AU Lee, MS Shah, AP Aragon, J Jamali, A Dohad, S Kar, S Makkar, RR AF Lee, MS Shah, AP Aragon, J Jamali, A Dohad, S Kar, S Makkar, RR TI Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE drug-eluting stent; percutaneous coronary intervention; saphenous vein graft ID ANGIOGRAPHIC FOLLOW-UP; CORONARY-ARTERY; PERCUTANEOUS TREATMENT; REGISTRY EXPERIENCE; BYPASS-SURGERY; INTERVENTION; IMPLANTATION; REOPERATION; PREDICTORS; RESTENOSIS AB This study compared the outcomes of percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) with drug-eluting stents (DES) with bare metal stents (BMS). PCI of degenerated SVG is associated with worse outcomes and high incidence of in-stent restenosis compared with PCI of native coronary arteries. There is a paucity of data on the outcomes of PCI of SVG with DES. Data from 223 consecutive patients who underwent PCI of SVG were imputed into a dedicated clinical database. We assessed the clinical outcomes at a mean follow-up of 9.1 +/- 2.1 months. A total of 139 patients underwent PCI of SVG with DES and 84 patients with BMS. The mean age of the SVG was 7.6 +/- 3.8 years in the DES group and 7.7 +/- 2.8 years in the BMS group (P = 0.38). Procedural success was achieved in all patients except for one patient in the BMS group who underwent emergent coronary artery bypass graft surgery for SVG dissection. There were no other in-hospital cardiac events in both groups. There was one cardiac death in the DES group and three deaths in the BMS group (P = 0.03). When compared to the BMS, PCI of SVG with DES was associated with a lower incidence of myocardial infarction (4.3% vs. 20.2%; P = 0.04) and target vessel revascularization (10.1% vs. 36.9%; P = 0.035). When compared with BMS, PCI of SVG with DES was associated with a lower incidence of death, myocardial infarction, and target vessel revascularization. (c) 2005 Wiley-Liss, Inc. C1 Cedars Sinai Med Ctr, Cardiovasc Intervent Ctr, Sch Med, Los Angeles, CA 90048 USA. W Los Angeles Vet Adm Hosp, Los Angeles, CA USA. RP Makkar, RR (reprint author), Cedars Sinai Med Ctr, Cardiovasc Intervent Ctr, Sch Med, 8631 W 3rd St,Room 415E, Los Angeles, CA 90048 USA. EM raj.makar@cshs.org NR 27 TC 59 Z9 65 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD DEC PY 2005 VL 66 IS 4 BP 507 EP 511 DI 10.1002/ccd.20498 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 991GJ UT WOS:000233800100009 PM 16270361 ER PT J AU Littler, CM Wehling, CA Fagan, KA Messing, RO Dempsey, EC AF Littler, CM Wehling, CA Fagan, KA Messing, RO Dempsey, EC TI Divergent contractile and structural responses of the murine protein kinase C-epsilon null pulmonary circulation to chronic hypoxia SO CHEST LA English DT Article; Proceedings Paper CT 47th Annual Thomas L Petty Aspen Lung Conference CY JUN 09-12, 2004 CL Given Inst Pathobiol, Aspen, CO HO Given Inst Pathobiol C1 Univ Colorado, Hlth Sci Ctr, Cardiovascular Pulm Res Lab, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA USA. RP Littler, CM (reprint author), Univ Colorado, Hlth Sci Ctr, Cardiovascular Pulm Res Lab, Box B133,4200 E 9th Ave, Denver, CO 80262 USA. EM cassana.littler@uchsc.edu RI Messing, Robert/D-3642-2015 OI Messing, Robert/0000-0002-5345-4431 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2005 VL 128 IS 6 SU S BP 620S EP 621S DI 10.1378/chest.128.6_suppl.620S PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 999EK UT WOS:000234371400059 PM 16373877 ER PT J AU Cohen, EEW Kane, MA List, MA Brockstein, BE Mehrotra, B Huo, DZ Mauer, AM Pierce, C Dekker, A Vokes, EE AF Cohen, EEW Kane, MA List, MA Brockstein, BE Mehrotra, B Huo, DZ Mauer, AM Pierce, C Dekker, A Vokes, EE TI Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck SO CLINICAL CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; LUNG-CANCER; ZD1839 IRESSA; SOLID TUMORS; POLYMORPHISM; MUTATIONS; ERLOTINIB; THERAPY; GENE AB Purpose: An objective response rate of 11% was reported in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with 500 mg daily gefitinib although the recommended dose in lung cancer is 250 mg. This study evaluated the efficacy and toxicity of 250 mg daily gefitinib in patients with recurrent and/or metastatic SCCHN. Experimental Design: Phase II trial with objective response rate as the primary end point. Measurements of quality of life and levels of Serum vascular endothelial growth factor and transforming growth factor-alpha were assessed before and during therapy. Results: In 70 patients, 1 (1.4%) partial response was observed. Median progression-free survival and overall survival were 1.8 and 5.5 months, respectively. Quality of life scores improved transiently during the first weeks of therapy before returning to baseline. Median vascular endothelial growth factor and transforming growth factor-alpha levels were above the normal range but were not predictive of outcome. Four patients experienced grade 3 drug-related adverse events. Rash of any grade was observed in 64% of subjects. Correlation between disease control (partial response + stable disease), progression-free survival, and overall survival and grade of cutaneous toxicity was observed (P = 0.001, 0.001, and 0.008 respectively). Conclusions: Gefitinib monotherapy at 250 mg in recurrent and/or metastatic SCCHN seems to have less activity than was previously observed for 500 mg daily. A dose-response relationship may exist for this agent in SCCHN and grade of cutaneous toxicity attributable to gefitinib is a clinical predictor of better outcome. C1 Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA. Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA. Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA. Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Northwestern Univ, Feinberg Sch Med, Evanston Northwestern Healthcare, Evanston, IL USA. Long Isl Jewish Med Ctr, Div Hematol & Oncol, New Hyde Pk, NY 11042 USA. RP Cohen, EEW (reprint author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC2115, Chicago, IL 60637 USA. EM ecohen@medicine.bsd.uchicago.edu OI Cohen, Ezra/0000-0002-9872-6242 FU NCI NIH HHS [5P30CA14599-31] NR 28 TC 144 Z9 148 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD DEC 1 PY 2005 VL 11 IS 23 BP 8418 EP 8424 DI 10.1158/1078-0432.CCR-05-1247 PG 7 WC Oncology SC Oncology GA 989VF UT WOS:000233701300028 PM 16322304 ER PT J AU Fung, HB Doan, TL AF Fung, HB Doan, TL TI Tinidazole: A nitroimidazole antiprotozoal agent SO CLINICAL THERAPEUTICS LA English DT Review DE tinidazole; trichomomasis; glardiasis; intestinal ameblasis; amebic liver abscess ID HELICOBACTER-PYLORI INFECTION; RANITIDINE BISMUTH CITRATE; SINGLE-DOSE TINIDAZOLE; RESISTANT TRICHOMONAS-VAGINALIS; INTESTINAL AMEBIASIS; TRIPLE THERAPY; GARDNERELLA-VAGINALIS; ANAEROBIC INFECTIONS; ERADICATION REGIMENS; ANTIMICROBIAL AGENTS AB Background: Tinidazole, a structural analogue of metronidazole, is an antiprotozoal agent that has been widely used in Europe and developing countries for > 2 decades with established efficacy and acceptable tolerability. It was recently approved by the US Food and Drug Administration for the treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver abscess. Objective: This article reviews the pharmacologic and pharmacokinetic properties and clinical usefulness of tinidazole. Methods: Relevant information was identified through a search of MEDLINE (1966-August 2005), Iowa Drug Information Service (1966-August 2005), and International Pharmaceutical Abstracts (1970-August 2005) using the terms tinidazole, Fasigyn, and nitroimidazole. Results: In vitro, tinidazole exhibits activity against pathogenic protozoa (eg, Trichomonas vaginalis, Entamoeba histolytica, Giardia duodenalis), a wide range of clinically significant anaerobic bacteria (eg, Bacteroides fragilis, Clostridium difficile), and the microaerophilic bacterium Helicobacter pylori. In susceptible protozoal and bacterial cells, tinidazole is reduced to cytotoxic intermediates that covalently bind to DNA, causing irreversible damage. In human adults, tinidazole had a bioavailability of 100% and a V-d of 50.7 L, was minimally bound to plasma protein (12%), had a plasma elimination t(1/2) of 12.3 hours, and was eliminated primarily by hepatic metabolism (similar to 63%). Dose adjustment does not appear to be necessary on the basis of race, sex, or renal function. No data were found on the disposition of tinidazole in patients with hepatic insufficiency; therefore, use of tinidazole in patients with severe hepatic impairment (Child-Pugh class C) is not recommended. Clinical cure rates in patients with trichomoniasis, giardiasis, amebiasis, and amebic liver abscess were generally > 90%. In comparative trials, tinidazole was as effective as metronidazole in the treatment of trichomonasis and was significantly more effective than metronidazole in the treatment of giardiasis (P < 0.05) and amebiasis (P < 0.05). The most commonly reported (> 1%) adverse effects included bitter taste, nausea, abdominal discomfort, anorexia, vomiting, and fatigue. The recommended dosage of tinidazole is a single dose of 2 g for trichomoniasis and giardiasis, and 2 g/d for 3 to 5 days for amebiasis. Conclusions: Tinidazole appears to be a promising agent for the treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver abscess. Clinical studies are needed to evaluate the use of tinidazole against anaerobic bacteria and H pylori. C1 James J Peters Vet Affairs Med Ctr, Med Surg Patient Care Ctr, Bronx, NY 10468 USA. Long Isl Jewish Med Ctr, Dept Pharm, New Hyde Pk, NY 11042 USA. RP Fung, HB (reprint author), James J Peters Vet Affairs Med Ctr, Med Surg Patient Care Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM horatio.fung@med.va.gov NR 85 TC 53 Z9 58 U1 0 U2 7 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD DEC PY 2005 VL 27 IS 12 BP 1859 EP 1884 DI 10.1016/j.clinthera.2005.12.012 PG 26 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 003SP UT WOS:000234702200001 PM 16507373 ER PT J AU Mendez, MF Anderson, E Shapira, JS AF Mendez, MF Anderson, E Shapira, JS TI An investigation of moral judgement in frontotemporal dementia SO COGNITIVE AND BEHAVIORAL NEUROLOGY LA English DT Article DE frontotemporal dementia; neurobehavior; morality; empathy ID FRONTAL-LOBE DEGENERATION; NON-ALZHEIMER TYPE; ACQUIRED SOCIOPATHY; PREFRONTAL CORTEX; CLINICAL PICTURE; WORK GROUP; DISEASE; DIAGNOSIS; DAMAGE; BASES AB Objective: To investigate the basis of disturbed moral judgment in patients with frontotemporal dementia (FTD). Background: FTD is characterized by difficulty in modulating social behavior. Patients lack social propriety and may perform sociopathic acts. In addition, FTD patients often lack empathy for others. These findings suggest alterations in the nature of morality in patients with FTD. Method: We administered an inventory of moral knowledge and two moral dilemmas to 26 patients with the frontal variant of FTD, 26 patients with Alzheimer disease (AD), and 26 normal control subjects. The FTD patients met Consensus Criteria for FTD and had corroborative frontal abnormalities on functional neuroimaging. The FTD and AD patients were comparably impaired on dementia measures. Results: All these groups showed the retention of knowledge for moral behavior and the ability to make "impersonal" moral judgments. In contrast, the FTD patients were impaired in their ability to make immediate, emotionally based moral judgments compared with the patients with AD and the normal control subjects. Conclusions: These findings are consistent with an attenuation of the automatic emotional identification with others that is part of the innate moral sense. Such a disturbance may result from neurodegenerative disease affecting the ventromedial frontal cortex. C1 VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Hampshire Coll, Amherst, MA 01002 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu NR 37 TC 140 Z9 144 U1 6 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1543-3633 J9 COGN BEHAV NEUROL JI Cogn. Behav. Neurol. PD DEC PY 2005 VL 18 IS 4 BP 193 EP 197 DI 10.1097/01.wnn.0000191292.17964.bb PG 5 WC Behavioral Sciences; Clinical Neurology SC Behavioral Sciences; Neurosciences & Neurology GA 994VS UT WOS:000234059900002 PM 16340391 ER PT J AU Hickman, DL Burkhart-Kasch, S Phillips, TJ AF Hickman, DL Burkhart-Kasch, S Phillips, TJ TI The effect of fostering on the genetic expression of locomotor sensitivity to alcohol SO COMPARATIVE MEDICINE LA English DT Article ID MOUSE HEPATITIS-VIRUS; EMBRYO-TRANSFER; NATURAL PATHOGENS; MATERNAL-CARE; MICE; ETHANOL; BEHAVIOR; LINES; REDERIVATION; TRANSMISSION AB Steps were taken to eradicate endemic mouse coronavirus from a colony that was part of a behavioral project characterizing the genetics of alcohol sensitivity. This behavioral study was conducted to determine whether changing the uterine or rearing environment (as is integral to common rederivation methods) would have a significant effect on the expression of the behavioral traits in question. Selected breeding pairs of the affected lines were divided into four treatment groups: 1) transfer of embryos to pseudopregnant B6D2F1 female mice, 2) fostering offspring to B6D2F1 dams, 3) fostering offspring to a different dam of the same line, and 4) offspring raised by the birth dam. Embryo transfers were successful only in one affected line. At approximately 50 days of age, the offspring were tested for locomotor behavior after intraperitoneal. administration of ethanol or normal saline. There were no statistically significant effects of embryo transfer on the ethanol phenotype (ethanol-induced locomotor depression). Fostering significantly reduced the stimulant response to ethanol of only one mouse line selectively bred for high sensitivity to ethanol-induced stimulation, although the stimulant response of the fostered groups was still quite robust. Overall, the results of this study showed that eradication efforts involving fostering of offspring have a modest impact on the stimulant response to ethanol, but there were insufficient data to draw conclusions regarding the use of embryo transfer. C1 Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. Oregon Hlth Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Hickman, DL (reprint author), Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. RI Hickman, Debra/D-3289-2009 FU NIAAA NIH HHS [P60 AA010760] NR 30 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1532-0820 J9 COMPARATIVE MED JI Comparative Med. PD DEC PY 2005 VL 55 IS 6 BP 498 EP 502 PG 5 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 002CR UT WOS:000234589500002 PM 16422144 ER PT J AU Palevsky, PM Baldwin, I Davenport, A Goldstein, S Paganini, E AF Palevsky, PM Baldwin, I Davenport, A Goldstein, S Paganini, E TI Renal replacement therapy and the kidney: minimizing the impact of renal replacement therapy on recovery of acute renal failure SO CURRENT OPINION IN CRITICAL CARE LA English DT Review DE acute renal failure; continuous renal replacement therapy; hemodialysis ID CRITICALLY-ILL PATIENTS; INTENSIVE-CARE; ANAPHYLACTOID REACTIONS; REQUIRING DIALYSIS; ROLLER-PUMPS; HEMODIALYSIS; MEMBRANES; INTERMITTENT; TRIAL; BIOCOMPATIBILITY AB Purpose of review Although renal replacement therapy is the mainstay of supportive care in patients with severe acute renal failure, performance can have untoward effects that contribute to the prolongation of renal failure or impede the ultimate recovery of renal function, In this review, we categorize the major complications associated with renal replacement therapy and assess their impact on recovery of renal function. Recent findings The major mechanisms by which renal replacement therapy is postulated to delay renal recovery include treatment-associated hemodynamic instability, vascular catheter-related bacteremia and sepsis, and cytokine activation by bioincompatible membranes. Clinical data regarding the role of dialysis catheter infections in delay of renal recovery are lacking. The data regarding the role of membrane biocompatibility and the modality and dose of renal replacement therapy are limited and conflicting. Summary Clinical recommendations must be limited to the broad admonishment that complications during renal replacement therapy, including hemodynamic instability and catheter-related bacteremia, be minimized by using best clinical practices, while recognizing that the impact of specific practices on recovery of renal function have not been evaluated. The data do not support recommendations regarding utilization of specific membranes or the modality or dose of renal replacement therapy on the basis of their impact on recovery of renal function. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. Austin Hosp, Heidelberg, Vic 3084, Australia. Royal Free Hosp, London NW3 2QG, England. Univ Coll Med Sch, London, England. Baylor Coll Med, Houston, TX 77030 USA. Texas Childrens Hosp, Houston, TX 77030 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Room 7E123 111F-U,Univ Dr Div, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 40 TC 34 Z9 36 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1070-5295 J9 CURR OPIN CRIT CARE JI Curr. Opin. Crit. Care PD DEC PY 2005 VL 11 IS 6 BP 548 EP 554 DI 10.1097/01.ccx.0000179936.21895.a3 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 987HC UT WOS:000233508000006 PM 16292058 ER PT J AU Brooks-Worrell, B Goel, A Chin, H Palmer, J AF Brooks-Worrell, B Goel, A Chin, H Palmer, J TI Metabolic and immunological comparisons between autoimmune and nonautoimmune diabetes SO DIABETES LA English DT Meeting Abstract CT 6th Servier-IGIS Symposium CY MAR 10-13, 2005 CL St Jean Cap Ferrat, FRANCE C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM bbrooks@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 2005 VL 54 SU 2 MA 01 BP S159 EP S159 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 990EZ UT WOS:000233727300023 ER PT J AU Brown, AF Gregg, EW Stevens, MR Karter, A Weinberger, M Safford, MM Gary, TL Caputo, DA Waitzfelder, B Kim, C Beckles, GL AF Brown, AF Gregg, EW Stevens, MR Karter, A Weinberger, M Safford, MM Gary, TL Caputo, DA Waitzfelder, B Kim, C Beckles, GL TI Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research Into Action for Diabetes (TRIAD) study SO DIABETES CARE LA English DT Article ID RACIAL-DIFFERENCES; GLYCEMIC CONTROL; RACIAL/ETHNIC DIFFERENCES; AFRICAN-AMERICANS; US ADULTS; POPULATION; DISPARITIES; MORTALITY; RETINOPATHY; HEALTH AB OBJECTIVE - To examine racial/ethnic and socioeconomic variation in diabetes care in managed-care settings. RESEARCH DESIGN AND METHODS - We studied 7,456 adults enrolled in health plans participating in the Translating Research Into Action for Diabetes study, a six-center cohort study of diabetes in managed care. Cross-sectional analyses using hierarchical regression models assessed processes of care (HbA(1C) [A1C], lipid, and proteinuria assessment; foot and dilated eye examinations; use or advice to use aspirin-, and influenza vaccination) and intermediate health outcomes (A1C, LDL, and blood pressure control). RESULTS - Most quality indicators and intermediate outcomes were comparable across race/ethnicity and socioeconomic position (SEP). Latinos and Asians/Pacific Islanders had similar or better processes and intermediate outcomes than whites with the exception of slightly higher A1C levels. Compared with whites, African Americans had lower rates of A1C and LDL measurement and influenza vaccination, higher rates of foot and dilated eye examinations, and the poorest blood pressure and lipid control. The main SEP difference was lower rates of dilated eye examinations among poorer and less educated individuals. In almost all instances, racial/ethnic minorities or low SEP participants with poor glycemic, blood pressure, and lipid control received similar or more appropriate intensification of therapy relative to whites or those with higher SEP. CONCLUSIONS - In these managed-care settings, minority race/ethnicity was not consistently associated With worse processes or outcomes, and not all differences favored whites. The only notable SEP disparity was in rates of dilated eye examinations. Social disparities in health may be reduced in managed-care settings. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Kaiser Permanente, Div Res, Oakland, CA USA. Univ N Carolina, Dept Hlth Policy & Adm, Chapel Hill, NC USA. Durham VAMC, Ctr Hlth Serv Res Primary Care, Durham, NC USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. Univ Alabama, Dept Prevent Med, Birmingham, AL USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. Univ Med & Dent New Jersey, New Brunswick, NJ USA. Pacific Hlth Res Inst, Honolulu, HI USA. Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Obstet Gynecol, Ann Arbor, MI 48109 USA. RP Brown, AF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. EM abrown@mednet.ucla.edu FU NIA NIH HHS [AG 02004] NR 44 TC 114 Z9 114 U1 1 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2005 VL 28 IS 12 BP 2864 EP 2870 DI 10.2337/diacare.28.12.2864 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 988HJ UT WOS:000233583500008 PM 16306546 ER PT J AU McGory, ML Maggard, MA Kang, HJ O'Connell, JB Ko, CY AF McGory, ML Maggard, MA Kang, HJ O'Connell, JB Ko, CY TI Malignancies of the appendix: Beyond case series reports SO DISEASES OF THE COLON & RECTUM LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Society-of-Colon-and-Rectal-Surgeons CY APR 30-MAY 05, 2005 CL Philadelphia, PA SP Amer Soc Colon & Rectal Surg DE appendiceal carcinoma; carcinoid; noncarcinoid; outcomes; surveillance; epidemiology and end results (SEER) ID CARCINOID-TUMORS; RIGHT HEMICOLECTOMY; PERITONEAL DISSEMINATION; MANAGEMENT; SURGERY; ADENOCARCINOMA; THERAPY AB PURPOSE: A comprehensive analysis was performed for five histologic types of appendiceal tumors to compare incidence, clinicopathologic features, survival, and appropriateness of surgery. METHODS: All patients diagnosed with mucinous adenocarcinoma (n = 951), adenocarcinoma (n 646), carcinoid (n = 435), goblet (n = 369), and signet-ring cell (n = 113) in the Surveillance, Epidemiology, and End Results database (1973-2001) were analyzed. Evaluation of incidence, stage, and five-year relative survival were determined for each histology. The appropriateness of the operative procedure (i.e., appendectomy vs. colectomy) was examined by tumor type and size. RESULTS: Tumor incidence, patient demographics, survival outcomes, and appropriateness of surgery varied significantly among the different appendiceal tumor histologies. The most common appendiceal tumors were mucinous. With regard to patient demographics, carcinoids presented at an earlier mean age of 41 years and 71 percent were female (P < 0.001 for both). Overall five-year survival was highest for carcinoid (83 percent) and lowest for signet ring (18 percent). Although current guidelines specify that a right hemicolectomy (rather than an appendectomy) be performed for all noncarcinoid tumors and carcinoid tumors >2 cm, we found that 30 percent of noncarcinoids underwent appendectomv. Similarly, 28 percent of carcinoids >2 cm underwent appendectomy, which is a lesser resection than is indicated. CONCLUSIONS: This study provides a population-based analysis of epidemiology, tumor characteristics, survival, and quality of care for appendiceal carcinomas. This characterization provides a novel description of the presentation and outcomes for malignancies of the appendix and highlights that it substantial number of patients with appendiceal tumors may not be receiving appropriate surgical resection. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Hlth Sci Ctr, Los Angeles, CA 90095 USA. Daehang Hosp, Dept Surg, Seoul, South Korea. VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP McGory, ML (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Hlth Sci Ctr, 10833 Conte Ave,72-215,Box 956904, Los Angeles, CA 90095 USA. EM mmcgory@mednet.ucla.edu NR 24 TC 80 Z9 89 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-3706 J9 DIS COLON RECTUM JI Dis. Colon Rectum PD DEC PY 2005 VL 48 IS 12 BP 2264 EP 2271 DI 10.1007/s10-005-0196-4 PG 8 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 990VW UT WOS:000233772300013 PM 16258711 ER PT J AU van Dijk, G de Vries, K Nyakas, C Buwalda, B Adage, T Kuipers, F Kas, MJH Adan, RAH Wilkinson, CW Thiele, TE Scheurink, AJW AF van Dijk, G de Vries, K Nyakas, C Buwalda, B Adage, T Kuipers, F Kas, MJH Adan, RAH Wilkinson, CW Thiele, TE Scheurink, AJW TI Reduced anorexigenic efficacy of leptin, but not of the melanocortin receptor agonist melanotan-II, predicts diet-induced obesity in rats SO ENDOCRINOLOGY LA English DT Article ID CORTICOTROPIN-RELEASING HORMONE; MELANOCYTE-STIMULATING HORMONE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; FOOD-INTAKE; INSULIN SENSITIVITY; CENTRAL INFUSION; WEIGHT-LOSS; RESPONSES; NEURONS; EXPRESSION AB Leptin gains access to the central nervous system where it influences activity of neuronal networks involved in ingestive behavior, neuroendocrine activity, and metabolism. In particular, the brain melanocortin (MC) system is important in leptin signaling and maintenance of energy balance. Although leptin or MC receptor insensitivity has been proposed to be associated with obesity, the present study compared central leptin and MC receptor stimulation on some of the above-mentioned parameters and investigated whether these treatments predict proneness to diet-induced obesity (DIO) in out-bred Wistar rats. Third-cerebroventricular administration of equianorexigenic doses of leptin and of the MC agonist melanotan-II caused comparable increases in plasma ACTH and corticosterone levels and c-Fos-labeling in approximately 70% of paraventricular hypothalamic (PVN) neuronal cell bodies containing CRH. This reinforces involvement of paraventricular CRH neurons in the short-term neuroendocrine and ingestive effects of leptin and melanocortins. In the DIO prediction study, anorexigenic efficacy of melanotan-II was not correlated with any parameter linked to DIO but was highly correlated with MC in situ binding (with labeled [Nle(4),D-Phe(7)] alpha-MSH) as well as CRH immunoreactivity in the PVN of DIO rats. This suggests intricate relationships among MC signaling, the CRH system, and ingestive behavior unrelated to DIO. In the same animals, leptin's anorexigenic efficacy was not correlated with PVN MC in situ binding or CRH immunoreactivity but correlated inversely to post-DIO plasma leptin, liver weight, and abdominal adiposity, the latter being correlated to insulin resistance. Thus, differences in leptin but not MC signaling might underlie DIO, visceral obesity, and insulin resistance. C1 Ctr Biol, Dept Anim Physiol, NL-9751 NN Haren, Netherlands. Univ Groningen, Med Ctr, Dept Pediat, Ctr Liver Pediat Digest & Metab Dis, NL-9747 AG Groningen, Netherlands. Semmelweis Univ, Hungarian Acad Sci, Brain Physiol Res Grp, H-1085 Budapest, Hungary. Univ Utrecht, Med Ctr, Dept Pharmacol & Anat, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. Ctr Geriatr Res Educ & Clin, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ N Carolina, Dept Psychol, Chapel Hill, NC 27514 USA. RP van Dijk, G (reprint author), Kerklaan 30, NL-9751 NN Haren, Netherlands. EM gertjan.van.dijk@rug.nl RI Buwalda, Bauke/L-1427-2013 OI van Dijk, Gertjan/0000-0002-6565-4019 FU NIAAA NIH HHS [AA013573, AA015148, R01 AA013573, R01 AA015148] NR 66 TC 6 Z9 6 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2005 VL 146 IS 12 BP 5247 EP 5256 DI 10.1210/en.2005-0472 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 984JY UT WOS:000233301000025 PM 16166222 ER PT J AU Rodriguez, L Tu, CL Cheng, ZQ Chen, TH Bikle, D Shoback, D Chang, WH AF Rodriguez, L Tu, CL Cheng, ZQ Chen, TH Bikle, D Shoback, D Chang, WH TI Expression and functional assessment of an alternatively spliced extracellular Ca2+-sensing receptor in growth plate chondrocytes SO ENDOCRINOLOGY LA English DT Article ID CALCIUM-SENSING RECEPTOR; BOVINE PARATHYROID CELLS; VITAMIN-D-RECEPTOR; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; MINERAL ION HOMEOSTASIS; N-LINKED GLYCOSYLATION; HUMAN CA2+ RECEPTOR; SKELETAL PHENOTYPE; SURFACE EXPRESSION AB The extracellular Ca-2 - sensing receptor (CaR) plays an essential role in mineral homeostasis. Studies to generate CaR-knockout (CaR-/-) mice indicate that insertion of a neomycin cassette into exon 5 of the mouse CaR gene blocks the expression of full-length CaRs. This strategy, however, allows for the expression of alternatively spliced CaRs missing exon 5 [(Exon5(-))CaRs]. These experiments addressed whether growth plate chondrocytes (GPCs) from CaR-/- mice express (Exon5(-)) CaRs and whether these receptors activate signaling. RT- PCR and immunocytochemistry confirmed the expression of (Exon5(-)) CaR in growth plates from CaR-/- mice. In Chinese hamster ovary or human embryonic kidney-293 cells, recombinant human (Exon5(-)) CaRs failed to activate phospholipase C likely due to their inability to reach the cell surface as assessed by intact-cell ELISA and immunocytochemistry. Human (Exon5(-)) CaRs, however, trafficked normally to the cell surface when overexpressed in wild-type or CaR-/- GPCs. Immunocytochemistry of growth plate sections and cultured GPCs from CaR-/- mice showed easily detectable cell-membrane expression of endogenous CaRs (presumably (Exon5(-)) CaRs), suggesting that trafficking of this receptor form to the membrane can occur in GPCs. In GPCs from CaR-/- mice, high extracellular [Ca2+] ([Ca2+](e)) increased inositol phosphate production with a potency comparable with that of wild-type GPCs. Raising [Ca2+](e) also promoted the differentiation of CaR-/- GPCs as indicated by changes in proteoglycan accumulation, mineral deposition, and matrix gene expression. Taken together, our data support the idea that expression of (Exon5(-)) CaRs may compensate for the loss of full-length CaRs and be responsible for sensing changes in [Ca2+](e) in GPCs in CaR-/- mice. C1 Univ Calif San Francisco, Endocrine Res Unit, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs Med Ctr,Dept Med, San Francisco, CA 94121 USA. RP Chang, WH (reprint author), Univ Calif San Francisco, Endocrine Res Unit, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs Med Ctr,Dept Med, 111N,4150 Clement St, San Francisco, CA 94121 USA. EM bambam@itsa.ucsf.edu FU NIA NIH HHS [AG-21353]; NIAMS NIH HHS [AR-050662] NR 53 TC 51 Z9 53 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2005 VL 146 IS 12 BP 5294 EP 5303 DI 10.1210/en.2005-0256 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 984JY UT WOS:000233301000030 PM 16166224 ER PT J AU Ao, Y Toy, N Song, MK Go, VLW Yang, H AF Ao, Y Toy, N Song, MK Go, VLW Yang, H TI Altered glucose and insulin responses to brain medullary thyrotropin-releasing hormone (TRH)-induced autonomic activation in type 2 diabetic Goto-Kakizaki rats SO ENDOCRINOLOGY LA English DT Article ID DORSAL VAGAL COMPLEX; ISLET BLOOD-FLOW; RAPHE PALLIDUS NEURONS; GASTRIC-ACID-SECRETION; NERVOUS-SYSTEM; GK-RAT; PHYSIOPHARMACOLOGICAL INVESTIGATIONS; STIMULATED HYPERGLYCEMIA; URETHANE ANESTHESIA; INTRACISTERNAL TRH AB Insulin secretion is impaired in type 2 diabetes (T2D). The insulin and glucose responses to central autonomic activation induced by excitation of brain medullary TRH receptors were studied in T2D Goto-Kakizaki (GK) rats. Blood glucose levels in normally fed, pentobarbital-anesthetized GK and nondiabetic Wistar rats were 193 and 119 mg/100 ml in males and 214 and 131 mg/100 ml in females. Intracisternal injection (ic) of the stable TRH analog RX 77368 (10 ng) induced significantly higher insulin response in both genders of overnight-fasted GK rats compared with Wistar rats and slightly increased blood glucose in female Wistar rats but significantly decreased it from 193 to 145 mg/100 ml in female GK rats. RX 77368 (50 ng) ic induced markedly greater glucose and relatively weaker insulin responses in male GK rats than Wistar rats. Bilateral vagotomy blocked ic RX 77368-induced insulin secretion, whereas adrenalectomy abolished its hyperglycemic effect. In adrenalectomized male GK but not Wistar rats, ic RX 77368 (50 ng) dramatically increased serum insulin levels by 6.5-fold and decreased blood glucose levels from 154 to 98 mg/100 ml; these changes were prevented by vagotomy. GK rats had higher basal pancreatic insulin II mRNA levels but a lower response to ic RX 77368 (50 ng) compared with Wistar rats. These results indicate that central-vagal activation-induced insulin secretion is susceptible in T2D GK rats. However, the dominant sympathetic-adrenal response to medullary TRH plays a suppressing role on vagal-mediated insulin secretion. This unbalanced vago-sympathetic activation by medullary TRH may contribute to the impaired insulin secretion in T2D. C1 Univ Calif Los Angeles, Digest Dis Res Ctr, Ctr Ulcer Res & Educ, Dept Med,Div Digest Dis & Brain Res Inst, Los Angeles, CA 90073 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA. RP Yang, H (reprint author), Univ Calif Los Angeles, Digest Dis Res Ctr, Ctr Ulcer Res & Educ, Dept Med,Div Digest Dis & Brain Res Inst, Vet Affairs Greater Los Angeles Healthcare Syst B, Los Angeles, CA 90073 USA. EM hoyang@ucla.edu FU NIDDK NIH HHS [DK-41301] NR 57 TC 8 Z9 8 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2005 VL 146 IS 12 BP 5425 EP 5432 DI 10.1210/en.2005-0553 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 984JY UT WOS:000233301000045 PM 16179412 ER PT J AU Handforth, A DeLorey, TM Homanics, GE Olsen, RW AF Handforth, A DeLorey, TM Homanics, GE Olsen, RW TI Pharmacologic evidence for abnormal thalamocortical functioning in GABA(A) receptor beta 3 subunit-deficient mice, a model of Angelman syndrome SO EPILEPSIA LA English DT Article DE Angelman; GABA receptor; ethosuximide; thalamus; electroencephalogram; seizures ID RECIPROCAL INHIBITORY CONNECTIONS; GENERALIZED ABSENCE SEIZURES; IN-VITRO; SYNCHRONIZED OSCILLATIONS; GAMMA-HYDROXYBUTYRATE; INDUCED CONVULSIONS; BETA(3) SUBUNIT; EPILEPSY; NUCLEUS; THALAMUS AB Purpose:gamma-Aminobutyric acid receptor (GABA(A)r) subunit beta 3-deficient mice model Angelman syndrome by displaying impaired learning, abnormal EEG with interictal spikes and slowing, myoclonus, and convulsions. The beta 3-subunit deficiency causes a failure of intrathalamic reticular nucleus inhibition, leading to abnormally synchronized thalamocortical oscillations. We postulated that this pathophysiology underlies the abnormal cortical EEG and triggers interictal spikes and seizures, but extrathalamic regions also contribute to interictal spikes and seizures, so that the EEG slowing should reveal an absence-like response profile, whereas spikes and seizures have dual responsiveness to absence and partial-seizure drugs. Methods: Recording electrodes were implanted over the parietal cortices of wild-type, heterozygotes, and homozygous null mice. In each experiment, EEG was recorded for 45 min, either drug or vehicle administered, and EEG recorded for another 3 h. Each EEG was scored for slow-wave activity, interictal spikes, and seizures by a reader blinded to treatments. Results: Interictal spiking and percentage of time in EEG slowing in heterozygotes were increased by the proabsence drug baclofen (GABA(B)-receptor agonist), whereas CGP 35348 (GABA(B)-receptor antagonist) had the opposite effect. The antiabsence drug ethosuximide markedly suppressed EEG slowing and interictal spiking in heterozygote and null mice. Broad-spectrum clonazepam and valproate were more effective on interictal spiking than on EEG slowing, and fosphenytoin suppressed only interictal spiking. Conclusions: The results suggest that this model of Angelman syndrome, although not expressing typical absence seizures, is characterized by hypersynchronous thalamocortical oscillations that possess absence-like pharmacologic responsiveness and promote EEG slowing, interictal spikes, and convulsive seizures. C1 VA Greater Los Angeles Healthcare Syst, Dept Neurol W127, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA. Mol Res Inst, Mountain View, CA USA. RP Handforth, A (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol W127, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM charles.handforth@med.va.gov FU NIAAA NIH HHS [AA10422]; NIGMS NIH HHS [GM52035]; NINDS NIH HHS [NS28772, NS35985] NR 49 TC 12 Z9 12 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD DEC PY 2005 VL 46 IS 12 BP 1860 EP 1870 DI 10.1111/j.1528-1167.2005.00287.x PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 988CI UT WOS:000233568600001 PM 16393151 ER PT J AU Fujikawa, DG AF Fujikawa, DG TI Prolonged seizures and cellular injury: Understanding the connection SO EPILEPSY & BEHAVIOR LA English DT Article; Proceedings Paper CT 58th Annual Meeting of the American-Epilepsy-Society CY DEC 03-07, 2004 CL New Orleans, LA SP Amer Epilepsy Soc DE seizures; status epilepticus; cellular injury; neuroprotection; excitotoxicity ID APOPTOSIS-INDUCING FACTOR; INDUCED NEURONAL DEATH; EPILEPTIC BRAIN-DAMAGE; SUSTAINED ELECTRICAL-STIMULATION; INTERNUCLEOSOMAL DNA CLEAVAGE; NMDA RECEPTOR ANTAGONIST; CASPASE-ACTIVATED DNASE; KAINIC ACID; RAT-BRAIN; CEREBRAL-ISCHEMIA AB Status epilepticus (SE)-induced neuronal death is morphologically necrotic and is initiated by excessive glutamate release, which activates postsynaptic N-methyl-D-aspartate (NMDA) receptors and triggers receptor-mediated calcium influx (excitotoxicity). This results in activation of intracellular proteases and neuronal nitric oxide synthase, with generation of free radicals, and damage to cellular membranes, structural proteins, and essential enzymes. Programmed cell death mechanisms, such as p53 activation, activation of cell deathpromoting Bcl-2 family members, and endonuclease-induced DNA laddering, occur in SE-induced neuronal death. Caspase-independent excitotoxic mechanisms, such as NMDA-induced calpain I activation, with activation and translocation of the cell death-promoting Bcl-2 family member Bid from cytoplasm to mitochondria, and subsequent translocation of apoptosis-inducing factor and endonuclease G to nuclei (which cause large-scale and internucleosomal DNA cleavage, respectively), may be triggered by SE. Poly(ADP-ribose) polymerase-1 (PARP-1) activation and cysteinyl cathepsin and DNase II release from lysosomes may occur following SE as well, but these events await future investigation. In the future, rational combinations of central nervous system-penetrable neuroprotective agents, based on our knowledge of excitotoxic mechanisms, may be useful in refractory human SE. Published by Elsevier Inc. C1 VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, Sepulveda, CA USA. Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, Sepulveda, CA USA. EM dfujikaw@ucla.edu NR 70 TC 110 Z9 112 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD DEC PY 2005 VL 7 SU 3 BP S3 EP S11 DI 10.1016/j.yebeh.2005.08.003 PG 9 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 995XK UT WOS:000234138000002 PM 16278099 ER PT J AU Restrepo, MI Anzueto, A AF Restrepo, MI Anzueto, A TI Guidelines for the diagnoses and treatment of adult lower respiratory tract infections: a true ''European cooperative effort'' SO EUROPEAN RESPIRATORY JOURNAL LA English DT Editorial Material ID COMMUNITY-ACQUIRED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; LENGTH-OF-STAY; ANTIMICROBIAL THERAPY; ANTIBIOTIC-THERAPY; CONTROLLED-TRIAL; MANAGEMENT; MORTALITY; PATHWAY; CARE C1 Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, S Texas Vet Hlth Care Syst Audie L Murphy Div San, San Antonio, TX 78284 USA. S Texas Vet hlth Care Syst, Audie L Murphy VA Hosp, VERDICT, San Antonio, TX USA. RP Anzueto, A (reprint author), Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, S Texas Vet Hlth Care Syst Audie L Murphy Div San, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM anzueto@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 NR 28 TC 4 Z9 5 U1 0 U2 1 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD DEC PY 2005 VL 26 IS 6 BP 979 EP 981 DI 10.1183/09031936.05.00102105 PG 3 WC Respiratory System SC Respiratory System GA 996VK UT WOS:000234203100001 PM 16319322 ER PT J AU Chiappelli, F Prolo, P Cajulis, OS AF Chiappelli, F Prolo, P Cajulis, OS TI Evidence-based research in complementary and alternative medicine I: History SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE evidence-based research; complementary and alternative medicine; mind-body interactions AB Contemporary Western medicine has witnessed a fragmentation of our conceptualization of the medical endeavor into 'traditional medicine' and 'non-traditional medicine'. The former is meant to refer to the Western medical tradition, the latter encompasses both 'complementary' and 'alternative' medical practices. Complementary medicine complements conventional medical treatments, and alternative modes of medical interventions are meant to replace traditional Western medicine. Evidence-based research must be directed at establishing the best available evidence in complementary and alternative medicine. This paper is the first of a set of four 'lectures' that reviews the process of evidence-based research, and discusses its implications and applications for the early decades of the 21st century. The purpose of this paper is to introduce the series by examining some of the historical and philosophical foundations of this research endeavor. C1 Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Psychoneuroimmunol Grp Inc, Los Angeles, CA 90073 USA. Dent Grp Sherman Oaks, Los Angeles, CA USA. RP Chiappelli, F (reprint author), Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, CHS 63-090, Los Angeles, CA 90095 USA. EM chiappelli@dent.ucla.edu NR 15 TC 26 Z9 30 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PD DEC PY 2005 VL 2 IS 4 BP 453 EP 458 DI 10.1093/ecam/neh106 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 988XT UT WOS:000233638200004 PM 16322801 ER PT J AU Cornia, PB Anawalt, BD AF Cornia, PB Anawalt, BD TI Male hormonal contraceptives: a potentially patentable and profitable product SO EXPERT OPINION ON THERAPEUTIC PATENTS LA English DT Review DE androgen; gonadotropin-releasing hormone analogue; gonadotropins; male contraception; progestogen; spermatogenesis; testosterone ID EFFECTIVELY SUPPRESSES SPERMATOGENESIS; TESTOSTERONE-DEPENDENT RESTORATION; DEPOT-MEDROXYPROGESTERONE ACETATE; NORMAL MEN; CYPROTERONE-ACETATE; CLINICAL-TRIAL; 5-ALPHA-REDUCTASE INHIBITOR; ETONOGESTREL IMPLANTS; NORETHISTERONE ENANTHATE; INJECTABLE TESTOSTERONE AB Although women have traditionally shouldered the responsibility of contraception, up to one-third of couples worldwide employ a male form of contraception (e.g., vasectomy or condoms). Vasectomy should be considered irreversible and long-term use of condoms is associated with a relatively high failure rate (pregnancy). Because many women are unable to use hormonal contraception and men want more contraceptive options, there is a need for a safe, effective, reversible and well-tolerated male hormonal contraceptive agent. Two large multicentre, multinational trials sponsored by the World Health Organization in the 1990s showed that high-dosage exogenous testosterone provided contraceptive efficacy similar to currently available female oral contraceptives. However, the supraphysiological dosages of testosterone used resulted in androgen-related adverse effects such as weight gain and suppression of high-density lipoprotein cholesterol levels. Subsequent efforts have been directed at combining testosterone with other agents, such as progestogens or gonaclotropin-releasing hormone analogues, to decrease the dosage of testosterone (and thus androgen-related side effects) whilst achieving uniform azoospermia. In this article, the latest developments in male hormonal contraception supporting the feasibility of such an agent will be reviewed and suggestions for future directions of research and development will be offered. C1 Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98108 USA. RP Cornia, PB (reprint author), Univ Washington, VA Puget Sound Healthcare Syst, 1660 S Columbian Way,S-111-GIMC, Seattle, WA 98108 USA. EM paul.cornia@med.va.gov NR 73 TC 1 Z9 1 U1 0 U2 5 PU ASHLEY PUBLICATIONS LTD PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1354-3776 J9 EXPERT OPIN THER PAT JI Expert Opin. Ther. Patents PD DEC PY 2005 VL 15 IS 12 BP 1727 EP 1737 DI 10.1517/13543776.15.12.1727 PG 11 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 000NJ UT WOS:000234468600005 ER PT J AU Taha, TA Kitatani, K El-Alwani, M Bielawski, J Hannun, YA Obeid, LM AF Taha, TA Kitatani, K El-Alwani, M Bielawski, J Hannun, YA Obeid, LM TI Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis SO FASEB JOURNAL LA English DT Article DE ceramide; Bax; mitochondria ID NECROSIS-FACTOR-ALPHA; PROSTATE-CANCER CELLS; SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE; SIGNAL-TRANSDUCTION; INHIBITS APOPTOSIS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; CYTOCHROME-C; CA2+ SIGNALS; TNF-ALPHA AB Activation of sphingosine kinase-1 (SK1) by overexpression or agonist stimulation promotes cell proliferation, survival, and anti-apoptosis. Studies on the function of endogenous SK1 are lacking. Endogenous SK1 has been shown to be down-regulated under stress, and knockdown of the enzyme reduces the percentage of viable MCF-7 breast cancer cells (Taha, T. A. et al. 2004. J. Biol. Chem. 279, 20546- 20554). In this study, we examined the mechanisms by which SK1 loss affects the growth of cells. Knockdown of the enzyme by small interfering RNA caused cell cycle arrest and induced apoptosis. Cell death involved effector caspase activation, cytochrome c release and Bax oligomerization in the mitochondrial membrane, thus placing SK1 knockdown upstream of the mitochondrial pathway of apoptosis. SK1 knockdown also induced significant increases in ceramide levels in whole cells and in mitochondria enriched fractions of cells. Inhibition of de novo sphingolipid biosynthesis with myriocin significantly attenuated Bax oligomerization and downstream caspase activation after SK1 loss. These studies for the first time implicate endogenous SK1 as an important survival enzyme in MCF-7 cells and link the biological consequences of knocking down the enzyme to its biochemical role as a regulator of sphingolipid metabolism. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847 NR 75 TC 5 Z9 5 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD DEC PY 2005 VL 19 IS 14 BP 482 EP + DI 10.1096/fj.05-4412fje PG 24 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 999QR UT WOS:000234405500015 ER PT J AU Blackwood, CB Yuen, TJ Sangeorzan, BJ Ledoux, WR AF Blackwood, CB Yuen, TJ Sangeorzan, BJ Ledoux, WR TI The midtarsal joint locking mechanism SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE biomechanics; foot; gait AB Background. The midtarsal joint, consisting of the talonavicular and the calcaneocuboid joints, is presumed to be responsible for the foot being both flexible and rigid during different parts of the stance phase of gait. However, this mechanism has never been well quantified. This study explores the midtarsal joint locking mechanism by comparing the effect of hindfoot inversion and eversion on midfoot and forefoot mobility. Methods: Motion of the tibia, talus, calcaneus, navicular, cuboid and the first, second, and fifth metatarsals were measured in nine cadaver feet using Polhemus Fastrak (R) electromagnetic sensors (EST GmbH & Co. KG, Kaiserslautern, Germany). The talus was fixed to the tibia, and then the forefoot was maximally dorsiflexed, plantarflexed, inverted, and everted, with the hindfoot in maximal eversion and inversion, for a total of eight test positions. The range of motion of the individual bones between maximal forefoot dorsiflexion and plantarflexion and between maximal forefoot inversion and eversion was calculated for the hindfoot in maximal eversion and inversion. Results: For the range of motion from maximal dorsiflexion to maximal plantarflexion there was significantly increased movement of the first, second, and fifth metatarsals in the sagittal plane (p-value = 0.003, 0.007, and 0.002, respectively) when the calcaneus was maximally everted compared to when the calcaneus was maximally inverted. No significant differences were detected for the range of motion from forefoot inversion to eversion for the two hindfoot positions. Conclusions: This study demonstrated that motion in the forefoot is influenced by hindfoot position through the midtarsal joint. Specifically, the sagittal plane range of motion of the metatarsals is increased when the hindfoot is in valgus. C1 VA Puget Sound, Healthcare Syst, Dept Vet Affairs, RRD Ctr Excellence Limb Loss Prevent & Prosthet E, Seattle, WA 98108 USA. Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, Healthcare Syst, Dept Vet Affairs, RRD Ctr Excellence Limb Loss Prevent & Prosthet E, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 10 TC 36 Z9 37 U1 0 U2 10 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD DEC PY 2005 VL 26 IS 12 BP 1074 EP 1080 PG 7 WC Orthopedics SC Orthopedics GA 993AH UT WOS:000233924600013 PM 16390642 ER PT J AU Esrailian, E Gralnek, IM AF Esrailian, E Gralnek, IM TI Nonvariceal upper gastrointestinal bleeding: Epidemiology and diagnosis SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Review ID UPPER-GI HEMORRHAGE; PEPTIC-ULCER HEMORRHAGE; CHRONIC-RENAL-FAILURE; PORTAL HYPERTENSIVE GASTROPATHY; ENDOSCOPIC HEMOCLIP PLACEMENT; RANDOMIZED CONTROLLED-TRIAL; ANTRAL VASCULAR ECTASIA; MALLORY-WEISS-SYNDROME; VON-WILLEBRAND-FACTOR; DIEULAFOYS LESION AB Nonvariceal upper gastrointestinal bleeding remains an important cause of patient morbidity, mortality, and use of considerable health care resources. An early and accurate diagnosis is critical for guiding appropriate management and facilitating patient care. Ibis article reviews the most recent epidemiologic data on acute nonvariceal upper gastrointestinal bleeding and outlines important aspects of making the diagnosis. C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, UCLA VA Ctr Outcomes Res & Educ, Los Angeles, CA 90073 USA. RP Gralnek, IM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, UCLA VA Ctr Outcomes Res & Educ, 11301 Wilshire Blvd,CURE Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM i_gralnek@rambam.health.gov.il NR 123 TC 36 Z9 37 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD DEC PY 2005 VL 34 IS 4 BP 589 EP + DI 10.1016/j.gtc.2005.08.006 PG 18 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 994ZP UT WOS:000234070000003 PM 16303572 ER PT J AU Rowan, AJ AF Rowan, AJ TI Epilepsy in older adults - Common morbidities influence development, treatment strategies, and expected outcomes SO GERIATRICS LA English DT Article DE antiepileptic drugs (AEDs); epilepsy; seizures; elderly; geriatrics ID TONIC CLONIC SEIZURES; CARBAMAZEPINE AB Given that that the average person has one chronic illness for each decade over age 50, one would expect that patients who develop seizures in late life would have associated medical and/or neurologic conditions. Cerebrovascular disease, hypertension, heart disease, diabetes mellitus, renal disease, and dementia all relate to epilepsy. Comorbidities not only contribute to the causation and consequences of seizures, they also interfere with effective treatment and optimal functioning. Because seizures in older individuals can lead to serious consequences, safe and effective treatment is essential. Yet, antiepileptic drugs (AEDs) may cause adverse effects that may be worse in older patients when compared to younger patients. Multiple medications lead to a high probability that medically significant drug interactions may occur and must be monitored for in geriatric patients. C1 Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Osher Inst, Boston, MA 02115 USA. St Josephs Hosp, HealthE Neurovasc Inst, St Paul, MN USA. Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. RP Rowan, AJ (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. NR 13 TC 18 Z9 18 U1 0 U2 3 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD DEC PY 2005 VL 60 IS 12 BP 30 EP + PG 4 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 995CA UT WOS:000234076300016 PM 16343034 ER PT J AU Bates-Jensen, BM Simmons, SF Schnelle, JF Alessi, C AF Bates-Jensen, BM Simmons, SF Schnelle, JF Alessi, C TI Evaluating the accuracy of minimum data set bed-mobility ratings against independent performance assessments: Systematic error and directions for improvement SO GERONTOLOGIST LA English DT Article DE activities of daily living assessment; bed mobility; minimum data set accuracy; physical performance assessments ID NURSING-HOME RESIDENTS; URINARY-INCONTINENCE; REFLECT DIFFERENCES; QUALITY INDICATORS; FUNCTIONAL STATUS; CARE; HEALTH; STABILITY; STAFF AB Purpose: The Minimum Data Set (MDS) Activities of Daily Living (ADL) bed-mobility item, which rates the staff-assistance level necessary for bed movement, is used to target scheduled repositioning interventions and to identify physical function changes in nursing home residents; however, accuracy of the item is uncertain. The purpose of this study was to evaluate the accuracy of the MDS ADL bed-mobility item as completed by nursing home nurses with independent performance assessments conducted by research staff. Design and Methods: A convenience sample of 197 long-stay residents from 26 California nursing homes participating in a larger project was used in this cross-sectional study to compare independent research-staff performance assessments (using graduated assistance protocols of residents' ability to move in bed) and nursing home nurse MDS bed-mobility ratings. Participants also wore movement monitors to verify performance assessments. Results: Poor agreement existed between the nursing home nurse MDS bed-mobility ratings and the research-staff performance assessments across all assistance levels (kappa range, kappa = 0.007, p = .918 to kappa = 0.484, p < .001), with better agreement seen in totally dependent participants and with fewer elapsed days between MDS ratings and performance assessments. The odds of nursing home nurse errors (underestimating or overestimating dependency) on the MDS bed-mobility item were 2.1 times higher for participants judged independent by research staff compared with participants judged as requiring physical assistance by research staff (95% confidence interval, 1.14-4.03) when adjusted for number of days between nurse MDS ratings and research-staff performance assessments. Implications: Nursing home nurses overestimated resident dependency in bed mobility. The systematic inaccuracies in MDS bed-mobility ratings have implications for their use as a basis for targeting residents for repositioning programs and determining changes in residents' physical function. Performance assessments utilizing graduated assistance protocols are recommended as a method of improving the accuracy of MDS bed-mobility ratings. C1 Univ Calif Los Angeles, Borun Ctr Gerontol Res, Jewish Home Aging, Reseda, CA 91335 USA. Univ Calif Los Angeles, Sch Med, Borun Ctr Gerontol Res, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. RP Bates-Jensen, BM (reprint author), Univ Calif Los Angeles, Borun Ctr Gerontol Res, Jewish Home Aging, 7150 Tampa Ave, Reseda, CA 91335 USA. EM batesjen@ucla.edu NR 27 TC 10 Z9 10 U1 2 U2 4 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 2005 VL 45 IS 6 BP 731 EP 738 PG 8 WC Gerontology SC Geriatrics & Gerontology GA 989UN UT WOS:000233699500002 PM 16326654 ER PT J AU Moffett, ML Morgan, RO Ashton, CM AF Moffett, ML Morgan, RO Ashton, CM TI Strategic opportunities in the oversight of the US hospital accreditation system SO HEALTH POLICY LA English DT Article DE hospital regulation; accreditation; JCAHO; double moral hazard ID ACUTE MYOCARDIAL-INFARCTION; QUALITY; CARE AB Hospital accreditation and state certification are the means that the Centers for Medicare & Medicaid Services (CMS) employs to meet quality of care requirements for medical care reimbursement. Hospitals can choose to use either a national accrediting agency or a state certification inspection in order to receive Medicare payments. Approximately, 80% of hospitals choose the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). The purpose of this paper is to analyze and discuss improvements on the structure of the accreditation process in a Principal-Agent-Supervisor framework with a special emphasis on the oversight by the principal (CMS) of the supervisor (JCAHO). Published by Elsevier Ireland Ltd C1 Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey Vet Affairs Med Ctr 152, Houston, TX 77030 USA. RP Moffett, ML (reprint author), Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mauricem@bcm.tmc.edu; rmorgan@bcm.tmc.edu; cashton@bcm.tmc.edu RI Morgan, Robert/A-8577-2009; Moffett, Maurice/I-6664-2013 OI Moffett, Maurice/0000-0002-4536-9843 NR 19 TC 3 Z9 3 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8510 J9 HEALTH POLICY JI Health Policy PD DEC PY 2005 VL 75 IS 1 BP 109 EP 115 DI 10.1016/j.healthpol.2005.03.005 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 991WY UT WOS:000233846500010 PM 16298233 ER PT J AU Ehrlich, LA Roodman, GD AF Ehrlich, LA Roodman, GD TI The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma SO IMMUNOLOGICAL REVIEWS LA English DT Review ID NECROSIS-FACTOR-ALPHA; MARROW STROMAL CELLS; KAPPA-B LIGAND; COLONY-STIMULATING FACTOR; HUMAN BONE-MARROW; PLASMA-CELLS; OSTEOCLAST DIFFERENTIATION; MULTINUCLEATED CELLS; RECEPTOR ACTIVATOR; DENDRITIC CELLS AB The osteoclast (OCL) is the primary cell involved in the pathogenesis of Paget's disease (PD) and the destructive bone process in multiple myeloma (MM). Both of these diseases are characterized by increased numbers of OCLs actively resorbing bone, but they differ in that bone formation is greatly increased in PD and is suppressed in MM. The marrow microenvironment plays a critical role in both disease processes, through the increased expression of inflammatory cytokines that enhance osteoclastogenesis and, in the case of MM, also suppress osteoblast (OBL) activity. In addition, the OCLs in PD are intrinsically abnormal, are markedly increased in number and size, and are hyper-responsive to inflammatory cytokines and 1,25-(OH)(2)D-3. This article discusses the role of immune cells and inflammatory cytokines and chemokines in the increased OCL activity in PD and MM bone disease, as well as the potential role of interleukin-3 in the suppression of OBL activity in MM. C1 VA Pittsburth Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med Hematol Oncol, Pittsburgh, PA USA. RP Roodman, GD (reprint author), VA Pittsburth Healthcare Syst, R&D,151 U,Room 2E-113,Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 111 TC 45 Z9 45 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0105-2896 J9 IMMUNOL REV JI Immunol. Rev. PD DEC PY 2005 VL 208 BP 252 EP 266 DI 10.1111/j.0105-2896.2005.00323.x PG 15 WC Immunology SC Immunology GA 986JN UT WOS:000233446000018 PM 16313353 ER PT J AU Rasgon, NL Reynolds, MF Elman, S Saad, M Frye, MA Bauer, M Altshuler, LL AF Rasgon, NL Reynolds, MF Elman, S Saad, M Frye, MA Bauer, M Altshuler, LL TI Longitudinal evaluation of reproductive function in women treated for bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE bipolar disorder; women; menstrual abnormalities; testosterone; insulin resistance; valproate ID POLYCYSTIC-OVARY-SYNDROME; ENDOCRINE DISORDERS; INSULIN RESISTANCE; VALPROATE; EPILEPSY; DEPRESSION; OBESITY; RISK; ABNORMALITIES AB Background: We assessed reproductive endocrine and metabolic markers in women treated for bipolar disorder over a 2-year time period, controlling for valproate use. Methods: Twenty-five women ages 18-45 with bipolar disorder underwent longitudinal evaluations. Subjects completed a reproductive health questionnaire and endocrinological exam at baseline. Total and free testosterone, progesterone, LH, FSH, fasting insulin and glucose, and other hormones were measured across the menstrual cycle at baseline and at 2-year follow-up. Results: Ten subjects were currently receiving valproate as a mood stabilizing agent; of the remaining subjects, six received lithium and five received atypical antipsychotics. Of all subjects, 41.7% reported current oligomenorrhea, while 40% reported oligomenorrhea before starting medication. Rates of oligomenorrhea and clinical hyperandrogenism did not differ by medication use. Eighty percent of women had a high homeostatic model assessment of insulin resistance (HOMA-IR) at baseline; all other measures were normal. Over time, all subjects exhibited a significant decrease in luteal phase progesterone and increase in free testosterone concentrations. Valproate use was associated with an increase over time in total testosterone. Baseline values and changes in BMI were similar across groups. Limitations: Limitations include small sample size and the absence of a control group. Conclusion: We confirm our previous observations of high rates of menstrual abnormalities, hyperandrogenemia and insulin resistance in women with bipolar disorder. These results tentatively support the role of valproate in hyperandrogenemia; however, rates of oligomenorrhea and clinical hyperandrogenism did not differ between medication groups. (c) 2005 Elsevier B.V. All rights reserved. C1 Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA. Charite Univ Med Berlin, Dept Psychiat & Psychotherapy, Berlin, Germany. Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Rasgon, NL (reprint author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd, Stanford, CA 94305 USA. EM nrasgon@stanford.edu NR 27 TC 28 Z9 29 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD DEC PY 2005 VL 89 IS 1-3 BP 217 EP 225 DI 10.1016/j.jad.2005.08.002 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 998YJ UT WOS:000234355500025 PM 16171873 ER PT J AU Brau, N AF Brau, N TI Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE pegylated interferon; ribavirin; highly active antiretroviral therapy; drug interactions ID INTERFERON-ALPHA-2B PLUS RIBAVIRIN; RANDOMIZED CONTROLLED-TRIAL; HIV-INFECTED PATIENTS; VIRUS-INFECTION; MITOCHONDRIAL TOXICITY; HIV/HCV-COINFECTION; CIRRHOSIS; ALPHA AB HIV-infected patients are living longer since the introduction of highly active antiretroviral therapy. However, coinfection with the hepatitis C virus (HCV) leads to increased morbidity from liver disease and higher overall mortality. The prevalence of chronic hepatitis C among patients with HIV/AIDS ranges from 7% (sexual transmission of HIV) to > 90% (injection drug use). Uncontrolled HIV infection seems to accelerate the progression of HCV-induced liver fibrosis. Forty-eight weeks of combination therapy with pegylated interferon alpha (2a or 2b) plus ribavirin achieves a sustained viral response in coinfected individuals in up to 38% with HCV genotype 1 and up to 73% with genotypes 2 or 3. The safety profile of this treatment is similar to therapy in HCV-monoinfected patients with influenza-like symptoms, cytopenia and neuropsychiatric symptoms dominating. However, HIV/HCV-coinfected patients who also take zidovudine develop more profound anaemia than those on other HIV nucleoside analogue therapy. Didanosine and stavudine are associated with rare but serious mitochondrial toxicity, such as pancreatitis or lactic acidosis. It does not appear that the addition of ribavirin increases that risk. There is currently no evidence that in HIV/HCV coinfection one pegylated interferon product is superior to the other. Contrary to common perception, it is also unproven that HIV/HCV-coinfected patients respond less well to therapy with peginterferon alpha plus ribavirin than HCV-monoinfected patients. Given the safety and efficacy of combination therapy with peginterferon plus ribavirin and the deleterious effects of chronic hepatitis C, all HIV/HCV-coinfected patients should be evaluated for therapy. C1 Bronx Vet Affairs Med Ctr, Mt Sinai Sch Med, Infect Dis Sect, Dept Med,Div Infect Dis, Bronx, NY 10468 USA. Mt Sinai Sch Med, Div Liver Dis, Bronx, NY 10468 USA. Vet Affairs Med Ctr, Bronx, NY USA. RP Brau, N (reprint author), Bronx Vet Affairs Med Ctr, Mt Sinai Sch Med, Infect Dis Sect, Dept Med,Div Infect Dis, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM norbert.brau@med.va.gov NR 24 TC 8 Z9 8 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD DEC PY 2005 VL 56 IS 6 BP 991 EP 995 DI 10.1093/jac/dki392 PG 5 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 993XE UT WOS:000233989900001 PM 16308419 ER PT J AU Miller, VM Clarkson, TB Harman, SM Brinton, EA Cedars, M Lobo, R Manson, JE Merriam, GR Naftolin, F Santoro, N AF Miller, VM Clarkson, TB Harman, SM Brinton, EA Cedars, M Lobo, R Manson, JE Merriam, GR Naftolin, F Santoro, N TI Eu-estrogenemia - Reply SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Letter ID WOMEN; GENE C1 Mayo Clin, Coll Med, Rochester, MN 55905 USA. Wake Forest Univ, Sch Med, Comparat Med Clin Res Ctr, Winston Salem, NC 27109 USA. Kronos Longev Res Inst, Phoenix, AZ USA. Univ Utah, Metab Sect, Salt Lake City, UT USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Columbia Univ, Coll Phys & Surg, New York, NY USA. Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div Prevent Med, Boston, MA 02115 USA. Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Tacoma, WA USA. Yale Univ, Sch Med, New Haven, CT USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. RP Miller, VM (reprint author), Mayo Clin, Coll Med, Rochester, MN 55905 USA. EM miller.virginia@mayo.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD DEC PY 2005 VL 99 IS 6 BP 2471 EP 2472 PG 2 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 984QH UT WOS:000233318900080 ER PT J AU Williams, DL Goldstein, G Carpenter, PA Minshew, NJ AF Williams, DL Goldstein, G Carpenter, PA Minshew, NJ TI Verbal spatial working memory in autism SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE autism; working memory; information processing ID HIGH-FUNCTIONING AUTISM; EXECUTIVE FUNCTION; DIAGNOSTIC INTERVIEW; NEOCORTICAL SYSTEMS; INDIVIDUALS; INTACT; MIND; COMPREHENSION; DYSFUNCTION; DISORDERS AB Verbal and spatial working memory were examined in high-functioning children, adolescents, and adults with autism compared to age and cognitive-matched controls. No deficit was found in verbal working memory in the individuals with autism using an N-back letter task and standardized measures. The distinction between the N-back task and others used previously to infer a working memory deficit in autism is that this task does not involve a complex cognitive demand. Deficits were found in spatial working memory. Understanding the basis for the dissociation between intact verbal working memory and impaired spatial working memory and the breakdown that occurs in verbal working memory as information processing demands are increased will likely provide valuable insights into the neural basis of autism. C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Sch Med, Pittsburgh, PA 15213 USA. Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. RP Minshew, NJ (reprint author), Univ Pittsburgh, Sch Med, Webster Hall,Suite 300,3811 OHara St, Pittsburgh, PA 15213 USA. EM minshewnj@upmc.edu FU NICHD NIH HHS [HD35469]; NIMH NIH HHS [T32-MH18951] NR 48 TC 85 Z9 86 U1 5 U2 28 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD DEC PY 2005 VL 35 IS 6 BP 747 EP 756 DI 10.1007/s10803-005-0021-x PG 10 WC Psychology, Developmental SC Psychology GA 003AG UT WOS:000234653400006 PM 16267641 ER PT J AU Ebrahimi, R Lincoff, AM Bittl, JA Chew, D Wolski, K Wadhan, N Toggart, EJ Topol, EJ AF Ebrahimi, R Lincoff, AM Bittl, JA Chew, D Wolski, K Wadhan, N Toggart, EJ Topol, EJ TI Bivalirudin vs heparin in percutaneous coronary intervention: A pooled analysis SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Review DE anticoagulation; percutaneous coronary intervention; bivalirudin ID GLYCOPROTEIN IIB/IIIA INHIBITION; REPLACE-2 RANDOMIZED-TRIAL; DIRECT THROMBIN INHIBITORS; LOW-DOSE HEPARIN; DIABETES-MELLITUS; HEART-ASSOCIATION; DYNAMIC REGISTRY; ANGIOPLASTY; OUTCOMES; REVASCULARIZATION AB Objective: This study evaluates Outcomes With bivalirudin vs heparin in various patient subgroups and the overall population during percutaneous coronary interventions (PCI). Background: Recent data suggest that bivalirudin, a reversible direct thrombin inhibitor, provides ischemic protection superior to heparin and comparable to heparin plus glycoprotein (GP) IIb/IIIa inhibitors but with significantly fewer bleeding complications. Whether this advantage persists in different subgroups has not been fully defined. To our knowledge, this is the largest pooled analysis of bivalirudin to date. Methods: Four randomized controlled trials were identified that compared bivalirudin to heparin (with or without GP IIb/IIIa inhibitors) in PCI. The incidence of death, myocardial infarction (MI), revascularization, and major bleeding at 48 hours was compared between these two agents overall and in patients with and without diabetes mellitus, hypertension, renal insufficiency, and advanced age. Results: The trials consisted of 11,638 patients (bivalirudin, 5,861; heparin, 5,777). There were no significant differences in patient characteristics between the two groups. At 48 hours, the incidence of death, MI, revascularization, and major bleeding was significantly reduced in the bivalirudin group (7.8% vs 1.08%, P <.001); individual ischemic end points were significantly reduced for death (0.01% vs 0.02%, P =.049) and revascularization (2.0% vs 2.7%, P =.02). with similar reductions for major bleeding (2.7% vs 5.8%, P <.001). Subgroup analysis was generally consistent with the overall findings. Conclusion: This analysis further supports the superiority of bivalirudin compared with heparin. Bivalirudin provides excellent ischemic protection with a significant reduction of bleeding complications, even in high-risk subgroups. C1 Univ Calif Los Angeles, Sch Med, Dept Med, Cardiol Sect 111E,GLAVA,W Los Angeles VA, Los Angeles, CA 90073 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Ocala Heart & Vasc Inst, Munroe Reg Med Ctr, Ocala, FL USA. Flinders Med Ctr, Bedford Pk, SA, Australia. RP Ebrahimi, R (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med, Cardiol Sect 111E,GLAVA,W Los Angeles VA, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ramin.ebrahimi@med.va.gov OI Topol, Eric/0000-0002-1478-4729 NR 31 TC 21 Z9 22 U1 0 U2 0 PU WESTMINSTER PUBL INC PI GLEN HEAD PA 708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA SN 1074-2484 J9 J CARDIOVASC PHARM T JI J. Cardiovasc. Pharmacol. Ther. PD DEC PY 2005 VL 10 IS 4 BP 209 EP 216 DI 10.1177/107424840501000401 PG 8 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 996LH UT WOS:000234174900001 PM 16382257 ER PT J AU Albers, LJ Ozdemir, V Marder, SR Leeder, JS Raggi, MA Aravagiri, M Pearce, RE Reist, C AF Albers, LJ Ozdemir, V Marder, SR Leeder, JS Raggi, MA Aravagiri, M Pearce, RE Reist, C TI A focus on CYP1A2 activity and N-desmethylolanzapine - Is there a potential role for olanzapine-induced metabolic syndrome? SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 06-09, 2005 CL Boca Raton, FL SP NIMH, New Clin Drug Evaluat Unit C1 Univ Calif Irvine, Dept Psychiat & Human Behav, Vet Adm Long Beach Healthcare Syst, Irvine, CA 92717 USA. Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Childrens Mercy Hosp, Div Pediat Clin Pharmacol & Med Toxicol, Kansas City, MO USA. Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy. RI Raggi, Maria Augusta/A-4545-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD DEC PY 2005 VL 15 IS 6 BP 862 EP 863 PG 2 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA 000EC UT WOS:000234442700031 ER PT J AU Groff, KE Lam, C Caroff, SN AF Groff, KE Lam, C Caroff, SN TI Extrapontine myelinolysis resembling neuroleptic malignant syndrome SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Letter ID CENTRAL PONTINE MYELINOLYSIS; RAPID CORRECTION; ATYPICAL ANTIPSYCHOTICS; DOPAMINERGIC TREATMENT; HYPONATREMIA; PARKINSONISM; RECOVERY C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Groff, KE (reprint author), Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. NR 18 TC 1 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2005 VL 25 IS 6 BP 620 EP 621 DI 10.1097/01.jcp.0000185342.32225.94 PG 2 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 988VC UT WOS:000233628200028 PM 16282856 ER PT J AU Albers, LJ Ozdemir, V Marder, SR Raggi, MA Aravagiri, M Endrenyi, L Reist, C AF Albers, LJ Ozdemir, V Marder, SR Raggi, MA Aravagiri, M Endrenyi, L Reist, C TI Does N-desmethylolanzapine increase, or reduce, the risk for antipsychotic-induced metabolic syndrome? SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Letter ID WEIGHT-GAIN; FLUVOXAMINE; OLANZAPINE; SCHIZOPHRENIA; AUGMENTATION; CLOZAPINE; INSULIN C1 Univ Calif Irvine, VA Long Beach Healthcare Syst, Irvine, CA 92697 USA. Univ Calif Irvine, Dept Psychiat & Human Behav, Coll Med, Irvine, CA 92717 USA. Educ Clin Ctr, VISN 22, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Bologna, Dept Pharmaceut Sci, Fac Pharm, Alma Mater Studiorum, I-40126 Bologna, Italy. Univ Toronto, Dept Pharmacol, Fac Med, Toronto, ON, Canada. RP Albers, LJ (reprint author), Univ Calif Irvine, VA Long Beach Healthcare Syst, Irvine, CA 92697 USA. EM larry.albers@med.va.gov RI Raggi, Maria Augusta/A-4545-2011 NR 11 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2005 VL 25 IS 6 BP 627 EP 628 DI 10.1097/01.jcp.0000185340.47472.96 PG 2 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 988VC UT WOS:000233628200034 ER PT J AU Johnson, SC Schmitz, TW Kawahara-Baccus, TN Rowley, HA Alexander, AL Lee, JH Davidson, RJ AF Johnson, SC Schmitz, TW Kawahara-Baccus, TN Rowley, HA Alexander, AL Lee, JH Davidson, RJ TI The cerebral response during subjective choice with and without self-reference SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID POSTERIOR CINGULATE CORTEX; MEDIAL PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; EVENT-RELATED FMRI; ALZHEIMERS-DISEASE; FRONTAL LOBES; DEFAULT-MODE; PHYSIOLOGICAL CONDITION; IMPAIRED AWARENESS; NEURAL MECHANISMS AB The anterior medial prefrontal (AMPFC) and retrosplenial (RSC) cortices are active during self-referential decision-making tasks such as when participants appraise traits and abilities, or current affect. Other appraisal tasks requiring an evaluative decision or mental representation, such as theory of mind and perspective-taking tasks, also involve these regions. In many instances, these types of decisions involve a subjective opinion or preference, but also a degree of ambiguity in the decision, rather than a strictly, veridical response. However, this ambiguity is generally not controlled for in studies that examine self-referential decision-making. In this functional magnetic resonance imaging experiment with 17 healthy adults, we examined neural processes associated with subjective decision-making with and without an overt self-referential component. The task required subjective decisions about colors-regarding self-preference (internal subjective decision) or color similarity (external subjective decision) under conditions where there was no objectively correct response. Results indicated greater activation in the AMPFC, RSC, and caudate nucleus during internal subjective decision-making. The findings suggest that self-referential processing, rather than subjective judgments among ambiguous response alternatives, accounted for the AMPFC and RSC response. C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM scj@medicine.wisc.edu FU NIMH NIH HHS [MH65723, R01 MH065723, R01 MH065723-03, R01 MH065723-04] NR 66 TC 61 Z9 63 U1 4 U2 8 PU M I T PRESS PI CAMBRIDGE PA 238 MAIN STREET, STE 500, CAMBRIDGE, MA 02142-1046 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD DEC PY 2005 VL 17 IS 12 BP 1897 EP 1906 DI 10.1162/089892905775008607 PG 10 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 993WW UT WOS:000233988600007 PM 16356327 ER PT J AU Collier, A Yohnson, KR Delamere, F Leonard, T Dellavalle, RP Williams, H AF Collier, Avanta Yohnson, Kathryn R. Delamere, Finola Leonard, Tina Dellavalle, Robert P. Williams, Hywel TI The cochrane skin group: Promoting the best evidence SO JOURNAL OF CUTANEOUS MEDICINE AND SURGERY LA English DT Article ID SYSTEMATIC REVIEWS; DERMATOLOGY AB Background. The international Cochrane Skin group, established in 1997, organizes, writes and disseminates systematic reviews of therapeutic interventions in dermatology. Objective To introduce the Cochrane Skin Group and what it offers to cutaneous medicine and surgery providers. Methods. Descriptive review of the structure and output of the Cochrane Collaboration Library and the Cochrane Skin Group. Results: Systematic reviews of randomized controlled trials produced through the Cochrane Skin Group provide a benchmark for evidence summaries for informing clinical decisions in dermatology. Conclusion: The work performed by the Cochrane Skin Group is an important component for informing the evidence base for the clinical practice of cutaneous and surgical dermatology. C1 Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Denver, CO 80262 USA. Denver VA Med Ctr, Denver, CO USA. Univ Nottingham, Queens Med Ctr, Nottingham NG7 2RD, England. RP Dellavalle, RP (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Denver, CO 80262 USA. EM roberr.dellavalle@uchsc.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X FU NCI NIH HHS [CA92550]; NIAMS NIH HHS [T32 AR07411] NR 18 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1203-4754 J9 J CUTAN MED SURG JI J. Cutan. Med. Surg. PD DEC PY 2005 VL 9 IS 6 BP 324 EP 331 DI 10.1007/s10227-005-0120-5 PG 8 WC Dermatology SC Dermatology GA 069OR UT WOS:000239458600008 PM 16699901 ER PT J AU Lin, JJ Hanten, WP Olson, SL Roddey, TS Soto-quijano, DA Lim, HK Sherwood, AM AF Lin, JJ Hanten, WP Olson, SL Roddey, TS Soto-quijano, DA Lim, HK Sherwood, AM TI Functional activity characteristics of individuals with shoulder dysfunctions SO JOURNAL OF ELECTROMYOGRAPHY AND KINESIOLOGY LA English DT Article DE electromyography; kinematics; shoulder; reliability; motion analysis ID SPINAL-CORD INJURY; IMPINGEMENT SYNDROME; UPPER EXTREMITY; MUSCLE-ACTIVITY; RELIABILITY; KINEMATICS; MOVEMENT; PAIN; ORIENTATION; MOTION AB Shoulder-related dysfunction affects individuals' ability to function independently and thus decreases quality of life. Functional task assessment is a key concern for a clinician in diagnostic assessment, outcome measurement, and planning of treatment programs. The purpose of this study was to test the reliability of the FASTRAK 3-dimensional (3-D) motion analysis and surface electromyography (sEMG) systems to analyze 3-D shoulder complex movements during functional tasks and compare motion patterns between subjects with and without shoulder dysfunctions (SDs). For the test, sEMG and 3-D motion analysis systems were used to characterize the functional tasks. Twenty-five asymptomatic male subjects and 21 male subjects with right shoulder disorders performed four functional tasks which involved arm reaching and raising activities with their dominant arms. Reliability was estimated by the intraclass correlation coefficient (ICC). Motion pattern was compared between two groups using mixed analysis of variances (ANOVAs). Shoulder complex kinematics and associated muscular activities during functional tasks were reliably quantified (ICC = 0.83-0.99) from the means of three trials. Relative to the group without SDs, the group with SDs showed significant alteration in shoulder complex kinematics (3 degrees-40 degrees) and associated muscular activities (3-10% maximum). Scapular tipping, scapular elevation, upper trapezius muscle function, and serratus anterior muscle function may have implications in the rehabilitation of patients with SDs. (c) 2005 Elsevier Ltd. All rights reserved. C1 Natl Taiwan Univ, Coll Med, Sch Phys Therapy, Taipei, Taiwan. Natl Taiwan Univ, Coll Med, Grad Inst Phys Therapy, Taipei, Taiwan. Texas Womans Univ, Sch Phys Therapy, Denton, TX 76204 USA. Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Lin, JJ (reprint author), Natl Taiwan Univ, Coll Med, Sch Phys Therapy, Taipei, Taiwan. EM lxjst@ha.mc.ntu.edu.tw RI lin, jiu jenq/H-4604-2014 OI lin, jiu jenq/0000-0001-9070-7939; Sherwood, Arthur/0000-0002-0110-4317 NR 44 TC 83 Z9 89 U1 2 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1050-6411 J9 J ELECTROMYOGR KINES JI J. Electromyogr. Kinesiol. PD DEC PY 2005 VL 15 IS 6 BP 576 EP 586 DI 10.1016/j.jelekin.2005.01.006 PG 11 WC Neurosciences; Physiology; Rehabilitation; Sport Sciences SC Neurosciences & Neurology; Physiology; Rehabilitation; Sport Sciences GA 982HU UT WOS:000233149500006 PM 16179197 ER PT J AU Meneghetti, AT Safadi, B Stewart, L Way, LW AF Meneghetti, AT Safadi, B Stewart, L Way, LW TI Local resection of ampullary tumors SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract CY MAY 14-18, 2005 CL Chicago, IL SP Soc Surg Alimentary Tract DE ampullary tumors; duodenal adenoma; periampullarv adenoma; ampullary adenoma; ampullary carcinoma; transduodenal resection; local resection ID ENDOSCOPIC SNARE EXCISION; MAJOR DUODENAL PAPILLA; VILLOUS TUMORS; PROGNOSTIC-FACTORS; FOLLOW-UP; VATER; ADENOMAS; CARCINOMA; MANAGEMENT; NEOPLASMS AB There is no consensus on the appropriateness of local resection for ampullary tumors, because malignant recurrence of what were thought to be benign tumors has been reported. This study examined the role of local resection in the management of ampullary tumors. Thirty patients (mean age 66 years) had transduodenal local resections performed at UCSF-Moffitt Hospital or the San Francisco VA Medical Center (February, 1992 to March, 2004). Mean follow-up time was 5.8 years. Preoperative biopsies (obtained in all patients) showed 18 adenomas, four adenomas with dysplasia, five adenomas with atypia, one adenoma with dysplasia and focal adenocarcinoma, and two tumors seen on endoscopy, whose biopsies showed only duodenal mucosa. In comparison with the final pathology findings, the results of frozen section examin- ations for malignancy in 20 patients, during the operation, were false-negative in three cases. The final pathologic diagnosis was 23 villous adenomas, six adenocarcinomas, and one paraganglioma. On preoperative biopsies, all patients who had high-grade dysplasia and one of five patients with atypia turned out to have invasive adenocarcinoma when the entire specimen was examined postoperatively. Two (33%) adenocarcinomas recurred at a mean of 4 years-, both had negative margins at the initial resection. Among the 23 adenomas, three (13%) recurred (all as adenomas) at a mean of 3.2 years; in only one of these cases was the margin positive at the time of resection. Tumor size did not influence recurrence rate. Ampullary tumors with high-grade dysplasia on preoperative biopsy should be treated by pancreaticoduodenectomy because they usually harbor malignancy. Recurrence is too common and unpredictable after local resection of malignant lesions for this to be considered an acceptable alternative to pancreaticoduodenectomy. Ampullary adenomas can be resected locally with good results, but the recurrence rate was 13 %, so endoscopic surveillance is indicated postoperatively. Frozen sections were obtained during the operation, but they were less reliable than expected. No adenomas recurred as carcinomas, suggesting that local resection is appropriate for these tumors in the absence of dysplasia or atypia on preoperative biopsies. C1 Univ Calif San Francisco, VAMC, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Stewart, L (reprint author), Univ Calif San Francisco, VAMC, Box 112, San Francisco, CA 94121 USA. EM lygia.stewart@med.va.gov NR 26 TC 23 Z9 26 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD DEC PY 2005 VL 9 IS 9 BP 1300 EP 1306 DI 10.1016/j.gassur.2005.08.031 PG 7 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 998RF UT WOS:000234336100023 PM 16332486 ER PT J AU DeSalvo, KB Gregg, J Kleinpeter, M Pedersen, BR Stepter, A Peabody, J AF DeSalvo, KB Gregg, J Kleinpeter, M Pedersen, BR Stepter, A Peabody, J TI Cardiac risk underestimation in urban, black women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT Regional Meeting of the Southern-Society-of-General-Internal-Medicine CY FEB 13, 2004 CL New Orleans, LA SP SO Soc Gen Internal Med DE women; cardiac risk factors; perceived risk; minority; stress ID CARDIOVASCULAR-DISEASE RISK; CORONARY HEART-DISEASE; PSYCHOSOCIAL STRESS; AFRICAN-AMERICANS; MENTAL STRESS; HEALTH; HYPERTENSION; DISPARITIES; ACCURACY; REVASCULARIZATION AB BACKGROUND: Black women have a disproportionately higher incidence of cardiovascular disease mortality than other groups and the reason for this health disparity is incompletely understood. Underestimation of personal cardiac risk may play a role. OBJECTIVE: We investigated the personal characteristics associated with underestimating cardiovascular disease in black women. DESIGN, SETTING, PARTICIPANTS: Trained surveyors interviewed 128 black women during the baseline evaluation for a randomized controlled trial in an urban, academic continuity clinic affiliated with a public hospital system. They provided information on the presence of cardiac risk factors and demographic and psychosocial characteristics. These self-report data were supplemented with medical record abstraction for weight. MEASUREMENTS AND MAIN RESULTS: The main outcome measure was the accurate perception of cardiac risk. Objective risk was determined by a simple count of major cardiac risk factors and perceived risk by respondent's answer to a survey question about personal cardiac risk. The burden of cardiac risk factors was high in this population: 77% were obese; 72% had hypertension; 48% had high cholesterol; 49% had a family history of heart disease; 31% had diabetes, and 22% currently used tobacco. Seventy-nine percent had 3 or more cardiac risk factors. Among those with 3 or more risk factors ("high risk"), 63% did not perceive themselves to be at risk for heart disease. Among all patients, objective and perceived cardiac risk was poorly correlated (kappa =0. 026). In a multivariable model, increased perceived personal stress and lower income were significant correlates of underestimating cardiac risk. CONCLUSIONS: Urban, disadvantaged black women in this study had many cardiac risk factors, yet routinely underestimated their risk of heart disease. We found that the strongest correlates of underestimation were perceived stress and lower personal income. C1 Tulane Univ, Hlth Sci Ctr, Sect Gen Internal Med & Geriatr, Dept Med, New Orleans, LA 70112 USA. Tulane Univ, Hlth Sci Ctr, Nephrol Sect, Dept Med, New Orleans, LA 70112 USA. Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. Amgen Inc, Thousand Oaks, CA USA. RP DeSalvo, KB (reprint author), Tulane Univ, Hlth Sci Ctr, Sect Gen Internal Med & Geriatr, Dept Med, 1430 Tulane Ave,SL-16, New Orleans, LA 70112 USA. EM kdesalv@tulane.edu NR 39 TC 23 Z9 23 U1 1 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2005 VL 20 IS 12 BP 1127 EP 1131 DI 10.1111/j.1525-1497.2005.0252.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 997OG UT WOS:000234254700009 PM 16423102 ER PT J AU Crothers, K Griffith, TA McGinnis, KA Rodriguez-Barradas, MC Leaf, DA Weissman, S Gibert, CL Butt, AA Justice, AC AF Crothers, K Griffith, TA McGinnis, KA Rodriguez-Barradas, MC Leaf, DA Weissman, S Gibert, CL Butt, AA Justice, AC TI The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV; AIDS; smoking; mortality; health-related quality of life ID HUMAN-IMMUNODEFICIENCY-VIRUS; AGING COHORT 3-SITE; BACTERIAL PNEUMONIA; HEALTH SURVEY; INFECTION; INDIVIDUALS; ASSOCIATION; AIDS AB BACKGROUND: The impact of smoking on outcomes among those with HIV infection has not been determined in the era of highly active; retroviral therapy (HAART). STUDY OBJECTIVE: Determine the impact of smoking on morbidity and mortality in HFV-positive patients post-HAART. DESIGN: Prospective observational study. PARTICIPANTS: Eight hundred and sixty-seven HIV-positive veterans enrolled in the Veterans Aging Cohort 3 Site Study. MEASUREMENTS: Clinical data were collected through patient questionnaire, International Classification of Diseases-9th edition codes, and standardized chart extraction, and laboratory and mortality data through the national VA database. Quality of life was assessed with the physical component summary (PCS) of the Short-Form 12. RESULTS: Current smokers had increased respiratory symptoms, chronic obstructive pulmonary disease (COPD), and bacterial pneumonia. In analyses adjusted for age, race/ethnicity, CD4 cell count, HIV RNA level, hemoglobin, illegal drug and alcohol use, quality of life was substantially decreased (beta = -3.3, 95% confidence interval [CI] -5.3 to -1.4) and mortality was significantly increased (hazard ratio 1.99, 95% CI 1.03 to 3.86) in current smokers compared with never smokers. CONCLUSIONS: HIV-positive patients who currently smoke have increased mortality and decreased quality of life, as well as increased respiratory symptoms, COPD, and bacterial pneumonia. These findings suggest that smoking cessation should be emphasized for HIV-infected patients. C1 VA Connecticut Healthcare Syst, Dept Internal Med, West Haven, CT 06516 USA. Yale Univ, Sch Med, Dept Internal Med, New Haven, CT USA. Univ Pittsburgh, Ctr Social & Urban Res, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equit Res & Promot, Pittsburgh, PA USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Michael E DeBakey VA Med Ctr, Houston, TX USA. Univ Calif Los Angeles, Dept Internal Med, Los Angeles, CA USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. Hosp St Raphael, Dept Internal Med, New Haven, CT USA. George Washington Univ, Dept Med, Washington, DC 20052 USA. VA Med Ctr, Infect Dis Sect, Washington, DC USA. Univ Pittsburgh, Sch Med, Dept Internal Med, Pittsburgh, PA USA. RP Justice, AC (reprint author), VA Connecticut Healthcare Syst, Dept Internal Med, 950 Campbell Ave,Mailstop 11 ASCLG, West Haven, CT 06516 USA. EM amy.justice2@med.va.gov OI Crothers, Kristina/0000-0001-9702-0371 FU NIA NIH HHS [K23 AG00826]; NIAAA NIH HHS [3U01 AA 13566, U01 AA013566] NR 19 TC 134 Z9 137 U1 2 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2005 VL 20 IS 12 BP 1142 EP 1145 DI 10.1111/j.1525-1497.2005.0255.x PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 997OG UT WOS:000234254700013 PM 16423106 ER PT J AU Tierney, WM Gerrity, MS AF Tierney, WM Gerrity, MS TI The best of JGIM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. Regenstrief Inst Inc, Indianapolis, IN USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Tierney, WM (reprint author), Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2005 VL 20 IS 12 BP 1191 EP 1195 DI 10.1111/j.1525-1497.2005.00275.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 997OG UT WOS:000234254700022 ER PT J AU Jarvik, LF La Rue, A Gokhman, I Harrison, T Holt, L Steh, B Harker, J Larson, S Yaralian, P Matsuyama, S Rasgon, N Geschwind, D Freimer, N Jimenez, E Schaeffer, J AF Jarvik, LF La Rue, A Gokhman, I Harrison, T Holt, L Steh, B Harker, J Larson, S Yaralian, P Matsuyama, S Rasgon, N Geschwind, D Freimer, N Jimenez, E Schaeffer, J TI Middle-aged children of Alzheimer parents, a pilot study: Stable neurocognitive performance at 20-year follow-up SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article; Proceedings Paper CT Workshop on Children of Alzheimer Parent CY MAR 06-07, 2005 CL San Diego, CA SP Natl Inst Hlth DE Alzheimer's disease; offspring; longitudinal; neurocognitive ID 1ST-DEGREE RELATIVES; LATE-LIFE; DISEASE; RISK; DIAGNOSIS AB The objective of this pilot study on a convenience sample of 25 offspring of Alzheimer patients (mean age 61.5 +/- 8.8 years; range, 50-82) was the early detection of neurocognitive decline. This preliminary report appears to be the first one dealing with 20-year follow-up of neurocognitive data of Alzheimer's disease (AD) children. Digit symbol (Wechsler Adult Intelligence Scale) was the only of 11 neurocognitive measures with a significant decline. And that decline between first and last testing (mean = 19.98 +/- 0.30 years) was on raw scores, not scaled scores. Neither parents' age at onset of AD nor autopsy confirmation or offspring APOE-e4 status influenced neurocognitive results. More robust data than currently available are needed to confirm the findings of this first pilot study and to determine both the trajectory of neurocognitive decline in AD and the risks of developing AD faced by children whose parent had the disease. C1 Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Wisconsin, Wisconsin Alzheimers Inst, Dept Med, Madison, WI USA. Charles R Drew Univ, Dept Psychiat & Human Behav, Los Angeles, CA USA. Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Biobehav Sci & Human Genet, Los Angeles, CA USA. RP Jarvik, LF (reprint author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, 760 Westwood Pl, Los Angeles, CA 90095 USA. EM ljarvik@ucla.edu NR 34 TC 8 Z9 8 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD DEC PY 2005 VL 18 IS 4 BP 187 EP 191 DI 10.1177/0891988705281862 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 986EO UT WOS:000233433100002 PM 16306237 ER PT J AU Ercoli, L Siddarth, P Harrison, T Jimenez, E Jarvik, LF AF Ercoli, L Siddarth, P Harrison, T Jimenez, E Jarvik, LF TI Similar neurocognitive performance of adults with and without a history of parental Alzheimer's disease: A pilot study SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article; Proceedings Paper CT Workshop on Children of Alzheimer Parent CY MAR 06-07, 2005 CL San Diego, CA SP Natl Inst Hlth DE Alzheimer's disease; neurocognitive; Mini-Mental State Examination (MMSE); offspring; parent; family history ID MINI-MENTAL-STATE; IMMEDIATE VISUAL MEMORY; COGNITIVE DECLINE; GENETIC RISK; DEPRESSION; NORMS; AGE; IMPAIRMENT; RELATIVES AB The first reported 20-year prospective follow-up of middle-aged children of Alzheimer patients failed to find statistically significant neurocognitive decline. Because that report did not include a comparison group, the current study compared the 20-year follow-up scores with scores obtained on the same 8 measures by an age-comparable sample of healthy adults without a family history of Alzheimer's disease. Both were convenience samples (n = 24). Statistical analyses (correcting for age) yielded no significant group differences in neurocognitive scores but did show a significantly higher mean score for the comparison group on the Mini-Mental State Examination (29.5 vs 28.8, P = .003, controlling for age). Even though this finding suggests that adult children of a parent with Alzheimer's disease performed well on a limited neurocognitive battery and on the Mini-Mental State Examination, the findings are preliminary and require confirmation on large representative samples with appropriate controls and long-term follow-up. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Ercoli, L (reprint author), Semel Inst Neurosci & Human Behav, 760 Westwood Pl,Suite 88-201, Los Angeles, CA 90024 USA. EM lercoli@mednet.ucla.edu FU CSR NIH HHS [RG2-96-051]; NCRR NIH HHS [M01RR00865]; NIA NIH HHS [AG100784, AG05128, AG10123, AG11268, AG13308, AG16570]; NIMH NIH HHS [MH52453]; NINDS NIH HHS [NS26630, NS31153] NR 30 TC 5 Z9 5 U1 3 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD DEC PY 2005 VL 18 IS 4 BP 208 EP 212 DI 10.1177/0891988705281866 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 986EO UT WOS:000233433100006 PM 16306241 ER PT J AU Tallaj, JA Franco, V Rayburn, BK Pinderski, L Benza, RL Pamboukian, S Foley, B Bourge, RC AF Tallaj, JA Franco, V Rayburn, BK Pinderski, L Benza, RL Pamboukian, S Foley, B Bourge, RC TI Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article ID LEFT-VENTRICULAR DYSFUNCTION; CARDIOTOXICITY; MORTALITY; TRANSPLANTATION; CARVEDILOL; METOPROLOL; ENALAPRIL; MORBIDITY; BLOCKADE AB Background: Doxorubicin (D) (Adriamycin) is a potent and efficacious chemotherapeutic agent in the treatment of various forms of cancer, but its use has been limited by the development of cardiac toxicity. Historically, D-induced cardiomyopathy (CMP) has been refractory to therapy. We report our experience with this form of CMP at the University of Alabama at Birmingham. Methods: Twenty-five patients (20 women, 5 men) with a clinical diagnosis of D-CMP were referred to our program from 1990 to 2003. Patient data were extracted from office charts. Results: Patients were followed-up for 71 +/- 58 months. On presentation, the average left ventricular ejection fraction (LVEF) was 26 +/- 9.2%, and 88% of patients were New York Heart Association (NYHA) Class III or W. Patients were treated with angiotensin-converting enzyme inhibitors (ACEi; n = 23) or angiotensin-receptor blocker (ARB; n = 2), and 15 were treated with a combination of ACEi and beta-blockers (BB). With medical therapy, LVEF improved significantly (26 +/- 9.2% vs 35 +/- 16.5%, p = 0.022), as did the NYHA class (p < 0.003). All survivors (n = 19) were NYHA Class I or 11 with medical therapy, with 10 (53%) being Class I. In the group of patients treated with ACEi + BB, there was a statistically significant improvement in LVEF (26 +/- 10.0% vs 37 +/- 17.6%, p = 0.028), which not seen in the ACEi group, with a strong trend toward normalization of LV function (47% vs 10%, p = 0.054). Conclusions: In the current era of management of heart failure, D-CMP carries a better prognosis than previously described. Early addition of BB may further improve LVEF. C1 Univ Alabama, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35294 USA. RP Tallaj, JA (reprint author), Univ Alabama, Div Cardiovasc Dis, Dept Med, THT 338,1900 Univ Blvd, Birmingham, AL 35294 USA. EM jtallaj@uab.edu RI Franco, Veronica/E-3080-2011 NR 21 TC 53 Z9 55 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD DEC PY 2005 VL 24 IS 12 BP 2196 EP 2201 DI 10.1016/j.healun.2004.12.108 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 998HH UT WOS:000234308700030 PM 16364871 ER PT J AU Chamlin, SL Cella, D Frieden, IJ Williams, ML Mancini, AJ Lai, JS Chren, MM AF Chamlin, SL Cella, D Frieden, IJ Williams, ML Mancini, AJ Lai, JS Chren, MM TI Development of the childhood atopic dermatitis impact scale: Initial validation of a quality-of-life measure for young children with atopic dermatitis and their families SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE atopic dermatitis; quality of life; sleep disorder; validity ID ECZEMA; INDEX AB To measure the effects of atopic dermatitis (AD) on the quality of life of affected young children and their families, we developed a prototype 62-item instrument, the Childhood Atopic Dermatitis Impact Scale (CADIS). The prototype CADIS was developed from a comprehensive conceptual framework based on data from parents and clinicians. The instrument had eight subscales (four each for child and parent): physical health, emotional health, physical functioning, and social functioning. The goal of this work was to test the validity of and to refine the prototype of CADIS. Two hundred seventy parents of children under the age of 6 y with AD responded to the instrument. Content validity was demonstrated by expert and parent reviews of the drafted and refined instrument, and by analyzing parents' responses to open-ended questions about their children's skin disease. Construct validity was assessed in exploratory factor analyses which supported a refinement in the conceptual framework to consist of two dimensions with five domains: child dimensions (symptoms and activity limitation/behavior), and parent dimensions (family/social function, sleep, and emotions). Seventeen items were eliminated, yielding a 45-item refined version of CADIS (score 0-180) with evidence of content and construct validity and suggested use in clinical research. C1 Childrens Mem Hosp, Div Pediat Dermatol, Chicago, IL 60614 USA. Evanston NW Healthcare, Ctr Outcomes Res & Educ, Chicago, IL USA. NW Feinberg Sch Med, Chicago, IL USA. Univ Calif San Francisco, Dept Dermatol & Pediat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Serv Dermatol, San Francisco, CA USA. RP Chamlin, SL (reprint author), Childrens Mem Hosp, Div Pediat Dermatol, Chicago, IL 60614 USA. EM schamlin@childrensmemorial.org OI Frieden, Ilona/0000-0001-7305-5940 FU NIAMS NIH HHS [K02 AR 02203-01] NR 16 TC 49 Z9 51 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD DEC PY 2005 VL 125 IS 6 BP 1106 EP 1111 DI 10.1111/j.0022-202X.2005.23911.x PG 6 WC Dermatology SC Dermatology GA 991OS UT WOS:000233823900009 PM 16354179 ER PT J AU Mazarati, AM Baldwin, RA Shinmei, S Sankar, R AF Mazarati, AM Baldwin, RA Shinmei, S Sankar, R TI In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE dorsal raphe; galanin receptor; hippocampus; seizures; serotonin ID STATUS EPILEPTICUS; HIPPOCAMPAL GALANIN; 5-HT1A RECEPTORS; RAT HIPPOCAMPUS; MESSENGER-RNA; GALR1; EXPRESSION; SUBTYPES; BRAIN; MICE AB The neuropeptide galanin suppresses seizure activity in the hippocampus by inhibiting glutamatergic neurotransmission. Galanin may also modulate limbic seizures through interaction with other neurotransmitters in neuronal populations that project to the hippocampus. We examined the role of galanin receptors types 1 and 2 in the dorsal raphe (DR) in the regulation of serotonergic transmission and limbic seizures. Infusion of a mixed agonist of galanin receptors types 1 and 2 [galanin (1 - 29)] into the DR augmented the severity of limbic seizures in both rats and wild- type mice and concurrently reduced serotonin concentration in the DR and hippocampus as measured by immunofluorescence or HPLC. In contrast, injection of the galanin receptor type 2 agonist galanin (2 - 11) mitigated the severity of seizures in both species and increased serotonin concentration in both areas. Injection of both galanin fragments into the DR of galanin receptor type 1 knockout mice exerted anticonvulsant effects. Both the proconvulsant activity of galanin (1 - 29) and seizure suppression by galanin (2 - 11) were abolished in serotonin- depleted animals. Our data indicate that, in the DR, galanin receptors types 1 and 2 modulate serotonergic transmission in a negative and a positive fashion, respectively, and that these effects translate into either facilitation or inhibition of limbic seizures. C1 Univ Calif Los Angeles, Dept Pediat, Div Pediat Neurol, D Geffen Sch Med, Los Angeles, CA 90095 USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Mazarati, AM (reprint author), Univ Calif Los Angeles, Dept Pediat, Div Pediat Neurol, D Geffen Sch Med, Box 951752,22-474 MDCC, Los Angeles, CA 90095 USA. EM mazarati@ucla.edu FU NINDS NIH HHS [R01 NS046516, NS043409, R01 NS043409, NS046516] NR 44 TC 40 Z9 41 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD DEC PY 2005 VL 95 IS 5 BP 1495 EP 1503 DI 10.1111/j.1471-4159.2005.03498.x PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 982NZ UT WOS:000233170200025 PM 16219029 ER PT J AU Cook, DG Li, XF Cherry, SD Cantrell, AR AF Cook, DG Li, XF Cherry, SD Cantrell, AR TI Presenilin 1 deficiency alters the activity of voltage-gated Ca2+ channels in cultured cortical neurons SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID FAMILIAL ALZHEIMERS-DISEASE; AMYLOID-BETA-PEPTIDE; KNOCK-IN MICE; CAPACITATIVE CALCIUM-ENTRY; GAMMA-SECRETASE CLEAVAGE; LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; INCREASED VULNERABILITY; INTRACELLULAR DOMAIN; MUTANT PRESENILIN-1 AB Cook, David G., Xiaofan Li, Sheree D. Cherry, and Angela R. Cantrell. Presenilin 1 deficiency alters the activity of voltage-gated Ca2+ channels in cultured cortical neurons. J Neurophysiol 94: 4421-4429, 2005. First published September 7, 2005; doi: 10.1152/jn.00745.2005. Presenilins 1 and 2 (PS1 and PS2, respectively) play a critical role in mediating gamma-secretase cleavage of the amyloid precursor protein (APP). Numerous mutations in the presenilins are known to cause early-onset familial Alzheimer's disease ( FAD). In addition, it is well established that PS1 deficiency leads to altered intracellular Ca2+ homeostasis involving endoplasmic reticulum Ca2+ stores. However, there has been little evidence suggesting Ca2+ signals from extracellular sources are influenced by PS1. Here we report that the Ca2+ currents carried by voltage-dependent Ca2+ channels are increased in PS1-deficient cortical neurons. This increase is mediated by a significant increase in the contributions of L- and P- type Ca2+ channels to the total voltage-mediated Ca2+ conductance in PS1 (-/-) neurons. In addition, chelating intracellular Ca2+ with 1,2-bis-(o-aminophenoxy) ethane-N,N,N' ,N' -tetraacetic acid (BAPTA) produced an increase in Ca2+ current amplitude that was comparable to the increase caused by PS1 deficiency. In contrast to this, BAPTA had no effect on voltage-dependent Ca2+ conductances in PS1-deficient neurons. These data suggest that PS1 deficiency may influence voltage-gated Ca2+ channel function by means that involve intracellular Ca2+ signaling. These findings reveal that PS1 functions at multiple levels to regulate and stabilize intracellular Ca2+ levels that ultimately control neuronal firing behavior and influence synaptic transmission. C1 Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA. GRECC, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98195 USA. RP Cantrell, AR (reprint author), Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave,Link 515, Memphis, TN 38163 USA. EM acantrell@utmem.edu FU NIA NIH HHS [AG-05136]; NIMH NIH HHS [K01 MH-01669] NR 68 TC 7 Z9 7 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 2005 VL 94 IS 6 BP 4421 EP 4429 DI 10.1152/jn.00745.2005 PG 9 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 984PP UT WOS:000233317100069 PM 16148264 ER PT J AU Weaver, F Follett, K Hur, K Ippolito, D Stern, M AF Weaver, F Follett, K Hur, K Ippolito, D Stern, M TI Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes SO JOURNAL OF NEUROSURGERY LA English DT Article DE Parkinson disease; deep brain stimulation; subthalamic nucleus; globus pallidus internus ID SUBTHALAMIC NUCLEUS STIMULATION; HIGH-FREQUENCY STIMULATION; QUALITY-OF-LIFE; GLOBUS-PALLIDUS INTERNUS; 2-YEAR FOLLOW-UP; BILATERAL STIMULATION; ELECTRICAL-STIMULATION; MOTOR FLUCTUATIONS; PARS INTERNA; PALLIDOTOMY AB Object. Deep brain stimulation (DBS) to treat advanced Parkinson disease (PD) has been focused on one of two anatomical targets: the subthalamic nucleus (STN) and the globus pallidus internus (GPI). Authors of more than 65 articles have reported on bilateral DBS outcomes. With one exception, these studies involved pre- and postintervention comparisons of a single target. Despite the paucity of data directly comparing STN and GPI DBS, many clinicians already consider the STN to be the preferred target site. In this study the authors conducted a metaanalysis of the existing literature on patient outcomes following DBS of the STN and the GPI. Methods. This metaanalysis includes 31 STN and 14 GPI studies. Motor function improved significantly following stimulation (54% in patients whose STN was targeted and 40% in those whose GPI was stimulated), with effect sizes (ESs) of 2.59 and 2.04, respectively. After controlling for participant and study characteristics, patients who had undergone either STN or GPI DBS experienced comparable improved motor function following surgery (p = 0.094). The performance of activities of daily living improved significantly in patients with either target (40%). Medication requirements were significantly reduced following stimulation of the STN (ES = 1.51) but did not change when the GPI was stimulated (ES = -0.02). Conclusions. In this analysis the authors highlight the need for uniform, detailed reporting of comprehensive motor and nonmotor DBS outcomes at multiple time points and for a randomized trial of bilateral STN and GPI DBS. C1 Hines VAMC, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. VA Iowa City Hlth Care Syst, Iowa City, IA USA. Univ Iowa, Iowa City, IA USA. Edward Hines Jr VA Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. RP Weaver, F (reprint author), Hines VAMC, Midwest Ctr Hlth Serv & Policy Res, POB 5000 151H, Hines, IL 60141 USA. EM Frances.Weaver@va.gov NR 83 TC 86 Z9 88 U1 1 U2 3 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD DEC PY 2005 VL 103 IS 6 BP 956 EP 967 DI 10.3171/jns.2005.103.6.0956 PG 12 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 990PT UT WOS:000233756400002 PM 16381181 ER PT J AU Morrison, RS Maroney-Galin, C Kralovec, PD Meier, DE AF Morrison, RS Maroney-Galin, C Kralovec, PD Meier, DE TI The growth of palliative care programs in United States hospitals SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; END; OLDER; CONSULTATIONS; IMPACT; PLACE; COSTS AB Background: Palliative care programs are becoming increasingly common in U.S. hospitals. Objective: To quantify the growth of hospital based palliative care programs from 2000-2003 and identify hospital characteristics associated with the development of a palliative care program. Design and measurements: Data were obtained from the 2001-2004 American Hospital Association Annual Surveys which covered calendar years 2000-2003. We identified all programs that self-reported the presence of a hospital-owned palliative care program and acute medical and surgical beds. Multivariate logistic regression was used to identify characteristics significantly associated with the presence of a palliative care program in the 2003 survey data. Results: Overall, the number of programs increased linearly from 632 (15% of hospitals) in 2000 to 1027 (25% of hospitals) in 2003. Significant predictors associated with an increased likelihood of having a palliative care program included greater numbers of hospital beds and critical care beds, geographic region, and being an academic medical center. Compared to not-for-profit hospitals, VA hospitals were significantly more likely to have a palliative care program and city, county or state and for-profit hospitals were significantly less likely to have a program. Hospitals operated by the Catholic Church, and hospitals that owned their own hospice program were significantly more likely to have a palliative care program than non-Catholic Church-operated hospitals and hospitals without hospice programs respectively. Conclusions: Our data suggest that although growth in palliative care programs has occurred throughout the nation's hospitals, larger hospitals, academic medical centers, not-for-profit hospitals, and VA hospitals are significantly more likely to develop a program compared to other hospitals. C1 CUNY Mt Sinai Sch Med, Brookdale Dept Geriatr, Hertzberg Palliat Care Inst, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Ctr Advance Palliat Care, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. Amer Hosp Assoc, Hlth Care Data Ctr, Chicago, IL USA. RP Morrison, RS (reprint author), CUNY Mt Sinai Sch Med, Brookdale Dept Geriatr, Hertzberg Palliat Care Inst, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU NIA NIH HHS [K24 AG022345, K07 AG00903] NR 38 TC 130 Z9 132 U1 6 U2 8 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2005 VL 8 IS 6 BP 1127 EP 1134 DI 10.1089/jpm.2005.8.1127 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 045XS UT WOS:000237776600011 PM 16351525 ER PT J AU Carlson, B Simopolous, N Goy, ER Jackson, A Ganzini, L AF Carlson, B Simopolous, N Goy, ER Jackson, A Ganzini, L TI Oregon hospice chaplains' experiences with patients requesting physician-assisted suicide SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID SOCIAL-WORKERS; TERMINALLY ILL; DIGNITY ACT; ATTITUDES; DEATH; EUTHANASIA; NURSES; DESIRE; CARE AB Background: Oregon's Death with Dignity Act (ODDA), which legalized physician-assisted suicide (PAS) for terminally ill individuals, was enacted in 1997. Eighty-six percent of the 171 patients who have died by PAS were enrolled in hospice. Objective: To survey hospice chaplains regarding their views on the ODDA and experiences working with patients who request PAS. Design: Single, anonymous, mailed survey. Subjects: All chaplains affiliated with one of Oregon's 50 hospices. Results: Fifty of 77 hospice chaplains whom we identified (65%) returned the survey. Forty-two percent of respondents opposed the ODDA and 40% supported it. Over half of respondents had, in the previous 3 years, worked with a patient who had made an explicit request for assisted suicide. Conversation with patients around PAS focused on the role of faith and spirituality in this decision, reasons for wanting hastened death, and family concerns or reactions to PAS. Chaplains did not feel that they had a strong influence on the patient's decisions about PAS (mean score of 4 on a 0-10 scale), though three chaplains reported a patient who withdrew their request for PAS because of the chaplain's involvement. Chaplains reported provision of a nonjudgmental presence helped the relationship with the patient. Conclusion: Oregon hospice chaplains are divided in their views on legalized PAS, but primarily see their role to deliver support to patients no matter what the patient's final decision regarding PAS. C1 Portland Vet Affairs Med Ctr, Div Mental Hlth, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. Oregon Hospice Assoc, Portland, OR USA. RP Ganzini, L (reprint author), Portland Vet Affairs Med Ctr, Div Mental Hlth, P3MHDC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM ganzinil@ohsu.edu NR 15 TC 13 Z9 13 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2005 VL 8 IS 6 BP 1160 EP 1166 DI 10.1089/jpm.2005.8.1160 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 045XS UT WOS:000237776600015 PM 16351529 ER PT J AU Doyle, PJ Hula, WD McNeil, MR Mikolic, JM Matthews, C AF Doyle, PJ Hula, WD McNeil, MR Mikolic, JM Matthews, C TI An application of Rasch analysis to the measurement of communicative functioning SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article; Proceedings Paper CT 34th Annual Clinical Aphasiology Conference CY 2004 CL Park City, UT DE communicative functioning; outcomes; Rasch analysis; measurement ID ITEM RESPONSE THEORY; STROKE IMPACT SCALE; RELIABILITY; SURVIVORS; VALIDITY; BURDEN; BOSS AB Purpose: The purposes of this investigation were to examine the construct dimensionality and range of ability effectively measured by 28 assessment items L obtained from 3 different patient-reported scales of communicative functioning, and to provide a demonstration of how the Rasch approach to measurement may contribute to the definition of latent constructs and the development of instruments to measure them. Method: Item responses obtained from 421 stroke survivors with and without communication disorders were examined using the Rasch partial credit model. The dimensionality of the item pool was evaluated by (a) examining correlations of Rasck person ability scores obtained separately from each of the 3 scales,. (b) iteratively excluding items exceeding mean square model fit criteria, and (c) using principal-components analysis of Rasch model residuals. The range of ability effectively measured by the item pool was examined by comparing item difficulty and category threshold calibrations to the distribution of person ability scores and by plotting the modeled standard error of person ability estimates as a function of person ability level. Results: The results indicate that most assessment items fit a unidimensional measurement model, with the notable exception of items relating to the use of written communication. The results also suggest that the range of ability that could be reliably measured by the current item pool was restricted relative to the range of ability observed in the patient sample. Conclusions: It is concluded that (a) a mature understanding of communicative functioning as a measurement construct will require further research, (b) patients with stroke-related communication disorders will be better served by the development of instruments measuring a wider range of communicative functioning ability, and (c) the theoretical and methodological tools provided by the Rasch family of measurement models may be productively applied to these efforts. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Doyle, PJ (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr,132A-H, Pittsburgh, PA 15206 USA. EM patrick.doyle@med.va.gov NR 52 TC 15 Z9 15 U1 0 U2 1 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD DEC PY 2005 VL 48 IS 6 BP 1412 EP 1428 DI 10.1044/1092-4388(2005/098) PG 17 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 022KY UT WOS:000236055900013 PM 16478380 ER PT J AU Walters, ST Matson, SA Baer, JS Ziedonis, DM AF Walters, ST Matson, SA Baer, JS Ziedonis, DM TI Effectiveness of workshop training for psychosocial addiction treatments: A systematic review SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Review DE workshop; training; clinicians; substance abuse; addiction ID COGNITIVE-BEHAVIORAL THERAPY; SUBSTANCE-ABUSE; EDUCATIONAL INTERVENTIONS; INTERVIEWING SKILLS; NETWORK THERAPY; CLINICAL-TRIALS; PRIMARY-CARE; ALCOHOL-USE; DISSEMINATION; PROGRAM AB Workshop training for psychosocial substance abuse treatment has been an important part of the transfer of evidence-based approaches into larger practice. Although they are widely used, training methods such as self-study reading, internet-based courses, and educational workshops have not traditionally been the focus of empirical investigations. Based on electronic and manual searches of the literature, we summarize 17 evaluations of workshop training that describe the training program and the educational outcomes. In general, training tends to improve attendees' knowledge, attitudes, and confidence in working with clients who have substance abuse problems. Some skill improvements, when measured, are usually seen immediately after training but are less often maintained over a longer time. Extended contact, through follow-up consultation, supervision, or feedback, appears to be necessary for the long-term adoption of skills. There are also a number of institutional factors that may influence the extent to which providers adopt new practices. Given the popularity of this training format, the role of workshop training needs to be a focus of future evaluative research. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Texas, Sch Publ Hlth, Dallas, TX 75390 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA. RP Walters, ST (reprint author), Univ Texas, Sch Publ Hlth, V-8,Room 112,5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM scott.walters@utsouthwestern.edu NR 41 TC 84 Z9 84 U1 2 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD DEC PY 2005 VL 29 IS 4 BP 283 EP 293 DI 10.1016/j.jsat.2005.08.006 PG 11 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 994YE UT WOS:000234066300007 PM 16311181 ER PT J AU Shireman, PK Quinones, MP AF Shireman, PK Quinones, MP TI Differential necrosis despite similar perfusion in mouse strains after ischemia SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE collateral circulation; laser Doppler imaging; arteriogenesis; hind limb ischemia ID ENDOTHELIAL PROGENITOR CELLS; ARTERY GROWTH ARTERIOGENESIS; CONVERTING ENZYME-INHIBITION; MURINE SKELETAL-MUSCLE; CRITICAL LIMB ISCHEMIA; INDUCED ANGIOGENESIS; COLLATERAL GROWTH; T-CELL; REPERFUSION INJURY; HINDLIMB ISCHEMIA AB Background. Numerous mouse models have been used to study the tissue response to ischemia, but multiple technical differences make comparisons difficult. We have comprehensively characterized the mouse hind limb ischemia model and determined how different genetic backgrounds of mice affect recovery. Materials and methods. Severity of tissue necrosis and restoration of perfusion after femoral artery excision or femoral artery transection, using five different surgical procedures, were evaluated using laser Doppler imaging in a mouse model of hind limb ischemia. Severity of necrosis was concurrently measured using a five-point scale. Results. Significant differences were observed depending upon the surgical procedure used to initiate ischemia as well as the strain of mouse used. First, a progressively delayed and incomplete recovery of vascular perfusion occurred in relation to the anatomical position and extent of the arterial defect. Second, among mouse strains, the severity of tissue necrosis varied despite similar restoration of perfusion. Thus, DBA/1J mice had significantly increased severity and incidence of tissue loss as compared with either C57BI/6J (P = 0.01) or BALB/c (P = 0.01) mice. Finally, contrary to previous reports, T-cell-mediated immune events did not modify ischemia-induced hind limb perfusion and necrosis as responses in nude mice were not different than controls on either BALB/c or C57BI/6J backgrounds. Conclusions. Surgical approach, mouse strain, and measures of hind limb perfusion and tissue injury are crucial considerations in the study of ischemia. Understanding how different genetic backgrounds in mice can affect necrosis may provide insights into the diverse healing responses observed in humans. (c) 2005 Elsevier Inc. All rights reserved. C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. Barshop Inst Longev & Aging Studies, Dept Med, San Antonio, TX USA. Barshop Inst Longev & Aging Studies, Dept Surg, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RP Shireman, PK (reprint author), Univ Texas, Hlth Sci Ctr, Dept Surg, Div Vasc Surg, MSC 7741,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU NHLBI NIH HHS [HL074236, HL070158] NR 53 TC 39 Z9 39 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2005 VL 129 IS 2 BP 242 EP 250 DI 10.1016/j.jss.2005.06.013 PG 9 WC Surgery SC Surgery GA 995WJ UT WOS:000234135000010 PM 16051277 ER PT J AU Rotunda, AM Ablon, G Kolodney, MS AF Rotunda, AM Ablon, G Kolodney, MS TI Lipomas treated with subcutaneous deoxycholate injections SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID MIXED MICELLES; FAT PADS; PHOSPHATIDYLCHOLINE; SOLUBILIZATION; MESOTHERAPY AB Background: Lipomas are benign neoplasms of mature fat cells. Current treatments are invasive and carry the risk of scarring. Injections of phosphatidylcholine solubilized with deoxycholate, a bile salt, have been used to reduce unwanted accumulations of fat. Recent in vitro and ex vivo investigations indicate that deoxycholate alone causes adipocyte lysis. Objective: We sought to report our experience treating lipomas subcutaneous deoxycholate injections. Methods: A total of 6 patients presenting with 12 lipomas were treated with intralesional injections of sodium deoxycholate (1.0%, 2.5% and 5.0%) at intervals of 2 to 20 weeks. Tumor size, cutaneous reactions, and patients' subjective responses were recorded before and after treatment. Results: All lipomas decreased in size (mean area reduction, 75%, range, 37%-100%) as determined by clinical measurement (with ultrasound in one lipoma) after an average of 2.2 treatments. Several lipomas fragmented or because softer in addition to decreasing in volume. Adverse effects, including transient burning, erythema, and local swelling, were associated with higher deoxycholate concentations but resolved without intervention. There was no clear association between deoxycholate concentration and efficacy. Conclusions: Our clinical experience supports our laboratory investigations demonstrating that deoxycholate, rather than phosphatidylcholine, is the active ingredient in subcutaneously injected formulas used to treat adipose tissue. this small series suggests that low concentration deoxycholate may be a relatively safe and effective treatment for small collections of fat. However, controlled clinical trials will ne necessary to substantiate these observations. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90024 USA. Harbor UCLA Med Ctr, W Los Angeles Vet Adm Med Ctr, Dept Dermatol, Torrance, CA 90509 USA. Harbor UCLA Med Ctr, Dept Med, Div Dermatol, Torrance, CA 90509 USA. Biomed Res Inst, Torrance, CA USA. RP Rotunda, AM (reprint author), Bennett Surg Ctr, St Johns Med Plaza,Suite 590, Santa Monica, CA 90404 USA. EM arotunda@hotmail.com NR 19 TC 46 Z9 48 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD DEC PY 2005 VL 53 IS 6 BP 973 EP 978 DI 10.1016/j.jaad.2005.07.068 PG 6 WC Dermatology SC Dermatology GA 990PQ UT WOS:000233756100005 PM 16310057 ER PT J AU Ganz, DA Higashi, T Rubenstein, LZ AF Ganz, DA Higashi, T Rubenstein, LZ TI Monitoring falls in cohort studies of community-dwelling older people: Effect of the recall interval SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE mental recall; falls; systematic review; bias; reproducibility of results ID RISK-FACTORS; EPIDEMIOLOGY AB OBJECTIVES: To determine whether the interval over which patients are asked to remember their falls affects fall reporting. DESIGN: Systematic literature review. SETTING: Community. PARTICIPANTS: Individuals being monitored for falls in prospective studies that asked participants to recall falls over varying intervals. MEASUREMENTS: Sensitivity and specificity of retrospective recall compared with a criterion-standard prospective assessment using some form of ongoing fall monitoring. RESULTS: Six studies met the inclusion criteria. Recall of falls in the previous year was specific (specificity 91-95%) but less sensitive (sensitivity 80-89%) than the criterion standard of ongoing prospective collection of fall data using fall calendars or postcards. Patients with injurious falls were more likely to recall their falls. Lower Mini-Mental State Examination score was associated with poorer recall of falls in the one study addressing this issue. CONCLUSION: Whenever accurate data on all falls are critical, such as with interventions to decrease the rate of falls, researchers should gather information on falls every week or every month from study participants. The optimal method of fall monitoring-postcard, calendar, diary, telephone, or some combination of these-remains unknown. C1 Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Mulicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. Univ Calif Los Angeles, Specialty Training & Adv Res Program, Los Angeles, CA USA. Kyoto Univ, Dept Epidemiol & Hlth Care Res, Kyoto, Japan. RP Ganz, DA (reprint author), Robert Wood Johnson Clin Scholars Program, 911 Broxton Pl,3rd Floor, Los Angeles, CA 90024 USA. EM dganz@mednet.ucla.edu NR 13 TC 172 Z9 175 U1 1 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2005 VL 53 IS 12 BP 2190 EP 2194 DI 10.1111/j.1532-5415.2005.00509.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 987PL UT WOS:000233529700022 PM 16398908 ER PT J AU Moody-Ayers, SY Stewart, AL Covinsky, KE Inouye, SK AF Moody-Ayers, SY Stewart, AL Covinsky, KE Inouye, SK TI Prevalence and correlates of perceived societal racism in older African-American adults with type 2 diabetes mellitus SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE perceived racism; racial or ethnic bias; discrimination; diabetes mellitus; African American ID SELF-RATED HEALTH; WHITE ADULTS; DISCRIMINATION; MORTALITY; PERCEPTIONS; COMMUNITY; RACE AB Although experiences of racism in day-to-day life may affect minority patients' interaction with the health system and may influence health outcomes, little is known about these experiences in patients with chronic diseases. The goal of this study was to explore the frequency and correlates of perceived societal racism in 42 African Americans aged 50 and older with type 2 diabetes mellitus. Twenty-seven items of the McNeilly Perceived Racism Scale were used to assess exposure to racist incidents in employment and public domains and emotional and coping responses to perceived racism in general. Mean age was 62, 71% were women, and more than half rated their health as fair/poor (55%). Overall, 95.2% of the participants reported at least some exposure to perceived societal racism. Higher mean lifetime exposure to societal racism, based on summary scores on the perceived racism scale, was reported by men (35.0 +/- 19.1) than women (19.7 +/- 14.4) (P <.01) and by those with higher household income (30.7 +/- 17.3) than those with lower household income (18.6 +/- 15.1) (P <.05). Greater passive coping (e.g., "avoiding it," "ignoring it") was associated with being female and having lower household income and fair/poor self-rated health. The findings that perception of racism and a range of emotional and coping responses were common in older African-American patients attending two diabetes clinics suggest that physicians and other healthcare providers may need to be more aware of patients' day-to-day experiences of societal racism and the influence these experiences may have on patient trust in the medical system and their adherence to medical advice or engagement in self-management of their chronic conditions. C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, Div Geriatr, Inst Hlth & Aging, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Aging Diverse Communities, Med Effectiveness Res Ctr Diverse Populat, Inst Hlth & Aging, San Francisco, CA 94143 USA. Yale Univ, Sch Med, Dept Med, New Haven, CT USA. RP Moody-Ayers, SY (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM sandra.moody@med.va.gov FU AHRQ HHS [K02HS000006-01]; NIA NIH HHS [1R01AG019827-01, K24AG00949, P30-AG15272, P30AG21342, R01AG12551] NR 29 TC 35 Z9 35 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2005 VL 53 IS 12 BP 2202 EP 2208 DI 10.1111/J.1532-5415.2005.00501.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 987PL UT WOS:000233529700024 PM 16398910 ER PT J AU Seliger, SL Longstreth, WT Katz, R Manolio, T Fried, LF Shlipak, M Stehman-Breen, CO Newman, A Sarnak, M Gillen, DL Bleyer, A Siscovick, DS AF Seliger, SL Longstreth, WT Katz, R Manolio, T Fried, LF Shlipak, M Stehman-Breen, CO Newman, A Sarnak, M Gillen, DL Bleyer, A Siscovick, DS TI Cystatin C and subclinical brain infarction SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 37th Annual Meeting of the American-Society-of-Nephrology CY OCT 27-NOV 01, 2004 CL St Louis, MO SP Amer Soc Nephrol ID STAGE RENAL-DISEASE; CARDIOVASCULAR-HEALTH; SERUM CREATININE; ELDERLY-PEOPLE; ROTTERDAM SCAN; OLDER-ADULTS; RISK; STROKE; ATHEROSCLEROSIS; INSUFFICIENCY AB Subclinical brain infarcts (SBI) are common in the elderly and are associated with covert neurologic and cognitive impairment. Although renal impairment is associated with accelerated cerebrovascular disease and an increased risk for clinically apparent brain infarct, few studies have examined the relationship between renal function and SBI, and these m ay have been limited by the inaccuracy of creatinine as a renal function marker. A cross-sectional study was performed among older adults in the Cardiovascular Health Study to examine associations between SBI and two serum markers of renal function: Serum creatinine (SCr) and cystatin C (CysC). Patients had cranial magnetic resonance imaging and renal markers measured in 1992 to 1993. Logistic regression was used to estimate the associations between renal function (estimated by 1/SCr and 1/CysC) and SBI, controlling for potential confounding factors. SBI were present in 789 (28.7%) of 2784 participants. A linear association with SBI was observed for 1/CysC (per 1-SD decrement; odds ratio [OR] 1.20; 95% confidence interval [CI] 1.09 to 1.32; P < 0.001) but not for 1/SCr (OR 1.08; 95% CI 0.98 to 1.19; P = 0.14), for which a quadratic U-shaped association was;suggested (P = 0.004). In a model with both markers, 1/CysC was linearly associated with SBI (OR 1.26; P < 0.001), whereas 1/SCr was not (OR 1.06; P = 0.3). The prevalence of SBI was directly associated with quintile of CysC, whereas the association 'between SCr and SBI was U-shaped, with greater prevalence at high and low levels. Compared with creatinine, CysC, a novel marker of renal function, has a stronger and more direct association with SBI in the elderly. C1 Univ Maryland, Div Nephrol, Baltimore, MD 21201 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol & Med, Seattle, WA 98195 USA. NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA. Pittsburgh VA Med Ctr, Div Nephrol, Pittsburgh, PA USA. San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA 02111 USA. Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. Wake Forest Univ, Div Nephrol, Winston Salem, NC 27109 USA. RP Seliger, SL (reprint author), Univ Maryland, Div Nephrol, N3W143,22 S Greene St, Baltimore, MD 21201 USA. EM sseliger@medicine.umaryland.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01-HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85086]; NIDDK NIH HHS [K23-DK063079] NR 31 TC 84 Z9 97 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2005 VL 16 IS 12 BP 3721 EP 3727 DI 10.1681/ASN.2005010006 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 992ON UT WOS:000233893600033 PM 16236809 ER PT J AU Fried, LF Katz, R Sarnak, MJ Shlipak, MG Chaves, PHM Jenny, NS Stehman-Breen, C Gillen, D Bleyer, AJ Hirsch, C Siscovick, D Newman, AB AF Fried, LF Katz, R Sarnak, MJ Shlipak, MG Chaves, PHM Jenny, NS Stehman-Breen, C Gillen, D Bleyer, AJ Hirsch, C Siscovick, D Newman, AB TI Kidney function as a predictor of noncardiovascular mortality SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR-DISEASE RISK; CHRONIC RENAL-INSUFFICIENCY; ELDERLY PERSONS; US ADULTS; MARKER; CREATININE; HEALTH; DEATH AB Chronic kidney disease is associated with a higher risk for cardiovascular mortality, as well as all-cause mortality. Whether chronic kidney disease is a predictor of noncardiovascular mortality is less clear. To further explore the latter, the association of kidney function with total noncardiovascular mortality and cause-specific mortality was assessed in the Cardiovascular Health Study, a community-based cohort of older individuals. Kidney disease was assessed using cystatin C and estimated GFR in 4637 participants in 1992 to 1993. Participants were followed until June 30, 2001. Deaths were adjudicated as cardiovascular or noncardiovascular disease by committee, and an underlying cause of death was assigned. The associations of kidney function with total noncardiovascular mortality and cause-specific mortality were analyzed by proportional hazards regression. Noncardiovascular mortality rates increased with higher cystatin C quartiles (16.8, 17.1, 21.6, and 50.0 per 1000 person-years). The association of cystatin C with noncardiovascular mortality persisted after adjustment for demographic factors; the presence of diabetes, C-reactive protein, hemoglobin, and prevalent cardiovascular disease; and measures of atherosclerosis (hazard ratio 1.69; 95% confidence interval 1.33 to 2.15, for the fourth quartile versus the first quartile). Results for estimated GFR were similar. The risk for noncardiac deaths attributed to pulmonary disease, infection, cancer, and other causes was similarly associated with cystatin C levels. Kidney function predicts noncardiovascular mortality from multiple causes in the elderly. Further research is needed to understand the mechanisms and evaluate interventions to reduce the high mortality rate in chronic kidney disease. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Div Renal & Electrolyte, Pittsburgh, PA 15240 USA. Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. Tufts Univ, New England Med Ctr, Dept Med, Div Nephrol, Boston, MA 02111 USA. Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. Johns Hopkins Univ, Dept Med, Baltimore, MD USA. Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. Univ Vermont, Dept Pathol, Coll Med, Burlington, VT USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Univ Calif Irvine, Dept Stat, Irvine, CA USA. Wake Forest Univ, Sch Med, Nephrol Sect, Winston Salem, NC 27109 USA. Univ Calif Davis, Med Ctr, Dept Med, Sacramento, CA 95817 USA. Univ Calif Davis, Med Ctr, Dept Publ Hlth Sci, Sacramento, CA 95817 USA. Univ Washington, Dept Med Epidemiol & Hlth Serv, Seattle, WA 98195 USA. Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Fried, LF (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM linda.fried@med.va.gov RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01-HC-85086, N01-HC-15103, N01-HC-35129, N01-HC-85079] NR 40 TC 176 Z9 179 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2005 VL 16 IS 12 BP 3728 EP 3735 DI 10.1681/ASN.2005040384 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 992ON UT WOS:000233893600034 PM 16251239 ER PT J AU Ikeno, Y Hubbard, GB Lee, S Richardson, A Strong, R Diaz, V Nelson, JF AF Ikeno, Y Hubbard, GB Lee, S Richardson, A Strong, R Diaz, V Nelson, JF TI Housing density does not influence the longevity effect of calorie restriction SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID GROWTH-FACTOR-I; LIFE-SPAN; FOOD RESTRICTION; DIETARY RESTRICTION; FISCHER-344 RATS; MICE; INSULIN; AGE; PATHOGENESIS; RETARDATION AB This study examined the effect of housing density on the longevity-extending and disease-delaying actions of calorie restriction (CR). Singly or multiply housed (four per cage) mice were either fed ad libitum (AL) or were on CR beginning at 2 months. All CR mice were fed 40% less food than were multiply housed AL mice. CR increased median longevity by 19%, and housing density had no effect on this increase. CR also reduced neoplastic lesions in both housing groups, but lymphoma, the most common neoplasm, was reduced more in singly than in multiply housed mice. Singly housed AL mice ate 40% more food than did multiply housed AL mice, but weighed the same and lived as long as multiply housed AL mice. These results indicate that CR can extend life span as effectively in multiply as in singly housed mice, even though housing density can differentially affect the cancer-reducing effect of CR. C1 UTHSCSA, Dept Physiol, San Antonio, TX 78229 USA. UTHSCSA, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. UTHSCSA, Dept Pharmacol, San Antonio, TX 78229 USA. UTHSCSA, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. SW Fdn Biomed Res, Dept Lab Anim Med, San Antonio, TX USA. RP Nelson, JF (reprint author), UTHSCSA, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM nelsonj@uthscsa.edu FU NIA NIH HHS [1P30-AG13319, AG19899] NR 40 TC 50 Z9 50 U1 3 U2 5 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2005 VL 60 IS 12 BP 1510 EP 1517 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 005RK UT WOS:000234841300003 PM 16424282 ER PT J AU Danda, RS Habiba, NM Rincon-Choles, H Bhandari, BK Barnes, JL Abboud, HE Pergola, PE AF Danda, RS Habiba, NM Rincon-Choles, H Bhandari, BK Barnes, JL Abboud, HE Pergola, PE TI Kidney involvement in a nongenetic rat model of type 2 diabetes SO KIDNEY INTERNATIONAL LA English DT Article DE nephropathy; insulin; streptozotocin; obesity; high fat diet; type 2 diabetes ID GROWTH-FACTOR-BETA; DIET-INDUCED OBESITY; RENAL EXPRESSION; BLOOD-PRESSURE; NEPHROPATHY; STREPTOZOTOCIN; HYPERTENSION; MELLITUS; INJURY; HYPERCHOLESTEROLEMIA AB Background. Rats fed a high fat diet and given a low dose of streptozotocin (STZ) (35 mg/kg) develop type 2 diabetes with insulin resistance, hyperinsulinemia, moderate hyperglycemia, hyperlipidemia, and salt-sensitive hypertension. We postulated that rats with noninsulinopenic (type 2) diabetes develop lesions of diabetic nephropathy significantly more prominent than those seen in classic insulinopenic (type 1) diabetic rats. Methods. Rats were fed regular chow or high fat diet (60% calories from fat and 70% animal fat). After 5 weeks, rats fed regular chow received vehicle (controls) or 55 mg/kg STZ (type 1 diabetes mellitus). Rats fed high fat diet received vehicle (high fat) or low dose STZ, 35 mg/kg (type 2 diabetes mellitus). Rats were sacrificed 14 weeks after STZ/vehicle injection. Results. Blood glucose, systolic blood pressure, and urinary protein excretion were significantly higher in both diabetes groups than in controls. Serum insulin levels (ng/mL) were higher in type 2 diabetes than in type 1 diabetes groups (0.49 +/- 0.12 vs. 0.07 +/- 0.07) (P = 0.01). Percentage of sclerosed glomeruli was significantly higher in type 2 diabetes group than in control and type 1 diabetes groups. Fibronectin expression was significantly increased in high fat, type 1 and type 2 diabetes groups compared to controls. The expression of type IV collagen, connective tissue growth factor (CTGF), and transforming growth factor-beta (TGF-beta) was significantly increased in high fat and type 2 diabetes groups compared to controls. Conclusion. Rats fed a high fat diet and given a low dose of STZ developed diabetes (with normal/high insulin levels), hypertension, and proteinuria. Kidney lesions in this type 2 model appear to be more pronounced than in type 1 diabetic rats despite lower blood glucose levels and proteinuria. We present a nongenetic rat model of type 2 diabetes mellitus and nephropathy. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Pergola, PE (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM pergola@uthscsa.edu FU NHLBI NIH HHS [T32 HL07446] NR 34 TC 66 Z9 79 U1 0 U2 11 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2005 VL 68 IS 6 BP 2562 EP 2571 DI 10.1111/j.1523-1755.2005.00727.x PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 983AU UT WOS:000233204300011 PM 16316331 ER PT J AU Oates, JC Varghese, S Bland, AM Taylor, TP Self, SE Stanislaus, R Almeida, JS Arthur, JM AF Oates, JC Varghese, S Bland, AM Taylor, TP Self, SE Stanislaus, R Almeida, JS Arthur, JM TI Prediction of urinary protein markers in lupus nephritis SO KIDNEY INTERNATIONAL LA English DT Article DE lupus nephritis; biomarkers; urine; electrophoresis; two-dimensional gel ID RENAL-ALLOGRAFT REJECTION; GEL-ELECTROPHORESIS; ERYTHEMATOSUS; PROTEOMICS; IDENTIFICATION; GLOMERULONEPHRITIS AB Background. Lupus nephritis is divided into six classes and scored according to activity and chronicity indices based on histologic findings. Treatment differs based on the pathologic findings. Renal biopsy is currently the only way to accurately predict class and activity and chronicity indices. We propose to use patterns of abundance of urine proteins to identify class and disease indices. Methods. Urine was collected from 20 consecutive patients immediately prior to biopsy for evaluation of lupus nephritis. The International Society of Nephrology/Renal Pathology Society (ISN/RPS) class of lupus nephritis, activity, and chronicity indices were determined by a renal pathologist. Proteins were separated by two-dimensional gel electrophoresis. Artificial neural networks were trained on normalized spot abundance values. Results. Biopsy specimens were classified in the database according to ISN/RPS class, activity, and chronicity. Nine samples had characteristics of more than one class present. Receiver operating characteristic (ROC) curves of the trained networks demonstrated areas under the curve ranging from 0.85 to 0.95. The sensitivity and specificity for the ISN/RPS classes were class II 100%, 100%; III 86%, 100%; IV 100%, 92%; and V 92%, 50%. Activity and chronicity indices had r values of 0.77 and 0.87, respectively. A list of spots was obtained that provided diagnostic sensitivity to the analysis. Conclusion. We have identified a list of protein spots that can be used to develop a clinical assay to predict ISN/RPS class and chronicity for patients with lupus nephritis. An assay based on antibodies against these spots could eliminate the need for renal biopsy, allow frequent evaluation of disease status, and begin specific therapy for patients with lupus nephritis. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, 829 CSB,96 Jonathon Lucas Dr, Charleston, SC 29425 USA. EM arthurj@musc.edu FU NCRR NIH HHS [M01 RR001070, M01 RR001070-30A15172, M01 RR001070-315791, RR01070]; NHLBI NIH HHS [N01-HV-28181, N01HV28181]; NIAMS NIH HHS [R21 AR051719, R21 AR051719-01, R21 AR051719-02, R21AR051719] NR 26 TC 46 Z9 47 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2005 VL 68 IS 6 BP 2588 EP 2592 DI 10.1111/j.1523-1755.2005.00730.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 983AU UT WOS:000233204300014 PM 16316334 ER PT J AU Jiang, T Liebman, SE Lucia, MS Li, JP Levi, M AF Jiang, T Liebman, SE Lucia, MS Li, JP Levi, M TI Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease SO KIDNEY INTERNATIONAL LA English DT Article DE SREBPs; cholesterol; triglycerides; nephropathy; glomerular basement membrane thickness; podocyte width ID LOW-DENSITY-LIPOPROTEIN; FATTY-ACID SYNTHESIS; MESANGIAL CELLS; DIABETIC-NEPHROPATHY; COLORIMETRIC DETERMINATION; CHOLESTEROL TRANSPORT; REPLACEMENT THERAPY; INSULIN-RESISTANCE; GLOMERULAR INJURY; GENE-EXPRESSION AB RBackground. There are well-known changes in age-related renal function and structure, including glomerulosclerosis and decline in glomerular filtration rate (GFR). The purpose of this study was to identify a potential role for lipids in mediating age-related renal disease. Methods. Mice of five different age groups (3, 6, 12, 19, and 23 months old) were studied. Results. We have found that in C57BL/6 mice there was a progressive increase in age-related glomerulosclerosis [increase in periodic acid-Schiff (PAS) staining and accumulation of extracellular matrix proteins including type IV collagen and fibronectin], increased glomerular basement thickness and podocyte width and effacement, and increased proteinuria. These changes were associated with age-related increase in lipid accumulation as determined by increased Oil Red O staining in kidney sections. Biochemical analysis indicated that these lipid deposits corresponded to significant increases in renal triglyceride and cholesterol content. We have also found significant age-related increases in the nuclear transcription factors, sterol regulatory element-binding proteins (SREBP-1 and SREBP-2), protein abundance and increased expression or activity of their target enzymes that play an important role in lipid synthesis. Conclusion. Our results indicated that there was an age-related increase in renal expression of SREBP-1 and SREBP-2 with resultant increases in lipid synthesis and triglyceride and cholesterol accumulation in the kidney. Because we have previously shown that increased expression of SREBPs in the kidney per se results in glomerulosclerosis and proteinuria, our data suggested that increased SREBPs' expression resulting in increased renal lipid accumulation may play an important role in age-related nephropathy. C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. RP Levi, M (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, 4200 E 9th Ave,C281, Denver, CO 80262 USA. EM Moshe.Levi@UCHSC.edu OI Levi, Moshe/0000-0002-6225-946X FU NIA NIH HHS [7R03 AG20361-02]; NIDDK NIH HHS [1F32 DK065407-01, 5R01 DK062209-02] NR 71 TC 53 Z9 56 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2005 VL 68 IS 6 BP 2608 EP 2620 DI 10.1111/j.1523-1755.2005.00733.x PG 13 WC Urology & Nephrology SC Urology & Nephrology GA 983AU UT WOS:000233204300017 PM 16316337 ER PT J AU Pereira, RI Draznin, B AF Pereira, RI Draznin, B TI Inhibition of the phosphatidylinositol 3 '-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID CORONARY-ARTERY-DISEASE; PROTEIN-ADIPONECTIN; PLASMA-CONCENTRATIONS; ADIPOSE-TISSUE; PHOSPHOINOSITIDE 3-KINASE; SKELETAL-MUSCLE; GENE-EXPRESSION; DEFICIENT MICE; RESISTANCE; KINASE AB Adiponectin is a protein secreted by adipocytes, which modulates insulin resistance and is thought to confer protection from atherosclerosis. Decreased circulating adiponectin is seen in states of insulin resistance, yet the cause of this decrease remains unclear. We investigated the role of insulin in adiponectin secretion and the effect of selective insulin resistance on insulin-stimulated adiponectin secretion by 3T3-L1 adipocytes. Inhibition of the phosphatidylinositol 3'-kinase (PI3K) insulin-signaling pathway was induced with wortmannin (WT) or with a kinase-inactive Akt adenoviral construct (Akt-KD), and inhibition of the mitogen-activated protein kinase pathway was induced with PD98059 or with a dominant-negative ras adenoviral construct (DNras). The PI3K pathway was activated with a constitutively active Akt adenoviral construct (Akt-myr). Adiponectin was measured by Western blot, and adiponectin messenger RNA (mRNA) levels were determined by real-time reverse transcription-polymerase chain reaction. Insulin treatment increased adiponectin secretion and decreased intracellular adiponectin. Treatment with 100 nmol/L insulin for 24 hours resulted in a 78% increase in secreted adiponectin (P < .05). Insulin had no effect on adiponectin mRNA. WT or Akt-KD, but not PD98059 or DNras, inhibited insulin-stimulated adiponectin secretion (P < .05). Activation of the PI3K pathway resulted in increased insulin-independent adiponectin secretion. Inhibition of the PI3K- or mitogen-activated protein kinase-dependent pathway decreased adiponectin mRNA by 50% (P < .01). We demonstrate a decrease in insulin-stimulated adiponectin secretion with selective inhibition of the PI3K pathway. These results suggest a mechanism for the observed decreased adiponectin levels associated with insulin resistance, when defects in the PI3K-dependent insulin-signaling pathway lead to decreased adiponectin production, inadequate adiponectin secretion, and therefore low circulating adiponectin levels. (c) 2005 Elsevier Inc. All rights reserved. C1 Denver Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA. Univ Colorado, Dept Med, Denver, CO 80262 USA. Hlth Sci Ctr, Denver, CO 80262 USA. RP Draznin, B (reprint author), Denver Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA. EM boris.draznin@med.va.gov NR 57 TC 35 Z9 37 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD DEC PY 2005 VL 54 IS 12 BP 1636 EP 1643 DI 10.1016/j.metabol.2005.07.002 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 995TU UT WOS:000234127800013 PM 16311098 ER PT J AU Knudsen, GM Medzihradszky, KF Lim, KC Hansell, E McKerrow, JH AF Knudsen, GM Medzihradszky, KF Lim, KC Hansell, E McKerrow, JH TI Proteomic analysis of Schistosoma mansoni cercarial secretions SO MOLECULAR & CELLULAR PROTEOMICS LA English DT Article ID IN-GEL DIGESTION; PROTEIN IDENTIFICATION; SERINE-PROTEASE; LIFE-CYCLE; CLONING; SKIN; ANTIGENS; TEGUMENT; IMMUNOGENICITY; PENETRATION AB Schistosomiasis is a global health problem caused by several species of schistosome blood flukes. The initial stage of infection is invasion of human skin by a multicellular larva, the cercaria. We identified proteins released by cercariae when they are experimentally induced to exhibit invasive behavior. Comparison of the proteome obtained from skin lipid-induced cercariae (the natural activator), a cleaner mechanical induction procedure, and an uninduced proteomic control allowed identification of protein groups contained in cercarial acetabular gland secretion versus other sources. These included a group of proteins involved in calcium binding, calcium regulation, and calcium-activated functions; two proteins (paramyosin and SPO-1) implicated in immune evasion; and protease isoforms implicated in degradation of host skin barriers. Several other protein families, traditionally found as cytosolic proteins, appeared concentrated in secretory cells. These included proteins with chaperone activity such as HSP70, -86, and -60. Comparison of the three experimental proteomes also allowed identification of protein contaminants from the environment that were identified because of the high sensitivity of the MS/MS system used. These included proteins from the intermediate host snail in which cercariae develop, the investigator, and the laboratory environment. Identification of proteins secreted by invasive larvae provides important new information for validation of models of skin invasion and immune evasion and aids in rational development of an anti-schistosome vaccine. C1 Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Sandler Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA. Univ Calif San Francisco, Mass Spectrometry Facil, Dept Pharmaceut Chem, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP McKerrow, JH (reprint author), Univ Calif San Francisco, Dept Pathol, QB3,Box 2550,McKerrow 508B, San Francisco, CA 94143 USA. EM jmck@cgl.ucsf.edu FU NCRR NIH HHS [RR001614, RR012961, RR015804]; NIGMS NIH HHS [P41 GM103481] NR 42 TC 123 Z9 130 U1 3 U2 19 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 1535-9476 J9 MOL CELL PROTEOMICS JI Mol. Cell. Proteomics PD DEC PY 2005 VL 4 IS 12 BP 1862 EP 1875 DI 10.1074/mcp.M500097-MCP200 PG 14 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 990WP UT WOS:000233774200003 PM 16112986 ER PT J AU Nishimura, RN Sharp, FR AF Nishimura, RN Sharp, FR TI Heat shock proteins and neuromuscular disease SO MUSCLE & NERVE LA English DT Review DE amyotrophic lateral sclerosis; cell injury; chaperones; heat shock proteins; inflammatory myopathy; motor neuron disease; muscle; muscular dystrophy; neuromuscular diseases; neuropathy; stress proteins ID ALPHA-B-CRYSTALLIN; HUMAN SKELETAL-MUSCLE; AMYOTROPHIC-LATERAL-SCLEROSIS; BULBAR MUSCULAR-ATROPHY; RAT HINDLIMB MUSCLES; CONTINUOUS CONTRACTILE ACTIVITY; ENDOPLASMIC-RETICULUM STRESS; ANDROGEN RECEPTOR PROTEIN; DESMIN-RELATED MYOPATHY; HSP72 GENE-EXPRESSION AB The heat shock proteins are families of proteins with known activities that include chaperoning nascent peptides within the cell and cytoprotection. Most work on the nervous system has related to the role of heat shock proteins in neuroprotection from either hypoxic-ischemic or traumatic injury. The role of these proteins during normal physiological activity and injury is still under investigation. Heat shock proteins in neuromuscular disease have been investigated to some extent but were largely neglected until recently. The goal of this review is to summarize the evidence linking heat shock proteins with neuromuscular disease and to provide some insight into the roles or functions of these proteins in disease states. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA. Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. RP Nishimura, RN (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, 16111 Plummer St, Sepulveda, CA 91343 USA. EM rnishimu@ucla.edu NR 169 TC 28 Z9 28 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD DEC PY 2005 VL 32 IS 6 BP 693 EP 709 DI 10.1002/mus.20373 PG 17 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 990HP UT WOS:000233734100001 PM 15962334 ER PT J AU Karlamangla, AS Singer, BH Chodosh, J McEwen, BS Seeman, TE AF Karlamangla, AS Singer, BH Chodosh, J McEwen, BS Seeman, TE TI Urinary cortisol excretion as a predictor of incident cognitive impairment SO NEUROBIOLOGY OF AGING LA English DT Article; Proceedings Paper CT SPARK Workshop 2004 CY JUL, 2004 CL Bar Harbor, ME DE urine cortisol; resting cortisol levels; incident cognitive impairment; cognitive decline; longitudinal study; prospective cohort ID MENTAL STATUS QUESTIONNAIRE; ALZHEIMERS-DISEASE; PLASMA-CORTISOL; DEHYDROEPIANDROSTERONE-SULFATE; VASCULAR DEMENTIA; MACARTHUR; BRAIN; CORTICOSTEROIDS; STRESS; WOMEN AB Elevated glucocorticoid levels have been associated with cognitive impairment, including dementia. However, few longitudinal studies have examined the association between resting cortisol levels and the incidence of cognitive impairment. We measured overnight urinary excretion of cortisol in 538 high-functioning men and women, 70-79 years of age, in 1988, and assessed their cognitive functioning in 1988, 199 1, and 1995 using the short portable mental status questionnaire (SPMSQ). Compared to participants in the bottom quartile of urinary cortisol at baseline, those in the top three quartiles had higher risk of incident cognitive impairment over the 7-year follow up (i.e., decline in SPMSQ score to below six out of nine). This association was not affected by adjustment for age, gender, education level, ethnicity, smoking, prevalent cardiovascular disease, and blood pressure (adjusted odds ratio for the highest quartile 2.34, 95% confidence interval, 1.07-5.14). There was no effect modification by gender; the association was equally strong in men and women. We conclude that urinary excretion of cortisol predicts incident cognitive impairment in older men and women. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA. VA Greater Los Angeles Hlth Syst, Hlth Serv Res, Los Angeles, CA USA. Rockefeller Univ, Neuroendocrinol Lab, New York, NY 10021 USA. RP Karlamangla, AS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, 10945 Le Conte 2339, Los Angeles, CA 90095 USA. EM akarlamangla@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 NR 36 TC 15 Z9 15 U1 5 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD DEC PY 2005 VL 26 SU 1 BP S80 EP S84 DI 10.1016/j.neurobiolaging.2005.09.037 PG 5 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 995SF UT WOS:000234123400018 ER PT J AU Floren, A Sollenberg, U Lundstrom, L Zorko, M Stojan, J Budihna, M Wheatley, M Martin, NP Kilk, K Mazarati, A Bartfai, T Lindgren, M Langel, U AF Floren, A Sollenberg, U Lundstrom, L Zorko, M Stojan, J Budihna, M Wheatley, M Martin, NP Kilk, K Mazarati, A Bartfai, T Lindgren, M Langel, U TI Multiple interaction sites of galnon trigger its biological effects SO NEUROPEPTIDES LA English DT Article DE galanin; galnon; G-protein; receptor; signaling ID GALANIN-RECEPTOR AGONIST; BETA-ADRENERGIC-RECEPTOR; HIPPOCAMPAL GALANIN; STATUS EPILEPTICUS; HIGH-AFFINITY; PEPTIDES; PROTEINS; LIGANDS; BRAIN; STIMULATION AB Galnon was first reported as a low molecular weight non-peptide agonist at galanin receptors [Saar et al. (2002) Proc. Natl. Acad. Sci. USA 99, 7136-7141]. Following its systemic administration, this synthetic ligand affected a range of important physiological processes including appetite, seizures and pain. Physiological activity of galnon could not be explained solely by the activation of the three known galanin receptors, GalR1, GalR2 and GalR3. Consequently, it was possible that galnon generates its manifold effects by interacting with other signaling pathway components, in addition to via GalR1-3. In this report, we establish that galnon: (i) can penetrate across the plasma membrane of cells, (ii) can activate intracellular G-proteins directly independent of receptor activation thereby triggering downstream signaling, (iii) demonstrates selectivity for different G-proteins, and (iiii) is a ligand to other G-protein coupled receptors (GPCRs) in addition to via GalR1-3. We conclude that galnon has multiple sites of interaction within the GPCR signaling cascade which mediate its physiological effects. (c) 2005 Elsevier Ltd. All rights reserved. C1 Univ Stockholm, Dept Neurochem, SE-10691 Stockholm, Sweden. Univ Ljubljana, Fac Med, Inst Biochem, Ljubljana 1000, Slovenia. Univ Ljubljana, Fac Med, Inst Pharmacol & Expt Toxicol, Ljubljana 1000, Slovenia. Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England. Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA. Univ Tartu, Ctr Mol & Clin Med, EE-51014 Tartu, Estonia. Univ Calif Los Angeles, Dept Neurol, W Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90073 USA. Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA. RP Langel, U (reprint author), Univ Stockholm, Dept Neurochem, S Arrheniusv 21 A, SE-10691 Stockholm, Sweden. EM ulo@neurochem.su.se OI Martin, Negin/0000-0003-3166-8989 FU NINDS NIH HHS [NS043409] NR 38 TC 24 Z9 25 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0143-4179 J9 NEUROPEPTIDES JI Neuropeptides PD DEC PY 2005 VL 39 IS 6 BP 547 EP 558 DI 10.1016/j.npep.2005.09.005 PG 12 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 993NF UT WOS:000233960100002 PM 16297447 ER PT J AU Olson, V AF Olson, V TI Norepinephrine in opiate reward, locomotion, and withdrawal: Evidence for distinct contributions by the locus coeruleus and the nucleus tractus solitarius SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 44th Annual Meeting of the American-College-Neuropsychopharmacology CY DEC 11-15, 2005 CL Waikoloa, HI SP Vanderbilt Univ Sch Med Dept Psychiat C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2005 VL 30 SU 1 BP S2 EP S2 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 986IA UT WOS:000233442100005 ER PT J AU Pierre, JM Peloian, JH Wirshing, DA Wirshing, WC Marder, SR AF Pierre, JM Peloian, JH Wirshing, DA Wirshing, WC Marder, SR TI A double-blind placebo controlled trial of modafinil for negative symptoms in schizophrenia SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 44th Annual Meeting of the American-College-Neuropsychopharmacology CY DEC 11-15, 2005 CL Waikoloa, HI SP Vanderbilt Univ Sch Med Dept Psychiat C1 VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2005 VL 30 SU 1 BP S207 EP S207 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 986IA UT WOS:000233442100538 ER PT J AU Ashraf, A Abdullatif, H Hardin, W Moates, JM AF Ashraf, A Abdullatif, H Hardin, W Moates, JM TI Unusual case of neonatal diabetes mellitus due to congenital pancreas agenesis SO PEDIATRIC DIABETES LA English DT Article DE gall bladder agenesis; Ipf-1; neonatal diabetes; pancreas agenesis; pancreas development ID INFLAMMATORY DEMYELINATING POLYNEUROPATHY; GUILLAIN-BARRE-SYNDROME; REGULATORY T-CELLS; SCHWANN-CELLS; SERUM LEVELS; NOD MICE; NEUROPATHY; POLYRADICULONEUROPATHY; SUSCEPTIBILITY; EXPRESSION AB Congenital absence of the pancreas is an extremely rare condition. We participated in the care of a patient with an unusual presentation of neonatal diabetes attributable to agenesis of the pancreas. Additional clinical features of the patient included cardiac septal defects, gall bladder agenesis and duodenal malrotation. Appropriate institution of insulin, exocrine pancreatic supplements and surgical repair of the cardiac and intestinal anomalies resulted in the infant's survival. Of the reported cases of congenital pancreas agenesis, two cases have been ascribed to mutations in the insulin promoter factor-1 (Ipf-1) gene. Deletion of the Ipf-1-homolog pdx-1 in mice results in the failure of pancreas to develop. Analysis of both exons of the Ipf-1 coding sequence from the presented patient's genomic DNA, however, did not identify a mutation. These results suggest that a congenital or genetic perturbation occurred in this infant most likely before the appearance of dorsal pancreatic bud in the 3 mm long embryonic stage, around the embryonic day 25 in human development, before the onset of Ipf-1 expression. C1 Childrens Hosp Alabama, Dept Pediat, Div Pediat Endocrinol & Metab, Birmingham, AL 35233 USA. Childrens Hosp Alabama, Dept Pediat Surg, Birmingham, AL 35233 USA. Univ Alabama, Sch Med, Dept Med, Div Endocrinol & Metab, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Ashraf, A (reprint author), Childrens Hosp Alabama, Dept Pediat, Div Pediat Endocrinol & Metab, 1600 7th Ave S, Birmingham, AL 35233 USA. EM aashraf@peds.uab.edu NR 30 TC 19 Z9 19 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1399-543X J9 PEDIATR DIABETES JI Pediatr. Diabetes PD DEC PY 2005 VL 6 IS 4 BP 239 EP 248 DI 10.1111/j.1399-543X.2005.00114.x PG 10 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 001XK UT WOS:000234575800010 PM 16390394 ER PT J AU Sachs, G Weeks, DL Wen, Y Marcus, EA Scott, DR Melchers, K AF Sachs, G Weeks, DL Wen, Y Marcus, EA Scott, DR Melchers, K TI Acid acclimation by Helicobacter pylori SO PHYSIOLOGY LA English DT Review ID PROTON MOTIVE FORCE; ESCHERICHIA-COLI; UREASE ACTIVITY; GASTRIC-MUCOSA; IN-VIVO; AGMATINE ANTIPORTER; VIBRIO-CHOLERAE; PH HOMEOSTASIS; GENES; RESISTANCE AB Helicobacter pylori is a Gram-negative neutralophile associated with peptic ulcers and gastric cancer. It has a unique ability to colonize the human stomach by acid acclimation. It uses the pH-gated urea channel, Urel, to enhance urea access to intrabacterial urease and a membrane-anchored periplasmic carbonic anhydrase to regulate periplasmic pH to similar to 6.1 in acidic media, whereas other neutralophiles cannot regulate periplasmic pH and thus only transit the stomach. C1 Univ Calif Los Angeles, David Geffen Sch Med, Lab Membrane Biol, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Altana Res Inst, Boston, MA USA. RP Sachs, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Lab Membrane Biol, Los Angeles, CA 90024 USA. EM gsachs@ucla.edu FU NIDDK NIH HHS [DK-46917, DK-53462, DK-58333] NR 63 TC 66 Z9 69 U1 2 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1548-9213 J9 PHYSIOLOGY JI Physiology PD DEC PY 2005 VL 20 BP 429 EP 438 DI 10.1152/physiol.00032.2005 PG 10 WC Physiology SC Physiology GA 986XA UT WOS:000233481800008 PM 16287992 ER PT J AU Xu, AW Kaelin, CB Morton, GJ Ogimoto, K Stanhope, K Graham, J Baskin, DG Havel, P Schwartz, MW Barsh, GS AF Xu, AW Kaelin, CB Morton, GJ Ogimoto, K Stanhope, K Graham, J Baskin, DG Havel, P Schwartz, MW Barsh, GS TI Effects of hypothalamic neurodegeneration on energy balance SO PLOS BIOLOGY LA English DT Article ID AGOUTI-RELATED PROTEIN; ARCUATE NUCLEUS; NEUROPEPTIDE-Y; GENE-EXPRESSION; FOOD-INTAKE; OB/OB MICE; NEURONS; PROOPIOMELANOCORTIN; LEPTIN; OBESITY AB Normal aging in humans and rodents is accompanied by a progressive increase in adiposity. To investigate the role of hypothalamic neuronal circuits in this process, we used a Cre-lox strategy to create mice with specific and progressive degeneration of hypothalamic neurons that express agouti-related protein (Agrp) or proopiomelanocortin (Pomc), neuropeptides that promote positive or negative energy balance, respectively, through their opposing effects on melanocortin receptor signaling. In previous studies, Pomc mutant mice became obese, but Agrp mutant mice were surprisingly normal, suggesting potential compensation by neuronal circuits or genetic redundancy. Here we find that Pomc-ablation mice develop obesity similar to that described for Pomc knockout mice, but also exhibit defects in compensatory hyperphagia similar to what occurs during normal aging. Agrp-ablation female mice exhibit reduced adiposity with normal compensatory hyperphagia, while animals ablated for both Pomc and Agrp neurons exhibit an additive interaction phenotype. These findings provide new insight into the roles of hypothalamic neurons in energy balance regulation, and provide a model for understanding defects in human energy balance associated with neurodegeneration and aging. C1 Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA. Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98195 USA. Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Barsh, GS (reprint author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA. EM gbarsh@cmgm.stanford.edu RI Schwartz, Michael/H-9950-2012 FU NIDDK NIH HHS [DK48506, DK68384, P01 DK068384, R01 DK048506] NR 43 TC 99 Z9 99 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD DEC PY 2005 VL 3 IS 12 BP 2168 EP 2176 AR e415 DI 10.1371/journal.pbio.0030415 PG 9 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 992SI UT WOS:000233903800012 PM 16296893 ER PT J AU Turner, E AF Turner, E TI Correction/clarification about FDA review documents SO PLOS MEDICINE LA English DT Letter ID TRIALS C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Turner, E (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. EM turnere@ohsu.edu RI Turner, Erick/A-4848-2008 OI Turner, Erick/0000-0002-3522-3357 NR 4 TC 3 Z9 3 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD DEC PY 2005 VL 2 IS 12 BP 1343 EP 1343 AR e422 DI 10.1371/journal.pmed.0020422 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 003XD UT WOS:000234714700022 PM 16363916 ER PT J AU Sonn, GA Aronson, W Litwin, MS AF Sonn, GA Aronson, W Litwin, MS TI Impact of diet on prostate cancer: a review SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Review DE prostate cancer; diet; supplements ID HIGH-FAT DIET; VITAMIN-E; PROSPECTIVE COHORT; UNITED-STATES; GREEN TEA; ALPHA-TOCOPHEROL; LNCAP TUMORS; NETHERLANDS-COHORT; INDUCED APOPTOSIS; DECREASED GROWTH AB Epidemiological studies suggest that environmental factors may mediate the transformation of latent prostate cancer into clinically apparent tumors and that diet appears to influence this progression. Close correlations between average per capita fat intake and prostate cancer mortality internationally generated interest in underlying mechanisms for this link, such as through serum levels of androgens, free radicals, proinflammatory fatty acid metabolites, or insulin-like growth factor. Much interest currently lies in the potential of HMG-CoA reductase inhibitors (statins) to play a chemopreventative role in prostate cancer. Lycopene, a potent antioxidant found in tomatoes, may exert a protective effect in the prostate. Selenium and vitamin E have also been shown to decrease the risk of prostate cancer in some men. Calcium may support vitamin D-related antiproliferative effects in prostate cancer. Certain soy proteins, common in the Asian diet, have been shown to inhibit prostate cancer cell growth. Finally, green tea may also have a chemopreventive effect by inducing apoptosis. Despite confounding factors present in clinical studies assessing the effect of diet on cancer risk, the data remain compelling that a variety of nutrients may prevent the development and progression of prostate cancer. C1 Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Litwin, MS (reprint author), Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Box 951738, Los Angeles, CA 90095 USA. EM mlitwin@mednet.ucla.edu NR 93 TC 89 Z9 91 U1 3 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD DEC PY 2005 VL 8 IS 4 BP 304 EP 310 DI 10.1038/sj.pcan.4500825 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 999VE UT WOS:000234418000002 PM 16130015 ER PT J AU Ray, R Doyle, GA Crowley, JJ Buono, RJ Oslin, DW Patkar, AA Mannelli, P DeMaria, PA O'Brien, CP Berrettini, WH AF Ray, R Doyle, GA Crowley, JJ Buono, RJ Oslin, DW Patkar, AA Mannelli, P DeMaria, PA O'Brien, CP Berrettini, WH TI A functional prodynorphin promoter polymorphism and opioid dependence SO PSYCHIATRIC GENETICS LA English DT Article DE addiction and genetics; dynorphin; opioid; polymorphism ID GENE; SUPPRESSION; WITHDRAWAL; EXPRESSION; DYNORPHIN; COCAINE AB Objectives The prodynorphin gene (PDYN) promoter has a repeat polymorphism that is functionally important in association with substance abuse. We examined this polymorphism for association in our sample of 168 opioid-dependent patients and 122 ethnically and geographically matched controls. Methods Patients were selected from university-affiliated residential and non-residential addiction treatment programs in the Philadelphia area. A sample of blood was drawn from consenting individuals and genomic DNA was isolated. Polymerase chain reaction amplification of the PDYN promoter was performed and various genotypes were determined on the basis of differing sizes of the polymerase chain reaction products. The genotype and allele data were analyzed by Fisher's exact test. Result A significant difference in genotype (P < 0.0006) and allele (p < 10(-5)) frequencies was found between the African American and European American populations. We did not detect any significant difference in genotype or allele frequencies between the patients and controls within the European American ethnic group. However, we detected a weak association (P= 0.013) when we compared allele frequencies of patients and controls in the African American population. Conclusions These data suggest that the PDYN repeat polymorphism should be studied in additional opioid-dependent populations. Psychiatr Genet 15:295-298 (c) 2005 Lippincott Williams & Wilkins. C1 Univ Penn, Sch Med, Ctr Neurobiol & Behav, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA USA. RP Berrettini, WH (reprint author), Univ Penn, Sch Med, Ctr Neurobiol & Behav, Dept Psychiat, Room 111,415 Curie Blvd, Philadelphia, PA 19104 USA. EM wadeb@mail.med.upenn.edu OI Crowley, James/0000-0001-9051-1557 FU PHS HHS [P60-05186] NR 10 TC 17 Z9 17 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0955-8829 J9 PSYCHIAT GENET JI Psychiatr. Genet. PD DEC PY 2005 VL 15 IS 4 BP 295 EP 298 DI 10.1097/00041444-200512000-00013 PG 4 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA 993UB UT WOS:000233979500012 PM 16314761 ER PT J AU Miller, DD McEvoy, JP Davis, SM Caroff, SN Saltz, BL Chakos, MH Swartz, MS Keefe, RSE Rosenheck, RA Stroup, TS Lieberman, JA AF Miller, DD McEvoy, JP Davis, SM Caroff, SN Saltz, BL Chakos, MH Swartz, MS Keefe, RSE Rosenheck, RA Stroup, TS Lieberman, JA TI Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial SO SCHIZOPHRENIA RESEARCH LA English DT Article DE tardive dyskinesia; schizophrenia; antipsychotic adverse effects; clinical features ID ABNORMAL INVOLUNTARY MOVEMENTS; RISK-FACTORS; ANTIPSYCHOTIC TRIALS; NEGATIVE SYMPTOMS; OLDER PATIENTS; PSYCHIATRIC-PATIENTS; DRUG-ADDICTION; USE DISORDERS; PREVALENCE; ASSOCIATION AB Objective: To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment. Methods: Baseline data on 1460 patients with schizophrenia were collected as part of the Clinical Antipsychotic, Trials of intervention Effectiveness schizophrenia study. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Multiple regression analyses were used to examine the relationship between TD and clinical variables. Results: 212 subjects met the Schooler-Kane criteria for probable TD and 1098 had no history or current evidence of TD. Subjects with TD were older, had a longer duration of receiving antipsychotic medication, and were more likely to have been receiving a conventional antipsychotic and an anticholinergic agent. After controlling for important baseline covariates, diabetes mellitus (DM) and hypertension did not predict TD, whereas substance abuse significantly predicted TD. Differences in cognitive functioning were not significantly different after controlling for baseline covariates. The. TD subjects also had higher ratings of psychopathology, EPSE, and akathisia. Conclusion: Our results confirm the established relationships between the presence of TD and age, duration of treatment with antipsychotics, treatment with a conventional antipsychotic, treatment with anticholinergics, the presence of EPS and akathisia, and substance abuse. Subjects with TD had higher ratings of psychopathology as measured by the PANSS. We found no support for DM or hypertension increasing the risk of TD, or for TD being associated with cognitive impairment. (c) 2005 Elsevier B.V. All rights reserved. C1 Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA. Duke Univ, Med Ctr, Durham, NC USA. Quintiles Inc, Res Triangle Pk, NC USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Mental Hlth Advocates Inc, Boca Raton, FL USA. Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. Yale Univ, Sch Med, West Haven, CT 06516 USA. Univ N Carolina, Sch Med, Neurosci Hosp, Chapel Hill, NC USA. RP Miller, DD (reprint author), Univ Iowa, Carver Coll Med, 2-105 MEB,500 Newton Rd, Iowa City, IA 52242 USA. EM del-miller@uiowa.edu RI Stroup, Thomas/F-9188-2014 OI Stroup, Thomas/0000-0002-3123-0672 FU NIMH NIH HHS [N01 MH90001] NR 64 TC 82 Z9 83 U1 3 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC 1 PY 2005 VL 80 IS 1 BP 33 EP 43 DI 10.1016/j.schres.2005.07.034 PG 11 WC Psychiatry SC Psychiatry GA 002KU UT WOS:000234611100005 PM 16171976 ER PT J AU Joehl, RJ AF Joehl, RJ TI Preoperative evaluation: Pulmonary, cardiac, renal dysfunction and comorbidities SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article ID MAJOR NONCARDIAC SURGERY; ABDOMINAL-SURGERY; RISK-ASSESSMENT; PERIOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES; VASCULAR-SURGERY; OBESE PATIENTS; SURGICAL RISK; TASK-FORCE; EVENTS AB This article reviews evidence supporting the exercise of risk assessment and demonstrates how it assists in determining which patients should undergo a planned invasive procedure. The article focuses on the preoperative functional assessment of three major organ systems-cardiac, pulmonary, and renal-and reviews guidelines for determining which patients need additional testing of organ system function. The article also discusses how to improve the condition of selected patients so that the surgeon can achieve the best possible result and outcome. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv 112, Hines, IL 60141 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. RP Joehl, RJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv 112, Roosevelt Rd & 5th Ave,POB 5000, Hines, IL 60141 USA. EM raymond.joel@med.va.gov NR 40 TC 8 Z9 8 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0039-6109 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD DEC PY 2005 VL 85 IS 6 BP 1061 EP + DI 10.1016/j.suc.2005.09.015 PG 14 WC Surgery SC Surgery GA 999JV UT WOS:000234386500003 PM 16326193 ER PT J AU Gibbs, VC AF Gibbs, VC TI Patient safety practices in the operating room: Correct-site surgery and nothing left behind SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article ID SURGICAL SPONGES AB Not until the late 1990s, after the publication of the National Academy of Medicine's treatise '' To Err Is Human,'' did safety standards specifically for patients begin to be considered in operating room practices. This report and other studies documented operating room mistakes including, for example, operations on the wrong hand or limb, operations on the wrong patient, and the performance of wrong procedures. Cases have also been documented of sponges or instruments being left by mistake inside patients following surgery. Poor communication is the most common root cause of errors. This article explores these issues and explains procedures and protocols developed to reduce surgical errors. C1 Univ Calif San Francisco, Dept Surg, QI Program, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Gibbs, VC (reprint author), Univ Calif San Francisco, Dept Surg, QI Program, 533 Parnassus Ave,U-157,Box 0617, San Francisco, CA 94143 USA. EM gibbsv@surgery.ucsf.edu NR 18 TC 28 Z9 28 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0039-6109 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD DEC PY 2005 VL 85 IS 6 BP 1307 EP + DI 10.1016/j.suc.2005.09.007 PG 14 WC Surgery SC Surgery GA 999JV UT WOS:000234386500021 PM 16326211 ER PT J AU Cai, JM Hatsukami, TS Ferguson, MS Kerwin, WS Saam, T Chu, BC Takaya, N Polissar, NL Yuan, C AF Cai, JM Hatsukami, TS Ferguson, MS Kerwin, WS Saam, T Chu, BC Takaya, N Polissar, NL Yuan, C TI In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque - Comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology SO CIRCULATION LA English DT Article DE magnetic resonance imaging; carotid arteries; contrast media; atherosclerosis; lipids ID SUDDEN CORONARY DEATH; LESIONS; MRI; CLASSIFICATION; RUPTURE; INTRAPLAQUE; COMPONENTS; THICKNESS; ACCURACY; STENOSIS AB Background - Previous studies with contrast- enhanced magnetic resonance imaging ( CEMRI) have shown that the fibrous cap ( FC) in atherosclerotic carotid plaques enhances with gadolinium- based contrast agents. Conversely, the lipid- rich necrotic core ( LR- NC), lacking both vasculature and matrix, shows no or only slight enhancement. The goal of this study was to assess whether CEMRI can be used to accurately measure the dimensions of the intact FC and LR- NC. Methods and Results - Twenty- one patients scheduled for carotid endarterectomy were imaged with a 1.5- T scanner. Precontrast images and CEMRI were obtained. One hundred eight locations with an intact FC were matched between MRI and the excised histology specimens. Quantitative measurements of FC length along the lumen circumference, FC area, and LR- NC area were collected from CEMRI images and histology sections. Blinded comparison of corresponding MR images and histology slices showed moderate to good correlation for length ( r = 0.73, P < 0.001) and area ( r = 0.80, P < 0.001) of the intact FC. The mean percentage LR- NC areas ( LR- NC area/ wall area) measured by CEMRI and histology were 30.1% and 32.7%, respectively, and were strongly correlated across locations ( r = 0.87, P < 0.001). Conclusions - In vivo high- resolution CEMRI is capable of quantitatively measuring the dimensions of the intact FC and LR- NC. These new parameters may be useful to evaluate plaque vulnerability and provide continuous variables for characterizing the intact FC and LR- NC in progression and regression studies. C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. Mtn Whisper Light Stat Consulting, Seattle, WA USA. RP Yuan, C (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM cyuan@u.washington.edu FU NHLBI NIH HHS [R01 HL56874, R01 HL61816] NR 29 TC 249 Z9 281 U1 0 U2 22 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 29 PY 2005 VL 112 IS 22 BP 3437 EP 3444 DI 10.1161/CIRCULATIONHA.104.528174 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 988AC UT WOS:000233558300013 PM 16301346 ER PT J AU Rattan, R Giri, S Singh, AK Singh, I AF Rattan, R Giri, S Singh, AK Singh, I TI 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MTOR SIGNALING PATHWAY; PEUTZ-JEGHERS-SYNDROME; FATTY-ACID OXIDATION; N-TERMINAL KINASE; INDUCED APOPTOSIS; PERMEABLE ACTIVATOR; MAMMALIAN TARGET; RIBONUCLEOSIDE; SURVIVAL; GROWTH AB 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside ( AICAR) is widely used as an AMP-kinase activator, which regulates energy homeostasis and response to metabolic stress. Here, we investigated the effect of AICAR, an AMPK activator, on proliferation of various cancer cells and observed that proliferation of all the examined cell lines was significantly inhibited by AICAR treatment due to arrest in S-phase accompanied with increased expression of p21, p27, and p53 proteins and inhibition of PI3K-Akt pathway. Inhibition in in vitro growth of cancer cells was mirrored in vivo with increased expression of p21, p27, and p53 and attenuation of Akt phosphorylation. Anti-proliferative effect of AICAR is mediated through activated AMP-activated protein kinase ( AMPK) as iodotubericidin and dominant-negative AMPK expression vector reversed the AICAR-mediated growth arrest. Moreover, constitutive active AMPK arrested the cells in S-phase by inducing the expression of p21, p27, and p53 proteins and inhibiting Akt phosphorylation, suggesting the involvement of AMPK. AICAR inhibited proliferation in both LKB and LKB knock-out mouse embryo fibroblasts to similar extent and arrested cells at S-phase when transfected with dominant negative expression vector of LKB. Altogether, these results indicate that AICAR can be utilized as a therapeutic drug to inhibit cancer, and AMPK can be a potential target for treatment of various cancers independent of the functional tumor suppressor gene, LKB. C1 Med Univ S Carolina, Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA. Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Childrens Res Inst, Dept Pediat, 173 Ashley Ave,5th Floor, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, NS-40810] NR 46 TC 251 Z9 260 U1 0 U2 11 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 25 PY 2005 VL 280 IS 47 BP 39582 EP 39593 DI 10.1074/jbc.M507443200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 985FL UT WOS:000233362200081 PM 16176927 ER PT J AU Gorin, Y Block, K Hernandez, J Bhandari, B Wagner, B Barnes, JL Abboud, HE AF Gorin, Y Block, K Hernandez, J Bhandari, B Wagner, B Barnes, JL Abboud, HE TI Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID GLOMERULAR MESANGIAL CELLS; AKT/PROTEIN KINASE-B; ANGIOTENSIN-II; OXIDATIVE STRESS; NADPH OXIDASE; HIGH-GLUCOSE; EXTRACELLULAR-MATRIX; PROTEIN-SYNTHESIS; GENE-EXPRESSION; DNA-DAMAGE AB Renal hypertrophy and extracellular matrix accumulation are early features of diabetic nephropathy. We investigated the role of the NAD(P) H oxidase Nox4 in generation of reactive oxygen species (ROS), hypertrophy, and fibronectin expression in a rat model of type 1 diabetes induced by streptozotocin. Phosphorothioated antisense (AS) or sense oligonucleotides for Nox4 were administered for 2 weeks with an osmotic minipump 72 h after streptozotocin treatment. Nox4 protein expression was increased in diabetic kidney cortex compared with non-diabetic controls and was down-regulated in AS-treated animals. AS oligonucleotides inhibited NADPH-dependent ROS generation in renal cortical and glomerular homogenates. ROS generation by intact isolated glomeruli from diabetic animals was increased compared with glomeruli isolated from AS-treated animals. AS treatment reduced whole kidney and glomerular hypertrophy. Moreover, the increased expression of fibronectin protein was markedly reduced in renal cortex including glomeruli of AS-treated diabetic rats. Akt/protein kinase B and ERK1/2, two protein kinases critical for cell growth and hypertrophy, were activated in diabetes, and AS treatment almost abolished their activation. In cultured mesangial cells, high glucose increased NADPH oxidase activity and fibronectin expression, effects that were prevented in cells transfected with AS oligonucleotides. These data establish a role for Nox4 as the major source of ROS in the kidneys during early stages of diabetes and establish that Nox4-derived ROS mediate renal hypertrophy and increased fibronectin expression. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA. RP Abboud, HE (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM abboud@uthsca.edu OI Gorin, Yves/0000-0003-4048-6925; Wagner, Brent/0000-0002-7063-0142 FU NIDDK NIH HHS [DK43988, DK33665] NR 62 TC 294 Z9 307 U1 2 U2 14 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 25 PY 2005 VL 280 IS 47 BP 39616 EP 39626 DI 10.1074/jbc.M502412200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 985FL UT WOS:000233362200085 PM 16135519 ER PT J AU Sandmaier, BM Maris, MB Maloney, DG Gooley, TA Shizuru, JA Niederwieser, DW Chauncey, TR Sahebi, F Agura, E Maziarz, RT Bruno, B Pulsipher, M Langston, AA Wade, J McSweeney, PA Epner, E Bethge, W Forman, SJ Blume, KG Storb, R AF Sandmaier, BM Maris, MB Maloney, DG Gooley, TA Shizuru, JA Niederwieser, DW Chauncey, TR Sahebi, F Agura, E Maziarz, RT Bruno, B Pulsipher, M Langston, AA Wade, J McSweeney, PA Epner, E Bethge, W Forman, SJ Blume, KG Storb, R TI Hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies using low-dose TBI conditioning. SO BLOOD LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-of-Hematology CY DEC 10-13, 2005 CL Atlanta, GA SP Amer Soc Hematol C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Washington, Seattle, WA 98195 USA. Stanford Univ, Stanford, CA 94305 USA. Univ Leipzig, D-7010 Leipzig, Germany. City Hope Natl Med Ctr, Duarte, CA 91010 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Turin, Turin, Italy. Baylor Univ, Dallas, TX USA. Rocky Mt Blood & Marrow Transplantat, Denver, CO USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Univ Utah, Salt Lake City, UT USA. Emory Univ, Atlanta, GA 30322 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Univ Tubingen, Tubingen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2005 VL 106 IS 11 MA 655 BP 194A EP 194A PN 1 PG 1 WC Hematology SC Hematology GA 986CF UT WOS:000233426001124 ER PT J AU Kerbauy, F Maris, M Storer, B Maloney, D Niederwieser, D Agura, E Pulsipher, M Chauncey, T Maziarz, R Forman, S Langston, A Wade, J Scott, B Deeg, J Storb, R Sandmaier, BM AF Kerbauy, F Maris, M Storer, B Maloney, D Niederwieser, D Agura, E Pulsipher, M Chauncey, T Maziarz, R Forman, S Langston, A Wade, J Scott, B Deeg, J Storb, R Sandmaier, BM TI Efficacy of nonmyeloablative hematopoietic cell transplant (HCT) in secondary myelodysplastic syndrome (MDS) and its impact on the primary disease. SO BLOOD LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-of-Hematology CY DEC 10-13, 2005 CL Atlanta, GA SP Amer Soc Hematol C1 Fred Hutchinson Canc Res Ctr, CRD, Seattle, WA 98104 USA. Univ Washington, Seattle, WA 98195 USA. Univ Leipzig, D-7010 Leipzig, Germany. Baylor Univ, Dallas, TX USA. Univ Utah, Salt Lake City, UT USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Emory Univ, Atlanta, GA 30322 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2005 VL 106 IS 11 MA 792 BP 234A EP 234A PN 1 PG 1 WC Hematology SC Hematology GA 986CF UT WOS:000233426001261 ER PT J AU Sharma, S Lichtenstein, A AF Sharma, S Lichtenstein, A TI Premature termination codon mutations in chronic lymphocytic leukemia (CLL): Identification of potential tumor suppressors in CLL including E-cadherin SO BLOOD LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-of-Hematology CY DEC 10-13, 2005 CL Atlanta, GA SP Amer Soc Hematol C1 Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2005 VL 106 IS 11 MA 2935 BP 824A EP 824A PN 1 PG 1 WC Hematology SC Hematology GA 986CF UT WOS:000233426005255 ER PT J AU Schittenhelm, MM Shiraga, S Schroeder, A Corbin, AS Griffith, D Lee, FY Deininger, MW Druker, BJ Heinrich, MC AF Schittenhelm, MM Shiraga, S Schroeder, A Corbin, AS Griffith, D Lee, FY Deininger, MW Druker, BJ Heinrich, MC TI Dasatinib (BMS-354825), a multi-targeted kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane and activation loop mutant kit isoforms associated with human malignancies SO BLOOD LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-of-Hematology CY DEC 10-13, 2005 CL Atlanta, GA SP Amer Soc Hematol C1 Univ Tubingen, Tubingen, Germany. Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Bristol Myers Squibb Co, Princeton, NJ 08543 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2005 VL 106 IS 11 MA 3358 BP 938A EP 939A PN 1 PG 2 WC Hematology SC Hematology GA 986CF UT WOS:000233426006142 ER PT J AU Frost, P Hoang, B Shi, YJ Yan, HJ Lichtenstein, A AF Frost, P Hoang, B Shi, YJ Yan, HJ Lichtenstein, A TI Anti-angiongenic effects of mTOR-inhibitors is regulated by AKT activity in multiple myeloma cells SO BLOOD LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-of-Hematology CY DEC 10-13, 2005 CL Atlanta, GA SP Amer Soc Hematol C1 W Los Angeles VA Med Ctr, Dept Hematol Oncol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2005 VL 106 IS 11 MA 3406 BP 951A EP 951A PN 1 PG 1 WC Hematology SC Hematology GA 986CF UT WOS:000233426006190 ER PT J AU Poorkaj, P Nutt, JG James, D Gancher, S Bird, TD Steinbart, E Schellenberg, GD Payami, H AF Poorkaj, P Nutt, JG James, D Gancher, S Bird, TD Steinbart, E Schellenberg, GD Payami, H TI Parkin mutation analysis in clinic patients with early-onset Parkinson's disease (vol 129, pg 44, 2004) SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Correction C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Washington, Div Gerontol & Geriat Med, Seattle, WA 98195 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. Kaiser Permanente, Portland, OR USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. Univ Washington, Dept Neurol & Pharmacol, Seattle, WA 98195 USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Div Genet Disorders, 120 New Scotland Ave, Albany, NY 12208 USA. EM hpayami@wadsworth.org NR 1 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD NOV 15 PY 2005 VL 139A IS 1 BP 56 EP 56 DI 10.1002/ajmg.a.30937 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA 981AL UT WOS:000233059300016 ER PT J AU Sundrud, MS VanCompernolle, SE Eger, KA Bruno, TC Subramaniam, A Mummidi, S Ahuja, SK Unutmaz, D AF Sundrud, MS VanCompernolle, SE Eger, KA Bruno, TC Subramaniam, A Mummidi, S Ahuja, SK Unutmaz, D TI Transcription factor GATA-1 potently represses the expression of the HIV-1 coreceptor CCR5 in human T cells and dendritic cells SO BLOOD LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTORS; ERYTHROID-CELLS; GENE-EXPRESSION; MAST-CELLS; TH2 CELLS; IN-VITRO; INFECTION; DIFFERENTIATION; PROMOTER AB CC chemokine receptor 5 (CCR5) is the major HIV-1 coreceptor and its expression levels are a critical determinant of HIV-1 infection. However, the molecular mechanisms of CCR5 regulation in primary targets of HIV-1 remain unknown. Despite binding to conserved DNA elements, we show that the transcription factors GATA binding protein 1 (GATA-1) and GATA-3 differentially suppress the expression of CCR5 in stem-cell-derived dendritic cells and primary human T-cell subsets. In addition, GATA-1 expression was also more potent than GATA-3 in suppressing T helper 1 (Th1)-associated genes, interferon-gamma (IFN gamma), and CXC chemokine receptor-3 (CXCR3). GATA-1, but not GATA-3, potently suppressed CCR5 transcription, thereby rendering human T cells resistant to CCR5-tropic HIV-1 infection. However, GATA-1 could also serve as a surrogate for GATA-3 in its canonic role of programming Th2 gene expression. These findings provide insight into GATA-3-mediated gene regulation during T-cell differentiation. Importantly, decoding the mechanisms of GATA-1-mediated repression of CCR5 may offer an opportunity to develop novel approaches to inhibit CCR5 expression in T cells. C1 Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Vet Adm Ctr AIDS & HIV Infect, San Antonio, TX USA. Sanofi Aventis Pharmaceut, Dept Internal Med, Bridgewater, NJ USA. RP Unutmaz, D (reprint author), Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, 21st Ave S,MCN-AA5206, Nashville, TN 37232 USA. EM AHUJAS@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 FU NIAID NIH HHS [R01-AI043279, R01-AI054206] NR 52 TC 11 Z9 11 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 2005 VL 106 IS 10 BP 3440 EP 3448 DI 10.1182/blood-2005-03-0857 PG 9 WC Hematology SC Hematology GA 982US UT WOS:000233187700028 PM 16091457 ER PT J AU Goemans, BF Zwaan, CM Harlow, A Loonen, AH Gibson, BES Hahlen, K Reinhardt, D Creutzig, U Heinrich, MC Kaspers, GJL AF Goemans, BF Zwaan, CM Harlow, A Loonen, AH Gibson, BES Hahlen, K Reinhardt, D Creutzig, U Heinrich, MC Kaspers, GJL TI In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets SO BLOOD LA English DT Article ID ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RAS GENE-MUTATIONS; FARNESYL TRANSFERASE INHIBITORS; ACUTE MYELOGENOUS LEUKEMIA; N-RAS; DRUG-RESISTANCE; FARNESYLTRANSFERASE INHIBITORS; MYELODYSPLASTIC SYNDROME; PROTEIN TRANSFERASE AB Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill assay and compared these results to those obtained with normal bone marrow (N BM) samples (n = 25). AML samples were significantly more sensitive to tipifarnib compared to B-cell precursor ALL (BCP ALL) or IN BM samples. Within AML, French-American-British (FAB) M5 samples were most sensitive to tipifarnib. T-cell ALL samples were significantly more sensitive than BCP ALL and N BM samples. In AML there was a marked correlation between tipifarnib resistance and daunorubicin or etoposide resistance, but not to cytarabine or 6-thioguanine. RAS mutations were present in 32% of AML and 18% of ALL samples, but there was no correlation between RAS mutational status and sensitivity to tipifarnib. Future studies are needed to identify biomarkers predictive of tipifarnib sensitivity. In addition, clinical studies, especially in T-cell ALL, seem warranted. C1 VU Univ, Med Ctr, Dept Pediat Oncol Hematol, NL-1007 MB Amsterdam, Netherlands. Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Hematol Oncol, Rotterdam, Netherlands. Oregon Hlth Sci Univ, Inst Canc, Div Hematol & Med Oncol, Dept Med, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. MRC, Childhood Leukaemia Working Party, Glasgow, Lanark, Scotland. Dutch Childhood Oncol Grp, The Hague, Netherlands. AML BFM Study Grp, Munster, Germany. RP Goemans, BF (reprint author), VU Univ, Med Ctr, Dept Pediat Oncol Hematol, POB 7057, NL-1007 MB Amsterdam, Netherlands. EM bf.goemans@vumc.nl RI Reinhardt, Dirk/D-3939-2011 OI Reinhardt, Dirk/0000-0003-4313-9056 NR 39 TC 22 Z9 22 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 2005 VL 106 IS 10 BP 3532 EP 3537 DI 10.1182/blood-2005-04-1640 PG 6 WC Hematology SC Hematology GA 982US UT WOS:000233187700039 PM 16051737 ER PT J AU Ganz, PA Farmer, MM Belman, MJ Garcia, CA Streja, L Dietrich, AJ Winchell, C Bastani, R Kahn, KL AF Ganz, PA Farmer, MM Belman, MJ Garcia, CA Streja, L Dietrich, AJ Winchell, C Bastani, R Kahn, KL TI Results of a randomized controlled Trial to increase Colorectal cancer screening in a managed care health plan SO CANCER LA English DT Article DE quality improvement; randomized clinical trial; provider organizations; colorectal cancer screening; managed care ID PHYSICIAN PERFORMANCE; MEDICAL GROUPS; PREVENTION; CALIFORNIA; ADHERENCE; RECOMMENDATIONS; ORGANIZATIONS; INTERVENTIONS; SERVICES; COVERAGE AB BACKGROUND. Colorectal cancer (CRC) is the third most common cause of cancer deaths; however, rates Of regular screening for this cancer are low. A quality improvement (QI) program to increase CRC screening was developed for use in a managed care health plan. METHODS. Thirty-six provider organizations (POs) contracting with the health plan were recruited for a randomized controlled effectiveness trial testing the QI program. The intervention was delivered over a 2-year period, and its effectiveness was assessed by chart review of a random sample of patients from each PO. RESULTS. Thirty-two of the 36 POs were evaluable for outcome assessment. During the 2-year intervention period, only 26% of the eligible patients received any CRC screening test. Twenty-nine percent of patients had any CRC screening test within guidelines, with no differences between the intervention or control POs. Significant predictors of having received CRC screening within guidelines were older age (P = 0.0004), receiving care in an integrated medical group (P < 0.0001) and having had a physical examination within the past 2 years (P < 0.0001). CONCLUSIONS. A facilitated QI intervention program for CRC screening that focused on the PO did not increase rates of CRC screening. Overall CRC screening rates are low and are in need of improvement. (c) 2005 American Cancer Society. C1 Univ Calif Los Angeles, Div Canc Prevent & Control Res, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory & Nursing Home Ctr, VA Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. Blue Cross Calif, Woodland Hills, CA USA. Dartmouth Coll Sch Med, Dept Community & Family Med, Hanover, NH USA. RAND Corp, Santa Monica, CA USA. RP Ganz, PA (reprint author), Univ Calif Los Angeles, Div Canc Prevent & Control Res, Jonsson Comprehens Canc Ctr, 650 Charles Young Dr S,CHS A2-125, Los Angeles, CA 90095 USA. EM pganz@ucla.edu FU NCI NIH HHS [R01 CA75544] NR 48 TC 21 Z9 22 U1 2 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD NOV 15 PY 2005 VL 104 IS 10 BP 2072 EP 2083 DI 10.1002/cncr.21434 PG 12 WC Oncology SC Oncology GA 981QL UT WOS:000233103000005 PM 16216030 ER PT J AU Su, HL Spinale, FG Dobrucki, LW Song, J Hua, J Sweterlitsch, S Dione, DP Cavaliere, P Chow, C Bourke, BN Hu, XY Azure, M Yalamanchili, P Liu, R Cheesman, EH Robinson, S Edwards, S Sinusas, AJ AF Su, HL Spinale, FG Dobrucki, LW Song, J Hua, J Sweterlitsch, S Dione, DP Cavaliere, P Chow, C Bourke, BN Hu, XY Azure, M Yalamanchili, P Liu, R Cheesman, EH Robinson, S Edwards, S Sinusas, AJ TI Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling SO CIRCULATION LA English DT Article DE myocardial infarction; metalloproteinases; remodeling; radionuclide imaging ID ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR ENLARGEMENT; HEART-FAILURE; POSTMYOCARDIAL INFARCTION; CLINICAL-IMPLICATIONS; IN-VIVO; INHIBITION; EXPRESSION; MICE; RAT AB Background: Time-dependent activation of matrix metalloproteinases (MMPs) after myocardial infarction (MI) contributes to adverse left ventricular (LV) remodeling; however, noninvasive methods to monitor this process serially are needed. Methods and Results: MMP-targeted radiotracers were developed that displayed selective binding kinetics to the active MMP catalytic domain. Initial nonimaging studies were performed with a In-111-labeled MMP-targeted radiotracer (In-111-RP782) and negative control compound (In-111-RP788) in control mice (Ctrl) and in mice 1 week after surgically induced MI. Localization of In-111-RP782 was demonstrated within the MI by microautoradiography. A 334 +/- 44% increase (P < 0.001 versus Ctrl) in relative retention of In-111-RP782 was confirmed by gamma well counting of myocardium. Subsequent high-resolution dual-isotope planar and hybrid micro-single-photon emission computed tomography/CT imaging studies with an analogous Tc-99m-labeled MMP-targeted radiotracer (Tc-99m-RP805) and Tl-201 demonstrated favorable biodistribution and clearance kinetics of Tc-99m-RP805 for in vivo cardiac imaging, with robust retention 1 to 3 weeks after MI in regions of decreased 201Tl perfusion. Gamma well counting yielded a similar approximate to 300% increase in relative myocardial retention of Tc-99m-RP805 in MI regions (Ctrl, 102 +/- 9%; 1 week, 351 +/- 77%; 2 weeks, 291 +/- 45%; 3 weeks, 292 +/- 41%; P < 0.05 versus Ctrl). Myocardial uptake in the MI region was also significantly increased approximate to 5-fold when expressed as percentage injected dose per gram tissue. There was also a significant 2-fold increase in myocardial activity in remote regions relative to control mice, suggesting activation of MMPs in regions remote from the MI. Conclusions: This novel noninvasive targeted MMP radiotracer imaging approach holds significant diagnostic potential for in vivo localization of MMP activation and tracking of MMP-mediated post-MI remodeling. C1 Yale Univ, Sch Med, Expt Nucl Cardiol Lab, Div Cardiovasc Med,Dept Internal Med, New Haven, CT 06520 USA. Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT USA. Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Bristol Myers Squibb Med Imaging, N Billerica, MA USA. RP Sinusas, AJ (reprint author), Yale Univ, Sch Med, Expt Nucl Cardiol Lab, Div Cardiovasc Med,Dept Internal Med, 3FMP,POB 208017, New Haven, CT 06520 USA. EM albert.sinusas@yale.edu RI Sinusas, Albert/A-7235-2009 OI Dobrucki, Wawrzyniec/0000-0002-6807-217X FU NHLBI NIH HHS [P01-HL-48788, R01 HL078650, R01 HL078650-04, R01-HL-59165, R01-HL-65662] NR 26 TC 116 Z9 118 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 15 PY 2005 VL 112 IS 20 BP 3157 EP 3167 DI 10.1161/CIRCULATIONAHA.105.583021 PG 11 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 983TN UT WOS:000233255100019 PM 16275862 ER PT J AU Darouiche, RO Thornby, JI Cerra-Stewart, C Donovan, WH Hull, RA AF Darouiche, RO Thornby, JI Cerra-Stewart, C Donovan, WH Hull, RA TI Bacterial interference for prevention of urinary tract infection: A prospective, randomized, placebo-controlled, double-blind pilot trial SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID SPINAL-CORD-INJURY; CATHETER-ASSOCIATED BACTERIURIA; ESCHERICHIA-COLI 83972; TRIMETHOPRIM-SULFAMETHOXAZOLE; MEATAL CARE; PROPHYLAXIS; DISINFECTANT; IRRIGATION; BLADDER; CREAM AB This prospective, randomized, placebo-controlled, doubleblind pilot trial examined the efficacy of bacterial interference in preventing urinary tract infection ( UTI) in 27 patients with spinal cord injury. Patients whose bladders became colonized with Escherichia coli 83972 were half as likely ( Pp) than noncolonized patients to develop UTI during the subsequent year. C1 Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. Inst Rehabil & Res, Houston, TX USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, 133 Moursund Ave,Ste A221, Houston, TX 77030 USA. EM rdarouiche@aol.com FU NICHD NIH HHS [HD35856] NR 19 TC 57 Z9 60 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2005 VL 41 IS 10 BP 1531 EP 1534 DI 10.1086/497272 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 975NY UT WOS:000232670400022 PM 16231269 ER PT J AU Grisar, T Chanas, G de Nijs, L Coumans, B Delgado-Escueta, AV Lakaye, B AF Grisar, T Chanas, G de Nijs, L Coumans, B Delgado-Escueta, AV Lakaye, B TI EFHC-I/Myoclonin implicated in juvenile myoclonic epilepsy exibits a DM 10 domain dependent binding to mitotic spindles and the alpha tubulin complex in dividing cells SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Meeting Abstract CT 18th World Congress of Neurology CY NOV 05-11, 2005 CL Sydney, AUSTRALIA C1 Univ Liege, CNCM, B-4000 Liege, Belgium. Univ Calif Los Angeles, Epilepsy Genet Genom Labs, David Geffen Sch Med, Comprehens Epilepsy Programme, Los Angeles, CA 90024 USA. VA GLAHS W Los Angeles, W Los Angeles DVA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD NOV 15 PY 2005 VL 238 SU 1 BP S89 EP S89 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 009CF UT WOS:000235088000339 ER PT J AU Wasterlain, CG Chen, JWY Suchomelova, L Liu, H AF Wasterlain, CG Chen, JWY Suchomelova, L Liu, H TI Status epilepticus SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Meeting Abstract CT 18th World Congress of Neurology CY NOV 05-11, 2005 CL Sydney, AUSTRALIA C1 Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD NOV 15 PY 2005 VL 238 SU 1 BP S7 EP S7 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 009CF UT WOS:000235088000028 ER PT J AU Jha, SK Ross, RJ Morrison, AR AF Jha, SK Ross, RJ Morrison, AR TI Sleep-related neurons in the central nucleus of the amygdala of rats and their modulation by the dorsal raphe nucleus SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE amygdala; electrical stimulation; single neuronal activity; sleep-wakefulness ID BASAL FOREBRAIN; UNIT-ACTIVITY; REM-SLEEP; FEAR; PROJECTIONS; SEROTONIN; CAT; CONNECTIONS; STIMULATION; RETROGRADE AB The amygdala (AMY) plays an important role in initiating appropriate neurobehavioral responses to emotionally arousing events. Its major efferents from the central nucleus (Ace) to the basal forebrain, hypothalamus and brainstem permit it to influence sleep mechanisms. To characterize further the neuronal activity of AMY during sleep and wakefulness, we recorded single neuronal activity in Ace across behavioral states in freely moving, normally behaving rats. Of the 49 neurons recorded from Ace, 24 neurons had firing patterns related to sleep -wakefulness (S-W). Of these, 50% (n = 12) had a high firing frequency during wakefulness (W) or both W and REM sleep (REM), 12% (n = 3) were non-REM (NREM)-related, 17% (n = 4) had a high firing rate in REM (REM-ON), and 20% (n = 5) fired at a low rate during REM. Because serotonin introduced into AMY during REM induces short-latency changes of state, we also studied the effects of low frequency (1 Hz) electrical stimulation of the dorsal raphe nucleus (DRN) on Ace neurons. All REM-ON neurons recorded from Ace were inhibited by DRN stimulation, and other cell types were unaffected. Thus, we found that the majority of cells in Ace related to S-W fired slowly during NREM and increased their discharge during W and/or REM, and that the DRN has the potential for modulating the spontaneous activity of REM-ON cells in rats. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Penn, Sch Vet Med, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Morrison, AR (reprint author), Univ Penn, Sch Vet Med, Dept Psychiat, Philadelphia, PA 19104 USA. EM armsleep@vet.upenn.edu OI Jha, Sushil/0000-0001-8638-898X FU NIMH NIH HHS [MH 42903] NR 49 TC 25 Z9 26 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD NOV 15 PY 2005 VL 86 IS 4 BP 415 EP 426 DI 10.1016/j.physbeh.2005.06.033 PG 12 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 986WG UT WOS:000233479800001 PM 16137725 ER PT J AU Katsel, P Davis, KL Haroutunian, V AF Katsel, P Davis, KL Haroutunian, V TI Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study SO SCHIZOPHRENIA RESEARCH LA English DT Review DE schizophrenia; postmortem; gene expression; microarray; oligodendrocyte; myelin; brain regions; hippocampus; cingulate cortex; temporal cortex ID CEREBRAL BLOOD-FLOW; CARDIO-FACIAL SYNDROME; CENTRAL-NERVOUS-SYSTEM; AXON-GLIA INTERACTIONS; RNA-BINDING PROTEINS; PREFRONTAL CORTEX; BIPOLAR DISORDER; MICROARRAY ANALYSIS; MAJOR DEPRESSION; ELDERLY-PATIENTS AB Large-scale gene expression studies in schizophrenia (SZ) have generally focused on the dorsolateral prefrontal cortex. Studies of other brain regions have been less frequent and have rarely been performed in the same subjects. We analyzed postmortem gene expression in multiple cortical regions (Brodmann areas 8, 10, 44, 46, 23/31, 24/32, 20, 21, 22, 36/28, 7 and 17, respectively) as well as in the hippocampus, caudate nucleus, and putamen of 13 SZ and 13 control subjects using Affymetrix GeneChip (R) microarrays. The superior temporal cortex (BA22) and cingulate cortices (BA24/32, 23/3 1) of subjects with SZ demonstrated more profound alterations of gene expression than other brain regions compared to controls [Katsel, P., Davis, K.L., Gorman, J.M., Haroutunian, V, in press. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res.]. Functional categorization of genes whose expression was altered revealed multiple gene ontology classes that included oligodendrocyte/myelin-related genes. These myelin-related ontologies were among the top scored categories in temporal and cingulate gyri and in the hippocampus relative to other brain regions. The most altered transcripts in SZ were those encoding for proteins involved in determination of glial differentiation, myelin structure and adhesion proteins participating in axoglial contacts. Hierarchical clustering demonstrated that these myelin-related gene expression abnormalities in SZ were most pronounced in the hippocampus, superior temporal and cingulate cortices. The high representation of abnormally expressed oligodendrocyte/myelin genes in brain regions with the largest numbers of abnormally expressed genes in SZ confirmed their involvement in the disease process and suggested that the integrity of axon-myelin interaction may be impaired in SZ. (c) 2005 Elsevier B.V. All rights reserved. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Haroutunian, V (reprint author), Bronx Vet Adm Med Ctr, Room 4F-33A,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM pavel.katsel@mssm.edu; kenneth.davis@mssm.edu; vahram.haroutunian@mssm.edu FU NCRR NIH HHS [M01-RR-00071]; NIMH NIH HHS [MH064673, MH45212] NR 113 TC 134 Z9 139 U1 3 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV 15 PY 2005 VL 79 IS 2-3 BP 157 EP 173 DI 10.1016/j.schres.2005.06.007 PG 17 WC Psychiatry SC Psychiatry GA 981GC UT WOS:000233074600002 PM 16139990 ER PT J AU Rehman, SU Hutchison, FN Okonofua, EC Egan, BM AF Rehman, SU Hutchison, FN Okonofua, EC Egan, BM TI Sex, not just race - Reply SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter C1 Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29401 USA. RP Rehman, SU (reprint author), Ralph H Johnson Vet Affairs Hosp, 109 Bee St 11C, Charleston, SC 29401 USA. EM shakaib.rehman@med.va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 14 PY 2005 VL 165 IS 20 BP 2433 EP 2433 DI 10.1001/archinte.165.20.2433-a PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 983SH UT WOS:000233251900024 ER PT J AU Reiber, GE Raugi, GJ AF Reiber, GE Raugi, GJ TI Preventing foot ulcers and amputations in diabetes SO LANCET LA English DT Editorial Material ID CHRONIC CARE MODEL; CHRONIC ILLNESS; MANAGEMENT C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Dept Dermatol, Seattle, WA 98101 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. EM greiber@u.washington.edu NR 15 TC 16 Z9 18 U1 1 U2 3 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD NOV 12 PY 2005 VL 366 IS 9498 BP 1676 EP 1677 DI 10.1016/S0140-6736(05)67674-X PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 983BP UT WOS:000233206400005 PM 16291047 ER PT J AU Lipsky, BA Armstrong, DG Citron, DM Tice, AD Morgenstern, DE Abramson, MA AF Lipsky, BA Armstrong, DG Citron, DM Tice, AD Morgenstern, DE Abramson, MA TI Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial SO LANCET LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; SKIN-STRUCTURE INFECTIONS; ANTIBIOTIC-THERAPY; ANTIMICROBIAL THERAPY; COMPLICATED SKIN; MANAGEMENT; ULCERS; PATHOGENS; PREVALENCE; AMPUTATION AB Background Diabetic foot infections are a common and serious problem, yet few randomised trials of adequate quality have compared the efficacy of the various antibiotic regimens available for their treatment. Our aim was to assess the efficacy and safety of ertapenem versus piperacillin/tazobactam for foot infections. Methods We did a randomised, double-blinded, multicentre trial in adults (n=586) with diabetes and a foot infection classified as moderate-to-severe and requiring intravenous antibiotics. We assigned patients intravenous ertapenem (1 g daily; n=295) or piperacillin/tazobactam (3.375 g every 6 h; n=291) given for a minimum of 5 days, after which oral amoxicillin/clavulanic acid (875/125 mg every 12 h) could be given for up to 23 days. Investigators retained the option to administer vancomycin to patients in either group to ensure adequate coverage for potentially antibiotic resistant Enterococcus spp and meticillin-resistant Staphylococcus aureus (MRSA). Our primary outcome was the proportion of patients with a favourable clinical response (cure or improvement) on the day that intravenous antibiotic was discontinued. Analyses were by an evaluable-patient only approach. This study is registered with ClinicalTrials.gov, number NCT00229112. Findings Of the 576 patients treated, 445 were available for assessment at the end of intravenous therapy. Both baseline characteristics and favourable clinical response rates were similar for the 226 who received ertapenem and the 219 who received piperacillin/tazobactam. (94% vs 92%, respectively; between treatment difference 1.9%, 95% CI -2.9 to 6.9). Rates of favourable microbiological responses (eradication rates and clinical outcomes, by pathogen) and adverse events did not differ between groups. Interpretation Clinical and microbiological outcomes for patients treated with ertapenem were equivalent to those for patients treated with piperacillin/tazobactam, suggesting that this once-daily antibiotic should be considered for parenteral. therapy of diabetic foot infections, when deemed appropriate. C1 Univ Washington, Sch Med, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Rosalind Franklin Univ Med & Sci, Scholl Coll Podiatr Med, Chicago, IL USA. Rosalind Franklin Univ Med & Sci, Ctr Lower Extrem Ambulatory Res, Chicago, IL USA. RM Alden Res Lab, Santa Monica, CA USA. Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA. Merck & Co Inc, West Point, PA USA. RP Lipsky, BA (reprint author), Univ Washington, Sch Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Benjamin.Lipsky@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 53 TC 114 Z9 116 U1 1 U2 9 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD NOV 12 PY 2005 VL 366 IS 9498 BP 1695 EP 1703 DI 10.1016/S0140-6736(05)67694-5 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 983BP UT WOS:000233206400024 ER PT J AU Cavanagh, PR Lipsky, BA Bradbury, AW Botek, G AF Cavanagh, PR Lipsky, BA Bradbury, AW Botek, G TI Treatment for diabetic foot ulcers SO LANCET LA English DT Review ID PERIPHERAL ARTERIAL-DISEASE; LOWER-EXTREMITY AMPUTATION; LOWER-LIMB ISCHEMIA; RESISTANT STAPHYLOCOCCUS-AUREUS; ERYTHROCYTE SEDIMENTATION-RATE; RANDOMIZED-CONTROLLED TRIAL; NEUROPATHIC FOOT; COST-EFFECTIVENESS; PLANTAR ULCERS; THERAPEUTIC FOOTWEAR AB People with diabetes develop foot ulcers because of neuropathy (sensory, motor, and autonomic deficits), ischaemia, or both. The initiating injury may be from acute mechanical or thermal trauma or from repetitively or continuously applied mechanical stress. Patients with clinically significant limb ischaemia should be assessed by a vascular surgeon to determine the need for angioplasty, stenting, or femorodistal bypass. When infection complicates a foot ulcer, the combination can be limb or life-threatening. Infection is defined clinically, but wound cultures reveal the causative pathogens. Tissue specimens are strongly preferred to wound swabs for wound cultures. Antimicrobial therapy should be guided by culture results, and should aim to cure the infection, not to heal the wound. Alleviation of the mechanical load on ulcers (off-loading) should always be a part of treatment. Neuropathic ulcers typically heal in 6 weeks with total contact casting, because it effectively relieves pressure at the ulcer site and enforces patient compliance. The success of other approaches to off-loading similarly depends on the patients' adherence to the effectiveness of pressure relief. Surgery to heal ulcers and prevent recurrence can include tenotomy, tendon lengthening, reconstruction, or removal of bony prominences. However, these procedures may result in secondary ulceration and other complications. Ulcer recurrence rates are high, but appropriate education for patients, the provision of posthealing footwear, and regular foot care can reduce rates of re-ulceration. C1 Cleveland Clin Fdn, Dept Biomed Engn, Diabet Foot Care Program, Cleveland, OH 44195 USA. Cleveland Clin Fdn, Dept Orthopaed Surg, Diabet Foot Care Programme, Cleveland, OH 44195 USA. Cleveland Clin Fdn, Orthopaed Res Ctr, Cleveland, OH 44195 USA. Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA. Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA USA. Univ Birmingham, Dept Vasc Surg, Birmingham, W Midlands, England. Heart England NHS Fdn Trust, Birmingham, W Midlands, England. RP Cavanagh, PR (reprint author), Cleveland Clin Fdn, Dept Biomed Engn, Diabet Foot Care Program, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA. EM cavanap@ccf.org OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 240 TC 170 Z9 179 U1 7 U2 42 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD NOV 12 PY 2005 VL 366 IS 9498 BP 1725 EP 1735 DI 10.1016/S0140-6736(05)67699-4 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 983BP UT WOS:000233206400029 PM 16291067 ER PT J AU Lee, JG Dahi, S Mahimkar, R Tulloch, NL Alfonso-Jaume, MA Lovett, DH Sarkar, R AF Lee, JG Dahi, S Mahimkar, R Tulloch, NL Alfonso-Jaume, MA Lovett, DH Sarkar, R TI Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE angiogenesis; gelatinase; gene expression; skeletal muscle; transcription factor ID SKELETAL-MUSCLE; HINDLIMB ISCHEMIA; MEMBRANE TYPE-1; GENE-EXPRESSION; NUCLEAR FACTOR; C-JUN; CELLS; ANGIOGENESIS; YB-1; FOS AB Matrix metalloproteinase-2 (MMP-2) plays an essential role in angiogenesis and arteriogenesis, two processes critical to restoration of tissue perfusion after ischemia. MMP-2 expression is increased in tissue ischemia, but the responsible mechanisms remain unknown. We studied the transcriptional activation of the MMP-2 gene in a model of hindlimb ischemia by using various MMP-2-lacZ reporter mice and chromatin immunoprecipitation. MMP-2 activity and mRNA were increased after hindlimb ischemia. Mice with targeted deletion of MMP-2 had impaired restoration of perfusion and a high incidence of limb gangrene, indicating that MMP-2 plays a critical role in ischemia-induced revascularization. Ischemia induced the expression and binding of c-Fos, c-Jun, JunB, FosB, and Fra2 to a noncanonical activating protein-1 (AP-1) site present in the MMP-2 promoter and decreased binding of the transcriptional repressor JunD. Ischemia also activated the expression and binding of p53 to an adjacent enhancer site (RE-1) and increased expression and binding of nuclear factor of activated T-cells-c2 to consensus sequences within the first intron. Deletion of either the 5' AP-1/RE-1 region of the promoter or substitution of the first intron abolished ischemia-induced MMP-2 transcription in vivo. Thus, AP-1 transcription factors and intronic activation by nuclear factor of activated T-cells-c2 act in concert to drive ischemia-induced MMP-2 transcription. These findings define a critical role for MMP-2 in ischemia-induced revascularization and identify both previously uncharacterized regulatory elements within the MMP-2 gene and the cognate transcription factors required for MMP-2 activation in vivo after tissue ischemia. C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Vasc Surg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Pacific Vasc Res Lab, San Francisco, CA 94121 USA. Univ Calif San Francisco, Vet Affairs Med Ctr, Div Nephrol, San Francisco, CA 94121 USA. RP Sarkar, R (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Vasc Surg, San Francisco, CA 94121 USA. EM sarkarr@surgery.ucsf.edu FU NHLBI NIH HHS [K08 HL004435, P01 HL 68738, P01 HL068738] NR 37 TC 36 Z9 36 U1 1 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 8 PY 2005 VL 102 IS 45 BP 16345 EP 16350 DI 10.1073/pnas.0508085102 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 984DW UT WOS:000233283700040 PM 16258061 ER PT J AU Sobell, JL Richard, C Wirshing, DA Heston, LL AF Sobell, JL Richard, C Wirshing, DA Heston, LL TI Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE RGS4 gene; schizophrenia; case-control; association; haplotype ID PROTEIN SIGNALING RGS; SUSCEPTIBILITY GENE; MESSENGER-RNA; HUMAN GENOME; REGULATOR; EXPRESSION; RECOMBINATION; POLYMORPHISMS; BLOCKS; BRAIN AB The regulator of G-protein signaling (RGS) and RGS-like proteins are a diverse family of over 30 molecules that function as GTPase activating proteins for G alpha subunits of the Gq and Gi families of heterotrimeric guanine nucleotide-binding proteins (G proteins). By accelerating GTPase activity, RGS proteins drive G proteins into their inactive GDP-bound forms. G-protein coupled dopamine, metabotropie glutamate, and other neurotransmitter receptors can be modulated by RGS4, the predominant form in brain. The recent finding of decreased RGS4 mRNA expression in post-mortem brains from schizophrenic patients, coupled with the map position of RGS4 to a region previously linked to schizophrenia, as well as other biological data, prompted the investigation of the gene as a disease candidate. Multiple family-based and case-control association studies have been conducted, with modest and conflicting support for particular single nucleotide polymorphism (SNP) markers and SNP marker haplotypes. The present case-control analysis of 568 patients and 689 controls, one of the largest single studies to date, failed to confirm support for association of particular RGS4 SNP alleles, or for association of any particular four, three, or two SNP haplotype. (c) 2005 Wiley-Liss, Inc. C1 Univ So Calif, Zilkha Neurogenet Inst, Los Angeles, CA 90089 USA. Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. RP Sobell, JL (reprint author), Univ So Calif, Zilkha Neurogenet Inst, 1501 San Pablo St,ZNI 339,MC 2821, Los Angeles, CA 90089 USA. EM sobell@usc.edu NR 23 TC 33 Z9 35 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD NOV 5 PY 2005 VL 139B IS 1 BP 23 EP 27 DI 10.1002/ajmg.b.30221 PG 5 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 979PY UT WOS:000232958500006 PM 16082709 ER PT J AU Tang, YL Anderson, GM Zabetian, CP Kohnke, MD Cubells, JF AF Tang, YL Anderson, GM Zabetian, CP Kohnke, MD Cubells, JF TI Haplotype-controlled analysis of the association of a non-synonymous single nucleotide polymorphism at DBH (+1603C -> T) with plasma dopamine beta-hydroxylase activity SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE dopamine beta-hydroxylase; haplotype; enzyme activity; association; polymorphism ID GENOTYPE-CONTROLLED ANALYSIS; FUNCTIONAL POLYMORPHISM; LINKAGE DISEQUILIBRIUM; GENE DBH; LOCUS AB The DBH locus controls plasma dopamine beta-hydroxylase activity (pD beta H). A 5'-upstream single nucleotide polymorphism (SNP) at DBH (-1021C -> T) explains similar to 45% of the variance in pD beta H, and a non-synonymous SNP in exon 11 (+1603C -> T) an additional 2%. However, that regression result underestimates the effect of +1603C -> T because of its low minor allele frequency. We estimated the biological effect of +1603C -> T on pD beta H by comparing subjects of identical -1021C gamma T genotype, in a diagnostically heterogeneous group of subjects of European origin (N = 367). +1603C -> T genotype associated with pD beta H within groups of identical genotype at -1021 C -> T, accounting for 5%-16% of the variance. There was no significant linkage disequilibrium between - 1021C -> T and + 1603C -> T (D - 0.0058, D'= 0.4774, d(2) = 0.0011, P > 0.05), confirming the validity of assessing the two polymorphisms independently. These results suggest that altered homospecific activity of the enzyme can contribute to variation in pD beta H. This conclusion informs how associations between DBH and psychiatric disorders should be approached. (c) 2005 Wiley-Liss, Inc. C1 Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Univ Tubingen Hosp, Univ Hosp Psychiat & Psychotherapy, Tubingen, Germany. RP Cubells, JF (reprint author), Emory Univ, Dept Human Genet, 615 Michael St,Suite 301, Atlanta, GA 30322 USA. EM jcubells@genetics.emory.edu FU NIDA NIH HHS [K02 DA015766, R01 DA12422]; NINDS NIH HHS [K08 NS44138] NR 15 TC 26 Z9 28 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD NOV 5 PY 2005 VL 139B IS 1 BP 88 EP 90 DI 10.1002/ajmg.b.30220 PG 3 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 979PY UT WOS:000232958500018 PM 16152569 ER PT J AU Faraone, SV Skol, AD Tsuang, DW Young, KA Haverstock, SL Prabhudesai, S Mena, F Menon, AS Leong, L Sautter, F Baldwin, C Bingham, S Weiss, D Collins, J Keith, T vanden Eng, JL Boehnke, M Tsuang, MT Schellenberg, GD AF Faraone, SV Skol, AD Tsuang, DW Young, KA Haverstock, SL Prabhudesai, S Mena, F Menon, AS Leong, L Sautter, F Baldwin, C Bingham, S Weiss, D Collins, J Keith, T vanden Eng, JL Boehnke, M Tsuang, MT Schellenberg, GD TI Genome scan of schizophrenia families in a large veterans affairs cooperative study sample: Evidence for linkage to 18p11.32 and for racial heterogeneity on chromosomes 6 and 14 SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE genome scan; schizophrenia; race; linkage; genetics; chromosome 18; racial heterogeneity ID CYCLASE-ACTIVATING POLYPEPTIDE; BANTU-SPEAKING FAMILIES; SUSCEPTIBILITY LOCI; BIPOLAR DISORDER; WIDE SCAN; GENETIC-LINKAGE; TYROSINE-HYDROXYLASE; DIAGNOSTIC INTERVIEW; EUROPEAN-AMERICAN; CORTICAL-NEURONS AB Genome-wide linkage analyses of schizophrenia have identified several regions that may harbor schizophrenia susceptibility genes but, given the complex etiology of the disorder, it is unlikely that all susceptibility regions have been detected. We report results from a genome scan of 166 schizophrenia families collected through the Department of Veterans Affairs Cooperative Studies Program. Our definition of affection status included schizophrenia and schizoaffective disorder, depressed type and we defined families as European American (EA) and African American (AA) based on the probands' and parents' races based on data collected by interviewing the probands. We also assessed evidence for racial heterogeneity in the regions most suggestive of linkage. The maximum LOD score across the genome was 2.96 for chromosome 18, at 0.5 cM in the combined race sample. Both racial groups showed LOD scores greater than 1.0 for chromosome 18. The empirical P-value associated with that LOD score is 0.04 assuming a single genome scan for the combined sample with race narrowly defined, and 0.06 for the combined sample allowing for broad and narrow definitions of race. The empirical P-value of observing a LOD score as large as 2.96 in the combined sample, and of at least 1.0 in each racial group, allowing for narrow and broad racial definitions, is 0.04. Evidence for the second and third largest linkage signals come solely from the AA sample on chromosomes 6 (LOD 2.11 at 33.2 cM) and 14 (LOD = 2.13 at 51.0). The linkage evidence differed between the AA and EA samples (chromosome 6 P-value = 0.007 and chromosome 14 P-value = 0.004). (c) 2005 Wiley-Liss, Inc. C1 SUNY Upstate Med Univ, Genet Res Program, Syracuse, NY 13210 USA. SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs Med Ctr, Waco, TX USA. Vet Affairs Med Ctr, Augusta, GA USA. Vet Affairs Med Ctr, Danville, IL USA. Vet Affairs Med Ctr, Tuskegee, AL USA. Vet Affairs Med Ctr, Cooperat Studies Program, Coordinating Ctr, Perry Point, MD USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Vet Affairs Med Ctr, New Orleans, LA USA. Vet Affairs Med Ctr, Northport, NY USA. Galileo Genom, Montreal, CA USA. Univ Calif San Diego, Inst Behav Genom, Dept Psychiat, San Diego, CA 92103 USA. VA San Diego Hlth Care Syst, San Diego, CA USA. Harvard Univ, Harvard Inst Psychiat Epidemiol & Genet, Dept Epidemiol, Boston, MA 02115 USA. Harvard Univ, Harvard Inst Psychiat Epidemiol & Genet, Dept Psychiat, Boston, MA 02115 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Faraone, SV (reprint author), SUNY Upstate Med Univ, Genet Res Program, 750 E Adams St, Syracuse, NY 13210 USA. EM faraones@upstate.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Faraone, Stephen/0000-0002-9217-3982 NR 90 TC 14 Z9 14 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD NOV 5 PY 2005 VL 139B IS 1 BP 91 EP 100 DI 10.1002/ajmg.b.30213 PG 10 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 979PY UT WOS:000232958500019 PM 16152571 ER PT J AU Raitt, M Connor, WE AF Raitt, M Connor, WE TI Fish oil supplementation and arrhythmias - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 Portland VA Med Ctr, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP Raitt, M (reprint author), Portland VA Med Ctr, Portland, OR 97207 USA. EM merritt.raitt@med.va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 2 PY 2005 VL 294 IS 17 BP 2165 EP 2166 DI 10.1001/jama.294.17.2165-b PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 979PQ UT WOS:000232957700009 ER PT J AU Tsukamoto, H AF Tsukamoto, H TI Adipogenic phenotype of hepatic stellate cells SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article; Proceedings Paper CT Satellite Symposium of the International-Society-on-Biomedocal-Research-on-Alcoholism CY SEP 26-28, 2004 CL Bordeaux, FRANCE SP Int Soc Biomed Res Alcoholism DE PPAR gamma; SREBP-1c; LXR alpha; liver fibrosis ID X-RECEPTOR; ACTIVATION; PROMOTER; ALPHA AB Transdifferentiation of hepatic stellate cells (HSC) constitutes a major cellular event in the genesis of alcoholic liver fibrosis and cirrhosis and molecular mechanisms underlying this process is incompletely understood. Our laboratory proposed several years ago that HSC quiescence requires the transcriptional program known to be integral to preadipocyte to adipocyte differentiation. In support of the hypothesis, our research demonstrates the expression of adipogenic transcription factors (C/EBPs, PPAR gamma, SREBP-1c, LXR alpha) and adipocyte-specific genes (adipsin, resistin) are high in quiescent HSC and depleted in activated HSC. Three gain-of-function approaches have been taken to test this notion: the treatment of activated HSC with the adipocyte differentiation cocktail; ectopic expression of PPAR gamma or SREBP-1c. All three treatments coordinately upregulate a panel of putative adipogenic transcrition factors and cause morphologic and biochemical reversal of activated HSC to quiescent cells. These findings establish a new conceptual framework for the treatment of liver fibrosis and propose an intriguing notion concerning the plasticity of HSC. C1 Univ So Calif, Keck Sch Med, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90089 USA. Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tsukamoto, H (reprint author), Univ So Calif, Keck Sch Med, Res Ctr Alcohol Liver & Pancreat Dis, 1333 San Pablo St,MMR-412, Los Angeles, CA 90089 USA. EM htsukamo@usc.edu NR 12 TC 34 Z9 35 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD NOV PY 2005 VL 29 IS 11 SU S BP 132S EP 133S DI 10.1097/01.alc.0000189279.92602.f0 PG 2 WC Substance Abuse SC Substance Abuse GA 995XA UT WOS:000234136800006 PM 16344597 ER PT J AU Stein, DJ El-Serag, HB Kuczynski, J Kramer, JR Sampliner, RE AF Stein, DJ El-Serag, HB Kuczynski, J Kramer, JR Sampliner, RE TI The association of body mass index with Barrett's oesophagus SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PROSPECTIVE MULTIVARIATE-ANALYSIS; HIATAL-HERNIA; GASTROESOPHAGEAL-REFLUX; ACID EXPOSURE; GASTRIC CARDIA; RISK-FACTORS; ADENOCARCINOMA; LENGTH; PREVALENCE; OBESITY AB Background: Obesity has been linked to gastro-oesophageal reflux disease symptoms and oesophageal adenocarcinoma; however, there is no published evidence for an association with Barrett's oesophagus. Aim: To investigate the association between obesity and Barrett's oesophagus. Methods: We conducted a retrospective cross-sectional study of patients who underwent upper endoscopy at the Southern Arizona Veteran's Affairs Healthcare System between 1998 and 2004. We examined male patients without malignancy, with available information on weight and height. Based on endoscopic and histological findings, patients were classified as cases with Barrett's oesophagus or non-cases without Barrett's oesophagus. Multivariable logistic regression analysis was conducted to examine the association of body mass index and obesity with Barrett's oesophagus and Barrett's oesophagus length while adjusting for age and race. Results: There were 65 cases with Barrett's oesophagus and 385 non-cases without Barrett's oesophagus. The mean body mass index was significantly higher in cases than in non-cases (29.8 vs. 28.0, P = 0.03). Cases had significantly greater mean weight than controls (206 lb vs. 190, P = 0.005). The proportions of cases with body mass index 25-30 and body mass index >= 30 were greater than those in non-cases (44.6% vs. 37.7%) and (40.0% vs. 33.5%), respectively (P = 0.08). In the multivariable logistic regression model adjusting for race and age, when compared with body mass index < 25, the odds ratio was 2.43 (95% confidence interval: 1.12-5.31) for body mass index 25-30 and 2.46 (1.11-5.44) for body mass index >= 30. When examined as a continuous variable the adjusted odd ratio for each five-point increase in body mass index was 1.35 (95% confidence interval: 1.06-1.71, P = 0.01). The association between weight and Barrett's oesophagus was also statistically significant (adjusted odd ratio for each 10 pound increase = 1.10, 1.03-1.17, P =0.002). Among the 65 cases of Barrett's oesophagus, there was no correlation between the length of Barrett's oesophagus at the time of diagnosis and the body mass index (correlation coefficient = 0.03, P = 0.79). Conclusion: This retrospective cross-sectional study in male veterans shows that overweight is associated with a two-and-half-fold increased risk of Barrett's oesophagus. Larger studies of the underlying mechanism are warranted to better understand how and why obese patients are at greater risk for Barrett's oesophagus. C1 So Arizona VA Healthcare Syst, Tucson, AZ USA. Univ Arizona, Hlth Sci Ctr, Tucson, AZ USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 29 TC 65 Z9 67 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD NOV PY 2005 VL 22 IS 10 BP 1005 EP 1010 DI 10.1111/j.1365-2036.2005.02674.x PG 6 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 978RU UT WOS:000232891500014 PM 16268976 ER PT J AU Pletcher, MJ Kiefe, CI Sidney, S Carr, JJ Lewis, CE Hulley, SB AF Pletcher, MJ Kiefe, CI Sidney, S Carr, JJ Lewis, CE Hulley, SB TI Cocaine and coronary calcification in young adults: The Coronary Artery Risk Development in Young Adults (CARDIA) study SO AMERICAN HEART JOURNAL LA English DT Article ID MYOCARDIAL-INFARCTION; CALCIUM; DISEASE; ATHEROSCLEROSIS; RECRUITMENT; PREVALENCE; USERS AB Background Cocaine use is associated with myocardial ischemia and infarction, but it is unclear whether this is only because of the acute effects of cocaine on heart rate, blood pressure, and vasomotor tone or whether accelerated atherosclerosis from long-term exposure to cocaine also contributes. Methods We sought to measure the association between cocaine exposure and coronary calcification, a marker for atherosclerosis, among participants in the CARDIA Study who received computed tomography scanning and answered questions about illicit drug use at the year 15 examination in 2000-2001. Results Among 3038 CARDIA participants (age 33-45 years, 55% women and 45% black), past cocaine exposure was reported by 35% and was more common among men, smokers, drinkers, and participants with less education. Powdered cocaine exposure was more common among whites, crack cocaine among blacks. Before adjustment, cocaine exposure was strongly associated with coronary calcification. After adjusting for age, sex, ethnicity, socioeconomic status, family history, and habits, however, these associations disappeared: adjusted odds ratios for coronary calcification were 0.9 (95% CI 0.6-1.3) for 1 to 10, 1.2 (95% CI 0.8-1.7) for 11 to 99, and 1.0 (95% CI 0.6-1.6) for >= 100 lifetime episodes of cocaine use, in comparison with none. Sex, tobacco, and alcohol use appeared to be primarily responsible for the confounding we observed in unadjusted models. Conclusion We found no evidence of a causal relationship between long-term exposure to cocaine and coronary calcification and conclude that acute nonatherogenic mechanisms probably explain most cocaine-associated myocardial infarction. C1 Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. Univ Alabama, Div Prevent Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Kaiser Permanente, Div Res, Oakland, CA USA. Wake Forest Univ Hlth Sci, Winston Salem, NC USA. RP Pletcher, MJ (reprint author), 500 Parnassus Ave,MU-420 W, San Francisco, CA 94143 USA. EM mpletcher@epi.ucsf.edu RI Carr, John/A-1938-2012 OI Carr, John/0000-0002-4398-8237 FU NHLBI NIH HHS [N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-95095] NR 30 TC 9 Z9 9 U1 2 U2 3 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD NOV PY 2005 VL 150 IS 5 BP 921 EP 926 DI 10.1016/j.ahj.2005.04.016 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 986VW UT WOS:000233478800014 PM 16290964 ER PT J AU Rumsfeld, JS Jones, PG Whooley, MA Sullivan, MD Pitt, B Weintraub, WS Spertus, JA AF Rumsfeld, JS Jones, PG Whooley, MA Sullivan, MD Pitt, B Weintraub, WS Spertus, JA TI Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure SO AMERICAN HEART JOURNAL LA English DT Article ID NATIONAL-REGISTRY; MAJOR DEPRESSION; RANDOMIZED-TRIAL; RATE-VARIABILITY; SYMPTOMS; RISK; DISEASE; SERTRALINE; DISORDERS; SEVERITY AB Background To evaluate whether depressive symptoms are independently predictive of mortality and hospitalization among patients with acute myocardial infarction (AMI) complicated by heart failure. Methods The EPHESUS trial enrolled patients with AMI complicated by heart failure. Patients from Canada, the UK, and the United States completed a Medical Outcomes Study-De press ion questionnaire at baseline in addition to a comprehensive clinical examination. Cox proportional hazards regression was used to determine the relationship between depressive symptoms and outcomes, including 2-year all-cause mortality and cardiovascular death or hospitalization, adjusting for baseline clinical variables. Results Overall, 143 of 634 patients (22.6%) had significant depressive symptoms at baseline (Medical Outcomes Study-Depression score >= 0.06). Depressed patients had higher 2-year mortality (29% vs 18%; P = .004) and cardiovascular death or hospitalization (42% vs 33%; P = .016). After risk adjustment, depressive symptoms remained significantly associated with mortality (hazard ratio 1.75, 95% CI 1.15-2.68, P = .01) and cardiovascular death or hospitalization (hazard ratio 1.41, 95% CI 1.03-1.93, P = .03). Results were consistent across demographic and clinical subgroups. Conclusions Depression is an independent predictor of all-cause mortality and cardiovascular death or hospitalization after AMI complicated by heart failure. Although many factors may mediate outcomes in patients with AMI, studies are warranted to evaluate whether a depression intervention can improve survival and/or reduce hospitalizations. C1 Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Univ Missouri, Dept Med, Kansas City, MO 64110 USA. San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA. Univ Michigan, Sch Med, Div Cardiol, Ann Arbor, MI USA. Emory Univ, Sch Med, Emory Ctr Outcomes Res, Atlanta, GA USA. RP Rumsfeld, JS (reprint author), Denver VA Med Ctr, Cardiol Sect, 1055 Clermont St, Denver, CO 80220 USA. EM john.rumsfeld@med.va.gov NR 32 TC 85 Z9 95 U1 1 U2 5 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD NOV PY 2005 VL 150 IS 5 BP 961 EP 967 DI 10.1016/j.ahj.2005.02.036 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 986VW UT WOS:000233478800022 PM 16290972 ER PT J AU Wilson, MMG Thomas, DR Rubenstein, LZ Chibnall, JT Anderson, S Baxi, A Diebold, MR Morley, JE AF Wilson, MMG Thomas, DR Rubenstein, LZ Chibnall, JT Anderson, S Baxi, A Diebold, MR Morley, JE TI Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE appetite; anorexia; weight loss; elderly; screening tools ID SYMPTOM ASSESSMENT SCALE; ANOREXIA; VALIDATION; MORTALITY; CACHEXIA; WOMEN; RISK; DOCUMENTATION; MALNUTRITION; PREVALENCE AB Background: Anorexia-related weight loss can have devastating consequences on quality-of-life, morbidity, and mortality. Without a simple tool to evaluate appetite, health care providers often use inaccurate surrogates, such as measurement of energy consumption and nutritional risk, to reflect appetite. Objective: We aimed to validate a simple tool for assessing appetite and predicting weight loss. Design: This was a cross-sectional measurement study conducted on long-term care residents and community-dwelling adults. Construct validity of the 8-item Council on Nutrition appetite questionnaire (CNAQ) and its 4-item derivative, the simplified nutritional appetite questionnaire (SNAQ), were examined through correlation with a previously validated research tool: the appetite hunger and sensory perception questionnaire (AHSP). The length and complexity of the AHSP render it inefficient for clinical use. The sensitivity and specificity of the CNAQ and SNAQ to predict significant weight loss were calculated. Results: Cronbach's alpha coefficients for the CNAQ were 0.47 (long-term care group) and 0.72 (community-dwelling group). In the long-term care group, the CNAQ correlated with the AHSP (r = 0.60, P < 0.001) and with the AHSP domains of taste (r = 0.47, P < 0.0001), hunger (r = 0.51, P < 0.0001), and smell (r = 0.53, P < 0.0001). The CNAQ showed sensitivities and specificities for 5% and 10% weight losses of 80.2 and 80.3 and 82.4 and 81.9, respectively. The SNAQ had sensitivities and specificities for 5% and 10% weight losses of 81.3 and 76.4 and 88.2 and 83.5, respectively. Conclusions: The SNAQ and CNAQ are short, simple appetite assessment tools that predict weight loss in community-dwelling adults and long-term care residents. The SNAQ is a 4-item derivative of the CNAQ and thus is clinically more efficient. C1 St Louis Univ, Div Geriatr Med, St Louis, MO 63104 USA. St Louis Univ, Dept Psychiat, St Louis, MO 63104 USA. St Louis Vet Affaris Med Ctr, St Louis, MO USA. VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. RP Wilson, MMG (reprint author), St Louis Univ, Div Geriatr Med, 1402 S Grand Blvd,Room M238, St Louis, MO 63104 USA. EM wilsonmg@slu.edu RI morley, john/F-9177-2011 OI morley, john/0000-0001-6444-2965 NR 39 TC 183 Z9 190 U1 2 U2 15 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD NOV PY 2005 VL 82 IS 5 BP 1074 EP 1081 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 982JC UT WOS:000233153000023 PM 16280441 ER PT J AU Tseng, CL Pogach, L Safford, M AF Tseng, CL Pogach, L Safford, M TI Re: "seasonal patterns in monthly hemoglobin A(1c) values" - Three authors reply SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Letter DE accidental falls; aged; estrogen replacement therapy; fractures; frail elderly; osteoporosis; pelvis C1 Dept Vet Affairs, Ctr Hlth Care Knowledge Management, New Jersey Hlth Care Syst, E Orange, NJ 07018 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med & Community Hlth, Newark, NJ 07101 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07101 USA. Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Tseng, CL (reprint author), Dept Vet Affairs, Ctr Hlth Care Knowledge Management, New Jersey Hlth Care Syst, E Orange, NJ 07018 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD NOV 1 PY 2005 VL 162 IS 9 DI 10.1093/aje/kwi298 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 976PP UT WOS:000232745900018 ER PT J AU Jensen, DM AF Jensen, DM TI Management of patients with severe hematochezia - With all current evidence available SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID DIVERTICULAR HEMORRHAGE; URGENT COLONOSCOPY; HOSPITAL STAY; DIAGNOSIS; HEMOSTASIS AB A randomized controlled trial (RCT) of routine urgent colonoscopy in severe lower gastrointestinal tract bleeding is reported in this journal from Duke. The only significant differences in results between the standard management (emergency red blood cell (RBC) scanning and angiography with elective colonoscopy) and urgent colonoscopy were in rates of finding a definitive bleeding site-one with a major stigmata of hemorrhage-and in not making a diagnosis. The trial was stopped early for logistics reasons a decade ago. The strengths and limitations of the study are discussed and contrasted with recent reports of other investigators. Similar to management of patients with non-variceal upper gastrointestinal tract (UGI) hemorrhage, triaging patients to level of care by comorbidity scores and stigmata of hemorrhage, successful colonoscopic hemostasis of focal lesions, and individualization of long-term medical, endoscopic, and surgical care are recommended based on promising reports by other investigators. Meanwhile, further RCTs for patients with severe hematochezia are warranted. C1 VA Greater Los Angeles Healthcare Syst, CURE Digest Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. RP Jensen, DM (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Res Ctr, Bldg 115,Rm 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 20 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2005 VL 100 IS 11 BP 2403 EP 2406 DI 10.1111/j.1572-0241.2005.00298.x PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 976ZD UT WOS:000232771300009 PM 16279892 ER PT J AU Jacobson, IM Gonzalez, SA Ahmed, F Lebovics, E Min, AD Bodenheimer, HC Esposito, SP Brown, RS Brau, N Klion, FM Tobias, H Bini, EJ Brodsky, N Cerulli, MA Aytaman, A Gardner, PW Geders, JM Spivack, JE Rahmin, MG Berman, DH Ehrlich, J Russo, MW Chait, M Rovner, D Edlin, BR AF Jacobson, IM Gonzalez, SA Ahmed, F Lebovics, E Min, AD Bodenheimer, HC Esposito, SP Brown, RS Brau, N Klion, FM Tobias, H Bini, EJ Brodsky, N Cerulli, MA Aytaman, A Gardner, PW Geders, JM Spivack, JE Rahmin, MG Berman, DH Ehrlich, J Russo, MW Chait, M Rovner, D Edlin, BR TI A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID SUSTAINED VIROLOGICAL RESPONSE; WEIGHT-BASED RIBAVIRIN; COMBINATION THERAPY; PEGINTERFERON ALPHA-2A; AFRICAN-AMERICANS; INITIAL TREATMENT; NONRESPONDERS; MULTICENTER; GENOTYPE-1; RESISTANT AB OBJECTIVES: The efficacy of combination therapy with pegylated interferon (PEG IFN) alpha plus ribavirin (RBV) in the retreatment of chronic hepatitis C (CHC) in patients who previously failed combination standard IFN plus RBV or IFN monotherapy has not been well established. METHODS: Three hundred and twenty-one CHC patients including virologic nonresponders to combination IFN plus RBV (n = 219) or IFN monotherapy (n = 47), and relapsers to combination therapy (n = 55) were randomized to receive PEG IFN alpha-2b 1.5 mu g/kg per wk plus RBV 800 mg per day (Regimen A, n = 160) or PEG IFN alpha-2b 1.0 mu g/kg per wk plus RBV 1,000-1,200 mg per day (Regimen B, n = 161) for 48 wks. RESULTS: Sustained virologic response (SVR) occurred in 16% of the overall study population (Regimen A vs B, 18%vs 13%, p= 0.21), in 8% of the combination therapy nonresponders (10%vs 6%, p= 0.35), in 21% of the IFN monotherapy nonresponders (16%vs 27%, p= 0.35), and in 42% of the combination therapy relapsers (50%vs 32%, p= 0.18). In nonresponders to prior combination therapy, HCV ribonucleic acid levels < 100,000 copies/mL at the end of the prior treatment course were associated with an increased SVR compared with levels >= 100,000 copies/mL (21%vs 5%, p= 0.002). In the overall study population, genotype 1 patients had lower SVR rates than others (14%vs 33%, p= 0.01), and African Americans had lower SVR than Caucasians (4%vs 18%, p= 0.01). CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. There was no significant effect of dosing regimen. C1 Cornell Univ, Weill Med Coll, Div Gastroenterol & Hepatol, New York, NY 10021 USA. Cornell Univ, Weill Med Coll, Ctr Study Hepatitis C, New York, NY 10021 USA. New York Med Coll, Div Gastroenterol & Hepatobiliary Dis, Valhalla, NY 10595 USA. Beth Israel Med Ctr, Div Digest Dis, New York, NY 10003 USA. Hepatobiliary Associates New York, Bayside, NY USA. Columbia Univ, Coll Phys & Surg, Ctr Liver Dis & Transplantat, New York, NY USA. Columbia Univ, Coll Phys & Surg, Div Digest & Liver Dis, New York, NY USA. Bronx Vet Adm Med Ctr, Div Infect Dis, Bronx, NY USA. Mt Sinai Sch Med, Div Liver Dis, New York, NY USA. NYU, Sch Med, Div Gastroenterol, New York, NY USA. New York VA Med Ctr, Div Gastroenterol & Hepatol, New York, NY USA. Palmadessa & Kuan Gastroenterol Associates, Flushing, NY USA. Brooklyn Hosp Ctr, Div Gastroenterol & Hepatol, Brooklyn, NY USA. VA New York Harbor Healthcare Syst, Div Gastroenterol, Brooklyn, NY USA. Gastroenterol Consultants, Stamford, CT USA. New York Methodist Hosp, Div Gastroenterol & Hepatol, Brooklyn, NY USA. Gastroenterol Associates Fairfield Cty, Fairfield, CT USA. Gastrointestinal Associates, Ridgewood, NJ USA. Pk Ave Med & Gastroenterol, New York, NY USA. Gastroenterol Westchester, Bronxville, NY USA. Hartsdale Med Grp, Hartsdale, NY USA. RP Jacobson, IM (reprint author), Cornell Univ, Weill Med Coll, Div Gastroenterol & Hepatol, 450 E 69th St, New York, NY 10021 USA. OI Edlin, Brian/0000-0001-8172-8797 NR 51 TC 90 Z9 97 U1 0 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2005 VL 100 IS 11 BP 2453 EP 2462 DI 10.1111/j.1572-0241.2005.00282.x PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 976ZD UT WOS:000232771300017 PM 16279900 ER PT J AU Donohue, J Hanlon, JT AF Donohue, J Hanlon, JT TI Helping Medicare patients benefit from the new Medicare drug benefit: An overview with practice tips SO AMERICAN JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Review ID BENEFICIARIES; QUALITY AB The new Medicare drug benefit (Part D) will expand drug coverage to the millions of Medicare beneficiaries who currently lack insurance protection against the costs of prescription drugs. This dramatic expansion of benefits could increase medication treatment for many chronic health conditions, but the impact of Part D on the affordability of prescription drugs depends on a series of choices beneficiaries must make including whether to sign up for the voluntary benefit and which of several drug plans to choose. Private prescription drug plans administering the benefit will vary in terms of the cost sharing, premiums, and formulary design. Providers can play an important role in providing patients with the resources necessary to make good choices regarding drug coverage. Medicare will also provide reimbursement for medication therapy management. The transition of Medicare beneficiaries to Part D drug plans provides an important opportunity for providers to review and possibly make changes to their elderly patients' drug regimens to maximize effectiveness while minimizing costs to patients. C1 Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Med Geriatr, Pittsburgh, PA 15261 USA. Vet Affairs Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Donohue, J (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 Desoto St, Pittsburgh, PA 15261 USA. EM jdonohue@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU NIA NIH HHS [P30 AG024827]; NICHD NIH HHS [1K12HD049109] NR 18 TC 1 Z9 1 U1 0 U2 0 PU LE JACQ LTD PI DARIEN PA 3 PARKLANDS DRIVE, DARIEN, CT 06820 USA SN 1076-7460 J9 AM J GERIATR CARDIOL JI Am. J. Geriatr. Cardiol. PD NOV-DEC PY 2005 VL 14 IS 6 BP 291 EP 297 DI 10.1111/j.1076-7460.2005.04914.x PG 7 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA 010DJ UT WOS:000235166800003 PM 16276125 ER PT J AU Harwood, DG Sultzer, DL Feil, D Monserratt, L Freedman, E Mandelkern, MA AF Harwood, DG Sultzer, DL Feil, D Monserratt, L Freedman, E Mandelkern, MA TI Frontal lobe hypometabolism and impaired insight in Alzheimer disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID NEUROBEHAVIORAL RATING-SCALE; COGNITIVE DEFICITS; BEHAVIORAL DISTURBANCES; PSYCHIATRIC-SYMPTOMS; ANOSOGNOSIA; AWARENESS; DEMENTIA; UNAWARENESS; DEPRESSION; VARIANT AB Objective: The authors examined the relationship between impaired insight regarding cognitive and functional deficits and frontal cortex hypometabolism in 41 patients with Alzheimer disease ( AD). Methods: Regional cerebral glucose metabolism was determined with (18F)fluorodeoxyglucose and positron emission tomography. Level of insight was measured with the clinician-rated Neurobehavioral Rating Scale, and severity of global cognitive impairment was determined with the Mini-Mental State Exam. Results: Inaccurate insight was correlated with glucose metabolic rate in the right lateral frontal cortex ( Brodmann areas 6 and 45, and the lateral aspect of Brodmann areas 8 and 9) after controlling for global cognitive dysfunction. Conclusions: The findings from this study help to further elucidate the neurobiological mechanisms underlying impaired insight in AD, indicating a link between this important clinical phenomenon and dysmetabolism in a focal region of the right prefrontal cortex. C1 Univ Calif Los Angeles, David Geffen Sch Med, Neuropsychiat Inst & Hosp, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Mental Hlth Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA USA. Univ Calif Irvine, Dept Phys & Radiol Sci, Irvine, CA 92717 USA. RP Sultzer, DL (reprint author), W Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,3 S,116AF, Los Angeles, CA 90073 USA. EM dsultzer@ucla.edu FU NIMH NIH HHS [MH56031] NR 52 TC 36 Z9 38 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV PY 2005 VL 13 IS 11 BP 934 EP 941 DI 10.1176/appi.ajgp.13.11.934 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 982NQ UT WOS:000233169300003 PM 16286436 ER PT J AU Watson, GS Cholerton, BA Reger, MA Baker, LD Plymate, SR Asthana, S Fishel, MA Kulstad, JJ Green, PS Cook, DG Kahn, SE Keeling, ML Craft, S AF Watson, GS Cholerton, BA Reger, MA Baker, LD Plymate, SR Asthana, S Fishel, MA Kulstad, JJ Green, PS Cook, DG Kahn, SE Keeling, ML Craft, S TI Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone - A preliminary study SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID AMYLOID PRECURSOR PROTEIN; INSULIN-RESISTANCE; GAMMA AGONISTS; MEMORY; RISK; PHOSPHORYLATION; MECHANISMS; A-BETA-42; MOLECULES; DEMENTIA AB Objective: Insulin resistance ( impaired insulin action) has been associated with Alzheimer disease ( AD) and memory impairment, independent of AD. Peroxisome proliferator-activated receptor-gamma ( PPAR-gamma) agonists improve insulin sensitivity and regulate in-vitro processing of the amyloid precursor protein (APP). Authors evaluated the effects of the PPAR-gamma agonist rosiglitazone on cognition and plasma levels of the APP derivative beta-amyloid (A beta) in humans. Methods: In a placebo-controlled, double-blind, parallel-group pilot study, 30 subjects with mild AD or amnestic mild cognitive impairment were randomized to a 6-month course of rosiglitazone ( 4 mg daily; N = 20) or placebo ( N = 10). Primary endpoints were cognitive performance and plasma Ab levels. Results: Relative to the placebo group, subjects receiving rosiglitazone exhibited better delayed recall ( at Months 4 and 6) and selective attention ( Month 6). At Month 6, plasma A beta levels were unchanged from baseline for subjects receiving rosiglitazone but declined for subjects receiving placebo, consistent with recent reports that plasma A beta 42 decreases with progression of AD. Conclusions: Findings provide preliminary support that rosiglitazone may offer a novel strategy for the treatment of cognitive decline associated with AD. Future confirmation in a larger study is needed to fully C1 VAPSHCS, GRECC, Seattle, WA 98108 USA. VAPSHCS, Res & Dev Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA. Univ Wisconsin, GRECC, William S Middleton Mem Vet Hosp, Madison, WI USA. RP Craft, S (reprint author), VAPSHCS, GRECC, S-1482-GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM scraft@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 NR 25 TC 338 Z9 363 U1 3 U2 21 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV PY 2005 VL 13 IS 11 BP 950 EP 958 DI 10.1176/appi.ajgp.13.11.950 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 982NQ UT WOS:000233169300005 PM 16286438 ER PT J AU Hirschman, KB Joyce, CM AF Hirschman, KB Joyce, CM TI Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 56th Annual Meeting of the Gerontological-Society-of-America CY NOV 21-25, 2003 CL San Diego, CA SP Gerontol Soc Amer ID PREFERENCES; TRIAL AB Objectives: The authors examined the factors associated with 1) caregivers' willingness to involve a relative with Alzheimer disease ( AD) in a decision to use an AD-slowing treatment; and 2) how caregivers would resolve a disagreement over this decision with the their relative. Methods: This was a cross-sectional interview study of 102 caregivers of patients with mild-to-severe-stage AD, enrolled in a University Memory Disorders Clinic. Results: Forty- four percent of caregivers (45/102) said that his or her relative would participate in a decision to use an AD-slowing treatment. Logistic regression showed that having less dementia severity, being a female caregiver, and a spousal relationship were all associated with caregivers' involving their relative in this decision. Among the caregivers who said they would involve their relative, the majority said they would resolve disagreements over whether to use the treatment in favor of what the patient wanted, versus what the family wanted for the patient. Male caregivers were less likely to resolve disagreements in favor of the patients' preferences. Conclusion: Although most caregivers of patients in mild-to-moderate stages would include these patients in an AD treatment decision, certain caregiver characteristics, such as gender and relationship, are associated with not involving patients in this decision. Physicians working with dementia patients and their family members should take these characteristics into account when discussing treatment options and work with patient-caregiver dyads to improve the communication of preferences. C1 Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. Univ Penn, Sch Nursing, Div Biobehav & Hlth Sci, Philadelphia, PA 19104 USA. Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Div Geriatr, Philadelphia, PA 19104 USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equit Res & Promot, Philadelphia, PA USA. RP Hirschman, KB (reprint author), Univ Penn, Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM hirschk@nursing.upenn.edu FU NIA NIH HHS [T32 AG-00255, K01 AG-00931, P30-AG10124] NR 23 TC 9 Z9 9 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV PY 2005 VL 13 IS 11 BP 1014 EP 1021 DI 10.1176/appi.ajgp.13.11.1014 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 982NQ UT WOS:000233169300013 PM 16286446 ER PT J AU Watnick, S Wang, PL Demadura, T Ganzini, L AF Watnick, S Wang, PL Demadura, T Ganzini, L TI Validation of 2 depression screening tools in dialysis patients SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE dialysis; depression; screening ID PATIENTS STARTING DIALYSIS; PRIMARY-CARE; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; MAJOR DEPRESSION; RENAL-DISEASE; MORTALITY; OUTCOMES; IDENTIFICATION; PREDICTOR AB Background Depression is the most common psychiatric disorder in long-term dialysis patients and is a risk factor for morbidity and mortality. An efficient and valid method of diagnosing depression might facilitate recognition and treatment. We sought to validate 2 depression assessment tools, the 21-question Beck Depression Inventory (BDI) and the 9-question Patient Health Questionnaire (PHQ-9), in a dialysis population. Methods: We surveyed patients who had received dialysis for at least 90 days in Portland, OR. We excluded patients with dementia, delirium, or a history of major psychiatric disorders other than depression. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, a gold-standard measure for depression, was administered by trained psychologists within 2 weeks of the BDI and PHQ-9. Results: Of 62 enrolled subjects, 16 were diagnosed with a depressive disorder, including 12 patients (19%) with major depression, 3 patients with dysthymia, and I patient with minor depression. Optimal BDI and PHQ-9 cutoff values for depressive disorders combined was 16 or greater and 10 or greater, respectively. Sensitivities were 91% and 92%, specificities were 86% and 92%, positive predictive values were 59% and 71 %, and negative predictive values were both 98%,with kappa valuesof 0.65 and 0.75, respectively. The difference between the 2 receiver operating characteristic curves was not statistically significant (P > 0.9). Conclusion: Our results validate the PHQ-9 and revalidate the BDI against a gold-standard measure for depressive disorders in the dialysis population. Both tools performed equally well. Because depression is prevalent, readily diagnosed, and associated with poor outcomes, screening by means of short and valid measurement tools may lead to better diagnosis and treatment of this modifiable risk factor. This may lead to improved clinical outcomes in dialysis patients. Am J Kidney Dis 46:919-924. (c) 2005 by the National Kidney Foundation, Inc. C1 Oregon Hlth Sci Univ, VA Dialysis Unit, Dept Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. Vet Adm Med Ctr, Div Mental Hlth, Portland, OR USA. Vet Adm Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. RP Watnick, S (reprint author), Oregon Hlth Sci Univ, VA Dialysis Unit, Dept Med, Portland, OR 97239 USA. EM watnicks@ohsu.edu NR 24 TC 144 Z9 147 U1 0 U2 7 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2005 VL 46 IS 5 BP 919 EP 924 DI 10.1053/j.ajkd.2005.08.006 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 993DR UT WOS:000233933400016 PM 16253733 ER PT J AU Luk, AJ Simkin, PA AF Luk, AJ Simkin, PA TI Epidemiology of hyperuricemia and gout SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID SERUM URIC-ACID; NUTRITION EXAMINATION SURVEY; PRACTICE RESEARCH DATABASE; 3RD NATIONAL-HEALTH; CHRONIC HEART-FAILURE; PURINE-RICH FOODS; METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; ASYMPTOMATIC HYPERURICEMIA; ANTIOXIDANT CAPACITY AB Gout is an increasingly common medical problem. The traditional risk factors of male sex and high red meat or alcohol consumption have been joined by a wave of newer risk factors, such as increased longevity, the metabolic syndrome (hypertension, diabetes, dyslipidemia, truncal obesity, increased cardiovascular disease risk), use of diuretics, low-dose aspirin, or cyclosporine, and end-stage renal disease. Atypical presentations of gout in the elderly can mimic osteoarthritis and rheumatoid arthritis. There is a resurgence of interest in hyperuricemia as an independent and potentially modifiable cardiovascular risk factor. The pharmacologic management of gout in general practice suffers from a number of quality-control issues. This article reviews these and other new epidemiologic data on this ancient disease. C1 Univ Washington, Div Rheumatol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Luk, AJ (reprint author), Univ Washington, Div Rheumatol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 72 TC 58 Z9 65 U1 0 U2 6 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2005 VL 11 IS 15 SU S BP S435 EP S442 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 988MD UT WOS:000233604400001 PM 16300457 ER PT J AU Rehman, SU Nietert, PJ Cope, DW Kilpatrick, AO AF Rehman, SU Nietert, PJ Cope, DW Kilpatrick, AO TI What to wear today? Effect of doctor's attire on the trust and confidence of patients SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE physician attire; physician dress; patient trust ID PHYSICIAN ATTIRE; WHITE COAT; ATTITUDES; CLOTHES; STYLE; COMMUNICATION; CONSULTATIONS; DRESS AB PURPOSE: There are very few studies about the impact of physicians' attire on patients' confidence and trust. The objective of this study was to determine whether the way a doctor dresses is an important factor in the degree of trust and confidence among respondents. METHODS: A cross-sectional descriptive study using survey methodology was conducted of patients and visitors in the waiting room of an internal medicine outpatient clinic. Respondents completed a written survey after reviewing pictures of physicians in four different dress styles. Respondents were asked questions related to their preference for physician dress as well as their trust and willingness to discuss sensitive issues. RESULTS: Four hundred respondents with a mean age of 52.4 years were enrolled; 54% were men, 58% were white, 38% were African-American, and 43% had greater than a high school. diploma. On all questions regarding physician dress style preferences, respondents significantly favored the professional attire with white coat (76.3%, P <.0001), followed by surgical scrubs (10.2%), business dress (8.8%), and casual dress (4.7%). Their trust and confidence was significantly associated with their preference for professional dress (P <.0001). Respondents also reported that they were significantly more willing to share their social, sexual, and psychological problems with the physician who is professionally dressed (P <.0001). The importance of physician's appearance was ranked similarly between male and female respondents (P =.54); however, female physicians' dress appeared to be significantly more important to respondents than male physicians' dress (P <.001). CONCLUSION: Respondents overwhelmingly favor physicians in professional attire with a white coat. Wearing professional dress (ie, a white coat with more formal attire) while providing patient care by physicians may favorably influence trust and confidence-building in the medical encounter. (c) 2005 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Mt Pleasant, SC 29464 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. Univ Calif Los Angeles, San Fernando Valley Program, Los Angeles, CA USA. Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. Med Univ S Carolina, Dept Hlth Adm & Policy, Charleston, SC 29425 USA. RP Rehman, SU (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 214 Hist Dr, Mt Pleasant, SC 29464 USA. EM rehmans@musc.edu OI Nietert, Paul/0000-0002-3933-4986 NR 40 TC 82 Z9 85 U1 1 U2 25 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD NOV PY 2005 VL 118 IS 11 BP 1279 EP 1286 DI 10.1016/j.amjmed.2005.04.026 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 981YD UT WOS:000233123000017 PM 16271913 ER PT J AU Nagai, H Ota, F Konopacki, R Connor, NP AF Nagai, H Ota, F Konopacki, R Connor, NP TI Discoordination of laryngeal and respiratory movements in aged rats SO AMERICAN JOURNAL OF OTOLARYNGOLOGY LA English DT Article ID HEAVY-CHAIN ISOFORMS; SWALLOWING DISORDERS; BREATHING PATTERN; INTERNAL BRANCH; MUSCLE-ACTIVITY; NERVE; CAT; VOCALIZATION; RESISTANCE; AFFERENTS AB Voice and swallowing actions require the coordination of multiple motor systems, and this coordination may be impaired with aging. Although recent work has reported impairments in age-related laryngeal kinematics in rats, the temporal relationship of laryngeal excursions to the respiratory cycle is unknown. The goal of this study was to assess laryngeal-respiratory coordination by examining temporal interrelationships between change in laryngeal aperture and chest wall movement during quiet breathing in a rat model. Glottal images were recorded, digitized, and synchronized with respiratory signals, and temporal features were measured. In the young animals, glottal opening began before the onset of inspiration, and glottal and respiratory cycles were phasic and stereotypic. In old animals, however, inspiration often began during the glottal closing phase, and both respiratory signals were asymmetric. Discoordination of laryngeal and respiratory motor actions associated with aging may be caused by a generalized decline in sensorimotor cranial functions and may contribute to age-related swallowing and communication impairment. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. Kitasato Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kanagawa, Japan. Jikei Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Tokyo, Japan. Univ Wisconsin, Dept Biostat, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Connor, NP (reprint author), Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. EM connor@surgery.wisc.edu NR 43 TC 9 Z9 10 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0196-0709 J9 AM J OTOLARYNG JI Am. J. Otolaryngol. PD NOV-DEC PY 2005 VL 26 IS 6 BP 377 EP 382 DI 10.1016/j.amjoto.2005.02.015 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 986TQ UT WOS:000233473000003 PM 16275405 ER PT J AU Faulkner, JL Szcykalski, LM Springer, F Barnes, JL AF Faulkner, JL Szcykalski, LM Springer, F Barnes, JL TI Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; 5/6 NEPHRECTOMIZED RATS; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; PROLIFERATIVE GLOMERULONEPHRITIS; PROGRESSIVE GLOMERULOSCLEROSIS; TUBULOINTERSTITIAL FIBROSIS; KIDNEY FIBROSIS; MESANGIAL CELLS; BONE-MARROW AB To determine whether previous renal injury accelerates the progression of glomerulosclerosis and interstitial fibrosis, we examined the effect of treating rats with angiotensin H after Habu venom injury. After initiating disease, we examined the origin of interstitial myofibroblasts by locating a-smooth muscle actin (alpha-SMA)-positive and Na+,K+-ATPase-positive cells relative to interstitial space, tubular epithelial cells, the tubular basement membrane (TBM), and vascular structures. Tubular epithelial-mesenchymal transition was also assessed by examining TBM integrity and by using Texas Red (TR)-dextran in intravital tracking experiments. The staining of alpha-SMA-positive myofibroblasts dramatically increased in peritubular interstitial spaces 48 hours after Habu venom plus angiotensin II, particularly in and around perivascular and periglomerular regions, while tubular epithelial cells were alpha-SMA-negative. Na+,K+-ATPase-positive and TR-dextran-labeled cells were restricted to the tubular epithelium and excluded from the interstitium. By 7 and 14 days, expanded interstitial space contained only alpha-STMA-positive myofibroblasts without TR-dextran endocytic particles. Epithelium of atrophic tubules containing TR-dextran remained confined by surrounding interstitium and myofibroblasts. These studies indicate that early expansion of a-SMA-positive cells in the interstitium and loss of tubular area occur via encroachment of interstitial myofibroblasts from perivascular into atrophic tubular spaces rather than via epithelial-mesenchymal transition and migration of tubular cells through the TBM into the interstitium. C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, Dept Med, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Med Res Serv, S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Barnes, JL (reprint author), Univ Texas, Hlth Sci Ctr, Div Nephrol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM barnesj@uthscsa.edu FU NIDDK NIH HHS [P50 DK061597] NR 53 TC 68 Z9 72 U1 0 U2 4 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD NOV PY 2005 VL 167 IS 5 BP 1193 EP 1205 DI 10.1016/S0002-9440(10)61208-4 PG 13 WC Pathology SC Pathology GA 979UK UT WOS:000232970200003 PM 16251405 ER PT J AU Yuan, PQ Yang, H AF Yuan, PQ Yang, H TI Hypothyroidism increases Fos immunoreactivity in cholinergic neurons of brain medullary dorsal vagal complex in rats SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE thyroid hormone; dorsal motor nucleus of the vagus; nucleus tractus solitarii; vagus nerve; area postrema ID THYROTROPIN-RELEASING-HORMONE; CENTRAL-NERVOUS-SYSTEM; CAUDAL RAPHE NUCLEI; THYROID-HORMONE; GENE-EXPRESSION; PARAVENTRICULAR NUCLEUS; RECEPTOR ISOFORM; ACETYLTRANSFERASE GENE; FEEDBACK-REGULATION; SUBSTANCE-P AB Hypo- or hyperthyroidism is associated with autonomic disorders. We studied Fos expression in the medullary dorsal motor nucleus of the vagus (DMV), nucleus tractus solitarii (NTS), and area postrema (AP) in four groups of rats with different thyroid states induced by a combination of drinking water and daily intraperitoneal injection for 1 - 4 wk: 1) tap water and vehicle; 2) 0.1% propylthiouracil (PTU) and vehicle; 3) PTU and thyroxine (T-4; 2 mu g/ 100 g); and 4) tap water and T4 ( 10 mu g/ 100 g). The numbers of Fos immunoreactive (IR) positive neurons in the DMV, NTS, and AP were low in euthyroid rats but significantly higher in the 4-wk duration in hypothyroid rats, which were prevented by simultaneous T4 replacement. Hyperthyroidism had no effect on Fos expression in these areas. There were significant negative correlations between T4 levels and the numbers of Fos-IR-positive neurons in the DMV ( r = - 0.6388, P < 0.008), NTS ( r = - 0.6741, P < 0.003), and AP ( r = - 0.5622, P < 0.004). Double staining showed that Fos immunoreactivity in the DMV of hypothyroid rats was mostly localized in choline acetyltransferase-containing neurons. Thyroid hormone receptors alpha 1 and beta 2 were localized in the observed nuclei. These results indicate that thyroid hormone influences the DMV/NTS/AP neuronal activity, which may contribute to the vagal-related visceral disorders observed in hypothyroidism. C1 Vet Affairs Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Div Digest Dis, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Yang, H (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Rm 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM hoyang@ucla.edu FU NIDDK NIH HHS [DK-41301] NR 53 TC 3 Z9 3 U1 1 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD NOV PY 2005 VL 289 IS 5 BP E892 EP E899 DI 10.1152/ajpendo.00108.2005 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 977ML UT WOS:000232807800020 PM 15985455 ER PT J AU Lee, JS Frevert, CW Matute-Bello, G Wurfel, MM Wong, VA Lin, SM Ruzinski, J Mongovin, S Goodman, RB Martin, TR AF Lee, JS Frevert, CW Matute-Bello, G Wurfel, MM Wong, VA Lin, SM Ruzinski, J Mongovin, S Goodman, RB Martin, TR TI TLR-4 pathway mediates the inflammatory response but not bacterial elimination in E-coli pneumonia SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE lipopolysaccharide; toll-like receptor-4; Escherichia coli; bacterial proliferation ID TOLL-LIKE RECEPTOR-4; GRAM-NEGATIVE PNEUMONIA; GENETIC-CONTROL; C57BL/10SCCR MICE; HOST-DEFENSE; MYCOBACTERIUM-TUBERCULOSIS; LEUCOCYTE RESPONSES; INFECTION; LPS; ENDOTOXIN AB We examined the role of Toll-like receptor ( TLR)-4 in modifying the lung inflammatory response and its effects on the bacterial recovery from the lungs following inhaled Escherichia coli in two different strains of TLR-4 mutant mice that are hyporesponsive to LPS. The C57BL/ 10ScN(tlr4(lps-del)) mice containing a deletion mutation in the TLR-4 gene showed lower proinflammatory cytokine levels, lower lung MPO activity, and less parenchymal and peribronchial inflammation compared with the C57BL/10ScSn mice, a related TLR-4 wild-type substrain. However, the C57BL/10ScN(tlr4(lps-del)) mutant showed lower bacterial recovery in the lungs following inhaled E. coli associated with a rapid but transient increase in air space neutrophil counts at 6 h. In comparison, the C3H/HeJ(tlr4(Lps-d)) mutant mice containing a Pro712His substitution in TLR-4 demonstrated lower proinflammatory cytokine levels, lower lung MPO activity, and lower neutrophil accumulation in the air spaces but showed no differences in the bacterial burden of inhaled E. coli at 6 h, when compared with the TLR-4 wild-type C3H/HeSnJ mice. Thus two different TLR-4 mutants showed attenuated inflammatory responses in the lungs, but the reduced inflammatory responses were not consistently associated with either improved or impaired bacterial elimination from the lungs. Our findings indicate that the inflammatory response to inhaled E. coli is TLR-4 dependent, but bacterial elimination depends on other factors in addition to TLR-4. C1 Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA 98108 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. Chang Gung Mem Hosp, Dept Thorac Med 2, Taipei 10591, Taiwan. RP Martin, TR (reprint author), Univ Washington, Dept Med, Div Pulm & Crit Care, 1600 S Columbian Way,GMR 151-L, Seattle, WA 98108 USA. EM trmartin@u.washington.edu FU NHLBI NIH HHS [HL-70178, HL-70840, HL-73996, HL-072923]; NIGMS NIH HHS [GM-37696] NR 32 TC 36 Z9 39 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD NOV PY 2005 VL 289 IS 5 BP L731 EP L738 DI 10.1152/ajplung.00196.2005 PG 8 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 972RB UT WOS:000232469800008 PM 16024722 ER PT J AU Sassi, RB Stanley, JA Axelson, D Brambilla, P Nicoletti, MA Keshavan, MS Ramos, RT Ryan, N Birmaher, B AF Sassi, RB Stanley, JA Axelson, D Brambilla, P Nicoletti, MA Keshavan, MS Ramos, RT Ryan, N Birmaher, B TI Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT 47th Annual Meeting of the American-College-of-Neuropsychopharmacology CY DEC 08-12, 2002 CL Waikoloa, HI SP Amer Coll Neuropsychopharmacol AB Objective: Converging evidence implicates prefrontal circuits in the pathophysiology of bipolar disorder. Proton spectroscopy studies performed in adult bipolar patients assessing prefrontal regions have suggested decreased levels of N-acetylaspartate (NAA), a putative marker of neuronal integrity. In order to examine whether such abnormalities would also be found in younger patients, a H-1 spectroscopy study was conducted that focused on the dorsolateral prefrontal cortex of children and adolescents with bipolar disorder. Method: The authors examined the levels of NAA, creatine plus phosphocreatine, and choline-containing molecules in the left dorsolateral prefrontal cortex of 14 bipolar disorder patients (mean age= 15.5 years, SD=3, eight female) and 18 healthy comparison subjects (mean age= 17.3, SD=3.7, seven female) using short echo time, single-voxel in vivo H-1 spectroscopy. Absolute metabolite levels were determined using the water signal as an internal reference. Results: Bipolar patients presented significantly lower NAA levels and a significant inverse correlation between choline-containing molecules and number of previous affective episodes. No differences were found for other metabolites. Conclusions: These findings suggest that young bipolar patients have decreased NAA levels in the dorsolateral prefrontal cortex, similar to what was previously reported in adult patients. Such changes may reflect an underdevelopment of dendritic arborizations and synaptic connections. These neuronal abnormalities in the dorsolateral prefrontal cortex of bipolar disorder youth are unlikely to represent long-term degenerative processes, at least in the subgroup of patients where the illness had relatively early onset. C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Harvard Univ, Sch Med, MGH McLean Psychiat, Dept Psychiat, Boston, MA USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. Univ Udine, Sect Psychiat, Dept Pathol & Expt & Clin Med, Udine, Italy. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Sassi, RB (reprint author), Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010; Ramos, Renato/G-1566-2013 OI brambilla, paolo/0000-0002-4021-8456; FU NIMH NIH HHS [MH-59929, MH-01736, MH-30915, MH-55123] NR 47 TC 48 Z9 51 U1 2 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD NOV PY 2005 VL 162 IS 11 BP 2109 EP 2115 DI 10.1176/appi.ajp.162.11.2109 PG 7 WC Psychiatry SC Psychiatry GA 979XF UT WOS:000232977600017 PM 16263851 ER PT J AU Chang, DS Lee, MH Lee, HY Barack, BM AF Chang, DS Lee, MH Lee, HY Barack, BM TI MDCT of left anterior descending coronary artery to main pulmonary artery fistula SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article C1 VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Gaffen Sch Med, Los Angeles, CA USA. Olive View UCLA Med Ctr, Dept Radiol, Sylmar, CA 91342 USA. VA Greater Los Angeles Healthcare Syst, Imaging Serv, Los Angeles, CA USA. RP Chang, DS (reprint author), VA Greater Los Angeles Healthcare Syst, Div Cardiol, 11301 Wilshire Blvd,111E, Los Angeles, CA 90073 USA. EM dchang@ucla.edu NR 9 TC 6 Z9 6 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD NOV PY 2005 VL 185 IS 5 BP 1258 EP 1260 DI 10.2214/AJR.04.1415 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 978XI UT WOS:000232905900033 PM 16247146 ER PT J AU Finan, KR Vick, CC Kiefe, CI Neumayer, L Hawn, MT AF Finan, KR Vick, CC Kiefe, CI Neumayer, L Hawn, MT TI Predictors of wound infection in ventral hernia repair SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 29th Annual Surgical Symposium of the Association-of-VA-Surgeons CY MAR 11-13, 2005 CL Salt Lake City, UT DE surgical wound infection; hernia; ventral; United States Department of Veterans Affairs; mesh; smoking ID RANDOMIZED CONTROLLED-TRIAL; OF-VETERANS-AFFAIRS; INCISIONAL HERNIA; RISK-FACTORS; MESH REPAIR; SURGICAL CARE; HERNIORRHAPHY; COMPLICATIONS; QUALITY; SUTURE AB Background: Postoperative wound infection is a significant risk factor for recurrence after ventral hernia repair (VHR). The current study examines patient- and procedure-specific variables associated with wound infection. Methods: A cohort of subjects undergoing VHR from 13 regional Veterans Health Administration (VHA) sites was identified. Patient-specific risk variables were obtained from National Surgical Quality Improvement Program (NSQIP) data. Operative variables were obtained from physician-abstracted operative notes. Univariate and multivariable logistic regression analysis was used to model predictors of postoperative wound infection. Results: A total of 1505 VHR cases were used for analysis; wound infection occurred in 5% (n = 74). Best-fit logistic regression models demonstrated that steroid use, smoking, prolonged operative time, and use of absorbable mesh, acting as a surrogate marker for a more complex procedure, were significant independent predictors of wound infection. Conclusion: Permanent mesh placement was not associated with postoperative wound infection. Smoking was the only modifiable risk factor and preoperative smoking cessation may improve. surgical outcomes in VHR. (c) 2005 Excerpta Medica Inc. All rights reserved. C1 Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effect, Birmingham, AL USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Salt Lake VA Hlth Care Syst, Dept Surg, Salt Lake City, UT USA. Univ Utah, Dept Surg, Salt Lake City, UT USA. RP Hawn, MT (reprint author), KB 429,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mhawn@uab.edu NR 35 TC 109 Z9 110 U1 0 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2005 VL 190 IS 5 BP 676 EP 681 DI 10.1016/j.amjsurg.2005.06.041 PG 6 WC Surgery SC Surgery GA 979II UT WOS:000232935200003 PM 16226938 ER PT J AU Fagan, SP Bellows, CF Albo, D Rodriquez-Barradas, M Feanny, M Awad, SS Berger, DH AF Fagan, SP Bellows, CF Albo, D Rodriquez-Barradas, M Feanny, M Awad, SS Berger, DH TI Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 29th Annual Surgical Symposium of the Association-of-VA-Surgeons CY MAR 11-13, 2005 CL Salt Lake City, UT DE Bowen's disease; anal carcinoma; HIV; immune status ID SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS INFECTION; HOMOSEXUAL-MEN; CELL CARCINOMA; HIV-INFECTION; POSITIVE MEN; NEOPLASIA; CANCER; INDIVIDUALS; PREVALENCE AB Background: The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV). We sought to determine if the duration of HIV disease or the patient's immune status were associated with the development of anal carcinoma. Methods: HIV-positive patients diagnosed with anal neoplasms were reviewed. Statistical analysis was performed via an unpaired Student t test and the Fisher exact test. Results: Fourteen patients were identified, 7 with anal intraepithelial neoplasms (group 1) and 7 with anal carcinoma (group 2). Human papillomavirus was detected in 100% of patients in group 1 and in 67% of patients in group 2. There was no significant difference in the level of immunosuppression as assessed by the CD4 counts (266.9 +/- 48.5 vs. 274.7 +/- 92.0 cell/mu l; P =.94) and viral loads (19,243 18,034 vs. 67,140 +/- 39,570 RNA/mL; P =.29) between groups I and 2, respectively. Group 2 had been HIV positive for a significantly longer period of time (12.6 +/- 2.3 y) compared with group 1 (5.9 +/- 2.0 y P =.05). Conclusions: The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease. As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem. (c) 2005 Excerpta Medica Inc. All rights reserved. C1 Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Operat Care Line, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Fagan, SP (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Operat Care Line, 2002 Holocombe Blvd,VA 112, Houston, TX 77030 USA. EM sfagan@houston.rr.com NR 23 TC 17 Z9 20 U1 1 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2005 VL 190 IS 5 BP 732 EP 735 DI 10.1016/j.amjsurg.2005.07.011 PG 4 WC Surgery SC Surgery GA 979II UT WOS:000232935200014 PM 16226949 ER PT J AU Stewart, L Griffiss, JM Way, LW AF Stewart, L Griffiss, JM Way, LW TI Spectrum of gallstone disease in the veterans population SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 29th Annual Surgical Symposium of the Association-of-VA-Surgeons CY MAR 11-13, 2005 CL Salt Lake City, UT DE gallstones; biliary infections; cholangitis; veterans ID NECROSIS-FACTOR-ALPHA; BILE-DUCT STONES; BILIARY-TRACT; PIGMENT GALLSTONES; BACTERIOLOGY; CHOLELITHIASIS; GALLBLADDER; CHOLANGITIS; PATHOGENESIS; ANTIBIOTICS AB Background: Elderly male patients are thought to have a higher incidence of biliary infections. This demographic is common among veterans, so we analyzed the spectrum of gallstone disease in a large veteran population. Methods: A total of 285 patients with gallstone disease were studied. There were 27 women and 258 men, with an average age of 62 years. Gallstones, bile, and blood (as indicated) were cultured. Illness severity was staged as none (no clinical infection), moderate (fever, leukocytosis), or severe (cholangitis, bacteremia, abscess, hypotension, organ failure). Gallstones were grouped by appearance. Three bacterial groups were defined: EK (Escherichia coli or Klebsiella species), N (Enterococcus), or Oth (all other species). Results: Biliary bacteria were present in 145 (51%) patients. Bacterial presence by patient age was 33% for those less than 50 years, 48% for those 50 to 70 years, and 65% for those more than 70 years (P <.02 vs. others). Bacterial presence by stone type was as follows: cholesterol, 11%; mixed, 51%; pigment, 71% (P <.01 vs. others). Illness severity by stone type was as follows for cholesterol: none, 73%; moderate, 27%; severe, 0%; for mixed: none, 62%; moderate, 25%; severe, 13%; for pigment: none, 41%; moderate, 17%; severe, 41% (P <.0001 vs. others). Illness severity by bacterial group was as follows for sterile: none, 77%; moderate, 23%; severe, 0%; for the Oth group: none, 57%; moderate, 22%; severe, 20%; for the N group: none, 32%; moderate, 16%; severe, 52%; for the EK group: none, 18%; moderate, 22%; severe, 60% (P <.0001 vs. sterile/Oth, P =.126 vs. N). Conclusions: Bacterial biliary tree colonization is prevalent in the veterans' population, it increases with age, and is more common with pigment stones. But not all bacterial species cause infectious manifestations. Patients with E coli and/or Klebsiella species commonly showed infectious manifestations, patients with Enterococcus were in an intermediate range, and those with other species had few infectious manifestations. (c) 2005 Excerpta Medica Inc. All rights reserved. C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Surg Serv, Dept Surg, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Ctr Immunochem, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. RP Stewart, L (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM lygia.stewart@med.va.gov NR 27 TC 12 Z9 12 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2005 VL 190 IS 5 BP 746 EP 751 DI 10.1016/j.amjsurg.2005.07.014 PG 6 WC Surgery SC Surgery GA 979II UT WOS:000232935200017 PM 16226952 ER PT J AU Nutting, PA Dickinson, LM Rubenstein, LV Keeley, RD Smith, JL Elliott, CE AF Nutting, PA Dickinson, LM Rubenstein, LV Keeley, RD Smith, JL Elliott, CE TI Improving detection of suicidal ideation among depressed patients in primary care SO ANNALS OF FAMILY MEDICINE LA English DT Article DE suicide; depression; primary care physicians; quality improvement ID RANDOMIZED-TRIAL; QUALITY IMPROVEMENT; GENERAL-PRACTITIONERS; MAJOR DEPRESSION; ECONOMIC BURDEN; MENTAL-ILLNESS; RISK; PHYSICIANS; INTERVENTION; MANAGEMENT AB PURPOSE Primary care clinicians have difficulty detecting suicidal patients. This report evaluates the effect of 2 primary care interventions on the detection and subsequent referral or treatment of patients with depression and recent suicidal ideation. METHODS Adult patients in 12 mixed-payer primary care practices and 9 not-for-profit staff model health maintenance organization (HMO) practices were screened for depression. Matched practices were randomized within plan type to intervention or usual care. The intervention for mixed-payer practices entailed brief training of physicians and office nurses to provide care management. The intervention for HMO practices consisted of guided development of quality improvement teams for depression care. A total of 880 enrolled patients met study criteria for depression, 232 of whom met criteria for recent suicidal ideation. Intervention effects on suicide detection and referral to mental health specialty care were evaluated with mixed-effects multilevel models in intent-to-treat analyses. RESULTS Depressed patients with recent suicidal ideation were detected on 40.7% of index visits in intervention practices, compared with 20.5% in usual care practices (odds ratio = 2.64, 95% confidence interval, 1.45-5.07), with HMO plan type and male sex associated with detection. The interventions had no effect on referral of patients, starting an antidepressant, or suicidal ideation reported at a 6-month follow-up, although power was limited for all 3 analyses. CONCLUSIONS Primary care interventions to improve depression care can improve detection of recent suicidal ideation. Further work is needed to improve physician response to detection, including referral to specialty care and more aggressive treatment, and to observe the effect on outcomes. C1 Ctr Res Strategies, Denver, CO 80203 USA. Univ Colorado, Dept Family Med, Hlth Sci Ctr, Denver, CO USA. RAND Corp, Hlth Program, Santa Monica, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Cent Arkansas Vet Healthcare Syst, QUERI, N Little Rock, AR USA. Colorado Fdn Med Care, Englewood, CO USA. RP Nutting, PA (reprint author), Ctr Res Strategies, 225 E 6th Ave,Suite 1150, Denver, CO 80203 USA. EM Paul.Nutting@CRSLLC.org FU NIMH NIH HHS [R01 MH54444] NR 62 TC 31 Z9 32 U1 4 U2 12 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672, UNITED STATES SN 1544-1709 J9 ANN FAM MED JI Ann. Fam. Med. PD NOV-DEC PY 2005 VL 3 IS 6 BP 529 EP 536 DI 10.1370/afm.371 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 993VX UT WOS:000233984700010 PM 16338917 ER PT J AU Kirkpatrick, WR Vallor, AC McAtee, RK Ryder, NS Fothergill, AW Rinaldi, MG Patterson, TF AF Kirkpatrick, WR Vallor, AC McAtee, RK Ryder, NS Fothergill, AW Rinaldi, MG Patterson, TF TI Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID EFFICACY AB Antagonistic effects of combination therapy using amphotericin B (AmB) with agents which block ergosterol synthesis are a concern. Terbinafine was evaluated with AmB to assess antagonism or synergy in a rabbit model of invasive aspergillosis. Terbinafine had relatively little activity but did not demonstrate antagonism against AmB in our model. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. Novartis Inst Biomed Res Inc, Concord, MA 01742 USA. RP Kirkpatrick, WR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,Mail Code 7881, San Antonio, TX 78229 USA. EM kirkpatrick@uthscsa.edu NR 12 TC 14 Z9 14 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2005 VL 49 IS 11 BP 4751 EP 4753 DI 10.1128/AAC.49.11-4751-4753.2005 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 980LV UT WOS:000233020900043 PM 16251321 ER PT J AU Namjou, B Kelly, JA Kilpatrick, J Kaufman, KM Nath, SK Scofield, RH Harley, JB AF Namjou, B Kelly, JA Kilpatrick, J Kaufman, KM Nath, SK Scofield, RH Harley, JB TI Linkage at 5q14.3-15 in multiplex systemic lupus erythematosus pedigrees stratified by autoimmune thyroid disease SO ARTHRITIS AND RHEUMATISM LA English DT Article ID SUSCEPTIBILITY LOCI; GENOME SCAN; AUTOANTIBODIES; IDENTIFICATION; PEROXIDASE; EPISTASIS; FAMILIES; 1Q AB Objective. To identify genetic effects potentially shared between systemic lupus erythematosus (SLE) and autoimmune thyroiditis (AITD). Methods. Families from the Lupus Multiplex Registry and Repository were studied in which there was at least 1 member who had both SLE and AITD (Graves' disease or Hashimoto thyroiditis). Genome scan genotyping findings in these pedigrees were evaluated for evidence of genetic linkage, by the maximum-likelihood parametric method. Nineteen pedigrees were used in the initial genome scan. Subsequently, an independent sample of 16 pedigrees was used to replicate findings. Results. Studies of the first set of 19 pedigrees yielded a 2-point parametric logarithm of odds (LOD) of 4.97, which was independently confirmed in the replication sample of 16 pedigrees (LOD 2.89). For all 35 pedigrees together, the 2-point LOD was 7.86, under a dominant model used for screening with 90% penetrance and a disease allele frequency of 10%. The multipoint locus homogeneity LOD in the 35 pedigrees was 6.90 (alpha = 1.0) at 5q14.3-15 between D5S1725 and D5S1453, a 12-cM interval, with the peak at D5S1462 at 96.64 cM (nonparametric linkage P = 0.00002). Fine mapping further confirmed the genetic linkage effect and narrowed the region likely to contain the gene to similar to 5 Mb. Conclusion. These results suggest that stratifying SLE pedigrees by the presence of other autoimmune disorders may facilitate the discovery of genes related I to SLE and that 5q14.3-15 harbors a susceptibility gene shared by SLE and AITD. C1 Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Harley, JB (reprint author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM john-harley@omrf.ouhsc.edu FU NCRR NIH HHS [RR 020143, RR 015577, RR 14467]; NIAID NIH HHS [AI 053747, AI 24717, AI 54117, AI 31584]; NIAMS NIH HHS [AR 12253, AR 48940, AR 049084, AR 42460]; NIDCR NIH HHS [DE 15223] NR 16 TC 18 Z9 20 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD NOV PY 2005 VL 52 IS 11 BP 3646 EP 3650 DI 10.1002/art.21413 PG 5 WC Rheumatology SC Rheumatology GA 984EN UT WOS:000233285400041 PM 16255059 ER PT J AU Liu, M Yang, SC Sharma, S Luo, J Cui, XY Huang, M Ramirez, RD Shay, JW Minna, JD Dubinett, SM AF Liu, M Yang, SC Sharma, S Luo, J Cui, XY Huang, M Ramirez, RD Shay, JW Minna, JD Dubinett, SM TI TGF-beta 1 and EGF modulate transcriptional and posttranscriptional expression of cyclooxygenase-2 in immortalized human bronchial epithelial cells. SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Meeting Abstract CT 4th Annual Conference on Frontiers in Cancer Prevention Research CY OCT 30-NOV 02, 2005 CL Baltimore, MD C1 Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Vet Affairs Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90024 USA. Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA. Dallas Vet Affairs Med Ctr, Dallas, TX USA. Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA. RI Shay, Jerry/F-7878-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD NOV PY 2005 VL 14 IS 11 SU S BP 2717S EP 2718S PN 2 PG 2 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 985BN UT WOS:000233351200152 ER PT J AU Dalwadi, H Krysan, K Heuze-Vourc'h, N Dohadwala, M Elashoff, D Sharma, S Cacalano, N Lichtenstein, A Dubinett, S AF Dalwadi, H Krysan, K Heuze-Vourc'h, N Dohadwala, M Elashoff, D Sharma, S Cacalano, N Lichtenstein, A Dubinett, S TI Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; CARCINOMA CELLS; GENE-REGULATION; UP-REGULATION; CONSTITUTIVE ACTIVATION; TYROSINE KINASES; STAT3 ACTIVATION; MESSENGER-RNA; EXPRESSION; ANGIOGENESIS AB Purpose: Cyclooxygenase-2 (COX-2), phosphorylated signal transducers and activators of transcription 3 (STAT3), and interleukin-6 (IL-6) are elevated in non - small cell lung cancer (NSCLC). These molecules affect numerous cellular pathways, including angiogenesis and apoptosis resistance, and, therefore, may act in concert in NSCLC. Experimental Design: We examined IL-6 and phosphorylated STAT3 in COX-2-overexpressing [COX-2 sense-oriented (COX-2-S)] NSCLC cells and control cells. The effect of IL-6, STAT3, phosphaticlylinositol 3-kinase, and mitogen- activated protein /extracellular signal-regulated kinase kinase on vascular endothelial growth factor (VEGF) production and apoptosis resistance was assessed in COX-2-overexpresing cells. Results: We report that NSCLC cells overexpressing COX-2 (COX-2-S) have increased IL-6 and phosphorylated STAT3 expression compared with control cells. IL-6 induced expression of VEGF in NSCLC cells. Moreover, blocking IL-6, mitogen-activated protein /extracellular signal -regulated kinase kinase, or phosphaticlylinositol 3-kinase decreased VEGF production in COX-2-S cells. The addition of IL-6 to NSCLC cells resulted in increased apoptosis resistance. Furthermore, the inhibition of STAT3 or IL-6 induced apoptosis and reduced survivin expression, a member of the inhibitor of apoptosis protein family in COX-2-S cells. Conclusions: Overall, these findings suggest a novel pathway in which COX-2 activates STAT3 by inducing IL-6 expression. This pathway could contribute to tumor formation by promoting survivin-dependent apoptosis resistance and VEGF production. These findings provide a rationale for the future development of STAT3, IL-6, and/or COX-2-targeted therapies for the treatment of lung cancer. C1 Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Dubinett, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Dept Med, 10833 Le Conte Ave,37-131 CHS, Los Angeles, CA 90095 USA. EM sdubinett@mednet.ucla.edu RI HEUZE-VOURC'H, Nathalie/P-8081-2016 FU NCI NIH HHS [CA-16042, P50CA90388]; NHLBI NIH HHS [T32HL072752]; NIAID NIH HHS [AI-28697] NR 56 TC 67 Z9 75 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 1 PY 2005 VL 11 IS 21 BP 7674 EP 7682 DI 10.1158/1078-0432.CCR-05-1205 PG 9 WC Oncology SC Oncology GA 984VC UT WOS:000233331400014 PM 16278387 ER PT J AU Freedland, SJ Aronson, WJ Trock, B Cohen, P Kane, CJ Amling, CL Presti, JC Terris, MK AF Freedland, SJ Aronson, WJ Trock, B Cohen, P Kane, CJ Amling, CL Presti, JC Terris, MK CA Shared Equal Regional Canc Hosp TI Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy SO CLINICAL CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR-I; FACTOR-BINDING PROTEIN-3; BONE-MINERAL DENSITY; BODY-MASS INDEX; CANCER RISK; IGF-I; AFRICAN-AMERICAN; EPITHELIAL-CELLS; NATIONAL-HEALTH; UNITED-STATES AB Purpose: Adult height, as a surrogate of childhood and adolescent hormone activity and diet, has been associated with the risk for development and death from prostate cancer in predominantly White populations. However, hormonal activity and diets vary between races. We examined whether height was significantly associated with biochemical progression following radical prostatectomy and whether there was an interaction between height and race. Experimental Design: Multivariate Cox proportional hazards analysis was used to determine if height significantly predicted biochemical progression among 1,503 men (450 Black and 1,053 White) treated with radical prostatectomy between 1988 and 2003. We examined for possible interactions between height and race. Results:Taller men (> 175.3 cm) were significantly younger (P = 0.001), treated in more recent years (P = 0.02), had more clinical stageT(1) disease (P = 0.001), and were less likely to have extraprostatic extension (P = 0.02) than shorter men (<= 175.3 cm). Height was not significantly related to race, preoperative serum prostate-specific antigen concentrations, biopsy or pathologic Gleason sum, positive surgical margins, seminal vesicle invasion, or lymph node metastasis. Height was significantly associated with progression among Black men [relative risk (RR), 1.67; 95% confidence interval (95% CI), 1.00-2.79] but not among White men (RR, 1.03; 95% CI, 0.77-1.38). The interaction between race and height for predicting biochemical progression was statistically significant (P-interaction = 0-05). Conclusions: There was an interaction between height and race in that height predicted progression for Black men but not for White men. The explanation for these findings is unclear, although lower insulin-like growth factor-binding protein-3 concentrations among Black men may be involved. C1 Johns Hopkins Sch Med, Dept Urol, Baltimore, MD 21287 USA. Univ Calif Los Angeles, Sch Med, Dept Surg, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA. San Diego Naval Hosp, Dept Urol, San Diego, CA USA. Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, Palo Alto, CA 94304 USA. Vet Adm Med Ctr, Dept Surg, Augusta, GA 30904 USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. RP Freedland, SJ (reprint author), Johns Hopkins Sch Med, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA. EM sfreedl1@jhmi.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA92131-01A1, R01CA100938]; NIA NIH HHS [R01AG20954]; NICHD NIH HHS [R01HD047013] NR 51 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 1 PY 2005 VL 11 IS 21 BP 7735 EP 7742 DI 10.1158/1078-0432.CCR-04-0785 PG 8 WC Oncology SC Oncology GA 984VC UT WOS:000233331400021 PM 16278394 ER PT J AU Giampietro, PF Raggio, CL Reynolds, CE Shukla, SK McPherson, E Ghebranious, N Jacobsen, FS Kumar, V Faciszewski, T Pauli, RM Rasmussen, K Burmester, JK Zaleski, C Merchant, S David, D Weber, JL Glurich, I Blank, RD AF Giampietro, PF Raggio, CL Reynolds, CE Shukla, SK McPherson, E Ghebranious, N Jacobsen, FS Kumar, V Faciszewski, T Pauli, RM Rasmussen, K Burmester, JK Zaleski, C Merchant, S David, D Weber, JL Glurich, I Blank, RD TI An analysis of PAX1 in the development of vertebral malformations SO CLINICAL GENETICS LA English DT Article DE CEPH diversity panel; PAX1; polymorphism; vertebral malformation ID SPONDYLOCOSTAL DYSOSTOSIS; CONGENITAL SCOLIOSIS; SPINA-BIFIDA; GENE; MUTATIONS; SEGMENTATION; ANOMALIES; DEFECTS; LIGAND; DLL3 AB Due to the sporadic occurrence of congenital vertebral malformations, traditional linkage approaches to identify genes associated with human vertebral development are not possible. We therefore identified PAX1 as a candidate gene in vertebral malformations and congenital scoliosis due to its mutation in the undulated mouse. We performed DNA sequence analysis of the PAX1 gene in a series of 48 patients with congenital vertebral malformations, collectively spanning the entire vertebral column length. DNA sequence coding variants were identified in the heterozygous state in exon 4 in two male patients with thoracic vertebral malformations. One patient had T9 hypoplasia, T12 hemivertebrae and absent T10 pedicle, incomplete fusion of T7 posterior elements, ventricular septal defect, and polydactyly. This patient had a C (c) under barC (Pro)-> C (T) under barC (Leu) change at amino acid 410. This variant was not observed in 180 chromosomes tested in the National Institute of Environmental Health Sciences (NIEHS) single nucleotide polymorphism (SNP) database and occurred at a frequency of 0.3% in a diversity panel of 1066 human samples. The second patient had a T11 wedge vertebra and a missense mutation at amino acid 413 corresponding to CCA (Pro)-> CTA (Leu). This particular variant has been reported to occur in one of 164 chromosomes in the NIEHS SNP database and was found to occur with a similar frequency of 0.8% in a diversity panel of 1066 human samples. Although each patient's mother was clinically asymptomatic and heterozygous for the respective variant allele, the possibility that these sequence variants have clinical significance is not excluded. C1 Marshfield Clin Fdn Med Res & Educ, Med Genet Serv, Marshfield, WI 54449 USA. Hosp Special Surg, New York, NY 10021 USA. Marshfield Clin & Res Fdn, Clin Res Ctr, Marshfield, WI USA. Marshfield Clin Fdn Med Res & Educ, Mol Diagnost Genotyping Lab, Marshfield, WI USA. Univ Wisconsin, Clin Genet Ctr, Madison, WI USA. Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. Univ Wisconsin, Dept Med, Endocrinol Sect, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Giampietro, PF (reprint author), Marshfield Clin Fdn Med Res & Educ, Med Genet Serv, 1000 N Oak Ave 3C1, Marshfield, WI 54449 USA. EM giampietro.philip@marshfieldclinic.org OI Blank, Robert Daniel/0000-0003-2950-1944 NR 18 TC 26 Z9 33 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0009-9163 J9 CLIN GENET JI Clin. Genet. PD NOV PY 2005 VL 68 IS 5 BP 448 EP 453 DI 10.1111/j.1399-0004.2005.00520.x PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 971NU UT WOS:000232392000011 PM 16207213 ER PT J AU Weiner, M Benator, D Peloquin, CA Burman, W Vernon, A Engle, M Khan, A Zhao, Z AF Weiner, M Benator, D Peloquin, CA Burman, W Vernon, A Engle, M Khan, A Zhao, Z CA Tuberculosis Trials Consortium TI Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Scientific Conference on New Trends in Landscape Ecology CY OCT 24-26, 2002 CL Piestany, SLOVAKIA SP Int Assoc Landscape Ecol ID PHARMACOKINETIC INTERACTIONS; RIFAMPICIN; ZIDOVUDINE; NEVIRAPINE; LAMIVUDINE; INDUCTION; THERAPY AB Background. Because of drug-drug interactions mediated by hepatic cytochrome P450, tuberculosis treatment guidelines recommend an increase in rifabutin from 300 mg to 450 or 600 mg when combined with efavirenz-based antiretroviral therapy. To assess this recommendation, rifabutin and efavirenz pharmacokinetic parameters were investigated. Methods. Plasma concentrations of rifabutin were determined as a baseline control in 15 patients with tuberculosis and human immunodeficiency virus (HIV) infection who were treated with rifabutin 300 mg and isoniazid 15 mg/kg ( up to 900 mg) twice weekly. Rifabutin, isoniazid, and efavirenz concentrations were determined after a median of 21 days (interquartile range, 20-34 days) of daily efavirenz-based antiretroviral therapy with twice-weekly rifabutin 600 mg and isoniazid 15 mg/kg. Results. The mean rifabutin area under the concentration-time curve (AUC(0-24)) increased 20% from the baseline value (geometric mean, 5.0 vs. 4.2 mu g*h/mL; ratio of geometric means, 1.2 [90% confidence interval, 1.0-1.4]). Also, the mean efavirenz AUC(0-24) in the 15 patients taking concomitant rifabutin 600 mg twice-weekly was 10% higher than that in 35 historical subjects with HIV infection who were not taking rifabutin. Efavirenz-based antiretroviral therapy was effective; HIV load decreased 2.6 log copies/mL, and the median CD4(+) T cell count increased from 141 to 240 cells/mm(3) after a median of 21 days of efavirenz-based antiretroviral therapy. No statistically significant differences in isoniazid pharmacokinetic parameters were found. Conclusions. The rifabutin dose increase from 300 mg to 600 mg was adequate to compensate for the efavirenz drug interaction in most patients, and no drug interaction with isoniazid was detected. Efavirenz therapy administered at a standard 600-mg dose achieved adequate plasma concentrations in patients receiving intermittent rifabutin and isoniazid therapy, was generally well tolerated, and demonstrated potent antiretroviral activity. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Vet Affairs Med Ctr, Washington, DC 20422 USA. George Washington Univ, Med Ctr, Washington, DC 20037 USA. Univ Colorado, Natl Jewish Med & Res Ctr, Sch Pharm, Denver, CO 80202 USA. Univ Colorado, Sch Med, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Denver Publ Hlth, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80202 USA. Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Weiner, M (reprint author), VAMC, Div Infect Dis, Rm 111F,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM weiner@uthscsa.edu FU NCRR NIH HHS [M01-RR-01346] NR 26 TC 30 Z9 32 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2005 VL 41 IS 9 BP 1343 EP 1349 DI 10.1086/496980 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 971BO UT WOS:000232356300028 PM 16206114 ER PT J AU Mackin, RS Horner, MD AF Mackin, RS Horner, MD TI Relationship of the Wender Utah Rating Scale to objective measures of attention SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID DEFICIT HYPERACTIVITY DISORDER; DEFICIT/HYPERACTIVITY DISORDER; PSYCHIATRIC STATUS; NEUROPSYCHOLOGICAL PERFORMANCE; FRONTAL-LOBE; ADULTS; DYSFUNCTION; SCHIZOPHRENIA; ADHD; BOYS AB The Wender Utah Rating Scale (WURS) is a 25-item self-report questionnaire for the retrospective assessment of childhood attention-deficit hyperactivity disorder (ADHD) symptoms; high scores indicate greater symptoms. The current study used 35 male Veterans Affairs outpatients to determine if WURS scores were associated with objective measures of current attentional functioning, including the Trail Making Test, Gordon Diagnostic System, Wechsler Adult Intelligence Scale-Revised digit span and digit symbol subtests, and Wechsler Memory Scale-Revised mental control subtest. Participants included both adults diagnosed with ADHD (n = 14) and non-ADHD adults (n = 21). After Bonferroni correction, Pearson product moment correlation coefficients revealed that greater symptoms on the WURS were associated with poorer digit symbol performance (r = -0.69, P <.05). To determine which indices best predicted WURS scores, scores on attention tests and demographic variables were entered into a stepwise multiple regression analysis. Digit symbol performance was the only significant predictor of WURS scores (R-2 = 0.59, P <.01). Thus, poor performance on a sensitive, but nonspecific, measure of attention with executive function, response speed, and visuomotor coordination components was related to greater self-report of childhood ADHD symptoms. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Mackin, RS (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. NR 40 TC 15 Z9 15 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0010-440X J9 COMPR PSYCHIAT JI Compr. Psychiat. PD NOV-DEC PY 2005 VL 46 IS 6 BP 468 EP 471 DI 10.1016/j.comppsych.2005.03.004 PG 4 WC Psychiatry SC Psychiatry GA 987EI UT WOS:000233500800010 PM 16275215 ER PT J AU Lapadat, R DeBiasi, RL Johnson, GL Tyler, KL Shah, I AF Lapadat, R DeBiasi, RL Johnson, GL Tyler, KL Shah, I TI Genes induced by reovirus infection have a distinct modular cis-regulatory architecture SO CURRENT GENOMICS LA English DT Article DE cis-regulation; gene arrays; promoters; sequence modules; transcription factors; Gene Ontology; signaling; reovirus; apoptosis ID NF-KAPPA-B; FACTOR-BINDING SITES; INDUCED APOPTOSIS; COREGULATED GENES; TARGET GENES; IDENTIFICATION; EXPRESSION; ACTIVATION; INTERFERON; DISCOVERY AB The availability of complete genomes and global gene expression profiling has greatly facilitated analysis of complex genetic regulatory systems. We describe the use of a bioinformatics strategy for analyzing the cis-regulatory design of genes diferentially regulated during viral infection of a target cell. The large-scale transcriptional activity of human embryonic kidney (HEK293) cells to reovirus (serotype 3 Abney) infection was measured using the Affymetrix HU95Av2 gene array. Comparing the 2000 base pairs of 5' upstream sequence for the most differentially expressed genes revealed highly preserved sequence regions, which we call "modules". Higher-order patterns of modules, called "supermodules", were significantly over-represented in the 5' upstream regions of transcriptionally responsive genes. These supermodules contain binding sites for multiple transcription factors and tend to define the role of genes in processes associated with reovirus infection. The supermodular design encodes a cis-regulatory logic for transducing upstream signaling for the control of expression of genes involved in similar biological processes. In the case of reovirus infection, these processes recapitulate the integrated response of cells including signal transduction, transcriptional regulation, cell cycle control, and apoptosis. The computational strategies described for analyzing gene expression data to discover cis-regulatory features and associating them with pathological processes represents a novel approach to studying the interaction of a pathogen with its target cells. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, Campus Box B-182,4200 E 9th Ave, Denver, CO 80262 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NIA NIH HHS [R01 AG014071]; NIAAA NIH HHS [U01 AA013524]; NIGMS NIH HHS [R01 GM030324, R37 GM030324]; NINDS NIH HHS [R01 NS050138, R01 NS051403] NR 49 TC 1 Z9 1 U1 0 U2 1 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-2029 J9 CURR GENOMICS JI Curr. Genomics PD NOV PY 2005 VL 6 IS 7 BP 501 EP 513 DI 10.2174/138920205775067675 PG 13 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 995LF UT WOS:000234101100002 PM 23335855 ER PT J AU Lu, H Yamaoka, Y Graham, DY AF Lu, H Yamaoka, Y Graham, DY TI Helicobacter pylori virulence factors: facts and fantasies SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article DE cag pathogenicity island; duodenal ulcer-promoting; Helicobacter pylori; outer inflammatory protein; VacA; virulence ID CAG PATHOGENICITY ISLAND; ENDONUCLEASE-REPLACING GENE; HUMAN DENDRITIC CELLS; VACUOLATING-CYTOTOXIN; PLASTICITY REGION; DUODENAL-ULCER; GASTRIC-CANCER; MONGOLIAN GERBILS; ANTIGEN-BINDING; PROTEIN AB Purpose of review Virulence factors are related to the ability of a microbe to induce disease. True virulence factors must therefore have a disease association, an in-vivo correlate with disease such as increased mucosal inflammation, or both. Recent findings The cytotoxin-associated gene pathogenicity island; the outer membrane inflammatory protein; the duodenal ulcer-promoting gene, and possibly the blood group antigen-binding adhesion, are the only factors that to date qualify as virulence factors. Numerous recent studies have investigated the interaction of vacuolating cytotoxin A or cytotoxin-associated gene A with cells and cell lines in vitro. It remains unclear, however, whether any of the findings, for example, in-vitro experiments showing that vacuolating cytotoxin A affect the regulation of T or B lymphocytes, have an in-vivo counterpart, or play any role in disease pathogenesis. Summary The criteria for a virulence factor include evidence of an association with a disease or a disease surrogate such as the severity of mucosal inflammation, epidemiologic consistency, and biologic plausibility. Confirmation of the proposed mechanism requires elimination of the effect by gene deletion and restoration by complementation. Cytotoxin-associated gene A has been the subject of elegant biochemistry despite lack of evidence that it is involved in pathogenesis. The current focus of research on Helicobacter pylori relates to exploring the biology of Helicobacter pylori, often using systems that only vaguely relate to the in-vivo conditions or to disease pathogenesis. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Rm 3A-320,111D 2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu NR 61 TC 72 Z9 75 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2005 VL 21 IS 6 BP 653 EP 659 DI 10.1097/01.mog.0000181711.04529.d5 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 976DK UT WOS:000232712800004 PM 16220040 ER PT J AU Heckemeyer, CM Kiefe, CI AF Heckemeyer, CM Kiefe, CI TI Glitazone in diabetes - Relationship to patient dual public/private sector use SO DIABETES CARE LA English DT Letter C1 Birmingham VA Med Ctr, Natl Qual Scholars Program, Birmingham, AL 35233 USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL 35233 USA. Univ Alabama, Div Prevent Med, Birmingham, AL USA. RP Heckemeyer, CM (reprint author), Birmingham VA Med Ctr, Natl Qual Scholars Program, Room 203,Mailbox B61,700 S 19th St, Birmingham, AL 35233 USA. EM christine.heckemeyer@med.va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2005 VL 28 IS 11 BP 2807 EP 2807 DI 10.2337/diacare.28.11.2807 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 001PH UT WOS:000234548300037 PM 16249563 ER PT J AU Powell, MP Glover, SH Probst, JC Laditka, SB AF Powell, MP Glover, SH Probst, JC Laditka, SB TI Barriers associated with the delivery of Medicare-reimbursed diabetes self-management education SO DIABETES EDUCATOR LA English DT Article ID HEALTH-CARE; PROGRAMS AB Purpose The purpose of this study was to explore the barriers that practitioners face in providing diabetes self-management education (DSME) to Medicare beneficiaries, with a special focus on barriers faced by rural providers. Methods Using an e-mail survey, Diabetes Control Program Coordinators (DCPCs) in all US states were asked 3 open-ended questions to understand problems with obtaining American Diabetes Association (ADA) recognition for Medicare reimbursement, differences in obtaining ADA recognition by rural and urban facilities, and facility-level barriers to providing DSME to Medicare patients. Using a mail survey administered to half of ADA-recognized diabetes education centers (DECs), information was collected about perceived barriers to providing DSME in all areas and rural areas. Results Most DCPCs believed it was more difficult for rural providers to obtain ADA recognition than for urban providers; the largest barriers were costs and reporting requirements. The top barriers for rural providers mentioned by DCPCs were the shortage of designated specialists, fewer resources, and high application fees for ADA recognition. Barriers identified by DEC respondents facing rural providers include staffing/institutional support, amount of Medicare reimbursement, lack of hours covered, and transportation. DEC respondents providing care in urban areas only were more likely to perceive barriers to providing diabetes education in rural areas than were rural providers. Conclusions Barriers to DSME are perceived to be higher for rural providers than urban providers. Urban providers perceived that many barriers to DSME are greater for rural providers. The ADA application process is perceived as expensive and laborious. Most respondents perceived Medicare reimbursement for DSME as inadequate. C1 Univ Alabama, Dept Hlth Serv Adm, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. S Carolina Rural Hlth Res Ctr, Columbia, SC USA. Univ S Carolina, Dept Hlth Serv Management & Policy, Columbia, SC 29208 USA. RP Powell, MP (reprint author), Univ Alabama, Dept Hlth Serv Adm, Webb 501,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mppowell@uab.edu NR 19 TC 11 Z9 12 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 J9 DIABETES EDUCATOR JI Diabetes Educ. PD NOV-DEC PY 2005 VL 31 IS 6 BP 890 EP 899 DI 10.1177/0145721705283039 PG 10 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA 987BM UT WOS:000233493400011 PM 16288096 ER PT J AU Goodarzi, MO Bryer-Ash, M AF Goodarzi, MO Bryer-Ash, M TI Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents SO DIABETES OBESITY & METABOLISM LA English DT Review DE biguanides; glucose; insulin sensitizer; metformin; oral antidiabetic agents ID DEPENDENT DIABETES-MELLITUS; POLYCYSTIC-OVARY-SYNDROME; ACTIVATED PROTEIN-KINASE; ORAL HYPOGLYCEMIC AGENTS; GLYCEMIC CONTROL; SKELETAL-MUSCLE; INSULIN-RESISTANCE; COMBINATION THERAPY; PLUS METFORMIN; BLOOD-PRESSURE AB Background: The usefulness of metformin as an oral antidiabetic agent is widely accepted. However, several other classes of oral antidiabetic agents have been recently introduced, raising the need to evaluate the role of metformin as initial therapy and in combination with these newer drugs for treatment of type 2 diabetes mellitus (DM). Methods: Synthesis of information was preceded by a comprehensive review of the English language literature using Medline. We also reviewed bibliographies of relevant articles. The studies most pertinent to the mechanism of action, efficacy, toxicity and administration of metformin were selected for citation in this review. Results: Metformin acts by increasing tissue sensitivity to insulin, principally in the liver. Beneficial properties of metformin include weight reduction, favourable effects on the lipid profile and the fibrinolytic pathway, and improvement of ovarian function in some insulin-resistant women. It does not cause hyperinsulinaemia or hypoglycaemia. Metformin is effective as monotherapy and, in combination with both insulin secretagogues and thiazolidinediones (TZDs), may obviate the need for insulin treatment. Several fixed-dose combination pills containing metformin and other agents are available. A protocol for the initiation of therapy with contemporary oral agents for type 2 DM is presented, with emphasis on the continuing central role of metformin. Conclusions: Metformin remains a safe and effective agent for the therapy of patients with type 2 DM. It is useful as monotherapy or in combination regimens with the newer insulin secretagogues, TZDs or insulin. It is still in most circumstances the agent of choice for initial therapy of the typical obese patient with type 2 DM and mild to moderate hyperglycaemia. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Gonda Goldschmied Diabet Ctr, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm Med Ctr, Med Serv, Los Angeles, CA USA. RP Bryer-Ash, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Cedars Sinai Med Ctr, 900 Vet Ave,Suite 24-130, Los Angeles, CA 90095 USA. EM mbryerash@mednet.ucla.edu NR 124 TC 69 Z9 69 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1462-8902 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD NOV PY 2005 VL 7 IS 6 BP 654 EP 665 DI 10.1111/j.1463-1326.2004.00448.x PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 971NH UT WOS:000232390600004 PM 16219009 ER PT J AU Fourlanos, S Dotta, F Greenbaum, CJ Palmer, JP Rolandsson, O Colman, PG Harrison, LC AF Fourlanos, S Dotta, F Greenbaum, CJ Palmer, JP Rolandsson, O Colman, PG Harrison, LC TI Latent autoimmune diabetes in adults (LADA) should be less latent SO DIABETOLOGIA LA English DT Review DE autoimmune diabetes; classification; diagnostic criteria; HLA; latent autoimmune diabetes in adults; LADA; Type 1 diabetes ID GLUTAMIC-ACID DECARBOXYLASE; ISLET-CELL ANTIBODIES; GENETIC-CHARACTERISTICS; POSITIVE PATIENTS; INSULIN GENE; HUMAN THYMUS; TYPE-1; MELLITUS; ONSET; AUTOANTIBODIES AB 'Latent autoimmune diabetes in adults' (LADA) is the term coined to describe adults who have a slowly progressive form of autoimmune or type 1 diabetes that can be treated initially without insulin injections. The diagnosis of LADA is currently based on three clinical criteria: (1) adult age at onset of diabetes; (2) the presence of circulating islet autoantibodies, which distinguishes LADA from type 2 diabetes; and (3) insulin independence at diagnosis, which distinguishes LADA from classic type 1 diabetes. The prevalence of LADA in adults presenting with non-insulin-requiring diabetes is approximately 10%. Recognition of LADA expands the concept and prevalence of autoimmune diabetes, but LADA remains poorly understood at both a clinical and research level. In this perspective, we review the nomenclature, diagnostic criteria, genetics, pathology and therapy of LADA, to arrive at recommendations that might advance knowledge and management of this form of diabetes. C1 Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Parkville, Vic 3050, Australia. Univ Siena, Dept Internal Med, Diabet Unit, I-53100 Siena, Italy. Univ Siena, Dept Endocrine & Metab Sci, I-53100 Siena, Italy. Policlin Le Scotte, I-53100 Siena, Italy. Benaroya Res Inst Virginia Mason, Seattle, WA USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Umea Univ, Umea, Sweden. Royal Melbourne Hosp, Dept Endocrinol & Diabet, Parkville, Vic 3050, Australia. RP Harrison, LC (reprint author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, 1G Royal Parade, Parkville, Vic 3050, Australia. EM harrison@wehi.edu.au RI Dotta, Francesco/H-3788-2012 OI Dotta, Francesco/0000-0003-4947-7478 NR 58 TC 131 Z9 159 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD NOV PY 2005 VL 48 IS 11 BP 2206 EP 2212 DI 10.1007/s00125-005-1960-7 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 983QW UT WOS:000233248200004 PM 16193284 ER PT J AU Utzschneider, KM Carr, DD Tong, J Wallace, TM Hull, RL Zraika, S Xiao, Q Mistry, JS Retzlaff, BM Knopp, RH Kahn, SE AF Utzschneider, KM Carr, DD Tong, J Wallace, TM Hull, RL Zraika, S Xiao, Q Mistry, JS Retzlaff, BM Knopp, RH Kahn, SE TI Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans SO DIABETOLOGIA LA English DT Article DE adiponectin; insulin resistance; insulin sensitivity; leptin; metabolic syndrome; plasminogen-activator inhibitor 1; resistin ID SERUM RESISTIN; ADIPOSITY; OBESE AB Aims/hypothesis: The aim of this study was to further elucidate the relationship between resistin and insulin sensitivity, body fat distribution and the metabolic syndrome in humans. Methodds: We measured plasma resistin levels in 177 non-diabetic subjects (75 male, 102 female; age 32-75 years). BMI, waist circumference, blood pressure, lipids, glucose, plasminogen-activator inhibitor 1 (PAI-1), adiponectin and leptin levels were also measured. The insulin sensitivity index (S-I) was quantified using Bergman's minimal model. Intra-abdominal fat (IAF) and subcutaneous fat (SQF) areas were quantified by CT scan. Presence of metabolic syndrome criteria was determined using the National Cholesterol Education Program Adult Treatment Panel III guidelines. Results: When subjects were divided into categories based on BMI (< or >= 27.5 kg/m(2)) and S-I (< or >= 7x10(-5) min(-1) [pmol/l](-1)), resistin levels did not differ between the lean, insulin-sensitive (n=53, 5.36 +/- 0.3 ng/ml), lean, insulin-resistant (n=67, 5.70 +/- 0.4 ng/ml) and obese, insulin-resistant groups (n=48, 5.94 +/- 0.4 ng/ml; ANOVA p=0.65). Resistin correlated with age (r=-0.22, p < 0.01), BMI (r=0.16, p=0.03) and SQF (r=0.19, p=0.01) but not with S-I (p=0.31) or IAF (p=0.52). Resistin did not correlate with the number of metabolic syndrome criteria or any of the individual metabolic syndrome criteria. In contrast, adiponectin, PAI-1 and leptin each correlated with IAF, SQF and S-I. Additionally, the number of metabolic syndrome criteria correlated with adiponectin (r=-0.32, p < 0.001), leptin (r=0.31, p < 0.001) and PAI-1 (r=0.26, p=0.001). Conclusions/interpretation: In contrast to other adipokines, resistin is only weakly associated with body fat and is unlikely to be a major mediator of insulin resistance or the metabolic syndrome in humans. C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Vet Affairs Pugent Sound Hlth Care Syst 151, Dept Med,Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Dept Obstet & Gynecol, Div Maternal Fetal Med, Seattle, WA 98195 USA. Linco Res, St Charles, MO USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. RP Utzschneider, KM (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Vet Affairs Pugent Sound Hlth Care Syst 151, Dept Med,Div Metab Endocrinol & Nutr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 FU NCRR NIH HHS [RR-16066, RR-37]; NHLBI NIH HHS [HL-07028, HL-30086]; NIDDK NIH HHS [DK-02654, DK-17047, DK-35747, DK-35816] NR 10 TC 103 Z9 112 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD NOV PY 2005 VL 48 IS 11 BP 2330 EP 2333 DI 10.1007/s00125-005-1932-y PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 983QW UT WOS:000233248200021 PM 16143861 ER PT J AU Bu, SZ Yamanaka, M Pei, HP Bielawska, A Bielawski, J Hannun, YA Obeid, L Trojanowska, M AF Bu, SZ Yamanaka, M Pei, HP Bielawska, A Bielawski, J Hannun, YA Obeid, L Trojanowska, M TI Dihydrosphingosine 1-phosphate stimulates MMP1 gene expression via activation of ERK1/2-Ets1 pathway in human fibroblasts SO FASEB JOURNAL LA English DT Article DE sphingosine 1-phosphate; ceramide; NF-kappa B; COX-2 ID NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; SPHINGOSINE KINASE; TNF-ALPHA; TRANSCRIPTIONAL REGULATION; PLASMA-MEMBRANE; COLLAGEN GENE; UP-REGULATION; TGF-BETA; CANCER AB Sphingosine kinase (SphK) is a conserved lipid kinase that catalyzes formation of important regulators of inter- and intracellular signaling, sphingosine-1 phosphate (S1P), and dihydrosphingosine 1-phosphate (dhS1P). In this study, we investigated the role of SphK1 in the regulation of expression of matrix metalloproteinase 1 (MMP1) in dermal fibroblasts, a key event in regulation of extra cellular matrix. We show that overexpression of SphK1 up-regulated MMP1 protein, MMP1 mRNA, and MMP1 promoter activity, and this action of SphK1 required activation of the ERK1/2-Ets1 and NF-kB pathways. Furthermore, experiments using SphK1 specific siRNA demonstrated that SphK1 is required for the TNF-alpha stimulation of MMP1. Additional data revealed a specific role of dhS1P, and not S1P, as a mediator of SphK1-dependent activation of ERK1/2 and up-regulation of MMP1. The stimulatory effect of dhS1P was sensitive to pertussis toxin, suggesting a possible involvement of a G-protein-coupled receptor. In contrast, S1P, but not dhS1P, stimulated the induction of COX-2, which demonstrated selective actions of these two closely related bioactive lipids. In conclusion, this study describes a novel mode of SphK1 signaling through generation of dhS1P with a key role in mediating transcriptional responses to TNF-alpha. This is the first report of selective function of dhS1P as compared with the better studied S1P. C1 Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC USA. RP Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 912,POB 250637, Charleston, SC 29425 USA. EM trojanme@musc.edu NR 28 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD NOV PY 2005 VL 19 IS 13 BP 184 EP + DI 10.1096/fj.05-4646.fje PG 20 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 994TC UT WOS:000234053100017 ER PT J AU Kim, A Oberley, LW Oberley, TD AF Kim, A Oberley, LW Oberley, TD TI Induction of apoptosis by adenovirus-mediated manganese superoxide dismutase overexpression in SV-40-transformed human fibroblasts SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article; Proceedings Paper CT 11th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine CY NOV 17-21, 2004 CL St Thomas, VI SP Soc Free Rad Biol & Med DE MnSOD; apoptosis; mitochondria; hydrogen peroxide; superoxide anion; peroxiredoxin; mitochondrial redox; ROS; free radicals ID INCREASES OXIDATIVE STRESS; PROSTATE CARCINOMA-CELLS; REACTIVE OXYGEN; PERMEABILITY TRANSITION; ROS GENERATION; UP-REGULATION; MITOCHONDRIAL; DEATH; TRANSCRIPTION; MECHANISMS AB Although mitochondrial reactive oxygen species (ROS) have been implicated both as an initiator and as an effector of apoptosis, the exact role of mitochondrial ROS has been difficult to establish due to the lack of an appropriate experimental system where ROS could be specifically generated from mitochondria and subsequent effects on cells analyzed. In this study, a manganese superoxide dismutase (MnSOD) activity-mediated apoptosis model was established and characterized. It was shown that despite early increases in the steady-state levels of ROS upon MnSOD overexpression, cellular oxidative damage was decreased significantly at later time points. Alterations in levels of peroxiredoxin (Prxnl) protein preceded the onset of apoptosis after MnSOD overexpression. A time course study demonstrated that increases in MnSOD activity prior to the onset of apoptosis correlated with alterations in the levels of nitration of tyrosine residue(s) of MnSOD protein. A direct correlation between MnSOD activity and the degree of apoptosis was demonstrated using a mutant MnSOD with decreased activity. The current study supports a causative role of mitochondrial ROS leading to the onset of apoptosis. The MnSOD activity-mediated apoptosis model described here could be further utilized to study mitochondrial apoptotic pathways. (c) 2005 Elsevier Inc. All rights reserved. C1 Stanford Univ, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA. Univ Iowa, Dept Radiat Oncol, Free Radical & Radiat Biol Program, Iowa City, IA USA. Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Oberley, TD (reprint author), Vet Mem Hosp, Room A35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@wisc.edu FU NCI NIH HHS [CA66081] NR 40 TC 13 Z9 13 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2005 VL 39 IS 9 BP 1128 EP 1141 DI 10.1016/j.freeradbiomed.2005.06.007 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 978JZ UT WOS:000232870700002 PM 16214029 ER PT J AU Ioannou, GN AF Ioannou, GN TI The natural history of NAFLD: Impressively unimpressive SO GASTROENTEROLOGY LA English DT Letter ID FATTY LIVER-DISEASE; POPULATION C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Res Enhancement Award Program, Seattle, WA USA. Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Res Enhancement Award Program, Seattle, WA USA. NR 3 TC 5 Z9 5 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD NOV PY 2005 VL 129 IS 5 BP 1805 EP 1805 DI 10.1053/j.gastro.2005.09.041 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 984IH UT WOS:000233296000047 PM 16285987 ER PT J AU Goldman, DP Shang, BP Hattacharya, J Garber, AM Hurd, M Joyce, GF Lakdawalla, DN Panis, C Shekelle, PG AF Goldman, DP Shang, BP Hattacharya, J Garber, AM Hurd, M Joyce, GF Lakdawalla, DN Panis, C Shekelle, PG TI Consequences of health trends and medical innovation for the future elderly SO HEALTH AFFAIRS LA English DT Article ID UNITED-STATES; CHRONIC DISABILITY; PREVALENCE AB Recent innovations in biomedicine seem poised to revolutionize medical practice. At the same time, disease and disability are increasing among younger populations. This paper considers how these confluent trends will affect the elderly's health status and health care spending over the next thirty years. Because healthier people live longer, cumulative Medicare spending varies little with a beneficiary's disease and disability status upon entering Medicare. On the other hand, ten of the most promising medical technologies are forecast to increase spending greatly. It is unlikely that a "silver bullet" will emerge to both improve health and dramatically reduce medical spending. C1 RAND Corp, Ctr Study Aging, Santa Monica, CA 90406 USA. Stanford Univ, Stanford, CA 94305 USA. VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. Deloitte & Touche LLP, Los Angeles, CA USA. RAND Corp, Evidence Based Practice Ctr, Santa Monica, CA USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Goldman, DP (reprint author), RAND Corp, Ctr Study Aging, Santa Monica, CA 90406 USA. EM dgoldman@rand.org RI Garber, Alan/F-1476-2010; Lakdawalla, Darius/B-4409-2011 FU NIA NIH HHS [P30AG024968] NR 12 TC 3 Z9 3 U1 0 U2 0 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD NOV-DEC PY 2005 VL 24 IS 6 BP W5R5 EP W5R17 PG 13 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 008IM UT WOS:000235033500053 PM 16186147 ER PT J AU Shekelle, PG Ortiz, E Newberry, SJ Rich, MW Rhodes, SL Brook, RH Goldman, DP AF Shekelle, PG Ortiz, E Newberry, SJ Rich, MW Rhodes, SL Brook, RH Goldman, DP TI Identifying potential health care innovations for the future elderly SO HEALTH AFFAIRS LA English DT Article ID ALZHEIMERS-DISEASE; ATRIAL-FIBRILLATION; RHYTHM CONTROL; VACCINE; THERAPY; CANCER; HUMANS AB We used a method that combined literature review and expert judgment to assess potential medical innovations for older adults. We evaluated innovations in four domains: cardiovascular disease, cancer, the biology of aging, and neurologic disease. The innovations can be categorized by common themes: improved disease prevention, better detection of subclinical or early clinical disease, and treatments for established disease. We report the likelihood, potential impact, and potential cost implications for thirty-four innovations, and we revisit this forecast five years later. Many of the innovations have the potential to greatly affect the costs and outcomes of health care. C1 RAND Corp, Evidence Based Practice Ctr, Santa Monica, CA 90406 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. George Washington Univ, Sch Med, Washington, DC 20052 USA. RAND Res Commun Grp, Santa Monica, CA USA. Univ Washington, Sch Med, St Louis, MO USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. RP Shekelle, PG (reprint author), RAND Corp, Evidence Based Practice Ctr, Santa Monica, CA 90406 USA. EM shekelle@rand.org NR 29 TC 1 Z9 1 U1 0 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD NOV-DEC PY 2005 VL 24 IS 6 BP W5R67 EP W5R76 DI 10.1377/hlthaff.W5.R67 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 008IM UT WOS:000235033500058 PM 16186152 ER PT J AU McGuire, J Bikson, K Blue-Howells, J AF McGuire, J Bikson, K Blue-Howells, J TI How many social workers are needed in primary care? A patient-based needs assessment example SO HEALTH & SOCIAL WORK LA English DT Article DE primary care; social needs; social work staffmg ID SYSTEM AB This study measured levels of self-reported social need in a sample of 684 veterans seen in four primary care clinics of a large Veterans Affairs health care system, using the Social Needs Checklist, and calculated levels of social work staffing to meet these needs. Data were obtained on the presence and severity of 15 areas of social needs, housing status, patient requests for social work services, and current access to other providers for social services. Data were also obtained from primary care social workers who estimated the average time needed to provide basic social work services. Nearly two-thirds of the sample had problems related to finances and personal stress. Three in four patients reported multiple needs. One-third requested social work services. Social work staffing needed for highest acuity patients was estimated to be 61 percent higher than actual staffing available. The study presents a method of estimating staffing levels based on social needs reported by patients. C1 W Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Publ Policy, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP McGuire, J (reprint author), W Los Angeles VA Healthcare Ctr, 10H-5,Bldg 500,Room 6651,11030 Wilshire Blvd, Los Angeles, CA 90073 USA. EM James.McGuire@med.va.gov NR 20 TC 7 Z9 7 U1 1 U2 5 PU NATL ASSOC SOCIAL WORKERS PI WASHINGTON PA 750 FIRST ST, NE, STE 700, WASHINGTON, DC 20002-4241 USA SN 0360-7283 J9 HEALTH SOC WORK JI Health Soc. Work PD NOV PY 2005 VL 30 IS 4 BP 305 EP 313 PG 9 WC Social Work SC Social Work GA 984RX UT WOS:000233323100005 PM 16323722 ER PT J AU Verma, A Artiushin, S Matsunaga, J Haake, DA Timoney, JF AF Verma, A Artiushin, S Matsunaga, J Haake, DA Timoney, JF TI LruA and LruB, novel lipoproteins of pathogenic Leptospira interrogans associated with equine recurrent uveitis SO INFECTION AND IMMUNITY LA English DT Article ID INDUCED IMMUNE DEVIATION; OUTER-MEMBRANE PROTEIN; AQUEOUS-HUMOR; MOLECULAR CHARACTERIZATION; MAMMALIAN INFECTION; ANTERIOR-CHAMBER; SHARES EPITOPES; SIGNAL PEPTIDES; HORSES; CORNEA AB Recurrent uveitis as a sequela to Leptospira infection is the most common infectious cause of blindness and impaired vision of horses worldwide. Leptospiral proteins expressed during prolonged survival in the eyes of horses with lesions of chronic uveitis were identified by screening a phage library of Leptospira interrogans DNA fragments with eye fluids from uveitic horses. Inserts of reactive phages encoded several known leptospiral proteins and two novel putative lipoproteins, LruA and LruB. LruA was intrinsically labeled during incubation of L. interrogans in medium containing [C-14] palmitic acid, confirming that it is a lipoprotein. lruA and lruB were detected by Southern blotting in infectious Leptospira interrogans but not in nonpathogenic Leptospira biflexa. Fractionation data from cultured Leptospira indicate that LruA and LruB are localized in the inner membrane. Uveitic eye fluids contained significantly higher levels of immunoglobulin A (IgA) and IgG specific for each protein than did companion sera, indicating strong local antibody responses. Moreover, LruA- and LruB-specific antisera reacted with equine ocular components, suggesting an immunopathogenic role in leptospiral uveitis. C1 Univ Kentucky, MH Gluck Equine Res Ctr 325, Dept Vet Sci, Lexington, KY 40546 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Timoney, JF (reprint author), Univ Kentucky, MH Gluck Equine Res Ctr 325, Dept Vet Sci, Lexington, KY 40546 USA. EM jtimoney@uky.edu FU NIAID NIH HHS [R01 AI034431-08, R21 AI034431, AI-34431, R29 AI034431, R01 AI034431] NR 47 TC 43 Z9 48 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD NOV PY 2005 VL 73 IS 11 BP 7259 EP 7266 DI 10.1128/IAI.73.11.7259-7266.2005 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 977WI UT WOS:000232833800021 PM 16239521 ER PT J AU Kudo, T Lu, H Wu, JY Graham, DY Casola, A Yamaoka, Y AF Kudo, T Lu, H Wu, JY Graham, DY Casola, A Yamaoka, Y TI Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori SO INFECTION AND IMMUNITY LA English DT Article ID CYTOKINE MESSENGER-RNA; NF-KAPPA-B; TRANSCRIPTION FACTORS; INTERLEUKIN-8 PRODUCTION; PATHOGENICITY ISLAND; MAP KINASES; C-JUN; EXPRESSION; MUCOSA; GENE AB RANTES, a CC chemokine, plays an important role in the inflammatory response associated with Helicobacter pylori infection. However, the mechanism by which H. pylori induces RANTES expression in the gastric mucosa is unknown. We cocultured gastric epithelial cells with wild-type H. pylori, isogenic oipA mutants, cag pathogenicity island (PAI) mutants, or double knockout mutants. Reverse transcriptase PCR showed that RANTES mRNA was induced by H. pylori and that the expression was both OipA and cag PAI dependent. Luciferase reporter gene assays and electrophoretic mobility shift assays showed that maximal H. pylori-induced RANTES gene transcription required the presence of the interferon-stimulated responsive element (ISRE), the cyclic AMP-responsive element (CRE), nuclear factor-interleukin 6 (NF-IL-6), and two NF-kappa B sites. OipA- and cag PAI-dependent pathways included NF-kappa B -> NF-kappa B/NF-IL-6/ISRE pathways, and cag PAI-dependent pathways additionally included Jun N-terminal kinase -> CRE/NF-kappa B pathways. The OipA-dependent pathways additionally included p38 -> CRE/ISRE pathways. We confirmed the in vitro effects in vivo by examining RANTES mRNA levels in biopsy specimens from human gastric antral mucosa. RANTES mRNA levels in the antral mucosa were significantly higher for patients infected with cag PAI/OipA-positive H. pylori than for those infected with cag PAI/OipA-negative H. pylori or uninfected patients. The mucosal inflammatory response to H. pylori infection involves different signaling pathways for activation of the RANTES promoter, with both OipA and the cag PAI being required for full activation of the RANTES promoter. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd,111D Rm 3A-320, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIAID NIH HHS [K08 AI01763]; NIDDK NIH HHS [R01 DK062813, R01 DK62813, R01 DK062813-03, DK56338, P30 DK056338] NR 39 TC 38 Z9 40 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD NOV PY 2005 VL 73 IS 11 BP 7602 EP 7612 DI 10.1128/IAi.73.11.7602-7612.2005 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 977WI UT WOS:000232833800064 PM 16239564 ER PT J AU Wright, JL Lin, DW Dewan, P Montgomery, RB AF Wright, JL Lin, DW Dewan, P Montgomery, RB TI Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer SO INTERNATIONAL JOURNAL OF UROLOGY LA English DT Article DE hormone refractory; prostate cancer; tumor lysis syndrome ID DOCETAXEL; MITOXANTRONE; PREDNISONE AB Tumor lysis syndrome (TLS) is an uncommon, but well described, clinical entity that typically occurs following chemotherapy in patients with rapidly growing hematological malignancies. It is rarely described in patients with solid tumors. We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy. C1 Univ Washington, Med Ctr, Dept Med, Div Oncol, Seattle, WA 98195 USA. Univ Washington, Dept Urol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care, Seattle, WA USA. RP Montgomery, RB (reprint author), Univ Washington, Med Ctr, Dept Med, Div Oncol, Hlth Sci Bldg,1959 NE Pacific,SP 1301,Box 358280, Seattle, WA 98195 USA. EM rbmontgo@u.washington.edu NR 7 TC 10 Z9 11 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0919-8172 J9 INT J UROL JI Int. J. Urol. PD NOV PY 2005 VL 12 IS 11 BP 1012 EP 1013 DI 10.1111/j.1442-2042.2005.01196.x PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 985WG UT WOS:000233408800017 PM 16351664 ER PT J AU Abadie, JM Allison, KH Black, DA Garbin, J Saxon, AJ Bankson, DD AF Abadie, JM Allison, KH Black, DA Garbin, J Saxon, AJ Bankson, DD TI Can an immunoassay become a standard technique in detecting oxycodone and its metabolites? SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID DRUG-ABUSE DEATHS; OPIATE IMMUNOASSAYS; URINE; INVOLVEMENT C1 Univ Washington, Med Ctr, Dept Lab Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol & Lab Med, Seattle, WA 98195 USA. RP Abadie, JM (reprint author), Univ Washington, Med Ctr, Dept Lab Med, 1959 NW Pacific St,NW 120,Box 357110, Seattle, WA 98195 USA. EM judeabadie@medscape.com NR 13 TC 8 Z9 8 U1 2 U2 4 PU PRESTON PUBLICATIONS INC PI NILES PA 7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648 USA SN 0146-4760 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD NOV-DEC PY 2005 VL 29 IS 8 BP 825 EP 829 PG 5 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA 986KP UT WOS:000233448800011 PM 16374942 ER PT J AU Gilliam, LK Brooks-Worrell, BA Palmer, JP Greenbaum, CJ Pihoker, C AF Gilliam, LK Brooks-Worrell, BA Palmer, JP Greenbaum, CJ Pihoker, C TI Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes SO JOURNAL OF AUTOIMMUNITY LA English DT Article; Proceedings Paper CT 5th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY MAY 12-16, 2005 CL Boston, MA SP Fed Clin Immunol Soc DE autoantibody; human leukocyte antigen; type 1 diabetes; type 2 diabetes; type 1.5 diabetes ID GLUTAMIC-ACID DECARBOXYLASE; AUTOANTIBODIES; RELATIVES; GAD65; YOUTH AB Aims: Both type 1 (T1D) and type 2 diabetes (T2D) are increasing in incidence in children; often an admixture of T1D and T2D features are present at diagnosis. We examined the relationship between diabetes autoantibodies (DAA), human leukocyte antigen (HLA), and clinical course in subjects grouped by clinical diabetes type. Methods: Subjects 8-18 years old with T1D, T2D, and mixed clinical features (T1.5D), were studied at diagnosis. DAA were measured in all subjects; a subset of subjects underwent HLA genotyping. Clinical course was followed in 84% of subjects for 47.9 + 8.7 months. Results: Eighty-nine percent of T1.5D subjects were positive for at least one DAA; 88% of HLA-typed subjects had risk HLA genotypes. Two subjects initially treated with oral agents were subsequently treated with insulin (50%); one had risk HLA, and the other was DAA positive. Thirty-three percent of T2D subjects were DAA positive and 93% were treated with oral agents at diagnosis. Three subjects were subsequently treated with insulin (21%); of these, two were DAA positive, and one had risk HLA. No subject who remained on diet therapy or oral agents had a combination of DAA-positivity and risk HLA genotype. Conclusions: Children clinically classified with T1.5D or T2D have a high frequency of autoimmune markers and T1D-associated HLA alleles which appears to indicate a more aggressive diabetes disease process, as has been shown for DAA-positive adults with phenotypic T2D. (c) 2005 Elsevier Ltd. All rights reserved. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Benaroya Res Inst, Seattle, WA 98101 USA. Univ Washington, Childrens Hosp, Dept Pediat, Div Pediat Endocrinol, Seattle, WA 98105 USA. Univ Washington, Reg Med Ctr, Seattle, WA 98105 USA. RP Gilliam, LK (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,Box 357710, Seattle, WA 98195 USA. EM lgilliam@u.washington.edu; bbrooks@u.washington.edu; jpp@u.washington.edu; cjgreen@benaroyaresearch.org; cpihok@chmc.org FU NCRR NIH HHS [M01-RR00037]; NIDDK NIH HHS [DK17047] NR 18 TC 37 Z9 39 U1 0 U2 1 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 J9 J AUTOIMMUN JI J. Autoimmun. PD NOV PY 2005 VL 25 IS 3 BP 244 EP 250 DI 10.1016/j.jaut.2005.09.013 PG 7 WC Immunology SC Immunology GA 992NQ UT WOS:000233891200011 PM 16243484 ER PT J AU Ricuarte, O Gutierrez, O Cardona, H Kim, JG Graham, DY El-Zimaity, HMT AF Ricuarte, O Gutierrez, O Cardona, H Kim, JG Graham, DY El-Zimaity, HMT TI Atrophic gastritis in young children and adolescents SO JOURNAL OF CLINICAL PATHOLOGY LA English DT Article ID HELICOBACTER-PYLORI INFECTION; INTESTINAL METAPLASIA; SYDNEY SYSTEM; CANCER; CLASSIFICATION; INFLAMMATION; LOUISIANA; BIOPSY; MUCOSA; CARCINOGENESIS AB Background: Helicobacter pylori associated gastric cancer arises via a multistage process, with atrophic gastritis being the precursor lesion. Helicobacter pylori is typically acquired in childhood, yet little is known of the prevalence of atrophic gastritis in childhood. Aim: To study atrophic gastritis among children from countries with high gastric cancer incidence. Methods: Sections from topographically mapped gastric biopsy specimens from children undergoing clinically indicated endoscopy in Korea and Colombia were evaluated using visual analogue scales. Atrophy was defined as loss of normal glandular components, including replacement with fibrosis, intestinal metaplasia (IM), and/or pseudopyloric metaplasia of the corpus (identified by the presence of pepsinogen I in mucosa that was topographically corpus but phenotypically antrum). Results: One hundred and seventy three children, 58 from Korea (median age, 14 years) and 115 from Colombia (median age, 13 years), were studied. Helicobacter pylori was present in 85% of Colombian children versus 17% of Korean children (p < 0.01). Atrophic mucosa near the antrum-corpus border was present in 16% of children, primarily as pseudopyloric metaplasia (31%, IM; 63%, pseudopyloric metaplasia; 6%, both). The median age of children with corpus atrophy was 15 (range, 7-17) years. Conclusion: Gastric atrophy occurs in H pylori infected children living in countries with high gastric cancer incidence. Identification and characterisation of the natural history of H pylori gastritis requires targeted biopsies to include the lesser and greater curve of the corpus, starting just proximal to the anatomical antrum-corpus junction, in addition to biopsies targeting the antrum and cardia. C1 Univ Nacl Colombia, Dept Gastroenterol, Bogota, Colombia. Korea Univ, Coll Med, Guro Hosp, Seoul 136701, South Korea. Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Dept Pathol, Houston, TX 77030 USA. RP El-Zimaity, HMT (reprint author), Michael E DeBakey VA Med Ctr, Gastrointestinal Mucosa Pathol Lab, 111-D,Room 3A-320,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hzimaity@bcm.tmc.edu FU NIDDK NIH HHS [P30 DK056338] NR 42 TC 38 Z9 44 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0021-9746 EI 1472-4146 J9 J CLIN PATHOL JI J. Clin. Pathol. PD NOV PY 2005 VL 58 IS 11 BP 1189 EP 1193 DI 10.1136/jcp.2005.026310 PG 5 WC Pathology SC Pathology GA 978RF UT WOS:000232890000014 PM 16254110 ER PT J AU Aspinall, SL DeSanzo, BE Trilli, LE Good, CB AF Aspinall, SL DeSanzo, BE Trilli, LE Good, CB TI Bleeding risk index in an anticoagulation clinic - Assessment by indication and implications for care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE bleeding risk; warfarin; anticoagulation clinic ID NONRHEUMATIC ATRIAL-FIBRILLATION; GASTROINTESTINAL HEMORRHAGE; WARFARIN; THERAPY; EPIDEMIOLOGY; PREDICTION; MANAGEMENT AB BACKGROUND: The Outpatient Bleeding Risk Index (BRI) prospectively classified patients who were at high, intermediate, or low risk for warfarin-related major bleeding. However, there are only 2 published validation studies of the index and neither included veterans. OBJECTIVE: To determine the accuracy of the BRI in patients attending a Veterans Affairs (VA) anticoagulation clinic and to specifically evaluate the accuracy of the BRI in patients with atrial fibrillation. DESIGN: Retrospective cohort study. PATIENTS AND MEASURMENTS: Using the BRI, all patients managed by the Anticoagulation Clinic between January 1, 2001 and December 31, 2002 were classified as high, intermediate, or low risk for major bleeding. Bleeds were identified via quality-assurance reports. Poisson regression was used to determine whether there was an association between the index and the development of bleeding. RESULTS: The rate of major bleeding was 10.6%, 2.5%, and 0.8% per patient-year of warfarin in the high-, intermediate-, and low-risk groups, respectively. Patients in the high-risk category had 14 times the rate of major bleeding of those in the low-risk group (incidence rate ratio (IRR) 14; 95% confidence interval (CI), 1.9 to 104.7). The rate of major bleeding was significantly different between the high- and intermediate-risk categories (P <.001). Among those with atrial fibrillation, patients in the high-risk category had 6 times the major bleeding rate of those in the intermediate- and low-risk groups combined (IRR=6; 95% CI, 2.4 to 15.3). CONCLUSIONS: The BRI discriminates between high- and intermediate-risk patients in a VA anticoagulation clinic, including those with atrial fibrillation. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot 151C CU, Pittsburgh, PA 15240 USA. Butler Vet Affairs Med Ctr, Dept Pharm, Butler, PA USA. VA Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA USA. RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot 151C CU, Univ Dr C, Pittsburgh, PA 15240 USA. EM sherrie.aspinall@med.va.gov NR 17 TC 31 Z9 32 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2005 VL 20 IS 11 BP 1008 EP 1013 DI 10.1111/j.1525-1497.2005.0229.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 978SH UT WOS:000232892800006 PM 16307625 ER PT J AU Peura, JL Zile, MR Feldman, DS Vanbakel, AB McClure, C Uber, W Haynes, H Pereira, NL AF Peura, JL Zile, MR Feldman, DS Vanbakel, AB McClure, C Uber, W Haynes, H Pereira, NL TI Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article ID TRANSPLANTATION; HYPERTENSION; HYPERTROPHY; EXPRESSION AB Twelve heart transplant recipients selected for conversion from cyclosporine to tacrolimus because of adverse effects of cyclosporine therapy underwent echocardiography at baseline and 6 months after conversion. Left ventricular mass decreased by 24% and left ventricular geometry returned toward normal at 6 months after conversion, without significant changes in blood pressure. C1 Med Univ S Carolina, Div Cardiol, Dept Internal Med, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Pereira, NL (reprint author), Med Univ S Carolina, Div Cardiol, Dept Internal Med, Gazes Cardiac Res Inst, 135 Rutledge Ave,Suite 1201,POB 250592, Charleston, SC 29425 USA. EM pereiran@musc.edu NR 9 TC 11 Z9 13 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD NOV PY 2005 VL 24 IS 11 BP 1969 EP 1972 DI 10.1016/j.healun.2005.02.011 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 985XP UT WOS:000233412300038 PM 16297806 ER PT J AU Rorabaugh, BR Gaivin, RJ Papay, RS Shi, T Simpson, PC Perez, DM AF Rorabaugh, BR Gaivin, RJ Papay, RS Shi, T Simpson, PC Perez, DM TI Both alpha(1A)- and alpha(1B)-adrenergic receptors crosstalk to downregulate beta(1)-ARs in mouse heart: coupling to differential PTX-sensitive pathways SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE adrenergic receptor; inotropy; transgenic; cardiac function ID RAT CARDIAC MYOCYTES; FAILING HUMAN-HEART; PROTEIN-KINASE; INOTROPIC RESPONSE; SIGNALING PATHWAYS; TRANSGENIC MICE; KNOCKOUT MOUSE; SUBTYPES; OVEREXPRESSION; HYPERTROPHY AB Adrenergic receptors (ARs) play an important role in the regulation of cardiac function. Cardiac inotropy is primarily regulated by (beta(1)-ARs. However, alpha(1)-ARs may play an important role in inotropy during heart failure. Previous work has suggested that the alpha(1B)-AR modulates beta(1)-AR function in the heart. The potential role of the alpha(1A)-AR has not been previously studied. We used transgenic mice that express constitutively active mutant (CAM) forms of the alpha(1A)-AR or alpha(1B)-AR regulated by their endogenous promoters. Expression of the CAM a,A-AR or CAM alpha(1B)-AR had no effect on basal cardiac function (developed pressure, +dP/dT, -dP/dT, heart rate, flow rate). However, both alpha(1)-AR subtypes significantly decreased isoproterenol-stimulated +dP/dT. Pertussis toxin had no effect on +dP/dT in CAM a, A-AR hearts but restored +dP/dT to non-transgenic values in CAM alpha(1B)-AR hearts. Radioligand binding indicated a selective decrease in the density of beta(1)-ARs in both CAM mice. However, G-proteins, cAMP, or the percentage of high and low affinity states were unchanged in either transgenic compared with control. These data demonstrate that CAM alpha(1A)- and alpha(1B)-ARs both downregulate beta(1)-AR-mediated inotropy in the mouse heart. However, alpha(1)-AR subtypes are coupled to different beta-AR mediated signaling pathways with the alpha(1B)-AR being pertussis toxin sensitive. (c) 2005 Elsevier Ltd. All rights reserved. C1 Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA. Univ Calif San Francisco, Div Cardiol, San Francisco VA Med Ctr, CVRI, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Perez, DM (reprint author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, NB5,9500 Euclid Ave, Cleveland, OH 44195 USA. EM perezd@ccf.org FU NHLBI NIH HHS [R01 HL31113, R01 HL61438, R01 HL031113, T32 HL07914] NR 35 TC 16 Z9 17 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD NOV PY 2005 VL 39 IS 5 BP 777 EP 784 DI 10.1016/j.yjmcc.2005.07.015 PG 8 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 982HS UT WOS:000233149300006 PM 16171811 ER PT J AU Hayashi, Y Shumsky, JS Connors, T Otsuka, T Fischer, I Tessler, A Murray, M AF Hayashi, Y Shumsky, JS Connors, T Otsuka, T Fischer, I Tessler, A Murray, M TI Immunosuppression with either cyclosporine A or FK506 supports survival of transplanted fibroblasts and promotes growth of host axons into the transplant after spinal cord injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE allograft survival; axonal growth; cyclosporine A; FK506; immunophilin ligands; spinal cord injury; transplantation ID TRAUMATIC BRAIN-INJURY; BDNF-PRODUCING FIBROBLASTS; IMMUNOPHILIN LIGAND FK506; RAT SCIATIC-NERVE; ADULT RATS; FUNCTIONAL RECOVERY; LIPID-PEROXIDATION; IMMUNE SUPPRESSION; SCHWANN-CELLS; IN-VIVO AB Fibroblasts that have been genetically modified to secrete neurotrophins can stimulate axonal regeneration, rescue injured neurons, and improve function when grafted into a spinal cord injury site. These grafts are usually allografts that require immunosuppression to prevent rejection. In this study, we compared the effects of two immunophilin-ligands (cyclosporine A [CsA] and FK506) that are used clinically to prevent transplant rejection on protection of grafted fibroblasts. As there are risks associated with prolonged immunosuppression, we compared the effects of 2 or 8 weeks of administration of these drugs, in combination with our standard methylprednisolone protocol, in animals that survived for 8 weeks, to determine whether a shorter course of immunosuppression would be effective. Outcome measures included fibroblast survival, infiltration of activated macrophages and microglia into the graft, final lesion size, and growth of host axons into the graft. The graft consisted of a Vitrogen matrix into which fibroblasts were suspended; the graft was placed into a C3/C4 lateral funiculus lesion. The fibroblasts were isolated from a transgenic strain of Fischer rats that produce the marker alkaline phosphatase (Fb/AP). This enabled us to track the grafted fibroblasts and to evaluate the extent of their survival. The grafted matrix filled the lesion cavity. The density of fibroblasts within the matrix differed according to treatment. Fibroblast survival was most robust in animals that received 8 weeks of immunophilin-ligand treatment. FK506 supported greater Fb/AP survival than CsA. ED-1 immunostaining for activated microglia and macrophages showed an inverse correlation between AP immunoreactivity and the density of immune cells within the graft. Thus, prolonged administration of either FK506 or CsA was necessary for maximal fibroblast survival and for limiting the macrophage invasion of the graft. None of the FK506 or CsA protocols modified the size of the lesion, indicating that these immunophilin-ligands had little effect on secondary enlargement of the lesion and therefore little neuroprotective effect. Because immunophilin-ligands have been shown to be neurotrophic, we used RT-97 immunostaining for neurofilaments and calcitonin gene related protein (CGRP) staining for dorsal root axons to visualize axons that grew into the graft. Some axons grew into the matrix even in the absence of immunophilin-ligand treatment, suggesting that the Vitrogen matrix itself is permissive, but all of the immunophilin-ligand protocols were much more effective in eliciting axonal growth. Growth of axons into the transplants was equally increased by drug treatment for 2 or 8 weeks. Thus, both treatments improved fibroblast survival, diminished immune cell invasion, and promoted axonal growth, and a 2-week course of treatment with either immunophilin-ligand was as effective as 8 weeks in stimulating axonal growth. C1 Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA. Nagoya City Univ, Sch Med, Dept Orthoped Surg, Nagoya, Aichi 467, Japan. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Murray, M (reprint author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 299 Queen Lane, Philadelphia, PA 19129 USA. EM mm72@drexel.edu RI Fischer, Itzhak/D-1080-2012 OI Fischer, Itzhak/0000-0003-3187-8740 FU NINDS NIH HHS [NS24707] NR 55 TC 28 Z9 34 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD NOV PY 2005 VL 22 IS 11 BP 1267 EP 1281 DI 10.1089/neu.2005.22.1267 PG 15 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 989OI UT WOS:000233683000001 PM 16305315 ER PT J AU Olender, L AF Olender, L TI Hospitalists - A chief nursing officer's perspective SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID HEALTH SYSTEM; MEDICINE; SERVICE; CARE; OUTCOMES; FACULTY AB The hospitalist "specialty" is sweeping the inpatient setting with numbers of physicians choosing this specialty expected to exceed 20,000 by 2010. Yet, little is known about the involvement of nursing in the design, implementation, and evaluation of a hospitalist initiative. The author suggests the chief nursing officer's pivotal role in proactively encouraging the design and implementation of a hospitalist-nurse manager patient-centered care delivery model. The chief nursing officer can create an environment to foster research designed to identify outcomes from this partnership of hospitalist and clinical (nurse) manager. C1 Bronx Vet Adm Med Ctr, Bronx, NY 10468 USA. RP Olender, L (reprint author), Bronx Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Lynda.olender@med.va.gov NR 23 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD NOV PY 2005 VL 35 IS 11 BP 497 EP 501 DI 10.1097/00005110-200511000-00006 PG 5 WC Nursing SC Nursing GA 986SD UT WOS:000233469100006 PM 16282827 ER PT J AU Lombardo, ER Tan, G Jensen, MP Anderson, KO AF Lombardo, ER Tan, G Jensen, MP Anderson, KO TI Anger management style and associations with self-efficacy and pain in male veterans SO JOURNAL OF PAIN LA English DT Article DE chronic pain; anger; self-efficacy; veterans ID NEGATIVE AFFECT; EXPERIENCE; SCALE; ADJUSTMENT; EXPRESSION; ARTHRITIS; PEOPLE; MOOD AB Despite the high prevalence of anger and maladaptive anger management among persons with chronic pain, the association between pain and anger has received little empirical attention. The purpose of the current study was to investigate the relationship between pain and anger management style and test for the hypothesized role of self-efficacy as a moderator of this association. Five hundred sixty-four veterans with chronic pain were administered measures of pain, self-efficacy, and anger management. As expected, the results demonstrated a significant positive relationship between pain intensity and maladaptive anger management and a significant negative association between self-efficacy and maladaptive anger. Furthermore, pain intensity and the interaction of self-efficacy and pain intensity were significant predictors of maladaptive anger management. Surprisingly, patients reporting high self-efficacy and high pain intensity demonstrated more maladaptive anger management than individuals reporting high self-efficacy and low pain intensity. Patients reporting low self-efficacy demonstrated high levels of maladaptive anger management, regardless of pain intensity level. Perspective: Maladaptive anger management is associated with pain intensity and self-efficacy beliefs. Additional research is needed to explore the interaction of pain and self-efficacy and its impact on anger management. (c) 2005 by the American Pain Society. C1 Dallas Mind Body Med, Dallas, TX 75205 USA. Baylor Coll Med, Chron Pain Ctr, VA Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Texas, MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA. RP Lombardo, ER (reprint author), Dallas Mind Body Med, 4514 Travis St,Suite 218, Dallas, TX 75205 USA. EM dr.Lombardo@mind-body-wellness.com NR 25 TC 18 Z9 19 U1 3 U2 6 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD NOV PY 2005 VL 6 IS 11 BP 765 EP 770 DI 10.1016/j.jpain.2005.07.003 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 987DF UT WOS:000233497900007 PM 16275601 ER PT J AU Tsao, JCI Dobalian, A Myers, CD Zeltzer, LK AF Tsao, JCI Dobalian, A Myers, CD Zeltzer, LK TI Pain and use of complementary and alternative medicine in a national sample of persons living with HIV SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE complementary medicine; alternative medicine; human immunodeficiency virus; pain ID HUMAN-IMMUNODEFICIENCY-VIRUS; AMBULATORY AIDS PATIENTS; LOW-PREVALENCE DISEASES; QUALITY-OF-LIFE; UNITED-STATES; INFECTED PATIENTS; SERVICES UTILIZATION; THERAPY USE; PROBABILITY SAMPLES; HEALTH SURVEY AB The current study investigated the relationship of pain to use of complementary and alternative medicine (CAM) in a U.S. nationally representative sample of 2466 persons with human immunodeficiency virus (HIV), using data from the HIV Cost and Services Utilization Study. Pain was conceptualized as a need characteristic within the context of predisposing, enabling, and need (PEN) characteristics following Andersen's Behavioral Model of Health Services Use. Multivariate analyses were used to examine the association of baseline PEN characteristics with CAM use by follow-up (approximately 6 months later), including use of five specific CAM domains. Change in pain from baseline to follow-up was also examined in relation to CAM use. Baseline pain was a strong predictor of CAM use, and increased pain over time was associated with use of unlicensed or underground drugs with potential for harm. These results highlight the importance of medical efforts to control pain in persons living with HIV. C1 Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Pediat Pain Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Anesthesiol, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst HSR&D, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Coll Med, Tampa, FL USA. RP Tsao, JCI (reprint author), Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Pediat Pain Program, 10940 Wilshire Blvd,Suite 1450, Los Angeles, CA 90024 USA. OI Zeltzer, Lonnie/0000-0001-9306-9450 FU AHRQ HHS [U01 HS008578, U01HS08578]; NIDA NIH HHS [DA017026, R03 DA017026] NR 48 TC 28 Z9 29 U1 7 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2005 VL 30 IS 5 BP 418 EP 432 DI 10.1016/j.jpainsymman.2005.05.012 PG 15 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 996LR UT WOS:000234175900005 PM 16310616 ER PT J AU Emery, MJ Krous, HF Nadeau-Manning, JM Marck, BT Matsumoto, AM AF Emery, MJ Krous, HF Nadeau-Manning, JM Marck, BT Matsumoto, AM TI Serum testosterone and estradiol in sudden infant death SO JOURNAL OF PEDIATRICS LA English DT Article ID OBSTRUCTIVE SLEEP-APNEA; CENTRAL NERVOUS-SYSTEM; SEXUAL-DIFFERENTIATION; HYPOGONADAL MEN; ARCUATE NUCLEUS; ANDROGENS; PATTERNS; STEROIDS; MORTALITY; PREMATURE AB Objective To test the hypothesis that among infants who die unexpectedly, testosterone and/or estradiol levels are elevated in those diagnosed with SIDS versus those with known causes of death (controls). Study design Postmortem blood was collected and coded from infant autopsies, and serum was prepared and frozen until assayed for total testosterone and estradiol by fluoroimniunoassay. Subject information was then collected from the medical examiner's report. Results Testosterone, but not estradiol, was significantly higher in 127 SIDS cases versus 42 controls for both males (4.8 +/- 0.4 vs 2.2 +/- 0.4 nmol, respectively; P <.005) and females (2.4 +/- 0.2 vs 1.6 +/- 0.2 nmol, respectively; P < 0.03). Conclusions Higher testosterone levels in infant victims of unexpected, unexplained death may indicate a role for testosterone or related steroids in SIDS. Further research is needed to understand the potential utility of testosterone as an indicator of SIDS risk. C1 Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL USA. Univ Miami, Sch Med, Dept Med, Miami, FL USA. Univ Miami, Sch Med, Dept Pediat, Miami, FL USA. Childrens Hosp, Dept Pathol, San Diego, CA USA. Childrens Hosp, Dept Pediat, San Diego, CA USA. Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. GRECC, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Emery, MJ (reprint author), Univ Washington, Dept Neurol, Sch Med, Box 356465, Seattle, WA 98195 USA. EM mjemery@u.washington.edu NR 34 TC 4 Z9 4 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD NOV PY 2005 VL 147 IS 5 BP 586 EP 591 DI 10.1016/j.jpeds.2005.05.011 PG 6 WC Pediatrics SC Pediatrics GA 987EA UT WOS:000233500000009 PM 16291346 ER PT J AU Shaw, SE Morris, DM Uswatte, G Mckay, S Meythaller, JM Taub, E AF Shaw, SE Morris, DM Uswatte, G Mckay, S Meythaller, JM Taub, E TI Constraint-induced movement therapy for recovery of upper-limb function following traumatic brain injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE behavioral therapy; constraint-induced movement therapy; functional abilities; massed practice; motor function; motor impairment; neurological injury; physical rehabilitation; training; traumatic brain injury ID MOTOR FUNCTION-TEST; LEARNED NONUSE; CHRONIC STROKE; CORTICAL REORGANIZATION; FORCED USE; REHABILITATION; PLASTICITY; INTENSITY; DEFICITS; OUTCOMES AB A volunteer sample of 22 participants with chronic traumatic brain injury (TBI) (onset > 1 year) and relative hemiplegia that revealed moderate disability in the more-affected upper limb (UL) participated. Constraint-induced (CI) movement therapy (CI therapy) was employed for a 2-week period; treatments included massed practice, shaping of the more-affected UL, behavioral contracts, and other behavioral techniques for affecting transfer to a real-world setting. We used the Wolf Motor Function Test, the Fugl-Meyer Motor Performance Assessment, and the Motor Activity Log to measure outcomes. All outcome measures improved significantly as a result of the intervention. More-adherent participants had more improvement compared with less-adherent participants. These preliminary results suggest that Cl therapy may be effective for improving UL motor function following chronic TBI. C1 Univ Alabama, Dept Phys Therapy, Birmingham, AL 35294 USA. Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Dept Vet Affairs, Res Serv, Birmingham, AL USA. RP Shaw, SE (reprint author), Univ Alabama, Dept Phys Therapy, RMSB 360,1530 3rd Ave S, Birmingham, AL 35294 USA. EM sshaw@uab.edu RI Uswatte, Gitendra/C-4913-2009 FU PHS HHS [R49/CCR 403541-12] NR 45 TC 36 Z9 40 U1 1 U2 8 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD NOV-DEC PY 2005 VL 42 IS 6 BP 769 EP 778 DI 10.1682/JRRD.2005.06.0094 PG 10 WC Rehabilitation SC Rehabilitation GA 047MQ UT WOS:000237883800007 PM 16680614 ER PT J AU Berge, JS Czerniecki, JM Klute, GK AF Berge, JS Czerniecki, JM Klute, GK TI Efficacy of shock-absorbing versus rigid pylons for impact reduction in transtibial amputees based on laboratory, field, and outcome metrics SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amputation.. artificial limbs; biomechanics; gait impact force; gait mechanics; prosthetics; rehabilitation; residual-limb pain; rigid pylon; shock-absorbing pylon ID GROUND REACTION FORCES; LEG STIFFNESS; LOWER-LIMB; GAIT; WALKING; PROSTHESIS; PARAMETERS; AMPUTATION; SURFACES; FATIGUE AB Prosthetic manufacturers have marketed shock-absorbing pylons (SAPs) for attenuation of injurious loads from foot-ground contact. In this study, we compared a commonly prescribed SAP with a conventional rigid pylon, using a within-subject design (n = 15 unilateral transtibial amputees), to assess effect on gait mechanics, measure transmitted accelerations in situ, and determine functional outcomes using step counts and questionnaires. No differences were found across pylons for self-selected walking speed, prosthetic-side step length, prosthetic-side loading rate and decelerative peak of the vertical ground reaction force, peak pylon acceleration, step count per week, or questionnaire results that examined pylon performance and subjects' pain and fatigue levels. The only statistically significant finding was for the prosthetic-side knee angle at initial contact, where subjects displayed an average of 2.6 degrees more flexion with the rigid pylon than the SAP while walking at a controlled speed (p = 0.004); this result indicates that transtibial amputees are able to modulate the effective stiffness of their residual limb in response to changes in prosthetic component stiffness. The results from the laboratory, field, and subjective outcome measurements suggest that the SAP in this study is as effective as a rigid pylon for unilateral transtibial amputees. C1 VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Seattle, WA 98108 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. RP Klute, GK (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, 1660 S Columbian Way,MS 151, Seattle, WA 98108 USA. EM gklute@u.washington.edu NR 30 TC 15 Z9 17 U1 2 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD NOV-DEC PY 2005 VL 42 IS 6 BP 795 EP 807 DI 10.1682/JRRD.2005.02.0034 PG 13 WC Rehabilitation SC Rehabilitation GA 047MQ UT WOS:000237883800010 PM 16680617 ER PT J AU Fitzgerald, SG Collins, DM Cooper, RA Tolerico, M Kelleher, A Hunt, P Martin, S Impink, B Cooper, R AF Fitzgerald, SG Collins, DM Cooper, RA Tolerico, M Kelleher, A Hunt, P Martin, S Impink, B Cooper, R TI Issues in maintenance and repairs of wheelchairs: A pilot study SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE community participation; maintenance; manual wheelchair; outcomes; power wheelchair; satisfaction; wheelchair; wheelchair age; wheelchair repairs; wheelchair use ID MANUAL WHEELCHAIRS; ANSI/RESNA STANDARDS; POWERED WHEELCHAIRS; OUTDOOR MOBILITY; UNITED-STATES; USERS; ACCIDENTS; SATISFACTION; TECHNOLOGY; RESIDENTS AB In this pilot study, we assessed wheelchair durability and its effect on user satisfaction. Specifically, we examined the characteristics of the participants' wheelchairs, the types of maintenance and repairs completed, and whether the participants' satisfaction was affected by problems with their wheelchairs. A convenience sample of 130 participants who used wheelchairs as their primary means of mobility was recruited. Participants completed a questionnaire about their wheelchairs, the maintenance and repair history.. and their satisfaction levels. Results showed that 26% of the participants had completed a wheelchair repair in the past 6 months, 16% had completed general maintenance, and 27% had completed tire repairs. Neither hours of wheelchair use nor wheelchair age affected repair or maintenance frequency. Participants were generally satisfied with their wheelchairs. Better understanding, of wheelchair maintenance and repair issues will guide improvements in wheelchair design and enhance the community participation of individuals who use wheelchairs. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, Dept Vet Affairs, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Engn, Dept Bioengn, Pittsburgh, PA 15260 USA. RP Fitzgerald, SG (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, Dept Vet Affairs, 7180 Highland Dr,Bldg 4,2nd Floor E,151R-1, Pittsburgh, PA 15213 USA. EM sgf9@pitt.edu NR 37 TC 12 Z9 12 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD NOV-DEC PY 2005 VL 42 IS 6 BP 853 EP 862 DI 10.1682/JRRD.2004.10.0130 PG 10 WC Rehabilitation SC Rehabilitation GA 047MQ UT WOS:000237883800015 PM 16680622 ER PT J AU Avansino, JR Chen, DC Hoagland, VD Woolman, JD Haigh, WG Stelzner, M AF Avansino, JR Chen, DC Hoagland, VD Woolman, JD Haigh, WG Stelzner, M TI Treatment of bile acid malabsorption using ileal stem cell transplantation SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID MUCOSAL NUTRIENT TRANSPORT; RESECTION AB BACKGROUND: We hypothesized that ileal stem cell clusters transplanted into a segment of jejunum can be used to treat bile acid malabsorption. STUDY DESIGN: In adult Lewis rats, a 15-cm segment of jejunum was isolated with its blood circulation left intact and partially stripped of enterocytes using luminal high-velocity perfusions with 3 mmol/L ethylenediamine tetra-acetic acid solutions. Continuity was restored by anastomosing the proximal and distal gut. Ileal stem cell clusters were harvested from neonatal Lewis rats and transplanted into the stripped segments to generate a "neoileum." After 4 weeks, recipients underwent resection of the native ileum, and the isolated neoileum was anastomosed in its place. After an additional 4 weeks, a 48-hour stool collection was performed. The engrafted segment was harvested for taurocholate uptake studies, ileal bile acid transporter (IBAT) protein by immunohistomorphometry, and IBAT mRNA quantitation by reverse transcription polymerease chain reaction. Data were analyzed by ANOVA/t-test. Rats undergoing ileectomy, jejunectomy, or sham operations served as controls. RESULTS: Total bile acid loss in the stool was markedly lower in rats with a neoileum compared with rats with an ileectomy (p < 0.001). Total taurocholate uptake was notably increased in the neoileum compared with the jejunum (p < 0.001). IBAT protein signal intensity was considerably higher in the neoileum compared with jejunum (p < 0.001). IBAT mRNA amounts in the neoileal group were comparable with those in normal rat ileum and were considerably higher (p = 0.003) than in the jejunum. CONCLUSIONS: Ileal stem cell clusters were used to establish a new zone of bile acid uptake and IBAT expression in a jejunal segment. This neoileum eliminated loss of bile acids in the stool after ileectomy. This is the first time that transplantation of intestinal stem cell clusters has been shown to correct a clinical malabsorption syndrome. C1 Univ Washington, Dept Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98105 USA. Univ Washington, Dept Gastroenterol, VA Puget Sound Hlth Care Syst, Seattle, WA 98105 USA. Univ Calif Los Angeles, Dept Surg, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA. RP Avansino, JR (reprint author), Univ Washington, Dept Surg, VA Puget Sound Hlth Care Syst, Box 356410, Seattle, WA 98105 USA. NR 20 TC 18 Z9 19 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD NOV PY 2005 VL 201 IS 5 BP 710 EP 720 DI 10.1016/j.jamcollsurg.2005.06.270 PG 11 WC Surgery SC Surgery GA 980OF UT WOS:000233027100009 PM 16256913 ER PT J AU Kielar, ML John, R Bennett, M Richardson, JA Shelton, JM Chen, LY Jeyarajah, DR Zhou, XJ Zhou, H Chiquett, B Nagami, GT Lu, CY AF Kielar, ML John, R Bennett, M Richardson, JA Shelton, JM Chen, LY Jeyarajah, DR Zhou, XJ Zhou, H Chiquett, B Nagami, GT Lu, CY TI Maladaptive role of IL-6 in ischemic acute renal failure SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID REPERFUSION INJURY; ISCHEMIA/REPERFUSION INJURY; INTERLEUKIN-6-DEFICIENT MICE; MACROPHAGE INFILTRATION; INFLAMMATORY RESPONSE; ADHESION MOLECULES; HEMORRHAGIC-SHOCK; IMMUNE-RESPONSES; CELLS; NEUTROPHIL AB The role of IL-6 was investigated in murine ischemic acute renal failure. The renal pedicles were clamped for 17 min, and the mice were studied at various times after reperfusion. We found that serum IL-6 increased after murine ischemic renal injury. This increase was associated with increased IL-6 mRNA in the ischemic kidney but not in the contralateral kidney or the liver. Maximal IL-6 production occurred at 4 to 8 h and decreased to baseline by 24 h. Reperfusion of the kidney was required for IL-6 production. In situ hybridization and immunohistochemistry showed that macro phages infiltrated areas adjacent to the vascular bundles in the outer medulla within hours of reperfusion and showed that these macrophages produced IL-6 mRNA. For understanding how macrophages were stimulated to produce IL-6, an in vitro model in which S3 proximal tubular cells were injured by reactive oxygen species was set up. These injured cells released molecules that activated macrophages to produce IL-6 in vitro. IL-6 that was produced in response to renal ischemia was maladaptive because transgenic knockout of IL-6 ameliorated renal injury as measured by serum creatinine and histology. IL-6 transgenic knockout mice were lethally irradiated, and their bone marrow was reconstituted with wild-type IL-6 cells. Such bone marrow transfers abolished the protective effects of transgenic IL-6 knockout. It is concluded that macrophages infiltrate the area of the vascular bundles of the outer medulla, these macrophages produce IL-6, and this IL-6 exacerbates ischemic murine acute renal failure. C1 Univ Texas, SW Med Sch, Dept Internal Med Nephrol, Dallas, TX 75390 USA. Univ Texas, SW Med Sch, Dept Pathol, Dallas, TX 75390 USA. Univ Texas, SW Med Sch, Dept Mol Biol, Dallas, TX 75390 USA. Univ Texas, SW Med Sch, Dept Internal Med Cardiol, Dallas, TX 75390 USA. Univ Texas, SW Med Sch, Dept Surg, Dallas, TX 75390 USA. Univ Texas, SW Med Sch, Grad Program Immunol, Dallas, TX 75390 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Med Res Serv, Serv Nephrol, Los Angeles, CA USA. RP Lu, CY (reprint author), Univ Texas, SW Med Sch, Dept Internal Med Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM christopher.lu@utsouthwestern.edu NR 50 TC 131 Z9 139 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD NOV PY 2005 VL 16 IS 11 BP 3315 EP 3325 DI 10.1681/asn.2003090757 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 978BS UT WOS:000232847800021 PM 16192425 ER PT J AU Onitilo, AA Kio, EA Singh, AK Lazarchick, J AF Onitilo, AA Kio, EA Singh, AK Lazarchick, J TI Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction SO LEUKEMIA & LYMPHOMA LA English DT Article DE cytogenetics; hypereosinophilic syndrome; imatinib; tyrosine kinase; FIP1-like-1-platelet-derived growth factor alpha (FIP1L1-PDGFRA); remission ID CHRONIC EOSINOPHILIC LEUKEMIA; FACTOR RECEPTOR-BETA; TYROSINE KINASE; MESYLATE; FUSION; INVOLVEMENT AB We report a 50-year-old patient with idiopathic hypereosinophilic syndrome with trisomy 8 who experienced a complete and durable hematological and cytogenetic remission with low-dose imatinib therapy. He also had a significant reversal of cardiac dysfunction with a reduction in cardiac hypertrophy, resolution of pericardial effusion and mitral and tricuspid regurgitation. He remained in remission 3 years after therapy. C1 Marshfield Clin Fdn Med Res & Educ, Wausau Ctr, Dept Hematol Oncol, Marshfield, WI 54449 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA. Ralph H Jphnson Vet Adm Med Ctr, Dept Lab Med & Pathol, Charleston, SC USA. RP Onitilo, AA (reprint author), Marshfield Clin Fdn Med Res & Educ, Wausau Ctr, Dept Hematol Oncol, 2727 Plaza Dr, Marshfield, WI 54449 USA. EM onitilo.adedayo@marshfieldclinic.org NR 21 TC 3 Z9 3 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD NOV PY 2005 VL 46 IS 11 BP 1667 EP 1670 DI 10.1080/10428190500220514 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 975RA UT WOS:000232678400019 PM 16236620 ER PT J AU Julapalli, VR Kramer, JR El-Serag, HB AF Julapalli, VR Kramer, JR El-Serag, HB TI Evaluation for liver transplantation: Adherence to AASLD referral guidelines in a large Veterans Affairs Center SO LIVER TRANSPLANTATION LA English DT Article ID ALCOHOLIC CIRRHOSIS; RENAL-TRANSPLANTATION; RACIAL-DIFFERENCES; ACCESS; DISEASE; RECIDIVISM; ALLOCATION; DISPARITY; SURVIVAL; COHORT AB Access of patients to liver transplantation involves three levels: referral for evaluation for transplantation, placement on a waiting list for transplantation, and receipt of a liver transplant. No study has formally evaluated access to liver transplantation at the referral level. Therefore, we sought to estimate the magnitude and determinants of consideration of liver transplantation in patients at a single, large Veterans Affairs medical center. Patients with liver disease were identified between October 2002 and September 2003, and their entire medical records were examined for encounters involving potential indications for liver transplantation according to American Association for the Study of Liver Diseases (AASLD) guidelines, mention of liver transplantation, and potential contraindications. Liver transplantation was mentioned in only 59 (20%) of 300 encounters, constituting 41 (21%) of 199 patients satisfying AASLD guidelines for referral. The significant negative independent determinants of mention of liver transplantation were older age (adjusted odds ratio [OR]: 0.31; 95% confidence interval [CI]: 0.13-0.77, P = 0.01), alcoholic liver disease (adjusted OR: 0.10; 95% CI: 0.02-0.57, P = 0.01), and black race (OR: 0.15; 95% CI: 0.02-0.96, P = 0.045). Most patients had potential contraindications that were inferred (but not documented) as reasons for not being evaluated for transplantation; however, a small but significant proportion (7%) had no recorded evidence of contraindications. In conclusion, we found a low rate of mention of liver transplantation in patients who satisfied AASLD guidelines for referral, particularly among patients with alcoholic liver disease and blacks. Deficiencies at the referral level may lead to disparities at further levels of access to liver transplantation. C1 Houston Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 31 TC 41 Z9 41 U1 2 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD NOV PY 2005 VL 11 IS 11 BP 1370 EP 1378 DI 10.1002/lt.20434 PG 9 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 978KA UT WOS:000232870800012 PM 16184521 ER PT J AU Parchman, ML Noel, PH Lee, S AF Parchman, ML Noel, PH Lee, S TI Primary care attributes, health care system hassles, and chronic illness SO MEDICAL CARE LA English DT Article ID PATIENT SATISFACTION; GENERAL-PRACTICE; VETERANS-HEALTH; COMORBIDITY; PREVALENCE; SERVICES; DISEASES; QUALITY; NUMBER AB Background: Patients with a chronic illness are likely to report difficulties in their encounters with the health care system. Although most patients with a chronic illness are managed by primary care clinicians, little is known about how the attributes of primary care might be related to health care system hassles. Objective: We sought to examine the relationship between attributes of primary care and health care system hassles among veterans with one or more chronic illnesses. Research Design: This was a cross-sectional mailed survey. Subjects: We included veterans with one or more chronic illnesses who were cared for in the South Texas Veteran's health care system. Measures: The Components of Primary Care Instrument was used to measure 4 attributes of primary care: accumulated knowledge of the patient by the clinician, coordination of care, communication, and preference for first contact with their primary care clinician. A 16-item health care systems hassles scale was constructed and demonstrated good face validity and reliability with a Cronbach's alpha of 0.94. Results: Of the 720 surveys administered by mail, 422 (59%) were returned. Patients with multiple chronic illnesses reported a higher level of hassles than patients with a single chronic illness. After controlling for patient characteristics, primary care communication and coordination of care were inversely associated with patient hassles score: as communication and coordination improved, the reported level of hassles decreased. Conclusions: Effective delivery of primary care to patients with one or more chronic illnesses may be important in decreasing the level of hassles they experience as they interact with the health care delivery system. C1 VERDICT Hlth Serv Res Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78285 USA. RP Parchman, ML (reprint author), Audie Murphy VA Hosp VERDICT, 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM parchman@uthscsa.edu OI Parchman, Michael/0000-0001-7129-2889 FU AHRQ HHS [K08 HS013008-02] NR 32 TC 29 Z9 29 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0025-7079 J9 MED CARE JI Med. Care PD NOV PY 2005 VL 43 IS 11 BP 1123 EP 1129 DI 10.1097/01.mlr.0000182530.52979.29 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 983YO UT WOS:000233268500009 PM 16224306 ER PT J AU Song, MK Rosenthal, MJ Song, AM Yang, H Ao, Y Yamaguchi, DT AF Song, MK Rosenthal, MJ Song, AM Yang, H Ao, Y Yamaguchi, DT TI Raw vegetable food containing high cyclo (his-pro) improved insulin sensitivity and body weight control SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID DEPENDENT DIABETES-MELLITUS; IMPROVED GLUCOSE-TOLERANCE; ARACHIDONIC-ACID; DEGRADING ENZYME; PPAR-GAMMA; ZINC SUPPLEMENTATION; GLYCEMIC CONTROL; RATS; TRANSPORT; OBESITY AB Cyclo (his-pro), controlled-energy diet, soy protein hydrolysate (SPH), and raw vegetable food (RVF) are known to improve insulin sensitivity and body weight (BW) control. Enhancement of high cyclo (his-pro) content in SPH (HCS) was performed by refluxing SPH with 1 N KH2CO3 dissolved in 70% ethanol for 2 weeks at room temperature. Using this material, we examined the effects of HCS plus RVF on glucose metabolism and BW control in genetically diabetic Goto-Kakizaki (G-K) and insulin-resistant aged overweight Sprague-Dawley (S-D) rats. Thirty 7-week-old G-K rats and 18 16- to 18-month-old S-D rats were divided into 3 groups and treated with normal chow (NC), RVF diet, or HCS diet for 8 weeks. Raw vegetable food diet was made of 1:3 RVF and 2:3 NC; HCS diet was made of 1:27 portion HCS, 8:27 RVF, and 2:3 NC. Oral glucose tolerance significantly improved in both RVF (P <.01) and HCS-treated (P <.001) G-K rats and worsened in NC-fed rats compared with the baseline values. Similarly, oral glucose tolerance also improved in aged overweight S-D rats when treated with RVF (P <.05) and with HCS (P <.01), compared with the baseline values. Although HCS diet treatment very significantly lowered fed plasma insulin levels compared with NC diet treatment in G-K rats (P <.01), RVF diet treatment alone did not decrease plasma insulin levels. In contrast, there was no change of insulin levels in overweight aged S-D rats after either RVF or HCS diet treatment. Postfeeding glucose levels in G-K rats fed RVF or HCS significantly fell, compared with the rats fed NC (P <.05). Interestingly, fasting blood glucose levels in RVF- or HCS-fed rats were very significantly lower than in NC-fed rats (P <.001). There was no change of blood glucose levels in S-D rats due to treatments with different diet. In G-K rats, food intake did not decrease during the first 3 weeks but fell very significantly from the fifth to eighth weeks with RVF (P <.01) and HCS (P <.001) treatments in G-K rats. However, food intake reduction in aged S-D rats was shown only for the HCS-treated rat group (P <.05). Water intake slightly decreased in G-K rats with either RVF or HCS treatment (P <.05) but very significantly decreased in S-D rats with HCS treatment (P <.01). Body weight gain in young G-K rats and BW in aged S-D rats significantly decreased only when rats were treated with HCS diet (P <.05). These data suggest that regular consumption of HCS diet helps to control blood glucose metabolism in diabetic G-K rats and BW control in aged obese S-D rats. (c) 2005 Elsevier Inc. All rights reserved. C1 VA Greater Los Angles Healthcare Syst, Res Serv, Los Angeles, CA 91326 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Educ Clin Ctr, Los Angeles, CA 90073 USA. Kaiser Permanente Med Ctr, Dept Surg, Panorama, CA 91402 USA. RP Song, MK (reprint author), VA Greater Los Angles Healthcare Syst, Res Serv, Los Angeles, CA 91326 USA. EM moon.song2@med.va.gov FU NIDDK NIH HHS [1 R43 DK 56546-01] NR 65 TC 17 Z9 17 U1 1 U2 5 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD NOV PY 2005 VL 54 IS 11 BP 1480 EP 1489 DI 10.1016/j.metabol.2005.05.014 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 984HP UT WOS:000233294000011 PM 16253637 ER PT J AU Yano, EM Asch, SM Phillips, B Anaya, H Bowman, C Chang, S Bozzette, S AF Yano, EM Asch, SM Phillips, B Anaya, H Bowman, C Chang, S Bozzette, S TI Organization and management of care for military veterans with human immunodeficiency virus/acquired immunodeficiency syndrome in Department of Veterans Affairs Medical Centers SO MILITARY MEDICINE LA English DT Article ID HIV-INFECTED VETERANS; UNITED-STATES; RURAL-AREAS; ANTIRETROVIRAL THERAPY; SERVICE DELIVERY; AMBULATORY CARE; CHRONIC ILLNESS; AIDS; HIV/AIDS; PHYSICIANS AB Objective: As the largest provider of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome health care services, the Department of Veterans Affairs (VA) has launched a national quality improvement program. As a first step, an assessment of how care for veterans with HIV/acquired immunodeficiency syndrome was organized was conducted. Methods: Structured surveys were administered to senior HIV clinicians in 118 VA facilities, about local approaches to structuring, staffing, and delivering HIV health services. Results: HIV care was chiefly delivered in special VA-based HIV clinics. HIV-related services were widely available on site, with non-VA referrals being more commonly needed to meet long-term care needs. Urban VA facilities had greater HIV caseloads, were more likely to have separate HIV clinics, and had greater access to HIV expertise, whereas rural practices focused on primary care-based models and tended to rely on off-site VA HIV experts. Conclusions: Understanding the organization and management of VA-based HIV services will help design systematic quality improvement efforts and meet the treatment needs of HIV-infected veterans. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Vet Affairs Greater Los Angeles Hlth Serv Res, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA. Vet Affairs San Diego Healthcare Syst, Vet Affairs Qual Enhancement Res Inst HIV, La Jolla, CA 92161 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. RAND Hlth, Santa Monica, CA 90407 USA. Vet Affairs Palo Alto Healthcare Syst, Vet Affairs Ctr Qual Management Publ Hlth, Palo Alto, CA 94304 USA. Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA. RP Yano, EM (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Vet Affairs Greater Los Angeles Hlth Serv Res, Sepulveda, CA 91343 USA. NR 64 TC 12 Z9 13 U1 1 U2 1 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD NOV PY 2005 VL 170 IS 11 BP 952 EP 959 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 019JS UT WOS:000235832000009 PM 16450823 ER PT J AU Kim, M Murphy, K Liu, F Parker, SE Dowling, ML Baff, W Kao, GD AF Kim, M Murphy, K Liu, F Parker, SE Dowling, ML Baff, W Kao, GD TI Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID ANAPHASE-PROMOTING COMPLEX; CHECKPOINT PROTEIN BUBR1; HUMAN CANCER-CELLS; HELA-CELLS; CENP-E; KINETOCHORE LOCALIZATION; INDUCED APOPTOSIS; HL-60 CELLS; PACLITAXEL; PHOSPHORYLATION AB The fidelity of chromosomal duplication is monitored by cell cycle checkpoints operational during mitosis. One such cell cycle delay is invoked by microtubule-targeting agents such as nocodazole or paclitaxel (Taxol) and is mediated by mitotic checkpoint proteins that include BubR1. Relatively little is known about the regulation of expression and stability of BubR1 (or other checkpoint proteins) and how these factors dictate the durability of the cell cycle delay. We report here that treatment of HeLa cells with spindle-disrupting agents resulted in caspase activation and precipitated the cleavage of BubR1. This mechanism ultimately leads to reduced levels of full-length protein, which are accompanied by abrogation of the mitotic block; the checkpoint abrogation is substantially accelerated by inhibition of de novo protein synthesis. In contrast, inhibition of caspase activity blocked BubR1 degradation and prolonged mitosis. To confirm a direct link between caspase activity and BubR1 protein expression, we identified by site-directed mutagenesis the specific caspase cleavage sites cleaved after exposure to paclitaxel. Surprisingly, BubR1 has two sites of cleavage: primarily at Asp607/Asp610 and secondarily at Asp576/Asp579. BubR1 mutated at both locations (BubR1 Delta 579 Delta 610) was resistant to paclitaxel-induced degradation. Expression of BubR1 Delta 579 Delta 610 augmented the mitotic delay induced by spindle disruption in transfected cells as well as in clones engineered to inducibly express the mutant protein upon exposure to doxycycline and ultimately led to increased aneuploidy. Underscoring the importance of these caspase cleavage sites, both tetrapeptide motifs are identified in the amino acid sequences of human, mouse, chicken, and Xenopus BubR1. These results are potentially the first to link the control of the stability of a key mitotic checkpoint protein to caspase activation, a regulatory pathway that may be involved in killing defective cells and that has been evolutionarily conserved. C1 Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. RP Kao, GD (reprint author), Univ Penn, Sch Med, Dept Radiat Oncol, John Morgan Bldg 180 H,3620 Hamilton Walk, Philadelphia, PA 19104 USA. EM Kao@xrt.upenn.edu FU NCI NIH HHS [T32 CA009677, CA 107956-01, R01 CA107956, 5T32 CA 009677] NR 48 TC 42 Z9 44 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD NOV PY 2005 VL 25 IS 21 BP 9232 EP 9248 DI 10.1128/MCB.25.21.9232-9248.2005 PG 17 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 976SW UT WOS:000232754600007 PM 16227576 ER PT J AU Fleming, A Cook, KF Nelson, ND Lai, EC AF Fleming, A Cook, KF Nelson, ND Lai, EC TI Proxy reports in Parkinson's disease: Caregiver and patient self-reports of quality of life and physical activity SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; health-related quality of life; proxy evaluation; PDQ-39 ID HEALTH; AGREEMENT; RELIABILITY; RESPONSES; INDEX; OLDER AB We evaluated patient-proxy agreement in a population of veterans with Parkinson's disease and compared levels of agreement by patient subgroups. Patient and caregiver pairs completed questionnaires composed of standard measures and additional demographic and activity questions. Participants completed the Center for Epidenniologic Studies Depression Scale (CES-D), the PD Questionnaire 39 (PDQ-39), and three questions regarding physical activity. Caregivers completed proxy forms of the PDQ-39 and the physical activity questionnaire. The proxy forms asked caregivers to choose the answers that best described their "friend's/patient's situation." The results of our comparison of patient and proxy reports of quality of life were consistent with findings in other diseases. On average, proxies rated patient disability higher and quality of life lower than did patients. However, our comparison of patient and proxy reports of frequency of exercise diverged from previously published work. Less agreement was observed between patient and proxy reports of physical activity, even though this is a more objective variable than are the domains measured by the PDQ-39. Proxy reports may diverge appreciably from patient self-reports. These differences should be considered in research design and clinical decision making. Alternative approaches to the measurement of patient relevant outcomes could supplement traditional, retrospective self-reports. (c) 2005 Movement Disorder Society. C1 Michael E DeBakey Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX USA. Univ Washington, Dept Rehabil Med, Seattle, WA USA. Baylor Coll Med, Dept Neurol, Houston, TX USA. METRIC, Houston, TX USA. RP Cook, KF (reprint author), Houston VAMC, 127-PD 801 Cortland St, Houston, TX 77007 USA. EM karonc2@u.washington.edu NR 20 TC 23 Z9 23 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2005 VL 20 IS 11 BP 1462 EP 1468 DI 10.1002/mds.20592 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 984TI UT WOS:000233326800010 PM 16028212 ER PT J AU Dackis, C O'Brien, C AF Dackis, C O'Brien, C TI Neurobiology of addiction: treatment and public policy ramifications SO NATURE NEUROSCIENCE LA English DT Editorial Material ID OPIOID RECEPTOR GENE; DOPAMINE-D-2 RECEPTORS; COCAINE DEPENDENCE; ALCOHOL DEPENDENCE; BETA-ENDORPHIN; EXTRACELLULAR DOPAMINE; NUCLEUS-ACCUMBENS; SEEKING BEHAVIOR; CENTRAL SWEDEN; D2 RECEPTORS AB In the United States, efforts to treat addiction are hampered by prejudice and a public view that treats it as a disorder of self-control, not a disease. We highlight select advances in addiction research that, if disseminated to the public, could reverse these misconceptions and facilitate changes in policy to improve treatment access and care delivery for this highly prevalent disease. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Treatment Res Ctr, Philadelphia, PA USA. RP Dackis, C (reprint author), Univ Penn, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM dackis@mail.med.upenn.edu NR 50 TC 107 Z9 109 U1 4 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD NOV PY 2005 VL 8 IS 11 BP 1431 EP 1436 DI 10.1038/nn1105-1431 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 979TB UT WOS:000232966600010 PM 16251982 ER PT J AU Obrzut, SL Koren, AO Mandelkern, MA Brody, AL Hoh, CK London, ED AF Obrzut, SL Koren, AO Mandelkern, MA Brody, AL Hoh, CK London, ED TI Whole-body radiation dosimetry of 2-[F-18]fluoro-A-85380 in human PET imaging studies SO NUCLEAR MEDICINE AND BIOLOGY LA English DT Article DE 2-[F-18]FA; dosimetry; PET; nicotinic acetylcholine receptor; whole-body distribution ID NICOTINIC ACETYLCHOLINE-RECEPTORS; IN-VIVO; HUMAN BRAIN; POSITRON-EMISSION; ALZHEIMER BRAINS; BINDING-SITES; H-3 NICOTINE; TRACER; BIODISTRIBUTION; QUANTIFICATION AB 2-[F-18]Fluoro-A-85380 (2- [F-18]fluoro-3-(2(S)-azetidinylmethoxy)pyridine, 2-[18F]FA) is a recently developed PET radioligand for noninvasive imaging of nicotinic acetylcholine receptors. Previous radiation absorbed dose estimates for 2-[F-18]FA were limited to evaluation of activity in only several critical organs. Here, we performed 2-[F-18]FA radiation dosimetry studies on two healthy human volunteers to obtain data for all important body organs. Intravenous injection of 2.9 MBq/kg of 2-[F-18]FA was followed by dynamic PET imaging. Regions of interest were placed over images of each organ to generate time-activity curves, from which we computed residence times. Radiation absorbed doses were calculated from the residence times using the MIRDOSE 3.0 program (version 3.0, ORISE, Oak Ridge, TN). The urinary bladder wall receives the highest radiation absorbed dose (0.153 mGy/MBq, 0.566 rad/mCi, for a 2.4-h voiding interval), followed by the liver (0.0496 mGy/MBq, 0.184 rad/mCi) and the kidneys (0.0470 mGy/MBq, 0.174 rad/mCi). The mean effective dose equivalent is estimated to be 0.0278 mSv/MBq (0.103 rem/mCi), indicating that radiation dosimetry associated with 2-[F-18]FA is within acceptable limits. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif San Diego, Div Nucl Med, Dept Radiol, La Jolla, CA 92093 USA. VA Greater Los Angeles Healthcare Syst, Positron Emiss Tomog Ctr, Los Angeles, CA 90073 USA. Univ Calif Irvine, Dept Phys, Irvine, CA 92697 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. RP London, ED (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu NR 32 TC 14 Z9 15 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0969-8051 J9 NUCL MED BIOL JI Nucl. Med. Biol. PD NOV PY 2005 VL 32 IS 8 BP 869 EP 874 DI 10.1016/j.nucmedbio.2005.06.005 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 983RM UT WOS:000233249800010 PM 16253812 ER PT J AU Dougherty, CM Thompson, EA Lewis, FM AF Dougherty, CM Thompson, EA Lewis, FM TI Long-term outcomes of a telephone intervention after an ICD SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE sudden cardiac arrest; ICD; clinical trial; telephone intervention; psychological; health care costs; nursing ID INTERNAL CARDIOVERTER-DEFIBRILLATOR; SUDDEN CARDIAC-ARREST; QUALITY-OF-LIFE; NURSING INTERVENTION; IMPACT; IMPLANTATION; DEPRESSION; VALIDATION; SYMPTOMS; ANXIETY AB Background: The purpose of this study was to determine the long-term benefits of participating in a structured, 8-week educational telephone intervention delivered by expert cardiovascular nurses post-ICD. The intervention was aimed to (1) increase physical functioning, (2) increase psychological adjustment, (3) improve self-efficacy in managing the challenges of ICD recovery, and (4) lower levels of health care utilization over usual care in the first 12 months post-ICD, This article reports on the 6- and 12-month outcomes of the nursing intervention trial. Methods and Results: A two-group (N = 168) randomized control group design was used to evaluate intervention efficacy with persons receiving an ICD for the secondary prevention of sudden cardiac arrest. Measures were obtained at baseline, 6 and 12 months post hospitalization. Outcomes included (1) physical functioning (Patient Concerns Assessment [PCA], Short Form Health Survey [SF-12], ICD shocks), (2) psychological adjustment (State-Trait Anxiety Inventory [STAI], Centers for Epidemiologic Studies-Depression [CES-D], fear of dying), (3) self-efficacy (Sudden Cardiac Arrest-Self-Efficacy [SCA-SE], Sudden Cardiac Arrest-Behavior [SCA-B], Sudden Cardiac Arrest-Knowledge [SCA-K]), and(4)health care utilization (emergency room [ER] visits, outpatient visits, hospitalizations). Using repeated measures ANOVA, the 6- and 12-month benefits of the intervention over usual care were in reductions in physical concerns (P = 0.006), anxiety (P = 0.04), and fear of dying (P = 0.01), with enhanced self-confidence (P = 0.04) and knowledge (P = 0.001) to manage ICD recovery There were no statistically significant differences between the groups on total outpatient visits, hospitalizations, or ER visits over 12 months. Conclusion: A structured 8-week post-hospital telephone nursing intervention after an ICD had sustained 12-month improvements on patient concerns, anxiety, fear of dying, self-efficacy, and knowledge. Results may not apply to individuals with congestive heart failure who receive an ICD for primary prevention of sudden cardiac arrest. C1 Univ Washington, Sch Nursing, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Dougherty, CM (reprint author), Univ Washington, Sch Nursing, Box 357266,Room T608D, Seattle, WA 98195 USA. EM cindyd@u.washington.edu FU NINR NIH HHS [R01NR04766] NR 32 TC 39 Z9 38 U1 2 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD NOV PY 2005 VL 28 IS 11 BP 1157 EP 1167 DI 10.1111/j.1540-8159.2005.09500.x PG 11 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 990MM UT WOS:000233747500002 PM 16359281 ER PT J AU Lu, Q Zeltzer, LK Tsao, JCI Kim, SC Turk, N Naliboff, BD AF Lu, Q Zeltzer, LK Tsao, JCI Kim, SC Turk, N Naliboff, BD TI Heart rate mediation of sex differences in pain tolerance in children SO PAIN LA English DT Article DE sex differences; laboratory pain; pain tolerance; heart rate; puberty; children and adolescents ID ADOLESCENTS SELF-ASSESSMENT; HEMODYNAMIC-RESPONSES; LABORATORY PAIN; MATURATION; STIMULI; GENDER; GIRLS; SENSITIVITY; DEPRESSION; VALIDITY AB Despite evidence supporting the existence of important sex-related differences in pain, the mechanisms underpinning such differences are not well understood. The aim of this study is to examine the relationship between sex and pubertal differences in autonomic arousal and pain tolerance to laboratory pain stimuli in healthy children. We tested the following specific hypotheses: (1) females would have greater autonomic arousal and less pain tolerance than males, and (2) this sex difference in pain tolerance would be mediated by autonomic arousal. Participants were 244 healthy children (50.8% female, mean age 12.73 +/- 2.98 years, range 8-18 years). Separate 4-trial blocks of cutaneous pressure and thermal pain stimuli were presented in counterbalanced order. Heart rate (HR) was recorded during 2-3 min periods preceding each block and a 1-min period between trials. Results indicated lower tolerance in females for cutaneous pressure, but not thermal pain, compared to males. In addition, pre-trial HR was greater for females than males. Mediation analyses Suggested that sex differences in pressure pain tolerance were accounted for by sex differences in pre-trial HR. There were also significant effects for puberty, but these did not vary by sex. Overall, early pubertal children had greater pre-trial HR and less pain tolerance than those in late puberty for both cutaneous pressure and thermal pain across sex. These results suggest that autonomic arousal may be a mediator of sex-related differences in pain responses in children. (c) 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, UCLA Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Pediat Pain Program, Los Angeles, CA 90073 USA. RP Naliboff, BD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, UCLA Ctr Neurovisceral Sci & Womens Hlth, Bldg 115,Rm 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM naliboff@ucla.edu OI Zeltzer, Lonnie/0000-0001-9306-9450 FU NCCIH NIH HHS [R24 AT002681]; NCRR NIH HHS [MO1-RR-00865]; NIDCR NIH HHS [R01 DE12754-01A1]; NINR NIH HHS [R01 NR007768] NR 39 TC 21 Z9 22 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD NOV PY 2005 VL 118 IS 1-2 BP 185 EP 193 DI 10.1016/j.pain.2005.08.008 PG 9 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 984DD UT WOS:000233281800024 PM 16213093 ER PT J AU Gallagher, RM AF Gallagher, RM TI Pulsed radiofrequency treatment: Biological mechanisms and clinical evidence SO PAIN MEDICINE LA English DT Editorial Material C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 5 TC 3 Z9 4 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD NOV-DEC PY 2005 VL 6 IS 6 BP 401 EP 402 DI 10.1111/j.1526-4637.2005.00077.x PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 989DX UT WOS:000233654200001 PM 16336476 ER PT J AU Mossey, JM Kerr, NDS Welz-Bosna, M Gallagher, RM AF Mossey, JM Kerr, NDS Welz-Bosna, M Gallagher, RM TI Preliminary evaluation of the Health Background Questionnaire for Pain and Clinical Encounter Form for Pain SO PAIN MEDICINE LA English DT Article DE Health Background Questionnaire; Medical Outcome Study Short Form-3; Clinical Encounter Form ID BACK-PAIN; INSTRUMENT; MANAGEMENT; MEDICINE; OUTCOMES; QUALITY; SF-36; ANGER; CARE AB Objectives. The principal aims of this study were to evaluate the extent to which patients completed, understood, and were satisfied with the Health Background Questionnaire for Pain (HBQ-P), a health and pain history questionnaire that includes a modification of the Medical Outcome Study Short Form-36, the Treatment Outcomes in Pain Survey, and to examine the degree to which the questionnaire produced reliable and valid responses. A secondary aim was to determine the length of time for a physician to complete the Clinician Evaluation Form for Pain (CEF-P), a brief questionnaire designed to obtain key elements resulting from clinical assessment and management decisions. Methods. This cross-sectional study utilized data from consecutive new patients seen from January to December 2001 in Drexel University College of Medicine's Pain Medicine and Comprehensive Rehabilitation Center at Graduate Hospital in Philadelphia, PA. The HBQ-P and an accompanying brief satisfaction inventory were completed at home by the patient prior to the individual's initial office visit. The CEF-P was completed by the physician after seeing the patient. Results. Ten of 11 comparisons of patient responses to similar questions on the HBQ-P showed significant consistency. Of eight comparisons between the CEF-P and HBQ-P, two pain duration comparisons showed moderate agreement and one depression comparison showed significant association. Patients consistently had difficulty in answering six single questions and two question sets. Overall patient satisfaction was high. The mean time for the physician to complete the CEF-P was 90 seconds. Conclusions. Analyses indicate patient responses to similar HBQ-P questions have sufficient reliability to support the use of the Health Background Questionnaire for clinically related data collection and for outcome evaluation of treatments for chronic and recurring pain. The consistently missed questions on the HBQ-P should be revised. C1 Philadelphia VA Med Ctr, Pain Management Serv, Philadelphia, PA 19014 USA. Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Pain Med Res & Policy, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Philadelphia VA Med Ctr, Pain Management Serv, Univ & Woodland Ave, Philadelphia, PA 19014 USA. EM rgallagh@mail.med.upenn.edu NR 26 TC 3 Z9 3 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD NOV-DEC PY 2005 VL 6 IS 6 BP 443 EP 451 DI 10.1111/j.1526-4637.2005.00075.x PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 989DX UT WOS:000233654200006 PM 16336481 ER PT J AU Rich, BA Casarett, D Battin, MP AF Rich, BA Casarett, D Battin, MP TI Ethics forum SO PAIN MEDICINE LA English DT Editorial Material C1 Univ Calif Davis, Sacramento, CA 95817 USA. Univ Penn, Div Geriatr Med, Philadelphia VAMC, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. Univ Utah, Dept Philosophy, Salt Lake City, UT USA. Univ Utah, Div Med Eth, Salt Lake City, UT USA. RP Rich, BA (reprint author), Univ Calif Davis, Sacramento, CA 95817 USA. NR 11 TC 2 Z9 2 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD NOV-DEC PY 2005 VL 6 IS 6 BP 459 EP 463 DI 10.1111/j.1526-4637.2005.00074.x PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 989DX UT WOS:000233654200008 PM 16336483 ER PT J AU Jonker, SS Faber, JJ Anderson, DF Thomburg, KL Rodgers, RK Hou, EF Giraud, GD AF Jonker, SS Faber, JJ Anderson, DF Thomburg, KL Rodgers, RK Hou, EF Giraud, GD TI Prenatal hypertension induced by plasma infusion programs cardiac growth and maturation in fetal sheep SO PEDIATRIC RESEARCH LA English DT Meeting Abstract CT 3rd International Congress on Developmental Origins of Health and Disease CY NOV 16-19, 2005 CL Toronto, CANADA C1 Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med Cardiol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Heart Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD NOV PY 2005 VL 58 IS 5 BP 1018 EP 1018 PG 1 WC Pediatrics SC Pediatrics GA 977CC UT WOS:000232779000066 ER PT J AU Jonker, SS Karamlou, T Faber, JJ Anderson, DF Giraud, GD Thornburg, KL AF Jonker, SS Karamlou, T Faber, JJ Anderson, DF Giraud, GD Thornburg, KL TI NCX and SERCA genes are not regulated by hemodynamic stress in the fetal sheep heart SO PEDIATRIC RESEARCH LA English DT Meeting Abstract CT 3rd International Congress on Developmental Origins of Health and Disease CY NOV 16-19, 2005 CL Toronto, CANADA C1 Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med Cardiol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD NOV PY 2005 VL 58 IS 5 BP 1082 EP 1082 PG 1 WC Pediatrics SC Pediatrics GA 977CC UT WOS:000232779000303 ER PT J AU Bagby, SP Roullet, JB Xue, H Saunders, K AF Bagby, SP Roullet, JB Xue, H Saunders, K TI Endothelium-independent mesenteric vascular hyperreactivity to pressors in hypertensive prepubertal microswine offspring exposed to maternal protein restriction SO PEDIATRIC RESEARCH LA English DT Meeting Abstract CT 3rd International Congress on Developmental Origins of Health and Disease CY NOV 16-19, 2005 CL Toronto, CANADA C1 Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Vasc Surg, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Comparat Med, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD NOV PY 2005 VL 58 IS 5 BP 1107 EP 1107 PG 1 WC Pediatrics SC Pediatrics GA 977CC UT WOS:000232779000393 ER PT J AU Naleid, AM Grace, MK Cummings, DE Levine, AS AF Naleid, AM Grace, MK Cummings, DE Levine, AS TI Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens SO PEPTIDES LA English DT Article DE ghrelin; reward; opioid; food intake; microinjection; rat ID OPIOID ANTAGONIST NALTREXONE; GROWTH-HORMONE SECRETAGOGUE; NEUROPEPTIDE-Y; ENERGY-BALANCE; FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; ARCUATE NUCLEUS; SOLITARY TRACT; MESSENGER-RNA; RAT AB Ghrelin, a powerful orexigenic peptide released from the gut, stimulates feeding when injected centrally and has thus far been implicated in regulation of metabolic, rather than hedonic, feeding behavior. Although ghrelin's effects are partially mediated at the hypothalamic arcuate nucleus, via activation of neurons that co-express neuropeptide Y and agouti-related protein (NPY/Agrp neurons), the ghrelin receptor is expressed also in other brain sites. One of these is the ventral tegmental area (VTA), a primary node of the mesolimbic reward pathway, which sends dopaminergic projections to the nucleus accumbens (Acb), among other sites. We injected saline or three doses of ghrelin (0, 0.003, 0.03, or 0.3 nmol) into the VTA or Acb of rats. We found a robust feeding response with VTA injection of ghrelin, and a more moderate response with Acb injection. Because opioids modulate feeding in the VTA and Acb, we hypothesized that ghrelin's effects in one site were dependent on opioid signaling in the opposite site. The general opioid antagonist, naltrexone (NTX), injected into the Acb did not affect feeding elicited by ghrelin, injection into the VTA, and NTX in the VTA did not affect feeding elicited by ghrelin injected into the Acb. These results suggest interaction of a metabolic factor with the reward system in feeding behavior, indicating that hedonic responses can be modulated by homeostatic factors. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Minnesota, Grad Program Neurosci, Minneapolis, MN 55415 USA. Vet Adm Med Ctr, Minnesota Obes Ctr, Minneapolis, MN 55417 USA. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Minnesota, Dept Food Sci & Nutr, St Paul, MN 55108 USA. Univ Minnesota, Minnesota Craniofacial Res Training Program, Minneapolis, MN 55455 USA. RP Levine, AS (reprint author), Univ Minnesota, Grad Program Neurosci, Minneapolis, MN 55415 USA. EM aslevine@umn.edu FU NIDA NIH HHS [DA-03999]; NIDCR NIH HHS [T32-DE07288]; NIDDK NIH HHS [P 30 DK-50456, P01 DK68384] NR 33 TC 213 Z9 217 U1 2 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD NOV PY 2005 VL 26 IS 11 BP 2274 EP 2279 DI 10.1016/j.peptides.2005.04.025 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 985JI UT WOS:000233373100032 PM 16137788 ER PT J AU O'Neill, JL Flanagan, PS Zaleon, CR Copeland, LA AF O'Neill, JL Flanagan, PS Zaleon, CR Copeland, LA TI Safety of outpatient dalteparin therapy in veterans with mechanical heart valves SO PHARMACOTHERAPY LA English DT Article DE dalteparin; low-molecular-weight heparin; LMWH; mechanical heart valve; periprocedural anticoagulation; international normalized ratio; INR AB Study Objectives. To determine the rate of bleeding and thromboembolic events within 1 month of outpatient dalteparin therapy in veterans with mechanical heart valves, to evaluate potential risk factors associated with these events, and to examine the prescribing patterns of dalteparin in this patient population. Design. Single-center retrospective electronic chart review. Setting. Large, academically affiliated Veterans Affairs hospital. Subjects. Thirty-eight men with mechanical heart valves who received outpatient prescriptions for dalteparin from October 1, 1998-june 30, 2003. Measurements and Main Results. Charts were reviewed for thromboembolic and bleeding events. Demographic, clinical, and drug utilization variables were assessed. The associations of adverse events with potential risk factors, indication for dalteparin therapy, and prescribing clinic were analyzed. Sixty-four dalteparin regimens were evaluated. No thromboembolic events were reported in any case within 1 month after receiving dalteparin for thromboembolic prophylaxis during warfarin interruption for periprocedural anticoagulation or for anticoagulation during an unintentional subtherapeutic international normalized ratio. Bleeding events occurred in 15 (23%) of the 64 regimens. Most bleeding events resolved spontaneously and without intervention. No potential risk factors for bleeding were identified. Conclusion. Dalteparin appeared to be a safe, effective means of short-term thromboembolic prophylaxis in this population of ambulatory male veterans with mechanical heart valves. Large, randomized, controlled, prospective trials are warranted. C1 Vet Affairs Ann Arbor Healtchare Syst, Dept Pharm, Ann Arbor, MI 48105 USA. Vet Affairs Ann Arbor Healtchare Syst, Dept Ambulatory Care, Ann Arbor, MI 48105 USA. S Texas Vet Healthcare Syst, Audie L Murphy Div, San Antonio, TX USA. RP O'Neill, JL (reprint author), Vet Affairs Ann Arbor Healtchare Syst, Dept Pharm, 2215 Fuller Rd 119,, Ann Arbor, MI 48105 USA. EM Jessica.Oneill@med.va.gov OI Copeland, Laurel/0000-0002-9478-0209 NR 16 TC 2 Z9 2 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD NOV PY 2005 VL 25 IS 11 BP 1560 EP 1565 DI 10.1592/phco.2005.25.11.1560 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 981AM UT WOS:000233059400006 PM 16232019 ER PT J AU Ruzek, JI Friedman, MJ Murray, S AF Ruzek, JI Friedman, MJ Murray, S TI Toward a knowledge management system for posttraumatic stress disorder treatment in. veterans healthcare SO PSYCHIATRIC ANNALS LA English DT Article ID EXPOSURE THERAPY; PRACTICE GUIDELINES; CLINICAL-PRACTICE; PTSD; IMPROVEMENT; DISSEMINATION; STRATEGIES; PATTERNS; PROGRAMS; CENTERS C1 US Dept Vet Affairs, Natl Ctr PTSD, VA Palo Alto Hlth Care Syst, Educ Div, Menlo Pk, CA 94025 USA. Vet Adm Med Ctr, Natl Ctr Post Traumat Stress Disorder, White River Jct, VT USA. Dartmouth Coll Sch Med, Hanover, NH USA. Upstate New York Vet Adm Healthcare Syst, Network 2, Behav Hlth Care Line, Albany, NY USA. RP Ruzek, JI (reprint author), US Dept Vet Affairs, Natl Ctr PTSD, VA Palo Alto Hlth Care Syst, Educ Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM josef.ruzek@med.va.gov NR 46 TC 4 Z9 4 U1 1 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD NOV PY 2005 VL 35 IS 11 BP 911 EP 920 PG 10 WC Psychiatry SC Psychiatry GA 984MI UT WOS:000233308600011 ER PT J AU Hashimoto, K Iyo, M Freedman, R Stevens, KE AF Hashimoto, K Iyo, M Freedman, R Stevens, KE TI Tropisetr in DBA/2 on improves deficient inhibitory auditory processing mice: role of alpha 7 nicotinic acetylcholine receptors SO PSYCHOPHARMACOLOGY LA English DT Article DE nicotinic receptors; schizophrenia; antipsychotic; sensory gating ID HIPPOCAMPAL INTERNEURONS; SENSORY INHIBITION; EVOKED-POTENTIALS; SCHIZOPHRENIA; RAT; MOUSE; MODULATION; P50; CLOZAPINE; AGONISTS AB Rationale: Deficient inhibitory processing of the P50 auditory evoked potential is a pathophysiological feature of schizophrenia. Several lines of evidence suggest that alpha 7 nicotinic receptors play a critical role in this phenomenon. Similar to schizophrenic patients, DBA/2 mice spontaneously exhibit a deficit in inhibitory processing of the P20-N40 auditory evoked potential, which is thought to be a rodent analog of the human P50 auditory evoked potential. Objective: The present study was undertaken to examine whether tropisetron, a partial agonist at alpha 7 nicotinic receptors and an antagonist at 5-hydroxytryptamine-3 receptors, improves this deficit in DBA/2 mice. Results: Administration of tropisetron (1 mg/kg i.p.) significantly improved the deficient inhibitory processing of the P20-N40 auditory evoked potential in DBA/2 mice. Coadministration of methyllycaconitine (MLA; 3 mg/kg i.p.), a partially selective antagonist at alpha 7 nicotinic receptors, significantly blocked the normalizing effect of tropisetron. Furthermore, MLA alone did not alter the deficient inhibitory processing of the P20-N40 auditory evoked potential in DBA/2 mice. Conclusions: The data suggest that tropisetron improves the deficient inhibitory processing of the P20-N40 auditory evoked potential in DBA/2 mice by effects on alpha 7 and perhaps alpha 4 beta 2 nicotinic receptors. Tropisetron may be useful for the treatment of deficient inhibitory processing in schizophrenia. C1 Chiba Univ, Div Clin Neurosci, Ctr Forens Mental Hlth, Chiba 2608670, Japan. Chiba Univ, Grad Sch Med, Dept Psychiat, Chiba 2608670, Japan. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Hashimoto, K (reprint author), Chiba Univ, Div Clin Neurosci, Ctr Forens Mental Hlth, 1-8-1 Inohana, Chiba 2608670, Japan. EM hashimoto@faculty.chiba-u.jp NR 52 TC 47 Z9 48 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD NOV PY 2005 VL 183 IS 1 BP 13 EP 19 DI 10.1007/s00213-005-0142-0 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 988BK UT WOS:000233566200002 PM 16136299 ER PT J AU Jovin, TG Gupta, R Uchino, K Jungreis, CA Wechsler, LR Hammer, MD Tayal, A Horowitz, MB AF Jovin, TG Gupta, R Uchino, K Jungreis, CA Wechsler, LR Hammer, MD Tayal, A Horowitz, MB TI Emergent stenting of extracranial internal carotid artery occlusion in acute stroke has a high revascularization rate SO STROKE LA English DT Article DE angioplasty; endovascular therapy; stents; carotid arteries ID INTRAARTERIAL THROMBOLYSIS; HYPERPERFUSION SYNDROME; COMPUTED-TOMOGRAPHY; ISCHEMIC-STROKE; RECANALIZATION; ENDARTERECTOMY; PENUMBRA AB Background and Purpose - Acute ischemic stroke attributable to extracranial internal carotid artery ( ICA) occlusion is frequently associated with severe disability or death. In selected cases, revascularization with carotid artery stenting has been reported, but the safety, recanalization rate, and clinical outcomes in consecutive case series are not known. Methods - We retrospectively reviewed all of the cases of ICA occlusions that underwent cerebral angiography with the intent to revascularize over a 38-month period. Two groups were identified: (1) patients who presented with an acute clinical presentation within 6 hours of symptom onset (n = 15); and (2) patients who presented subacutely with neurologic fluctuations because of the ICA occlusion (n = 10). Results - Twenty-five patients with a mean age of 62 +/- 11 years and median National Institutes of Health Stroke Scale ( NIHSS) of 14 were identified. Twenty-three of the 25 patients (92%) were successfully revascularized with carotid artery stenting. Patients in group 1 were younger and more likely to have a tandem occlusion and higher baseline NIHSS when compared with group 2. Patients in group 2 were more likely to show early clinical improvement defined as a reduction of their NIHSS by >= 4 points and a modified Rankin Score of <= 2 at 30-day follow-up. Two clinically insignificant adverse events were noted: 1 asymptomatic hemorrhage and 1 nonflow-limiting dissection. Conclusions - Endovascular treatment of acute ICA occlusion appears to have a high-recanalization rate and be relatively safe in our cohort of patients with acute ICA occlusion. Future prospective studies are necessary to determine which patients are most likely to benefit from this form of therapy. C1 Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA 15213 USA. Dept Neurol, Pittsburgh, PA USA. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Dept Radiol, Pittsburgh, PA USA. Dept Neurosurg, Pittsburgh, PA USA. RP Uchino, K (reprint author), Univ Pittsburgh, Med Ctr, Stroke Inst, PUH C-400,200 Lothrop St, Pittsburgh, PA 15213 USA. EM uchinok@upmc.edu OI Uchino, Ken/0000-0001-9468-4172 NR 18 TC 113 Z9 116 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0039-2499 J9 STROKE JI Stroke PD NOV PY 2005 VL 36 IS 11 BP 2426 EP 2430 DI 10.1161/01.STR.0000185924.22918.51 PG 5 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 977VS UT WOS:000232832200032 PM 16224082 ER PT J AU Jeong, J Becker, ER Mauldin, PD Weintraub, WS AF Jeong, J Becker, ER Mauldin, PD Weintraub, WS TI A comparison of self-selectivity corrections in economic evaluations and outcomes research SO VALUE IN HEALTH LA English DT Article DE angioplasty; bypass surgery; multipart model; sample selection model; self-selectivity ID SAMPLE-SELECTION; CORONARY ANGIOPLASTY; LEAST-SQUARES; 2-PART MODELS; VARIABLES; SURGERY; CHOICE AB Objective: Two alternative selectivity correction methods have been widely applied in the health economics literature: the sample selection model (SSM) and the multipart model (MPM). The difference between these two approaches results from their initial assumptions about the distribution of error terms. Because the distributional assumptions cannot be theoretically verified, the usefulness of the methods can only be evaluated by real world comparison. This article reviews and empirically tests the two alternative selectivity correction methods to give a reality-based evaluation. Methods: Using a randomized sample of patients as the "gold standard," the SSM and MPM are applied to a nonrandomized sample of patients with an identical set of dependent and independent variables. By comparing the actual estimates of the two methods, we evaluate the robustness of the two approaches. Results: The results show that neither method is empirically robust in replicating the results of the randomized trial. There is no consistent pattern in the coefficients from either selectivity-correction method for replicating the coefficients in the randomized sample. Conclusions: Researchers should be cautious in applying these correction methods, and any conclusions based on these approaches may need to be qualified. C1 Yonsei Univ, Dept Econ, Seoul 120749, South Korea. Emory Univ, Sch Publ Hlth, Atlanta, GA USA. Med Univ S Carolina, Coll Pharm, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Emory Univ, Sch Med, Atlanta, GA USA. RP Jeong, J (reprint author), Yonsei Univ, Dept Econ, Seoul 120749, South Korea. EM jinook@yonsei.ac.kr NR 19 TC 0 Z9 0 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1098-3015 J9 VALUE HEALTH JI Value Health PD NOV-DEC PY 2005 VL 8 IS 6 BP 656 EP 666 DI 10.1111/j.1524-4733.2005.00054.x PG 11 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 980MD UT WOS:000233021700006 PM 16283866 ER PT J AU Armstrong, DG Lipsky, B Joseph, W Lavery, L AF Armstrong, DG Lipsky, B Joseph, W Lavery, L TI A guide to new classifications for diabetic foot infections SO WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE LA English DT Editorial Material C1 Rosalind Franklin Univ Med, William M Scholl Coll Padiat Med, Chicago, IL USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Antiobiot Res Clin, Seattle, WA USA. Coatesville Vet Affairs Med Ctr, Coatesville, PA USA. Texas A&M Univ, Dept Surg, Hlth Sci Ctr, Coll Med, College Stn, TX 77843 USA. RP Armstrong, DG (reprint author), Rosalind Franklin Univ Med, William M Scholl Coll Padiat Med, Chicago, IL USA. RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 0 TC 0 Z9 0 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1044-7946 J9 WOUNDS JI Wounds-Compend. Clin. Res. Pract. PD NOV PY 2005 SU S BP 6 EP 9 PG 4 WC Dermatology; Surgery SC Dermatology; Surgery GA 993SF UT WOS:000233974500002 ER PT J AU Armstrong, DG Lavery, L Lipsky, BA Joseph, WS AF Armstrong, DG Lavery, L Lipsky, BA Joseph, WS TI Current concepts in culturing and treating infected wounds SO WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE LA English DT Editorial Material C1 Rosalind Franklin Univ Med, William M Scholl Coll Padiat Med, Chicago, IL USA. Coatesville Vet Affairs Med Ctr, Coatesville, PA USA. Texas A&M Univ, Dept Surg, Hlth Sci Ctr, Coll Med, College Stn, TX 77843 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Antiobiot Res Clin, Seattle, WA USA. RP Armstrong, DG (reprint author), Rosalind Franklin Univ Med, William M Scholl Coll Padiat Med, Chicago, IL USA. RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 0 TC 0 Z9 0 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1044-7946 J9 WOUNDS JI Wounds-Compend. Clin. Res. Pract. PD NOV PY 2005 SU S BP 10 EP 12 PG 3 WC Dermatology; Surgery SC Dermatology; Surgery GA 993SF UT WOS:000233974500003 ER PT J AU Armstrong, DG Lavery, L Lipsky, BA Joseph, WS AF Armstrong, DG Lavery, L Lipsky, BA Joseph, WS TI Key considerations in appropriate antibiotic selection SO WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE LA English DT Editorial Material C1 Rosalind Franklin Univ Med, William M Scholl Coll Podiat Med, Chicago, IL USA. Coatesville Vet Affairs Med Ctr, Coatesville, PA USA. Texas A&M Univ, Dept Surg, Hlth Sci Ctr, Coll Med, College Stn, TX 77843 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. VA puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA USA. VA puget Sound Hlth Care Syst, Antiobiot Res Clin, Seattle, WA USA. RP Armstrong, DG (reprint author), Rosalind Franklin Univ Med, William M Scholl Coll Podiat Med, Chicago, IL USA. RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 0 TC 0 Z9 0 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1044-7946 J9 WOUNDS JI Wounds-Compend. Clin. Res. Pract. PD NOV PY 2005 SU S BP 13 EP 16 PG 4 WC Dermatology; Surgery SC Dermatology; Surgery GA 993SF UT WOS:000233974500004 ER PT J AU Huang, LQ Cao, J Wang, H Vo, LA Brand, JG AF Huang, LQ Cao, J Wang, H Vo, LA Brand, JG TI Identification and functional characterization of a voltage-gated chloride channel and its novel splice variant in taste bud cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RECEPTOR-CELLS; SWEET TASTE; ALPHA-GUSTDUCIN; MESSENGER-RNA; BITTER TASTE; SOUR TASTE; CYCLIC-NUCLEOTIDES; SYNAPTIC VESICLES; MEMBRANE CURRENTS; ACTION-POTENTIALS AB Taste bud cells are epithelial cells with neuronal properties. Voltage-dependent ion channels have been physiologically described in these cells. Here, we report the molecular identification and functional characterization of a voltage-gated chloride channel (ClC-4) and its novel splice variant (ClC-4A) from taste bud cells. ClC-4A skipped an exon near its 5'-end, incurring the loss of 60 amino acids at the N terminus. In situ hybridization and immunohistochemistry localized these two channels' transcripts and proteins to a subset of taste bud cells. Electrophysiological recordings of the heterologously expressed channels in Xenopus oocytes showed that ClC-4 and ClC-4A have opposite sensitivity to pH and unique ion selectivity. The chloride channel blockers niflumic acid and 5-nitro-2-(3-phenylpropylamino) benzoic acid had a slight or no inhibitory effect on the conductance of ClC-4, but both blockers inhibited ClC-4A, suggesting that ClC-4A is a candidate channel for an acid-induced 5-nitro-2-( 3-phenylpropylamino) benzoic acid-sensitive current. Furthermore, these two channels may play a role in bitter-, sweet-, and umami-mediated taste transmission by regulating transmitter uptake into synaptic vesicles. C1 Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Biochem, Philadelphia, PA 19104 USA. RP Huang, LQ (reprint author), Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA. EM lhuang@monell.org FU NIDCD NIH HHS [DC05154, R03 DC005154, R03 DC005154-04] NR 82 TC 14 Z9 16 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 28 PY 2005 VL 280 IS 43 BP 36150 EP 36157 DI 10.1074/jbc.M507706200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 976IM UT WOS:000232726900046 PM 16129671 ER PT J AU Siegel, JM AF Siegel, JM TI Clues to the functions of mammalian sleep SO NATURE LA English DT Review ID SLOW-WAVE SLEEP; REM-SLEEP; BRAIN-STEM; RAT-BRAIN; DROSOPHILA-MELANOGASTER; PARADOXICAL SLEEP; TACHYGLOSSUS-ACULEATUS; MEMORY CONSOLIDATION; RETICULAR-FORMATION; ENERGY-METABOLISM AB The functions of mammalian sleep remain unclear. Most theories suggest a role for non-rapid eye movement (NREM) sleep in energy conservation and in nervous system recuperation. Theories of REM sleep have suggested a role for this state in periodic brain activation during sleep, in localized recuperative processes and in emotional regulation. Across mammals, the amount and nature of sleep are correlated with age, body size and ecological variables, such as whether the animals live in a terrestrial or an aquatic environment, their diet and the safety of their sleeping site. Sleep may be an efficient time for the completion of a number of functions, but variations in sleep expression indicate that these functions may differ across species. C1 Univ Calif Los Angeles, Sch Med, Dept Psychiat, VA GLAHS Sepulveda, North Hills, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, North Hills, CA 91343 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Sch Med, Dept Psychiat, VA GLAHS Sepulveda, North Hills, CA 91343 USA. EM JSiegel@ucla.edu NR 100 TC 297 Z9 305 U1 10 U2 109 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD OCT 27 PY 2005 VL 437 IS 7063 BP 1264 EP 1271 DI 10.1038/nature04285 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 977UQ UT WOS:000232829100039 PM 16251951 ER PT J AU Slee, SJ Higgs, MH Fairhall, AL Spain, WJ AF Slee, SJ Higgs, MH Fairhall, AL Spain, WJ TI Two-dimensional time coding in the auditory brainstem SO JOURNAL OF NEUROSCIENCE LA English DT Article DE sound localization; covariance analysis; phase-locking; potassium channel; spike; nucleus magnocellularis ID RETINAL GANGLION-CELLS; AVIAN NUCLEUS MAGNOCELLULARIS; CONTRAST GAIN-CONTROL; COCHLEAR NUCLEUS; SPIKE TRAINS; RECEPTIVE-FIELDS; SINGLE-NEURON; INFORMATION; ADAPTATION; MODEL AB Avian nucleus magnocellularis (NM) spikes provide a temporal code representing sound arrival times to downstream neurons that compute sound source location. NMcells act as high-pass filters by responding only to discrete synaptic events while ignoring temporally summed EPSPs. This high degree of input selectivity insures that each output spike from NM unambiguously represents inputs that contain precise temporal information. However, we lack a quantitative description of the computation performed by NM cells. A powerful model for predicting output firing rate given an arbitrary current input is given by a linear/nonlinear cascade: the stimulus is compared with a known relevant feature by linear filtering, and based on that comparison, a nonlinear function predicts the firing response. Spike-triggered covariance analysis allows us to determine a generalization of this model in which firing depends on more than one spike-triggering feature or stimulus dimension. We found two current features relevant for NM spike generation; the most important simply smooths the current on short time scales, whereas the second confers sensitivity to rapid changes. A model based on these two features captured more mutual information between current and spikes than a model based on a single feature. We used this analysis to characterize the changes in the computation brought about by pharmacological manipulation of the biophysical properties of the neurons. Blockage of low-threshold voltage-gated potassium channels selectively eliminated the requirement for the second stimulus feature, generalizing our understanding of input selectivity by NM cells. This study demonstrates the power of covariance analysis for investigating single neuron computation. C1 Univ Washington, Dept Neurol 127, Seattle, WA 98108 USA. Univ Washington, Dept Physiol & Biophys, Seattle, WA 98108 USA. Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98108 USA. RP Spain, WJ (reprint author), Univ Washington, Dept Neurol 127, 1660 S Columbian Way, Seattle, WA 98108 USA. EM spain@u.washington.edu FU BLRD VA [I01 BX000386] NR 54 TC 57 Z9 57 U1 1 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD OCT 26 PY 2005 VL 25 IS 43 BP 9978 EP 9988 DI 10.1523/JNEUROSCI.2666-05.2005 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 977VU UT WOS:000232832400018 PM 16251446 ER PT J AU Mareninova, O Shin, JM Vagin, O Turdikulova, S Hallen, S Sachs, G AF Mareninova, O Shin, JM Vagin, O Turdikulova, S Hallen, S Sachs, G TI Topography of the membrane domain of the liver Na+-dependent bile acid transporter SO BIOCHEMISTRY LA English DT Article ID IN-VITRO TRANSLATION; TRANSMEMBRANE ORIENTATION; TOPOGENIC SIGNALS; P-GLYCOPROTEIN; TOPOLOGY; PROTEINS; COTRANSPORTER; INSERTION; IDENTIFICATION; CLONING AB The ileal apical and liver basolateral bile acid transporters catalyze the Na+-dependent uptake of these amphipathic molecules in the intestine and liver. They contain nine predicted helical hydrophobic sequences (H1-H9) between the exoplasmic N-glycosylated N terminus and the cytoplasmic C terminus. Previous in vitro translation and in vivo alanine insertion scanning studies gave evidence for either nine or seven transmembrane segments, with H3 and H8 noninserted in the latter model. N-terminal GFP constructs containing either successive predicted segments or only the last two domains of the liver, a membrane anchor signal were expressed in HEK-293 cells, and a C-terminal transporter following glycosylation flag allowed detection of membrane insertion. Western blot analysis with anti-GFP antibody after alkali and PNGase treatment showed that H1, H2, H3 behaved as competent transmembrane (TM) sequences. Results from longer constructs were difficult to interpret. H9, however, but not H8 was membrane-inserted. To analyze the intact transporter, a C-terminal YFP fusion protein was expressed as a functionally active protein in the plasma membrane of HEK-293 cells as seen by confocal microscopy. After limited tryptic digestion to ensure the accessibility of only exoplasmic lysine or arginine residues, molecular weight (MW) analysis of the five cleavage products on SDS-PAGE predicted the presence of seven transmembrane seaments, HI, H2, H3, H4, H5, H6, and H9, with H7 and H8 exoplasmic. This new method provided evidence for seven membrane segments giving a new model of the membrane domain of this protein and probably the homologous ileal transporter, with H7/H8 as the transport region. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Va Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Sachs, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. EM gsachs@ucla.edu OI Turdikulova, Shahlo/0000-0003-0764-2332 FU NIDDK NIH HHS [R01 DK046917, DK46917, DK53462, DK58333, R01 DK053642, R01 DK058333] NR 31 TC 30 Z9 32 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD OCT 25 PY 2005 VL 44 IS 42 BP 13702 EP 13712 DI 10.1021/bi051291x PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 979OK UT WOS:000232954500008 PM 16229460 ER PT J AU Cotter, G Kobrin, I Torre-Amione, G John, TR McMurray, JJ Frey, A Perchenet, L Hoover, P O'Connor, CM AF Cotter, G Kobrin, I Torre-Amione, G John, TR McMurray, JJ Frey, A Perchenet, L Hoover, P O'Connor, CM TI In-hospital worsening heart failure in patients with acute heart failure: Relation to renal failure, need for intotropes, CAD, hyponatremia and increased respiratory rate. A sub-group analysis from The VERITAS trial SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Duke Univ, Ctr Med, Durham, NC USA. Actel Pharmaceut Ltd, Allschwil, Switzerland. Winters Ctr Heart Failure Res, Methodist DeBakey Heart Ctr, Houston, TX USA. San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Glasgow, Dept Med & Therapeut, Glasgow G12 8QQ, Lanark, Scotland. Duke Univ, Ctr Med, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 2833 BP U661 EP U661 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956404137 ER PT J AU Ebrahimi, R Shah, AP Wadhani, N Shingate, M Toggart, EJ Saleh, J AF Ebrahimi, R Shah, AP Wadhani, N Shingate, M Toggart, EJ Saleh, J TI Statin administration prior to percutaneous coronary interventions reduces adverse cardiovascular events - A meta-analysis SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Univ Calif Los Angeles, Sch Med, W Los Angeles VA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 2327 BP U544 EP U544 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956403248 ER PT J AU Ho, PM Rumsfeld, JS Curtis, JP Eng, MH Havranek, EP Jones, PG Krumholz, HM Magid, DJ Messenger, JC Peterson, ED Rathore, SS Spertus, JA Masoudi, FA AF Ho, PM Rumsfeld, JS Curtis, JP Eng, MH Havranek, EP Jones, PG Krumholz, HM Magid, DJ Messenger, JC Peterson, ED Rathore, SS Spertus, JA Masoudi, FA TI Age and health status following non-ST elevation myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Denver VA Med Ctr, Denver, CO USA. Yale Univ, Sch Med, New Haven, CT USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Univ Denver, Hlth Med Ctr, Denver, CO 80202 USA. Mid Amer Heart Inst, Kansas City, KS USA. Yale Univ, Sch Med, New Haven, CT USA. Colorado Kaiser Permanente, Clin Res Unit, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Duke Univ, Clin Res Inst, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU 2 MA 3739 BP U883 EP U883 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956406136 ER PT J AU Ho, PM Spertus, JA Masoudi, FA Reid, KJ Peterson, ED Krumholz, HM Rumsfeld, JS AF Ho, PM Spertus, JA Masoudi, FA Reid, KJ Peterson, ED Krumholz, HM Rumsfeld, JS TI Factors associated with discontinuing medications after acute myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Denver VA Med Ctr, Denver, CO USA. Mid Amer Heart Inst, Kansas City, KS USA. Denver Hlth Med Ctr, Denver, CO USA. Duke Univ, Clin Res Inst, Durham, NC USA. Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU 2 BP U883 EP U883 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956406137 ER PT J AU Kerwin, WS Ferguson, MS O'Brien, K Hatsukami, TS Yuan, C AF Kerwin, WS Ferguson, MS O'Brien, K Hatsukami, TS Yuan, C TI Why plaques enhance: A dynamic contrast-enhanced magnetic resonance imaging study SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Univ Washington, Seattle, WA 98195 USA. Va Puget Sound Healthcare Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 2660 BP U622 EP U623 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956403580 ER PT J AU Paramsothy, P Retzlaff, BM Knopp, RH Fish, B Kahn, SE Ostlund, RE AF Paramsothy, P Retzlaff, BM Knopp, RH Fish, B Kahn, SE Ostlund, RE TI Diminished cholesterol absorption and heightened synthesis in obesity and insulin resistance: Evidence from plasma sterol levels SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Univ Washington, Div Cardiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Washington Univ, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 1083 BP U265 EP U265 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956401321 ER PT J AU Persson, H Lonn, E Edner, M Baruch, L Lang, CC Morton, JJ Ostergren, J McKelvie, RS AF Persson, H Lonn, E Edner, M Baruch, L Lang, CC Morton, JJ Ostergren, J McKelvie, RS TI Diastolic dysfunction in heart failure with preserved systolic - Function need for objective evidence. Results from the CHARM echocardiographic substudy - CHARMES SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Danderyd Hosp, Stockholm, Sweden. Populat Hlth Res Inst, Hamilton, ON, Canada. Bronx Vet Affairs Med Ctr, Bronx, NY USA. Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland. Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland. Karolinska Univ Hosp, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 1991 BP U469 EP U469 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956402573 ER PT J AU Plomondon, ME Magid, DJ Masoudi, FA Jones, PG Barry, LC Havranek, E Peterson, ED Krumholz, HM Spertus, JA Rumsfeld, JS AF Plomondon, ME Magid, DJ Masoudi, FA Jones, PG Barry, LC Havranek, E Peterson, ED Krumholz, HM Spertus, JA Rumsfeld, JS TI The impact of angina on patient satisfaction after acute myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Denver VA Med Ctr, Denver, CO USA. Colorado Permanente Med Grp, Aurora, CO USA. Denver Hlth Med Ctr, Denver, CO USA. UMKC, Mid Amer Heart Inst, Kansas City, MO USA. Yale Univ, Med Ctr, New Haven, CT USA. Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 3813 BP U899 EP U899 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956406210 ER PT J AU Shah, AP Ebrahimi, R Wadhani, N Toggart, EJ Rubin, SA AF Shah, AP Ebrahimi, R Wadhani, N Toggart, EJ Rubin, SA TI Beta-blocker therapy in acute myocardial infarction: A meta-analysis of clinical trials SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 2096 BP U493 EP U493 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956403018 ER PT J AU Singh, BN Geffen, D Hohnloser, SH AF Singh, BN Geffen, D Hohnloser, SH TI Dronedarone is safe and effective in maintaining sinus rhythm in atrial fibrillation in patients with pre-specified recurrence risk factors SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 VA Greater Los Angeles Healthcare Syst W Los Ange, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Frankfurt Klinikum, Med Klin 4, D-6000 Frankfurt, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 2366 BP U553 EP U553 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956403287 ER PT J AU Sonel, AF Zahid, M Fine, MJ Good, CB AF Sonel, AF Zahid, M Fine, MJ Good, CB TI Do physicians assess risk of adverse outcomes differently in black vs. white patients?: A comparison of an objective risk score and physician assessed risk in non-ST-elevation acute coronary syndromes SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Rsch & Promot, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 3700 BP U862 EP U863 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956406097 ER PT J AU Teerlink, JR Bergman, MR Li, LY Zhu, BQ Karliner, JS Lovett, DH AF Teerlink, JR Bergman, MR Li, LY Zhu, BQ Karliner, JS Lovett, DH TI Chronic cardiac MMP-2 transgene expression independently induces marked ventricular remodeling and systolic dysfunction SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 San Francisco VA Med Ctr, San Francisco, CA USA. RI Teerlink, John/D-2986-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 564 BP U154 EP U154 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956400509 ER PT J AU Udelson, JE McGrew, F Flores, E Ibrahim, H Koshkarian, G Katz, S O'Brien, T Johnson, RH Zimmer, C Orlandi, C Konstam, MA AF Udelson, JE McGrew, F Flores, E Ibrahim, H Koshkarian, G Katz, S O'Brien, T Johnson, RH Zimmer, C Orlandi, C Konstam, MA TI Effects of the vasopressin V2 receptor antagonist, tolvaptan, on the long-term progression of left ventricular dilatation in patients with heart failure SO CIRCULATION LA English DT Meeting Abstract CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc C1 Tufts New England Med Ctr, Boston, MA USA. Stern Cardiovasc Ctr, Memphis, TN USA. Georgia Heart Specialists, Covington, GA USA. N Ohio Res, Sandusky, OH USA. Desert Cardiol Tucson, Tucson, AZ USA. Yale Univ, New Haven, CT 06520 USA. Ralph H Johnson VAMC, Charleston, SC USA. Otsuka Maryland Res Inst, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 25 PY 2005 VL 112 IS 17 SU S MA 2415 BP U564 EP U564 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 979PD UT WOS:000232956403336 ER PT J AU Blouin, AM Thannickal, TC Worley, PF Baraban, JM Reti, IM Siegel, JM AF Blouin, AM Thannickal, TC Worley, PF Baraban, JM Reti, IM Siegel, JM TI Narp immunostaining of human hypocretin (orexin) neurons - Loss in narcolepsy SO NEUROLOGY LA English DT Article; Proceedings Paper CT 34th Annual Meeting of the Society-for-Neuroscience CY OCT 23-27, 2004 CL San Diego, CA SP Soc Neurosci ID EXPRESSION AB Objective: To investigate whether neuronal activity-regulated pentraxin (Narp) colocalizes with hypocretin ( Hcrt or orexin) in the normal human brain and to determine if Narp staining is lost in the narcoleptic human brain. Background: Human narcolepsy is characterized by a loss of the peptide hypocretin in the hypothalamus. This loss could result from the degeneration of neurons containing hypocretin or from a more specific loss of the ability of these neurons to synthesize Hcrt. Narp has been found to colocalize with hypocretin in the rat hypothalamus. Methods: We investigated the distribution of Narp in three normal and four narcoleptic human postmortem brains using immunohistochemistry with an antibody to Narp. Colocalization studies of Narp and hypocretin were also performed in two normal brains using immunohistochemistry with an antibody to Narp and an antibody to hypocretin. Results: We found that Narp colocalizes with hypocretin in the lateral hypothalamic area (LHA), the dorsomedial hypothalamus (DMH), the dorsal hypothalamic area (DHA), and the posterior hypothalamic area (PHA) of the normal human. The number of Narp-positive neurons was reduced by 89% in these areas of the narcoleptic hypothalamus. In contrast, Narp staining in the paraventricular (Pa) and supraoptic nuclei (SO) of the human hypothalamus did not differ between normal and narcoleptic brains. Conclusions: This finding supports the hypothesis that narcolepsy results from the specific loss of hypocretin neurons. Loss of hypothalamic Narp may contribute to the symptoms of narcolepsy. C1 VA Greater Los Angeles Healthcare Sys, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA. Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD USA. Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD USA. Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA. RP Siegel, JM (reprint author), VA Greater Los Angeles Healthcare Sys, 16111 Plummer St,Neurobiol Res 151A3, North Hills, CA 91343 USA. EM jsiegel@ucla.edu OI Baraban, Jay/0000-0002-8165-2638 FU NHLBI NIH HHS [HL41370]; NIMH NIH HHS [MH64109]; NINDS NIH HHS [NS14610] NR 9 TC 78 Z9 80 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD OCT 25 PY 2005 VL 65 IS 8 BP 1189 EP 1192 DI 10.1212/01.wnl.0000175219.01544.c8 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 977OR UT WOS:000232813600011 PM 16135770 ER PT J AU Ganesh, S Tsurutani, N Amano, K Mittal, S Uchikawa, C Delgado-Escueta, AV Yamakawa, K AF Ganesh, S Tsurutani, N Amano, K Mittal, S Uchikawa, C Delgado-Escueta, AV Yamakawa, K TI Transcriptional profiling of a mouse model for Lafora disease reveals dysregulation of genes involved in the expression and modification of proteins SO NEUROSCIENCE LETTERS LA English DT Article DE epilepsy; microarray; neuronal death; phosphatase; post-translation modification of proteins; polyglucosan inclusions ID PROGRESSIVE MYOCLONUS EPILEPSY; EPM2A GENE; CELL-DEATH; SUBUNIT; NEURODEGENERATION; INTERACTS; PROMOTES; PRODUCT; GLUCOSE; DOMAIN AB Lafora's progressive myoclonus epilepsy (Lafora disease: LD) is caused by mutations in the EPM2A or NHLRC1 gene, but cellular mechanisms of the pathogenesis remain unclear. In an attempt to understand and elucidate the disease pathway, we have investigated the global gene expression profile in a mouse model for LD that developed a phenotype similar to that observed in human patients, including presence of Lafora bodies, neurodegeneration and profound neurological disturbances. We found 62 differentially expressed genes in the Epm2a knockout mice brains. These genes encode factors involved in protein catabolism, phosphatase, transcription factors, and molecules involved in protein translation, and homeostasis. The two largest functional groups of mRNAs that showed altered expression were predicted to be involved in post-translational modification of proteins and transcriptional regulation, suggesting that defects in protein activity and/or turnover may be the key trigger in the pathophysiology of LD. Furthermore we show that changes in gene expression are not limited to brain and are seen in other organs that develop Lafora bodies. Our study may provide valuable insights into the pathophysiology of LD and may aid in developing potential therapeutic targets. (C) 2005 Elsevier Ireland Ltd. All rights reserved. C1 Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India. RIKEN, Brain Sci Inst, Neurogenet Lab, Wako, Saitama 3510198, Japan. Univ Calif Los Angeles, Sch Med, Comprehens Epilepsy Program, Epilepsy Genet Genom Labs, Los Angeles, CA USA. VA GLAHS W Los Angeles Med Ctr, Los Angeles, CA USA. RP Ganesh, S (reprint author), Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India. EM sganesh@iitk.ac.in; yamakawa@brain.riken.go.jp RI Ganesh, Subramniam/B-4131-2009; Yamakawa, Kazuhiro/N-5050-2015 OI Delgado-Escueta, Antonio V./0000-0002-1581-6999 FU NINDS NIH HHS [NS42376] NR 25 TC 3 Z9 4 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD OCT 21 PY 2005 VL 387 IS 2 BP 62 EP 67 DI 10.1016/j.neulet.2005.07.002 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 958YI UT WOS:000231483700002 PM 16084644 ER PT J AU Warden, SJ Bliziotes, MM Wiren, KM Eshleman, AJ Turner, CH AF Warden, SJ Bliziotes, MM Wiren, KM Eshleman, AJ Turner, CH TI Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine) SO MOLECULAR AND CELLULAR ENDOCRINOLOGY LA English DT Review DE bone density; leptin; neurotransmitter; osteoporosis; SSRI ID GENE-RELATED PEPTIDE; SYMPATHETIC-NERVOUS-SYSTEM; BETA-BLOCKER USE; REUPTAKE INHIBITORS; MINERAL DENSITY; SUBSTANCE-P; MAJOR DEPRESSION; OLDER WOMEN; ANTIDEPRESSANT MEDICATIONS; TRICYCLIC ANTIDEPRESSANTS AB There is increasing evidence for a contribution of the neural system to the regulation of bone metabolism. The skeleton is richly innervated by both sympathetic and sensory neurons. While these nerves serve sensory and vascular functions, they are also being found to influence bone cell activities. The most convincing evidence for this has been provided by studies into the skeletal effects of the hormone leptin, which has been shown to centrally regulate bone mass, and through studies into the skeletal effects of hypothalamic neuropeptide Y2 and Y4 receptors. This paper discusses recent evidence for the neural regulation of bone metabolism and, in particular, the potential role of the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Recent studies have demonstrated the presence of functional pathways in bone for both responding to and regulating the uptake of 5-HT. This is of high clinical relevance given the role of the serotonergic system in affective disorders, and the wide use of pharmacological agents that target the 5-HT system to manage these disorders. Initial data suggest that exposure to these agents at different stages during the lifespan may have significant effects on the skeleton. (c) 2005 Elsevier Ireland Ltd. All rights reserved. C1 Indiana Univ, Dept Phys Therapy, Indianapolis, IN 46202 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA. RP Warden, SJ (reprint author), Indiana Univ, Dept Phys Therapy, 1140 W Michigan St,CF-326, Indianapolis, IN 46202 USA. EM stwarden@iupui.edu RI Warden, Stuart/C-5287-2012 OI Wiren, Kristine/0000-0002-6159-4450; Warden, Stuart/0000-0002-6415-4936 FU NIA NIH HHS [P01AG18397]; NIAMS NIH HHS [R01 AR046530] NR 120 TC 44 Z9 47 U1 2 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0303-7207 J9 MOL CELL ENDOCRINOL JI Mol. Cell. Endocrinol. PD OCT 20 PY 2005 VL 242 IS 1-2 BP 1 EP 9 DI 10.1016/j.mce.2005.06.005 PG 9 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 978BK UT WOS:000232847000001 PM 16085354 ER PT J AU Zingmond, DS McGory, ML Ko, CY AF Zingmond, DS McGory, ML Ko, CY TI Hospitalization before and after gastric bypass surgery SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID MORBIDLY OBESE-PATIENTS; BARIATRIC SURGERY; COST-EFFECTIVENESS; CARE; METAANALYSIS; OUTCOMES; IMPACT AB Context The use of Roux-en-Y gastric bypass (RYGB) has been reported to be effective in the treatment of obesity and its related comorbidities. Utilization of inpatient services after RYGB is less well understood. Objective To determine the rates and indications for inpatient hospital use before and after RYGB. Design, Setting, and Participants Retrospective study of Californians receiving RYGB in California hospitals from 1995 to 2004. Main Outcome Measure Hospitalization in the 1 to 3 years after RYGB. Results In California from 1995 to 2004, 60077 patients underwent RYGB - 11659 in 2004 alone. The rate of hospitalization in the year following RYGB was more than double the rate in the year preceding RYGB (19.3% vs 7.9%, P<.001). Furthermore, in the subset of patients (n = 24 678) with full 3-year follow-up, a mean of 8.4% were admitted a year before RYGB while 20.2% were readmitted in the year after RYGB, 18.4% in the second year after RYGB, and 14.9% in the third year after RYGB. The most common reasons for admission prior to RYGB were obesity-related problems (eg, osteoarthritis, lower extremity cellulitis), and elective operation (eg, hysterectomy), while the most common reasons for admission after RYGB were complications often thought to be procedure related, such as ventral hernia repair and gastric revision. In multivariate logistic regression models predicting 1-year readmission after RYGB, increasing Charlson Comorbidity Index score, and hospitalization in the 3-year period prior to RYGB were significantly associated with readmission within a year. Conclusions Increases in hospital use after surgery appear to be related to RYGB. Payers, clinicians, and patients must consider the not-inconsequential rate of rehospitalization after this type of surgery. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Surg Outcomes & Qual, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Zingmond, DS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza, Los Angeles, CA 90095 USA. EM dzingmond@mednet.ucla.edu FU NIA NIH HHS [K08 AG023024-01A1] NR 19 TC 128 Z9 130 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 19 PY 2005 VL 294 IS 15 BP 1918 EP 1924 DI 10.1001/jama.294.15.1918 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 974OZ UT WOS:000232602600021 PM 16234498 ER PT J AU Holmes, WC Sammel, MD AF Holmes, WC Sammel, MD TI Brief communication: Physical abuse of boys and possible associations with poor adult outcomes SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PARTNER VIOLENCE; CHILDHOOD ABUSE; SEXUAL-ABUSE; WOMEN; INSTRUMENT; VALIDITY; DISORDER AB Background: men's childhood physical abuse experiences are understudied. Objective: To obtain descriptions about men's personal childhood physical abuse histories and estimate their association with adult outcomes. Design: Population-based telephone survey. Setting: urban areas with high frequency of domestic violence against girls and women. Participants: 298 men recruited through random-digit dialing. Measurements: 6 Conflict Tactics Scale items and psychiatric, sexual, and legal history questions. Results: One hundred of 197 (51%) participants had a history of childhood physical abuse. Most (73%) participants were abused by a parent. Childhood physical abuse history was associated with depression symptoms (P = 0.003), post-traumatic stress disorder symptoms (P < 0.001), number of lifetime sexual partners (P = 0.035), legal troubles (P = 0.002), and incarceration (P = 0.007) in unadjusted analyses and with depression symptoms (P = 0.015) and post-traumatic stress disorder symptoms (P = 0.003) in adjusted analyses. Limitations: There may have been inaccurate recall of past events. Lack of exposure time data disallowed direct comparison of abuse perpetration by mothers versus fathers. Other unmeasured variables related to childhood physical abuse might better explain poor adult outcomes. Conclusions: The high frequency of childhood physical abuse histories in this population-based male sample, coupled with the high proportion of parent perpetrators and the association between childhood physical abuse and adult outcomes that are often associated with perpetration of violence, argues for more study of and clinical attentiveness to potential adult outcomes of men's own childhood physical abuse histories. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Holmes, WC (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 733 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM holmeswc@mail.med.upenn.edu FU NIDA NIH HHS [DA015635] NR 20 TC 19 Z9 21 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 18 PY 2005 VL 143 IS 8 BP 581 EP 586 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 975PI UT WOS:000232674000008 PM 16230724 ER PT J AU Casserly, IP Abou-Chebl, A Fathi, RB Lee, DS Saw, J Exaire, JE Kapadia, SR Bajzer, CT Yadav, JS AF Casserly, IP Abou-Chebl, A Fathi, RB Lee, DS Saw, J Exaire, JE Kapadia, SR Bajzer, CT Yadav, JS TI Slow-flow phenomenon during carotid artery intervention with embolic protection devices - Predictors and clinical outcome SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID CEREBRAL PROTECTION; HISTOPATHOLOGIC ANALYSIS; EMBOLIZATION AB OBJECTIVES The purpose of this research was to define the predictors of the "slow-reflow" phenomenon during carotid artery intervention with filter-type embolic protection devices (EPDs) and to determine its prognostic significance. BACKGROUND During carotid artery intervention using filter-type EPDs, we have observed cases in which there is angiographic evidence of a significant reduction in antegrade flow in the internal carotid artery proximal to the filter device, termed "slow-flow." The predictors of this phenomenon and its prognostic significance are unknown. METHODS Using a single-center prospective carotid intervention registry, patients with slow-flow were compared to patients with normal flow during carotid intervention with respect to clinical, procedural, and lesion characteristics, and the 30-day incidence of death and stroke. RESULTS A total of 414 patients underwent 453 carotid artery interventions using EPDs. Slow-flow occurred in 42 patients (10.1%) undergoing 42 carotid interventions (9.3%), and most commonly occurred after post-stent balloon dilatation (71.4%). Multivariate logistic regression analysis identified the following predictors of slow-flow: recent history (< 6 months) of stroke or transient ischemic attack (odds ratio [OR] 2.8, 95% confidence interval [CI] 1.4 to 5.6, p = 0.004), increased stent diameter (OR 1.4, 95% CI 1.02 to 1.94, p = 0.044), and increased patient age (OR 1.05, 95% CI 1.01 to 1.09, p = 0.025). Among patients with slow-flow, the 30-day incidence of stroke or death was 9.5% compared to 2.9% in patients with normal flow (chi-square = 4.73, p = 0.03). This difference was driven by the disparity in the 30-day incidence of stroke (9.5% vs. 1.7%). CONCLUSIONS Slow-flow during carotid intervention with EPDs is a frequent event that is associated with an excess risk of periprocedural stroke. The association of the phenomenon with clinically symptomatic carotid lesions and use of larger stent diameters C1 Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Vancouver Gen Hosp, Vancouver, BC, Canada. Natl Inst Hlth, Mexico City, DF, Mexico. RP Yadav, JS (reprint author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave,Desk F25, Cleveland, OH 44195 USA. EM yadavj@ccf.org NR 8 TC 59 Z9 62 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 18 PY 2005 VL 46 IS 8 BP 1466 EP 1472 DI 10.1016/j.jacc.2005.05.082 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 974GN UT WOS:000232579400008 PM 16226169 ER PT J AU Ebrahimi, R Shah, AP Wadhani, N Saleh, JR Toggart, E AF Ebrahimi, R Shah, AP Wadhani, N Saleh, JR Toggart, E TI Statin administration prior to percutaneous coronary interventions reduces adverse cardiovascular events - A meta-analysis SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Meeting Abstract CT 17th Annual Transcatheter Cardiovascular Therapeutics Symposium CY OCT 17-21, 2005 CL Washington, DC SP Cardiovasc Res Fdn, Columbia Univ Med Ctr C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 17 PY 2005 VL 96 IS 7A SU S BP 155H EP 156H PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 976HW UT WOS:000232725200391 ER PT J AU Aujesky, D Obrosky, DS Stone, RA Auble, TE Perrier, A Cornuz, J Roy, PM Fine, MJ AF Aujesky, D Obrosky, DS Stone, RA Auble, TE Perrier, A Cornuz, J Roy, PM Fine, MJ TI Derivation and validation of a prognostic model for pulmonary embolism SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE mortality; prognosis; pulmonary embolism ID DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; OUTPATIENT TREATMENT; UNFRACTIONATED HEPARIN; VENOUS THROMBOSIS; RISK SCORE; TROPONIN-T; TOTAL HIP; OUTCOMES; HYPONATREMIA AB Rationale: An objective and simple prognostic model for patients with pulmonary embolism could be helpful in guiding initial intensity of treatment. Objectives:To develop a clinical prediction rule that accurately classifies patients with pulmonary embolism into categories of increasing risk of mortality and other adverse medical outcomes. Methods: We randomly allocated 15,531 inpatient discharges with pulmonary embolism from 186 Pennsylvania hospitals to derivation (67%) and internal validation (33%) samples. We derived our prediction rule using logistic regression with 30-day mortality as the primary outcome, and patient demographic and clinical data routinely available at presentation as potential predictor variables. We externally validated the rule in 221 inpatients with pulmonary embolism from Switzerland and France. Measurements: We compared mortality and nonfatal adverse medical outcomes across the derivation and two validation samples. Main Results: The prediction rule is based on 11 simple patient characteristics that were independently associated with mortality and stratifies patients with pulmonary embolism into five severity classes, with 30-day mortality rates of 0-1.6% in class I, 1.7-3.5% in class II, 3.2-7.1% in class III, 4.0-11.4% in class IV, and 10.0-24.5% in class V across the derivation and validation samples. Inpatient death and nonfatal complications were <= 1.1% among patients in class I and <= 1.9% among patients in class II. Conclusions: Our rule accurately classifies patients with pulmonary embolism into classes of increasing risk of mortality and other adverse medical outcomes. Further validation of the rule is important before its implementation as a decision aid to guide the initial management of patients with pulmonary embolism. C1 Univ Lausanne, Div Gen Internal Med, Clin Epidemiol Ctr, CH-1015 Lausanne, Switzerland. Univ Lausanne, Outpatient Clin, CH-1015 Lausanne, Switzerland. Univ Geneva, Dept Internal Med, Div Gen Internal Med, CH-1211 Geneva, Switzerland. Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA. VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Angers, Dept Emergency Med, Angers, France. RP Aujesky, D (reprint author), CHU Vaudois, Serv Med Interne, BH10-622, CH-1011 Lausanne, Switzerland. EM drahomir.aujesky@chuv.ch RI Perrier, Arnaud/M-2263-2014 FU NHLBI NIH HHS [1 R21 HL075521-01A1]; NIAID NIH HHS [K24 AI001769] NR 35 TC 332 Z9 342 U1 0 U2 7 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 15 PY 2005 VL 172 IS 8 BP 1041 EP 1046 DI 10.1164/rccm.200506-862OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 975OM UT WOS:000232671800018 PM 16020800 ER PT J AU Kozel, FA Johnson, KA Mu, QW Grenesko, EL Laken, SJ George, MS AF Kozel, FA Johnson, KA Mu, QW Grenesko, EL Laken, SJ George, MS TI Detecting deception using functional magnetic resonance imaging SO BIOLOGICAL PSYCHIATRY LA English DT Article DE deception; lie; detection; fMRI; BOLD; individual ID LIE DETECTION; INTERFERENCE TASK; COUNTERMEASURES; POLYGRAPH; CONFLICT; STROOP; CORTEX; TESTS; FMRI AB Background: The ability to accurately detect deception is presently very limited. Detecting deception might be more accurately achieved by measuring the brain correlates of lying in an individual. In addition, a method to investigate the neurocircuitry of deception might provide a unique opportunity to test the neurocircuitry of persons in whom deception is a prominent component (i.e., conduct disorder. antisocial personality disorder, etc,). Methods: In this study. we used functional magnetic resonance imaging (fMRI) to show that specific regions were reproducibly activated when subjects deceived. Subjects participated in a mock crime stealing either a ring or a watch. While undergoing an fMRI, the subjects denied taking either object, thus telling the truth with some responses, and lying with others. A Model-Building Group (MBG, n = 30) was used to develop the analysis methods, and the methods were subsequently applied to an independent Model-Testing Group (MTG, n = 31). Results: Me were able to correctly, differentiate truthful from deceptive responses, correctly identifying The object stolen, for 93% of the sujects in the MBG and 90% of the subjects in the MTG. Conclusions: This is the first study to use fMRI to detect deception at the individual level. Further work is required to determine bow well this technology will work in different settings and populations. C1 Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Ralph H Johnson VA Hosp, Charleston, SC USA. Cephos Corp, Pepperell, MA USA. RP Kozel, FA (reprint author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM andrew.kozel@utsouthwestern.edu RI Kozel, Frank/I-5366-2012 NR 31 TC 146 Z9 153 U1 7 U2 36 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 15 PY 2005 VL 58 IS 8 BP 605 EP 613 DI 10.1016/j.biopsych.2005.07.040 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 981NU UT WOS:000233096100002 PM 16185668 ER PT J AU Hazlett, EA New, AS Newmark, R Haznedar, MM Lo, JN Speiser, LJ Chen, AD Mitropoulou, V Minzenberg, M Siever, LJ Buchsbaum, MS AF Hazlett, EA New, AS Newmark, R Haznedar, MM Lo, JN Speiser, LJ Chen, AD Mitropoulou, V Minzenberg, M Siever, LJ Buchsbaum, MS TI Reduced anterior and posterior cingulate gray matter in borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE borderline personality disorder; schizotypal personality disorder; magnetic resonance imaging; cingulate; gray matter volume; white matter volume ID POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE; GLUCOSE-METABOLISM; BRAIN ABNORMALITIES; CHILDHOOD ABUSE; FEMALE-PATIENTS; BRODMANN AREAS; 1ST EPISODE; CORTEX; SCHIZOPHRENIA AB Background: Structural abnormalities in prefrontal and cingulate gyrus regions-important in affective processing, impulse control and cognition may contribute to the psychopathology of borderline personality disorder (BPD). Previous MRI studies examining volume have reported that compared with healthy controls, BPD patients have decreases in tight anterior cingulate, no differences in dorsolateral prefrontal cortex, and mixed findings for prefrontal cortex. We extended this investigation by examining gray and white matter volume of frontal and cingulate gyrus Brodmann areas (BAs) in a large group of patients and healthy controls. Methods. MRI scans were acquired in 50 BPD patients (n = 13 with comorbid diagnosis of BPD and Schizotypal Personality Disorder (SPD) and n = 3 7 without SPD) and 50 healthy controls, and gray/white matter volume in cingulate gyrus and frontal lobe BAs were assessed. Normal BPD and BPD subgroup comparisons were conducted. Results. Compared with controls, BPD patients showed reduced gray matter volume in BA 24 and 31 of the cingulate. BPD patients without comorbid SPD bad isolated gray matter volume loss in BA 24, but were spared for BA 31 in contrast to BPD patients with SPD. There were no group differences in whole cingulate or frontal lobe volume. Conclusions. The finding of more pervasive cingulate shrinkage in the patients with BPD and SPD comorbidity resembles recent observations with the same methods in patients with schizophrenia. The pattern of reduced anterior and posterior cingulate gray matter volume in BPD patients, particularly those comorbid for SPD is consistent with the affective and attentional deficits observed in these personality disorders. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, New York, NY USA. RP Hazlett, EA (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1505, New York, NY 10029 USA. EM erin.hazlett@mssm.edu FU NCRR NIH HHS [M01 RR 00071]; NIMH NIH HHS [MH 56606, MH 40071, MH 56489] NR 67 TC 107 Z9 110 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 15 PY 2005 VL 58 IS 8 BP 614 EP 623 DI 10.1016/j.biopsych.2005.04.029 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 981NU UT WOS:000233096100003 PM 15993861 ER PT J AU Gotlib, J Berube, C Growney, JD Chen, CC George, TI Williams, C Kajiguchi, T Ruan, J Lilleberg, SL Durocher, JA Lichy, JH Wang, YF Cohen, PS Arber, DA Heinrich, MC Neckers, L Galli, SJ Gilliland, DG Coutre, SE AF Gotlib, J Berube, C Growney, JD Chen, CC George, TI Williams, C Kajiguchi, T Ruan, J Lilleberg, SL Durocher, JA Lichy, JH Wang, YF Cohen, PS Arber, DA Heinrich, MC Neckers, L Galli, SJ Gilliland, DG Coutre, SE TI Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation SO BLOOD LA English DT Article ID PROTOONCOGENE C-KIT; SYSTEMIC MASTOCYTOSIS; ACTIVATING MUTATION; WILD-TYPE; IMATINIB; PROTEIN; IDENTIFICATION; RESISTANT; DISORDER; DISEASE AB The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation. We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nlM. The patient exhibited a partial response with significant resolution of liver function abnormalities. In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency. The patient died after 3 months of therapy due to progression of her MDS/MPD to acute myeloid leukemia (AML). This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease. C1 Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA. Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA. Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA. NCI, Urol Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. Transgenomic, Gaithersburg, MD USA. Armed Forces Inst Pathol, Dept Mol Pathol, Washington, DC 20306 USA. Novartis Pharmaceut, E Hanover, NJ USA. Oregon Hlth & Sci Univ, Inst Canc, Portland VA Med Ctr, Portland, OR USA. Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. RP Gotlib, J (reprint author), Stanford Canc Ctr, 875 Blake Wilbur Dr,Rm 2327B, Stanford, CA 94305 USA. EM jason.gotlib@stanford.edu RI Chen, Ching-Cheng/C-1259-2009 OI Chen, Ching-Cheng/0000-0003-4499-0889 FU NCI NIH HHS [CA-72074, CA66996]; NHLBI NIH HHS [K23HL04409]; NIAID NIH HHS [AI-23990, AI-41995]; NIDDK NIH HHS [DK50654] NR 29 TC 153 Z9 156 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD OCT 15 PY 2005 VL 106 IS 8 BP 2865 EP 2870 DI 10.1182/blood-2005-04-1568 PG 6 WC Hematology SC Hematology GA 972PP UT WOS:000232466000047 PM 15972446 ER PT J AU Rassovsky, Y Green, MF Nuechterlein, KH Breitmeyer, BG Mintz, J AF Rassovsky, Y Green, MF Nuechterlein, KH Breitmeyer, BG Mintz, J TI Visual processing in schizophrenia: Structural equation modeling of visual masking performance SO SCHIZOPHRENIA RESEARCH LA English DT Article DE visual masking; paracontrast; metacontrast; schizophrenia; neurocognition ID BACKWARD-MASKING; CHANNELS; METACONTRAST; PARACONTRAST; TRANSIENT; MECHANISM; DEFICITS; MANIA AB Schizophrenic patients consistently demonstrate performance deficits on visual masking procedures. In visual masking, the subject's ability to process a target stimulus is reduced by another stimulus (mask) presented either before (forward masking) or after (backward masking) the target. Masking procedures employed in schizophrenia research have used several experimental paradigms. Most early studies have used high-energy masks (i.e., the mask is stronger than the target) and spatially overlapping target and mask. More recently, studies have begun to employ relatively weak (i.e., low-energy) masks, as well as masks that surround, but do not spatially overlap, the target. Data for forward and backward masking components of four masking conditions (target location and identification with a high-energy mask, target identification with a low-energy mask, and target identification with equal energy paracontrast/metacontrast) were collected from 75 patients with schizophrenia. Based on theoretical distinctions among masking procedures, we compared four models of visual masking using structural equation modeling. Although high zero-order correlations were found among the masking parameters, a four-factor model, in which factors were separated on the type of response (target location and identification), the shape of the function (monotonic and nonmonotonic), and the overlap of the stimuli (overlapping and non-overlapping), provided the best fit for the data. These findings suggest that the four masking procedures used in this study may tap unique aspects of visual processing and are not redundant. The results also support theories of the different mechanisms underlying performance on these measures. (c) 2005 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Univ Houston, Dept Psychol, Houston, TX 77004 USA. RP Rassovsky, Y (reprint author), Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza C8-747-NPI, Los Angeles, CA 90024 USA. EM yurir@ucla.edu FU NIMH NIH HHS [MH-65707, MH-43292] NR 31 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT 15 PY 2005 VL 78 IS 2-3 BP 251 EP 260 DI 10.1016/j.schres.2005.05.011 PG 10 WC Psychiatry SC Psychiatry GA 968PI UT WOS:000232174100016 PM 15975768 ER PT J AU Switzer, GE Dew, MA Harrington, DJ Crowley-Matoka, M Myaskovsky, L Abress, L Confer, DL AF Switzer, GE Dew, MA Harrington, DJ Crowley-Matoka, M Myaskovsky, L Abress, L Confer, DL TI Ethnic differences in donation-related characteristics among potential hematopoietic stem cell donors SO TRANSPLANTATION LA English DT Article DE hematopoietic stem cell donation; ethnicity ID BONE-MARROW DONORS; TRANSPLANTATION; ATTRITION; RACE; WILLINGNESS; SELECTION; REGISTRY; ORGANS; STATE; CARE AB Background. Although the National Marrow Donor Program has been highly successful at recruiting ethnic minorities as potential hematopoietic stem cell donors, there have been no systematic investigations of whether donor characteristics that might be linked to the donation experience vary by ethnicity. Methods. Questionnaires assessing four domains-demographic, volunteer-related, general psychosocial, and donation-related-were mailed to potential donors after they were contacted as a preliminary match for a patient and had agreed to donate. in all, 1,679 potential donors completed and returned a predonation questionnaire. Data from potential donors belonging to five major ethnic groups were analyzed; white, black, Asian/Pacific Islander, Hispanic, and Native American. Results. Bivariate analyses indicated that virtually all factors in the four domains were associated with ethnicity. Direct discriminant function analysis identified three significant functions. The most striking of the three functions indicated that Asian Americans were more highly educated, more ambivalent (reluctant about donation), more concerned (medical, work/family), and more anxious and depressed than all other ethnic groups. Key differences among other ethnic group members were also identified. Conclusions. This study provides the first evidence of ethnic group differences in key predonation variables. Findings suggest that Asian/Pacific Islanders possess a number of characteristics that are known psychosocial risk factors for less positive postdonation outcomes and that more intensive pre and postdonation contact with this group may be necessary. Strategies for improving future research in this area are discussed. C1 Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA. Natl Marrow Donor Program, Minneapolis, MN USA. RP Switzer, GE (reprint author), Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Iroquois Bldg,Suite 502,3600 Forbes Ave, Pittsburgh, PA 15213 USA. EM SwitzerGE@upmc.edu FU NHLBI NIH HHS [R29-HL56901] NR 25 TC 13 Z9 13 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD OCT 15 PY 2005 VL 80 IS 7 BP 890 EP 896 DI 10.1097/01.TP.0000173648.60978.30 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 978YL UT WOS:000232908900003 PM 16249735 ER PT J AU Volpp, KG Konetzka, RT Zhu, JS Parsons, L Peterson, E AF Volpp, KG Konetzka, RT Zhu, JS Parsons, L Peterson, E CA National Registry Myocardial Infa TI Effect of cuts in medicare reimbursement on process and outcome of care for acute myocardial infarction patients SO CIRCULATION LA English DT Article DE delivery of health care; health policy; outcome assessment (health care) ID HOSPITAL CHARACTERISTICS; QUALITY; MORTALITY AB Background - The Balanced Budget Act ( BBA) of 1997 was designed to reduce Medicare reimbursements by $116.4 billion from 1998 to 2002. The objective of this study was to determine whether the process of care for acute myocardial infarction ( AMI) worsened to a greater degree in hospitals under increased financial strain from the BBA and whether vulnerable populations such as the uninsured were disproportionately affected. Methods and Results - We examined how process-of-care measures and in-hospital mortality for AMI patients changed in accordance with the degree of BBA-induced financial stress using data on 236 506 patients from the National Registry of Myocardial Infarction ( NRMI) and Medicare Cost Reports from 1996 to 2001. BBA-induced reductions in hospital net revenues were estimated at 1.5% ($2.9 million) for hospitals with low BBA impact and 3.2% ($ 3.7 million) for hospitals with a high impact in 1998, worsening to 2.2% ($ 4.4 million) and 4.7% ($6.0 million), respectively, by 2001. For both insured and uninsured patients in high-versus low-impact hospitals, there was no systematic worsening of time to thrombolytic therapy, balloon inflation, medication use on admission, medication use on discharge, or mortality. There was no systematic pattern of different treatment among the insured and uninsured. Operating margins decreased to a degree commensurate with the degree of revenue reduction in high-versus low-impact hospitals. Conclusions - BBA created a moderate financial strain on hospitals. However, process-of-care measures for both insured and uninsured patients with AMI were not appreciably affected by these revenue reductions. It is important to note that these results apply only to AMI patients; we do not know the degree to which these findings generalize to other conditions. C1 Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. Univ Chicago, Chicago, IL 60637 USA. Ovat Res Grp, Seattle, WA USA. Duke Univ, Durham, NC USA. RP Volpp, KG (reprint author), 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu NR 23 TC 32 Z9 32 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 11 PY 2005 VL 112 IS 15 BP 2268 EP 2275 DI 10.1161/CIRCULATIONAHA.105.534164 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 972SJ UT WOS:000232473200009 PM 16203913 ER PT J AU Li, G Shofer, JB Kukull, WA Peskind, ER Tsuang, DW Breitner, JCS McCormick, W Bowen, JD Teri, L Schellenberg, GD Larson, EB AF Li, G Shofer, JB Kukull, WA Peskind, ER Tsuang, DW Breitner, JCS McCormick, W Bowen, JD Teri, L Schellenberg, GD Larson, EB TI Serum cholesterol and risk of Alzheimer disease - A community-based cohort study SO NEUROLOGY LA English DT Article ID APOLIPOPROTEIN-E POLYMORPHISM; TRANSGENIC MOUSE MODEL; CORONARY HEART-DISEASE; VASCULAR DEMENTIA; LATE-LIFE; AMYLOID PATHOLOGY; CONTROLLED TRIAL; PLASMA-LIPIDS; LIPOPROTEINS; ALLELE AB Objectives: To examine the association of serum total cholesterol (TC) and high density lipoprotein (HDL) levels and subsequent incidence of dementia and Alzheimer disease (AD) in a population-based cohort study. Methods: A cohort of cognitively intact persons, aged 65 and older, was randomly selected from Group Health Cooperative (GHC), a large health maintenance organization, and was assessed biennially for dementia. Premorbid levels of TC and HDL were obtained from a computerized clinical laboratory database at GHC. Cox proportional hazards regression was used to calculate hazard ratios (HR, 95% CI) for dementia and AD associated with quartiles of TC and HDL levels. Results: Of the 2,356 eligible participants, 2,141 had at least one serum TC measure prior to the initial enrollment. Using the lowest TC quartiles as the reference group, the HR in the highest TC quartiles was not significantly elevated for dementia (1.16, 0.81 to 1.67) or for AD (1.00, 0.61 to 1.62) after adjusting for age, sex, education, baseline cognition, vascular comorbidities, body mass index, and lipid-lowering agent use. Serum HDL showed a similar lack of significant association with risk of dementia or AD. Models that included the presence of one or more APOE-epsilon 4 alleles showed a typical association of epsilon 4 with AD risk. This association was not materially modified by inclusion of TC level. Conclusion: The data do not support an association between serum total cholesterol or high density lipoprotein in late life and subsequent risk of dementia or Alzheimer disease (AD). The increased risk of AD with APOE-epsilon 4 is probably not mediated by serum total cholesterol levels. C1 VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Mental Illness Res & Educ Clin Ctr, Seattle, WA 98108 USA. Ctr Hlth Studies, Grp Hlth Cooperat, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA. Univ Washington, Dept Geriatr & Gerontol, Seattle, WA 98195 USA. RP Li, G (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way,Mailstop S-116 MIRECC, Seattle, WA 98108 USA. EM gli@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Kukull, Walter/0000-0001-8761-9014 FU NIA NIH HHS [AG05136, AG06781, AG16976, AG20020] NR 47 TC 77 Z9 80 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD OCT 11 PY 2005 VL 65 IS 7 BP 1045 EP 1050 DI 10.1212/01.wnl.0000178989.87072.11 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 972RF UT WOS:000232470200015 PM 16217057 ER PT J AU Blumberg, MS Seelke, AMH Lowen, SB Karlsson, KAE AF Blumberg, MS Seelke, AMH Lowen, SB Karlsson, KAE TI Dynamics of sleep-wake cyclicity in developing rats SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE atonia; renewal process; Markov process; development ID FRACTAL RENEWAL PROCESSES; INFANT RATS; REM-SLEEP; TRANSITIONS; ATONIA; ORGANIZATION; MODEL; EEG AB Adult mammals cycle between periods of sleep and wakefulness. Recent assessments of these cycles in humans and other mammals [Lo, C. C., Amaral, L. A. N., Havlin, S., Ivanov, P. Ch., Penzel, T., Peter, J.H. & Stanley, H. E. (2002) Europhys. Lett. 57,625-631 and Lo, C. C., Chou, T., Penzel, T., Scammell, T. E., Strecker, R. E., Stanley, H. E. & Ivanov, P. Ch. (2004) Proc. Natl. Acad. Sci. 101, 17545-17548] indicate that sleep bout durations exhibit an exponential distribution, whereas wake bout durations exhibit a power-law distribution. Moreover, it was found that wake bout distributions, but not sleep bout distributions, exhibit scale invariance across mammals of different body sizes. Here we test the generalizability of these findings by examining the distributions of sleep and wake bout durations in infant rats between 2 and 21 days of age. In agreement with Lo et al., we find that sleep bout durations exhibit exponential distributions at all ages examined. In contrast, however, wake bout durations also exhibit exponential distributions at the younger ages, with a clear power-law distribution only emerging at the older ages. Further analyses failed to find substantial evidence either of short- or long-term correlations in the data, thus suggesting that the durations of current sleep and wake bouts evolve through time without memory of the durations of preceding bouts. These findings further support the notion that bouts of sleep and wakefulness are regulated independently. Moreover, in light of recent evidence that developmental changes in sleep and wake bouts can be attributed in part to increasing forebrain influences, these findings suggest the possibility of identifying specific neural circuits that modulate the changing complexity of sleep and wake dynamics during development. C1 Univ Iowa, Dept Psychol, Program Behav & Cognit Neurosci, Iowa City, IA 52242 USA. Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, Belmont, MA 02478 USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Neurobiol Res Unit 15A3, North Hills, CA 94313 USA. RP Blumberg, MS (reprint author), Univ Iowa, Dept Psychol, Program Behav & Cognit Neurosci, E11 Seashore Hall, Iowa City, IA 52242 USA. EM mark-blumberg@uiowa.edu OI Blumberg, Mark/0000-0001-6969-2955 FU NIMH NIH HHS [K02 MH066424, MH66424, MH50701, R01 MH050701, R29 MH050701] NR 23 TC 78 Z9 79 U1 0 U2 6 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD OCT 11 PY 2005 VL 102 IS 41 BP 14860 EP 14864 DI 10.1073/pnas.0506340102 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 974PJ UT WOS:000232603600068 PM 16192355 ER PT J AU Szot, P White, SS Greenup, JL Leverenz, JB Peskind, ER Raskind, MA AF Szot, P White, SS Greenup, JL Leverenz, JB Peskind, ER Raskind, MA TI alpha(1)-Adrenoreceptor in human hippocarnpus: Binding and receptor subtype mRNA expression SO MOLECULAR BRAIN RESEARCH LA English DT Article DE norepinephrine; hippocampus; prazosin; alpha(1A)-adrenoreceptor; alpha(1D)-adrenoreceptor; in situ; receptor binding ID RAT-BRAIN; PHARMACOLOGICAL CHARACTERIZATION; ALPHA-1-ADRENERGIC RECEPTORS; ADRENERGIC-RECEPTOR; MOLECULAR-CLONING; CDNA; HIPPOCAMPUS; NOREPINEPHRINE; LOCALIZATION; SEQUENCE AB alpha(1)-Adrenoreceptors (AR), of which three subtypes exist (alpha(1A)-, alpha(1B)- and alpha(1D)-AR) are G-protein-coupled receptors that mediate the actions of norepinephrine and epinephrine both peripherally and centrally. In the CNS, alpha(1)-ARs are found in the hippocampus where animal studies have shown the ability of alpha(1)-AR agents to modulate long-term potentiation and memory; however, the precise distribution of alpha(1)-AR expression and its subtypes in the human brain is unknown making functional comparisons difficult. In the human hippocampus, 3 H-prazosin (a(1)-AR antagonist) labels only the dentate gyrus (molecular, granule and polymorphic layers) and the stratum lucidum of the CA3 homogenously. Human alpha(1A)-AR mRNA in the hippocampus is observed only in the dentate gyrus granule cell layer, while alpha(1D)-AR mRNA expression is observed only in the pyramidal cell layers of CA1, CA2 and CA3, regions where 3 H-prazosin did not bind. alpha(1B)-AR mRNA is not expressed at detectable levels in the human hippocampus. These results confirm a difference in hippocampal alpha(1)-AR localization between rat and humans and further describe a difference in the localization of the alpha(1A)- and alpha(1D)-AR mRNA subtype between rats and humans. Published by Elsevier B.V. C1 VA Puget Sound Hlth Care Syst, NW Network Mental Illness Res Educ & Clin Ctr S11, MIRECC S 116, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Szot, P (reprint author), VA Puget Sound Hlth Care Syst, NW Network Mental Illness Res Educ & Clin Ctr S11, MIRECC S 116, 1660 S Columbian Way, Seattle, WA 98108 USA. EM szot@u.washington.edu NR 27 TC 12 Z9 13 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-328X J9 MOL BRAIN RES JI Mol. Brain Res. PD OCT 3 PY 2005 VL 139 IS 2 BP 367 EP 371 DI 10.1016/j.molbrainres.2005.06.013 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 973IF UT WOS:000232515400021 ER PT J AU Yushkevich, P Dubb, A Xie, ZY Gur, R Gur, R Gee, J AF Yushkevich, P Dubb, A Xie, ZY Gur, R Gur, R Gee, J TI Regional structural characterization of the brain of schizophrenia patients SO ACADEMIC RADIOLOGY LA English DT Article DE brain atlases; registration; schizophrenia; brain morphology ID CHILDHOOD-ONSET SCHIZOPHRENIA; GRAY-MATTER; VOLUMETRIC-ANALYSIS; NEUROLEPTIC-NAIVE; WHITE-MATTER; SEGMENTATION; ADOLESCENCE; COMPETITION; HYPOTHESIS; CHILDREN AB Rationale and Objectives. We study morphologic characteristics and age-related changes in patients with schizophrenia to investigate whether abnormal neurodevelopment and brain structure have a role in the pathophysiological course of this disease. Materials and Methods. Our data consist of a set of cranial magnetic resonance images of 46 patients with schizophrenia and age- and sex-matched healthy controls. We deformed a template brain image to our set of subject images. Jacobian fields of these deformations were reduced to sets of 52 normalized region volumes for each subject by using a neuroanatornic atlas. Normalized regional volumes of the control and patient groups were compared by using Student t-test, and age correlation of each region volume was calculated for the two groups. All results were corrected for multiple comparisons by using permutation testing. We used a classifier based on support vector machines and a feature selection method to determine our ability to discriminate brains of controls from those of patients. Results. Analysis of normalized region volumes shows enlargement of the third ventricle in patients. The age-correlation study showed a significant positive correlation in the third ventricle and right thalamus of controls, but not patients. Using an average of 6.5 features, our classifier was able to correctly identify 72% of patients and 70% of controls. Conclusion. In addition to enlargement of the third ventricle, brains of patients with schizophrenia show a different pattern of age-related changes. C1 Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. VirtualScop LLC, Rochester, NY USA. RP Yushkevich, P (reprint author), Univ Penn, Dept Radiol, 3600 Market St,Suite 370, Philadelphia, PA 19104 USA. EM pauly2@grasp.upenn.edu OI Yushkevich, Paul/0000-0001-8543-4016 FU NCRR NIH HHS [M01RR0040]; NIA NIH HHS [AG-15116, AG-17586]; NIDA NIH HHS [DA-14418]; NIMH NIH HHS [MH-19112, MH-62100, MH60722]; NLM NIH HHS [LM-03504]; PHS HHS [P30-NNC] NR 58 TC 14 Z9 14 U1 0 U2 1 PU ASSOC UNIV RADIOLOGISTS PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523-2251 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD OCT PY 2005 VL 12 IS 10 BP 1250 EP 1261 DI 10.1016/j.acra.2005.06.014 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 967VR UT WOS:000232119800004 PM 16179202 ER PT J AU Backus, LI Boothroyd, D Deyton, LR AF Backus, LI Boothroyd, D Deyton, LR TI HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations SO AIDS LA English DT Article; Proceedings Paper CT Symposium on HIV/Hepatitis C Co-Infection - Impact on Nervous System Disease Burden CY OCT 02-03, 2003 CL Bethesda, MD SP NIH DE alcoholism; drug users; hepatitis C virus infection; HIV infection; psychiatry; risk factors ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; ALPHA-2A PLUS RIBAVIRIN; INTERFERON-ALPHA; INFECTED PATIENTS; NATURAL-HISTORY; LIVER FIBROSIS; CLINICAL-COURSE; PROGRESSION; MORTALITY AB Objective: To describe basic patient demographic and clinical characteristics of HIV-infected and HIV/hepatitis C virus (HCV)-co-infected patients receiving care in the Department of Veterans Affairs (VA) with a focus on some patient factors that place such patients at an increased risk of poor health outcomes. Design: An observational retrospective cohort study. Methods: The study cohort consisted of veterans in the VA Immunology Case Registry who received care in the VA in 2002. Results: Of 18 349 HIV-infected patients, 6782 (37.0%) were HCV seropositive. Compared with HIV-alone-infected patients, HIV/HCV-co-infected patients were older, more likely to be men, more likely to be black or Hispanic, and more likely to report intravenous drug use as a risk factor for HIV acquisition. HIV/HCV-co-infected patients were more likely to have diagnoses of mental health illness, depression, alcohol abuse, substance abuse and hard drug abuse compared with HIV-alone-infected patients. Co-infected patients were less likely to have a history of an AIDS opportunistic infection ever and were less likely to have received HIV antiretroviral drugs in 2002. Conclusion: The VA's HIV and HIV/HCV-co-infected patient populations have very high rates of additional comorbid conditions that complicate both the pharmacological therapy and clinical course of both HIV and HCV infections. Given the overlap in viral illness and comorbidities, optimal models of integrated care need to be developed for populations with HIV, HCV, and HIV/HCV co-infection and who need substance abuse treatment or mental healthcare. (c) 2005 Lippincott Williams & Wilkins C1 US Dept Vet Affairs, PHSHCG 13B, Washington, DC 20420 USA. US Dept Vet Affairs, Ctr Qual Management Publ Hlth, Palo Alto, CA USA. RP Deyton, LR (reprint author), US Dept Vet Affairs, PHSHCG 13B, 810 Vermont Ave NW, Washington, DC 20420 USA. EM dr.bopper.deyton@hq.med.va.gov NR 39 TC 41 Z9 42 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0269-9370 J9 AIDS JI Aids PD OCT PY 2005 VL 19 SU 3 BP S13 EP S19 DI 10.1097/01.aids.0000192065.09281.01 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 988DF UT WOS:000233570900004 PM 16251809 ER PT J AU Huckans, MS Blackwell, AD Harms, TA Indest, DW Hauser, P AF Huckans, MS Blackwell, AD Harms, TA Indest, DW Hauser, P TI Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection SO AIDS LA English DT Article; Proceedings Paper CT Symposium on HIV/Hepatitis C Co-Infection - Impact on Nervous System Disease Burden CY OCT 02-03, 2003 CL Bethesda, MD SP NIH DE comorbidity; hepatitis C; HIV; literature review; mental disorders; prevalence; substance-related disorders ID SEVERE MENTAL-ILLNESS; HUMAN-IMMUNODEFICIENCY; VETERANS; PREVALENCE; SERVICES; HEALTH; DEPRESSION; HIV/AIDS; AIDS AB Objectives: To examine hepatitis C virus (HCV) and HIV testing patterns within the Northwest Veterans Integrated Service Network (VISN 20). Methods: Using a comprehensive VISN 20 database, we retrospectively reviewed medical records of 293 445 veterans. Results: 32.8% of patients were tested for HCV, 5.5% were tested for HIV, and 4.3% were co-tested. Of those tested, 12.3% were HCV positive, 5.4% were HIV positive, and 1.6% were co-infected. 79.1 % of HIV-positive patients were tested for HCV, 29.2% of whom tested positive. 34.8% of HCV-positive patients were tested for HIV, 4.9% of whom tested positive. Of those tested, HCV-positive patients were significantly more likely than HCV-negative patients to test positive for HIV; HIV-positive patients were no more likely to test positive for HCV than HIV-negative patients. HIV-positive patients with substance use disorders (SUD) were significantly more likely to test HCV positive than those without. Within the total sample, veterans with SUD were significantly more likely to be tested for both diseases and to test positive for HCV but not HIV. After controlling for other categories of SUD, veterans with a history of cocaine abuse compared with those without were at an increased risk of HIV infection and co-infection. Conclusion: 79.1 % of HIV-positive but only 34.8% of HCV-positive veterans were cotested, suggesting barriers to HIV testing may exist in VISN 20. Results also indicate that HCV-positive patients are at increased risk for HIV infection and that HIV-positive patients with SUD are at increased risk of HCV infection; routine co-testing for these patients is therefore warranted. Given significant co-infection rates, HCV and HIV screening and testing should be increasingly integrated. Increased infection rates among patients with SUD also warrant integration of HCV and HIV screening and testing into mental health and addiction programmes. (c) 2005 Lippincott Williams & Wilkins. C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, JENS Lab, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR USA. Univ Oregon, Dept Anthropol, Eugene, OR USA. RP Hauser, P (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM peter.hauser2@med.va.gov RI Blackwell, Aaron/B-5258-2008 OI Blackwell, Aaron/0000-0002-5871-9865 NR 26 TC 20 Z9 20 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0269-9370 J9 AIDS JI Aids PD OCT PY 2005 VL 19 SU 3 BP S106 EP S115 DI 10.1097/01.aids.0000192078.49185.b0 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 988DF UT WOS:000233570900017 PM 16251805 ER PT J AU Peskind, ER Riekse, R Quinn, JF Kaye, J Clark, CM Farlow, MR DeCarli, C Chabal, C Vavrek, D Raskind, MA Galasko, D AF Peskind, ER Riekse, R Quinn, JF Kaye, J Clark, CM Farlow, MR DeCarli, C Chabal, C Vavrek, D Raskind, MA Galasko, D TI Safety and acceptability of the research lumbar puncture SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; lumbar puncture; post lumbar-puncture headache ID TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; SPINAL NEEDLES; ALZHEIMERS-DISEASE; AMERICAN-ACADEMY; CLINICAL-TRIAL; DOUBLE-BLIND; HEADACHE; THERAPEUTICS; PREVENTION; NEUROLOGY AB Three hundred forty-two Subjects underwent 428 research lumbar punctures for Studies of cerebrospinal fluid (CSF) biomarkers. Subjects were 67 Alzheimer disease or mild cognitive impairment (AD/MCI) patients and 275 cognitively normal adults aged 21 to 88. Lumbar puncture was performed in the lateral decubitus or sitting position using the Sprotte 24g atraumatic spinal needle. Up to 34 ill] of cerebrospinal fluid were collected. Anxiety and pain experienced during lumbar puncture were rated on a visual analog scale. The frequency of any adverse event (11.7%), clinically significant adverse events (3.97%), and typical Post-lumbar puncture headache (PLPHA) (0.93%) was low. Risk of post-lumbar puncture headache was un-related to age, gender, position during lumbar puncture, till of cerebrospinal fluid collected, or minutes of recumbent rest following lumbar puncture. The frequency of post-lumbar puncture headache was lower in AD/MCI (P = 0.03) than any other subject group. Anxiety and pain ratings were low, Younger subjects reported more anxiety than old (P = 0.001) and AD/MCI subjects (P = 0.008) and more pain than older normal subjects (P = 0.013). Pain ratings for women were higher than those for men (P = 0.006). Using the Sprotte 24g spinal needle, research lumbar puncture can be performed with a very low rate of clinically significant adverse events and with good acceptability in cognitively impaired persons and cognitively normal adults Of all ages. C1 Univ Washington, Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, MIRECC,Sch Med, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Univ Penn, Inst Aging, Dept Neurol, Philadelphia, PA 19104 USA. Portland VA Med Ctr, Portland, OR USA. Indiana Univ, Dept Neurol, Sch Med, Indianapolis, IN USA. Univ Calif Davis, Dept Neurol, Sacramento, CA 95616 USA. Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA. Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. VA Med Ctr, San Diego, CA USA. RP Peskind, ER (reprint author), Univ Washington, Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, MIRECC,Sch Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM peskind@u.washington.edu RI DeCarli, Charles/B-5541-2009 OI Kaye, Jeffrey/0000-0002-9971-3478 FU NCRR NIH HHS [M01 RR00034]; NIA NIH HHS [AG010133, AG023185, AG05136, AG08419, AG10124] NR 21 TC 99 Z9 99 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2005 VL 19 IS 4 BP 220 EP 225 DI 10.1097/01.wad.0000194014.43575.fd PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 993ZD UT WOS:000233998000008 PM 16327349 ER PT J AU Spertus, J Peterson, E Conard, MW Heidenreich, PA Krumholz, HM Jones, P McCullough, PA Pina, I Tooley, J Weintraub, WS Rumsfeld, JS AF Spertus, J Peterson, E Conard, MW Heidenreich, PA Krumholz, HM Jones, P McCullough, PA Pina, I Tooley, J Weintraub, WS Rumsfeld, JS CA Cardiovascular Outcomes Res Consor TI Monitoring clinical changes in patients with heart failure: A comparison of methods SO AMERICAN HEART JOURNAL LA English DT Article ID QUALITY-OF-LIFE; DISEASE MANAGEMENT; HEALTH-STATUS; NATRIURETIC PEPTIDE; QUESTIONNAIRE; READMISSION; RELIABILITY; EFFICACY; VALIDITY; OUTCOMES AB Background Although monitoring the clinical status of patients with heart failure rests at the core of clinical medicine, the ability of different techniques to reflect clinical change has not been evaluated. This study sought to describe changes in various measures of disease status associated with gradations of clinical change. Methods A prospective, 14-center cohort of 476 outpatients was assessed at baseline and 6 +/- 2 weeks to compare changes in 7 heart failure measures with clinically observed change. Measures included health status instruments (the Kansas City Cardiomyopathy Questionnaire [KCCQ], Short Form-12, and EQ-5D), physician-assessed functional class (New York Heart Association [NYHA]), an exercise test (6-minute walk), patient weight, and a biomarker (B-type natriuretic peptide). Cardiologists, blinded to all measures except weight and NYHA, categorized clinical change ranging from large deterioration to large improvement. Results The KCCQ, NYHA, and 6-minute walk test were most sensitive to clinical change. For patients with large, moderate, and small deteriorations, the KCCQ decreased by 25 +/- 16, 17 +/- 14, and 5.3 +/- 11 points, respectively. For patients with small, moderate, and large improvements, the KCCQ increased by 5.7 +/- 16, 10.5 +/- 16, and 22.3 +/- 16 points, respectively (P <.01 for all compared with the no change group). New York Heart Association and 6-minute walk distance were significantly different for those with moderate and large changes ( P <.05) but neither revealed a difference between those with small versus no clinical deterioration. The KCCQ had the highest c statistic for monitoring individual patients, followed by NYHA and 6-minute walk. Conclusion The KCCQ, followed by the NYHA and the 6-minute walk test, most accurately reflected clinical change in patients with heart failure. C1 St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Univ Missouri, Kansas City, MO 64110 USA. Pharmacia Inc, Chicago, IL USA. Yale Univ, New Haven, CT USA. Denver VA Med Ctr, Denver, CO USA. Palo Alto VA Med Ctr, Palo Alto, CA USA. Duke Univ, Med Ctr, Durham, NC USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. Emory Univ, Atlanta, GA 30322 USA. RP Spertus, J (reprint author), 4401 Wornall Rd, Kansas City, MO 64111 USA. EM spertusj@umkc.edu OI Heidenreich, Paul/0000-0001-7730-8490 NR 26 TC 154 Z9 156 U1 0 U2 6 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD OCT PY 2005 VL 150 IS 4 BP 707 EP 715 DI 10.1016/j.ahj.2004.12.010 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 979NY UT WOS:000232953300016 PM 16209970 ER PT J AU Visnegarwala, F Raghavan, SS Mullin, CM Bartsch, G Wang, J Kotler, D Gibert, CL Shlay, J Grunfeld, C Carr, A El-Sadr, W AF Visnegarwala, F Raghavan, SS Mullin, CM Bartsch, G Wang, J Kotler, D Gibert, CL Shlay, J Grunfeld, C Carr, A El-Sadr, W CA Terry Beirn Community Program TI Sex differences in the associations of HIV disease characteristics and body composition in anti retroviral-naive persons SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE HIV infection; antiretroviral-naive patients; sex differences; body composition; anthropometric analysis; bioelectrical impedance ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENERGY-EXPENDITURE; FAT DISTRIBUTION; INFECTED WOMEN; WEIGHT-LOSS; MASS INDEX; ANTIRETROVIRAL THERAPY; IMPEDANCE ANALYSIS; RACIAL-DIFFERENCES; ADIPOSE-TISSUE AB Background: Data on associations of body composition with HIV disease characteristics are limited. Objective: We compared sex-specific associations between HIV disease characteristics and body composition in an racially-ethnically diverse cohort of antiretroviral-naive patients. Design: The study was a cross-sectional analysis of participants enrolled in a metabolic substudy of a multicenter trial. Regional fat was measured, and total body fat (TBF) was derived by using the Durnin-Womersley formula (DWF) and bioelectrical impedance analysis (BIA). Body cell mass (BCM) was measured by BIA. Results: Among 422 participants, 22% were women, 60% were African American, and 36% had prior AIDS-defining illnesses. Mean (+/- SD) age was 38.2 +/- 9.6 y, CD4(+) count was 215 184 cellS/mm(3), and HIV RNA log(10) was 5.0 +/- 0.8 copies/mL. On multivariate analysis, women with AIDS-defining illness had significantly (P < 0.005) lower regional body fat and TBF (BIA: - 9.5 kg; DWF: -7.3 kg) but nonsignificantly lower BCM (- 1.3 kg) than did women without such illnesses, whereas men with AIDS-defining illness had significantly (P < 0.005) lower BCM (- 1.7 kg) but nonsignificantly lower TBF (BIA: - 1.3 kg; DWF: - 1.83 kg) than did men without such illnesses (P < 0.05 for sex differences in TBF). Significant negative associations of HIV RNA with BCM (-0.9 kg/log RNA; P = 0.03), TBF by BIA (- 1.4 kg/log RNA; P = 0.05) and by DWF (- 1.6 kg/log RNA; P = 0.01), and regional fat were observed in men only. Conclusions: The effect of prior AIDS illness on body fat differed significantly between the sexes: women with prior AIDS-defining illness had significantly less fat than did women without such illnesses. An independent effect of HIV viremia on BCM and fat was seen in men. These distinctions may be due to inherent biological differences between the sexes. C1 Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA. HART, Houston, TX USA. Harlem Hosp Med Ctr, New York, NY USA. Columbia Univ, New York, NY 10027 USA. Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA. Columbia Univ, St Lukes Roosevelt Hosp, Body Composit Unit, New York, NY 10027 USA. George Washington Univ, Washington, DC 20052 USA. Vet Affairs Med Ctr, Washington, DC 20422 USA. Denver Community Program Clin Res AIDS, Denver, CO USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. St Vincents Hosp, Sydney, NSW 2010, Australia. RP Visnegarwala, F (reprint author), Baylor Coll Med, Infect Dis Sect, Dept Med, 1 Baylor Plaza,BCM 465 EC, Houston, TX 77030 USA. EM fehmidav@bcm.tmc.edu FU PHS HHS [5U0146362-03, 5U0142170-1] NR 48 TC 19 Z9 20 U1 0 U2 0 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2005 VL 82 IS 4 BP 850 EP 856 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 973CN UT WOS:000232500600020 PM 16210716 ER PT J AU Fong, D Shen, P AF Fong, D Shen, P TI Temporal pattern of mean corpuscular volume as putative evidence for thalassemia SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Clinical-Pathology CY OCT 08-11, 2005 CL Seattle, WA SP Amer Soc Clin Pathol C1 Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Dept Pathol & Lab Med, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD OCT PY 2005 VL 124 IS 4 MA 048 BP 641 EP 642 PG 2 WC Pathology SC Pathology GA 966RD UT WOS:000232037700070 ER PT J AU Fong, D Shen, P AF Fong, D Shen, P TI Erythrocytosis is frequent in adult iron deficiency anemia SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Clinical-Pathology CY OCT 08-11, 2005 CL Seattle, WA SP Amer Soc Clin Pathol C1 Univ Colorado, Sch Med, Denver, CO 80202 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD OCT PY 2005 VL 124 IS 4 MA 060 BP 646 EP 646 PG 1 WC Pathology SC Pathology GA 966RD UT WOS:000232037700082 ER PT J AU El-Serag, HB Kvapil, P Hacken-Bitar, J Kramer, JR AF El-Serag, HB Kvapil, P Hacken-Bitar, J Kramer, JR TI Abdominal obesity and the risk of Barrett's esophagus SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID GASTROESOPHAGEAL-REFLUX SYMPTOMS; BODY-FAT DISTRIBUTION; WAIST-HIP RATIO; COMPUTED-TOMOGRAPHY; GASTRIC CARDIA; UNITED-STATES; MASS INDEX; ADENOCARCINOMA; DISEASE; WOMEN AB BACKGROUND: The association between overweight/obesity and the risk of Barrett's esophagus (BE) is unclear. Further, the association between body fat distribution and the risk of BE is unknown. METHODS: We conducted a retrospective case-control study in patients who underwent endoscopy at a single large VA Medical Center between 2000 and 2003. Cases were patients with documented BE who had an abdominal CT scan within 1 yr of the endoscopy, whereas controls were patients without BE (with or without erosive esophagitis) who also had an abdominal CT scan. The surface areas of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were calculated from CT scan images at level of intervertebral disc between L4 and L5, and body mass index (BMI) in kg/m(2) at the time of endoscopy was also recorded. Cases and controls were compared in univariate and multivariable analyses. RESULTS: We identified 36 cases and 93 controls. There were no significant differences between cases and controls in age (mean 63 yr), gender (98% men), or race (71% white Caucasian). BMI was significantly greater in cases than controls (27 vs 24; p= 0.006). BMI > 30 kg/m(2) was associated with a greater risk of BE than lower BMI (odds ratio 4.0; 95% CI: 1.4-11.1, p= 0.008). VAT was approximately 1.5-fold greater in cases than controls (183 vs 115 cm(2); p < 0.0001), whereas SAT was less different (248 vs 200 cm(2); p= 0.03). We estimated that each 10-cm(2) increase in VAT was associated with 9% increase in risk of BE. Interestingly, VAT remained independently associated with BE in the model that adjusted for BMI, and in that model, BMI was not significantly associated with BE. CONCLUSIONS: Obesity seems to be associated with an increased risk of BE. Abdominal visceral adiposity might mediate most of this risk. C1 Houston Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. Houston Dept Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. Houston Dept Vet Affairs Med Ctr, Dept Radiol, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 37 TC 133 Z9 137 U1 1 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2005 VL 100 IS 10 BP 2151 EP 2156 DI 10.1111/j.1572-0241.2005.00251.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 965KX UT WOS:000231950500004 PM 16181362 ER PT J AU Cheung, RC Currie, S Shen, H Ho, SB Bini, EJ Anand, BS Brau, N Wright, TL AF Cheung, RC Currie, S Shen, H Ho, SB Bini, EJ Anand, BS Brau, N Wright, TL CA VA HCV-001 Study Grp TI Chronic hepatitis C in Latinos: Natural history, treatment eligibility, acceptance, and outcomes SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID VIRUS-INFECTION; RACIAL-DIFFERENCES; UNITED-STATES; VETERANS; THERAPY; RIBAVIRIN; INTERFERON; PREVALENCE AB OBJECTIVES: The natural history of chronic hepatitis C and treatment response are different between blacks and Caucasians, but little comparable data is available about Latinos. METHODS: A cross-sectional secondary analysis to investigate differences between 421 anti-HCV-positive, treatment-naive, HCV-viremic Latinos and 2,510 Caucasians in 24 VA medical centers enrolled in a prospective study. RESULTS: Latinos were infected at a younger age and were less likely to have blood contact during combat, surgery, and needle stick injury, but were more frequently HIV coinfected (20.4%vs 3.9%, p < 0.0001) and prior HAV infection (39.9%vs 26.4%, p= 0.0001). Latinos were more likely to be treatment candidates, but less likely to actually initiate treatment. Liver histology (123 Latinos, 743 Caucasians) showed no difference in fibrosis or fibrosis rate, but steatosis (54.7%vs 43.2%, p= 0.038) was more common in Latinos. Eighty-eight Latinos and 481 Caucasians were subsequently treated with interferon-ribavirin: body mass index (BMI), duration of infection, baseline tests, liver histology and genotype distribution were similar. Compared with Caucasians, Latinos discontinued treatment prematurely more often (39.8%vs 28.9%, p= 0.043) and tended to have lower sustained virological response (SVR) rates (14.8%vs 22.5%, p= 0.10). Multivariate analysis found Latino race and history of recent alcohol use to be associated with early treatment discontinuation, whereas genotype and viral load but not ethnicity to be associated with SVR. CONCLUSIONS: Latinos were infected younger, more frequently HIV coinfected, more likely to meet criteria for antiviral therapy yet less likely to initiate treatment and had a trend toward lower SVR rates than Caucasians, but not in severity of liver disease. Latino ethnicity was associated with early discontinuation but not as an independent predictor of SVR. C1 VA Palo Alto HCS, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. VA Med Ctr, San Francisco, CA USA. VA Med Ctr, Minneapolis, MN USA. VA Med Ctr, New York, NY USA. VA Med Ctr, Houston, TX USA. VA Med Ctr, Bronx, NY USA. RP Cheung, RC (reprint author), VA Palo Alto HCS, Div Gastroenterol & Hepatol, 154C,3801 Miranda Ave, Palo Alto, CA 94304 USA. NR 22 TC 51 Z9 51 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2005 VL 100 IS 10 BP 2186 EP 2193 DI 10.1111/j.1572-0241.2005.00240.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 965KX UT WOS:000231950500009 PM 16181367 ER PT J AU Auslander, JN Lieberman, DA Sonnenberg, A AF Auslander, JN Lieberman, DA Sonnenberg, A TI Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; HOSPITAL ADMISSIONS; COLORECTAL-CANCER; UNITED-STATES; EXACERBATIONS; PERIODICITY; COLONOSCOPY; MORTALITY; SCOTLAND; RELAPSE AB BACKGROUND: Conflicting data have been reported about the seasonal variation of inflammatory bowel diseases (IBD). The purpose of the present analysis was to assess the occurrence of seasonal variations in the endoscopic diagnosis of Crohn's disease (CD) and ulcerative colitis (UC). METHODS: The Clinical Outcomes Research Initiative (CORI) uses a computerized endoscopic report generator to collect endoscopic data from 73 diverse practice sites throughout the United States. We utilized the CORI database to analyze the date-specific occurrence of colonoscopy, as well as the colonoscopic diagnoses of CD and UC. Time trends were analyzed by autocorrelation, linear, and nonlinear regression. RESULTS: Between January 2000 and December 2003, the number of colonoscopies increased 4.1-fold. The proportion of colonoscopies with a CD diagnosis fell by 28%, and the proportion of colonoscopies with a UC diagnosis fell by 50%. The occurrence of neither CD nor UC was shaped by any clear-cut seasonal periodicity. However, the trends of the two diseases revealed strikingly similar patterns with four resembling peaks superimposed on their monthly fluctuations. CONCLUSIONS: Endoscopic diagnosis of IBD is unaffected by any seasonal variation. The decline in the diagnostic rate of colonic IBD may reflect a relative increase in the utilization of colonoscopy for colon cancer screening. The similarity in the monthly fluctuations of both IBD suggests that their incidence or flare-ups may be influenced by identical exogenous risk factors. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. FU NIDDK NIH HHS [2-U01-DK057132-06A1, 5-R33-DK061778-03] NR 29 TC 17 Z9 17 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2005 VL 100 IS 10 BP 2233 EP 2238 DI 10.1111/j.1572-0241.2005.50127.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 965KX UT WOS:000231950500017 PM 16181375 ER PT J AU Spiegel, BMR Kanwal, F Naliboff, B Mayer, E AF Spiegel, BMR Kanwal, F Naliboff, B Mayer, E TI The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID QUALITY-OF-LIFE; SOMATIC SYMPTOMS; DISORDERS; COSTS; WOMEN AB BACKGROUND: It is unclear why patients with irritable bowel syndrome (IBS) consume a disproportionate amount of health-care resources versus matched controls. One possibility is the presence of comorbid somatization-a process marked by multiple unexplained somatic complaints that is highly prevalent in IBS. We sought to determine whether higher levels of somatization are associated with higher levels of gastrointestinal (GI) resource utilization in IBS. METHODS: A total of 1,410 patients > 18 yr with IBS were evaluated at a university-based clinic. Subjects completed a symptom questionnaire, the SCL-90R psychometric checklist, and the SF-36 Health Survey. We measured two outcomes: (1) a 1-yr direct GI health-care costs and (2) a 1-yr number of GI physician visits. Our primary regressor was somatization as measured by the somatization subscale of the SCL-90R. We performed regression analyses to measure the adjusted influence of somatization on GI resource utilization. RESULTS: In the full sample of patients, there were no differences in the likelihood of expending versus not expending previous GI health-care costs among groups with varying levels of somatization. Similarly, there were no differences in either the likelihood of visiting a GI physician or the number of overall physician visits among patients with varying levels of somatization. However, in the subset of patients expending at least $1.00 in GI costs in the previous year (53% of cohort), there was a significantly higher cost of care for subjects with high versus low levels of somatization. CONCLUSIONS: IBS patients with high levels of somatization are not more likely to seek GI care compared to patients with low levels of somatization. However, once they are evaluated for care, patients with high somatization expend significantly more GI health-care costs. This suggests that somatization is positively associated with health-care costs in IBS, and that the association may be driven more by physicians than patients. C1 VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90073 USA. Ctr Study Digest Healthcare Qual & Outcome, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215E, Los Angeles, CA 90073 USA. FU NCCIH NIH HHS [1 R24 AT002681]; NIDDK NIH HHS [P50 DK-64539, R01 DK-07768, R01 DK-48351] NR 33 TC 36 Z9 37 U1 5 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2005 VL 100 IS 10 BP 2262 EP 2273 DI 10.1111/j.1572-0241.2005.00269.x PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 965KX UT WOS:000231950500021 PM 16181379 ER PT J AU Weintraub, D Stern, MB AF Weintraub, D Stern, MB TI Psychiatric complications in Parkinson disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Review ID DRUG-INDUCED PSYCHOSIS; PLACEBO-CONTROLLED TRIAL; NURSING-HOME PLACEMENT; COGNITIVE IMPAIRMENT; RISK-FACTORS; LEWY BODIES; VISUAL HALLUCINATIONS; ALZHEIMERS-DISEASE; DEPRESSION; DEMENTIA AB Although Parkinson disease (PD) is primarily considered a movement disorder, the high prevalence of psychiatric complications suggests that it is more accurately conceptualized as a neuropsychiatric disease. Affective disorders, cognitive impairment, and psychosis are particularly common in PD and are associated with excess disability, worse quality of life, poorer outcomes, and caregiver distress. Yet, in spite of this and their frequent occurrence, there is incomplete understanding of the epidemiology, phenomenology, risk factors, neuropathophysiology, and optimal treatment strategies for these disorders, Psychiatric complications are typically comorbid, and there is great intra- and inter-individual variability in presentation. The hallmark neuropathophysiological changes that occur in PD plus the association between exposure to dopaminergic medications and certain psychiatric disorders suggest a neurobiological basis for most psychiatric symptoms, although psychological factors are probably involved in the development of affective disorders. Although antidepressants, antipsychotics, and cognition-enhancing agents are commonly prescribed in PD, controlled studies demonstrating efficacy and tolerability of these drugs are virtually nonexistent, Because of the high prevalence and complexity of psychiatric complications in PD, geriatric psychiatrists are in a position to offer valuable consultation and clinical care to this population. This article provides an overview of the epidemiology, pathophysiology, clinical presentation, and management of the most common psychiatric complications in PD. C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, PADRECC, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3535 Market St,Room 3003, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU NIMH NIH HHS [K23MH067894] NR 78 TC 72 Z9 74 U1 0 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD OCT PY 2005 VL 13 IS 10 BP 844 EP 851 DI 10.1176/appi.ajgp.13.10.844 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 972TK UT WOS:000232475900003 PM 16223962 ER PT J AU Newsome, BB Warnock, DG Kiefe, CI Weissman, NW Houston, TK Centor, RM Person, SD McClellan, WM Allison, JJ AF Newsome, BB Warnock, DG Kiefe, CI Weissman, NW Houston, TK Centor, RM Person, SD McClellan, WM Allison, JJ TI Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE kidney; reperfusion; coronary disease ID ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; ACUTE CORONARY SYNDROMES; STAGE RENAL-DISEASE; QUALITY-OF-CARE; ELDERLY-PATIENTS; INSUFFICIENCY; OUTCOMES; THERAPY; ANGIOPLASTY AB Background Patients with kidney disease and acute myocardial infarction (AMI) receive standard therapy, including thrombolytic medication, less frequently than patients with normal kidney function. Our goal is to identify potential differences in thrombolytic medication delays and thrombolytic-associated bleeding events by severity of kidney disease. Methods: This is a retrospective cohort analysis of Cooperative Cardiovascular Project data for all Medicare patients with AMI from 4,601 hospitals. Outcome measures included time to administration of thrombolytic medication censored at 6 hours and bleeding events. Results. Of 109,169 patients (mean age, 77.4 years; 50.6% women), 13.9% received thrombolysis therapy. Average time to thrombolytic therapy was longer in patients with worse kidney function. Adjusted hazard ratios for minutes to thrombolytic therapy were 0.83 (95% confidence interval [CI], 0.79 to 0.87) for patients with a serum creatinine level of 1.6 to 2.0 mg/dL (141 to 177 mu mol/L) and 0.58 (95% Cl, 0.53 to 0.63) for patients with a creatinine level greater than 2.0 mg/dL (>177 mu mol/L) or on dialysis therapy compared with those with normal kidney function. Odds ratios for bleeding events in patients administered thrombolytics versus those who were not decreased with worse kidney function: adjusted odds ratios, 2.28 (95% Cl, 2.16 to 2.42) in patients with normal kidney function and 1.84 (95% Cl, 1.09 to 3.10) in dialysis patients. Conclusion: Patients with worse kidney function experienced treatment delays, but were not at greater risk for thrombolysis-associated excess bleeding events. Physician concerns of thrombolytic-associated bleeding may not be sufficient reason to delay the administration of thrombolytic medication. C1 Ctr Outcomes & Effectiveness Res & Educ, Dept Med, Div Nephrol, Birmingham, AL USA. Ctr Outcomes & Effectiveness Res & Educ, Dept Med, Div Prevent Med, Birmingham, AL USA. Ctr Outcomes & Effectiveness Res & Educ, Div Gen Internal Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Dept Med, Div Prevent Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Dept Med, Div Gen Internal Med, Birmingham, AL USA. Dept Hlth Serv Adm, Birmingham, AL USA. Univ Alabama Birmingham, Birmingham, AL USA. Georgia Med Care Fdn, Atlanta, GA USA. Emory Univ, Sch Med, Dept Med, Div Renal, Atlanta, GA USA. RP Newsome, BB (reprint author), 1530 3rd Ave S,MT 401E2, Birmingham, AL 35294 USA. EM bnewsome@uab.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 FU AHRQ HHS [T32 HS013852]; NHLBI NIH HHS [R01 HL70786]; None [HS013852] NR 30 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2005 VL 46 IS 4 BP 595 EP 602 DI 10.1053/j.ajkd.2005.06.008 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 993DQ UT WOS:000233933300004 PM 16183413 ER PT J AU Henderson, MC Meyers, FJ Tierney, LM AF Henderson, MC Meyers, FJ Tierney, LM TI Confronting the brutal facts in health care SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material ID MEDICINE; FUTURE C1 Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. Alliance Acad Internal Med, Washington, DC USA. US Dept Vet Affairs, Med Ctr, San Francisco, CA USA. RP Henderson, MC (reprint author), Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. NR 32 TC 6 Z9 6 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD OCT PY 2005 VL 118 IS 10 BP 1061 EP 1063 DI 10.1016/j.amjmed.2005.08.003 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 972SA UT WOS:000232472300001 PM 16194632 ER PT J AU Hull, RL Watts, MR Kodama, K Shen, ZP Utzschneider, KM Carr, DB Vidal, J Kahn, SE AF Hull, RL Watts, MR Kodama, K Shen, ZP Utzschneider, KM Carr, DB Vidal, J Kahn, SE TI Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE islet amyloid; islet amyloid polypeptide; genetic background; beta-cell mass; beta-cell dysfunction; insulin secretion ID DIABETES-MELLITUS; GLUCOSE-TOLERANCE; MOUSE MODEL; JAPANESE-AMERICANS; INSULIN-RESISTANCE; AMYLIN RELEASE; C57BL/6J MICE; PIMA-INDIANS; EXPRESSION; CELLS AB Genetic background is important in determining susceptibility to metabolic abnormalities such as insulin resistance and beta-cell dysfunction. Islet amyloid is associated with reduced beta-cell mass and function and develops in the majority of our C57BL/6J x DBA/2J (F-1) male human islet amyloid polypeptide (hIAPP) transgenic mice after 1 yr of increased fat feeding. To determine the relative contribution of each parental strain, C57BL/6J (BL6) and DBA/2J (DBA2), to islet amyloid formation, we studied male hIAPP mice on each background strain (BL6, n = 13; and DBA2 n = 11) and C57BL/6J x DBA/2J F-1 mice (n = 17) on a 9% (wt/wt) fat diet for 1 yr. At the end of 12 mo, islet amyloid deposition was quantified from thioflavin S-stained pancreas sections. The majority of mice in all groups developed islet amyloid (BL6: 91%, F-1: 76%, DBA2: 100%). However, the prevalence (% amyloid-positive islets; BL6: 14 +/- 3%, F-1: 44 +/- 8%, DBA2: 49 +/- 9%, P < 0.05) and severity (% islet area occupied by amyloid; BL6: 0.03 +/- 0.01%, F-1: 9.2 +/- 2.9%, DBA2: 5.7 +/- 2.3%, p <= 0.01) were significantly lower in BL6 than F1 and DBA2 mice. Increased islet amyloid severity was negatively correlated with insulin-positive area per islet, in F-1 (r(2) = 0.75, P < 0.001) and DBA2 (r(2) = 0.87, P < 0.001) mice but not BL6 mice (r(2) = 0.07). In summary, the extent of islet amyloid formation in hIAPP transgenic mice is determined by background strain, with mice expressing DBA/2J genes ( F1 and DBA2 mice) being more susceptible to amyloid deposition that replaces beta-cell mass. These findings underscore the importance of genetic and environmental factors in studying metabolic disease. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Dept Obstet & Gynecol, Div Maternal Fetal Med, Seattle, WA 98195 USA. RP Hull, RL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM rhull@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU NCRR NIH HHS [RR-06066]; NHLBI NIH HHS [HL-07028]; NIDDK NIH HHS [DK-17047, DK-50703] NR 45 TC 8 Z9 8 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD OCT PY 2005 VL 289 IS 4 BP E703 EP E709 DI 10.1152/ajpendo.00471.2004 PG 7 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 962MV UT WOS:000231737800024 PM 15899941 ER PT J AU Nareika, A He, L Game, BA Slate, EH Sanders, JJ London, SD Lopes-Virella, MF Huang, Y AF Nareika, A He, L Game, BA Slate, EH Sanders, JJ London, SD Lopes-Virella, MF Huang, Y TI Sodium lactate increases LPS-stimulated MMP and cytokine expression in U937 histiocytes by enhancing AP-1 and NF-kappa B transcriptional activities SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE diabetes mellitus; lactate; lipopolysaccharide; matrix metalloproteinases; nuclear factor-kappa B; activating protein-1; cytokines ID ACTIVATED PROTEIN-KINASES; C-REACTIVE PROTEIN; INSULIN-RESISTANCE; DIABETES-MELLITUS; ATHEROSCLEROSIS RISK; GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; INFLAMMATION; MACROPHAGES AB The plasma lactate concentration in patients with obesity and type 2 diabetes is often higher than that in nondiabetic individuals. Although it is known that increased lactate concentration is an independent risk factor for developing type 2 diabetes, the underlying mechanisms are not well understood. Because inflammation plays an important role in the development of type 2 diabetes, we postulated that increased lactate level might contribute to the pathogenesis of type 2 diabetes by enhancing inflammation. In the present study, we demonstrated that preexposure of U937 macrophage-like cells to sodium lactate increased LPS-stimulated matrix metalloproteinase (MMP)-1, IL-1 beta, and IL-6 secretion. Augmentation of LPS-stimulated MMP-1 secretion was diminished when sodium lactate was replaced by lactic acid that reduced pH in the culture medium. Furthermore, quantitative real-time PCR indicated that the increased secretion of MMP-1, IL-1 beta, and IL-6 was due to increased mRNA expression. To explore the underlying signaling mechanism, blocking studies using specific inhibitors for NF-kappa B and MAPK cascades were performed. Results showed that blocking of either NF-kappa B or MAPK pathways led to the inhibition of MMP-1, IL-1 beta, and IL- 6 expression stimulated by sodium lactate, LPS, or both. Finally, electrophoretic mobility shift assays showed a synergy between sodium lactate and LPS on AP-1 and NF-kappa B transcriptional activities. In conclusion, this study has demonstrated for the first time that sodium lactate and LPS exert synergistic effect on MMP and cytokine expression through NF-kappa B and MAPK pathways and revealed a novel mechanism potentially involved in the development of type 2 diabetes and its complications. C1 Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA. Med Univ S Carolina, Coll Dent Med, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29403 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu NR 41 TC 37 Z9 38 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD OCT PY 2005 VL 289 IS 4 BP E534 EP E542 DI 10.1152/ajpendo.00462.2004 PG 9 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 962MV UT WOS:000231737800003 PM 15941782 ER PT J AU Akiba, Y Jung, M Ouk, S Kaunitz, JD AF Akiba, Y Jung, M Ouk, S Kaunitz, JD TI A novel small molecule CFTR inhibitor attenuates HCO3- secretion and duodenal ulcer formation in rats SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE CFTRinh-172; duodenal bicarbonate secretion; duodenal ulcer; cysteamine; luminal acid ID MUCOSAL ALKALINE SECRETION; CYSTIC-FIBROSIS; BICARBONATE SECRETION; INTRACELLULAR PH; FLUID SECRETION; ACID-SECRETION; LUMINAL ACID; CYSTEAMINE; MECHANISMS; PROTECTION AB The cystic fibrosis (CF) transmembrane conductance regulator ( CFTR) plays a crucial role in mediating duodenal bicarbonate (HCO3-) secretion (DBS). Although impaired DBS is observed in CF mutant mice and in CF patients, which would predict increased ulcer susceptibility, duodenal injury is rarely observed in CF patients and is reduced in CF mutant mice. To explain this apparent paradox, we hypothesized that CFTR dysfunction increases cellular [HCO3-] and buffering power. To further test this hypothesis, we examined the effect of a novel, potent, and highly selective CFTR inhibitor, CFTRinh-172, on DBS and duodenal ulceration in rats. DBS was measured in situ using a standard loop perfusion model with a pH stat under isoflurane anesthesia. Duodenal ulcers were induced in rats by cysteamine with or without CFTRinh-172 pretreatment 1 h before cysteamine. Superfusion of CFTRinh-172 (0.1 - 10 mu M) over the duodenal mucosa had no effect on basal DBS but at 10 mu M inhibited acid-induced DBS, suggesting that its effect was limited to CFTR activation. Acid-induced DBS was abolished at 1 and 3 h and was reduced 24 h after treatment with CFTRinh-172, although basal DBS was increased at 24 h. CFTRinh-172 treatment had no effect on gastric acid or HCO3- secretion. Duodenal ulcers were observed 24 h after cysteamine treatment but were reduced in CFTRinh-172-pretreated rats. CFTRinh-172 acutely produces CFTR dysfunction in rodents for up to 24 h. CFTR inhibition reduces acid-induced DBS but also prevents duodenal ulcer formation, supporting our hypothesis that intracellular HCO3- may be an important protective mechanism for duodenal epithelial cells. C1 Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90024 USA. Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Los Angeles, CA USA. Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01-DK-54221, P30-DK-0413] NR 52 TC 26 Z9 28 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD OCT PY 2005 VL 289 IS 4 BP G753 EP G759 DI 10.1152/ajpgi.00130.2005 PG 7 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 963VF UT WOS:000231833500017 PM 15905414 ER PT J AU Narita, M Fujitani, S Haake, DA Paterson, DL AF Narita, M Fujitani, S Haake, DA Paterson, DL TI Leptospirosis after recreational exposure to water in the Yaeyama Islands, Japan SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID UNITED-STATES; CLIMATE VARIABILITY; OUTBREAK; LIPOPOLYSACCHARIDE; CHEMOPROPHYLAXIS; INFECTIONS; CARRIAGE; EPIDEMIC; BARBADOS; IMPACTS AB Leptospirosis is a global zoonotic disease with a variety of clinical manifestations. We report an outbreak of leptospirosis in the Yaeyama Islands, Japan, in the summer of 1999 associated with heavy rainfall. Fourteen people were diagnosed with leptospirosis and required hospitalization. All cases were found to have exposure to contaminated soil or water. A history of recreational activities involving water sports was more frequent (71%) than occupational risk factors related to agriculture or construction (29%). Fever was the primary symptom in all cases, followed by chills (93%), headache (86%), myalgias (57%) and conjunctival suffusion (57%). All cases were successfully treated with antimicrobial therapy except one patient who improved spontaneously. Jarisch-Herxheimer reactions were seen in six cases (43%). The increasing incidence of leptospirosis related to recreational sports is an important public health problem in resort areas. A high-index of suspicion, early treatment, and prevention are crucial in this latently endemic area. C1 Univ Pittsburgh, Dept Internal Med, Presbyterian Shadyside Internal Med Residency Pro, Pittsburgh, PA 15232 USA. Univ Pittsburgh, Med Ctr, Presbyterian Shadyside, Pittsburgh, PA 15232 USA. Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. RP Narita, M (reprint author), Univ Pittsburgh, Dept Internal Med, Presbyterian Shadyside Internal Med Residency Pro, 5230 Ctr Ave, Pittsburgh, PA 15232 USA. EM naritam@upmc.edu RI Paterson, David/A-9258-2010 FU NIAID NIH HHS [R01 AI034431-08, R01 AI034431] NR 37 TC 39 Z9 40 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2005 VL 73 IS 4 BP 652 EP 656 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 973UR UT WOS:000232548600002 PM 16222003 ER PT J AU Lin, P Campbell, DG Chaney, EE Liu, CF Heagerty, P Felker, BL Hedrick, SC AF Lin, P Campbell, DG Chaney, EE Liu, CF Heagerty, P Felker, BL Hedrick, SC TI The influence of patient preference on depression treatment in primary care SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE CARE; MAJOR DEPRESSION; VETERANS; MANAGEMENT; HEALTH; GUIDELINES; SCORE AB Background: The chronic illness model encourages consideration of patients' treatment preferences. Moreover, research suggests that matching treatment to preference might affect outcomes for patients with depression. Purpose: This investigation explored factors associated with treatment preference matching and the effects of matching on depression treatment outcomes. Methods: Treatment preferences were assessed among primary care patients with depression participating in a large randomized trial of depression management. Patients were offered antidepressant medication and/or counseling based on preference and several other factors. Depression was assessed at 3 and 9 months. Results: Participants who preferred medication were older were in worse physical health, and were more likely to already be taking antidepressants. Participants who preferred both medication and counseling evidenced greater agreement with the statement that depression is a medical illness. Overall, 72% of participants were matched with their preferred treatment; matched participants demonstrated more rapid improvement in depression symptomatology than unmatched participants. Conclusions: Obtaining preferred treatment appears to contribute to improved treatment outcome. Continued attempts to assess for and accommodate treatment preferences might result in better response to depression treatment. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Hedrick, SC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, HSR&D 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM susan.hedrick@med.va.gov NR 31 TC 81 Z9 84 U1 4 U2 7 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD OCT PY 2005 VL 30 IS 2 BP 164 EP 173 DI 10.1207/s15324796abm3002_9 PG 10 WC Psychology, Multidisciplinary SC Psychology GA 972CM UT WOS:000232431600009 PM 16173913 ER PT J AU Arar, NH Hazuda, H Steinbach, R Arar, MY Abboud, HE AF Arar, NH Hazuda, H Steinbach, R Arar, MY Abboud, HE TI Ethical issues associated with conducting genetic family studies of complex disease SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE genetic family studies; ethical issues; Contextual Assessment Approach; subject-centered approach ID INFORMED-CONSENT; CANCER; PARTICIPATION; PRIVACY; SCIENCE; RACE AB PURPOSE: To examine subjects' recognition of the risks and ethical issues associated with enrollment in genetic family studies (GFS) and explore how this recognition affects their informed and voluntary participation. METHODS: A cross-sectional study design including both quantitative and qualitative data was employed. Structured interviews using the Contextual Assessment Approach Questionnaire (CAA-Q) were conducted with 246 Mexican American (MA) participants. To gain in-depth understanding of questionnaire responses, semi-structured interviews with 30 participants were conducted. All participants were interviewed before their enrollment in the Family Investigation of Nephropathy and Diabetes (FIND). RESULTS: Subjects' average age was 56 years; 62% were females. Seventy-eight percent of participants were not formally educated beyond high school and 72% reported an annual household income of <= $20,000. Eighty-five percent agreed to provide researchers with information on relatives' ages, gender, and education. Sixty-five percent of participants were willing to provide identifiable information such as names, addresses, and phone numbers of relatives. Sixty-three percent of participants indicated that there were direct benefits (i.e., supporting research) to disclosing relatives' information. Seventy-six percent stated that there were no risks associated with participation in GFS (e.g., discrimination or confidentiality of genetic information) compared with 10% who said that there were such risks. While discussing potential risks, subjects did not consider these to influence their decision to participate. CONCLUSIONS: Subjects enrolled in GFS did not recognize and tended to underestimate the social and cultural risks associated with their participation in GFS. If subjects do not fully comprehend the risks, this raises questions concerning their ability to provide informed consent and to voluntarily participate. We propose a subject-centered approach that views enrollment as an active process in which subjects and recruiters give and receive information on risks and ethical issues related to participation, which enhances protection of the rights and welfare of subjects participating in GFS. C1 Univ Texas, Ctr Hlth Sci, Dept Med Nephrol, Div Nephrol, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Div Nephrol, Dept Pediat, San Antonio, TX 78284 USA. RP Arar, NH (reprint author), Univ Texas, Ctr Hlth Sci, Dept Med Nephrol, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ararn@uthscsa.edu FU NHGRI NIH HHS [1 R03 HG 02 381]; NIDDK NIH HHS [5 U01 DK57295] NR 46 TC 16 Z9 16 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD OCT PY 2005 VL 15 IS 9 BP 712 EP 719 DI 10.1016/j.annepidem.2004.09.010 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 969NF UT WOS:000232240200007 PM 16157258 ER PT J AU Ota, F Connor, NP Konopacki, R AF Ota, F Connor, NP Konopacki, R TI Alterations in contractile properties of tongue muscles in old rats SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article; Proceedings Paper CT 106th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery CY SEP 22-25, 2002 CL SAN DIEGO, CA SP Amer Acad Otolaryngol Head & Neck Surg DE aging; deglutition disorder; muscle contraction; tongue ID AGE-RELATED-CHANGES; NEUROMUSCULAR-JUNCTIONS; GENIOGLOSSUS MUSCLE; MEN; STIMULATION; PHARYNGEAL; MORPHOLOGY; FIBERS; FORCE AB Objectives: Fatigue and weakness are well-known signs of aging that are related to sarcopenia, or loss of skeletal muscle mass, organization, and strength. Sarcopenia may affect swallowing. The tongue plays a vital role in swallowing, but there is limited knowledge regarding age-related changes in lingual muscle contractile properties. Our purpose was to determine whether alterations in tongue force, temporal features of tongue muscle contraction, and fatigability are manifested as a function of aging in old rats. Methods: We evaluated tongue muscle contractile properties in young and old Fischer 344/Brown Norway rats. Contractions were elicited via bilateral electrical stimulation of the hypoglossal nerves. Results: Maximum tongue forces and fatigability were-not significantly altered in old animals, but aging was associated with significantly longer twitch contraction time and longer half-decay recovery time intervals (p <.01). Conclusions: The results indicated that old animals generated sufficient maximum tongue forces, but were slower in achieving these forces than young animals. These findings are consistent with reports of altered temporal parameters of tongue actions during swallowing in humans, and suggest that a disruption in the timing of muscle contraction onset and recovery may contribute to the altered tongue kinetics observed with aging. C1 Univ Wisconsin, Clin Sci Ctr, Madison, WI 53792 USA. Univ Wisconsin, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. Univ Wisconsin, Dept Surg, Dept Biostat & Med Informat, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. Jikei Univ, Dept Otolaryngol Head & Neck Surg, Tokyo, Japan. RP Connor, NP (reprint author), Univ Wisconsin, Clin Sci Ctr, Room K4-711,600 Highland Ave, Madison, WI 53792 USA. FU NIDCD NIH HHS [R01DC005935] NR 32 TC 19 Z9 20 U1 4 U2 5 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 USA SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD OCT PY 2005 VL 114 IS 10 BP 799 EP 803 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 972AW UT WOS:000232427200010 PM 16285271 ER PT J AU Tapp, AM Wood, AE Kilzieh, N Kennedy, A Raskind, MA AF Tapp, AM Wood, AE Kilzieh, N Kennedy, A Raskind, MA TI Antipsychotic polypharmacy: do benefits justify the risks? SO ANNALS OF PHARMACOTHERAPY LA English DT Letter ID DOUBLE-BLIND; CLOZAPINE; SCHIZOPHRENIA; RISPERIDONE C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, Dept Psychiat & Behav Sci, Tacoma, WA 98493 USA. Seattle Inst Biomed & Clin Res, Seattle, WA USA. RP Tapp, AM (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, Dept Psychiat & Behav Sci, A-116-R, Tacoma, WA 98493 USA. EM Andre.Tapp@med.va.gov NR 5 TC 4 Z9 4 U1 0 U2 0 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD OCT PY 2005 VL 39 IS 10 BP 1759 EP 1760 DI 10.1345/aph.1E429 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 969BX UT WOS:000232209500029 PM 16144885 ER PT J AU Wexler, HM Engel, AE Glass, D Li, CD AF Wexler, HM Engel, AE Glass, D Li, CD TI In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID VIVO ANTIBACTERIAL ACTIVITIES; PSEUDOMONAS-AERUGINOSA; BACTEROIDES-FRAGILIS; PARENTERAL CARBAPENEM; BILOPHILA-WADSWORTHIA; ANTIMICROBIAL AGENTS; PENEM ANTIBIOTICS; SPIRAL GRADIENT; AGAR DILUTION; END-POINT AB The in vitro activities of doripenem against 364 anaerobic isolates were measured and compared to those of ertapenem, imipenem, meropenem, ceftriaxone, and levotloxacin. All of the carbapenems were active against nearly all Bacteroides fragilis group isolates. Doripenem was either comparable to or slightly less active than imipenem and meropenem against most isolates but more active than the other penems against Clostridium difficile. Doripenem appears to have excellent activity against a broad range of anaerobes. C1 Greater Los Angeles Vet Adm Hlth Care Serv, Med & Res Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Wexler, HM (reprint author), Wadsworth Anaerobe Lab, Bldg 304,Room E3-224,GLAVAHCS 691-151J, Los Angeles, CA 90073 USA. EM hwexler@ucla.edu NR 20 TC 37 Z9 38 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2005 VL 49 IS 10 BP 4413 EP 4417 DI 10.1128/AAC.49.10.4413-4417.2005 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 969OW UT WOS:000232244700067 PM 16189137 ER PT J AU O'Brien, CP AF O'Brien, CP TI Adolescent opioid abuse SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP O'Brien, CP (reprint author), Univ Penn, Philadelphia VA Med Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM obrien@mail.trc.upenn.edu NR 1 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD OCT PY 2005 VL 62 IS 10 BP 1165 EP 1165 DI 10.1001/archpsyc.62.10.1165 PG 1 WC Psychiatry SC Psychiatry GA 972CD UT WOS:000232430600012 PM 16203962 ER PT J AU Yueh, B McDowell, JA Collins, M Souza, PE Loovis, CF Deyo, RA AF Yueh, B McDowell, JA Collins, M Souza, PE Loovis, CF Deyo, RA TI Development and validation of the effectiveness of the auditory rehabilitation scale SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID QUALITY-OF-LIFE; HEARING PERFORMANCE INVENTORY; HANDICAP INVENTORY; COMMUNICATION PROFILE; RANDOMIZED TRIAL; OLDER-ADULTS; AID BENEFIT; TIME-COURSE; AMPLIFICATION; IMPAIRMENT AB Objective: To develop a new scale of hearing-related function and quality of life in patients with hearing Aids that addresses overlooked concerns, such as hearing-aid comfort, convenience, and cosmetic appearance, that may influence hearing-aid adherence while maintaining brevity and sensitivity to clinical change. Design: Prospective, multicenter instrument validation. Setting: Four diverse sites in Washington State, including 2 private practices, I university setting, and 1 Veterans Affairs hospital. Patients: Seventy-eight patients with hearing aids. Interventions: We created 2 modules in the Effectiveness of Auditory Rehabilitation (EAR) scale. The first module (Inner EAR) covers intrinsic hearing issues such as hearing in quiet and hearing in noise and is administered both before and after treatment. The second module (Outer EAR) covers extrinsic (hearing-aid related) issues such as comfort, appearance, and convenience and is administered after hearing-aid fitting. Main Outcome Measures: Both scales were developed and validated in 3 stages. Stage I used a qualitative approach from multiple data sources to develop preliminary instruments. Stage 2 used approaches from classic test theory to reduce the number of items and psychometrically validate the instruments. Stage 3 examined the responsiveness or sensitivity to clinical change. Results: A 10-item Inner EAR module and a 10-item Outer EAR module were created and validated. Internal consistency of individual domains (Cronbach alpha=0.85 and 0.72, respectively) and test-retest reliability (intraclass correlation coefficients=0.76 and 0.81, respectively) were excellent. Evidence of construct validity included concurrent validity with other hearing scales and global visual analog scales, discriminant validity with dizziness handicap correlation with hearing-aid adherence, and confirmatory factor analyses., Both scales had strong evidence of responsiveness (sensitivity to change), with higher effect sizes and Guyatt responsiveness statistics than the. 2 widely used hearing scales in this study. The scales took an average of 5 minutes to complete. Conclusions: The EAR scale is a valid and reliable mea sure of the effectiveness of amplification in the treatment of sensorineural hearing loss. It addresses the range of issues that are of importance to hearing-aid patients. The scales have excellent psychometric properties, are more responsive than several widely used hearing scales, and are minimally burdensome for patients to complete. The EAR may be a valuable outcome measure in future studies of both existing hearing aids and newer hearing-aid technologies, such as bone-anchored aids or middle ear implants. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA 98108 USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Yueh, B (reprint author), VA Puget Sound Hlth Care Syst, Surg Serv, 1120TO,1660 S Columbian Way, Seattle, WA 98108 USA. EM byueh@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 FU NIA NIH HHS [R-03 AG18150] NR 42 TC 13 Z9 13 U1 5 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD OCT PY 2005 VL 131 IS 10 BP 851 EP 856 DI 10.1001/archotol.131.10.851 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 972BG UT WOS:000232428200002 PM 16230585 ER PT J AU Ibrahim, SA Stone, RA Han, XY Cohen, P Fine, MJ Henderson, WG Khuri, SF Kwoh, CK AF Ibrahim, SA Stone, RA Han, XY Cohen, P Fine, MJ Henderson, WG Khuri, SF Kwoh, CK TI Racial/ethnic differences in surgical outcomes in veterans following knee or hip arthroplasty SO ARTHRITIS AND RHEUMATISM LA English DT Article ID SURGEON PROCEDURE VOLUME; RISK ADJUSTMENT; UNITED-STATES; RHEUMATOID-ARTHRITIS; JOINT REPLACEMENT; MEDICARE PATIENTS; HEALTH-CARE; QUALITY; OSTEOARTHRITIS; MORTALITY AB Objective. The utilization of joint arthroplasty for knee or hip osteoarthritis varies markedly by patient race/ethnicity. Because of concerns about surgical risk, black patients are less willing to consider this treatment. There are few published race/ethnicity-specific data on joint arthroplasty outcomes. The present study was undertaken to examine racial/ethnic differences in mortality and morbidity following elective knee or hip arthroplasty. Methods. Using information from the Veterans Administration National Surgical Quality Improvement Program database, data on 12,108 patients who underwent knee arthroplasty and 6,703 patients who underwent hip arthroplasty over a 5-year period were analyzed. Racial/ethnic differences were determined using prospectively collected data on patient characteristics, procedures, and short-term outcomes. The main outcome measures were risk-adjusted 30-day mortality and complication rates. Results. Adjusted rates of both non-infection-related and infection-related complications after knee arthroplasty were higher among black patients compared with white patients (relative risk [RR] 1.50, 95% confidence interval [95% CI] 1.08-2.10 and RR 1.42, 95% CI 1.06-1.90, respectively). Hispanic patients had a significantly higher risk of infection-related complications after knee arthroplasty (RR 1.64, 95% Cl 1.082.49) relative to otherwise similar white patients. Race/ethnicity was not significantly associated with the risk of non-infection-related complications (RR 0.97, 95% CI 0.68-1.38 in blacks; RR 1.18, 95% CI 0.60-2.30 in Hispanics) or infection-related complications (RR 1.27, 95% Cl 0.91-1.78 in blacks; RR 1.22, 95% CI 0.63-2.36 in Hispanics) after hip arthroplasty. The overall 30-day mortality was 0.6% following knee arthroplasty and 0.7% following hip arthroplasty, with no significant differences by race/ethnicity observed for either procedure. Conclusion. Although absolute risks of complication are low, our findings indicate that, after adjustment, black patients have significantly higher rates of infection-related and non-infection-related complications following knee arthroplasty, compared with white patients. In addition, adjusted rates of infection - related complications after knee arthroplasty are higher in Hispanic patients than in white patients. Such differences between ethnic groups are not seen following hip arthroplasty. These groups do not appear to differ significantly in terms of post-arthroplasty mortality rates. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equal Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Pittsburgh, PA USA. Univ Colorado, Denver, CO 80202 USA. VA Natl Surg Qual Improvement Program, Boston, MA USA. RP Ibrahim, SA (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equal Res & Promot, 151-C, Pittsburgh, PA 15240 USA. EM said.ibrahim2@med.va.gov NR 36 TC 69 Z9 70 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD OCT PY 2005 VL 52 IS 10 BP 3143 EP 3151 DI 10.1002/art.21304 PG 9 WC Rheumatology SC Rheumatology GA 973UT UT WOS:000232548800024 PM 16200594 ER PT J AU Caetano, SC Olvera, RL Glahn, D Fonseca, M Pliszka, S Soares, JC AF Caetano, SC Olvera, RL Glahn, D Fonseca, M Pliszka, S Soares, JC TI Fronto-limbic brain abnormalities in juvenile onset bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Conference on Pediatric Bipolar Disorder CY APR 02-03, 2004 CL Boston, MA DE bipolar disorder; MRI; MRS; children; adolescents ID MAGNETIC-RESONANCE SPECTROSCOPY; SUBGENUAL PREFRONTAL CORTEX; WHITE-MATTER HYPERINTENSITIES; ANTERIOR CINGULATE CORTEX; TEMPORAL-LOBE STRUCTURES; PROTON MR SPECTROSCOPY; MOOD DISORDERS; I DISORDER; EUTHYMIC PATIENTS; ADOLESCENT PATIENTS AB Background: Advances in brain imaging techniques and cognitive neuropsychology have brought new possibilities for the in vivo study of the pathophysiology of neuropsychiatric disorders, including bipolar disorder (BD), Recently, such studies have been extended to the pediatric age range. Here we review the neuroimaging and neuropsycbological studies conducted in BD children and adolescents. Methods: A review of the peer-reviewed published literature was conducted in Medline for the period of 1966 to April 2005. Results: Magnetic resonance imaging (MPI) and magnetic resonance spectroscopy (MRS) studies suggest abnormalities in fronto-limbic structures in pediatric BD patients, similar to those found in adults. A notable exception in pediatric BD patients is smaller amygdala volumes compared to healthy controls, contrary to what has been reported in most adult studies. Conclusions. Further research evaluating children and adolescents is needed to study the normal neurodevelopmental process and to answer bow and when the illness processes that result in bipolar disorder exert their effects on the developing brain. C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Dept Psychiat, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Fed Rio Grande Sul, Sch Med, Psychiat Res Unit, Med Sch Postgrad Program, Porto Alegre, RS, Brazil. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 FU NCRR NIH HHS [M01-RR-01346]; NIMH NIH HHS [MH069774, 5 U13 MH64077-03, K23-MH068280, MH01736, MH068662] NR 90 TC 27 Z9 29 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 1 PY 2005 VL 58 IS 7 BP 525 EP 531 DI 10.1016/j.biopsych.2005.04.027 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 978IH UT WOS:000232866300003 PM 16018982 ER PT J AU Huynh, N Dolan, B Lee, S Whitcher, JP Stanley, J Whitcher, JP Lee, S AF Huynh, N Dolan, B Lee, S Whitcher, JP Stanley, J Whitcher, JP Lee, S TI Management of phaeniciatic ophthalmomyiasis externa SO BRITISH JOURNAL OF OPHTHALMOLOGY LA English DT Article C1 Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94122 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Lee, S (reprint author), Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94122 USA. EM selee@itsa.ucsf.edu NR 4 TC 2 Z9 4 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0007-1161 J9 BRIT J OPHTHALMOL JI Br. J. Ophthalmol. PD OCT PY 2005 VL 89 IS 10 BP 1377 EP 1378 DI 10.1136/bjo.2005.071597 PG 2 WC Ophthalmology SC Ophthalmology GA 965UD UT WOS:000231974900040 PM 16170142 ER PT J AU Copeland, LA Elshaikh, MA Jackson, J Penner, LA Underwood, W AF Copeland, LA Elshaikh, MA Jackson, J Penner, LA Underwood, W TI Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma SO CANCER LA English DT Article DE permanent prostate brachytherapy; radical prostatectomy; external-beam radiation therapy; prostate carcinoma ID DATA-BASE REPORT; RADIATION-THERAPY; BEAM RADIATION; CANCER; PREFERENCES; MORBIDITY; ROBOTICS; OUTCOMES; MEN; US AB BACKGROUND. The impact of the increased use of permanent prostate brachy-therapy compared with other treatment modalities (such as radical prostatectomy and external-beam radiation therapy [EBRT]) for the treatment of clinically localized prostate carcinoma, and the previously reported regional, racial, and age-related variations in prostate carcinoma treatment, have not been well characterized to date. Therefore, the authors evaluated the impact of permanent prostate brachytherapy on the relative rates of the use of specific prostate carcinoma treatment modalities over time. METHODS. Surveillance, Epidemiology, and End Results (SEER) cancer registry data from 1995 to 2000 were analyzed in a longitudinal, observational study utilizing bivariate and multivariate techniques. RESULTS. Differential changes in the use of specific definitive treatment modalities were noted by region, age group, racial/ethnic group, and marital status. Increasing use of permanent prostate brachytherapy, with and without concomitant EBRT, was proportional to the decreasing use of radical prostatectomy alone and EBRT alone over time. CONCLUSIONS. The current study revealed that permanent prostate brachytherapy appears to be replacing other treatment modalities in increasing numbers of clinically localized prostate carcinoma cases. Persistent regional, racial/ethnic, marital status, and age-related differences in the use of permanent prostate brachytherapy merit further investigation. C1 Univ Michigan, Urol Ctr, Dept Urol, Div Clin Res & Qual Assurance, Ann Arbor, MI 48109 USA. Vet Affairs Ctr Practice Management & Outcomes Re, Ann Arbor, MI USA. Wayne State Univ, Dept Family Med, Detroit, MI USA. Wayne State Univ, Karmanos Canc Inst, Commun & Behav Oncol Program, Detroit, MI USA. Univ Michigan, Ctr African Amer & African Studies, Ann Arbor, MI 48109 USA. Univ Michigan, Inst Social Res, Res Ctr Grp Dynam, Ann Arbor, MI 48109 USA. Vet Affairs Med Ctr, Dept Radiat Oncol, Ann Arbor, MI USA. Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Psychiat, San Antonio, TX USA. RP Underwood, W (reprint author), Univ Michigan, Urol Ctr, Dept Urol, Div Clin Res & Qual Assurance, TC 3746,POB 0330,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM wunderwo@umich.edu OI Copeland, Laurel/0000-0002-9478-0209 NR 25 TC 8 Z9 8 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD OCT 1 PY 2005 VL 104 IS 7 BP 1372 EP 1380 DI 10.1002/cncr.21341 PG 9 WC Oncology SC Oncology GA 966EA UT WOS:000232001200006 PM 16118801 ER PT J AU Levine, GN Lincoff, AM Ferguson, JJ Mahaffey, KW Goodman, SG Cannon, CP Theroux, P Fox, KAA AF Levine, GN Lincoff, AM Ferguson, JJ Mahaffey, KW Goodman, SG Cannon, CP Theroux, P Fox, KAA TI Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE non-ST segment elevation acute coronary syndrome; management ID PLATELET GLYCOPROTEIN IIB/IIIA; INVASIVE CARDIAC PROCEDURES; ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; UNITED-STATES; UNFRACTIONATED HEPARIN; RANDOMIZED-TRIAL; PCI-CURE; MANAGEMENT; OUTCOMES AB The degree to which catheterization and revascularization procedures are utilized in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) during hospitalization has broad implications with respect to initial pharmacotherapeutic decisions (upfront therapies), treatment and hospital transfer protocols, guideline recommendations, and allocation of training, material, and financial resources. Analysis of data from multiple trials and registries of patients with NSTE-ACS has the potential to assess more broadly utilization of invasive and revascularization procedures and provide a wide angle or bird's-eye view of the management of such patients, complementing the data obtained from any one trial or registry. We therefore undertook a systematic overview of all large trials and registries of patients with NSTE-ACS conducted over the last decade that were deemed appropriate to provide information on catheterization and revascularization procedures. Although not unexpectedly the percentage of patients with NSTE-ACS managed with cardiac catheterization, percutaneous coronary intervention (PCI), and coronary artery bypass grafting varies in different clinical trials and registries, general findings and trends were still discernable from these studies. During the initial treatment period, the majority of patients were ultimately treated with medical therapy alone (e.g., without revascularization). The percentage of those NSTE-ACS patients undergoing diagnostic cardiac catheterization who were then managed with PCI increased over the last decade and now stands at approximately 50%. Of NSTE-ACS patients who undergo revascularization, the percentage of those patients who are revascularized via PCI similarly increased, and PCI is currently the revascularization procedure utilized in approximately three-fourths of patients undergoing revascularization. The percentages of patients undergoing invasive and revascularization procedures were consistently higher in the U.S. cohorts of study subjects when compared to non-U.S. cohorts of study subjects. (c), 2005 Wiley-Liss, Inc. C1 Houston VA Med Ctr, Cardiol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Univ Texas, Hlth Sci Ctr, Texas Heart Inst, Houston, TX USA. Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA. Univ Toronto, St Michaels Hosp, Canadian Heart Res Ctr, Toronto, ON M5B 1W8, Canada. Univ Toronto, St Michaels Hosp, Terrence Donnelly Heart Ctr, Toronto, ON M5B 1W8, Canada. Brigham & Womens Hosp, Div Cardiovasc, Thrombolysis Myocardial Infarct Study Grp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Montreal, Montreal Heart Inst, Montreal, PQ H3C 3J7, Canada. Univ Edinburgh, Cardiovasc Res Ctr, Cardiovasc Res Unit, Edinburgh EH8 9YL, Midlothian, Scotland. RP Levine, GN (reprint author), Houston VA Med Ctr, Cardiol Sect, 3C-330,111-B,2002 Holcombe Blvd, Houston, TX 77030 USA. EM glevine@bcm.tmc.edu NR 28 TC 10 Z9 10 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD OCT PY 2005 VL 66 IS 2 BP 149 EP 157 DI 10.1002/ccd.20469 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 971MF UT WOS:000232387600001 PM 16152646 ER PT J AU Mortensen, E Restrepo, M Anzueto, A Pugh, J AF Mortensen, E Restrepo, M Anzueto, A Pugh, J TI Impact of guideline-concordant antibiotic therapy on mortality within 48 hours of admission for patients hospitalized with community-acquired pneumonia SO CHEST LA English DT Meeting Abstract CT Chest 2005 Conference CY OCT 29-NOV 03, 2005 CL Montreal, CANADA C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2005 VL 128 IS 4 SU S BP 148S EP 148S PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 977JT UT WOS:000232800300061 ER PT J AU Mularski, RA Asch, SM Shrank, WH Kerr, EA Setodji, C Adams, J Keesey, J McGlynn, EA AF Mularski, RA Asch, SM Shrank, WH Kerr, EA Setodji, C Adams, J Keesey, J McGlynn, EA TI The quality of health care delivered to Americans with obstructive lung disease SO CHEST LA English DT Meeting Abstract CT Chest 2005 Conference CY OCT 29-NOV 03, 2005 CL Montreal, CANADA C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2005 VL 128 IS 4 SU S BP 179S EP 179S PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 977JT UT WOS:000232800300154 ER PT J AU Jones, SF Cooper, JA Dransfield, MT AF Jones, SF Cooper, JA Dransfield, MT TI Single measurements of inspiratory capacity are not better than FEV1 in predicting symptom scores in COPD SO CHEST LA English DT Meeting Abstract CT Chest 2005 Conference CY OCT 29-NOV 03, 2005 CL Montreal, CANADA C1 Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2005 VL 128 IS 4 SU S BP 247S EP 248S PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 977JT UT WOS:000232800301010 ER PT J AU Mularski, RA Mularski, KS Asch, SM AF Mularski, RA Mularski, KS Asch, SM TI Hazards of opiate mismanagement in the ICU SO CHEST LA English DT Meeting Abstract CT Chest 2005 Conference CY OCT 29-NOV 03, 2005 CL Montreal, CANADA C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2005 VL 128 IS 4 SU S BP 419S EP 420S PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 977JT UT WOS:000232800302139 ER PT J AU Hoo, GWS Wen, YE Nguyen, TV Goetz, MB AF Hoo, GWS Wen, YE Nguyen, TV Goetz, MB TI Impact of clinical guidelines in the management of severe hospital-acquired pneumonia SO CHEST LA English DT Article DE guidelines; nosocomial pneumonia; ventilator-associated pneumonia ID VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE-UNIT; INADEQUATE ANTIMICROBIAL TREATMENT; NOSOCOMIAL PNEUMONIA; ATTRIBUTABLE MORTALITY; ANTIBIOTIC-TREATMENT; DIAGNOSTIC-ACCURACY; RESISTANT-BACTERIA; STRATEGY; THERAPY AB Study objectives: To asses the impact of locally developed antimicrobial treatment guidelines in the initial empiric treatment of ICU patients with severe hospital-acquired pneumonia (HAP). Design: Observational cohort study with preguideline and postguideline data collection. Patients: A total of 48 preguideline patients with 56 episodes of severe HAP defined by the National Nosocomial Infections Surveillance (NNIS) compared with 58 guideline-treated (GUIDE) patients with 61 episodes of severe HAP. Results: The two groups were similar in terms of mean (+/- SD) age (NNIS group, 67.7 +/- 9.6 years; GUIDE group, 68.0 +/- 11.5 years) and simplified acute physiology score (NNIS group, 12.9 +/- 3.9; GUIDE group, 12.6 +/- 3.1) at the HAP diagnosis, and the proportion of the most frequent isolates (ie, Pseudomonas and methicillin-resistant Staphylococcus aureus). There was wide variation in initial antibiotic use in NNIS-treated patients, with cefotaxime, ceftazidime, and piperacillin being the most common agents compared with all of the GUIDE patients who received an imipenem-cilastin-based regimen. Vancomycin use was similar in both groups. The GUIDE patients had a higher percentage of adequately treated patients (SI% vs 46%, respectively; p < 0.01) with a lower mortality rate at 14 days (8% vs 23%, respectively; p = 0.03). A lower mortality rate was also noted at the end of 30 days and the end of hospitalization but was not statistically significant. Appropriate imipenem use (as defined by the guidelines) occurred in 74% of the cases, and there was no increase in the number of imipenem-resistant organisms isolated during the course of the study. Conclusions: These guidelines represent a successful implementation of a "deescalation" approach, because the recommended empiric therapy with broad-spectrum antibiotics was switched to therapy with narrower spectrum agents after 3 days. Based on our experience, this approach improves the adequacy of antibiotic treatment, with improvement in short-term survival and without increasing the emergence of resistant organisms. C1 Univ Calif Los Angeles, Pulm & Crit Care Sect, Geffen Sch Med, VA Greater Los Angeles Healthcare Syst,W Los Ange, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Infect Dis Sect, Geffen Sch Med, VA Greater Los Angeles Healthcare Syst,W Los Ange, Los Angeles, CA 90073 USA. RP Hoo, GWS (reprint author), Univ Calif Los Angeles, Pulm & Crit Care Sect, Geffen Sch Med, VA Greater Los Angeles Healthcare Syst,W Los Ange, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Guy.Soohoo@med.va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 38 TC 89 Z9 94 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2005 VL 128 IS 4 BP 2778 EP 2787 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 975RK UT WOS:000232679400127 PM 16236955 ER PT J AU O'Hare, T Walters, DK Stoffregen, EP Sherbenou, DW Heinrich, MC Deininger, MWN Druker, BJ AF O'Hare, T Walters, DK Stoffregen, EP Sherbenou, DW Heinrich, MC Deininger, MWN Druker, BJ TI Combined AN inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib SO CLINICAL CANCER RESEARCH LA English DT Article ID ABL KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL; TYROSINE KINASE; CHRONIC-PHASE; PHILADELPHIA-CHROMOSOME; CYTOGENETIC RESPONSES; DOMAIN MUTATIONS; BLAST CRISIS; WILD-TYPE AB Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However, reactivatiori of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse. As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated. Experimental Design: To test this approach, cellular proliferation and Bcr-Abl tyrosine phosphorylation assays were done on Ba/F3 cells expressing wild-type (WT) Bcr-Abl and four common imatinib-resistant mutants (Y253F, E255K,T315I, and M351T). Colony-forming assays with primary CML cells were also done. Results: Both Src/Abl inhibitors retained full inhibitory capacity when coadministered with imatinib at concentrations above typical clinical levels. For cells expressing WT Bcr-Abl or the marginally imatinib-resistant mutant M351T, inclusion of imatinib at therapeutic levels enhanced the effects of the Src/Abl inhibitors. By comparison, for the highly imatinib-resistant mutants Y253F and E255K, inclusion of imatinib at clinical levels resulted in only a slight enhancement beyond the effects of the Src/Abl inhibitors. None of the inhibitors affected Bcr-Abl T315I cells. Colony-forming assays with primary CML cells yielded analogous results. Conclusions: Our results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML. C1 Oregon Hlth Sci Univ, Howard Hughes Med Inst, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Inst Canc, Div Hematol & Med Oncol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP O'Hare, T (reprint author), Oregon Hlth Sci Univ, Howard Hughes Med Inst, L592,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM oharet@ohsu.edu NR 38 TC 73 Z9 78 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD OCT 1 PY 2005 VL 11 IS 19 BP 6987 EP 6993 DI 10.1158/1078-0432.CCR-05-0622 PN 1 PG 7 WC Oncology SC Oncology GA 969MK UT WOS:000232238100035 PM 16203792 ER PT J AU LoTempio, MM Veena, MS Steele, HL Ramamurthy, B Ramalingam, TS Cohen, AN Chakrabarti, R Srivatsan, ES Wang, MB AF LoTempio, MM Veena, MS Steele, HL Ramamurthy, B Ramalingam, TS Cohen, AN Chakrabarti, R Srivatsan, ES Wang, MB TI Curcumin suppresses growth of head and neck squamous cell carcinoma SO CLINICAL CANCER RESEARCH LA English DT Article ID NF-KAPPA-B; QUALITY-OF-LIFE; BCL-X-L; IN-VITRO; GENE-THERAPY; CANCER CELLS; MEDIATED APOPTOSIS; SURVIVAL; DIFERULOYLMETHANE; CARCINOGENESIS AB Purpose: The purpose of this study was to determine whether curcumin would trigger cell death in the head and neck squamous cell carcinoma (HNSCC) cell lines CCL 23, CAL 27, and UM-SCC1 in a dose-dependent fashion. Experimental Design: HNSCC cells were treated with curcumin and assayed for in vitro growth suppression using 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyl tetrazolium bromide and fluorescence-activated cell sorting analyses. Expression of p16, cyclin D1, phospho-I kappa beta, and nuclear factor-kappa beta (NF-kappa beta) were measured by Western blotting, gel shift, and immunofluorescence. Results: Addition of curcumin resulted in a dose-dependent growth inhibition of all three cell lines. Curcumin treatment resulted in reduced nuclear expression of NF-kappa beta. This effect on NF-kappa beta was further reflected in the decreased expression of phospho-I kappa beta-alpha. Whereas the expression of cyclin D1, an NF-kappa beta-activated protein, was also reduced, there was no difference in the expression of p16 at the initial times after curcumin treatment. In vivo growth studies were done using nude mice xenograft tumors. Curcumin was applied as a noninvasive topical paste to the tumors and inhibition of tumor growth was observed in xenografts from the CAL27 cell line. Conclusions: Curcumin treatment resulted in suppression of HNSCC growth both in vitro and in vivo. Our data support further investigation into the potential use for curcumin as an adjuvant or chemopreventive agent in head and neck cancer. C1 Univ Calif Los Angeles, Div Head & Neck Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Wang, MB (reprint author), Univ Calif Los Angeles, Div Head & Neck Surg, David Geffen Sch Med, CHS 62-132,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mbwang@ucla.edu NR 46 TC 101 Z9 107 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD OCT 1 PY 2005 VL 11 IS 19 BP 6994 EP 7002 DI 10.1158/1078-0432.CCR-05.0301 PN 1 PG 9 WC Oncology SC Oncology GA 969MK UT WOS:000232238100036 PM 16203793 ER PT J AU Khalid, A McGrath, KM Zahid, M Wilson, M Brody, D Swalsky, P Moser, AJ Lee, KK Slivka, A Whitcomb, DC Finkelstein, S AF Khalid, A McGrath, KM Zahid, M Wilson, M Brody, D Swalsky, P Moser, AJ Lee, KK Slivka, A Whitcomb, DC Finkelstein, S TI The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID TUMOR-SUPPRESSOR GENE; INTRAEPITHELIAL NEOPLASIA; LESIONS; P53; ADENOCARCINOMA; EXPRESSION; MUTATIONS; DIAGNOSIS; CANCER; DPC4 AB Background & Aims: Current methods to detect malignancy in mucinous cystic neoplasms of the pancreas remain inadequate. The role of detailed molecular analysis in this context was investigated. Methods: Endoscopic ultrasound-guided pancreatic cyst aspirates were prospectively collected during a period of 19 months and studied for cytology, carcinoembryonic antigen level, and molecular analysis. Molecular evaluation incorporated DNA quantification (amount and quality), k-ras point mutation, and broad panel tumor suppressor linked microsatellite marker allelic loss analysis by using fluorescent capillary electrophoresis. The sequence of mutation acquisition was also calculated on the basis of a clonal expansion model, and comparison was made to the final pathology. Results: Thirty-six cysts with confirmed histology were analyzed. There were 11 malignant, 15 premalignant, and 10 benign cysts. Malignant cysts could be differentiated from premalignant cysts on the basis of fluid carcinoembryonic antigen level (P =.034), DNA quality (P =.009), number of mutations (P =.002), and on the sequence of mutations acquired (P <.001). Early k-ras mutation followed by allelic loss was the most predictive of a malignant cyst (sensitivity, 91%; specificity, 93%). Conclusions: Malignant cyst fluid contains adequate DNA to allow mutational analysis. A first hit k-ras mutation followed by allelic loss is most predictive of the presence of malignancy in a pancreatic cyst. This approach should serve as an ancillary tool to the conventional work-up of pancreatic cysts. Cumulative amount and timing of detectable mutational damage can assist in diagnosis and clinical management. C1 Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA. Redpath Integrated Pathol, Pittsburgh, PA USA. RP Khalid, A (reprint author), Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, M2,C Wing,PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM khalida@upmc.edu NR 21 TC 126 Z9 127 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD OCT PY 2005 VL 3 IS 10 BP 967 EP 973 DI 10.1053/S1542-3565(05)00409-X PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 995NC UT WOS:000234106000008 PM 16234041 ER PT J AU Spiegel, BMR Chen, K Chiou, CF Robbins, S Younossi, ZM AF Spiegel, BMR Chen, K Chiou, CF Robbins, S Younossi, ZM TI Erythropoietic growth factors for treatment-induced anemia in hepatitis C: A cost-effectiveness analysis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID QUALITY-OF-LIFE; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; HCV-INFECTED PATIENTS; INITIAL TREATMENT; VIROLOGICAL RESPONSE; COMBINATION THERAPY; ESOPHAGEAL-VARICES; SUSTAINED RESPONSE; RANDOMIZED-TRIAL; NATURAL-HISTORY AB Background & Aims: Treatment-induced anemia undermines the efficacy of antiviral therapy in hepatitis C by mandating ribavirin dose reduction and diminishing adherence to therapy. Erythropoietic growth factors (EGFs) may correct treatment-induced anemia, facilitate maintenance of full-dose therapy, and improve rates of sustained virologic response (SVR). We sought to determine the cost effectiveness of adjunctive treatment with an EGF vs standard care in the treatment of hepatitis C. Methods: We used a decision analysis to calculate the cost effectiveness of 2 treatment strategies for a patient cohort with chronic hepatitis C, increased transaminase levels, and no cirrhosis who were receiving pegylated-interferon and ribavirin (RBV): (1) RBV dose-reduction for anemia, followed by discontinuation of therapy if anemia persisted (standard care strategy), (2) adjunctive treatment with EGF therapy for anemia, with RBV dose reduction reserved for persistent anemia despite EGF therapy (EGF strategy). We conducted cost-effectiveness and cost-utility analyses to compare short- and long-term outcomes between the strategies. Results: The percentage achieving SVR was 52.3% in the standard care strategy and 59.5% in the EGF strategy. Compared with standard care, the EGF strategy cost an incremental $36,568 per unadjusted life-year gained and $16,443 per quality-adjusted life-year gained. In a sensitivity analysis, if a third-party payer was willing to pay $50,000 per quality-adjusted life-year gained for the use of an EGF, then 86.1% of patients would be within the budget. Conclusions: Compared with standard care, adjunctive therapy with an EGF for the management of treatment-induced anemia may increase the probability of achieving SVR, increase unadjusted lifespan, and increase quality-adjusted lifespan at an acceptable cost. C1 Univ Calif Los Angeles, UCLA VA Ctr Outcomes Res & Educ, David Geffen Sch Med,Div Digest Dis, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. Cerner Hlth Insights, Beverly Hills, CA USA. Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA. Inova Fairfax Hosp, Annandale, VA USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, UCLA VA Ctr Outcomes Res & Educ, David Geffen Sch Med,Div Digest Dis, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215E, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu NR 50 TC 22 Z9 23 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD OCT PY 2005 VL 3 IS 10 BP 1034 EP 1042 DI 10.1053/S1542-3565(05)00695-6 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 995NC UT WOS:000234106000018 PM 16234051 ER PT J AU Gupta, MA Johnson, AM Chren, MM AF Gupta, MA Johnson, AM Chren, MM TI Evaluating clinical rating scales for evidence-based dermatology: Some basic concepts SO DERMATOLOGIC CLINICS LA English DT Article ID QUALITY-OF-LIFE AB Evidence-based dermatology has necessitated the development of rating scales that measure multidimensional and abstract constructs, such as quality of life. This article discusses some basic psychometric concepts, such as reliability, validity, standardization, and measurement precision, which need to be considered when choosing a clinical rating instrument. Also discussed is the impact of these parameters on increasing the statistical power of a clinical trial. C1 Univ Western Ontario, Dept Psychiat, London, ON N6A 3K7, Canada. Univ Western Ontario, Fac Hlth Sci, London, ON N6A 3K7, Canada. Mediprobe Res Inc, London, ON, Canada. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. RP Gupta, MA (reprint author), 645 Windermere Rd, London, ON N5X 2P1, Canada. EM magupta@uwo.ca NR 9 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0733-8635 J9 DERMATOL CLIN JI Dermatol. Clin. PD OCT PY 2005 VL 23 IS 4 BP 703 EP + DI 10.1016/j.det.2005.05.004 PG 5 WC Dermatology SC Dermatology GA 966CH UT WOS:000231996700015 PM 16112447 ER PT J AU Schwartz, GG Olson, AG Szarek, M Sasiela, WJ AF Schwartz, GG Olson, AG Szarek, M Sasiela, WJ TI Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial SO DIABETES CARE LA English DT Article ID DIABETES-MELLITUS; NONDIABETIC PATIENTS; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; CLINICAL-OUTCOMES; ARTERY-DISEASE; INFARCTION; HYPERTENSION; HISTORY; OBESITY AB OBJECTIVE - We examined relations between characteristics of the metabolic syndrome, early cardiovascular risk, and effect of early, intensive statin therapy after acute coronary syndrome. RESEARCH DESIGN AND METHODS - A total of 3,038 patients in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial were characterized by the presence or absence of a history of diabetes, a history of hypertension and/or blood pressure >= 130/>= 85, BMI >30 kg/m(2), HDL cholesterol <40 mg/dl (men) or <50 mg/dl (women), and triglycerides E 150 mg/dl. Patients with three or more of these characteristics were categorized as having metabolic syndrome. RESULTS - A total of 38% of patients (n = 1, 161) met criteria for metabolic syndrome as defined in this study and had a 19% incidence of a primary end point event (death, nonfatal myocardial infarction, cardiac arrest, or recurrent unstable myocardial ischemia) during the 16-week trial. Patients with two or fewer characteristics (n = 1,877) were classified as not having metabolic syndrome and had a 14% incidence of a primary end point event. In univariate analysis, the individual characteristics that bore a significant relation to risk were diabetes and low HDL cholesterol. In a multivariable model including age, sex, and randomized treatment assignment, presence of metabolic syndrome was associated with a hazard ratio of 1.49 (95% CI 1.24-1.79, P < 0.0001). Relative risk reduction with 80 mg atorvastatin daily compared wit placebo was similar in patients with and without metabolic syndrome. CONCLUSIONS - Metabolic syndrome, as defined in the context of this clinical trial, is a strong predictor of early recurrent ischemic events after acute coronary syndrome. C1 Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Linkoping Univ, Dept Internal Med, Linkoping, Sweden. Pifzer, New York, NY USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect, 111B, Denver, CO 80220 USA. EM gregory.schwartz@med.va.gov NR 30 TC 47 Z9 50 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2005 VL 28 IS 10 BP 2508 EP 2513 DI 10.2337/diacare.28.10.2508 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 971CO UT WOS:000232358900028 PM 16186288 ER PT J AU DuBois, S Eng, S Bhattacharya, R Rulyak, S Hubbard, T Putnam, D Kearney, DJ AF DuBois, S Eng, S Bhattacharya, R Rulyak, S Hubbard, T Putnam, D Kearney, DJ TI Breath ammonia testing for diagnosis of hepatic encephalopathy SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE encephalopathy; cirrhosis; ammonia ID NUMBER-CONNECTION TESTS; LIVER-DISEASE; BLOOD AMMONIA AB Measurement of arterial ammonia has been used as a diagnostic test for hepatic encephalopathy, but obtaining an arterial specimen is an invasive procedure. The aim of this study was to evaluate the ability of a minimally invasive, highly sensitive optical sensing device to detect ammonia in the breath of patients with end-stage liver disease and to evaluate the correlation of breath ammonia levels, arterial ammonia levels, and psychometric testing. Fifteen subjects with liver cirrhosis and clinical evidence of hepatic encephalopathy underwent mini-mental status examination, number connection test, focused neurological examination, and arterial ammonia testing. On the same day, breath ammonia testing was performed using an apparatus that consists of a sensor (a thin membrane embedded with a pH-sensitive dye) attached to a fiberoptic apparatus that detects optical absorption. Helicobacter pylori testing was performed using the C-14 urea breath test. A positive correlation was found between arterial ammonia level and time to complete the number connection test (r = 0.31, P = 0.03). However, a negative correlation was found between breath ammonia level and number connection testing (r = -0.55, P = 0.03). Furthermore, no correlation was found between breath and arterial ammonia levels (r = -0.005, P = 0.98). There is a significant correlation between the trailmaking test and arterial ammonia levels in patients with cirrhosis. However, no correlation was found between breath and arterial ammonia levels using the fiberoptic ammonia sensor apparatus in this small study. C1 Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Pacific Technol, Kirkland, WA USA. RP Kearney, DJ (reprint author), Seattle VAMC, 111GI,1660 S Columbian Way, Seattle, WA 98108 USA. EM kearney@u.washington.edu NR 17 TC 44 Z9 44 U1 1 U2 19 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2005 VL 50 IS 10 BP 1780 EP 1784 DI 10.1007/s10620-005-2937-6 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 968KS UT WOS:000232162000005 PM 16187173 ER PT J AU Stefan, M Ji, H Simmons, RA Cummings, DE Ahima, RS Friedman, MI Nicholls, RD AF Stefan, M Ji, H Simmons, RA Cummings, DE Ahima, RS Friedman, MI Nicholls, RD TI Hormonal and metabolic defects in a Prader-Willi syndrome mouse model with neonatal failure to thrive SO ENDOCRINOLOGY LA English DT Article ID FACTOR BINDING PROTEIN-1; GROWTH-HORMONE; BODY-COMPOSITION; POSTNATAL LETHALITY; ANGELMAN-SYNDROMES; RAT HEPATOCYTES; ENERGY-BALANCE; GHRELIN LEVELS; FOOD-INTAKE; IGF-I AB Prader-Willi syndrome (PWS) has a biphasic clinical phenotype with failure to thrive in the neonatal period followed by hyperphagia and severe obesity commencing in childhood among other endocrinological and neurobehavioral abnormalities. The syndrome results from loss of function of several clustered, paternally expressed genes in chromosome 15q11q13. PWS is assumed to result from a hypothalamic defect, but the pathophysiological basis of the disorder is unknown. We hypothesize that a fetal developmental abnormality in PWS leads to the neonatal phenotype, whereas the adult phenotype results from a failure in compensatory mechanisms. To address this hypothesis and better characterize the neonatal failure to thrive phenotype during postnatal life, we studied a transgenic deletion PWS (TgPWS) mouse model that shares similarities with the first stage of the human syndrome. TgPWS mice have fetal and neonatal growth retardation associated with profoundly reduced insulin and glucagon levels. Consistent with growth retardation, TgPWS mice have deregulated liver expression of IGF system components, as revealed by quantitative gene expression studies. Lethality in TgPWS mice appears to result from severe hypoglycemia after postnatal d 2 after depletion of liver glycogen stores. Consistent with hypoglycemia, TgPWS mice appear to have increased fat oxidation. Ghrelin levels increase in TgPWS reciprocally with the falling glucose levels, suggesting that the rise in ghrelin reported in PWS patients may be secondary to a perceived energy deficiency. Together, the data reveal defects in endocrine pancreatic function as well as glucose and hepatic energy metabolism that may underlie the neonatal phenotype of PWS. C1 Childrens Hosp Pittsburgh, Dept Pediat, Birth Defects Labs, Rangos Res Ctr, Pittsburgh, PA 15213 USA. Univ Penn, Sch Med, Dept Psychiat, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA. Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Genet, Sch Med, Philadelphia, PA 19104 USA. Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Nicholls, RD (reprint author), Childrens Hosp Pittsburgh, Dept Pediat, Birth Defects Labs, Rangos Res Ctr, 3460 5th Ave,Room 2109, Pittsburgh, PA 15213 USA. EM robert.nicholls@chp.edu FU NIA NIH HHS [AG20898]; NICHD NIH HHS [HD36079, HD31491]; NIDDK NIH HHS [DK53109, DK61516, DK49210, DK19525, DK55704] NR 59 TC 30 Z9 30 U1 1 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD OCT PY 2005 VL 146 IS 10 BP 4377 EP 4385 DI 10.1210/en.2005-0371 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 964QR UT WOS:000231896100028 PM 16002520 ER PT J AU Sharma, VK Eliakim, R Sharma, P Faigel, D AF Sharma, VK Eliakim, R Sharma, P Faigel, D TI ICCE consensus for esophageal capsule endoscopy SO ENDOSCOPY LA English DT Article; Proceedings Paper CT 4th International Conference on Capsule Endoscopy CY MAR 07-09, 2005 CL Miami Beach, FL ID BARRETTS-ESOPHAGUS; UNITED-STATES; ADENOCARCINOMA; DISEASES C1 Mayo Clin Scottsdale, Dept Internal Med, Div Gastroenterol & Hepatol, Scottsdale, AZ 85259 USA. Technion Israel Inst Technol, Rambam Med Ctr, Dept Gastroenterol, Haifa, Israel. Univ Kansas, Sch Med, Div Gastroenterol Hepatol & Nutr, Kansas City, MO USA. VA Med Ctr, Kansas City, MO USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Dept Med, Portland, OR 97201 USA. RP Sharma, VK (reprint author), Mayo Clin Scottsdale, Div Gastroenterol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. EM sharma.virender@mayo.edu NR 17 TC 22 Z9 25 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X J9 ENDOSCOPY JI Endoscopy PD OCT PY 2005 VL 37 IS 10 BP 1060 EP 1064 DI 10.1055/s-870311 PG 5 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 974HC UT WOS:000232581000029 PM 16189791 ER PT J AU Guzman-Marin, R Suntsova, N Methippara, M Greiffenstein, R Szymusiak, R McGinty, D AF Guzman-Marin, R Suntsova, N Methippara, M Greiffenstein, R Szymusiak, R McGinty, D TI Sleep deprivation suppresses neurogenesis in the adult hippocampus of rats SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE BrdU; dentate gyrus; hippocampus; neurogenesis; plasticity; sleep deprivation ID CEREBRAL PROTEIN-SYNTHESIS; GENERATED GRANULE CELLS; DENTATE GYRUS; AXONAL PROJECTIONS; STRESS; PROLIFERATION; EXPRESSION; INCREASES; NEURONS; DOUBLECORTIN AB We reported previously that 96 h of sleep deprivation (SD) reduced cell proliferation in the dentate gyrus (DG) of the hippocampus in adult rats. We now report that SD reduces the number of new cells expressing a mature neuronal marker, neuronal nuclear antigen (NeuN). Rats were sleep-deprived for 96 h, using an intermittent treadmill system. Total sleep time was reduced to 6.9% by this method in SD animals, but total treadmill movement was equated in SD and treadmill control (CT) groups. Rats were allowed to survive for 3 weeks after 5-bromo-2-deoxyuridine (BrdU) injection. The phenotype of BrdU-positive cells in the DG was assessed by immunofluorescence and confocal microscopy. After 3 weeks the number of BrdU-positive cells was reduced by 39.6% in the SD group compared with the CT. The percentage of cells that co-localized BrdU and NeuN was also lower in the SD group (SD: 46.6 +/- 1.8% vs. CT: 71.9 +/- 2.1, P < 0.001). The percentages of BrdU-labeled cells co-expressing markers of immature neuronal (DCX) or glial (S100-beta) cells were not different in SD and CT groups. Thus, SD reduces neurogenesis in the DG by affecting both total proliferation and the percentage of cells expressing a mature neuronal phenotype. We hypothesize that sleep provides anabolic or signaling support for proliferation and cell fate determination. C1 VA Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Rostov State Univ, AB Kogan Res Inst Neurocybernet, Rostov Na Donu 344006, Russia. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP McGinty, D (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. EM dmcginty@ucla.edu FU NHLBI NIH HHS [HL 60296]; PHS HHS [47480] NR 51 TC 96 Z9 99 U1 0 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD OCT PY 2005 VL 22 IS 8 BP 2111 EP 2116 DI 10.1111/j.1460-9568.2005.04376.x PG 6 WC Neurosciences SC Neurosciences & Neurology GA 976ZN UT WOS:000232772300027 PM 16262649 ER PT J AU Retzinger, GS Takayama, K AF Retzinger, GS Takayama, K TI Mitogenicity of a spread film of monophosphoryl lipid A SO EXPERIMENTAL AND MOLECULAR PATHOLOGY LA English DT Article DE monophosphoryl lipid A; lipid A; lipopolysaccharide; adsorbed film; surface properties; mitogenicity; innate immunity ID TREHALOSE 6,6'-DIMYCOLATE; STRUCTURAL DETERMINATION; BIOLOGICAL-ACTIVITIES; MOLECULAR-MECHANISMS; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE; ENDOTOXIN; PURIFICATION; RECOGNITION; MACROPHAGES AB When spread at the air-water interface, monophosphoryl lipid A (MPLA) forms stable insoluble monolayers that collapse at similar to 55 dyn/ cm. At collapse, the exclusion area of each molecule is similar to 119 angstrom(2), consistent with the cross-sectional area of the lipid's 6 acyl chains. The nominal thickness of such films is similar to 22 angstrom, determined, presumably, by the length of the acyl chains. For biological modeling of MPLA films, a system was developed in which monolayers of the lipid are supported by monodisperse hydrophobic beads of microscopic dimensions. Beads coated with MPLA monolayers within which the nominal area of each molecule is approximately equivalent to the "take-off" area of the lipid at the air-water interface, 280 angstrom(2), are mitogenic for spleen cells. Given the natural occurrence of lipid A in the bacterial cell wall as well as the inherent stability of lipid A films, it seems reasonable to assume that at least some of the biological activities attributed to the lipid derive from its presentation/operation at an interface, i.e., on a surface. We propose beads coated with adsorbed films of lipid A will prove useful tools for modeling the activities of the lipid both in vitro and in vivo, and for elucidating the surface dependency and structural requirements of those activities. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA. William S Middleton Mem Vet Adm Med Ctr, Mycobacteriol Res Lab, Madison, WI 53705 USA. RP Retzinger, GS (reprint author), Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA. EM retzings@email.uc.edu FU NCI NIH HHS [R21CA106257] NR 29 TC 1 Z9 1 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4800 J9 EXP MOL PATHOL JI Exp. Mol. Pathol. PD OCT PY 2005 VL 79 IS 2 BP 161 EP 167 DI 10.1016/j.yexmp.2005.06.004 PG 7 WC Pathology SC Pathology GA 968VF UT WOS:000232190300010 PM 16054128 ER PT J AU Goody, RJ Hoyt, CC Tyler, KL AF Goody, RJ Hoyt, CC Tyler, KL TI Reovirus infection of the CNS enhances NOS expression in areas of virus-induced injury SO EXPERIMENTAL NEUROLOGY LA English DT Article DE reovirus; nitric oxide; viral encephalitis; nitric oxide synthase; neurons; microglia ID NITRIC-OXIDE SYNTHASE; CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; INDUCED APOPTOSIS REQUIRES; IN-VIVO EXPRESSION; TRANSCRIPTION FACTOR; NEURONAL APOPTOSIS; S-NITROSYLATION; DNA-BINDING; INHIBITION AB Nitric oxide (NO) has been implicated as a contributor to the host's innate defense against viral infections including those affecting the CNS. Reovirus infection of the CNS is a classic experimental system for understanding the pathogenesis of neurotropic viral infection. Infection with serotype 3 strains is associated with perturbations in various cellular signaling pathways including NF-kappa B and NO plays a regulatory role in many of these same pathways. We therefore examined whether NO production is dysregulated following reovirus serotype 3 strain Abney (T3A) infection of the mouse CNS. Nitric oxide synthase (NOS) activity was significantly higher in brain homogenates from T3A-infected animals compared to mock infected. Increased NOS activity correlated with inducible NOS (iNOS) expression in brain homogenates of M-infected animals. Expression of iNOS was confined to areas of viral infection and injury. T3A infection of primary neuronal and glial cultures was also associated with enhanced expression of iNOS. Immunocytochemical studies of primary glial cultures demonstrated that, in addition to its known neuronotropism, T3A was also capable of infecting immature microglial cells. T3A infection did not alter expression of either neuronal or endothelial NOS isoforms in neuronal or glial cultures or in mouse brain. The NO donor S-Nitroso-N-acetyl penicillamine (SNAP) significantly inhibited T3A growth in neuronal cultures, conversely the NOS inhibitor N-omega-Nitro-L-arginine methyl ester hydrochloride (L-NAME) augmented viral growth. Our findings provide the first evidence of reovirus-induced iNOS expression and the first demonstration that NO inhibits mammalian reovirus replication, suggesting that NO may play an antiviral role during reovirus infection. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol B182, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B182, 4200 E 9th Ave, Denver, CO 80262 USA. EM Ken.Tyler@uchse.edu FU NINDS NIH HHS [R01 NS051403-03, R01 NS050138-04, R01 NS051403, R01 NS050138] NR 52 TC 18 Z9 18 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD OCT PY 2005 VL 195 IS 2 BP 379 EP 390 DI 10.1016/j.expneurol.2005.05.016 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 968VI UT WOS:000232190600011 PM 16004984 ER PT J AU Ko, CW Sonnenberg, A AF Ko, CW Sonnenberg, A TI Comparing risks and benefits of colorectal cancer screening in elderly patients SO GASTROENTEROLOGY LA English DT Article ID FECAL-OCCULT-BLOOD; RANDOMIZED CONTROLLED TRIAL; COST-EFFECTIVENESS; FLEXIBLE SIGMOIDOSCOPY; ONE-TIME; COLONOSCOPY; MORTALITY; COMPLICATIONS; PERFORATION; POPULATION AB Background& Aims: In patients with limited life expectancy, the risks of colorectal cancer screening may outweigh the benefits. The aim of this study was to quantify risks and benefits of different screening strategies in elderly patients with varying life expectancies. Methods: We examined risks and benefits of screening in patients aged 70-94 years with differing health status using 3 strategies: annual fecal occult blood tests, flexible sigmoldoscopy every 5 years, or colonoscopy every :10 years. We compared the number needed to screen to prevent one cancer-related death and the number needed to encounter one screening-related complication for different strategies. Results: The potential benefit from screening varied widely with age, life expectancy, and screening modality. One cancer-related death would be prevented by screening 42 healthy men aged 70-74 years with colonoscopy, 178 healthy women aged 70-74 years with fecal occult blood tests, 431 women aged 75-79 years in poor health with colonoscopy, or 945 men aged 80-84 years in average health with fecal occult blood tests. Colonoscopy screening had the greatest benefit but the highest risk of complications. The potential for screening-related complications was greater than estimated benefit in some population subgroups aged 70 years and older. At all ages and life expectancies, the potential reduction in mortality from screening outweighed the risk of colon oscopy-related death. Conclusions: The potential benefits and risks of screening vary in elderly patients of different life expectancies. For any individual patient, the potential for harm from screening must be weighed against the likelihood of benefit, especially with shorter life expectancy. C1 Univ Washington, Div Gastroenterol, Dept Med, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Ko, CW (reprint author), Univ Washington, Div Gastroenterol, Dept Med, Box 356424, Seattle, WA 98195 USA. EM cwko@u.washington.edu NR 34 TC 49 Z9 50 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2005 VL 129 IS 4 BP 1163 EP 1170 DI 10.1053/j.gastro.2005.07.027 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 974IX UT WOS:000232586000006 PM 16230070 ER PT J AU Abraham, NS El-Serag, HB Johnson, ML Hartman, C Richardson, P Ray, WA Smalley, W AF Abraham, NS El-Serag, HB Johnson, ML Hartman, C Richardson, P Ray, WA Smalley, W TI National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs SO GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT 69th Annual Meeting of the American-College-of-Gastroenterology CY OCT 29-NOV 03, 2004 CL Orlando, FL SP Amer Coll Gastroenterol ID SERIOUS GASTROINTESTINAL COMPLICATIONS; PEPTIC-ULCER; RHEUMATOID-ARTHRITIS; CONTROLLED-TRIAL; ELDERLY PERSONS; CONSENSUS PANEL; RISK; OSTEOARTHRITIS; OMEPRAZOLE; PREVENTION AB Background & Aims: Our objective was to assess adherence to evidence-based guidelines by providers of the Department of Veterans Affairs nationwide. Methods: This was a cross-sectional study among veterans prescribed a nonsteroidal anti-inflammatory drug (NSAID) from January 1, 2002, to December 31, 2002. Prescription data were linked to inpatient and outpatient medical records and death files. The population was characterized as high risk based on the following: age 65 years or older, concurrent corticosterold or anticoagulant use, history of peptic ulcer, and high average daily dose of NSAIDs. Adherence was defined as the prescription of a traditional NSAID with gastroprotection or a coxib in high-risk NSAID users. Univariate and multivarlate analyses assessed the potential predictors of adherence. Results: Three hundred three thousand seven hundred eighty-seven met our definition of high risk. Most (97.3%) were male; 55.6% were white, 9.6% black, and 34.8% of other/unknown race. Age 65 years or older was the largest high-risk subset (87.1%). Overall, only 27.2% of high-risk veterans (n = 82,766) were prescribed an adherent strategy. Among veterans with at least 2 risk factors, adherence was 39.7%; among those with 3 risk factors, adherence was 41.8%. Predictors of adherence included history of upper gastrointestinal events, anticoagulant use, rheumatologic disease, high Deyo comorbidity index score, use of low-dose salicylates, and concurrent corticosterold use. Predictors of nonadherence included prescriptions >= 90 days and high average daily dose of NSAIDs. Conclusions: Adherence to evidence-based guidelines for safe prescription of NSAIDs in the Department of Veterans Affairs is low (27.2%). The likelihood of adherence is further decreased if veterans are prescribed NSAIDs for 2:90 days. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Gastroenterol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Vanderbilt Univ, Dept Prevent Med, Nashville, TN USA. Vanderbilt Univ, Dept Med, Nashville, TN USA. Vet Affairs Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. RP Abraham, NS (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Gastroenterol, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM nabraham@bcm.tmc.edu NR 43 TC 94 Z9 96 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2005 VL 129 IS 4 BP 1171 EP 1178 DI 10.1053/j.gastro.2005.08.003 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 974IX UT WOS:000232586000007 PM 16230071 ER PT J AU Al Jurdi, R Pulakhandam, S Kunik, ME Marangell, LB AF Al Jurdi, R Pulakhandam, S Kunik, ME Marangell, LB TI Late-life mania - Assessment and treatment of late-life manic symptoms SO GERIATRICS LA English DT Article ID BIPOLAR DISORDER; EFFICACY; LITHIUM; ONSET; AGE C1 Michael E DeBakey Vet Affairs Med Ctr, Mood Disorders Clin, Houston, TX USA. Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA. Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Al Jurdi, R (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Mood Disorders Clin, Houston, TX USA. NR 14 TC 2 Z9 2 U1 0 U2 0 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD OCT PY 2005 VL 60 IS 10 BP 18 EP + PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 978ZD UT WOS:000232910800009 PM 16218763 ER PT J AU Huynh, T Sanchez-Reilly, S AF Huynh, T Sanchez-Reilly, S TI Geriatric assessment clinic in a major cancer center: A needed interdisciplinary partnership among geriatrics and oncology SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 10 EP 11 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000021 ER PT J AU Underwood, W Copeland, L Elshaikh, M Penner, L Jackson, J AF Underwood, W Copeland, L Elshaikh, M Penner, L Jackson, J TI The use of brachytherapy for the treatment of clinically localized prostate cancer in older aged men SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Michigan, Ann Arbor, MI 48109 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Karmanos Canc Inst, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 10 EP 10 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000019 ER PT J AU Sonntag, W Carter, C Ikeno, Y Lee, S AF Sonntag, W Carter, C Ikeno, Y Lee, S TI Increased growth hormone and IGF-1 during adolescence are required for longer lifespan in a model of adult-onset growth hormone/IGF-1 deficiency SO GERONTOLOGIST LA English DT Meeting Abstract C1 Wake Forest Univ Hlth Sci, Winston Salem, NC USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Dept Vet Affairs Med Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 67 EP 68 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000188 ER PT J AU Abdel-Karim, I Sanchez-Reilly, S AF Abdel-Karim, I Sanchez-Reilly, S TI A combined consultation service in geriatrics and palliative care for geriatric oncology patients: A clinical case SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Affairs Hlth Care Syst, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, GRECC, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 112 EP 113 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000303 ER PT J AU Markland, A Gerety, M Kraus, S Espino, D AF Markland, A Gerety, M Kraus, S Espino, D TI Diabetes and urinary incontinence associations among older, hispanic women SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Adm, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 121 EP 122 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000323 ER PT J AU Underwood, W Copeland, L Elshaikh, M Penner, L Jackson, J AF Underwood, W Copeland, L Elshaikh, M Penner, L Jackson, J TI Racial variations in the use of specific prostate cancer treatment modalities SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Michigan, Ann Arbor, MI 48109 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Karmanos Canc Inst, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 125 EP 126 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000334 ER PT J AU Huynh, T Sanchez-Reilly, S AF Huynh, T Sanchez-Reilly, S TI To treat or not to treat is not the question SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 234 EP 235 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000607 ER PT J AU Owings, K Sanchez-Reilly, S AF Owings, K Sanchez-Reilly, S TI Answering a geriatrics consult in "postoperative dementia": An elderly surgical patient with delirium SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 234 EP 234 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000605 ER PT J AU Hedrick, S Chapko, M Sullivan, J Barry, S Zhou, A Wang, L Guihan, M Manheim, L AF Hedrick, S Chapko, M Sullivan, J Barry, S Zhou, A Wang, L Guihan, M Manheim, L TI Outcomes of the assisted living pilot project: How does assisted living work in VA? SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 271 EP 272 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000712 ER PT J AU Guihan, M Thomas, M Hedrick, S AF Guihan, M Thomas, M Hedrick, S TI Participation of assisted living providers in VA Assisted Living Pilot Program SO GERONTOLOGIST LA English DT Meeting Abstract C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 272 EP 272 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000713 ER PT J AU Akhtar, A Sanchez-Reilly, S AF Akhtar, A Sanchez-Reilly, S TI Combining geriatrics and palliative care into an inpatient consultation service: A innovative model of care for the elderly SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 292 EP 293 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000763 ER PT J AU Walker, W Drexler, M Moody-Ayers, S Walker, W AF Walker, W Drexler, M Moody-Ayers, S Walker, W TI Interdisciplinary group behavorial intervention for dementia in long-term care SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 337 EP 337 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615000883 ER PT J AU Petersen, N Ford, M Matthiesen, E Cox, V Teng, E Kallen, M AF Petersen, N Ford, M Matthiesen, E Cox, V Teng, E Kallen, M TI Effects of social support on comprehension and recall of consent form information SO GERONTOLOGIST LA English DT Meeting Abstract C1 Baylor Coll Med, VA HRS&D COE, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 417 EP 418 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615001208 ER PT J AU Williams, C Williams, B Burgio, K Shuster, J AF Williams, C Williams, B Burgio, K Shuster, J TI Recruiting older adults for medical research: The who, what and why SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Alabama, Div Gerontol & Geriatr Med, Birmingham, AL USA. Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 SI 2 BP 468 EP 468 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 988QF UT WOS:000233615001348 ER PT J AU Schnelle, JF Osterweil, D Simmons, SF AF Schnelle, JF Osterweil, D Simmons, SF TI Improving the quality of nursing home care and medical-record accuracy with direct observational technologies SO GERONTOLOGIST LA English DT Article DE observations; nursing home quality assessment; nursing home survey ID MINIMUM DATA SET; RESIDENTS; RELIABILITY AB Nursing home medical-record documentation of dlaily-care occurrence may be inaccurate, and information is not documented about important quality-of-life domains. The inadequacy of medical record data creates a barrier to improving care quality, because it supports an illusion of care consistent with regulations, which reduces the motivation and ability of providers to identify areas for improvement. Observational protocols designed for use by survey and quality-assurance staff can provide the independent information necessary for improving both medical record accuracy and residents' quality of life. Unfortunately, observational protocols currently used in survey and quality-assurance activities are not designed in a manner that is consistent with the scientific principles that guide observational measurement. The purpose of this article is to describe the steps to develop a standardized and scientifically defensible observational system to assess nursing home care quality. C1 Univ Calif Los Angeles, Dept Med, Div Geriatr, Reseda, CA 91335 USA. VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. Los Angeles Jewish Home Aging, Borun Ctr Gerontol Res, Los Angeles, CA USA. RP Schnelle, JF (reprint author), Univ Calif Los Angeles, Dept Med, Div Geriatr, 7150 Tampa Ave, Reseda, CA 91335 USA. EM jschnell@ucla.edu NR 21 TC 22 Z9 22 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2005 VL 45 IS 5 BP 576 EP 582 PG 7 WC Gerontology SC Geriatrics & Gerontology GA 969RH UT WOS:000232251900001 PM 16199391 ER PT J AU Tillisch, K Mayer, EA Labus, JS Stains, J Chang, L Naliboff, BD AF Tillisch, K Mayer, EA Labus, JS Stains, J Chang, L Naliboff, BD TI Sex specific alterations in autonomic function among patients with irritable bowel syndrome SO GUT LA English DT Article ID HEART-RATE-VARIABILITY; NERVOUS-SYSTEM FUNCTION; DIARRHEA-PREDOMINANT; VISCERAL PERCEPTION; DEPRESSION SCALE; HOSPITAL ANXIETY; POWER SPECTRUM; IBS PATIENTS; RESPONSES; GENDER AB Background: Irritable bowel syndrome (IBS) is associated with increased psychological symptoms, early life stressors, and alterations in visceral perception and brain responses to noxious visceral stimuli. The autonomic nervous system (ANS) is a likely mediator for these brain-gut interactions. The few studies directly examining ANS measures have been suggestive of alterations in some IBS patients, but no studies to date have examined the potentially critical variables of sex differences or response to visceral stimulation. Aims: ( 1) To test differences in ANS function during rest and during a visceral stressor ( rectosigmoid balloon distension) between IBS patients and healthy control subjects. ( 2) To examine the role of sex on the autonomic responses of IBS patients. Methods: Baseline autonomic measures were evaluated from 130 Rome I positive IBS patients and 55 healthy control subjects. Data were also collected from a subset of 46 IBS patients and 16 healthy control subjects during a sigmoid balloon distension study. Heart rate variability measures of peak power ratio (PPR) and peak power high frequency (PPHF) were analysed to assess sympathetic balance and parasympathetic response, respectively. Peripheral sympathetic response was measured by skin conductance. Results: IBS patients showed a greater skin conductance response to visceral distension than controls. IBS patients had higher PPR and lower PPHF across conditions. Male IBS patients had higher skin conductance and PPR than females and lower PPHF. Conclusions: IBS patients have altered autonomic responsiveness to a visceral stressor, with increased sympathetic and decreased parasympathetic activity. These differences are predominantly seen in males. C1 Univ Calif Los Angeles, David Geffen Sch Med, CNS WH Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tillisch, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CNS WH Ctr Neurovisceral Sci & Womens Hlth, CURE Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ktillisch@mednet.ucla.edu FU NIDDK NIH HHS [P50 DK064539]; NINR NIH HHS [NR007768, R01 NR007768] NR 46 TC 85 Z9 88 U1 2 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD OCT PY 2005 VL 54 IS 10 BP 1396 EP 1401 DI 10.1136/gut.2004.058685 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964JC UT WOS:000231876000014 PM 15923667 ER PT J AU Anand, BS Thornby, J AF Anand, BS Thornby, J TI Alcohol has no effect on hepatitis C virus replication: a meta-analysis SO GUT LA English DT Article ID LIVER-DISEASE; NATURAL-HISTORY; HEPATOCELLULAR-CARCINOMA; INFECTION; PROGRESSION; PREVALENCE; FIBROSIS; CONSUMPTION; CIRRHOSIS; ABUSE AB Background: Patients with chronic hepatitis C virus (HCV) infection who consume large quantities of alcohol have more severe liver disease compared with HCV patients without a history of alcohol consumption. The mechanism by which alcohol worsens HCV related liver disease is not properly understood. One possibility is that alcohol stimulates HCV replication, and the present meta-analysis was performed to examine this issue. Methods: The effect of alcohol on viral titres was assessed in three ways: comparison of the heaviest drinkers with non-drinkers; effect of graded doses of alcohol; and effect of abstinence in the same individual. Results: A total of 14 studies were identified. Comparison of patients with the highest alcohol use with the abstinent group showed a significant association with viral load in three studies, five studies had a positive direction, while the remaining four studies found a negative relationship. Analysis of the combined results showed no association between alcohol consumption and virus levels ( p = 0.29). Assessment of graded doses of alcohol also showed no significant difference between non-drinkers and moderate drinkers ( p = 0.50), between non-drinkers and heavy drinkers ( p = 0.35), or between moderate drinkers and heavy drinkers ( p = 0.32). Five studies examined the influence of abstinence on viral titres but none provided sufficient data for statistical analysis. Conclusions: The present study has failed to show an association between alcohol use and HCV viral titres. These observations raise the possibility that the hepatic damage caused by alcohol and HCV may be purely additive, involving different mechanisms and pathways. C1 Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Anand, BS (reprint author), VA Med Ctr, Digest Dis Sect 111D, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM ana0@flash.net NR 32 TC 19 Z9 20 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD OCT PY 2005 VL 54 IS 10 BP 1468 EP 1472 DI 10.1136/gut.2004.056697 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964JC UT WOS:000231876000024 PM 16162952 ER PT J AU Fortney, JC Steffick, DE Burgess, JF Maciejewski, ML Petersen, LA AF Fortney, JC Steffick, DE Burgess, JF Maciejewski, ML Petersen, LA TI Are primary care services a substitute or complement for specialty and inpatient services? SO HEALTH SERVICES RESEARCH LA English DT Article; Proceedings Paper CT AcademyHealth Annual Meeting CY JUN, 2004 CL San Diego, CA DE primary care; service substitution; cost; managed care ID INSTRUMENTAL VARIABLES; PREVENTIVE SERVICES; AMBULATORY CARE; UNITED-STATES; MEDICAL-CARE; ACCESS; HOSPITALIZATIONS; OUTCOMES; COSTS; CONTINUITY AB Objective. To determine whether strategies designed to increase members' use of primary care services result in decreases (substitution) or increases (complementation) in the use and cost of other types of health services. Study Setting. Encounter and cost data were extracted from the Department of Veterans Affairs (VA) administrative data sources for the period 1995-1999. This time-frame captures the VA's natural experiment of increasing geographic access to primary care by establishing new satellite primary care clinics, known as Community-Based Outpatient Clinics (CBOCs). Study Design. We exploited this natural experiment to estimate the substitutability of primary care for other health services and its impact on cost. Hypotheses were tested using ordinary least squares (OLS) regression, which was potentially subject to endogeneity bias. Endogeneity bias was assessed using a Hausman test. Endogeneity bias was accounted for by using instrumental variables analysis, which capitalized on the establishment of CBOCs to provide an exogenous identifier (change in travel distance to primary care). Data Collection. Demographic, encounter, and cost data were collected for all veterans using VA health services who resided in the catchment areas of new CBOCs and for a matched group of veterans residing outside CBOC catchment areas. Principal Findings. Change in distance to primary care was a significant and substantial predictor of change in primary care visits. OLS analyses indicated that an increase in primary care service use was associated with increases in the use of all specialty outpatient services and inpatient services, as well as increases in inpatient and outpatient costs. Hausman tests confirmed that OLS results for specialty mental health encounters and mental health admissions were unbiased, but that results for specialty medical encounters, physical health admissions, and outpatient costs were biased. Instrumental variables analyses indicated that an increase in primary care encounters was associated with a decrease in specialty medical encounters and was not associated with an increase in physical health admissions, or outpatient costs. Conclusions. Results provide evidence that health systems can implement strategies to encourage their members to use more primary care services without driving up physical health costs. C1 Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev, Ctr Mental Hlth & Outcomes Res, N Little Rock, AR 72114 USA. Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR USA. Boston Univ, Sch Publ Hlth, Boston, MA USA. Management Sci Grp, Dept Vet Affairs, Bedford, MA USA. VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Hlth Serv Res & Dev, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA USA. Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev, Houston VA, Houston, TX USA. Baylor Coll Med, Sect Hlth Serv Res, Houston, TX USA. RP Fortney, JC (reprint author), Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev, Ctr Mental Hlth & Outcomes Res, 2200 Fort Roots Dr, N Little Rock, AR 72114 USA. OI Burgess, James/0000-0002-6646-7071 NR 39 TC 30 Z9 31 U1 5 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2005 VL 40 IS 5 BP 1422 EP 1442 DI 10.1111/j.1475-6773.2005.00424.x PN 1 PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 962CG UT WOS:000231708000010 PM 16174141 ER PT J AU Kelly, PA O'Malley, KJ Kallen, MA Ford, ME AF Kelly, PA O'Malley, KJ Kallen, MA Ford, ME TI Integrating validity theory with use of measurement instruments in clinical settings SO HEALTH SERVICES RESEARCH LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med DE decision making; measurement; psychometrics; survey research; veterans ID VALIDATION; PSYCHOMETRICS; RELIABILITY; MULTITRAIT; FOCUS AB Objective. To present validity concepts in a conceptual framework useful for research in clinical settings. Principal Findings. We present a three-level decision rubric for validating measurement instruments, to guide health services researchers step-by-step in gathering and evaluating validity evidence within their specific situation. We address construct precision, the capacity of an instrument to measure constructs it purports to measure and differentiate from other, unrelated constructs; quantification precision, the reliability of the instrument; and translation precision, the ability to generalize scores from an instrument across subjects from the same or similar populations. We illustrate with specific examples, such as an approach to validating a measurement instrument for veterans when prior evidence of instrument validity for this population does not exist. Conclusions. Validity should be viewed as a property of the interpretations and uses of scores from an instrument, not of the instrument itself: how scores are used and the consequences of this use are integral to validity. Our advice is to liken validation to building a court case, including discovering evidence, weighing the evidence, and recognizing when the evidence is weak and more evidence is needed. C1 US Dept Vet Affairs, Hlth Serv Res & Dev Serv, METRIC, Houston, TX 77030 USA. Pearson Educ Measurement, Austin, TX USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. RP Kelly, PA (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, METRIC, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. NR 19 TC 7 Z9 7 U1 16 U2 17 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2005 VL 40 IS 5 BP 1605 EP 1619 DI 10.1111/j.1475-6773.2005.00445.x PN 2 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 964VF UT WOS:000231908400004 PM 16178998 ER PT J AU O'Malley, KJ Cook, KF Price, MD Wildes, KR Hurdle, JF Ashton, CM AF O'Malley, KJ Cook, KF Price, MD Wildes, KR Hurdle, JF Ashton, CM TI Measuring diagnoses: ICD code accuracy SO HEALTH SERVICES RESEARCH LA English DT Article DE ICD codes; accuracy; error sources ID TRANSIENT ISCHEMIC ATTACK; US ADULTS; STROKE; QUALITY; CARE; CLASSIFICATION; RELIABILITY; PATIENT; RECORDS; SYSTEM AB Objective. To examine potential sources of errors at each step of the described inpatient International Classification of Diseases (ICD) coding process. Data Sources/Study Setting. The use of disease codes from the ICD has expanded from classifying morbidity and mortality information for statistical purposes to diverse sets of applications in research, health care policy, and health care finance. By describing a brief history of ICD coding, detailing the process for assigning codes, identifying where errors can be introduced into the process, and reviewing methods for examining code accuracy, we help code users more systematically evaluate code accuracy for their particular applications. Study Design/Methods. We summarize the inpatient ICD diagnostic coding process from patient admission to diagnostic code assignment. We examine potential sources of errors at each step and offer code users a tool for systematically evaluating code accuracy. Principle Findings. Main error sources along the "patient trajectory" include amount and quality of information at admission, communication among patients and providers, the clinician's knowledge and experience with the illness, and the clinician's attention to detail. Main error sources along the "paper trail" include variance in the electronic and written records, coder training and experience, facility quality-control efforts, and unintentional and intentional coder errors, such as misspecification, unbundling, and upcoding. Conclusions. By clearly specifying the code assignment process and heightening their awareness of potential error sources, code users can better evaluate the applicability and limitations of codes for their particular situations. ICD codes can then be used in the most appropriate ways. C1 Pearson Educ Measurement, Austin, TX 78758 USA. Michael E DeBakey VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX USA. Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, VA Med Ctr, Dept Med, Sect Hlth Serv Res,Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. RP O'Malley, KJ (reprint author), Pearson Educ Measurement, 2201 Donley Dr,Suite 195, Austin, TX 78758 USA. NR 39 TC 249 Z9 252 U1 2 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2005 VL 40 IS 5 BP 1620 EP 1639 DI 10.1111/j.1475-6773.2005.00444.x PN 2 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 964VF UT WOS:000231908400005 PM 16178999 ER PT J AU Ford, ME Kelly, PA AF Ford, ME Kelly, PA TI Conceptualizing and categorizing race and ethnicity in health services research SO HEALTH SERVICES RESEARCH LA English DT Article DE race and ethnicity; measurement; health disparities ID PUBLIC-HEALTH; ACCULTURATION SCALE; UNITED-STATES; 2000 CENSUS; US CENSUS; RACE/ETHNICITY; HISPANICS; COMMUNITY; RACISM; DISCRIMINATION AB Objectives. Veterans Affairs (VA) patient populations are becoming increasingly diverse in race and ethnicity. The purpose of this paper is to (1) document the importance of using consistent standards of conceptualizing and categorizing race and ethnicity in health services research, (2) provide an overview of different methods currently used to assess race and ethnicity in health services research, and (3) suggest assessment methods that could be incorporated into health services research to ensure accurate assessment of disease prevalence and incidence, as well as accounts of appropriate health services use, in patients with different racial and ethnic backgrounds. Design. A critical review of published literature was used. Principal Findings. Race is a complex, multidimensional construct. For some individuals, institutionalized racism and internalized racism are intertwined in the effects of race on health outcomes and health services use. Ethnicity is most commonly used as a social-political construct and includes shared origin, shared language, and shared cultural traditions. Acculturation appears to affect the strength of the relationships among ethnicity, health outcomes, and health services use. Conclusion. Improved and consistent methods of data collection need to be developed for use by VA researchers across the country. VA research sites with patients representing specific population groups could use a core set of demographic items in addition to expanded modules designed to assess the ethnic diversity within these population groups. Improved and consistent methods of data collection could result in the collection of higher-quality data, which could lead to the identification of race- and ethnic-specific health services needs. These investigations could in turn lead to the development of interventions designed to reduce or eliminate these disparities. C1 Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. US Dept Vet Affairs, METRIC, Hlth Serv Res & Dev Serv, Houston, TX USA. RP Ford, ME (reprint author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, 135 Cannon St,Suite 303,POB 250835, Charleston, SC 29425 USA. FU NIA NIH HHS [1 P30 AG 21677, P30 AG021677] NR 47 TC 41 Z9 41 U1 1 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2005 VL 40 IS 5 BP 1658 EP 1675 DI 10.1111/j.1475-6773.2005.00449.x PN 2 PG 18 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 964VF UT WOS:000231908400007 PM 16179001 ER PT J AU Imamura, S Mitsufuji, S Shiomi, S Yamaoka, Y Tachibana, S Kato, N Fukumoto, K Sumida, Y Kanemasa, K Konishi, H Okanoue, T AF Imamura, S Mitsufuji, S Shiomi, S Yamaoka, Y Tachibana, S Kato, N Fukumoto, K Sumida, Y Kanemasa, K Konishi, H Okanoue, T TI Helicobacter pylori infection protects against pollen allergy SO HELICOBACTER LA English DT Meeting Abstract CT 18th International Workshop on Gastrointestinal Pathology and Helicobactor CY OCT 12-14, 2005 CL Copenhagen, DENMARK SP European Helicobacter Study Grp C1 Nara City Hosp, Nara, Japan. Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan. Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD OCT PY 2005 VL 10 IS 5 BP 512 EP 512 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 965LK UT WOS:000231951800174 ER PT J AU Behari, J Swaminathan, V Bryce, C Cacciarelli, TV Shakil, OA Ahmad, J AF Behari, J Swaminathan, V Bryce, C Cacciarelli, TV Shakil, OA Ahmad, J TI Racial differences in model for end-stage liver disease (MELD) scores, change in meld (DELTA MELD) on the transplant list, and waiting times of liver transplant recipients in the United States SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 205A EP 205A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480300024 ER PT J AU Kanwal, F Farid, M Martin, P Chen, G Gralnek, IM Dulai, GS Spiegel, BM AF Kanwal, F Farid, M Martin, P Chen, G Gralnek, IM Dulai, GS Spiegel, BM TI Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 W Los Angeles VA, Los Angeles, CA USA. Greater Los Angeles Healthcare Syst W LA, Los Angeles, CA USA. Mt Sinai Sch Med, New York, NY USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 351A EP 351A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480300388 ER PT J AU Anand, BS DeBakey, ME Currie, S Bini, EJ Shen, H Ho, SB Dieperink, E Wright, TL AF Anand, BS DeBakey, ME Currie, S Bini, EJ Shen, H Ho, SB Dieperink, E Wright, TL TI Alcohol use in US veterans: A multicenter study of 4,061 hepatitis C-infected patients SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Michael E DeBakey VA Med Ctr, Houston, TX USA. San Francisco VA Med Ctr, San Francisco, CA USA. VA New York Harbor Healthcare Syst, New York, NY USA. San Francisco VA Med Ctr, San Francisco, CA USA. Mineapolis VA Med Ctr, Minneapolis, MN USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 423A EP 423A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480301118 ER PT J AU Butt, AA Skanderson, M McGinnis, K Ahuja, T Bryce, C Barnato, A Chang, CCH AF Butt, AA Skanderson, M McGinnis, K Ahuja, T Bryce, C Barnato, A Chang, CCH TI Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Texas, Med Branch Galveston, Galveston, TX 77555 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 430A EP 430A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480301134 ER PT J AU Hoyumpa, A Sharkey, FE Brock, PS Page, RT Brock, PS Kashi, MR Herrera, AM Smith, W Poy, IG Webb, AL Ali, O AF Hoyumpa, A Sharkey, FE Brock, PS Page, RT Brock, PS Kashi, MR Herrera, AM Smith, W Poy, IG Webb, AL Ali, O TI Greater prevalence of cirrhosis in Hispanics than in Caucasians or African Americans SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Univ Texas, Ctr Hlth Sci, San Antonio, TX 78285 USA. Univ Texas, Phys Grp, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 442A EP 442A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480301163 ER PT J AU Soule, JL Olyaei, A Schwartz, M Rosen, HR Ham, JM Orloff, SL AF Soule, JL Olyaei, A Schwartz, M Rosen, HR Ham, JM Orloff, SL TI Recurrent hepatitis C is a risk factor for poor outcome after liver retransplantation SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 484A EP 485A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480301274 ER PT J AU Chang, SYP Chan, JP Santini, CD Sigua, CL Hu, XL Yee, L Li, HZ Wright, TL Sninsky, JJ AF Chang, SYP Chan, JP Santini, CD Sigua, CL Hu, XL Yee, L Li, HZ Wright, TL Sninsky, JJ TI Predictive value of gene expression of host factors at 12-weeks of pegylated interferon-alpha plus ribavirin treatment in hepatitis C patients SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Celera Diagnost, Alameda, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 520A EP 520A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480301368 ER PT J AU Ebinuma, H Li, Y Valiga, M Chan, KM AF Ebinuma, H Li, Y Valiga, M Chan, KM TI HCV persistence is associated with impaired proliferative function of CD25-negative CD4 T cell subset SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 556A EP 556A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480301456 ER PT J AU Lieber, CS Leo, MA Cao, Q Mak, KM Ren, CL Ponomarenko, A Wang, XL DeCarli, LM AF Lieber, CS Leo, MA Cao, Q Mak, KM Ren, CL Ponomarenko, A Wang, XL DeCarli, LM TI Detrimental effects of medium-chain triglycerides (MCT) in nonalcoholic steatohepatitis (NASH): Contrast with their beneficial action in alcoholic liver disease SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Mt Sinai Sch Med, Bronx, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 570A EP 570A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480302010 ER PT J AU Bini, EJ Anand, BS Aytaman, A Samanta, A Cordoba-Rellosa, I Nemchausky, B Trevino, HH Mah'moud, MA Weston, AP Pimstone, NR Stancic, S Chang, KM AF Bini, EJ Anand, BS Aytaman, A Samanta, A Cordoba-Rellosa, I Nemchausky, B Trevino, HH Mah'moud, MA Weston, AP Pimstone, NR Stancic, S Chang, KM TI Glucose-6-phosphate dehydrogenase deficiency is associated with severe anemia during interferon and ribavirin therapy SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 VA New York Harbor Healthcare Syst, New York, NY USA. NYU, Sch Med, New York, NY USA. Houston VAMC, Houston, TX USA. VA New York Harbor Healthcare Syst, Brooklyn, NY USA. E Orange VAMC, E Orange, NJ USA. Hines VAMC, Hines, IL USA. San Antonio VAMC, San Antonio, TX USA. VAMC, Columbia, SC USA. VAMC, Kansas City, MO USA. VAMC, Mather, CA USA. VAMC, Hudson Valley, NY USA. VAMC, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 648A EP 648A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480302209 ER PT J AU Naqvi, Z Eldeiry, L Brau, N Rosman, AS Greenberg, PD AF Naqvi, Z Eldeiry, L Brau, N Rosman, AS Greenberg, PD TI Reduction in hemoglobin A1c values in diabetic patients during hepatitis C combination therapy: A combined effect of ribavirin-induced hemolysis and decreased glucose levels SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 662A EP 662A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480302242 ER PT J AU Huckans, MS Loftis, JM Hauser, P AF Huckans, MS Loftis, JM Hauser, P TI Interferon therapy completion and response rates for hepatitis C among patients with schizophrenia, schizoaffective disorder, and substance use disorders SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 665A EP 665A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480302250 ER PT J AU Lieber, CS Anand, BS Bini, EJ Leo, MA Lowe, N Murthy, U Paronetto, F Schiff, E Simon, D AF Lieber, CS Anand, BS Bini, EJ Leo, MA Lowe, N Murthy, U Paronetto, F Schiff, E Simon, D TI Polyenylphosphatidylcholine (PPC) is beneficial for the treatment of hepatitis C patients SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Mt Sinai Sch Med, Bronx, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Baylor Coll Med, Med Ctr, Houston, TX 77030 USA. VA New York Harbor Healthcare Syst, New York, NY USA. Syracuse VA Med Ctr, Syracuse, NY USA. Univ Miami, Miami, FL 33152 USA. Jacobi Med Ctr, Bronx, NY USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 695A EP 695A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480302320 ER PT J AU Cao, Q Mak, KM Lieber, CS AF Cao, Q Mak, KM Lieber, CS TI Leptin represses matrix metalloproteinase (MMP)-1 gene expression in human hepatic stellate cells which contributes to its fibrogenic effect SO HEPATOLOGY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 Mt Sinai Sch Med, Bronx, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 SU 1 BP 731A EP 732A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 972VC UT WOS:000232480302411 ER PT J AU Deng, QG She, HY Cheng, JH French, SW Koop, DR Xiong, SG Tsukamoto, H AF Deng, QG She, HY Cheng, JH French, SW Koop, DR Xiong, SG Tsukamoto, H TI Steatohepatitis induced by intragastric overfeeding in mice SO HEPATOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; HEPATIC CYTOCHROME-P450 2E1; ACTIVATED PROTEIN-KINASE; INDUCED LIVER-INJURY; INSULIN-RESISTANCE; NONALCOHOLIC STEATOHEPATITIS; LEPTIN RECEPTOR; FATTY LIVER; GENE-EXPRESSION; X-RECEPTORS AB Nonalcoholic steatoliepatitis is prevalent among obese individuals with excessive caloric intake, insulin resistance, and type 11 diabetes. However, no animal models exist that recapitulate this important association. This study produced and characterized steatoliepatitis (SH) caused by intragastric overfeeding in mice. C57BL/6, tumor necrosis factor (TNF) type 1 receptor-deficient, and genetically matched wild type mice were fed via an implanted gastrostomy tube a high-fat diet for 9 weeks in the increasing amount up to 85% in excess of the standard intake. Animals were examined for weight gain, insulin sensitivity, and histology and biochemistry of liver and white adipose tissue (WAT). Overfed C57BL/6 mice progressively became obese, with 71% larger final body weights. They had increased visceral WAT, hyperglycemia, hyperinsulinemia, hyperleptinemia, glucose intolerance, and insulin resistance. Of these mice, 46% developed SH with increased plasma alanine aminotransferase (121 +/- 27 vs. 13 +/- 1 U/L), neutrophilic infiltration, and sinusoidal and pericellular fibrosis. Obese WAT showed increased TNF alpha and leptin expression and reciprocally reduced adiponectin expression. The expression of lipogenic transcription factors (SREBP-1c, PPAR gamma, LXR alpha) was increased, whereas that of a lipolytic nuclear factor PPAR alpha was reduced in SH. SH was associated with reduced cytochrome P450 (Cyp)2el but increased Cyp4a. TNF type 1 receptor deficiency did not prevent obesity and SH. In conclusion, forced overfeeding with a high-fat diet in mice induces obesity, insulin resistance, and SH in the absence of TNF signaling or Cyp2e1 induction. C1 Univ So Calif, Keck Sch Med, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA. Harbor UCLA Med Ctr, Ctr Med, Torrance, CA 90509 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tsukamoto, H (reprint author), 1333 San Pablo St,MMR-412, Los Angeles, CA 90033 USA. EM htsukamo@usc.edu FU NIAAA NIH HHS [P50 AA11999, R37 AA006603] NR 50 TC 146 Z9 150 U1 0 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2005 VL 42 IS 4 BP 905 EP 914 DI 10.1002/hep.20877 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 970XB UT WOS:000232344600020 PM 16175602 ER PT J AU Wu, HM Fornek, M Schwab, KJ Chapin, AR Gibson, K Schwab, E Spencer, C Henning, K AF Wu, HM Fornek, M Schwab, KJ Chapin, AR Gibson, K Schwab, E Spencer, C Henning, K TI A norovirus outbreak at a long-term-care facility: The role of environmental surface contamination SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT 2nd World Calicivirus Conference CY NOV 06-10, 2004 CL Dijon, FRANCE ID NORWALK-LIKE VIRUSES; ROUND-STRUCTURED VIRUSES; VIRAL GASTROENTERITIS; UNITED-STATES; HOSPITAL OUTBREAK; HOTEL OUTBREAK; NURSING-HOME; NLV; TRANSMISSION; INFECTION AB BACKGROUND: The role of environmental surface contamination in the propagation of norovirus outbreaks is unclear. An outbreak of acute gastroenteritis was reported among residents of a 240-bed veterans long-term-care facility. OBJECTIVES: To identify the likely mode of transmission, to characterize risk factors for illness, and to evaluate for environmental contamination in this norovirus outbreak. METHODS: An outbreak investigation was conducted to identify risk factors for illness among residents and employees. Stool and vomitus samples were tested for norovirus by reverse transcription polymerase chain reaction (RT-PCR). Fourteen days after outbreak detection, ongoing cases among the residents prompted environmental surface testing for norovirus by RT-PCR. RESULTS: One hundred twenty-seven (52%) of 246 residents and 84 (46%) of 181 surveyed employees had gastroenteritis. Case-residents did not differ from non-case-residents by comorbidities, diet, room type, or level of mobility. Index cases were among the nursing staff. Eight of 11 resident stool or vomitus samples tested positive for genogroup II norovirus. The all-cause mortality rate during the month of the outbreak peak was significantly higher than the expected rate. Environmental surface swabs from case-resident rooms, a dining room table, and an elevator button used only by employees were positive for norovirus. Environmental and clinical norovirus sequences were identical. CONCLUSION: Extensive contamination of environmental surfaces may play a role in prolonged norovirus outbreaks and should be addressed in control interventions. C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Wu, HM (reprint author), Drexel Univ, Coll Med, Mailstop 461,245 N 15th St, Philadelphia, PA 19102 USA. EM hwu@drexelmed.edu RI Sapkota, Amy/A-6046-2011 NR 40 TC 118 Z9 123 U1 2 U2 20 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2005 VL 26 IS 10 BP 802 EP 810 DI 10.1086/502497 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 975TE UT WOS:000232684000003 PM 16276954 ER PT J AU Lorenz, K Ryan, G Morton, SC Chan, KS Wang, S Shekelle, PG AF Lorenz, K Ryan, G Morton, SC Chan, KS Wang, S Shekelle, PG TI A qualitative examination of primary care providers' and physician managers' uses and views of research evidence SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE evidence-based medicine; focus groups ID EVIDENCE-BASED MEDICINE; GENERAL-PRACTITIONERS; ATRIAL-FIBRILLATION; AUSTRALIAN GPS; UNITED-STATES; OF-CARE AB Objectives. To examine the reasons and search strategies related to physicians' search for evidence and to compare clinician and physician manager approaches. Design. Qualitative analysis of verbatim transcripts of four focus groups in 2002. Study setting. Clinicians and managers in community practices in Southern California. Participants. Pediatricians, family practitioners, and general internists (i.e. child and adult primary care providers) in nonacademic practice and physician managers whose primary responsibility involved making management decisions within a moderate to large sized health care delivery system (e.g. health plan, community hospital, large group practice). Main outcome measures. Themes related to clinician and manager reasons for using evidence and approach to selecting among evidence sources. Results. Clinicians and managers differed substantially in their reasons for using evidence. Whereas clinicians consistently invoked clinical intuition as a guide to most routine clinical decisions, managers articulated both motivation and interest in using medical research to guide decision-making, most commonly prompted by cost. Both clinicians and managers rated trustworthiness as a paramount consideration in arbitrating between evidence sources, because neither group evinced comfort with the complexity of primary literature. Both groups expressed a preference for tested, convenient, and respected evidence sources such as expert colleagues and professional societies. Conclusions. Because clinicians invoke intuition in confronting the challenges of daily practice, evidence-based medicine interventions that target managers are likely to have larger effects on health outcomes than those that target primary care providers and individual patient treatment. Ensuring trustworthiness of evidence is of the utmost importance. Because both groups express discomfort with the format of primary evidence sources, strategies should probably not rely on individual appraisal. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Lorenz, K (reprint author), Vet Integrated Palliat Program, 11301 Wishire Blvd,Code 111-G, Los Angeles, CA 90064 USA. EM karl.lorenz@med.va.gov NR 29 TC 17 Z9 17 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD OCT PY 2005 VL 17 IS 5 BP 409 EP 414 DI 10.1093/intqhc/mzi054 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 974GO UT WOS:000232579500006 PM 15923281 ER PT J AU Kaulin, YA Takemoto, JY Schagina, LV Ostroumova, OS Wangspa, R Teeter, JH Brand, JG AF Kaulin, YA Takemoto, JY Schagina, LV Ostroumova, OS Wangspa, R Teeter, JH Brand, JG TI Sphingolipids influence the sensitivity of lipid bilayers to fungicide, syringomycin E SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES LA English DT Article DE syringomycin E; ion channels; bilayer lipid membranes; sphingolipid; fungicide; Pseudomonas syringae ID SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS-SYRINGAE; YEAST SPHINGOLIPIDS; PLASMA-MEMBRANE; CHANNELS; RECEPTORS; PHYTOTOXIN; MECHANISM; CELLS AB Sphingolipids with long chain bases hydroxylated at the C4 position are a requisite for the yeast, Saccharomyces cerevisia, to be sensitive to the ion channel forming antifungal agent, syringomycin E (SRE). A mutant S. cerevisiae strain, Delta syr2, having sphingolipids with a sphingoid base devoid of C4-hydroxylation, is resistant to SRE. To explore the mechanism of this resistance, we investigated the channel forming activity of SRE in lipid bilayers of varying composition. We found that the addition of sphingolipid-rich fraction from Delta syr2 to the membrane-forming solution (DOPS/DOPE/ergosterol) resulted in lipid bilayers with lower sensitivity to SRE compared with those containing sphingolipid fraction from wild-type S. cerevisiae. Other conditions being equal, the rate of increase of bilayer conductance was about 40 times slower, and the number of SRE channels was about 40 times less, with membranes containing Delta syr2 versus wild-type sphingolipids. Delta syr2 sphingolipids altered neither SRE single channel conductance nor the gating charge but the ability of SRE channels to open synchronously was diminished. The results suggest that the resistance of the Delta syr2 mutant to SRE may be partly due to the ability of sphingolipids without the C4 hydroxyl group to decrease the channel forming activity of SRE. C1 Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. Russian Acad Sci, Inst Cytol, Philadelphia, PA 19104 USA. Utah State Univ, Dept Biol, Logan, UT 84322 USA. Univ Penn, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kaulin, YA (reprint author), Thomas Jefferson Univ, Dept Pathol, Jefferson Med Coll, 1020 Locust St, Philadelphia, PA 19107 USA. EM yuri.kaulin@jefferson.edu; brand@monell.org RI Ostroumova, Olga/N-8636-2013; Takemoto, Jon/A-5309-2011 OI Takemoto, Jon/0000-0001-9919-9168 NR 30 TC 14 Z9 14 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0145-479X J9 J BIOENERG BIOMEMBR JI J. Bioenerg. Biomembr. PD OCT PY 2005 VL 37 IS 5 BP 339 EP 348 DI 10.1007/s10863-005-8645-2 PG 10 WC Biophysics; Cell Biology SC Biophysics; Cell Biology GA 992EX UT WOS:000233868300007 PM 16341778 ER PT J AU Cooper, GF Abraham, V Aliferis, CF Aronis, JM Buchanan, BG Caruana, R Fine, MJ Janosky, JE Livingston, G Mitchell, T Monti, S Spirtes, P AF Cooper, GF Abraham, V Aliferis, CF Aronis, JM Buchanan, BG Caruana, R Fine, MJ Janosky, JE Livingston, G Mitchell, T Monti, S Spirtes, P TI Predicting dire outcomes of patients with community acquired pneumonia SO JOURNAL OF BIOMEDICAL INFORMATICS LA English DT Article DE machine learning; community acquired pneumonia; outcome prediction; quality and cost of healthcare delivery ID LIKELIHOOD; SELECTION; COST AB Comm unity-acquired pneumonia (CAP) is an important clinical condition with regard to patient mortality, patient morbidity, and healthcare resource utilization. The assessment of the likely clinical course of a CAP patient can significantly influence decision making about whether to treat the patient as an inpatient or as an outpatient. That decision can in turn influence resource utilization, as well as patient well being. Predicting dire outcomes, such as mortality or severe clinical complications, is a particularly important component in assessing the clinical course of patients. We used a training set of 1601 CAP patient cases to construct 11 statistical and machine-learning models that predict dire outcomes. We evaluated the resulting models on 686 additional CAP-patient cases. The primary goal was not to compare these learning algorithms as a study end point; rather, it was to develop the best model possible to predict dire outcomes. A special version of an artificial neural network (NN) model predicted dire outcomes the best. Using the 686 test cases, we estimated the expected healthcare quality and cost impact of applying the NN model in practice. The particular, quantitative results of this analysis are based on a number of assumptions that we make explicit; they will require further study and validation. Nonetheless, the general implication of the analysis seems robust, namely, that even small improvements in predictive performance for prevalent and costly diseases, such as CAP, are likely to result in significant improvements in the quality and efficiency of healthcare delivery. Therefore, seeking models with the highest possible level of predictive performance is important. Consequently, seeking ever better machine-learning and statistical modeling methods is of great practical significance. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Pittsburgh, Ctr Biomed Informat, Pittsburgh, PA 15213 USA. Stanford Univ, Meyler Lib 260, Stanford, CA 94305 USA. Vanderbilt Univ, Dept Biomed Informat, Eskind Lib 412, Nashville, TN 37232 USA. Univ Pittsburgh, Dept Comp Sci, Pittsburgh, PA 15260 USA. Cornell Univ, Dept Comp Sci, Ithaca, NY 14853 USA. Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Family Med & Clin Epidemiol, Pittsburgh, PA 15261 USA. Univ Massachusetts, Dept Comp Sci, Lowell, MA 01854 USA. Carnegie Mellon Univ, Ctr Automated Learning & Discovery, Pittsburgh, PA 15213 USA. MIT, Broad Inst, Cambridge, MA 02141 USA. Harvard Univ, Cambridge, MA 02141 USA. Carnegie Mellon Univ, Dept Philosophy, Pittsburgh, PA 15213 USA. RP Cooper, GF (reprint author), Univ Pittsburgh, Ctr Biomed Informat, Suite 8084 Forber Tower,200 Lothrop St, Pittsburgh, PA 15213 USA. EM gfc@cbmi.pitt.edu OI Monti, Stefano/0000-0002-9376-0660 NR 34 TC 10 Z9 10 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-0464 J9 J BIOMED INFORM JI J. Biomed. Inform. PD OCT PY 2005 VL 38 IS 5 BP 347 EP 366 DI 10.1016/j.jbi.2005.02.005 PG 20 WC Computer Science, Interdisciplinary Applications; Medical Informatics SC Computer Science; Medical Informatics GA 976MV UT WOS:000232738600002 PM 16198995 ER PT J AU Carson, P Massie, BM McKelvie, R McMurray, J Komajda, M Zile, M Ptaszynska, A Frangin, G AF Carson, P Massie, BM McKelvie, R McMurray, J Komajda, M Zile, M Ptaszynska, A Frangin, G CA I-PRESERVE Investigators TI The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: Rationale and design SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE AT(1)-receptor blockers; ACE inhibition; left ventricular function; congestive heart failure ID VENTRICULAR EJECTION FRACTION; ANGIOTENSIN-CONVERTING ENZYME; CLINICAL CHARACTERISTICS; DIAGNOSIS; HYPERTROPHY; DYSFUNCTION; RELAXATION; PROGNOSIS; MORTALITY; OUTCOMES AB Background: Although 40% to 50% of patients with chronic heart failure (HE) have relatively preserved systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not include evidence-based recommendations. Methods and Results: The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations. The principal inclusion criteria are age >= 60 years, heart failure symptoms, an ejection fraction >= 45%, and either hospitalization for heart failure within 6 months or corroborative evidence of heart failure or the substrate for diastolic heart failure. Additional secondary end points include cardiovascular mortality, cattle-specific mortality and morbidity, change in New York Heart Association functional class, quality of life, and N-terminal pro-BNP measurements. Follow-up will continue until 1440 patients experience a primary end point. Substudies will evaluate changes in echocardiographic measurements and serum collagen markers. Conclusion: I-PRESERVE is the largest trial in this understudied area and will provide crucial information on the characteristics and course of the syndrome, as well as the efficacy of the angiotensin receptor blocker irbesartan. C1 Georgetown Univ Hosp, Dept Vet Affairs Med Ctr, Washington, DC 20007 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VAMC, San Francisco, CA USA. McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada. Univ Glasgow, CRI Heart Failure, Glasgow G12 8QQ, Lanark, Scotland. Hop La Pitie Salpetriere, Dept Cardiol, Paris, France. Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA. Bristol Myers Squibb Co, Div Cardiol, Princeton, NJ USA. Sanofi Synthelabo Rech, Montpellier, France. RP Carson, P (reprint author), MICU, 50 Irving St, Washington, DC 20420 USA. RI Brito, Dulce/G-9650-2016; Casademont, Jordi/A-6828-2010 OI Brito, Dulce/0000-0003-1278-1847; Casademont, Jordi/0000-0002-8100-1827; mcmurray, john/0000-0002-6317-3975 NR 24 TC 77 Z9 81 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD OCT PY 2005 VL 11 IS 8 BP 576 EP 585 DI 10.1016/j.cardfail.2005.06.432 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 981MR UT WOS:000233093200002 PM 16230259 ER PT J AU London, MJ Henderson, WG AF London, MJ Henderson, WG TI Perioperative pharmacologic cardioprotection and sodium hydrogen ion exchange inhibitors: One step forward and two steps back? SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Editorial Material C1 Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Colorado, Hlth Sci Ctr, Colorado Hlth Outcomes Program, Natl Surg Qual Improvement Program, Aurora, CO USA. Univ Colorado, Hlth Sci Ctr, Colorado Hlth Outcomes Program, Dept Prevent Med & Biometr, Aurora, CO USA. RP London, MJ (reprint author), Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. NR 62 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 1053-0770 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD OCT PY 2005 VL 19 IS 5 BP 565 EP 569 DI 10.1053/j.jvca.2005.07.027 PG 5 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA 980YP UT WOS:000233054400001 PM 16202887 ER PT J AU Tofovic, SP Salah, EM Mady, HH Jackson, EK Melhem, ME AF Tofovic, SP Salah, EM Mady, HH Jackson, EK Melhem, ME TI Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE 17 beta estradiol; metabolites; pulmonary arterial hypertension ID VASCULAR ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; PHYSIOLOGICAL CONCENTRATIONS; ESTROGEN METABOLITE; CHRONIC HYPOXIA; 2-METHOXYESTRADIOL; PROLIFERATION; APOPTOSIS; 2-HYDROXYESTRADIOL; EXPRESSION AB Pulmonary arterial hypertension (PH) is a deadly disease characterized by pulmonary arterial vasoconstriction and hypertension, pulmonary vasculature remodeling, and right ventricular hypertrophy. Our previous in vivo studies, performed in several models of cardiac, vascular, and/or renal injury, suggest that the metabolites of 17 beta-estradiol may inhibit vascular and cardiac remodeling. The goal of this study was to determine whether 2-methoxyestradiol (2ME), major non-estrogenic estradiol metabolite, prevents the development and/or retards the progression of monocrotaline (MCT)-induced PH. First, a total of 27 male Sprague Dawley rats were injected with distillated water (Cont, n = 6) or monocrotaline (MCT; 60 mg/kg, i.p.; n = 21). Subsets of MCT animals (n = 7 per group) received 2ME or its metabolic precursor 2-hydroxyestradiol (2HE; 10 mu g/kg/h via osmotic minipumps) for 21 days. Next, an additional set (n = 24) of control and MCT rats was monitored for 28 days, before right ventricular peak systolic pressure (RVPSP) was measured. Some pulmonary hypertensive animals (n = 8) were treated with 2ME (10 mu g/kg/h) beginning from day 14 after MCT administration. MCT caused pulmonary hypertension (ie, increased right ventricle/left ventricle + septum [RV/LV+S] ratio and wall thickness of small-sized pulmonary arteries, and elevated RVPSP) and produced high and late (days 22 to 27) mortality. Pulmonary hypertension was associated with strong proliferative response (PCNA staining) and marked inflammation (ED1 + cells) in lungs. Both metabolites significantly attenuated the RV/LV+S ratio and pulmonary arteries media hypertrophy and reduced proliferative and inflammatory responses in the lungs. Furthermore, in diseased animals, 2ME (given from day 14 to 28) significantly decreased RVPSP, RV/LV+S ratio and wall thickness, and reduced mortality by 80% (mortality rate: 62.5% vs. 12.5%, MCT vs. MCT+2ME day 14 to 28). This study provides the first evidence that 2ME, a major non-estrogenic, non-carcinogenic metabolite of estradiol, prevents the development and retards the progression of monocrotaline-induced pulmonary hypertension. Further evaluation of 2ME for management of pulmonary arterial hypertension is warranted. C1 Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, Pittsburgh, PA 15219 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pharmacol, Sch Med, Pittsburgh, PA USA. RP Tofovic, SP (reprint author), Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, 100 Technol Dr,Suite 450, Pittsburgh, PA 15219 USA. EM tofovic@dom.pitt.edu NR 49 TC 36 Z9 36 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD OCT PY 2005 VL 46 IS 4 BP 430 EP 437 DI 10.1097/01.fjc.0000175878.32920.17 PG 8 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 009EL UT WOS:000235094000005 PM 16160593 ER PT J AU Rasouli, N Hale, T Kahn, SE Spencer, HJ Elbein, SC AF Rasouli, N Hale, T Kahn, SE Spencer, HJ Elbein, SC TI Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GLUCOSE-TOLERANCE; NICOTINIC-ACID; ISLET ADAPTATION; SECRETION; SENSITIVITY; PATHOGENESIS; MELLITUS; COMPENSATION; HERITABILITY; DYSFUNCTION AB Context: Normal glucose homeostasis is maintained despite reductions in insulin sensitivity by increasing insulin secretion. This ability to compensate for reduced insulin sensitivity is highly heritable, but the mechanisms for this compensation or its failure in type 2 diabetes (T2DM) are unknown. Objective: The objective of this study was to test whether individuals with a family history of T2DM have a fixed decrease in beta-cell mass or function that would be revealed as an impaired insulin secretory response to short-term insulin resistance. Design: Glucose tolerance, insulin sensitivity (SI), and insulin response to iv glucose (AIR(G)) were compared in nondiabetic individuals with and without a family history of diabetes before and after nicotinic acid (NA) treatment. Setting: This study was performed at the Ambulatory General Clinical Research Center. Subjects: Healthy, nonobese, nondiabetic individuals with or without a family history of T2DM were studied. Interventions: Oral NA was given, with a final dose of 2 g/d, for at least 7 d. Main Outcome Measure: The main outcome measure was the disposition index (insulin sensitivity X insulin response) in response to NA. Results: Postchallenge plasma glucose levels rose during NA therapy regardless of family history. Neither group adequately increased their AIRG to maintain the disposition index. Family members did not differ from controls at baseline or after NA treatment for any outcome measure, but only 28 of 52 subjects experienced a 25% or greater fall in SI with NA treatment. Conclusions: Short-term beta-cell compensation to NA-induced insulin resistance was incomplete and did not differ by genetic predisposition. A genetic defect controlling beta-cell growth in response to chronic insulin resistance better explains differences in the ability to compensate for insulin resistance than an inherited, fixed defect in beta-cell mass. C1 Cent Arkansas Vet Healthcare Syst, Med & Res Serv, Little Rock, AR 72205 USA. Univ Arkansas Med Sci, Coll Publ Hlth, Div Endocrine, Dept Med, Little Rock, AR 72205 USA. Univ Arkansas Med Sci, Coll Med, Dept Biostat, Little Rock, AR 72205 USA. Vet Affairs Puget Sound Healthcare Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Seattle, WA 98108 USA. RP Elbein, SC (reprint author), Cent Arkansas Vet Healthcare Syst, Med & Res Serv, Endorcinol 111J-LR, Little Rock, AR 72205 USA. EM elbeinstevenc@uams.edu FU NCRR NIH HHS [M01-RR-14288]; NIDDK NIH HHS [DK-02654, DK-39311] NR 32 TC 20 Z9 21 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2005 VL 90 IS 10 BP 5825 EP 5833 DI 10.1210/jc.2005-0048 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 971FJ UT WOS:000232367400047 PM 16091496 ER PT J AU Brawman-Mintzer, O Knapp, RG Nietert, PJ AF Brawman-Mintzer, O Knapp, RG Nietert, PJ TI Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 16th Congress of the European-College-of-Neuropsychopharmacology CY SEP 20-24, 2003 CL PRAGUE, CZECH REPUBLIC SP European Coll Neuropsychopharmacol ID DEPRESSION SCALE AB Objective: Although significant advances have been made in recent years in the treatment of generalized anxiety disorder (GAD), many patients remain symptomatic despite ongoing treatment, underscoring the need for adjunctive new treatments to help improve response. Method: Forty patients with a primary diagnosis of DSM-IV GAD, who continued to experience GAD symptoms despite current anxiolytic treatment of at least 4 weeks' duration, as evidenced by Hamilton Rating Scale for Anxiety (HAM-A) total score >= 18 and Clinical Global Impressions-Severity of Illness scale score of moderate or greater, completed a 1-week screening phase and were then randomly assigned to 5 weeks of double-blind adjunctive treatment with placebo or risperidone at flexible doses of 0.5 to 1.5 mg/day. Patients continued to take their anxiolytics throughout the study. The study was conducted from June 2001 through March 2003. Results: Adjunctive risperidone was associated with statistically significant improvements in core anxiety symptoms, as demonstrated by greater reductions in HAM-A total scores (p = .034) and HAM-A psychic anxiety factor scores (p = .047) compared with placebo. Although change scores on other outcome variables, including response rates, were higher in the risperidone group, differences did not achieve statistical significance. Conclusion: Study findings suggest that risperidone at low doses may represent a useful tool in the management of symptomatic GAD patients. C1 Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Brawman-Mintzer, O (reprint author), 5900 Core Rd,Suite 203, Charleston, SC 29406 USA. EM mintzero@musc.edu OI Nietert, Paul/0000-0002-3933-4986 NR 20 TC 79 Z9 81 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2005 VL 66 IS 10 BP 1321 EP 1325 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 978ZJ UT WOS:000232911500016 PM 16259547 ER PT J AU Andrikopoulos, S Massa, CM Aston-Mourney, K Funkat, A Fam, BC Hull, RL Kahn, SE Proietto, J AF Andrikopoulos, S Massa, CM Aston-Mourney, K Funkat, A Fam, BC Hull, RL Kahn, SE Proietto, J TI Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet SO JOURNAL OF ENDOCRINOLOGY LA English DT Article ID GENETIC BACKGROUND DETERMINES; INDUCED OBESITY; DIABETES LOCUS; BETA-CELLS; MICE; RESISTANCE; GLUCOSE; EXPRESSION; SENSITIVITY; MECHANISMS AB The increasing production of genetically-modified mouse models has necessitated studies to determine the inherent physiological characteristics of commonly used mouse strains. In this study we examined insulin secretory function in response to an intravenous bolus of glucose or glucose plus arginine in anesthetized C57BL/6, DBA/2 and 129T2 mice fed either a control or high fat diet for 6 weeks. The results show that 129T2 mice had higher fasting plasma glucose levels and lower fasting plasma insulin levels compared with C57BL/6 and DBA/2 mice regardless of diet. Furthermore, 129T2 mice were glucose intolerant and secreted significantly less insulin in response to glucose and glucose plus arginine irrespective of diet compared with the other two strains of mice. DBA/2 mice hypersecreted insulin in response to glucose and glucose plus arginine compared with C57BL/6 and 129T2 mice. Moreover while first phase insulin secretion was appropriately increased in response to the high fat diet in C57BL/6 and 129T2 mice, this was not the case for DBA/2 mice. Mean islet area was decreased in response to a high fat diet in DBA/2 mice, while there was no dietary effect on the other two strains. This study highlights the inherent genetic differences that exist among seemingly normal strains of mice that are commonly used to make transgenic and knockout mice. Understanding these differences will provide researchers with the information to choose the appropriate genetic background on which to express their particular genetic alteration. C1 Univ Melbourne, Dept Med AH NH, Heidelberg Repatriat Hosp, Heidelberg Heights, Vic 3081, Australia. VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98108 USA. RP Andrikopoulos, S (reprint author), Univ Melbourne, Dept Med AH NH, Heidelberg Repatriat Hosp, 300 Waterdale Rd, Heidelberg Heights, Vic 3081, Australia. EM sof@unimelb.edu.au RI Proietto, Joseph/B-3780-2012 OI Aston-Mourney, Kathryn/0000-0003-1412-6715; Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 FU NIDDK NIH HHS [DK-17047] NR 35 TC 72 Z9 75 U1 2 U2 5 PU SOC ENDOCRINOLOGY PI BRISTOL PA 22 APEX COURT, WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0022-0795 J9 J ENDOCRINOL JI J. Endocrinol. PD OCT PY 2005 VL 187 IS 1 BP 45 EP 53 DI 10.1677/joe.1.06333 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 976DY UT WOS:000232714200005 PM 16214940 ER PT J AU Perry, SF Gilmour, KM Swenson, ER Vulesevic, B Chew, SF Ip, YK AF Perry, SF Gilmour, KM Swenson, ER Vulesevic, B Chew, SF Ip, YK TI An investigation of the role of carbonic anhydrase in aquatic and aerial gas transfer in the African lungfish Protopterus dolloi SO JOURNAL OF EXPERIMENTAL BIOLOGY LA English DT Article DE carbon dioxide excretion; oxygen uptake; gill; lung; acetazolamide; benzolamide; breathing; lungfish; Protopterus dolloi; carbonic anhydrase ID TROUT ONCORHYNCHUS-MYKISS; SOUTH-AMERICAN LUNGFISH; CO2 EXCRETION; RAINBOW-TROUT; RESPIRATORY PROPERTIES; LEPIDOSIREN-PARADOXA; HCO3-DEHYDRATION; EXCHANGE ORGANS; ANION-EXCHANGE; BLOOD AB Experiments were performed on bimodally breathing African lungfish Protopterus dolloi to examine the effects of inhibition of extracellular vs total (extracellular and intracellular) carbonic anhydrase (CA) activity on pulmonary and branchial/cutaneous gas transfer. In contrast to previous studies on Protopterus, which showed that the vast majority of CO2 is excreted into the water through the gill and/or skin whereas O-2 uptake largely occurs via the lung, P. dolloi appeared to use the lung for the bulk of both 0, uptake (91.0 +/- 2.9%) and CO2 excretion (76.0 +/- 6.6%). In support of the lung as the more important site Of CO2 transfer, aerial hypercapnia (P-CO2=40 mmHg) caused a significant rise in partial pressure of arterial blood CO2 (Pa-CO2) whereas a similar degree of aquatic hypercapnia was without effect on Pa-CO2. Intravascular injection of low levels (1.2 mg kg(-1)) of the slowly permanent CA inhibitor, benzolamide, was without effect on red blood cell CA activity after 30 min, thus confirming its suitability as a short-term selective inhibitor of extracellular CA. Benzolamide treatment did not affect CO2 excretion, blood acid-base status or any other measured variable within the 30 min measurement period. Injection of the permeant CA inhibitor acetazolamide (30 mg kg(-1)) resulted in the complete inhibition of red cell CA activity within 10 min. However, CO2 excretion (measured for 2 h after injection) and arterial blood acid-base status (assessed for 24 h after injection) were unaffected by acetazolamide treatment. Intra-arterial injection of bovine CA (2 mg kg(-1)) caused a significant increase in overall CO2 excretion (from 0.41 +/- 0.03 to 0.58 +/- 0.03 mmol kg(-1) h(-1)) and an increase in air breathing frequency (from 19.0 +/- 1.3 to 24.7 +/- 1.8 breaths min(-1)) that was accompanied by a slight, but significant, reduction in Pa-CO2 (from 21.6 +/- 1.6 to 19.6 +/- 1.8 mmHg). The findings of this study are significant because they (i) demonstrate that, unlike in other species of African lungfish that have been examined, the gill/skin is not the major route Of CO2 excretion in P. dolloi, and (ii) suggest that CO2 excretion in Protopterus may be less reliant on carbonic anhydrase than in most other fish species. C1 Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Nanyang Technol Univ, Natl Inst Educ, Dept Nat Sci, Singapore, Singapore. Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore. RP Perry, SF (reprint author), Univ Ottawa, Dept Biol, 150 Louis Pasteur, Ottawa, ON K1N 6N5, Canada. EM sfperry@science.uottawa.ca RI Ip, Yuen Kwong/H-8041-2012; Chew, Shit Fun/I-2248-2012 NR 54 TC 25 Z9 26 U1 0 U2 2 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0022-0949 J9 J EXP BIOL JI J. Exp. Biol. PD OCT PY 2005 VL 208 IS 19 BP 3805 EP 3815 DI 10.1242/jeb.01780 PG 11 WC Biology SC Life Sciences & Biomedicine - Other Topics GA 981ZT UT WOS:000233127200026 PM 16169956 ER PT J AU Shekelle, PG Hardy, M Morton, SC Venuturupalli, S Favreau, J Hilton, LK AF Shekelle, PG Hardy, M Morton, SC Venuturupalli, S Favreau, J Hilton, LK TI Are Ayurvedic herbs for diabetes effective? SO JOURNAL OF FAMILY PRACTICE LA English DT Article ID GYMNEMA-SYLVESTRE; CONTROLLED TRIALS; LEAF EXTRACT; MELLITUS; QUALITY; BIAS; METAANALYSES; PRINCIPLES AB Objective To evaluate and synthesize the evidence on the effect of Ayurvedic therapies for diabetes mellitus. Design Systematic review of trials. Measurements and main results We found no study that assessed Ayurvedic as a system of care. Botanical therapy was by far the most commonly studied Ayurvedic treatment. Herbs were studied either singly or as formulas. In all, 993 titles in Western computerized databases and 318 titles identified by hand-searching journals in India were examined, yielding 54 articles reporting the results of 62 studies. The most-studied herbs were G sylvestre, C indica, fenugreek, and Eugenia jambolana. A number of herbal formulas were tested, but Ayush-82 and D-400 were most often studied. Thirty-five of the studies included came from the Western literature, 27 from the Indian. Seven were randomized controlled trials (RCTs) and 10 controlled clinical trials (CCTs) or natural experiments. Twenty-two studies went on to further analysis based on a set of criteria. Of these, 10 were RCTs, CCTs, or natural experiments, 12 were case series or cohort studies. There is evidence to suggest that the herbs C indica, holy basil, fenugreek, and G sylvestre, and the herbal formulas Ayush-82 and D-400 have a glucose-lowering effect and deserve further study. Evidence of effectiveness of several other herbs is less extensive (C tamala, E jambolana, and Momordica charantia). Conclusions There is heterogeneity in the available literature on Ayurvedic treatment for diabetes. Most studies test herbal therapy. Heterogeneity exists in the herbs and formulas tested (more than 44 different interventions identified) and in the method of their preparation. Despite these limitations, there are sufficient data for several herbs or herbal formulas to warrant further studies. C1 RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90407 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Shekelle, PG (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM shekelle@rand.org NR 34 TC 7 Z9 8 U1 0 U2 0 PU DOWDEN PUBLISHING CORP PI MONTVALE PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA SN 0094-3509 J9 J FAM PRACTICE JI J. Fam. Pract. PD OCT PY 2005 VL 54 IS 10 BP 876 EP + PG 11 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 976CV UT WOS:000232711300012 PM 16202376 ER PT J AU Guerra, CE Dominguez, F Shea, JA AF Guerra, CE Dominguez, F Shea, JA TI Literacy and knowledge, attitudes, and behavior about colorectal cancer screening SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 01-05, 2002 CL ATLANTA, GA SP Soc Gen Internal Med ID FECAL-OCCULT-BLOOD; HEALTH LITERACY; OLDER WOMEN; SIGMOIDOSCOPY; MAMMOGRAPHY; MORTALITY; RECOMMENDATIONS; PARTICIPATION; ORGANIZATION; PREVENTION AB This cross-sectional survey explored the association between functional health literacy and knowledge of, beliefs and attitudes about, and reported usage of colorectal cancer screening tests. The results indicate that functional health literacy, as assessed by the Short Test of Functional Health Literacy in Adults (STOFHLA), is not an independent predictor of colorectal cancer screening knowledge, beliefs, attitudes, or behavior. Latino ethnicity and education, however, often predicted screening responses, suggesting that efforts to improve communication about colorectal cancer screening with Latino patients and patients with low education clearly are needed to reduce the disparities in awareness and utilization of colorectal cancer screening tests. This study also explored influences on intended screening behavior. Physician recommendation was found to be a powerful motivator of intention to undergo colorectal cancer screening regardless of literacy level, indicating that interventions aimed at increasing physician recommendation of colorectal cancer screening may be an effective way of increasing screening rates. C1 Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. USA, Dwight D Eisenhower Med Ctr, Dept Med, Ft Gordon, GA USA. Philadelphia Vet Affairs Med Ctr, CHERP, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Guerra, CE (reprint author), Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, 1221 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM carmen.guerra@uphs.upenn.edu FU AHRQ HHS [R01 HS10299] NR 33 TC 49 Z9 49 U1 2 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PD OCT-NOV PY 2005 VL 10 IS 7 BP 651 EP 663 DI 10.1080/10810730500267720 PG 13 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 981VA UT WOS:000233114900006 PM 16278201 ER PT J AU Chren, MM AF Chren, MM TI Measurement of vital signs for skin diseases SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Editorial Material ID QUALITY-OF-LIFE; DERMATOLOGY C1 Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Serv Dermatol, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. FU NIAMS NIH HHS [K02 AR 02203-01] NR 12 TC 8 Z9 8 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD OCT PY 2005 VL 125 IS 4 BP VIII EP IX DI 10.1111/j.0022-202X.2005.23796.x PG 2 WC Dermatology SC Dermatology GA 973XU UT WOS:000232556700001 PM 16185256 ER PT J AU Zhang, YP Da, RR Hilgenberg, LG Tourtellotte, WW Sobel, RA Smith, MA Olek, M Nagra, R Sudhir, G van den Noort, S Qin, YF AF Zhang, YP Da, RR Hilgenberg, LG Tourtellotte, WW Sobel, RA Smith, MA Olek, M Nagra, R Sudhir, G van den Noort, S Qin, YF TI Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE IgA and IgG plasma cells; clonal expansion; axonal reactive antibody in lesion; multiple sclerosis ID CENTRAL-NERVOUS-SYSTEM; IMMUNOGLOBULIN-CONTAINING CELLS; MULTIPLE-SCLEROSIS LESIONS; MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; SOMATIC MUTATION; DNA-POLYMERASE; B-CELLS; BRAIN; MATURATION AB Immunoglobulin A (IgA), the predominant immunoglobulin class in mucosal secretions, has been found in the cerebrospinal fluid of patients with multiple sclerosis (MS). In this study we examined the infiltration of clonally expanded IgA plasma cells in lesions of MS brains. Sequences of complementarity-determining region 3 of IgA variable heavy chain (V-H) genes demonstrated the clonal expansion of IgA-bearing plasma cells in MS lesions. Somatic mutations and ongoing intra-clonal mutations occurred in their V-H genes. Immunohistochemical study demonstrated infiltration of dimer and polymer IgAl- and A2-positive plasma cells in perivascular spaces, in the parenchyma of MS lesions, and in the adjacent white matter. Double immunofluorescence staining showed binding of IgA antibody on axons and walls of microvessels in the areas of chronic active and inactive demyelination. Bielshowsky's silver impregnation revealed axonal damage in these areas. These findings suggest that IgA in the CNS are localized on axons in lesions and may contribute to axonal damage in MS. (C) 2005 Elsevier B.V. All rights reserved. C1 Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA. Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA. VA Greater Los Angeles Healthcare Syst, Serv Neurol, Los Angeles, CA USA. Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA. Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA. RP Qin, YF (reprint author), Univ Calif Irvine, Dept Neurol, 100 Irvine Hall, Irvine, CA 92697 USA. EM qiny@uci.edu FU NINDS NIH HHS [R01 NS40534-01A1, NS 046414] NR 43 TC 32 Z9 33 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD OCT PY 2005 VL 167 IS 1-2 BP 120 EP 130 DI 10.1016/j.jneuroim.2005.05.006 PG 11 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 970XA UT WOS:000232344500014 PM 16099056 ER PT J AU Wallis, RA Panizzon, KL AF Wallis, RA Panizzon, KL TI Modulation of the mitochondrial ATP-sensitive potassium channel by cromakalim provides protection against CA1 neuronal injury induced by hypoxia and oxidative stress SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 23rd Annual National-Neurotrauma-Society Symposium CY NOV 10-11, 2005 CL Washington, DC SP Natl Neurotrauma Soc C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD OCT PY 2005 VL 22 IS 10 MA P20 BP 1168 EP 1168 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 977ZS UT WOS:000232842600032 ER PT J AU Sales, AE Sharp, ND Li, YF Greiner, GT Lowy, E Mitchell, P Sochalski, JA Cournoyer, P AF Sales, AE Sharp, ND Li, YF Greiner, GT Lowy, E Mitchell, P Sochalski, JA Cournoyer, P TI Nurse staffing and patient outcomes in veterans affairs hospitals SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID PRACTICE ENVIRONMENT; HEALTH-CARE; WORK INDEX; MORTALITY AB Objective: To assess characteristics and perceptions of nurses working in the Veterans Health Administration (VHA), comparing types of nursing personnel, to benchmark to prior studies across healthcare systems. Background: Prior studies have shown relationships between positive registered nurse (RN) perceptions of the practice environment and patient outcomes. To date, no study has reported the comparison of RN perceptions of the practice environment in hospital nursing with those of non-RN nursing personnel. This study is the first to offer a more comprehensive look at perceptions of practice environment from the full range of the nursing work force and may shed light on issues such as the relationship of skill mix to nurse and patient outcomes. Methods: Cross-sectional observational study with a mailed survey administered to all nursing personnel in 125 VA Medical Centers between February and June 2003. Results: Compared with other types of nursing personnel in the VHA, RNs are generally less positive about their practice environments. However, compared with RNs in other countries and particularly with other RNs in the United States (Pennsylvania), VHA RNs are generally more positive about their practice environment and express more job satisfaction. Conclusions: The nursing work force of the VHA has some unique characteristics. The practice environment for nurses in the VHA is relatively positive, and may indicate that the VHA, as a system, provides an environment that is more like magnet hospitals. This is significant for a public sector hospital system. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Sales, AE (reprint author), VA Puget Sound Hlth Care Syst, HSR&D 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM ann.sales@med.va.gov RI Sales, Anne/D-9678-2012 OI Sales, Anne/0000-0001-9360-3334 NR 22 TC 21 Z9 21 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD OCT PY 2005 VL 35 IS 10 BP 459 EP 466 DI 10.1097/00005110-200510000-00007 PG 8 WC Nursing SC Nursing GA 974EH UT WOS:000232573600007 PM 16220059 ER PT J AU Best, RG Stapleton, LM Downey, RG AF Best, Richard G. Stapleton, Laura M. Downey, Ronald G. TI Core self-evaluations and job burnout: The test of alternative models SO JOURNAL OF OCCUPATIONAL HEALTH PSYCHOLOGY LA English DT Article DE burnout; core self-evaluations; job satisfaction; perceived organizational constraints ID SATISFACTION; PERFORMANCE; EFFICACY; PERSONALITY; DIRECTIONS; STRESS AB Research on job burnout has traditionally focused on contextual antecedent conditions, although a theoretically appropriate conception implicates person-environment relationships. The authors tested several models featuring various combinations of personal and contextual influences on burnout and job satisfaction. Measures of core self-evaluations, organizational constraints, burnout, and job satisfaction were collected from 859 health care employees. Results from structural equations modeling analyses revealed an influence of core self-evaluations and perceived organizational constraints on job burnout and satisfaction, suggesting personal and contextual contributions. These results favor a broadening of current thinking about the impact of situational constraints on the expression of job burnout, as well as for the role of disposition for affective responding to effectively address occupational health problems. C1 Univ Texas Hlth Sci Ctr, S Texas Vet Hlth Syst, Dept Gen Med, VERDICT Field Program, San Antonio, TX 78229 USA. [Stapleton, Laura M.] Univ Texas Austin, Dept Educ Psychol, Austin, TX USA. [Downey, Ronald G.] Kansas State Univ, Dept Psychol, Manhattan, KS 66506 USA. RP Best, RG (reprint author), Univ Texas Hlth Sci Ctr, S Texas Vet Hlth Syst, Dept Gen Med, VERDICT Field Program, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM rbest@verdict.uthscsa.edu RI Stapleton, Laura/A-2357-2016 OI Stapleton, Laura/0000-0003-2383-772X NR 39 TC 77 Z9 84 U1 4 U2 25 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1076-8998 J9 J OCCUP HEALTH PSYCH JI J. Occup. Health Psychol. PD OCT PY 2005 VL 10 IS 4 BP 441 EP 451 DI 10.1037/1076-8998.10.4.441 PG 11 WC Public, Environmental & Occupational Health; Psychology, Applied SC Public, Environmental & Occupational Health; Psychology GA V43VT UT WOS:000202963300011 PM 16248691 ER PT J AU Du, Y Pullman-Mooar, S Schumacher, HR AF Du, Y Pullman-Mooar, S Schumacher, HR TI Synovial sarcoma of the foot mimicking acute gouty arthritis SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE synovial sarcoma; acute gouty arthritis ID SYT AB Synovial sarcoma is a slow-growing soft tissue sarcoma that mainly affects young adults. Patients commonly present with a slowly enlarging mass in the paraarticular regions of extremities. We describe a case of synovial sarcoma with an unusually acute presentation near the first metatarsophalangeal joint that resembled acute gouty arthritis. C1 Univ Penn, Sch Med, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Rheumatol Sect, Philadelphia, PA USA. RP Schumacher, HR (reprint author), Hosp Univ Penn, Div Rheumatol, 5 Maloney,Suite 504,3400 Spruce St, Philadelphia, PA 19104 USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2005 VL 32 IS 10 BP 2006 EP 2008 PG 3 WC Rheumatology SC Rheumatology GA 971KV UT WOS:000232383800027 PM 16206359 ER PT J AU Stelzner, M AF Stelzner, M TI Achieving balance in academic surgery SO JOURNAL OF SURGICAL RESEARCH LA English DT Article; Proceedings Paper CT Fundamentals of Surgical Research Course of the Association-for-Academic-Surgery CY NOV, 2004 CL Houston, TX SP Assoc Acad Surg DE balance; surgeon-scientist; family life; research ID INTESTINE; FALLS C1 Univ Washington, VAPSHCS Surg Serv 112, Dept Surg, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Stelzner, M (reprint author), Univ Washington, VAPSHCS Surg Serv 112, Dept Surg, 1660 S Columbian Way, Seattle, WA 98108 USA. EM stelzner@u.washington.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD OCT PY 2005 VL 128 IS 2 SI SI BP 189 EP 193 DI 10.1016/j.jss.2005.09.005 PG 5 WC Surgery SC Surgery GA 979RS UT WOS:000232963100009 ER PT J AU Min, LC Reuben, DB MacLean, CH Shekelle, PG Solomon, DH Higashi, T Chang, JT Roth, CP Kamberg, CJ Adams, J Young, RT Wenger, NS AF Min, LC Reuben, DB MacLean, CH Shekelle, PG Solomon, DH Higashi, T Chang, JT Roth, CP Kamberg, CJ Adams, J Young, RT Wenger, NS TI Predictors of overall quality of care provided to vulnerable older people SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE quality of care; care processes; quality indicators; aged; risk factors ID CORONARY-ARTERY-DISEASE; SEX-DIFFERENCES; COMPETING DEMANDS; MAMMOGRAPHY USE; UNITED-STATES; MANAGED CARE; HEALTH-CARE; WOMEN; COMMUNITY; PERFORMANCE AB OBJECTIVES: Prior research shows that the quality of care provided to vulnerable older persons is suboptimal, but little is known about the factors associated with care quality for this group. In this study, the influences of clinical conditions, types of care processes, and sociodemographic characteristics on the quality of care received by vulnerable older people were evaluated. DESIGN: Observational cohort study. SETTING: Two senior managed care plans. PARTICIPANTS: Three hundred sixty-two community-dwelling patients aged 65 and older identified as vulnerable by the Vulnerable Elder Survey (VES-13). MEASUREMENTS: Outcome variable: patients' observed-minus-expected overall quality score. Predictor variables: types of care processes, types and number of clinical conditions, sex, age, VES-13 score (composite score of function and self-rated health), income, education, mental health status, and number of quality indicators triggered. RESULTS: Patients whose conditions required more history-taking, counseling, and medication-prescribing care processes and patients with diabetes mellitus received lower-than-expected quality of care. A greater number of comorbid conditions was associated with higher-than-expected quality of care. Age, sex, VES-13 score, and other sociodemographic variables were not associated with quality of care. CONCLUSION: Complexity, vulnerability, and age do not predispose older persons to receive poorer-quality care. In contrast, older patients whose care requires time-consuming processes such as history taking and counseling are at risk for worse quality of care and should be a target for intervention to improve care. C1 Univ Calif Los Angeles, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Hlth Serv Res, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Min, LC (reprint author), Univ Calif Los Angeles, Dept Med, Div Geriatr, 10945 Conte Ave,Suite 2339,Box 951687, Los Angeles, CA 90095 USA. EM lmin@mednet.ucla.edu FU BHP HRSA HHS [PE-19001] NR 33 TC 38 Z9 38 U1 2 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2005 VL 53 IS 10 BP 1705 EP 1711 DI 10.1111/j.1532-5415.2005.53520.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 966FR UT WOS:000232006000008 PM 16181169 ER PT J AU Blonder, LX Heilman, KM Ketterson, T Rosenbek, J Raymer, A Crosson, B Maher, L Glueckauf, R Roth, LG AF Blonder, LX Heilman, KM Ketterson, T Rosenbek, J Raymer, A Crosson, B Maher, L Glueckauf, R Roth, LG TI Affective facial and lexical expression in aprosodic versus aphasic stroke patients SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE emotion; language; nonverbal communication; cerebral infarction; laterality; facial expression ID BRAIN-DAMAGED PATIENTS; RIGHT-HEMISPHERE; EMOTIONAL EXPRESSION; PROSODY; LANGUAGE; PERCEPTION; COMMUNICATION; VALIDATION; DISEASE; SPEECH AB Past research has shown that lesions in the left cerebral hemisphere often result in aphasia, while lesions in the right hemisphere frequently impair the production of emotional prosody and facial expression. At least 3 processing deficits might account for these affective symptoms: (1) failure to understand the conditions that evoke emotional response; (2) inability to experience emotions; (3) disruption in the capacity to encode non-verbal signals. To better understand these disorders and their underlying mechanisms, we investigated spontaneous affective communication in right hemisphere damaged (RHD) stroke patients with aprosody and left hemisphere damaged (LHD) stroke patients with aphasia. Nine aprosodic RHD patients and 14 aphasic LHD patients participated in a videotaped interview within a larger treatment protocol. Two naive raters viewed segments of videotape and rated facial expressivity. Verbal affect production was tabulated using specialized software. Results indicated that RHD patients smiled and laughed significantly less than LHD patients. In contrast, RHD patients produced a greater percentage of emotion words relative to total words than did LHD patients. These findings suggest that impairments in emotional prosodic production and facial expressivity associated with RHD are not induced by affective- conceptual deficits or an inability to experience emotions. Rather, they likely represent channel-specific nonverbal encoding abnormalities. C1 Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. Univ Kentucky, Dept Behav Sci, Lexington, KY 40536 USA. VA Med Ctr, BRRC, Gainesville, FL USA. Univ Florida, Dept Neurol, Gainesville, FL USA. Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. Univ Florida, Dept Commun Disorders, Gainesville, FL USA. Old Dominion Univ, Norfolk, VA USA. Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Houston VA Med Ctr, Houston, TX USA. Florida State Univ, Dept Med Humanities & Social Sci, Tallahassee, FL 32306 USA. RP Blonder, LX (reprint author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. EM lxblond@email.uky.edu RI Crosson, Bruce/L-3128-2013 FU NIDCD NIH HHS [P50DC03888] NR 43 TC 20 Z9 21 U1 2 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD OCT PY 2005 VL 11 IS 6 BP 677 EP 685 DI 10.1017/S13556177050794 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 980NQ UT WOS:000233025600003 PM 16248903 ER PT J AU Zhang, P Guccione, JM Nicholas, SI Walker, JC Crawford, PC Shamal, A Saloner, DA Wallace, AW Ratcliffe, MB AF Zhang, P Guccione, JM Nicholas, SI Walker, JC Crawford, PC Shamal, A Saloner, DA Wallace, AW Ratcliffe, MB TI Left ventricular volume and function after endoventricular patch plasty for dyskinetic anteroapical left ventricular aneurysm in sheep SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID FINITE-ELEMENT MODEL; REDUCTION SURGERY; RESTORATION; EXTENSION; STIFFNESS AB Objective: Endoventricular patch plasty (the Dor procedure) has gained favor as a surgical treatment for heart failure associated with large anteroapical myocardial infarction. We tested the hypothesis that the Dor procedure reduces left ventricular volume, increases end-systolic elastance, decreases diastolic compliance, and maintains left ventricular function. Methods: In 6 male Dorsett sheep, the left anterior descending coronary artery and its second diagonal branch were ligated 40% of the distance from apex to base. Sixteen weeks after myocardial infarction, a Dor procedure was performed with a Dacron patch that was 50% of the infarct neck dimension. Absolute left ventricular volume was measured with magnetic resonance imaging, and left ventricular pressure and relative left ventricular volume changes during pharmacologic preload reduction were measured with a volume conductance catheter 2 weeks before and 2 and 6 weeks after the Dor procedure. End-systolic elastance, diastolic compliance, and Starling relationships were calculated from the resultant left ventricular pressure/volume loops. Results: Two weeks after the Dor procedure, the left ventricular volume at end systole and end diastole was significantly reduced, and there was no redilation at 6 weeks. Six weeks after the Dor procedure, the ejection fraction was significantly increased. Although stroke volume increased slightly at 6 weeks, the change was not significant. The slopes of end-systolic elastance, diastolic compliance, and Starling relationships were unchanged at 2 and 6 weeks. Conclusions: The Dor procedure significantly reduces left ventricular volume. Unlike linear repair, left ventricular volume changes seem stable. The ejection fraction is improved, and left ventricular function (stroke volume and the Starling relationship) is maintained. C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. Dept Vet Affairs Med Ctr, San Francisco, CA USA. RP Ratcliffe, MB (reprint author), San Francisco Vet Affairs Med Ctr, Div Surg Serv 112D, 4150 Clement St, San Francisco, CA 94121 USA. EM Mark.Ratcliffe@med.va.gov FU NHLBI NIH HHS [R01-HL-58759, R01-HL-63348, R01 HL063348] NR 24 TC 20 Z9 21 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD OCT PY 2005 VL 130 IS 4 BP 1032 EP 1038 DI 10.1016/j.jtcvs.2005.05.039 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 973SX UT WOS:000232544000013 PM 16214516 ER PT J AU Zhu, M Maslow, J Mikota, SK Isaza, R Dunker, F Riddle, H Peloquin, CA AF Zhu, M Maslow, J Mikota, SK Isaza, R Dunker, F Riddle, H Peloquin, CA TI Population pharmacokinetics of pyrazinamide in elephants SO JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS LA English DT Article ID BOVIS SUBSP CAPRAE; MYCOBACTERIUM-TUBERCULOSIS; MAXIMUS AB This study was undertaken to characterize the population pharmacokinetics (PK) therapeutic dose, and preferred route of administration for pyrazinamide (PZA) in elephants. Twenty-three African (Loxodonta africana) and Asian (Elephas maximus) elephants infected with or in contact with others culture positive for Mycobacterium tuberculosis were dosed under treatment conditions. PZA was dosed daily at 20-30 mg/kg via oral (fasting or nonfasting state) or rectal (enema or suppository) administration. Blood samples were collected 0-24 h postdose. Population PK was estimated using nonlinear mixed effect modeling. Drug absorption was rapid with T-max at or before 2 h regardless of the method of drug administration. C-max at a mean dose of 25.6 (+/- 4.6) mg/kg was 19.6 (+/- 9.5 mu g/mL) for PZA given orally under fasting conditions. Under nonfasting conditions at a mean dose of 26.1 +/- 4.2 mg/kg, C-max was 25% (4.87 +/- 4.89 mu g/mL) and area under concentration curve (AUC) was 30% of the values observed under fasting conditions. Mean rectal dose of 32.6 +/- 15.2 mg/kg yielded Cmax of 12.3 +/- 6.3 mu g/mL, but comparable AUC to PZA administered orally while fasting. Both oral and rectal administration of PZA appeared to be acceptable and oral dosing is preferred because of the higher C-max and lower inter-subject variability. A starting dose of 30 mg/kg is recommended with drug monitoring between I and 2 h postdose. Higher doses may be required if the achieved C-max values are below the recommended 2050 mu g/mL range. C1 Vet Affairs Med Ctr, Infect Dis Sect, Philadelphia, PA 19104 USA. Natl Jewish Med & Res Ctr, Denver, CO USA. Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA. Elephant Care Int, Waveland, MS USA. Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA. San Francisco Zool Gardens, San Francisco, CA USA. Riddle Elephant & Wildlife Sancutary, Greenbriar, AR USA. Univ Colorado, Sch Pharm, Denver, CO 80202 USA. Univ Colorado, Sch Med, Denver, CO 80202 USA. RP Maslow, J (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, 151 Univ & Woodlands Aves, Philadelphia, PA 19104 USA. EM joel.maslow@med.va.gov NR 19 TC 12 Z9 12 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0140-7783 J9 J VET PHARMACOL THER JI J. Vet. Pharmacol. Ther. PD OCT PY 2005 VL 28 IS 5 BP 403 EP 409 DI 10.1111/j.1365-2885.2005.00670.x PG 7 WC Pharmacology & Pharmacy; Veterinary Sciences SC Pharmacology & Pharmacy; Veterinary Sciences GA 979YD UT WOS:000232980200001 PM 16207301 ER PT J AU Ahmed, A Ness, J Howard, G Aronow, WS AF Ahmed, A Ness, J Howard, G Aronow, WS TI Cerebrovascular diseases as primary hospital discharge diagnoses: National trend (1970-2000) among older adults SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID STROKE INCIDENCE; UNITED-STATES; SURVIVAL; MORTALITY; 1ST-EVER; BLACKS AB Background. Cerebrovascular diseases are a common cause of mortality, morbidity, and hospitalization among older adults. However, the long-term national trends in cerebrovascular disease-related hospitalizations in this age group are not well known. Methods. We used the National Center for Health Statistics trend data from the National Hospital Discharge Surveys (1970-2000) to determine incidence of cerebrovascular disease-related hospitalizations among persons 65 years and older in the United States. Only patients discharged with a primary discharge diagnosis of cerebrovascular disease were included. We estimated rates of hospitalization per 1000 civilian residents 65 years and older, for all patients and stratified by age, sex, and race. Results. Among persons 65 years of age and older, the total number of cerebrovascular disease-related hospitalizations increased from 372,000 in 1970 to 711,000 in 2000. However, the rates of hospitalization due to cerebrovascular disease remained unchanged at 20.7/1000 in 1970 and 20.4/1000 in 2000. The rates for persons 75-84 years and > 85 years were, respectively, 2 and 3 times higher than that for persons 65-74 years throughout the study period. Rates for men and women were comparable and stable during the study period. Rates for African Americans, in contrast, increased from 14/1000 in 1970 to 20.6/1000 in 2000, peaking in 1985 (27.4/1000). Conclusions. The overall rates of hospitalization due to cerebrovascular disease remained high yet stable. However, the absolute number of hospitalizations due to cerebrovascular disease increased considerably, with potential for serious social, financial, and public health implications for the coming decades. C1 Univ Alabama, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Birmingham, AL USA. Univ Alabama, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Ctr Aging, Birmingham, AL 35294 USA. Univ Alabama, Geriatr Heart Failure Clin, Birmingham, AL USA. Birmingham VA Med Ctr, Sect Geriatr, Birmingham, AL USA. Birmingham VA Med Ctr, Geriatr Heart Failure Clin, Birmingham, AL USA. Alabama Qual Assurance Fdn, Heart Failure Project, Birmingham, AL USA. Univ Iowa Hlth Care, Div Gen Internal Med, Dept Internal Med, Iowa City, IA USA. Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. New York Med Coll, Dept Med, Sect Cardiol, Valhalla, NY 10595 USA. New York Med Coll, Dept Med, Sect Geriatr, Valhalla, NY 10595 USA. Mt Sinai Sch Med, New York, NY USA. RP Ness, J (reprint author), Univ Iowa Hosp & Clin, Dept Internal Med, Div Gen Internal Med, SE624,GH,200 Hawkins Dr, Iowa City, IA 52242 USA. EM jose-ness@uiowa.edu NR 21 TC 4 Z9 4 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2005 VL 60 IS 10 BP 1328 EP 1332 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 985XN UT WOS:000233412100019 PM 16282569 ER PT J AU Feliers, D Chen, XY Akis, N Choudhury, GG Madaio, M Kasinath, BS AF Feliers, D Chen, XY Akis, N Choudhury, GG Madaio, M Kasinath, BS TI VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells SO KIDNEY INTERNATIONAL LA English DT Article DE glomerular endothelial cells; VEGF; signal transduction; eNOS ID RENAL EPITHELIAL-CELLS; VASCULAR-PERMEABILITY FACTOR; GROWTH-FACTOR EXPRESSION; PROTEIN-SYNTHESIS; TYROSINE KINASE; ANGIOTENSIN-II; ANGIOGENESIS; PATHWAY; ACTIVATION; FLT-1 AB VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Background. Vascular endothelial growth factor (VEGF) regulation of endothelial nitric oxide synthase (eNOS) and signaling pathways involved have not been well studied in glomerular endothelial cells (GENCs). Methods. GENCs grown from tsA58 Immortomice (R) were used. Immunoblotting and in-cell Western blot analysis were employed to assess changes in VEGF receptor signaling pathway and eNOS phosphorylation of ser1177. Immunokinase assay and immunoblotting with phosphospecific antibodies were performed to assess activity of kinases. Results. VEGF rapidly induced tyrosine phosphorylation of type 1 and type 2 VEGF receptors. Physical association between VEGF-receptor 2 (VEGF-R2) and insulin receptor substrate (IRS-1) and phosphatidylinositol 3'-kinase (PI3K) was induced by VEGF, which augmented PI3K activity in VEGF-R2 immunoprecipitates. VEGF stimulated Akt phosphorylation in a PI3K-dependent manner. VEGF increased eNOS phosphorylation on Ser1177. Activation of eNOS was associated with nitric oxide generation as measured by medium nitrite content. Signaling mechanisms involved in VEGF stimulation of eNOS were explored. VEGF-induced eNOS phosphorylation was abolished by SU1498, a VEGF-R2 inhibitor, LY294002, a PI3K inhibitor, and infection of cells with an adenovirus carrying a dominant negative-mutant of Akt, demonstrating the requirement of the VEGF-R2/IRS-1/PI3K/Akt axis for activation of eNOS. VEGF also activated extracellular signal-regulated protein kinase (ERK) in a time-dependent manner; and VEGF-stimulated eNOS phosphorylation on Ser1177 was prevented by PD098059, an upstream inhibitor of ERK, demonstrating that ERK was involved in VEGF regulation of eNOS. ERK phosphorylation was abolished by LY294002, suggesting ERK was downstream of PI3K in VEGF-treated GENC. Conclusions. Our data demonstrate that in GENC, VEGF stimulates VEGF-R2/IRS-1/PI3K/Akt axis to regulate eNOS phosphorylation on Ser1177 in conjunction with the ERK signaling pathway. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol,S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, OBrien Kidney Res Ctr, San Antonio, TX 78229 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Kasinath, BS (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol,S Texas Vet Healthcare Syst, 7703 Floyd Curl Dr,Mail Code 7882, San Antonio, TX 78229 USA. EM kasinath@uthscsa.edu RI Akis, Nese/A-5745-2017 OI Akis, Nese/0000-0002-8491-2685 FU NIDDK NIH HHS [DK55815, T32 DK7006, DK53088] NR 40 TC 40 Z9 40 U1 1 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD OCT PY 2005 VL 68 IS 4 BP 1648 EP 1659 DI 10.1111/j.1523-1755.2005.00575.x PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 963JT UT WOS:000231801300030 PM 16164642 ER PT J AU Stringer, KD Komers, R Osman, SA Oyama, TT Lindsley, JN Anderson, S AF Stringer, KD Komers, R Osman, SA Oyama, TT Lindsley, JN Anderson, S TI Gender hormones and the progression of experimental polycystic kidney disease SO KIDNEY INTERNATIONAL LA English DT Article DE gender; estrogen; polycystic kidney disease; VEGF; nitric oxide; endothelin ID RENIN-ANGIOTENSIN SYSTEM; RECEPTOR GENE-EXPRESSION; HAN-SPRD RATS; RENAL-DISEASE; GROWTH-FACTOR; REPLACEMENT THERAPY; FAMILY MEMBERS; SEX-HORMONES; NITRIC-OXIDE; ESTROGEN AB Background. Male gender is a risk factor for progression of autosomal-dominant polycystic kidney disease (ADPKD), clinically and in the Han:SPRD rat model. Orchiectomy limits progression, but mechanisms of the detrimental effect of androgen, and/or beneficial effects of estrogen, are not known. This protocol tested the hypothesis that male gender (intact androgen status) promotes progression, while female gender (intact estrogen status) is protective; and that these disease-modifying effects are due to changes in expression of known fibrotic mediators. Methods. Studies were performed in male and female noncystic control (+/+) and cystic (+/-) rats subjected to orchiectomy, ovariectomy, or sham operation. At 12 weeks of age, renal function was measured. Blood and kidneys were taken for measurement of plasma and renal renin, endothelin (ET-1), endothelial nitric oxide synthase (eNOS), and vascular endothelial growth factor (VEGF), using biochemical, protein expression, and immunohistochemical methods. Results. Cystic male rats exhibited significantly reduced glomerular filtration (GFR) and effective renal plasma flow (ERPF) rates, with suppression of plasma and renal renin, up-regulation of renal ET-1 and eNOS, and down-regulation of renal VEGF expression. Orchiectomy attenuated the fall in GFR and ERPF, while numerically limiting changes in eNOS and VEGF. Female rats exhibited less cystic growth, with normal renin status, lesser elevation of renal ET-1, and proportionately lesser changes in VEGF and eNOS. Ovariectomy led to higher blood pressure and reduced GFR and ERPF, with a trend toward upregulation of ET-1, and significant down-regulation of VEGF and eNOS. Conclusion. Female gender is protective, but ovariectomy attenuates the protective effect of female gender, in association with changes in renal expression of ET-1, VEGF, and eNOS. The accelerated disease in male rats can be attenuated by orchiectomy and consequent changes in expression of disease mediators. C1 Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. Inst Clin & Expt Med, Ctr Diabet, Prague, Czech Republic. Portland VA Med Ctr, Portland, OR USA. RP Anderson, S (reprint author), Oregon Hlth Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM anderssh@ohsu.edu NR 64 TC 30 Z9 32 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD OCT PY 2005 VL 68 IS 4 BP 1729 EP 1739 DI 10.1111/j.1523-1755.2005.00589.x PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 963JT UT WOS:000231801300037 PM 16164649 ER PT J AU Shuster, E AF Shuster, E TI Justice at Nuremberg: Leo Alexander and the Nazi doctors' trial SO MEDICAL HISTORY LA English DT Book Review C1 Vet Affairs Med Ctr, Philadelphia, PA USA. RP Shuster, E (reprint author), Vet Affairs Med Ctr, Philadelphia, PA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0025-7273 EI 2048-8343 J9 MED HIST JI Med. Hist. PD OCT PY 2005 VL 49 IS 4 BP 538 EP 539 PG 2 WC Health Care Sciences & Services; History & Philosophy Of Science SC Health Care Sciences & Services; History & Philosophy of Science GA 979VV UT WOS:000232974000019 ER PT J AU Cook, JM Elhai, JD Cassidy, EL Ruzek, JI Ram, GD Sheikh, JI AF Cook, JM Elhai, JD Cassidy, EL Ruzek, JI Ram, GD Sheikh, JI TI Assessment of trauma exposure and post-traumatic stress in long-term care veterans: Preliminary data on psychometrics and post-traumatic stress disorder prevalence SO MILITARY MEDICINE LA English DT Article ID PTSD CHECKLIST; OLDER-ADULTS; COMMUNITY; SYMPTOMS; DEMENTIA AB This article reports preliminary data on trauma and post-traumatic stress disorder (PTSD) prevalence, as well as test psychometrics, among 35 cognitively intact veterans residing in long-term care settings. Participants received a traumatic event screening, the Mini-Mental Status Examination, Combat Exposure Scale (CES), PTSD Checklist (PCL), and Mississippi Combat PTSD Scale (M-PTSD). Results demonstrated adequate reliability for the CES, PCL, and M-PTSD for use in these settings, with several significant intercorrelations. A high prevalence of trauma exposure was found, in particular combat. Based on the PCL and M-PTSD, although most veterans did not meet full PTSD diagnostic criteria, a moderate proportion met partial criteria. The need for assessment and treatment of trauma exposure and PTSD in Veterans Affairs long-term care settings is emphasized. C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ S Dakota, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA. VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Cook, JM (reprint author), Columbia Univ, New York State Psychiat Inst, 1051 Riverside Dr,Box 69, New York, NY 10032 USA. EM jc2676@columbia.edu NR 35 TC 12 Z9 12 U1 0 U2 0 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD OCT PY 2005 VL 170 IS 10 BP 862 EP 866 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 019JR UT WOS:000235831900011 PM 16435760 ER PT J AU Butts, BD Hudson, HR Linseman, DA Le, SS Ryan, KR Bouchard, RJ Heidenreich, KA AF Butts, BD Hudson, HR Linseman, DA Le, SS Ryan, KR Bouchard, RJ Heidenreich, KA TI Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors SO MOLECULAR AND CELLULAR NEUROSCIENCE LA English DT Article ID CEREBELLAR GRANULE NEURONS; CYTOCHROME-C RELEASE; UBIQUITIN-PROTEIN LIGASE; KAPPA-B ACTIVATION; ENHANCER FACTOR 2A; GROWTH-FACTOR-I; FACTOR 2D MEF2D; PARKINSONS-DISEASE; PROTEOLYTIC PATHWAY; CORTICAL-NEURONS AB The role of the proteasome in neuronal apoptosis is poorly understood since both anti- and pro-apoptotic effects result from proteasome inhibition. We studied the effects of proteasome inhibition in cultured rat cerebellar granule neurons. Acute exposure to proteasome inhibitors MG-132 and lactacystin blocked caspase activation induced by removal of depolarizing medium. However, chronic treatment with MG-132 activated caspases in neurons maintained in depolarizing potassium. The biphasic effect of MG-132 was hypothesized to be due to differential degradation of anti- and pro-apoptotic proteins. Accordingly, acute exposure to MG-132 inhibited the hyperphosphorylation, loss of DNA binding, ubiquitination, and degradation of the pro-survival transcription factor MEF2D induced by removal of depolarizing medium. In contrast, chronic exposure to MG-132 increased the expression and phosphorylation of c-Jun, elevated levels of the pro-apoptotic protein Bim, and triggered neuronal apoptosis, even in the presence of depolarizing medium. Thus, proteasome inhibition exerts an acute pro-survival action by stabilizing MEF2 transcription factors. However, chronic proteasome inhibition causes a build-up of phosphorylated c-Jun and Bim, which eventually overwhelms the effects of MEF2 and triggers apoptosis. (c) 2005 Published by Elsevier Inc. C1 Univ Colorado, Hlth Sci Ctr, Aurora, CO 80045 USA. Denver VA Med Ctr, Denver, CO 80220 USA. RP Heidenreich, KA (reprint author), Univ Colorado, Hlth Sci Ctr, Aurora, CO 80045 USA. EM kim.heidenreich@uchsc.edu NR 50 TC 28 Z9 30 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1044-7431 J9 MOL CELL NEUROSCI JI Mol. Cell. Neurosci. PD OCT PY 2005 VL 30 IS 2 BP 279 EP 289 DI 10.1016/j.mcn.2005.07.011 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 967AP UT WOS:000232064200011 PM 16112871 ER PT J AU Lu, H Wu, JY Kudo, T Ohno, T Graham, DY Yamaoka, Y AF Lu, H Wu, JY Kudo, T Ohno, T Graham, DY Yamaoka, Y TI Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; PATHOGENICITY ISLAND; VIRULENCE FACTORS; C-FOS; MUCOSAL INTERLEUKIN-8; SIGNAL-TRANSDUCTION; MESSENGER-RNA; FACTOR-ALPHA AB The regulation of Helicobacter pylori induced interleukin (IL)-6 in the gastric epithelium remains unclear. Primary gastric epithelial cells and MKN28 cells were cocultured with H. pylori and its isogenic cag pathogenicity island (PAI) mutant and/or oipA mutants. H. pylori infection-induced IL-6 mRNA expression and IL-6 protein production, which was further enhanced by the cag PAI and OipA. Luciferase reporter gene assays and electrophoretic mobility shift assays showed that full IL-6 transcription required binding sites for nuclear factor-kappa B (NF-kappa B), cAMP response element (CRE), CCAAT/enhancer binding protein (C/EBP), and activator protein (AP)-1. The cag PAI and OipA were involved in binding to NF-kappa B AP-1, CRE, and C/EBP sites. The cag PAI activated the extracellular signal-regulated kinase (ERK) and Jun N-terminal kinase (JNK) pathways; OipA activated the p38 pathway. Transfection of dominant negative G-protein confirmed roles for Raf, Rac1, and RhoA in IL-6 induction. Overall, the cag PAI-related IL-6 signal transduction pathway involved the Ras/Raf/MEK1/2/ERK/AP-1/CRE pathway and the JNK/AP-1/CRE pathway; the OipA-related pathway is p38/AP-1/CRE and both the cag PAI and OipA appear to be involved in the RhoA/Rac1/NF-kappa B pathway. Combination of different pathways by the cag PAI and OipA will lead to the maximum IL-6 induction. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Kyoto Prefectural Univ Med, Dept Gastroenterol & Hepatol, Kyoto 6020841, Japan. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [DK56338, P30 DK056338, R01 DK062813, R01 DK062813-03, R01 DK62813] NR 47 TC 55 Z9 57 U1 0 U2 1 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PD OCT PY 2005 VL 16 IS 10 BP 4954 EP 4966 DI 10.1091/mbc.E05-05-0426 PG 13 WC Cell Biology SC Cell Biology GA 969TM UT WOS:000232257700041 PM 16030249 ER PT J AU Shi, YJ Yan, HJ Frost, P Gera, J Lichtenstein, A AF Shi, YJ Yan, HJ Frost, P Gera, J Lichtenstein, A TI Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID TUMOR-CELLS; PHOSPHORYLATION; SUBSTRATE-1; PATHWAY; INTERLEUKIN-6; DEGRADATION; MODULATION; RESISTANCE; MECHANISM; PROTEINS AB Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin and CCI-779, have shown preclinical potential as therapy for multiple myeloma. By inhibiting expression of cell cycle proteins, these agents induce G, arrest. However, by also inhibiting an mTOR-dependent serine phosphorylation of insulin receptor substrate-1 (IRS-1), they may enhance insulin-like growth factor-1 (IGF-1) signaling and downstream phosphatidylinositol 3-kinase (PI3K)/AKT activation. This may be a particular problem in multiple myeloma where IGF-1-induced activation of AKT is an important antiapoptotic cascade. We, therefore, studied AKT activation in multiple myeloma cells treated with mTOR inhibitors. Rapamycin enhanced basal AKT activity, AKT phosphorylation, and PI3K activity in multiple myeloma cells and prolonged activation of AKT induced by exogenous IGF-I. CCI-779, used in a xenograft model, also resulted in multiple myeloma cell AKT activation in vivo. Blockade of lGF-I receptor function prevented rapamycin's activation of AKT. Furthermore, rapamycin prevented serine phosphorylation of IRS-1, enhanced IRS-1 association with IGF-I receptors, and prevented IRS-1 degradation. Although similarly blocking IRS-1 degradation, proteasome inhibitors did not activate AKT. Thus, mTOR inhibitors activate PI3-K/AKT in multiple myeloma cells; activation depends on basal IGF-R signaling; and enhanced IRS-1/IGF-I receptor interactions secondary to inhibited IRS-1 serine phosphorylation may play a role in activation of the cascade. In cotreatment experiments, rapamycin inhibited myeloma cell apoptosis induced by PS-341. These results provide a caveat for future use of mTOR inhibitors in myeloma patients if they are to be combined with apoptosis-inducing agents. C1 Univ Calif Los Angeles, W Los Angeles Vet Adm, Med Ctr, Div Hematol Oncol, Los Angeles, CA USA. Univ Calif Los Angeles, Johnson Comprehens Canc Ctr, Los Angeles, CA USA. RP Lichtenstein, A (reprint author), Vet Adm W Los Angeles Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM alichten@ucla.edu OI Frost, Patrick/0000-0003-3348-5983 FU NCI NIH HHS [CA111448-01, CA096920] NR 25 TC 217 Z9 224 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD OCT PY 2005 VL 4 IS 10 BP 1533 EP 1540 DI 10.1158/1535-7163.MCT-05-0068 PG 8 WC Oncology SC Oncology GA 974AS UT WOS:000232564300009 PM 16227402 ER PT J AU Deswal, A Mann, DL AF Deswal, A Mann, DL TI Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients? SO NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE LA English DT Editorial Material DE angiotensin receptor blocker; atrial fibrillation; heart failure; valsartan ID VENTRICULAR DYSFUNCTION; PREVENTION C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. RP Deswal, A (reprint author), VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM adeswal@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 NR 6 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1743-4297 J9 NAT CLIN PRACT CARD JI Nat. Clin. Pract. Cardiovasc. Med. PD OCT PY 2005 VL 2 IS 10 BP 502 EP 503 DI 10.1038/ncpcardio0325 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 966UF UT WOS:000232046900004 PM 16186843 ER PT J AU Kuhlenbaumer, G Hannibal, MC Nelis, E Schirmacher, A Verpoorten, N Meuleman, J Watts, GDJ De Vriendt, E Young, P Stogbauer, F Halfter, H Irobi, J Goossens, D Del-Favero, J Betz, BG Hor, H Kurlemann, G Bird, TD Airaksinen, E Mononen, T Serradell, AP Prats, JM Van Broeckhoven, C De Jonghe, P Timmerman, V Ringelstein, EB Chance, PF AF Kuhlenbaumer, G Hannibal, MC Nelis, E Schirmacher, A Verpoorten, N Meuleman, J Watts, GDJ De Vriendt, E Young, P Stogbauer, F Halfter, H Irobi, J Goossens, D Del-Favero, J Betz, BG Hor, H Kurlemann, G Bird, TD Airaksinen, E Mononen, T Serradell, AP Prats, JM Van Broeckhoven, C De Jonghe, P Timmerman, V Ringelstein, EB Chance, PF TI Mutations in SEPT9 cause hereditary neuralgic amyotrophy SO NATURE GENETICS LA English DT Article ID MAMMALIAN SEPTIN; CHROMOSOME 17Q25; HNA LOCUS; MICROTUBULES; REFINEMENT; GENE AB Hereditary neuralgic amyotrophy (HNA) is an autosomal dominant recurrent neuropathy affecting the brachial plexus. HNA is triggered by environmental factors such as infection or parturition. We report three mutations in the gene septin 9 (SEPT9) in six families with HNA linked to chromosome 17q25. HNA is the first monogenetic disease caused by mutations in a gene of the septin family. Septins are implicated in formation of the cytoskeleton, cell division and tumorigenesis. C1 Univ Munster, Dept Neurol, D-48149 Munster, Germany. Univ Munster, Leibniz Inst Atherosclerosis Res, D-48149 Munster, Germany. Univ Antwerp VIB, Dept Mol Genet, B-2020 Antwerp, Belgium. Univ Washington, Dept Pediat, Div Genet & Dev Med, Seattle, WA 98195 USA. Univ Munster, Dept Pediat Neurol, D-4400 Munster, Germany. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Kuopio, Dept Paediat, FIN-70211 Kuopio, Finland. Kuopio Univ Hosp, Dept Clin Genet, SF-70210 Kuopio, Finland. Autonome Univ Barcelona, Hosp Mar, Dept Neurol, Barcelona, Spain. Hosp Cruces, Div Child Neurol, Baracaldo, Basque Country, Spain. Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium. RP Kuhlenbaumer, G (reprint author), Univ Munster, Dept Neurol, Domagkstr 3, D-48149 Munster, Germany. EM gkuhlen@uni-muenster.de RI Kuhlenbaumer, Gregor/A-5110-2009 OI Del Favero, jurgen/0000-0002-7427-7489 NR 12 TC 106 Z9 113 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD OCT PY 2005 VL 37 IS 10 BP 1044 EP 1046 DI 10.1038/ng1649 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 968TP UT WOS:000232185600014 PM 16186812 ER PT J AU Yehuda, R Bryant, R Marmar, C Zohar, J AF Yehuda, R Bryant, R Marmar, C Zohar, J TI Pathological responses to terrorism SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE terrorism; posttraumatic stress disorder; risk factors; biological studies; prospective studies ID POSTTRAUMATIC-STRESS-DISORDER; MOTOR-VEHICLE ACCIDENTS; 2-YEAR PROSPECTIVE EVALUATION; AUDITORY STARTLE RESPONSE; TRAUMATIC BRAIN-INJURY; ROAD TRAFFIC ACCIDENTS; DELAYED-ONSET PTSD; NEW-YORK-CITY; PERITRAUMATIC DISSOCIATION; PREDICTING PTSD AB Many important gains have been made in understanding PTSD and other responses to trauma as a result of neuroscience- based observations. Yet there are many gaps in our knowledge that currently impede our ability to predict those who will develop pathologic responses. Such knowledge is essential for developing appropriate strategies for mounting a mental health response in the aftermath of terrorism and for facilitating the recovery of individuals and society. This paper reviews clinical and biological studies that have led to an identification of pathologic responses following psychological trauma, including terrorism, and highlights areas of future-research. It is important to not only determine risk factors for the development of short-and long-term mental health responses to terrorism, but also apply these risk factors to the prediction of such responses on an individual level. It is also critical to consider the full spectrum of responses to terrorism, as well as the interplay between biological and psychological variables that contribute to these responses. Finally, it is essential to remove the barriers to collecting data in the aftermath of trauma by creating a culture of education in which the academic community can communicate to the public what is and is not known so that survivors of trauma and terrorism will understand the value of their participation in research to the generation of useful knowledge, and by maintaining the acquisition of knowledge as a priority for the government and those involved in the immediate delivery of services in the aftermath of large-scale disaster or trauma. C1 Bronx Vet Affairs Med Ctr, Psychiat OOMH, Bronx, NY 10468 USA. RP Yehuda, R (reprint author), Bronx Vet Affairs Med Ctr, Psychiat OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@med.va.gov OI Bryant, Richard/0000-0002-9607-819X NR 89 TC 18 Z9 18 U1 11 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD OCT PY 2005 VL 30 IS 10 BP 1793 EP 1805 DI 10.1038/sj.npp.1300816 PG 13 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 965VJ UT WOS:000231978200003 PM 16012535 ER PT J AU Tsai, AG Glick, HA Shera, D Stern, L Samaha, FF AF Tsai, AG Glick, HA Shera, D Stern, L Samaha, FF TI Cost-effectiveness of a low-carbohydrate diet and a standard diet in severe obesity SO OBESITY RESEARCH LA English DT Article; Proceedings Paper CT 10th Annual National Research Service Award Trainees Research Conference CY JUN 05, 2004 CL San Diego, CA ID LOW-FAT DIET; WEIGHT-LOSS; RANDOMIZED-TRIAL; FOLLOW-UP; LIFE; INTERVENTION; REDUCTION; METFORMIN; ADULTS; CARE AB Objective: Low-carbohydrate diets have become a popular alternative to standard diets for weight loss. Our aim was to compare the cost-effectiveness of these two diets. Research Methods and Procedures: The patient population included 129 severely obese subjects (BMI = 42.9) from a randomized trial; participants had a high prevalence of diabetes or metabolic syndrome. We compared within-trial costs, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (CER) for the two study groups. We imputed missing values for QALYs. The CER was bootstrapped to derive 95% confidence intervals and to define acceptability cut-offs. We took a societal perspective for our analysis. Results: Total costs during the one year of the trial were $6742 +/- 6675 and $6249 +/- 5100 for the low-carbohydrate and standard groups, respectively (p = 0.78). Participants experienced 0.64 +/- 0.02 and 0.61 +/- 0.02 QALYs during the one year of the study, respectively (p = 0.17 for difference). The point estimate of the incremental CER was $-1225/QALY (i.e., the low-carbohydrate diet dominated the standard diet). However, in the bootstrap analysis, the wide spread of CERs caused the 95% confidence interval to be undefined. The probabilities that the low-carbohydrate diet was acceptable, using cut-offs of $50,000/QALY, $100,000/QALY, and $150,000/QALY, were 72.4% 78.6%, and 79.8%, respectively. Discussion: The low-carbohydrate diet was not more cost-effective for weight loss than the Standard diet in the patient population studied. Larger studies are needed to better assess the cost-effectiveness of dietary therapies for weight loss. C1 Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Div Cardiovasc, Dept Med, Philadelphia, PA 19104 USA. Childrens Hosp Philadelphia, Div Biostat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Tsai, AG (reprint author), Univ Penn, Weight & Eating Disorders Program, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM gildena@mail.med.upenn.edu FU PHS HHS [2-T32-HP-010026] NR 32 TC 13 Z9 13 U1 1 U2 6 PU NORTH AMER ASSOC STUDY OBESITY PI SILVER SPRING PA 8630 FENTON ST, SUITE 918, SILVER SPRING, MD 20910 USA SN 1071-7323 J9 OBES RES JI Obes. Res. PD OCT PY 2005 VL 13 IS 10 BP 1834 EP 1840 DI 10.1038/oby.2005.223 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 987GS UT WOS:000233507000022 PM 16286532 ER PT J AU Young, MRI Lathers, DMR AF Young, MRI Lathers, DMR TI Combination docetaxel plus vitamin D-3 as an immune therapy in animals bearing squamous cell carcinomas SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID CD34(+) PROGENITOR CELLS; NECK-CANCER PATIENTS; PERIPHERAL-BLOOD; DENDRITIC CELLS; BREAST-CANCER; HEAD; DIFFERENTIATION; LYMPHOCYTES; SUPPRESSION; PROLIFERATION AB OBJECTIVE: Background tumor growth results in the mobilization of immune inhibitory CD34(+) progenitor cells. However, vitamin D, can differentiate the CD34(+) cells into immune stimulatory dendritic cells. This study determined if docetaxel treatment could increase the impact of the vitamin D, to generate dendritic cells. METHODS: The murine squamous cell carcinoma model, SCC VII/SF, which is often used as a head and neck cancer model, was used to determine the immunological effects of two cycles of docetaxel plus vitamin D,. RESULTS: Vitamin D, with or without docetaxel was similarly effective in reducing CD34(+) cell levels within the spleen, lymph nodes, and tumor. Dendritic cell levels were similarly enhanced in the lymph nodes by vitamin D, alone or combined with docetaxel. However, the combination treatment caused a prominent increase in intratumoral levels of active T cells, which was not observed by the individual treatments. CONCLUSION: Incorporating docetaxel treatment with vitamin D-3 differentiation-inducing treatment enhances intratumoral immune responsiveness. (C) 2005 American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. All rights reserved. C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Res Serv 151, Dept Res Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29401 USA. RP Young, MRI (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Res Serv 151, Dept Res Serv, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@med.va.gov FU NCI NIH HHS [CA97813, CA85266] NR 21 TC 4 Z9 4 U1 0 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD OCT PY 2005 VL 133 IS 4 BP 611 EP 618 DI 10.1016/j.otohns.2005.05.658 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 972NR UT WOS:000232461000024 PM 16213938 ER PT J AU Cohen, DM AF Cohen, DM TI TRPV4 and the mammalian kidney SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY LA English DT Review ID RECEPTOR POTENTIAL VANILLOID-4; HEAT-EVOKED ACTIVATION; CELL-VOLUME REGULATION; CATION CHANNEL TRPV4; ASCITES TUMOR-CELLS; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE A(2); ION-CHANNEL; SRC KINASE; PROTEIN AB Transient receptor potential vanilloid 4 (TRPV4) was identified as the mammalian homologue of the Caenorhabditis elegans osmosensory channel protein, OSM-9. In mammals, TRPV4 is activated by a variety of stimuli including thermal stress, fatty acid metabolites, and hypotonicity. Two distinct mechanisms have been described through which TRPV4 may be activated by hypotonicity: one involves the Src family of nonreceptor protein tyrosine kinases, whereas a second is mediated via arachidonic acid metabolites. TRPV4 likely plays a role in systemic osmoregulation; accordingly, it is expressed in the blood-brain barrier-deficient osmosensory nuclei of the hypothalamus. TRPV4 is also abundantly expressed in the kidney, and its precisely demarcated distribution along the kidney tubule permits speculation about a physiological role in this tissue. TRPV4-expressing and TRPV4-negative tubule segments co-exist at all levels of the kidney, from the cortex through the inner medulla. It is conceivable that basolaterally expressed TRPV4 transmits signals arising in the interstitium (e.g, changing tonicity) to more-distal tubule segments where "fine-tuning" of the incipient urine takes place. C1 Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, 3314 SW US Vet Hosp Rd,Mailcode PP262, Portland, OR 97239 USA. EM cohend@ohsu.edu NR 54 TC 37 Z9 41 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0031-6768 J9 PFLUG ARCH EUR J PHY JI Pflugers Arch. PD OCT PY 2005 VL 451 IS 1 BP 168 EP 175 DI 10.1007/s00424-005-1456-9 PG 8 WC Physiology SC Physiology GA 971GS UT WOS:000232372800020 PM 15988590 ER PT J AU Saxon, AJ McCarty, D AF Saxon, AJ McCarty, D TI Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs SO PHARMACOLOGY & THERAPEUTICS LA English DT Review DE buprenorphine; pharmacotherapy; adoption of innovations ID COCAINE-DEPENDENT OUTPATIENTS; PLACEBO-CONTROLLED TRIAL; FOLLOW-UP OUTCOMES; UNITED-STATES; METHADONE-MAINTENANCE; COST-EFFECTIVENESS; SUBSTANCE-ABUSE; NARCOTIC ADDICTION; FIELD EXPERIENCE; OPIATE ADDICTION AB The adoption of pharmacotherapies for the treatment of alcohol and drug use disorders has progressed slowly despite the approval of new and effective medications. This paper begins with overviews of the prevalence of alcohol and drug abuse and dependence, the costs of addiction to the nation, and the value of treatment services. The role of pharmacotherapy in the treatment of addictive diseases is examined, and factors that affect the adoption and use of medications for alcohol and drug treatment are identified and discussed. Investigations that tested the effectiveness of buprenorphine for treatment of opioid dependence in new settings illustrate physician and counselor training and mentorship strategies that may promote the adoption of medications in the treatment of alcohol and drug use disorders. The paper concludes with a discussion of barriers and ways to surmount the barriers and to foster greater use of medications in alcohol and drug treatment. (c) 2005 Published by Elsevier Inc. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. RP Saxon, AJ (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM andrew.saxon@med.va.gov NR 77 TC 34 Z9 34 U1 6 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0163-7258 J9 PHARMACOL THERAPEUT JI Pharmacol. Ther. PD OCT PY 2005 VL 108 IS 1 BP 119 EP 128 DI 10.1016/j.pharmthera.2005.06.014 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 974KB UT WOS:000232589200010 PM 16055196 ER PT J AU McMaster, NL Tschirhart, SAJ Erwin, TC Linn, WD AF McMaster, NL Tschirhart, SAJ Erwin, TC Linn, WD TI Modifiable coronary heart disease risk factors: quality of care in an academic VA geriatrics clinic. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 23-26, 2005 CL San Francisco, CA SP Amer Coll Clin Pharmacy C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2005 VL 25 IS 10 BP 1449 EP 1450 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 971BP UT WOS:000232356400087 ER PT J AU Gressmann, H Linz, B Ghai, R Pleissner, KP Schlapbach, R Yamaoka, Y Kraft, C Suerbaum, S Meyer, TF Achtman, M AF Gressmann, H Linz, B Ghai, R Pleissner, KP Schlapbach, R Yamaoka, Y Kraft, C Suerbaum, S Meyer, TF Achtman, M TI Gain and loss of multiple genes during the evolution of Helicobacter pylori SO PLOS GENETICS LA English DT Article ID COMPLETE GENOME SEQUENCE; GASTRIC EPITHELIAL-CELLS; MYCOBACTERIUM-TUBERCULOSIS; YERSINIA-PESTIS; IV SECRETION; HUMAN HOST; DIVERSITY; STRAINS; CAGA; RECOMBINATION AB Sequence diversity and gene content distinguish most isolates of Helicobacter pylori. Even greater sequence differences differentiate distinct populations of H. pylori from different continents, but it was not clear whether these populations also differ in gene content. To address this question, we tested 56 globally representative strains of H. pylori and four strains of Helicobacter acinonychis with whole genome microarrays. Of the weighted average of 1,531 genes present in the two sequenced genomes, 25% are absent in at least one strain of H. pylori and 21% were absent or variable in H. acinonychis. We extrapolate that the core genome present in all isolates of H. pylori contains 11,1111 genes. Variable genes tend to be small and possess unusual GC content; many of them have probably been imported by horizontal gene transfer. Phylogenetic trees based on the microarray data differ from those based on sequences of seven genes from the core genome. These discrepancies are due to homoplasies resulting from independent gene loss by deletion or recombination in multiple strains, which distort phylogenetic patterns. The patterns of these discrepancies versus population structure allow a reconstruction of the timing of the acquisition of variable genes within this species. Variable genes that are located within the cog pathogenicity island were apparently first acquired en bloc after speciation. In contrast, most other variable genes are of unknown function or encode restriction/ modification enzymes, transposases, or outer membrane proteins. These seem to have been acquired prior to speciation of H. pylori and were subsequently lost by convergent evolution within individual strains. Thus, the use of microarrays can reveal patterns of gene gain or loss when examined within a phylogenetic context that is based on sequences of core genes. C1 Max Planck Inst Infektionsbiol, Dept Mol Biol, Berlin, Germany. Univ Giessen, Inst Med Microbiol, Giessen, Germany. Max Planck Inst Infektionsbiol, Core Facil Bioinformat, Berlin, Germany. Univ Zurich, ETH, Funct Genom Ctr, Zurich, Switzerland. ME DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Hannover Med Sch, Inst Med Mikrobiol & Krankenhaushyg, Hannover, Germany. RP Achtman, M (reprint author), Max Planck Inst Infektionsbiol, Dept Mol Biol, Berlin, Germany. EM achtman@mpiib-berlin.mpg.de RI Meyer, Thomas F./J-2485-2013; Ghai, Rohit/E-7086-2012; Schlapbach, Ralph/R-8234-2016 OI Meyer, Thomas F./0000-0002-6120-8679; NR 60 TC 132 Z9 137 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD OCT PY 2005 VL 1 IS 4 BP 419 EP 428 AR e43 DI 10.1371/journal.pgen.0010043 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 003XE UT WOS:000234714800002 PM 16217547 ER PT J AU Montgomery, RB Bonham, M Nelson, PS Grim, J Makary, E Vessella, R Stahl, WL AF Montgomery, RB Bonham, M Nelson, PS Grim, J Makary, E Vessella, R Stahl, WL TI Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells SO PROSTATE LA English DT Article DE prostate cancer; tubulin; estrogen; paclitaxel; diethylstilbestrol ID ISOTYPE EXPRESSION; MICROTUBULE DYNAMICS; CARCINOMA-CELLS; PC-SPES; 2-METHOXYESTRADIOL; GROWTH; TAXOL; DIETHYLSTILBESTROL; POLYMERIZATION; CHEMOTHERAPY AB BACKGROUND. The present study was designed to determine if estrogens change microtubule polymerization and modulate cell cycle progression in vitro, related to modulation of tubulin expression and to determine if estrogens had antagonistic or synergistic effects with microtubule active agents. METHODS. cDNA array analysis of LNCaP cells treated with the estrogens, estradiol, estrone, diethylstilbestrol (DES), and 2-methoxyestradiol (2-ME) was carried out and the results confirmed by PCR and Western blotting. Microtubule arrays in cells treated with estrogens were assessed using indirect immunofluorescence. The effects of combining estrogens with taxane was assessed by MTT assay and flow cytometry for cell cycle kinetics. Human prostate cancer xenografts were treated with DES and docetaxel to assess the effects of combining estrogens and taxane in vivo. RESULTS. Treatment of LNCaP cells with DES and 2-ME suppressed transcripts and protein for beta-tubulin isotype lVa. This effect on tubulin synthesis was not blocked by estrogen or androgen receptor modulators. Other estrogens had no effect on beta-tubulin expression. 2-ME and DES decreased the density of microtubules. The administration of DES or 2-ME with paclitaxel enhanced cytotoxicity and G(2)-M arrest in vitro. DES enhanced tumor suppression in a human prostate cancer xenograft model when combined with the taxane docetaxel. CONCLUSION. The use of DES and 2-ME enhances the effects of taxanes and may be a novel and important means of increasing therapeutic efficacy of cytotoxic chemotherapy against prostate carcinoma. C1 VA Puget Sound HCS, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Oncol, Seattle, WA USA. Univ Washington, Dept Neurol, Seattle, WA USA. Univ Washington, Dept Physiol, Seattle, WA USA. Univ Washington, Dept Biophys, Seattle, WA USA. Univ Washington, Dept Urol, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA. RP Montgomery, RB (reprint author), VA Puget Sound HCS, Mailstop 111ONC,1660 S Columbian Way, Seattle, WA 98108 USA. EM rbmontgo@u.washington.edu NR 34 TC 20 Z9 20 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD OCT 1 PY 2005 VL 65 IS 2 BP 141 EP 150 DI 10.1002/pros.20246 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 968DP UT WOS:000232142400006 PM 15924336 ER PT J AU Beahrs, JO AF Beahrs, JO TI A social brain interpretation of psychotherapy SO PSYCHIATRIC ANNALS LA English DT Article; Proceedings Paper CT 155th Annual Meeting of the American-Psychiatric-Association CY MAY 18-23, 2002 CL PHILADELPHIA, PA SP Amer Psychiat Assoc ID MEMORY C1 Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Beahrs, JO (reprint author), 3318 NE Hancock St, Portland, OR 97212 USA. EM intarts@teleport.com NR 40 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 EI 1938-2456 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD OCT PY 2005 VL 35 IS 10 BP 816 EP 822 PG 7 WC Psychiatry SC Psychiatry GA 974JC UT WOS:000232586600006 ER PT J AU Lopez, MF Becker, HC AF Lopez, MF Becker, HC TI Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice SO PSYCHOPHARMACOLOGY LA English DT Article DE ethanol; withdrawal; self-administration; mice; relapse; limited access ID ALCOHOL-WITHDRAWAL; DEPENDENT RATS; ANIMAL-MODEL; DRINKING; DEPRIVATION; ALLOSTASIS; PREFERENCE; EPISODES; ANXIETY; ABSTINENCE AB Rationale: We previously demonstrated that chronic ethanol exposure and withdrawal experience significantly increased subsequent voluntary ethanol intake in C57BL/6J mice. This study was conducted to examine chronic ethanol conditions that optimize this enhanced ethanol-drinking behavior. Objectives: The purpose of this study was to examine whether the pattern and/or number of chronic ethanol exposures influence subsequent ethanol intake. Methods: C57BL/6J mice were trained to drink ethanol (15% v/v) in a limited access situation (2 h/day) until stable intake was achieved. In experiment 1, mice received two cycles of chronic ethanol exposure delivered either in an intermittent [multiple withdrawal (MW)] or continuous [continuous exposure (CE)] pattern. One week of daily drinking sessions followed each exposure. In experiment 2, mice received either two or four cycles of chronic intermittent ethanol exposure (MW), each followed by a week of testing sessions. Three additional weeks of ethanol intake testing followed the last ethanol (or air) exposure. Results: Experiment 1: Only the MW group evidenced a significant increase in ethanol intake compared to controls after the first chronic ethanol exposure. Both MW and CE groups consumed more ethanol than controls after the second ethanol-exposure period. Experiment 2: Ethanol intake in MW mice compared to controls significantly increased after two or four cycles of chronic ethanol exposure/withdrawal, and this heightened ethanol intake lasted longer in mice that received four cycles of chronic intermittent ethanol exposure. Conclusions: Increased voluntary ethanol intake after chronic ethanol exposure and withdrawal experience may be accelerated by intermittent (as opposed to continuous) ethanol exposure, and the effect may last longer with increased number of such experiences. C1 Med Univ S Carolina, Charles Alcohol Res Ctr, Ctr Drug & Alcohol Programs, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Lopez, MF (reprint author), Med Univ S Carolina, Charles Alcohol Res Ctr, Ctr Drug & Alcohol Programs, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. EM lopezm@musc.edu FU NIAAA NIH HHS [AA013885, AA014095, P50-AA10761] NR 41 TC 121 Z9 121 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD OCT PY 2005 VL 181 IS 4 BP 688 EP 696 DI 10.1007/s00213-005-0026-3 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 975KL UT WOS:000232661300006 PM 16001125 ER PT J AU Soto, JA Barish, MA Yee, J AF Soto, JA Barish, MA Yee, J TI Reader training in CT colonography: How much is enough? SO RADIOLOGY LA English DT Editorial Material ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; VIRTUAL COLONOSCOPY; COLORECTAL NEOPLASIA; CONVENTIONAL COLONOSCOPY; POLYPS; PERFORMANCE C1 Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA. Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. San Francisco Vet Adm Med Ctr, Dept Radiol, San Francisco, CA USA. RP Soto, JA (reprint author), Boston Univ, Med Ctr, Dept Radiol, 88 E Newton St, Boston, MA 02118 USA. EM jorge.Soto@bmc.org OI Soto, Jorge/0000-0003-2533-3015 NR 18 TC 35 Z9 37 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD OCT PY 2005 VL 237 IS 1 BP 26 EP 27 DI 10.1148/radiol.2371050003 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 965RM UT WOS:000231968000007 PM 16183923 ER PT J AU Green, MF Olivier, B Crawley, JN Penn, DL Silverstein, S AF Green, MF Olivier, B Crawley, JN Penn, DL Silverstein, S TI Social cognition in schizophrenia: Recommendations from the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference SO SCHIZOPHRENIA BULLETIN LA English DT Article; Proceedings Paper CT 7th Biennial Sinai Conference on Cognitionn in Schizophrenia CY APR 02, 2005 CL Savannah, GA DE social cognition; schizophrenia; MATRICS; animal models ID EMOTION PERCEPTION; NEURAL BASIS; MICE LACKING; BEHAVIOR; RECOGNITION; IDENTIFICATION; NEUROBIOLOGY; NEUROSCIENCE; VASOPRESSIN; PERFORMANCE AB This article summarizes the discussion from a breakout group at the National Institute of Mental Health-Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference on social cognition in schizophrenia. During this discussion, the reasons for the recent growth of research on social cognition in schizophrenia were examined. The discussion group established consensus on several points, including the importance of viewing social cognition from interdisciplinary perspectives (including outcomes research, social psychology, cognitive psychology, cognitive neuroscience, and animal models) and the need for clearer definition of terms. There was also general agreement that social cognition is a valuable construct for understanding the nature and disability of schizophrenia. One of the objectives of this group was to generate recommendations for subsequent human and animal studies, and these research agendas are summarized in this report. C1 Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, NPI, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Utrecht, Inst Pharmacol Sci, Dept Psychopharmacol, Utrecht, Netherlands. Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. RP Green, MF (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM mgreen@ucla.edu NR 60 TC 203 Z9 213 U1 10 U2 21 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD OCT PY 2005 VL 31 IS 4 BP 882 EP 887 DI 10.1093/schbul/sbi049 PG 6 WC Psychiatry SC Psychiatry GA 971ZA UT WOS:000232422400013 PM 16135561 ER PT J AU Bromley, E AF Bromley, E TI A collaborative approach to targeted treatment development for schizophrenia: A qualitative evaluation of the NIMH-MATRICS project SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; cognition; psychotropic drugs; therapeutic use; diffusion of innovation; qualitative research ID CONSENSUS COGNITIVE BATTERY; NEUROCOGNITIVE DEFICITS; IMPROVE COGNITION; CLINICAL-PRACTICE; ENDOPHENOTYPE; SUPPORT; MEMORY; CARE; PERSPECTIVE; OUTCOMES AB Introduction: In 2002, the National Institute of Mental Health (NIMH) initiated a multistakeholder research process designed to stimulate the development and evaluation of medications targeting the cognitive deficits associated with schizophrenia. The first phase, Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), sought consensus on laboratory measures for cognition, clinical trial outcome measures, and drug registration requirements. MATRICS constitutes a unique drug development model because it targeted a specific endophenotype of schizophrenia and because it engaged academic, industry, and government stakeholders in a consensus-oriented process. This study offers a preliminary qualitative evaluation of the NIMH-MATRICS project. Method: Interview data are used to describe how MATRICS participants regard 3 aspects of the development of cognitive medications: the definition of the treatment target, stakeholders' role in the early development process, and anticipated dissemination complexities. Results: MATRICS participants describe the treatment target in highly varied ways and envision a wide range of public health benefits. MATRICS is perceived as inclusive, despite minimal representation from some end users. According to informants, clinical detection, documentation, and monitoring of cognition and functioning may prove problematic. More thoroughly than non-industry-employed informants, industry-employed MATRICS participants articulate strategies by which treatments can be integrated into clinical practice. Discussion: The MATRICS process did not produce a clinical concept of cognitive impairment in schizophrenia, and significant challenges remain to be addressed regarding the rational clinical use of novel pharmaceuticals for cognition. Broader inclusion of end users in translational science projects may streamline implementation and facilitate improvements in real-world outcomes. C1 Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Bromley, E (reprint author), Mail 911 Broxton Plaza,3rd Floor, Los Angeles, CA 90024 USA. EM ebromley@ucla.edu NR 59 TC 12 Z9 12 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD OCT PY 2005 VL 31 IS 4 BP 954 EP 961 DI 10.1093/schbul/sbi059 PG 8 WC Psychiatry SC Psychiatry GA 971ZA UT WOS:000232422400021 PM 16166607 ER PT J AU Goffaux, J Friesinger, GC Lambert, W Shroyer, LW Moritz, TE McCarthy, M Henderson, WG Hammermeister, KE AF Goffaux, J Friesinger, GC Lambert, W Shroyer, LW Moritz, TE McCarthy, M Henderson, WG Hammermeister, KE TI Biological age - A concept whose time has come: A preliminary study SO SOUTHERN MEDICAL JOURNAL LA English DT Article ID MINI-MENTAL-STATE; ACUTE MYOCARDIAL-INFARCTION; BYPASS GRAFT-SURGERY; FUNCTIONAL STATUS; OLDER-ADULTS; CONTINUOUS IMPROVEMENT; CARDIOVASCULAR HEALTH; PHYSICAL PERFORMANCE; CALCULATING RISK; ELDERLY-PATIENTS AB Objective: Chronology poorly predicts biological age (BA) or physiologic reserve (PR). An objective approach to the heterogeneity of aging would greatly help clinical decision making in the elderly. Materials And Methods: The first pilot study evaluated 130 "healthy" volunteers, ages 70 to 95 years. A summary BA/PR index was developed, using measures of endurance, strength, flexibility, balance, cognition, depression, comorbidity, and exercise. The second study applied the BA/PR concept to prediction of death after a first elective coronary artery bypass graft, using a Veterans Administration database. Results: The BA/PR index was a better predictor of 3-year functional outcomes and death than was chronological age. In the coronary artery bypass graft Study, the inclusion of BA/PR variables significantly improved prediction of 6-month and long-term death for Veterans Administration patients. Conclusions: The usefulness of a biological age (BA/PR) approach in predicting outcomes in the elderly was supported. Needed research Should develop tools for routine "tracking" of the aging process. C1 Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA. Vanderbilt Univ, Inst Publ Policy Studies, Nashville, TN 37232 USA. Denver VA Med Ctr, Cardiol Sect 111B, Denver, CO USA. Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program, Coordinating Ctr, Chicago, IL USA. Northwestern Univ, Colorado Hlth Outcomes Program F 443, Chicago, IL 60611 USA. RP Friesinger, GC (reprint author), Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, 383 PRB,2220 Pierce Ave, Nashville, TN 37232 USA. EM Gottlieb.friesinger@vanderbilt.edu RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 NR 89 TC 7 Z9 7 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD OCT PY 2005 VL 98 IS 10 BP 985 EP 993 DI 10.1097/01.smj.0000182178.22607.47 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 982RC UT WOS:000233178300008 PM 16295813 ER PT J AU Ko, CY Maggard, M Agustin, M AF Ko, CY Maggard, M Agustin, M TI Quality in surgery: Current issues for the future SO WORLD JOURNAL OF SURGERY LA English DT Article ID 10-YEAR PROSPECTIVE COHORT; COLON-CANCER RESECTION; 8 COMMON OPERATIONS; HOSPITAL VOLUME; IMPROVEMENT PROGRAM; TECHNOLOGY-ASSESSMENT; HEALTH-CARE; RADICAL PROSTATECTOMY; PATIENT OUTCOMES; SURGICAL VOLUME C1 Univ Calif Los Angeles, David Geffen Sch Med, Ctr Surg Outcomes & Qual, Dept Surg, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Ko, CY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Surg Outcomes & Qual, Dept Surg, 10833 Ave CHS Room 72-215, Los Angeles, CA 90095 USA. EM cko@mednet.ucla.edu NR 55 TC 19 Z9 19 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD OCT PY 2005 VL 29 IS 10 BP 1204 EP 1209 DI 10.1007/s00268-005-7990-y PG 6 WC Surgery SC Surgery GA 973AH UT WOS:000232494800002 PM 16136282 ER PT J AU Carabello, BA AF Carabello, BA TI Vasodilators in aortic regurgitation - Where is the evidence of their effectiveness? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID ASYMPTOMATIC PATIENTS; MITRAL REGURGITATION; VALVE-REPLACEMENT; NIFEDIPINE; INSUFFICIENCY; PERFORMANCE; THERAPY C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Carabello, BA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. NR 13 TC 11 Z9 11 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 29 PY 2005 VL 353 IS 13 BP 1400 EP 1402 DI 10.1056/NEJMe058213 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 968FB UT WOS:000232146200015 PM 16192487 ER PT J AU Oh, DH Yeh, K AF Oh, DH Yeh, K TI Differentiating human keratinocytes are deficient in p53 but retain global nucleotide excision repair following ultraviolet radiation SO DNA REPAIR LA English DT Article DE DNA repair; ultraviolet rays; thymine dimer; keratinocyte; differentiation ID CYCLOBUTANE PYRIMIDINE DIMERS; HUMAN-SKIN INVIVO; GROUP-C GENE; DNA-DAMAGE; GENOMIC REPAIR; UV-IRRADIATION; EPIDERMAL-KERATINOCYTES; HUMAN FIBROBLASTS; TUMOR-SUPPRESSOR; BINDING-FACTOR AB Terminally differentiating keratinocytes constitute the predominant cell type within the skin epidermis and play an important role in the overall photobiology of human skin following ultraviolet radiation. However, the DNA repair capacity of differentiating keratinocytes is unclear, and little is known regarding how such repair activity is regulated in these cells. We systematically compared the global genomic nucleotide excision repair response of cultured undifferentiated human keratinocytes to those that were allowed to differentiate in 1.2 mM Ca2+, in some cases supplemented with phorbol ester or Vitamin C. Differentiated cells ceased replication and expressed typical markers of differentiation. Following ultraviolet radiation, keratinocytes that were differentiated up to 12 days removed cyclobutane pyrimidine dimers and pyrimidine(6,4)pyrimidone photoproducts from the global genome as efficiently as undifferentiated cells. However, following the onset of calcium-induced differentiation, basal levels of p53 were nearly undetectable by 12 days of differentiation when global repair activity was unaffected. Following ultraviolet radiation, induction of p53 following ultraviolet radiation was abrogated by 6 days of calcium-induced differentiation. Basal levels of mRNA encoding the DNA damage recognition proteins, XPC and DDB2, were relatively insensitive to differentiation and p53 levels. However, following ultraviolet radiation, inductions of mRNA encoding the DNA damage recognition proteins, DDB2 and XPC, were differentially affected by differentiation. Rapid loss of DDB2 mRNA induction was associated with differentiation, while XPC mRNA induction diminished more slowly with differentiation. These results indicate that human keratinocytes preserve global nucleotide excision repair as well as expression of genes encoding key DNA damage recognition proteins well into the terminal differentiation process. perhaps using mechanisms other than p53. (c) 2005 Elsevier B.V. All rights reserved. C1 Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Dermatol Serv 190, San Francisco, CA 94121 USA. RP Oh, DH (reprint author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. EM dennisoh@itsa.ucsf.edu NR 63 TC 14 Z9 14 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-7864 J9 DNA REPAIR JI DNA Repair PD SEP 28 PY 2005 VL 4 IS 10 BP 1149 EP 1159 DI 10.1016/j.dnarep.2005.06.004 PG 11 WC Genetics & Heredity; Toxicology SC Genetics & Heredity; Toxicology GA 972BP UT WOS:000232429100011 PM 16043423 ER PT J AU Peterfy, M Phan, J Reue, K AF Peterfy, M Phan, J Reue, K TI Alternatively spliced lipin isoforms exhibit distinct expression pattern, subcellular localization, and role in adipogenesis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID KINASE-C-BETA; TRANSCRIPTION FACTOR; MESSENGER-RNA; INSULIN; GENE; PROTEIN; LIPODYSTROPHY; MUTATION; OBESITY; CELLS AB We recently identified mutations in the Lpin1 ( lipin) gene to be responsible for lipodystrophy in the fatty liver dystrophy (fld) mouse strain. Previous studies revealed that lipin plays a critical role in adipogenesis, explaining the adipose-deficient phenotype of the fld mouse. In the current study, we demonstrate that alternative mRNA splicing generates two lipin isoforms, lipin-alpha and lipin-beta, which are differentially expressed during adipocyte differentiation. Lipin-alpha expression peaks at day 2 of 3T3-L1 cell differentiation, after which its levels gradually decrease. In contrast, lipin-beta expression is transiently elevated at 10 h, followed by a drop to background levels at 20 h and a gradual increase between days 2 and 6 of differentiation. The two lipin isoforms also exhibit differences in subcellular localization. Lipin-alpha is predominantly nuclear, whereas lipin-beta is primarily located in the cytoplasm of 3T3-L1 adipocytes, suggesting distinct cellular functions. Using primary mouse embryonic fibroblasts expressing either lipin-alpha or lipin-alpha, we demonstrate functional differences between the two isoforms. Whereas effect of lipin-beta expression is the induction of lipogenic genes. In vivo, overexpression of lipin-beta specifically in mature adipocytes leads to elevated expression of lipogenic genes and adipocyte hypertrophy, confirming a role of lipin-beta in the regulation of lipogenesis. In conclusion, our data suggest that the two lipin isoforms have distinct, but complementary, functions in adipogenesis, with lipin-alpha playing a primary role in differentiation and lipin-beta being predominantly involved in lipogenesis. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Reue, K (reprint author), 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA. EM reuek@ucla.edu FU NHLBI NIH HHS [HL24841]; NIGMS NIH HHS [GM08042] NR 30 TC 138 Z9 147 U1 2 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 23 PY 2005 VL 280 IS 38 BP 32883 EP 32889 DI 10.1074/jbc.M503885200 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 964ZU UT WOS:000231920300042 PM 16049017 ER PT J AU Chodosh, J Morton, SC Mojica, W Maglione, M Suttorp, MJ Hilton, L Rhodes, S Shekelle, P AF Chodosh, J Morton, SC Mojica, W Maglione, M Suttorp, MJ Hilton, L Rhodes, S Shekelle, P TI Meta-analysis: Chronic disease self-management programs for older adults SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; DEPENDENT DIABETES-MELLITUS; LIFE-STYLE MODIFICATION; BLOOD-PRESSURE; PRIMARY-CARE; CHRONIC ILLNESS; ESSENTIAL-HYPERTENSION; PATIENT EDUCATION; METABOLIC CONTROL; GLYCEMIC CONTROL AB Background: Although enthusiasm is growing for self-management programs for chronic conditions, there are conflicting data regarding their effectiveness and no agreement on their essential components. Purpose: To assess the effectiveness and essential components of self-management programs for hypertension, osteoarthritis, and diabetes mellitus. Data Sources: The authors searched multiple sources dated through September 2004, including the Cochrane Library, MEDLINE, PSycINFO, and Nursing and Allied Health databases, and bibliographies of 87 previous reviews. Study Selection: Randomized trials that compared outcomes of self-management interventions with a control or with usual care for diabetes mellitus, osteoarthritis, or hypertension; outcomes included hemoglobin A,c level, fasting blood glucose level, weight, blood pressure, pain, or function. Data Extraction: Two reviewers independently identified trials and extracted data regarding whether the intervention used tailored adjustments to meet individual patient needs, a group setting, feedback, and psychological services, and whether the intervention was provided by the patient's usual physician. Data Synthesis: Of 780 studies screened, 53 studies contributed data to the random-effects meta-analysis (26 diabetes studies, 14 osteoarthritis studies, and 13 hypertension studies). Self-management interventions led to a statistically and clinically significant pooled effect size of -0.36 (95% CI, -0.52 to -0.21) for hemoglobin A,c, equivalent to a reduction in hemoglobin A,, level of about 0.81%. Self-management interventions decreased systolic blood pressure by 5 mm Hg (effect size, -0.39 [CI, -0.51 to -0.28]) and decreased diastolic blood pressure by 4.3 mm Hg (effect size, -0.51 [CI, -0.73 to -0.30]). Pooled effects of self-management interventions were statistically significant but clinically trivial for pain and function outcomes for osteoarthritis. No consistent results supported any of the 5 characteristics examined as essential for program success. Limitations: Studies had variable quality, and possible publication bias was evident. Conclusions: Self-management programs for diabetes mellitus and hypertension probably produce clinically important benefits. The elements of the programs most responsible for benefits cannot be determined from existing data, and this inhibits specification of optimally effective or cost-effective programs. Osteoarthritis self-management programs do not appear to have clinically beneficial effects on pain or function. C1 Greater Los Angeles Vet Affairs Healthcare Syst, GRECC 11G, Los Angeles, CA 90073 USA. So Calif Evidence Based Practice Ctr, RAND Hlth Div, Santa Monica, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Chodosh, J (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, GRECC 11G, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 88 TC 371 Z9 378 U1 8 U2 54 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 20 PY 2005 VL 143 IS 6 BP 427 EP 438 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 967OG UT WOS:000232099900004 PM 16172441 ER PT J AU Massie, BM AF Massie, BM TI Aspirin use in chronic heart failure - What should we recommend to the practitioner? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID CONVERTING-ENZYME-INHIBITORS; MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; RANDOMIZED TRIALS; ELDERLY-PATIENTS; DEATH; PREVENTION; ENALAPRIL; SURVIVAL; DISEASE AB There has been ongoing controversy as to whether aspirin should be used in patients with chronic heart failure (CHF). The argument for aspirin is that many patients have underlying coronary disease, and aspirin prevents reinfarction and other vascular events. Arguments against the routine use of aspirin are that many CHF patients do not have underlying coronary disease, and that the benefit of aspirin lessens after the first 6 to 12 months after infarction. Also, several analyses suggest that aspirin may actually worsen outcomes in CkF patients, possibly because it inhibits prostaglandins, with resulting adverse hemodynamic and renal effects. Two recent prospective randomized studies have found that aspirin is associated with more frequent hospitalizations for worsening heart failure, although it did not have an adverse effect on vascular events. These results suggest that aspirin should not be routinely used in CHF patients and be avoided in those with refractory CHF, but that it may be beneficial in patients with recent infarction or multiple vascular risk factors. C1 San Francisco VAMC, Div Cardiol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. RP Massie, BM (reprint author), San Francisco VAMC, Div Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA. EM barry.massie@med.va.gov NR 28 TC 17 Z9 17 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 20 PY 2005 VL 46 IS 6 BP 963 EP 966 DI 10.1016/j.jacc.2004.10.082 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 966AI UT WOS:000231991600003 PM 16168276 ER PT J AU Bayram, M De Luca, L Massie, MB Gheorghiade, M AF Bayram, M De Luca, L Massie, MB Gheorghiade, M TI Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID MYOCARDIAL OXYGEN-CONSUMPTION; RANDOMIZED CONTROLLED TRIAL; NATIONAL REGISTRY ADHERE; BETA-BLOCKER THERAPY; DILATED CARDIOMYOPATHY; HIBERNATING MYOCARDIUM; INTRAVENOUS MILRINONE; HOSPITALIZED-PATIENTS; INOTROPIC THERAPY; DOUBLE-BLIND AB The appropriate role of intravenous inodilator therapy (inotropic agents with vasodilator properties) in the management of acute heart failure syndromes (AHFS) has long been a subject of controversy, mainly because of the lack of prospective, placebo-controlled trials and a lack of alternative therapies. The use of intravenous inodilator,infusions, however, remains common, but highly variable. As new options emerge for the treatment of AHFS, the available information should be reviewed to determine which approaches are supported by evidence, which are used empirically without evidence, and which should be considered inappropriate. For these purposes, we reviewed data available from randomized controlled trials on short-term, intermittent, and long-term use of intravenous inodilator agents (dobutamine, dopamine, and milrinone) in AHFS. Randomized controlled trials failed to show benefits with current medications and suggested that acute, intermittent, or continuous use of inodilator infusions may increase morbidity and mortality in patients with AHFS. Their use should be restricted to patients who are hypotensive as a result of low cardiac output despite a high left ventricular filling pressure. (c) 2005 Elsevier Inc. C1 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA. Univ Michigan, Dept Med, Residency Training Program, Ann Arbor, MI 48109 USA. Univ Roma La Sapienza, Dept Cardiovasc & Resp Sci, Rome, Italy. San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA. Univ San Francisco, Sch Med, San Francisco, CA 94143 USA. RP Bayram, M (reprint author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, Galter 10-240,201 E Huron St, Chicago, IL 60611 USA. EM m-gheorghiade@northwestern.edu NR 79 TC 66 Z9 77 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD SEP 19 PY 2005 VL 96 IS 6A SU S BP 47G EP 58G DI 10.1016/j.amjcard.2005.07.021 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 969BR UT WOS:000232208900008 PM 16181823 ER PT J AU Teerlink, JR AF Teerlink, JR TI Overview of randomized clinical trials in acute heart failure syndromes SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; WORSENING RENAL-FUNCTION; SOCIETY-OF-CARDIOLOGY; DOUBLE-BLIND; RECEPTOR ANTAGONIST; NATRIURETIC PEPTIDE; INTRAVENOUS LEVOSIMENDAN; PULMONARY-EDEMA; BG9719 CVT-124 AB Acute heart failure syndromes (AHFS) are among the most frequent causes of hospitalizations in the United States. and Europe. Despite current therapies, patients with AHFS have high readmission and mortality rates. The randomized, controlled clinical trial is the standard by which contemporary therapies are evaluated, yet this tool of clinical science only recently has been rigorously applied to the development of novel therapies for patients with AHFS. This review briefly discusses some of the challenges presented in designing a clinical trial of therapies for AHFS and to describe some of the recent trials with respect to these issues in established drugs (such as milrinone, dobutamine, nitroglycerin, nitroprusside, and nesiritide) that have been approved by the US Food and Drug Administration (FDA). Recent trials of current investigational agents, such as levosimendan (the Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short-Term Treatment of Decompensated Heart Failure [REVIVE], the Calcium Sensitizer or Inotrope or None in Low-Output Heart Failure [CASINO] study, and the Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support [SURVIVE] trial), tezosentan (the Randomized Intravenous Tezosentan [RITZ] study and the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies [VERITAS]), and tolvaptan (the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure [ACTIV-CHF] study), are also discussed. (c) 2005 Elsevier Inc. C1 San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. RP Teerlink, JR (reprint author), San Francisco Vet Affairs Med Ctr, Cardiol Sect, 111C,4150 Clement St, San Francisco, CA 94121 USA. EM johnt@itsa.ucsf.edu RI Teerlink, John/D-2986-2012 NR 55 TC 23 Z9 23 U1 0 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD SEP 19 PY 2005 VL 96 IS 6A SU S BP 59G EP 67G DI 10.1016/j.amjcard.2005.07.022 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 969BR UT WOS:000232208900009 PM 16181824 ER PT J AU Gheorghiade, M Teerlink, JR Mebazaa, A AF Gheorghiade, M Teerlink, JR Mebazaa, A TI Pharmacology of new agents for acute heart failure syndromes SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CARDIAC TROPONIN-C; CALCIUM-SENSITIZING DRUG; GUINEA-PIG HEART; ENDOTHELIN RECEPTOR ANTAGONIST; PLASMA ARGININE VASOPRESSIN; FAILING HUMAN MYOCARDIUM; K-ATP CHANNELS; LEVOSIMENDAN IMPROVES; CONTINUOUS-INFUSION; HEALTHY-VOLUNTEERS AB Current therapies for acute heart failure syndromes (AHFS) target hemodynamics by decreasing congestion or increasing myocardial contraction. Several new agents for AHFS use novel mechanisms of action that focus on new treatment targets, such as those providing anti-ischemic and antistunning effects, blocking vasopressin receptors, or blocking endothelin-1 receptors. For example, levosimendan acts as a calcium, sensitizer and adenosine triphosphate-dependent potassium (K-ATP) channel opener that increases contraction, causes vasodilation, and provides cardioprotective effects. This is accomplished by its dual mechanism of action. Levosimendan binds to cardiac troponin C, thereby enhancing calcium myofilament responsiveness and increasing myocardial contraction without increasing intracellular calcium levels. Thus, contraction is increased with no significant increase in myocardial oxygen consumption. The opening of K-ATP channels by levosimendan causes vasodilation and exerts anti-ischemic and antistunning effects on the myocardium. Other new agents target neurohormonal pathways. Tezosentan is an antagonist of endothelin-1 receptors A and B. By inhibiting endothelin-1 receptors, tezosentan may counteract the activities of endothelin-1, which include vasoconstriction, proarrhythmic activities, potentiation of other neurohormones, and mediation of increased vascular permeability. Tolvaptan is a vasopressin V-2-receptor antagonist that functions as an aquaretic (ie, it increases urine volume and serum sodium with little or no sodium loss). Therefore, by using novel mechanisms of action, these agents may provide new opportunities for helping patients with AHFS. (c) 2005 Elsevier Inc. C1 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA. San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. Hop Lariboisiere, Dept Anesthesiol & Crit Care Med, F-75475 Paris, France. RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, Galter 10-240,201 E Huron St, Chicago, IL 60611 USA. EM m-gheorghiade@northwestern.edu RI Teerlink, John/D-2986-2012 NR 84 TC 23 Z9 31 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD SEP 19 PY 2005 VL 96 IS 6A SU S BP 68G EP 73G DI 10.1016/j.amjcard.2005.07.023 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 969BR UT WOS:000232208900010 PM 16181825 ER PT J AU Gesty-Palmer, D El Shewy, H Kohout, TA Luttrell, LM AF Gesty-Palmer, D El Shewy, H Kohout, TA Luttrell, LM TI beta-arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASE-1; BETA-ARRESTIN; ANGIOTENSIN-II; EGF RECEPTOR; ERK ACTIVATION; MAP KINASE; PATHWAYS; TRANSACTIVATION; ENDOCYTOSIS AB G protein-coupled receptors often employ novel signaling mechanisms, such as transactivation of epidermal growth factor (EGF) receptors or G protein-independent signals transmitted by beta-arrestins, to control the activity of extracellular signal-regulated kinases 1 and 2 (ERK1/2). In this study we investigated the role of beta-arrestins in lysophosphatidic acid (LPA) receptor-stimulated ERK1/ 2 activation using fibroblast lines derived from wild type, beta-arrestin 1, beta-arrestin 2, and beta-arrestin 1/2 knock-out mice. LPA stimulation produced robust ERK1/ 2 phosphorylation in all four backgrounds. In cells lacking beta-arrestin 2, > 80% of LPA-stimulated ERK1/ 2 phosphorylation was mediated by transactivated EGF receptors. In contrast, ERK1/ 2 activation in cells expressing beta-arrestin 2 was predominantly EGF receptor-independent. Introducing FLAG epitope-tagged beta-arrestin 2 into the beta-arrestin 1/2 null background restored EGF receptor-independent ERK1/ 2 activation, indicating that beta-arrestin 2 expression confers ERK1/ 2 activation via a distinct mechanism. To determine the contributions of beta-arrestin 2, transactivated EGF receptors, and ERK1/ 2 to LPA-stimulated transcriptional responses, we employed gene expression arrays containing cDNA markers for G protein-coupled receptor-mediated signaling. In the beta-arrestin 1/2 null background, 1 h of exposure to LPA significantly increased transcription of seven marker genes. Six of these responses were EGF receptor-dependent, and two required ERK1/ 2 activation. In beta-arrestin 2 expressing cells, three of the seven LPA-stimulated transcriptional responses observed in the beta-arrestin 1/2 null background were lost. The four residual responses were independent of EGF receptor transactivation, but all were ERK1/2-dependent. These data indicate that beta-arrestin 2 functions both to attenuate EGF receptor transactivation-dependent signaling and to promote a distinct subset of ERK1/2-mediated responses to LPA receptor activation. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. Neurocrine Biosci Inc, Dept Exploratory Discovery, San Diego, CA 92121 USA. Neurocrine Biosci Inc, Dept Mol Biol, San Diego, CA 92121 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu FU NIDDK NIH HHS [DK64353, DK55524] NR 43 TC 31 Z9 31 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 16 PY 2005 VL 280 IS 37 BP 32157 EP 32167 DI 10.1074/jbc.M50746200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 963HM UT WOS:000231794800016 PM 16027114 ER PT J AU Sonnenberg, A AF Sonnenberg, A TI Personal view: passing the buck and taking a free ride - a game-theoretical approach to evasive management strategies in gastroenterology SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID DECISION-MAKING AB Background: 'Free-riding' physicians enjoy the status, prestige and income of their profession without fully contributing to its overall mission. By shifting the costs of potential medical complications and difficult patient encounters to other physicians, they reap the benefits of their profession without carrying its full weight. Aim: To describe this phenomenon in terms of decision analysis and characterize the parameters affecting its occurrence. Methods: The interaction between two physicians is modeled as a non-zero-sum game. Two strategies of either contributing to patient management or taking a free ride are available to both physicians. The four possible outcomes are arranged in a two-by-two game matrix. Results: Physicians practice medicine because their personal benefit exceeds their cost. High cost to the physician results in a high probability of taking a free ride and copping out from potentially risky management. Increasing the benefit decreases the probability of free riding. As the number of possible encounters with other physicians increases, the probability of free riding increases and the probability for effective management by each individual physician decreases. Conclusion: If individual gastroenterologists felt less threatened by administrative repercussions and medico-legal consequences of untoward events, each one of them would contribute more to effective patient management. C1 Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland VA Med Ctr, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 18 TC 3 Z9 3 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD SEP 15 PY 2005 VL 22 IS 6 BP 513 EP 518 DI 10.1111/j.1365-2036.2005.02627.x PG 6 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 963RY UT WOS:000231824800002 PM 16167967 ER PT J AU Aujesky, D Fine, MJ AF Aujesky, D Fine, MJ TI Does guideline adherence for empiric antibiotic therapy reduce mortality in community-acquired pneumonia? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID ANTIMICROBIAL THERAPY; MEDICAL OUTCOMES; ELDERLY-PATIENTS; MANAGEMENT; ADULTS C1 Univ Lausanne, CH-1015 Lausanne, Switzerland. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Aujesky, D (reprint author), Univ Lausanne, CH-1015 Lausanne, Switzerland. NR 16 TC 12 Z9 12 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2005 VL 172 IS 6 BP 655 EP 656 DI 10.1164/rccm.2506009 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 965AC UT WOS:000231921100001 PM 16148192 ER PT J AU Restrepo, MI Angel, LF Mortensen, EM Anzueto, A AF Restrepo, MI Angel, LF Mortensen, EM Anzueto, A TI Steroid infusion for severe pneumonia: Not so fast... SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA C1 VERDICT, S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. RP Restrepo, MI (reprint author), VERDICT, S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 3 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2005 VL 172 IS 6 BP 781 EP 781 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 965AC UT WOS:000231921100022 PM 16148197 ER PT J AU Didenko, VV Ngo, H Baskin, DS AF Didenko, VV Ngo, H Baskin, DS TI Polyethyleneimine as a transmembrane carrier of fluorescently labeled proteins and antibodies SO ANALYTICAL BIOCHEMISTRY LA English DT Article DE polyethyleneimine; PEI; protein delivery; avidin; Alexa avidin conjugates; lamin; glial cells; fibroblasts; antibody delivery; protein carrier; fluorescent detection ID BIOLOGICALLY-ACTIVE PROTEINS; GENE DELIVERY; MAMMALIAN-CELLS AB Polyethyleneimine (PEI) has been used previously as a nonviral DNA transfer vector. In this article, we demonstrate its use as a vehicle for transmembrane delivery of proteins in cell culture conditions. Linking proteins to PEI required no other treatment beyond mixing them with PEI. The bond between PEI and protein combined at optimal ratios was maintained in electrophoresis, even in the presence of 2.5% sodium dodecyl sulfate (SIDS). The optimal time for delivery of proteins was determined to be 24 h. We have successfully delivered an Alexa 488-labeled avidin protein into human glioblastoma cells. A functional antibody against the nuclear protein lamin was delivered into human fibroblasts and reacted with lamin inside live cells. PEI-based delivery of antibodies and fluorescently labeled proteins can be used for fluorescent detection, tracking, and evaluation of cellular protein function in vivo. (C) 2005 Elsevier Inc. All rights reserved. C1 Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Methodist Neurol Inst, Houston, TX 77030 USA. RP Didenko, VV (reprint author), Baylor Coll Med, Houston, TX 77030 USA. EM vdidenko@bcm.tmc.edu FU NIA NIH HHS [R03 AG022664] NR 12 TC 24 Z9 26 U1 0 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0003-2697 J9 ANAL BIOCHEM JI Anal. Biochem. PD SEP 15 PY 2005 VL 344 IS 2 BP 168 EP 173 DI 10.1016/j.ab.2005.06.011 PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 962XP UT WOS:000231767000002 PM 16095551 ER PT J AU Matute-Bello, G Lee, JS Liles, WC Frevert, CW Mongovin, S Wong, V Ballman, K Sutlief, S Martin, TR AF Matute-Bello, G Lee, JS Liles, WC Frevert, CW Mongovin, S Wong, V Ballman, K Sutlief, S Martin, TR TI Fas-mediated acute lung injury requires Fas expression on nonmyeloid cells of the lung SO JOURNAL OF IMMUNOLOGY LA English DT Article ID RESPIRATORY-DISTRESS-SYNDROME; FAS/FAS LIGAND SYSTEM; PROTEIN PERMEABILITY; PULMONARY-FIBROSIS; EPITHELIAL-CELLS; SOLUBLE FORM; APOPTOSIS; MICE; INDUCTION; HUMANS AB Fas (CD95) is a membrane surface receptor, which, in the lungs, is expressed in macrophages, neutrophils, and epithelial cells. In mice, Fas activation leads to a form of lung injury characterized by increased alveolar permeability. We investigated whether Fas-mediated lung injury occurs primarily as a result of Fas activation in myeloid cells (such as macrophages) or in nommyeloid cells (such as epithelial cells). Chimeric mice lacking Fas in either myeloid or nonmyeloid cells were generated by transplanting marrow cells from lpr mice (which lack Fas) into lethally irradiated C57BL/6 mice (MyFas(-) group) or vice versa (MyFas(+) group). Additional mice transplanted with marrow cells from their same strain served as controls (Fas(+) ctr and Fas(-) ctr groups). Sixty days after transplantation, the mice received intratracheal instillations of the Fas-activating mAb Jo2 (n = 10/group), or an isotype control Ab (n = 10/group), and were euthanized 24-h later. Only animals expressing Fas in nonmyeloid cells (Fas(+) ctr and MyFas-) showed significant increases in lung neutrophil content and in alveolar permeability. These same mice showed tissue evidence of lung injury and caspase-3 activation in cells of the alveolar walls. Despite differences in the neutrophilic response and lung injury, there was no statistical difference in the lung cytokine concentrations (KC and MIP-2) among groups. We conclude that Fas-mediated lung injury requires expression of Fas on nonmyeloid cells of the lungs. These findings suggest that the alveolar epithelium is the primary target of Fas-mediated acute lung injury, and demonstrate that apoptotic processes may be associated with neutrophilic inflammation. C1 Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA. Vet Affairs Puget Sound Healthcare Syst, Med Res Serv, Seattle, WA 98108 USA. Vet Affairs Puget Sound Healthcare Syst, Sect Radiat Oncol, Seattle, WA 98108 USA. RP Matute-Bello, G (reprint author), 1660 S Columbian Way,GMR 151-L, Seattle, WA 98108 USA. EM matuteb@u.washington.edu FU NHLBI NIH HHS [HL73966, HL62995, HL70840, HL70178] NR 33 TC 35 Z9 38 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD SEP 15 PY 2005 VL 175 IS 6 BP 4069 EP 4075 PG 7 WC Immunology SC Immunology GA 966HN UT WOS:000232010800074 PM 16148156 ER PT J AU Offner, H Subramanian, S Wang, CH Afentoulis, M Vandenbark, AA Huan, JY Burrows, GG AF Offner, H Subramanian, S Wang, CH Afentoulis, M Vandenbark, AA Huan, JY Burrows, GG TI Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MHC CLASS-II; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ENCEPHALITOGENIC T-CELLS; BOUND SINGLE PEPTIDES; MULTIPLE-SCLEROSIS; MYASTHENIA-GRAVIS; RECEPTOR LIGANDS; TH1 CELLS; COMPLEXES; ACTIVATION AB The major goal of this study was to evaluate the efficacy and mechanism of a rTCR ligand (RTL) construct (I-A(S)/proteolipid protein (PLP)-139-151 peptide = RTL401) for treatment of SJL/J mice developing passive experimental autoimmune encephalomyelitis (EAE) that did not involve coimmunization with the highly inflammatory CFA. Our results demonstrated clearly that RTL401 was highly effective in treating passive EAE, with kinetics of recovery from disease very similar to treatment of actively induced EAE. The potent RTL401 treatment effect was reflected by a partial reduction of infiltrating mononuclear cells into CNS, minimal inflammatory lesions in spinal cord, and preservation of axons injured in vehicle-treated mice during the progression of EAE. Interestingly, in the absence of CFA, RTL401 treatment strongly enhanced production of the Th2 cytokine, IL-13, in spleen, blood, and spinal cord tissue, with variable effects on other Th1 and Th2 cytokines, and no significant effect on the TH cytokine, TGF-beta 1, or on FoxP3 that is expressed by regulatory T cells. Moreover, pretreatment of PLP-139-151-specific T cells with RTL401 in vitro induced high levels of secreted IL-13, with lesser induction of other pro- and anti-inflammatory cytokines. Given the importance of IL-13 for protection against EAE, these data strongly implicate IL-13 as a dominant regulatory cytokine induced by RTL therapy. Pronounced IL-13 levels coupled with marked reduction in IL-6 levels secreted by PLP-specitic T cells from blood after treatment of mice with RTL401 indicate that IL-13 and IL-6 may be useful markers for following effects of RTL therapy in future clinical trials in multiple sclerosis. C1 Portland Vet Affairs Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland Vet Affairs Med Ctr, Neuroimmunol Res R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIAID NIH HHS [AI43960]; NINDS NIH HHS [NS46877, NS41965, NS23444, NS47661] NR 37 TC 29 Z9 29 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD SEP 15 PY 2005 VL 175 IS 6 BP 4103 EP 4111 PG 9 WC Immunology SC Immunology GA 966HN UT WOS:000232010800078 PM 16148160 ER PT J AU Bryant, AE Bayer, CR Chen, RYZ Guth, PH Wallace, RJ Stevens, DL AF Bryant, AE Bayer, CR Chen, RYZ Guth, PH Wallace, RJ Stevens, DL TI Vascular dysfunction and ischemic destruction of tissue in streptococcus pyogenes infection: The role of streptolysin O - Induced platelet/neutrophil complexes SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 42nd Annual Meeting of the Infectious-Diseases-Society-of-America CY SEP 30-OCT 03, 2004 CL Boston, MA SP Infect Dis Soc Amer ID PLATELET-ACTIVATING-FACTOR; CLOSTRIDIAL GAS-GANGRENE; LEUKOCYTE INTERACTION; ADHERENT PLATELETS; ORGAN DYSFUNCTION; PHOSPHOLIPASE-C; P-SELECTIN; NEUTROPHIL; ACCUMULATION; PERFRINGENS AB Rapid tissue destruction in group A streptococcal (GAS) necrotizing fasciitis/myonecrosis often necessitates extensive debridement to ensure survival. The mechanisms responsible for this fulminant process remain unknown; we hypothesized that toxin-induced ischemia contributes to necrosis. In a rat model, Doppler flowmetry was used to measure local blood flow at the site of the intramuscular injection of exotoxins from an invasive M-type 1 GAS, which caused a rapid, dose-dependent decrease in perfusion that was irreversible at the highest toxin concentration tested. Videomicroscopic results revealed that blood flow was impeded by occlusive intravascular cellular aggregates. Flow-cytometric results confirmed that GAS toxins induced the coaggregation of platelets and neutrophils, that this activity was attributable to streptolysin O, and that platelet/neutrophil complex formation was largely mediated by platelet P-selectin (CD62P). Strategies that target platelet adherence molecules may prevent vascular occlusion, maintain tissue viability, and reduce the need for amputation in necrotizing GAS infections. C1 Dept Vet Affairs Med Ctr, Res & Dev Serv, Infect Dis Sect, Boise, ID 83702 USA. Univ Idaho, Moscow, ID 83843 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Anesthesiol, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Washington, Sch Med, Seattle, WA USA. RP Bryant, AE (reprint author), Dept Vet Affairs Med Ctr, Res & Dev Serv, Infect Dis Sect, 500 W Ft St,Bldg 45, Boise, ID 83702 USA. EM bryant@mindspring.com FU NCRR NIH HHS [P20RR15587] NR 28 TC 42 Z9 42 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 15 PY 2005 VL 192 IS 6 BP 1014 EP 1022 DI 10.1086/432729 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 960WJ UT WOS:000231623600011 PM 16107954 ER PT J AU Lieu, SN Million, M Oh, DS Waschek, JA Tache, Y Pisegna, JR Germano, PM AF Lieu, SN Million, M Oh, DS Waschek, JA Tache, Y Pisegna, JR Germano, PM TI PACAP and its receptor, PAC(1) exert a protective effect in preventing dextran sulfate sodium (DSS)-induced colitis SO REGULATORY PEPTIDES LA English DT Meeting Abstract CT 7th International Symposium on VIP, PACAP and Related Peptides CY SEP 11-14, 2005 CL Rouen, FRANCE SP Conseil Reg Haute-Normandie, Agglomerat Rouen, Inst Fed Rech Multidisciplinaires Peptides, Inst Natl Sante Rech Med, Municipal Rouen, Sci Act Haute-Normandie, Tech Chime-Biol Sante, Univ Paris 7, Univ Rouen C1 VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD SEP 15 PY 2005 VL 130 IS 3 BP 168 EP 169 PG 2 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 959OL UT WOS:000231527400097 ER PT J AU Lieu, SN Oh, DS Lambrecht, N Yakubov I Sachs, G Pisegna Jr Germano, PM AF Lieu, SN Oh, DS Lambrecht, N Yakubov, I Sachs, G Pisegna, JR Germano, PM TI PACAP activation of secretory and proliferative signaling pathways in BON cells is mediated through PKA, calmodulin and RAS SO REGULATORY PEPTIDES LA English DT Meeting Abstract CT 7th International Symposium on VIP, PACAP and Related Peptides CY SEP 11-14, 2005 CL Rouen, FRANCE SP Conseil Reg Haute-Normandie, Agglomerat Rouen, Inst Fed Rech Multidisciplinaires Peptides, Inst Natl Sante Rech Med, Municipal Rouen, Sci Act Haute-Normandie, Tech Chime-Biol Sante, Univ Paris 7, Univ Rouen C1 VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, CURE VA UCLA Digest Dis Res Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD SEP 15 PY 2005 VL 130 IS 3 BP 168 EP 168 PG 1 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 959OL UT WOS:000231527400096 ER PT J AU Katsel, P Davis, KL Gorman, JM Haroutunian, V AF Katsel, P Davis, KL Gorman, JM Haroutunian, V TI Variations in differential gene expression patterns across multiple brain regions in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; postmortem; gene expression; microarray; brain regions; hippocampus; cingulate cortex; temporal cortex; hippocampus ID CEREBRAL BLOOD-FLOW; DORSOLATERAL PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; HIPPOCAMPAL-FORMATION; ELDERLY-PATIENTS; AUDITORY HALLUCINATIONS; MICROARRAY ANALYSIS; NEURONAL DENSITY; BIPOLAR DISORDER; WORKING-MEMORY AB Large-scale gene expression studies in schizophrenia (SZ) have generally focused on the dorsolateral prefrontal cortex. Despite a wealth of evidence implicating multiple other brain regions in the disease, studies of other brain regions have been less frequent and have rarely been performed in the same subjects. We analyzed postmortem gene expression in the frontal, cingulate, temporal, parietal and occipital cortices (Brodmann areas 8, 10, 44, 46, 23/31, 24/32, 20, 21, 22, 36/28, 7 and 17, respectively) as well as in the hippocampus, caudate nucleus and putamen of persons with schizophrenia and control subjects (N's = 13) using Affymetrix GeneChip (R) microarrays. Under identical data filtering conditions, the superior temporal cortex (BA22) of schizophrenia subjects showed the maximal number of altered transcripts (similar to 1200) compared to controls. Anterior and posterior cingulate cortices (BA23/31, 24/32) and the hippocampus followed the superior temporal cortex with two-times lower numbers of altered transcripts. The dorsolateral prefrontal cortex (BA46), a frequent target of SZ-associated studies, showed substantially fewer altered transcripts (similar to 33). These regional differences in differentially expressed genes could not be accounted for by factors such as total numbers of genes expressed or the filtering conditions and criteria used for identification of differentially expressed genes. These findings suggest that the temporal and cingulate cortices and the hippocampal formation represent brain regions of particular abnormality in SZ and may be more susceptible to the disease process(es) than other regions thus far studied. (c) 2005 Elsevier B.V. All rights reserved. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Haroutunian, V (reprint author), Bronx Vet Adm Med Ctr, Room 4F-33A,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu NR 98 TC 90 Z9 90 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD SEP 15 PY 2005 VL 77 IS 2-3 BP 241 EP 252 DI 10.1016/j.schres.2005.03.020 PG 12 WC Psychiatry SC Psychiatry GA 962RE UT WOS:000231749100012 PM 15923110 ER PT J AU Brekke, JS Nakagami, E Kee, KS Green, MF AF Brekke, JS Nakagami, E Kee, KS Green, MF TI Cross-ethnic differences in perception of emotion in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE culture; ethnicity; perception of emotion; neurocognition; schizophrenia ID JAPANESE CULTURAL-DIFFERENCES; GENERALIZED POOR PERFORMANCE; UNIVERSAL FACIAL EXPRESSIONS; AFFECT RECOGNITION; SUBJECTIVE EXPERIENCE; SOCIAL COGNITION; MENTAL-HEALTH; DEFICIT; FACE; JUDGMENTS AB Background: The purpose of this study was to examine cross-ethnic differences in Perception of Emotion (POE) in schizophrenia. POE is an emerging construct in schizophrenia and involves the recognition and accurate identification of emotion in the facial and vocal expression of others. It has been implicated as relevant to instrumental functioning in schizophrenia, as well as a potential core deficit or marker for the disorder. Studies have shown the role of culture in shaping the expression and perception of emotion in non-clinical samples. It was hypothesized that ethnic minorities would have lower POE scores than Caucasians, and that the differences on POE would remain significant after controlling for neurocognition. Method: Individuals, 13 1, diagnosed with schizophrenia or schizoaffective disorder participated in the study. There were 59 Euro-American Caucasian, 56 were African-American, and 16 were Latino. Neurocognition was measured as a standardized sum of five neuropsychological measures. Perception of Emotion was measured with facial and voice recognition tasks. Results: Both Latinos and African-Americans scored lower on POE than Caucasians. The cross-ethnic differences on POE remained significant after controlling for neurocognition and overall symptom level. Post hoc analyses showed some support for the predictive validity of the POE measure across cultural contexts. Conclusions: These results suggest that POE in schizophrenia is influenced by ethnicity, and that the ethno-cultural mechanisms influencing POE transcend the shared variation of POE and neurocognition. These results have implications for theories of cross-cultural emotion recognition, measurement bias in POE research, and for the place of culture in the study of POE in schizophrenia. (c) 2005 Elsevier B.V. All rights reserved. C1 Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Brekke, JS (reprint author), Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. EM brekke@usc.edu FU NIMH NIH HHS [MH01628, MH53282] NR 74 TC 17 Z9 19 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD SEP 15 PY 2005 VL 77 IS 2-3 BP 289 EP 298 DI 10.1016/j.schres.2005.04.004 PG 10 WC Psychiatry SC Psychiatry GA 962RE UT WOS:000231749100017 PM 15923111 ER PT J AU Zabetian, CP Samii, A Mosley, AD Roberts, JW Leis, BC Yearout, D Raskind, WH Griffith, A AF Zabetian, CP Samii, A Mosley, AD Roberts, JW Leis, BC Yearout, D Raskind, WH Griffith, A TI A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations SO NEUROLOGY LA English DT Article ID AUTOSOMAL-DOMINANT PARKINSONISM AB Referral-based studies indicate that a mutation (G2019S) in exon 41 of the LRRK2 gene might be a common cause of Parkinson disease (PD). The authors sequenced leucine-rich repeat kinase 2 (LRRK2) exons 31, 35, and 41 in 371 consecutively recruited patients with PD and found mutations in six (1.6%) subjects, including two heterozygous for new putative pathogenic variants (R1441H, IVS31 + 3A -> G). These data confirm the important contribution of LRRK2 to PD susceptibility in a clinic-based population. C1 VA Puget Sound Hlth Care Syst, Geriat Res Educ & Clin Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, NW Parkinsons Dis Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. Virginia Mason Med Ctr, Seattle, WA USA. Evergreen Hosp, Med Ctr, Kirkland, WA USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Geriat Res Educ & Clin Ctr, S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306 FU NINDS NIH HHS [K08-NS44138] NR 10 TC 112 Z9 117 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD SEP 13 PY 2005 VL 65 IS 5 BP 741 EP 744 DI 10.1212/01.WNL.0000172630.22804.73 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 963RH UT WOS:000231821300016 PM 16157909 ER PT J AU Niewoehner, DE Rice, K Cote, C Paulson, D Cooper, JAD Korducki, L Cassino, C Kesten, S AF Niewoehner, DE Rice, K Cote, C Paulson, D Cooper, JAD Korducki, L Cassino, C Kesten, S TI Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator - A Randomized trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID COPD; MULTICENTER; MANAGEMENT; THERAPY; SYSTEM; CELLS AB Background: Patients with chronic obstructive pulmonary disease (COPD) frequently develop exacerbations, leading to major clinical and health resource use ramifications. Objective: To prospectively evaluate the effectiveness of a long-acting inhaled anticholinergic bronchodilator, tiotropium, in reducing COPD exacerbations and exacerbation-related health care utilization. Design: Randomized, double-blind study. Setting: 26 Veterans Affairs medical centers. Patients: 1829 patients with moderate to severe COPD (mean baseline FEV1, 36% predicted). Intervention: once-daily tiotropium (18 mu g) or placebo for 6 months. Patients otherwise received usual care, except for other anticholinergic bronchodilators. Measurements: The coprimary end points were the percentage of patients with a COPD exacerbation and the percentage of patients with a COPD-related hospitalization. Results: Tiotropium significantly reduced the percentage of patients experiencing 1 or more exacerbations compared with placebo (27.9% vs. 32.3%, respectively; difference, -5.7 percentage points [95% CI, -10.4 to -1.0 percentage points]; P = 0.037). Fewer tiotropium patients were hospitalized because of COPD exacerbation (7.0% vs. 9.5%, respectively; difference, -3.0 percentage points [CI, -5.9 to -0.1 percentage points]; P = 0.056), although this difference was of borderline statistical significance. Analysis of secondary outcomes indicates that tiotropium may lengthen the time to first COPD exacerbation (P = 0.028) and reduce health care utilization for exacerbations, including the frequency of hospitalizations (P = 0.047), unscheduled clinic visits (P = 0.019), and days of antibiotic treatment (P = 0.015). Tiotropium did not statistically significantly reduce all-cause hospitalization rates. Limitations: Trial participants were enrolled from 1 health care system, and 99% were men. The follow-up period extended for only 6 months. Conclusions: Tiotropium reduces COPD exacerbations and may reduce related health care utilization in patients with moderate to severe COPD. C1 Vet Adm Med Ctr, Pulm Sect 111N, Minneapolis, MN 55417 USA. Bay Pines Vet Affairs Med Ctr, Bay Pines, FL USA. Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA. RP Niewoehner, DE (reprint author), Vet Adm Med Ctr, Pulm Sect 111N, 1 Vet Dr, Minneapolis, MN 55417 USA. EM niewo001@umn.edu NR 25 TC 277 Z9 284 U1 1 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 6 PY 2005 VL 143 IS 5 BP 317 EP 326 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 961TE UT WOS:000231683900001 PM 16144890 ER PT J AU Turner, JH Raymond, JR AF Turner, JH Raymond, JR TI Interaction of calmodulin with the serotonin 5-hydroxytryptamine(2A) receptor - A putative regulator of G protein coupling and receptor phosphorylation by protein kinase C SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID 2ND INTRACELLULAR LOOP; GROWTH-FACTOR RECEPTOR; ARACHIDONIC-ACID METABOLISM; MEDIATED ERK ACTIVATION; CYCLIC-AMP ACCUMULATION; RENAL MESANGIAL CELLS; 5-HT2A RECEPTOR; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL AB The 5-hydroxytryptamine(2A) (5-HT2A) receptor is a G(q/11)-coupled serotonin receptor that activates phospholipase C and increases diacylglycerol formation. In this report, we demonstrated that calmodulin (CaM) co-immunoprecipitates with the 5-HT2A receptor in NIH-3T3 fibroblasts in an agonist-dependent manner and that the receptor contains two putative CaM binding regions. The putative CaM binding regions of the 5-HT2A receptor are localized to the second intracellular loop and carboxyl terminus. In an in vitro binding assay peptides encompassing the putative second intracellular loop (i2) and carboxyl-terminal (ct) CaM binding regions bound CaM in a Ca2+-dependent manner. The i2 peptide bound with apparent higher affinity and shifted the mobility of CaM in a nondenaturing gel shift assay. Fluorescence emission spectral analyses of dansyl-CaM showed apparent K-D values of 65 +/- 30 nM for the i2 peptide and 168 +/- 38 nM for the ct peptide. The ct CaM-binding domain overlaps with a putative protein kinase C (PKC) site, which was readily phosphorylated by PKC in vitro. CaM binding and phosphorylation of the ct peptide were found to be antagonistic, suggesting a putative role for CaM in the regulation of 5-HT2A receptor phosphorylation and desensitization. Finally, we showed that CaM decreases 5-HT2A receptor-mediated [S-35]GTP gamma S binding to NIH-3T3 cell membranes, supporting a possible role for CaM in regulating receptor-G protein coupling. These data indicate that the serotonin 5-HT2A receptor contains two high affinity CaM-binding domains that may play important roles in signaling and function. C1 Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. RP Raymond, JR (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA. EM raymondj@musc.edu FU NIDDK NIH HHS [DK52448]; NIGMS NIH HHS [GM08716, GM63909] NR 75 TC 48 Z9 50 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 2 PY 2005 VL 280 IS 35 BP 30741 EP 30750 DI 10.1074/jbc.M50169200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 958ZX UT WOS:000231487800013 PM 15970592 ER PT J AU Levine, AJ Hinkin, CH Castellon, SA Mason, KI Lam, MN Perkins, A Robinet, M Longshore, D Newton, T Myers, H Durvasula, RS Hardy, DJ AF Levine, AJ Hinkin, CH Castellon, SA Mason, KI Lam, MN Perkins, A Robinet, M Longshore, D Newton, T Myers, H Durvasula, RS Hardy, DJ TI Variations in patterns of highly active antiretroviral therapy (HAART) adherence SO AIDS AND BEHAVIOR LA English DT Article DE antiretroviral therapy; HAART; adherence; HIV; substance abuse ID MEDICATION ADHERENCE; PROTEASE INHIBITORS; VIRAL LOAD; PREDICTORS; COHORT; ADULTS AB Strict adherence to highly active antiretroviral therapy ( HAART) is necessary for successful suppression of HIV replication. A large number of individuals are not adherent, however, and the reasons for non-adherence are varied and complex. We utilized cluster analyses to identify subgroups of adherers in a sample of 222 HIV positive individuals whose HAART use was electronically monitored. Five distinct subgroups were identified, with characteristic variations across the week and over the course of the 4-week study. Additional comparisons of demographic and behavioral variables found the worst adherers to have higher rates of substance use, and that a group with higher rates of cognitive impairment had a consistent drop in adherence during the weekends. In addition, the group with the best adherence had more individuals over the age of 50 years. The results of the current study indicate that distinct subgroups of adherers may exist, and suggest that interventions designed to improve adherence can be designed to accommodate this variability in behavior. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Neuropsychiat Inst, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Calif State Univ Los Angeles, Los Angeles, CA 90032 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Levine, AJ (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Neuropsychiat Inst, 760 Westwood Plaza,Room C8-747, Los Angeles, CA 90024 USA. EM ajlevine@mednet.ucla.edu OI newton, thomas/0000-0002-3198-5901 FU NIDA NIH HHS [R01 DA013799, R01 DA13799]; NIMH NIH HHS [R01 MH058552, R01 MH58552] NR 16 TC 42 Z9 45 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD SEP PY 2005 VL 9 IS 3 BP 355 EP 362 DI 10.1007/s10461-005-9009-y PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 980CE UT WOS:000232990700010 PM 16088365 ER PT J AU Canto, JG Kiefe, CI AF Canto, JG Kiefe, CI TI Door-to-needle time in myocardial infarction: Is there an ideal benchmark? SO AMERICAN HEART JOURNAL LA English DT Editorial Material ID NATIONAL REGISTRY; REPERFUSION THERAPY; MORTALITY C1 Watson Clin, Ctr Cardiovasc Prevent Res & Educ, Lakeland, FL 33801 USA. Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham Vet Affairs Med Ctr, Div Cardiovasc Dis, Birmingham, AL USA. Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham Vet Affairs Med Ctr, Div Prevent Med, Birmingham, AL USA. Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. RP Canto, JG (reprint author), Watson Clin, Ctr Cardiovasc Prevent Res & Educ, Lakeland, FL 33801 USA. NR 10 TC 3 Z9 3 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD SEP PY 2005 VL 150 IS 3 BP 365 EP 367 DI 10.1016/j.ahj.2005.04.026 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 970WQ UT WOS:000232343500001 PM 16169308 ER PT J AU Wolf, RL Cauley, JA Pettinger, M Jackson, R Lacroix, A Leboff, MS Lewis, CE Nevitt, MC Simon, JA Stone, KL Wactawski-Wende, J AF Wolf, RL Cauley, JA Pettinger, M Jackson, R Lacroix, A Leboff, MS Lewis, CE Nevitt, MC Simon, JA Stone, KL Wactawski-Wende, J TI Lack of a relation between vitamin and mineral antioxidants and bone mineral density: results from the Women's Health Initiative SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE antioxidants; diet; serum; bone mineral density; osteoporosis; Women's Health Initiative ID ASCORBIC-ACID CONCENTRATIONS; CALCIUM SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; ORAL-CONTRACEPTIVES; HIP FRACTURE; ELDERLY-WOMEN; PLASMA; RISK; OSTEOPOROSIS; AGE AB Background: Antioxidant defenses are one possible mechanism for decreasing oxidative damage and its potentially negative effects on age-related bone mass. Objective: This study cross-sectionally examined whether higher dietary intakes, total intakes, and serum concentrations of antioxidants may be associated with higher bone mineral density (BMD). Design: Total hip (and subregions), spine, and total-body BMDs were measured in 11068 women aged 50-79 y enrolled in,, the Women's Health Initiative Observational Study and Clinical Trial at 3 clinics. Antioxidant intakes from diet (vitamin A, retinol, beta-carotene. vitamin C, vitamin E, and selenium) were estimated by using a self-reported food-frequency questionnaire. Antioxidants from supplements were estimated with an interviewer-administered questionnaire. A random subset (n = 379) had serum concentrations of retinol, carotenoids, and tocopherols measured. Results: After adjustment for important BMD-related covariates, increasing intakes of antioxidants were not independently associated with BMD. A significant interaction effect was observed between intake of total vitamin C (lower three-fourths compared with highest one-fourth) and use of hormone therapy (HT) (P < 0.01). The beneficial effect of current FIT use on femoral neck BMD appeared to be greater in women with higher concentrations of total vitamin C. This interaction was also significant for total-body (P < 0.045), spine (P = 0.03), and total-hip BMDs (P = 0.029). Conclusions: Our results do not support independent associations between dietary intake, total intake, or serum concentrations of antioxidants and BMD in women participating in the Women's Health Initiative. The extent to which HT use may interact with vitamin C intake and BMD warrants further exploration. C1 Columbia Univ, Teachers Coll, Dept Hlth & Behav Studies, Nutr Program, New York, NY 10027 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Ohio State Univ, Columbus, OH 43210 USA. Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA. Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. SUNY Buffalo, Buffalo, NY USA. RP Wolf, RL (reprint author), Columbia Univ, Teachers Coll, Dept Hlth & Behav Studies, Nutr Program, 525 W 120th St,Box 137, New York, NY 10027 USA. EM wolf@exchange.tc.columbia.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU NIA NIH HHS [5T32AG000181-15] NR 47 TC 72 Z9 78 U1 0 U2 7 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD SEP PY 2005 VL 82 IS 3 BP 581 EP 588 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 963NB UT WOS:000231809900015 PM 16155271 ER PT J AU MacLean, CH Mojica, WA Newberry, SJ Pencharz, J Garland, RH Tu, WL Hilton, LG Gralnek, IM Rhodes, S Khanna, P Morton, SC AF MacLean, CH Mojica, WA Newberry, SJ Pencharz, J Garland, RH Tu, WL Hilton, LG Gralnek, IM Rhodes, S Khanna, P Morton, SC TI Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Review DE n-3 fatty acids; inflammatory bowel disease ID ULCERATIVE-COLITIS; FISH-OIL; CROHNS-DISEASE; DOUBLE-BLIND; EMPIRICAL-EVIDENCE; RANDOMIZED-TRIALS; SUPPLEMENTATION; EPIDEMIOLOGY; REMISSION; QUALITY AB Background: n - 3 Fatty acids are purported to have health effects in patients with inflammatory bowel disease (IBD), but Studies have reported mixed results. Objective: We aimed to synthesize published and unpublished evidence to determine estimates of the effect of n-3 fatty acids on clinical outcomes in IBD and whether n-3 fatty acids modify the effects of or need for treatment with other agents. Design: Computerized databases were searched for studies of n-3 fatty acids in immune-mediated diseases from 1966 to 2003. We also contacted experts in the nutraceutical industry to identify unpublished studies, however, none were identified. Results: Reviewers identified 13 controlled trials that assessed the effects of n-3 fatty acids on clinical, sigmoidoscopic, or histologic scores, rates of induced remission or relapse; or requirements for steroids and other immunosuppressive agents in Crohn disease or ulcerative colitis. Most clinical trials were of good quality. Fewer than 6 were identified that assessed the effects of n-3 fatty acids on any single outcome of clinical, endoscopic, or histologic scores or remission or relapse rates. Consistent across 3 studies was the finding that n-3 fatty acids reduce corticosteroid requirements, although statistical significance was shown in only 1 of these studies. Conclusion: The available data are insufficient to draw conclusions about the effects of n-3 fatty acids on clinical, endoscopic, or histologic scores or remission or relapse rates. C1 RAND Hlth, Santa Monica, CA 90407 USA. So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. Greater Los Angeles VA Healthcare Syst, Div Rheumatol, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. Toronto Gen Hosp, Toronto Gen Res Inst, Clin Decis Making & Healthcare, Toronto, ON, Canada. Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON, Canada. RP MacLean, CH (reprint author), RAND Hlth, 1700 Main St,M23-C, Santa Monica, CA 90407 USA. EM maclean@rand.org NR 33 TC 69 Z9 73 U1 0 U2 5 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD SEP PY 2005 VL 82 IS 3 BP 611 EP 619 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 963NB UT WOS:000231809900019 PM 16155275 ER PT J AU Kanwal, F Gralnek, IM Hays, RD Dulai, GS Spiegel, BMR Bozzette, S Asch, S AF Kanwal, F Gralnek, IM Hays, RD Dulai, GS Spiegel, BMR Bozzette, S Asch, S TI Impact of chronic viral hepatitis on health-related quality of life in HIV: Results from a nationally representative sample SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; LOW-PREVALENCE DISEASES; STAGE LIVER-DISEASE; C VIRUS; INFECTED PATIENTS; SERVICES UTILIZATION; B-VIRUS; PROBABILITY SAMPLES; MEDICAL OUTCOMES AB BACKGROUND: Little is known about the health burden of chronic viral hepatitis in HIV-infected patients. We compared health-related quality of life (HRQOL) of patients with HIV and hepatitis C virus (HCV) or HIV and hepatitis B virus (HBV) coinfection to those with HIV monoinfection. METHODS: Using a nationally representative sample of 1,874 adults with HIV who completed a baseline and two follow-up interviews, we identified those with HIV monoinfection (n = 1,493), HIV-HCV coinfection (n = 279), and HIV-HBV coinfection (n = 122). We measured baseline and change over time scores for physical and mental health (PHS, MHS), overall quality of life (QOL), overall health, and disability days. To identify the independent effect of coinfection, we adjusted for demographic and clinical predictors of HRQOL using multivariable regression. RESULTS: Despite significant differences in socio-demographic characteristics between groups, there were no differences in the baseline scores for PHS, MHS, overall QOL, overall health, or disability days between groups. The HRQOL did not decline significantly over time for the HIV patients with or without HCV or HBV coinfection. All groups reported similar longitudinal changes in the HRQOL scores for all measures. CONCLUSIONS: We found no significant differences in disease burden as assessed by a generic HRQOL instrument between patients with HIV monoinfection and HIV-HCV or HIV-HBV coinfection. These data are relevant in counseling coinfected patients regarding the impact of coinfection on HRQOL, and are important in designing clinical trials and conducting cost-effectiveness analyses including this vulnerable cohort. C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. VA Greater Los Angeles Hlth Care Syst, Div Gastroenterol Hepatol, Los Angeles, CA USA. VA Greater Los Angeles Hlth Care Syst, Div Gen Internal Med Hlth Serv Res, Los Angeles, CA USA. CURE Digest Dis Res, Los Angeles, CA USA. Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA USA. Univ Calif Los Angeles, Div Gen Internal Med Hlth Serv Res, Los Angeles, CA 90024 USA. RAND Corp, Hlth Sci Program, Santa Monica, CA USA. VA La Jolla Med Ctr, Div Internal Med Infect Dis, Los Angeles, CA USA. RP Kanwal, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215B, Los Angeles, CA 90073 USA. RI Hays, Ronald/D-5629-2013 FU NCRR NIH HHS [K23 RR0016188]; NIA NIH HHS [AG-02-004]; NIMHD NIH HHS [P20-MD00148-01] NR 47 TC 17 Z9 18 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 BP 1984 EP 1994 DI 10.1111/j.1572-0241.2005.41962.x PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BL UT WOS:000231853600016 PM 16128943 ER PT J AU Germano, P Lieu, S Million, M Oh, D Waschek, J Tache, Y Pisegna, J AF Germano, P Lieu, S Million, M Oh, D Waschek, J Tache, Y Pisegna, J TI PACAP and its receptor, PAC1 exert a protective effect in preventing dextran sulfate sodium (DSS)-induced colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-College-of-Gastroenterology CY OCT 30-NOV 02, 2005 CL Honolulu, HI SP Amer Coll Gastroenterol C1 Univ Calif Los Angeles, David Geffen Sch Med, CURE DDRC, Div Digest Dis, Los Angeles, CA 90024 USA. VA Greater LA Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 SU S MA 837 BP S308 EP S309 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BK UT WOS:000231853502095 ER PT J AU Go, MF Clark, H Christison, BBS Hatton-Ward, S Sonnenberg, N AF Go, MF Clark, H Christison, BBS Hatton-Ward, S Sonnenberg, N TI Prolonged exposure to H-pylori (Hp) in developing countries: Is there an increased risk of infection? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-College-of-Gastroenterology CY OCT 30-NOV 02, 2005 CL Honolulu, HI SP Amer Coll Gastroenterol C1 VA SLC Hlth Care Syst, Salt Lake City, UT USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 SU S MA 95 BP S54 EP S55 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BK UT WOS:000231853500096 ER PT J AU Gralnek, IM Dulai, GS Fennerty, B Spiegel, BMR AF Gralnek, IM Dulai, GS Fennerty, B Spiegel, BMR TI Esomeprazole (ESO) versus alternative proton pump inhibitors (PPI) in erosive esophagitis (EE): A meta-analysis of trials reporting healing rates and symptom relief SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-College-of-Gastroenterology CY OCT 30-NOV 02, 2005 CL Honolulu, HI SP Amer Coll Gastroenterol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles, Los Angeles, CA USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 SU S MA 742 BP S277 EP S277 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BK UT WOS:000231853502001 ER PT J AU Loftis, JM Rifai, MA Hauser, P AF Loftis, JM Rifai, MA Hauser, P TI Depression and sustained viral response in patients with hepatitis C SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-College-of-Gastroenterology CY OCT 30-NOV 02, 2005 CL Honolulu, HI SP Amer Coll Gastroenterol C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NIMH, Off Clin Director, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 SU S MA 277 BP S114 EP S114 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BK UT WOS:000231853500278 ER PT J AU Machicado, GA Jensen, DM Hirabayashi, K AF Machicado, GA Jensen, DM Hirabayashi, K TI Randomized controlled study of a new InScope multi-clip applier, Olympus QuickClip2, MPEC, injection and combination therapy comparing hemostasis and healing of bleeding canine acute gastric ulcers SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-College-of-Gastroenterology CY OCT 30-NOV 02, 2005 CL Honolulu, HI SP Amer Coll Gastroenterol C1 VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Digest Dis Res Ctr, BA CURE, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 SU S MA 973 BP S355 EP S356 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BK UT WOS:000231853502230 ER PT J AU Wang, HS Oh, DS Ohning, GV Pisegna, JR AF Wang, HS Oh, DS Ohning, GV Pisegna, JR TI Validation of endoscopic gastric analysis (EGA) as a method to determine gastric acid output performed during a standard esophagogastroduodenoscopy (EGD) SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-College-of-Gastroenterology CY OCT 30-NOV 02, 2005 CL Honolulu, HI SP Amer Coll Gastroenterol C1 VA Greater LA Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 SU S MA 966 BP S353 EP S353 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BK UT WOS:000231853502223 ER PT J AU Wang, HS Oh, DS Ohning, GV Pisegna, JR AF Wang, HS Oh, DS Ohning, GV Pisegna, JR TI Elevated serum bioactive ghrelin levels in patients with metastatic neuroendocrine tumors maintains body weight SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-College-of-Gastroenterology CY OCT 30-NOV 02, 2005 CL Honolulu, HI SP Amer Coll Gastroenterol C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. VA Greater LA Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2005 VL 100 IS 9 SU S MA 166 BP S78 EP S78 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 964BK UT WOS:000231853500167 ER PT J AU Olson, AL Zwillich, C AF Olson, AL Zwillich, C TI The obesity hypoventilation syndrome SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE obesity hypoventilation syndrome; obstructive sleep apnea syndrome; obstructive sleep apnea-hypopnea syndrome; hypercapnia; hypoventilation; Pickwickian syndrome; obesity ID OBSTRUCTIVE SLEEP-APNEA; PICKWICKIAN-SYNDROME; OXYGEN DESATURATION; MORBID-OBESITY; LUNG-DISEASE; WEIGHT-LOSS; LEPTIN; HYPERCAPNIA; VENTILATION; PREVALENCE AB The obesity hypoventilation syndrome, which is defined as a combination of obesity and chronic hypoventilation, utimately results in pulmonary hypertension, cor pulmonale, and probable early mortality. Since the classical description of this syndrome nearly fifty years ago, research has led to a better understanding of the pathophysiologic mechanisms involved in this disease process, and to the development of effective treatment options. However, recent data indicate the obesity hypoventilation syndrome is under-recognized, and under-treated. Because obesity has become a national epidemic, it is critical that physicians are able to recognize and treat obesity-associated diseases. This article reviews current definitions of the obesity hypoventilation syndrome, clinical presentation and diagnosis, present understanding of the pathophysiology, and treatment options. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Olson, AL (reprint author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave, Denver, CO 80262 USA. EM amy.olson@uchsc.edu NR 69 TC 129 Z9 133 U1 2 U2 12 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP PY 2005 VL 118 IS 9 BP 948 EP 956 DI 10.1016/j.amjmed.2005.03.042 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 963MB UT WOS:000231807300004 PM 16164877 ER PT J AU Good, CB Kelley, CL AF Good, CB Kelley, CL TI The Vioxx debacte revisited SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID RHEUMATOID-ARTHRITIS; ROFECOXIB C1 Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. Pharm Benefits Management Strat Healthcare Grp, Dept Vet Affairs, Hines, IL USA. RP Good, CB (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, 4200 5th Ave, Pittsburgh, PA 15260 USA. NR 6 TC 1 Z9 1 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP PY 2005 VL 118 IS 9 BP 1055 EP 1056 DI 10.1016/j.amjmed.2005.04.020 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 963MB UT WOS:000231807300030 PM 16164902 ER PT J AU Daikh, DI AF Daikh, DI TI Untitled SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Daikh, DI (reprint author), Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP PY 2005 VL 118 IS 9 BP 1057 EP 1057 DI 10.1016/j.amjmed.2005.04.028 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 963MB UT WOS:000231807300034 PM 16164908 ER PT J AU Chang, EY Barbosa, E Paintlia, MK Singh, A Singh, I AF Chang, EY Barbosa, E Paintlia, MK Singh, A Singh, I TI The use of N-acetylcysteine for the prevention of hypertension in the-reduced uterine perfusion pressure model for preeclampsia in Sprague-Dawley rats SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 09-12, 2005 CL Reno, NV SP Soc Maternal Fetal Med DE preeclampsia; animal model; antioxidants; nuclear factor kappa B ID ENDOTHELIAL GROWTH-FACTOR; KAPPA-B; NITRIC-OXIDE; OXIDATIVE STRESS; CELLS; RISK; SUPEROXIDE; INHIBITION; ACTIVATION; WOMEN AB Objective: To determine whether N-acetylcysteine attenuates abnormal changes in the reduced uterine perfusion pressure model. Study design: Twenty-four timed-pregnant Sprague-Dawley rats underwent sham surgery or the reduced uterine perfusion pressure procedure on day 15 of 22. Reduced uterine perfusion pressure animals were treated with N-acetylcysteine (100 mg/kg) or saline twice daily until delivery. On day 21 of 22, mean arterial pressure was determined and maternal tissue was collected and stored. Pups and pup brains were weighed. Statistical analysis was performed using I-way analysis of variance and the Tukey-Kramer test with significance at P<.05. Results: There was a significant increase in blood pressure with the reduced uterine perfusion pressure procedure (P =.016), which was alleviated by N-acetylcysteine (P = .044). There was a significant decrease in pup weight and brain weight with the reduced uterine perfusion pressure procedure (P =.043 and P =.046, respectively). N-acetyleysteine restored pup brain weight (P =.021) but had no significant effect on pup weight. Conclusion: N-acetylcysteine reduced blood pressure without adversely effecting fetal weight. (C) 2005 Mosby, Inc. All rights reserved. C1 Med Univ S Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat & Neurol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Chang, EY (reprint author), Med Univ S Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, 96 Jonathan Lucas St,Suite 634,POB 250619, Charleston, SC 29425 USA. EM changey@musc.edu FU NIAMS NIH HHS [1 P50 ARO49551] NR 25 TC 9 Z9 10 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2005 VL 193 IS 3 BP 952 EP 956 DI 10.1016/j.ajog.2005.05.083 PN 2 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 966IQ UT WOS:000232013700009 PM 16157093 ER PT J AU Bruel, BM Dajoyag-Mejia, MA AF Bruel, BM Dajoyag-Mejia, MA TI Shoulder mass and pain in a patient with C5 American Spinal Injury Association grade A tetraplegia SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Editorial Material ID DESMOID TUMOR C1 Michael E Debakey Vet Affairs Med Ctr, Spinal Cord Injury Care Line, Houston, TX 77030 USA. Univ Texas, Baylor Coll Med, Houston Med Sch Phys Med & Rehabil Alliance, Houston, TX USA. Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. RP Dajoyag-Mejia, MA (reprint author), Michael E Debakey Vet Affairs Med Ctr, Spinal Cord Injury Care Line, 2002 Holcombe Blvd 128, Houston, TX 77030 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD SEP PY 2005 VL 84 IS 9 BP 725 EP 725 DI 10.1097/01.phm.0000176417.96898.79 PG 1 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 962XS UT WOS:000231767300013 PM 16141754 ER PT J AU Baker, FC Angara, C Szymusiak, R McGinty, D AF Baker, FC Angara, C Szymusiak, R McGinty, D TI Persistence of sleep-temperature coupling after suprachiasmatic nuclei lesions in rats SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE brain temperature; ambient temperature; rapid eye movement sleep; slow wave activity ID CIRCADIAN-RHYTHMS; BODY-TEMPERATURE; REM-SLEEP; RECOVERY SLEEP; DEPRIVATION; WAKEFULNESS; HOMEOSTASIS; RESPONSES; HAMSTERS; SYSTEM AB The suprachiasmatic nucleus (SCN) regulates the circadian rhythms of body temperature (T-b) and vigilance states in mammals. We studied rats in which circadian rhythmicity was abolished after SCN lesions (SCNx rats) to investigate the association between the ultradian rhythms of sleep-wake states and brain temperature (T-br), which are exposed after lesions. Ultradian rhythms of T-br (mean period: 3.6 h) and sleep were closely associated in SCNx rats. Within each ultradian cycle, nonrapid eye movement (NREM) sleep was initiated 5 +/- 1 min after T-br peaks, after which temperature continued a slow decline (0.02 +/- 0.006 degrees C/min) until it reached a minimum. Sleep and slow wave activity (SWA), an index of sleep intensity, were associated with declining temperature. Cross-correlation analysis revealed that the rhythm of T-br preceded that of SWA by 2-10 min. We also investigated the thermoregulatory and sleep-wake responses of SCNx rats and controls to mild ambient cooling (18 degrees C) and warming (30 degrees C) over 24-h periods. SCNx rats and controls responded similarly to changes in ambient temperature. Cooling decreased REM sleep and increased wake. Warming increased T-br, blunted the amplitude of ultradian T-br rhythms, and increased the number of transitions into NREM sleep. SCNx rats and controls had similar percentages of NREM sleep, REM sleep, and wake, as well as the same average T-b within each 24-h period. Our results suggest that, in rats, the SCN modulates the timing but not the amount of sleep or the homeostatic control of sleep-wake states or T-b during deviations in ambient temperature. C1 VA Grester Los Angeles Healthcare Syst, Res Serv 151A3, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA. Univ Witwatersrand, Sch Physiol, Brain Funct Res Unit, Johannesburg, South Africa. RP McGinty, D (reprint author), VA Grester Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM dmcginty@ucla.edu FU NIMH NIH HHS [MH 004708, MH 47480] NR 45 TC 16 Z9 16 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP PY 2005 VL 289 IS 3 BP R827 EP R838 DI 10.1152/ajpregu.00093.2005 PG 12 WC Physiology SC Physiology GA 955RC UT WOS:000231243700025 PM 15860650 ER PT J AU Johansen, KL Doyle, J Sakkas, GK Kent-Braun, JA AF Johansen, KL Doyle, J Sakkas, GK Kent-Braun, JA TI Neural and metabolic mechanisms of excessive muscle fatigue in maintenance hemodialysis patients SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE oxidative phosphorylation; central fatigue; electromyography; muscle activation; P-31 magnetic resonance spectroscopy ID HUMAN SKELETAL-MUSCLE; CHRONIC-RENAL-FAILURE; PERIPHERAL ARTERIAL-DISEASE; VOLUNTARY CONTRACTIONS; OXIDATIVE-METABOLISM; EXERCISE CAPACITY; MUSCULAR FATIGUE; SEX-DIFFERENCES; ERYTHROPOIETIN; ACTIVATION AB Dialysis patients have severe exercise limitations related to metabolic disturbances, but muscle fatigue has not been well studied in this population. We investigated the magnitude and mechanisms of fatigue of the ankle dorsiflexor muscles in patients on maintenance hemodialysis. Thirty-three dialysis patients and twelve healthy control subjects performed incremental isometric dorsiflexion exercise, beginning at 10% of their maximal voluntary contraction (MVC) and increasing by 10% every 2 min. Muscle fatigue (fall of MVC), completeness of voluntary activation, and metabolic responses to exercise were measured. Before exercise, dialysis subjects exhibited reduced strength and impaired peripheral activation (lower compound muscle activation potential amplitude) but no metabolic perturbation. During exercise, dialysis subjects demonstrated threefold greater fatigue than controls with evidence of central activation failure but no change in peripheral activation. All metabolic parameters were significantly more perturbed at end exercise in dialysis subjects than in controls, including lower phosphocreatine (PCr) and pH, and higher P-i, P-i/PCr, and H2PO4-. Oxidative potential was markedly lower in patients than in controls [62.5 (SD 27.2) vs. 134.6 ( SD 31.7), P < 0.0001]. Muscle fatigue was negatively correlated with oxidative potential among dialysis subjects (r = -0.52, P = 0.04) but not controls. Changes in central activation ratio were also correlated with muscle fatigue in the dialysis subjects (r = 0.59, P = 0.001) but not the controls. This study provides new information regarding the excessive muscular fatigue of dialysis patients and demonstrates that the mechanisms of this fatigue include both intramuscular energy metabolism and central activation failure. C1 San Francisco Vet Affairs Med Ctr, Dialysis Unit, Nephrol Sect, Dept Med, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. No Calif Inst Res & Educ, San Francisco, CA USA. Univ Massachusetts, Dept Exercise Sci, Amherst, MA 01003 USA. RP Johansen, KL (reprint author), San Francisco Vet Affairs Med Ctr, Dialysis Unit, Nephrol Sect, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA. EM johanse@itsa.ucsf.edu FU NCRR NIH HHS [RR 00083]; NIDDK NIH HHS [R01 DK 56182] NR 56 TC 37 Z9 42 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP PY 2005 VL 289 IS 3 BP R805 EP R813 DI 10.1152/ajpregu.00187.2005 PG 9 WC Physiology SC Physiology GA 955RC UT WOS:000231243700023 PM 15905222 ER PT J AU Kaur, S Sassi, RB Axelson, D Nicoletti, M Brambilla, P Monkul, ES Hatch, JP Keshavan, MS Ryan, N Birmaher, B Soares, JC AF Kaur, S Sassi, RB Axelson, D Nicoletti, M Brambilla, P Monkul, ES Hatch, JP Keshavan, MS Ryan, N Birmaher, B Soares, JC TI Cingulate cortex anatomical abnormalities in children and adolescents with bipolar disorder SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT 58th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 15-17, 2003 CL SAN FRANCISCO, CA SP Soc Biol Psychiat ID POSITRON-EMISSION-TOMOGRAPHY; SUBGENUAL PREFRONTAL CORTEX; ANTERIOR CINGULATE; MOOD DISORDERS; VOLUME ASYMMETRIES; SCHIZOPHRENIA; RESONANCE; DEPRESSION; BRAIN; MANIA AB Objective: In vivo imaging studies have suggested anatomical and functional abnormalities in the anterior cingulate in adults with mood disorders. This anatomical magnetic resonance imaging study examined the cingulate cortex in children and adolescents with bipolar disorder and matched healthy comparison subjects. Method: Sixteen patients ( mean age= 15.5 years, SD= 3.4) with DSM-IV bipolar disorder and 21 matched healthy comparison subjects ( mean age= 16.9 years, SD= 3.8) were studied. Three-dimensional gradient echo imaging was performed ( TR= 25 msec, TE= 5 msec, slice thickness= 1.5 mm) in a 1.5-n T GE Signa magnet. Cingulate volumes were compared by using analysis of covariance, with age and intracranial volume as covariates. Results: The patients with bipolar disorder had significantly smaller mean volumes relative to the healthy subjects in the left anterior cingulate ( mean= 2.49 cm(3) [ SD= 0.28] versus 3.60 cm(3) [ SD= 0.12], respectively), left posterior cingulate ( 2.53 cm(3) [ SD= 0.32] versus 2.89 cm(3) [ SD= 0.09]), and right posterior cingulate ( 2.19 cm3 [ SD= 0.13] versus 2.28 cm(3) [ SD= 0.08]). No significant between-group difference was found for the right anterior cingulate ( 2.64 cm3 [ SD= 0.21] versus 2.71 cm(3) [ SD= 0.10]). Conclusions: The findings indicate smaller cingulate volumes in children and adolescents with bipolar disorder, suggesting that such abnormalities may be present early in the illness course. C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Udine, Sect Psychiat, Dept Pathol & Expt & Clin Med, I-33100 Udine, Italy. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH-59929, MH-01736, MH-30915, MH-55123] NR 43 TC 75 Z9 75 U1 1 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD SEP PY 2005 VL 162 IS 9 BP 1637 EP 1643 DI 10.1176/appi.ajp.162.9.1637 PG 7 WC Psychiatry SC Psychiatry GA 959ZT UT WOS:000231559300010 PM 16135622 ER PT J AU Pai, M Lewinsohn, DM AF Pai, M Lewinsohn, DM TI Interferon-gamma assays for tuberculosis - Is anergy the Achilles' heel? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID INFECTION; ANTIGENS; CHILDREN; HIV C1 Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94143 USA. Oregon Hlth Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Pai, M (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94143 USA. RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 NR 14 TC 46 Z9 47 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 1 PY 2005 VL 172 IS 5 BP 519 EP 521 DI 10.1164/rccm.2506003 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 960FB UT WOS:000231574500003 PM 16120714 ER PT J AU Goetz, LL Stiens, SA AF Goetz, LL Stiens, SA TI Abdominal electric stimulation facilitates penile vibratory stimulation for ejaculation after spinal cord injury: A single-subject trial SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation CY NOV 20-24, 2002 CL ORLANDO, FL SP Amer Acad Phys Med & Rehabil DE ejaculation; electric stimulation; fertility; rehabilitation; spinal cord injuries ID RETROGRADE EJACULATION; SEMEN QUALITY; MEN; ELECTROEJACULATION; SPERM; PREDICTORS; EMISSION AB Objective: To compare the success rate of penile vibratory stimulation (PVS) alone with PVS and abdominal electric stimulation (AES). Design: Single-subject trials. Setting: Outpatient. Participant: Man with chronic T3 complete (American Spinal Injury Association Impairment Scale grade A) spinal cord injury. Spasticity, Babinski response, anal wink, and bulbocav-ernosus reflexes were all present. Intervention: Stimulation was presented to the frenulum using a Ferti Care Personal vibrator set at maximal settings (frequency, 110Hz; amplitude, 3.55mm). AES was applied to the abdomen using a commercially available muscle stimulator at maximal stimulus intensity and duration settings. Trials were randomized to PVS only or PVS plus AES. Main Outcome Measures: Presence or absence of ejaculation, and time to ejaculation. Results: Only 4 of 30 trials were positive with PVS alone, while 31 of 34 trials were positive with PVS plus AES. Additionally, 17 of 26 PVS trials, which were initially negative with PVS alone, were then positive with the addition of AES. This represents a clinically relevant improvement with use of AES. Time to ejaculation for positive trials with either technique was not statistically significant. Conclusions: AES significantly lowered the threshold for ejaculation elicited with vibratory stimulation and increased the success rate over that when PVS alone was used. C1 VA SCI Ctr 128, Spinal Cord Injury Ctr, Dallas, TX 75216 USA. Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75230 USA. Vet Affairs Puget Sound Hlth Care Syst, Spinal Cord Injury Ctr, Seattle, WA USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Goetz, LL (reprint author), VA SCI Ctr 128, Spinal Cord Injury Ctr, 4500 S Lancaster Rd, Dallas, TX 75216 USA. EM lance.goetz@med.va.gov NR 24 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD SEP PY 2005 VL 86 IS 9 BP 1879 EP 1883 DI 10.1016/j.apmr.2005.03.023 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 962QM UT WOS:000231747300027 PM 16181958 ER PT J AU Naqibuddin, M Sampedro, M Wallace, DJ Weisman, MH Brey, RL Holliday, SL Carson, KA Petri, M AF Naqibuddin, M Sampedro, M Wallace, DJ Weisman, MH Brey, RL Holliday, SL Carson, KA Petri, M TI Anti-NR2 and anti-dsDNA in newly diagnosed systemic lupus erythematosus: Analysis of cognitive function, brain MRI and PET. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Johns Hopkins Univ, Baltimore, MD USA. Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD SEP PY 2005 VL 52 IS 9 SU S BP S621 EP S622 PG 2 WC Rheumatology SC Rheumatology GA 969BG UT WOS:000232207803216 ER PT J AU Naqibuddin, M Wallace, DJ Weisman, MH Brey, RL Sampedro, M Carson, KA Holliday, SL Petri, M AF Naqibuddin, M Wallace, DJ Weisman, MH Brey, RL Sampedro, M Carson, KA Holliday, SL Petri, M TI Change in cognitive function in newly diagnosed systemic lupus erythematosus patients. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Johns Hopkins Univ, Baltimore, MD USA. Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD SEP PY 2005 VL 52 IS 9 SU S BP S380 EP S380 PG 1 WC Rheumatology SC Rheumatology GA 969BG UT WOS:000232207802004 ER PT J AU Naqibuddin, M Wallace, DJ Weisman, MH Brey, RL Sampedro, M Carson, KA Holliday, SL Petri, M AF Naqibuddin, M Wallace, DJ Weisman, MH Brey, RL Sampedro, M Carson, KA Holliday, SL Petri, M TI Depression is associated with poorer cognitive function in newly diagnosed systemic lupus erythematosus patients. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 12-17, 2005 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Johns Hopkins Univ, Baltimore, MD USA. Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD SEP PY 2005 VL 52 IS 9 SU S BP S379 EP S380 PG 2 WC Rheumatology SC Rheumatology GA 969BG UT WOS:000232207802003 ER PT J AU Budoff, JE Rodin, D Ochiai, D Nirschl, RP AF Budoff, JE Rodin, D Ochiai, D Nirschl, RP TI Arthroscopic rotator cuff debridement without decompression for the treatment of tendinosis SO ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY LA English DT Article DE rotator cuff; debridement; partial-thickness tears; impingement syndrome ID FULL-THICKNESS TEARS; NONOPERATIVE MANAGEMENT; FOLLOW-UP; ASYMPTOMATIC SHOULDERS; IMPINGEMENT SYNDROME; ACROMIOPLASTY; REPAIR; DEGENERATION; TENDON; ARCH AB Purpose: The treatment of rotator cuff injury in the absence of a full-thickness tear has traditionally consisted of acromioplasty. However, this disorder may also be treated by arthroscopic rotator cuff debridement without acromioplasty. Our previous study of 79 shoulders so treated reported 87% good or excellent results at an average 53-month follow-up. The purpose of this article is to report the long-term, average 9.5-year follow-up of this cohort. Type of Study: Long-term follow-up of case series. Methods: We retrospectively reviewed the records of 62 shoulders in 60 patients who had undergone arthroscopic rotator cuff debridement for partial-thickness rotator cuff tears. Demographic criteria, residual pain, and the ability to return to recreational athletics were noted. The UCLA Shoulder Score and the Simple Shoulder Test scores were determined and statistical analysis performed. Results: Using the UCLA Shoulder Score, there were 79% excellent or good results at an average 114 months of follow-up. Patients with Workers' Compensation claims had significantly worse results, with only 40% rated good or excellent. Of the 60 patients, 77% had no or only minimal pain, 57% were still able to perform recreational athletics without difficulty, and 20% could participate at a lower level of intensity. Conclusions: Arthroscopic debridement of rotator cuff injury in the absence of a full-thickness tear has good long-term results and minimizes additional surgical trauma. Level of Evidence: Level IV, case series. C1 Baylor Coll Med, Houston Vet Adm Med Ctr, Dept Orthopaed Surg, Houston, TX 77030 USA. Virginia Hosp Ctr, Nirschl Orthopaed Ctr Sportsmed & Joint Reconstru, Dept Orthopaed Surg, Arlington, VA USA. RP Budoff, JE (reprint author), 6550 Fannin #2525, Houston, TX 77030 USA. EM Jbudoff@houston.rr.com NR 52 TC 33 Z9 35 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-8063 J9 ARTHROSCOPY JI Arthroscopy PD SEP PY 2005 VL 21 IS 9 BP 1081 EP 1089 DI 10.1016/j.arthro.2005.05.019 PG 9 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 969YX UT WOS:000232273300020 PM 16171633 ER PT J AU Cohen, LJ Fitzgerald, SG Lane, S Boninger, ML AF Cohen, LJ Fitzgerald, SG Lane, S Boninger, ML TI Development of the seating and mobility script concordance test for spinal cord injury: Obtaining content validity evidence SO ASSISTIVE TECHNOLOGY LA English DT Article DE professional practice; clinical competence; rehabilitation; seating and mobility; educational measurement; validity evidence ID DIAGNOSTIC KNOWLEDGE; PERFORMANCE; EXPERTISE; CAPACITY AB The appropriateness of a consumer's seating and mobility system varies considerably depending on the competence, proficiency, and experience of the professionals assisting the user. At present, there is a scarcity of skilled and knowledgeable therapists to evaluate and recommend seating and mobility devices. There is also a lack of measurement tests available to evaluate the impact of educational experiences or clinical practice on the ability to make specialized clinical decisions about seating and mobility needs. The Seating and Mobility Script Concordance Test (SMSCT) is a new assessment tool, grounded in the hypothetico-deductive and schema theories of clinical reasoning. The test is designed to assess therapists by examining the organization of their knowledge, associations between items of their knowledge, and the adequacy of their clinical decisions as compared to expert consensus. This article describes the interview, test development, and content/item review processes used for the collection of content validity evidence. The iterative process employed and the appraisal of the content validity evidence that resulted in the final version of the SMSCT are presented. The SMSCT appears to be a promising assessment tool representing content within the domain of seating and mobility for individuals with spinal cord injuries. The process utilized to develop the SMSCT in spinal cord injury can be replicated for other diagnoses and domains. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Educ, Dept Educ Psychol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Engn, Dept Bioengn, Pittsburgh, PA 15260 USA. RP Fitzgerald, SG (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Ctr Excellence Wheelchairs & Related Technol, 151R-1,7180 Highland Dr, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 25 TC 7 Z9 7 U1 0 U2 3 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD FAL PY 2005 VL 17 IS 2 BP 122 EP 132 PG 11 WC Rehabilitation SC Rehabilitation GA 004BM UT WOS:000234727000004 PM 16392716 ER PT J AU Cooper, RA Ding, D Simpson, R Fitzgerald, SG Spaeth, DM Guo, SF Koontz, AM Cooper, R Kim, J Boninger, ML AF Cooper, RA Ding, D Simpson, R Fitzgerald, SG Spaeth, DM Guo, SF Koontz, AM Cooper, R Kim, J Boninger, ML TI Virtual reality and computer enhanced training applied to wheeled mobility: An overview of work in Pittsburgh SO ASSISTIVE TECHNOLOGY LA English DT Review DE virtual reality; assistive technology; simulation; wheelchairs ID POWER-ASSISTED WHEELCHAIR; PUSHRIM BIOMECHANICS; EXERCISE; PROPULSION; SYSTEM; REHABILITATION; ADHERENCE; ERGOMETRY; POSITION; KINETICS AB Some aspects of assistive technology can be enhanced by the application of virtual reality. Although virtual simulation offers a range of new possibilities, learning to navigate in a virtual environment is not equivalent to learning to navigate in the real world. Therefore, virtual reality simulation is advocate as a useful preparation for assessment and training within the physical environment. We are engaged in several efforts to develop virtual environments and devices for mobility skills assessment and training, exercise training, and environment assessment. Virtual reality offers wheelchair users a training tool in different risk-free environments without any indoor (e.g., walls, furniture, and stairs) and outdoor (e.g., curb cuts, uneven terrain, and street traffic) physical constraints. Virtual reality technology will probably become more common in the field of assistive technology, especially given the rapid expansion of gaming technology and the continued exponential growth of computing power. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil R&D Ctr Excellence Wheelchairs & Assoc, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil R&D Ctr Excellence Wheelchairs & Assoc, 151-R1,7180 Highland Dr, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 46 TC 13 Z9 13 U1 3 U2 6 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD FAL PY 2005 VL 17 IS 2 BP 159 EP 170 PG 12 WC Rehabilitation SC Rehabilitation GA 004BM UT WOS:000234727000007 PM 16392719 ER PT J AU George, MS Rush, AJ Marangell, LB Sackeim, HA Brannan, SK Davis, SM Howland, R Kling, MA Moreno, F Rittberg, B Dunner, D Schwartz, T Carpenter, L Burke, M Ninan, P Goodnick, P AF George, MS Rush, AJ Marangell, LB Sackeim, HA Brannan, SK Davis, SM Howland, R Kling, MA Moreno, F Rittberg, B Dunner, D Schwartz, T Carpenter, L Burke, M Ninan, P Goodnick, P TI A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression SO BIOLOGICAL PSYCHIATRY LA English DT Article DE vagus nerve stimulation; major depressive disorder; bipolar disorder; treatment-resistant depression; clinical trial; efficacy; side effects ID REPORT QIDS-SR; ELECTROCONVULSIVE-THERAPY; MAJOR DEPRESSION; CONTINUATION PHARMACOTHERAPY; PSYCHOMETRIC EVALUATION; MEDICATION RESISTANCE; CLINICAL-RESPONSE; QUICK INVENTORY; SYMPTOMATOLOGY; OUTCOMES AB Background: Previous reports have described the effects of vagus nerve stimulation plus treatment as usual (VNS + TAU) during open trials of patients with treatment-resistant depression (TRD). To better understand these effects on long-term outcome, we compared 12-month VNS + TAU outcomes with those of a comparable TPD group. Metbods: Admission criteria were similar for those receiving VNS + TAU (n = 205) or only TAU (n = 124). In the primary analysis, repeated-measures linear regression was used to compare the VNS + TAU group (monthly data) with the TAU group (quarterly data) according to scores of the 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30). Results: The two groups bad similar baseline demographic data, psychiatric and treatment histories, and degrees of treatment resistance, except that more TAU participants bad at least 10 prior major depressive episodes, and the VNS + TAU group bad more electroconvulsive therapy before study entry. Vagus nerve stimulation plus treatment as usual was associated with greater improvement per month in IDS-SR30 than TAU across 12 months (p < . 001). Response rates according to the 24-item Hamilton Rating Scale for Depression (last observation carried forward) at 12 months were 27% for VNS + TAU and 13% for TAU (p < .011). Both groups received similar TAU (drugs and electroconvulsive therapy) during follow-up. Conclusions: This comparison of two similar but nonrandomized TRD groups showed that VNS + TAU was associated with a greater antidepressant benefit over 12 months. C1 Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Ralph H Johnson Vet Hosp, Charleston, SC USA. Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75230 USA. Baylor Coll Med, S Cent Mental Illness Res, Educ & Clin Ctr, Dept Psychiat, Houston, TX 77030 USA. Cyberon Inc, Houston, TX USA. New York State Psychiat Inst & Hosp, Dept Biol Psychiat, New York, NY 10032 USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10027 USA. Columbia Univ, Coll Phys & Surg, Dept Radiol, New York, NY USA. SUNY Syracuse, Dept Psychiat, Syracuse, NY 13210 USA. Quintiles Inc, Durham, NC USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Mental Hlth Clin Ctr, Dept Vet Affairs, Baltimore, MD USA. Univ Arizona, Dept Psychiat, Tucson, AZ USA. Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA. Univ Washington, Ctr Anxiety & Depress, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Butler Hosp, Dept Psychiat, Providence, RI 02906 USA. Inst Psychiat Res Via Christi, Wichita, KS USA. Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA. Univ Miami, Dept Psychiat, Miami, FL 33152 USA. RP George, MS (reprint author), Med Univ S Carolina, Dept Psychiat, 67 President St,502-N,POB 250861, Charleston, SC 29425 USA. EM georgem@musc.edu RI Kling, Mitchel/F-4152-2010; Howland, Robert/K-6937-2015 OI Kling, Mitchel/0000-0002-2232-1409; Howland, Robert/0000-0002-6533-6010; Rush, Augustus/0000-0003-2004-2382; Ninan, Philip/0000-0001-6633-1142 NR 25 TC 179 Z9 185 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD SEP 1 PY 2005 VL 58 IS 5 BP 364 EP 373 DI 10.1016/j.biopsych.2005.07.028 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 959YD UT WOS:000231554600003 PM 16139582 ER PT J AU Janoff, DM Peterson, C Mongoue-Tchokote, S Peters, L Beer, TM Wersinger, EM Mori, M Garzotto, M AF Janoff, DM Peterson, C Mongoue-Tchokote, S Peters, L Beer, TM Wersinger, EM Mori, M Garzotto, M TI Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer SO BJU INTERNATIONAL LA English DT Article DE prostate; cancer; androgen deprivation; hormone ablation; treatment ID BILATERAL ORCHIECTOMY; RADICAL PROSTATECTOMY; CURATIVE INTENT; PATIENT AGE; MEN; OSTEOPOROSIS; CARCINOMA; MANAGEMENT; DIAGNOSIS; BLOCKADE AB Objective To characterize the clinical outcomes of androgen deprivation therapy (ADT) as the sole therapy for localized prostate cancer, and to determine independent predictors of disease progression, as recent studies indicate an increasing use of ADT. Patients and Methods The records of all patients with cT1-4NXM0 adenocarcinoma of the prostate treated with ADT as the primary initial therapy at the Portland Veterans Affairs Medical Center between 1993 and 2000 were reviewed. Age, race, Charlson Health Index, family history, prostate-specific antigen (PSA) level, PSA density, digital rectal examination (DRE) findings, Gleason score, and percentage of positive biopsy cores at diagnosis were recorded for 81 patients. Patients had a median (SD range) age of 73 (5.6, 58-84) years, a PSA level of 14.3 (34.6, 1.4-252) ng/mL and tumours were classified as Gleason score <= 5 in 9% of patients, 6 in 31%, 7 in 31% and 8-10 in 30%. Outcomes extracted were PSA progression, PSA nadir, bone fractures, local progression, distant progression and overall survival. Results With a median (range) follow-up of 54 (6-115) months, the incidence of local progression, distant progression, bone fractures, PSA progression, and death were 10%, 7%, 25%, 21% and 41% respectively. The percentage of positive biopsy cores >= 83%, age < 70 years, Gleason score >= 7, abnormal DRE, and PSA nadir >= 0.2 ng/mL were significantly associated with PSA progression by univariate analysis. The multivariate analysis identified age < 70 years (hazard ratio 6.52, 95% confidence interval 2.29-18.55) and Gleason score >= 6 (4.0, 2.0-12.0) as independent risk factors for PSA progression. Conclusions ADT resulted in modest control of localized prostate cancer, but younger patients and those with Gleason >= 6 cancers were at higher risk of treatment failure. Toxicity, principally in the form of bone fractures, was high. C1 Portland Vet Affairs Med Ctr, Urol Sect, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Urol, Portland, OR USA. Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR USA. Oregon Hlth & Sci Univ, Inst Canc, Portland, OR USA. RP Garzotto, M (reprint author), Portland Vet Affairs Med Ctr, Urol Sect, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM garzotto@ohsu.edu FU NCI NIH HHS [P30 CA69533] NR 26 TC 26 Z9 28 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1464-4096 J9 BJU INT JI BJU Int. PD SEP PY 2005 VL 96 IS 4 BP 503 EP 507 DI 10.1111/j.1464-410X.2005.05674.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 957QK UT WOS:000231387900011 PM 16104900 ER PT J AU Waldman, KL Debakey, ME AF Waldman, KL Debakey, ME TI Cognitive-bebavioral treatment of obesity: A clinician's guide SO BULLETIN OF THE MENNINGER CLINIC LA English DT Book Review C1 Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. RP Waldman, KL (reprint author), Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0025-9284 J9 B MENNINGER CLIN JI Bull. Menninger Clin. PD FAL PY 2005 VL 69 IS 4 BP 343 EP 344 PG 2 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA 996CY UT WOS:000234153200009 ER PT J AU Atwood, CW AF Atwood, CW TI Sleep-related hypoventilation: The evolving role of leptin SO CHEST LA English DT Editorial Material ID RESPIRATORY DEPRESSION; HUMAN OBESITY; NITRIC-OXIDE C1 Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Atwood, CW (reprint author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, NW628 MUH, Pittsburgh, PA 15260 USA. EM atwoodcw@upmc.edu NR 14 TC 12 Z9 12 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD SEP PY 2005 VL 128 IS 3 BP 1079 EP 1081 DI 10.1378/chest.128.3.1079 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 964YN UT WOS:000231917000001 PM 16162684 ER PT J AU Littner, MR Leung, FW Ballard, ED Huang, BD Samra, NK AF Littner, MR Leung, FW Ballard, ED Huang, BD Samra, NK CA Lansoprazole Asthman Study Grp TI Effects of 24 weeks of lansoprazole therapy, on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms SO CHEST LA English DT Article; Proceedings Paper CT 67th Annual Meeting of the American-College-of-Gastroenterology CY OCT 18-23, 2002 CL SEATTLE, WA SP Amer Coll Gastroenterol DE asthma; exacerbation; gastroesophagael acid reflux; lansoprazole; proton-pump inhibitor ID GASTROESOPHAGEAL-REFLUX; DOUBLE-BLIND; BUDESONIDE; OMEPRAZOLE; DISEASE; QUESTIONNAIRE; FORMOTEROL; REGIMEN; TRIAL; PH AB Background: Difficult-to-control asthma has been associated with gastroesophageal acid reflux. Acid-suppressive treatment has been inconsistent in improving asthma control. Objective: To determine whether a proton-pump inhibitor improves asthma control in adult asthmatic patients with acid reflux symptoms. Design: Multicenter, double-blind, randomized, placebo-controlled trial. Setting: Twenty-nine private practices and 3 academic practices in the United States. Patients: Two hundred seven patients receiving usual asthma care including an inhaled corticosteroid (ICS). Patients had acid reflux symptoms and moderate-to-severe persistent asthma. Intervention: Lansoprazole, 30 mg bid, or placebo, bid, for 24 weeks. Measurements: The primary outcome measure was daily asthma symptoms by diary,. Secondary asthma outcomes included rescue albuterol use, daily morning and evening peak expiratory flow, FEV1, FVC, asthma quality of life with standardized activities (AQLQS) questionnaire score, investigator-assessed symptoms, exacerbations, and oral corticosteroid-treated exacerbations. Results: Daily asthma symptoms, albuterol use, peak expiratory flow, FEN1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly,with lansoprazole treatment compared to placebo. The AQLQS emotional function domain improved at 24 weeks (p = 0.025) with lansoprazole therapy. Fewer patients receiving lansoprazole (8.1% vs 20.4%, respectively, p = 0.017) had exacerbations and oral corticosteroid-treated (ie, moderate-to-severe) exacerbatons (4% vs 13.9%, respectively; p = 0.016) of asthma. A post hoc subgroup analysis revealed that fewer patients receiving one or more long-term asthma-control medications in addition to an ICS experienced exacerbations (6.5% vs 24.6%, respectively; p = 0.016) and moderate-to-severe exacerbations (2.2% vs 17.5%, respectively; p = 0.021) with lansoprazole therapy. Conclusion: In adult patients with moderate-to-severe persistent asthma and symptoms of acid reflux, treatment with 30 mg of lansoprazole bid for 24 weeks did not improve asthma symptoms or pulmonary function, or reduce albuterol use. However, this dose significantly reduced asthma exacerbations and improved asthma quality of life, particularly in those patients receiving more than one asthma-control medication. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Sepulveda, CA USA. TAP Pharmaceut Prod Inc, Lake Forest, IL USA. Abbott Labs, Abbott Pk, IL 60064 USA. RP Littner, MR (reprint author), Vet Adm Med Ctr, 111P, Sepulveda, CA 91343 USA. EM mlittner@ucla.edu NR 23 TC 109 Z9 116 U1 0 U2 3 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD SEP PY 2005 VL 128 IS 3 BP 1128 EP 1135 DI 10.1378/chest.128.3.1128 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 964YN UT WOS:000231917000014 PM 16162697 ER PT J AU Dhillon, SS Mahadevan, K Bandi, V Zheng, ZL Smith, W Rumbaut, RE AF Dhillon, SS Mahadevan, K Bandi, V Zheng, ZL Smith, W Rumbaut, RE TI Neutrophils, nitric oxide, and microvascular permeability in severe sepsis SO CHEST LA English DT Article DE alpha(4)-integrin; capillary permeability; neutrophils; nitric oxide; plethysmography; sepsis ID VENOUS CONGESTION PLETHYSMOGRAPHY; HUMAN SEPTIC SHOCK; CAPILLARY-PERMEABILITY; VASCULAR-PERMEABILITY; RAT MODEL; L-NAME; NITRITE/NITRATE; INHIBITION; SYNTHASE; PATHWAY AB Study objectives: Alterations in microvascular permeability are prevalent in patients with sepsis; a recent study reported that patients with septic shock had increased capillary filtration coefficient (Kf), a noninvasive index of microvascular permeability. We aimed to determine whether patients with severe sepsis had increased Kf, and whether the magnitude of Kf correlated with indexes of nitric oxide activity and neutrophil activation. Design: Single-center, prospective study. Setting: Twenty-five-bed ICU of a medical college-affiliated teaching hospital. Patients: Fifteen ICU patients with severe sepsis based on the American College of Chest Physicians/Society of Critical Care Medicine consensus criteria of 1992, and 10 nonseptic ICU patients as control subjects. Interventions: Kf was measured by, venous congestion plethysmography, plasma nitrate/nitrite (NOx) by chemiluminescence, and neutrophil expression alpha(4)-integrin (an index of neutrophil activation) by flow cytometry. Measurements and results: Septic patients had higher Kf than nonseptic control subjects. Kr of septic patients was 5.6 +/- 0.6 X 10(-3) mL-min center dot 100 mL tissue(-1) mm Hg-1 (mean +/- SEM, mL center dot min(-1) 100 mL tissue(-1)center dot mm Hg-1 = Kf units [KfU]) as compared to 3.9 +/- 0.5 X 10(-3) KfU in nonseptic ICU patients (p < 0.05). There was no correlation between plasma NOx and Kf, or between neurophil alpha(4)-integtin expression and Kr in patients with sepsis. Septic patients with clinical evidence of edema had significantly higher Kf (p < 0.05) than nonedematous septic patients. Conclusions: ICU patients with severe sepsis have increased Kf, a noninvasive index of microvascular water permeability. The magnitude of hyperpermeability did not correlate with NOx levels or one index of neutrophil activation (alpha(4)-integrin expression). Presence of peripheral edema in these patients was associated with increased Kf, and may, represent a simple, clinical in sepsis. indicator of altered microvascular permeability in sepsis. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. VA Med Ctr, Med Care Line, Houston, TX USA. RP Rumbaut, RE (reprint author), Baylor Coll Med, Dept Med, CNRC Bldg,Room 6014,110 Bates St, Houston, TX 77030 USA. EM rrumbaut@bcm.fmc.edu OI Dhillon, Samjot/0000-0003-2955-2266 FU NHLBI NIH HHS [HL-070537] NR 33 TC 25 Z9 26 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD SEP PY 2005 VL 128 IS 3 BP 1706 EP 1712 DI 10.1378/chest.128.3.1706 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 964YN UT WOS:000231917000095 PM 16162778 ER PT J AU Fultz, SL Goulet, JL Weissman, S Rimland, D Leaf, D Gibert, C Rodriguea-Barradas, MC Justice, AC AF Fultz, SL Goulet, JL Weissman, S Rimland, D Leaf, D Gibert, C Rodriguea-Barradas, MC Justice, AC TI Differences between infectious diseases-certified physicians and general medicine-certified physicians in the level of comfort with providing primary care to patients SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII-PNEUMONIA; UNITED-STATES; EXPERIENCE; SPECIALTY; ASSOCIATION; MORTALITY; HIV/AIDS; PATTERNS; THERAPY AB Background. Human immunodeficiency virus (HIV)-related mortality has decreased because of highly active antiretroviral therapy. As the life expectancy of HIV-infected patients has increased, the management of comorbid disease in such patients has become a more important concern. We examined the level of comfort self-reported by experts in HIV medicine with prescribing medications to HIV-infected patients for hyperlipidemia, diabetes, hypertension, and depression. Methods. As part of a larger project (the Veterans Aging Cohort Study), physicians at infectious diseases (ID) clinics and physicians at general medical (GM) clinics were asked to complete a survey requesting information about demographic characteristics, training and certification received, and self-reported comfort with prescribing medications for patients with hyperlipidemia, diabetes, hypertension, and/or depression. Comfort was rated using a 5-point Likert scale, with scores of 4-5 classified as "comfortable." Results. Of 150 attending physicians surveyed, 51 (34%) were ID certified, 33 (22%) were GM certified but practicing at an ID clinic, and 66 were GM certified and practicing at a GM clinic. Comorbid conditions were common among HIV-infected patients treated at the ID clinics (22% of these patients had hyperlipidemia, 17% had diabetes, 40% had hypertension, and 27% had depression). However, comfort with treating these conditions was less among physicians at the ID clinic. For example, comfort treating patients with hyperlipidemia was greater for GM-certified physicians at GM clinics than for GM-certified physicians and ID-certified physicians at ID clinics (98% vs. 73% and 71%, respectively (P < .001); for trend). A similar pattern was seen for treating patients with diabetes and hypertension (P < .0001). Comfort with treating patients with depression was generally lower, particularly among physicians at ID clinics (P < .0001). Conclusions. We found that ID-certified physicians and GM-certified physicians at ID clinics reported less comfort prescribing medications for common comorbid conditions, compared with generalist physicians at GM clinics, despite a substantial prevalence of these conditions at the ID clinics. Methods are needed to increase physicians' level of comfort for prescribing treatment and/or to facilitate referral to other physicians for treatment. C1 Vet Affairs Connecticut Healthcare Syst, West Haven, CT 06516 USA. Yale Univ, Sch Med, Sect Gen Med, New Haven, CT USA. Hosp St Raphael, New Haven, CT USA. Vet Affairs Med Ctr, Atlanta, GA 30033 USA. Emory Univ, Sch Med, Atlanta, GA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. Vet Affairs Med Ctr, Washington, DC 20422 USA. George Washington Univ, Med Ctr, Dept Med, Washington, DC 20037 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Justice, AC (reprint author), Vet Affairs Connecticut Healthcare Syst, Bldg 35A,Rm 2-212 11-ACSLG,950 Campbell Ave, West Haven, CT 06516 USA. EM amy.justice2@med.va.gov OI Goulet, Joseph/0000-0002-0842-804X FU NIA NIH HHS [K08 AG00826]; PHS HHS [U01-13566] NR 16 TC 27 Z9 27 U1 1 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2005 VL 41 IS 5 BP 738 EP 743 DI 10.1086/432621 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 952HW UT WOS:000230995600023 PM 16080098 ER PT J AU Jan, YK Brienza, DM Geyer, MJ AF Jan, YK Brienza, DM Geyer, MJ TI Analysis of week-to-week variability in skin blood flow measurements using wavelet transforms SO CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING LA English DT Article DE heating; laser Doppler; spectrum analysis; vascular control; vasomotion ID LASER-DOPPLER FLOWMETRY; HEART-RATE-VARIABILITY; ARTERIAL OCCLUSIVE DISEASE; NITRIC-OXIDE; CUTANEOUS MICROCIRCULATION; MUSCLE FATIGUE; FLUX MOTION; OSCILLATIONS; VASOMOTION; PRESSURE AB The study of skin blood flow responses is confounded by temporal variability in blood flow measurements. Spectral analysis has been shown useful in isolating the effects of distinct control mechanisms on various stimuli in the microcirculatory system. However, the sensitivity of spectral analysis to temporal blood blow variability has not been reported. This study was designed to assess week-to-week variability in blood flow measurements using wavelet-based spectrum analysis. Ten healthy, young subjects (mean age +/- SD, 30.0 +/- 3.1 years) were recruited into the study. Incremental heating (35-45 degrees C, 1 degrees step min(-1)) was applied on the skin over the sacrum once per week for three consecutive weeks. Wavelet analysis was used to decompose the laser Doppler blood flow signal into frequency bands determined to be associated with endothelial nitric oxide (0.008-0.02 Hz), neurogenic (0.02-0.05 Hz), myogenic (0.05-0.15 Hz), respiratory (0.15-0.4 Hz), and cardiac (0.4-2.0 Hz) control mechanisms. The results showed that coefficients of variation for the power in each frequency band at baseline are smaller than the coefficients of variation of blood flow at baseline or at maximal blood flow ratio (P < 0.05). Myogenic and respiratory frequency bands showed the highest coefficients of variation among the five frequency bands. An increase in power in the endothelial nitric oxide frequency band and a decrease in power in the myogenic frequency band of the maximal blood flow response were reproduced in three consecutive weeks. Our study suggests that wavelet analysis is an effective method to overcome temporal variability in skin blood flow measurements. C1 Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Lymphedema & Wound Management Serv & Res, Pittsburgh, PA USA. RP Jan, YK (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Forbes Tower,Suite 5044, Pittsburgh, PA 15260 USA. EM yij2@pitt.edu RI Jan, Yih-Kuen/A-5374-2013 OI Jan, Yih-Kuen/0000-0001-7149-4034 NR 64 TC 23 Z9 23 U1 0 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1475-0961 J9 CLIN PHYSIOL FUNCT I JI Clin. Physiol. Funct. Imaging PD SEP PY 2005 VL 25 IS 5 BP 253 EP 262 DI 10.1111/j.1475-097X.2005.00621.x PG 10 WC Physiology SC Physiology GA 955XI UT WOS:000231262200001 PM 16117727 ER PT J AU Kozora, E Arciniegas, DB Filley, CM Ellison, MC West, SG Brown, MS Simon, JH AF Kozora, E Arciniegas, DB Filley, CM Ellison, MC West, SG Brown, MS Simon, JH TI Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus - Preliminary data SO COGNITIVE AND BEHAVIORAL NEUROLOGY LA English DT Article DE system lupus erythematosus; cognition; neurometabolites; magnetic resonance imaging volumetrics ID MAGNETIC-RESONANCE-SPECTROSCOPY; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; HIPPOCAMPAL VOLUME; MULTIPLE-SCLEROSIS; WHITE-MATTER; DISEASE; PREVALENCE; DEFICITS; MARKERS AB Objective: To correlate cognitive dysfunction with structural and neurometabolic brain findings in patients with non-neuropsychiatric systemic lupus erythematosus (non-NPSLE). Background: Over 25% of non-NPSLE patients have cognitive dysfunction, but the cerebral basis of this observation is not well understood. Method: Seven patients with non-NPSLE and seven control subjects were given a series of neuropsychological tests and neuroimaging with magnetic resonance imaging and magnetic resonance spectroscopy. Analyses of cognitive function and structural and neurometabolic measures of the brain were performed. Results: Compared with controls, the non-NPSLE patients were significantly impaired on a global cognitive impairment index (CII). No significant differences between the groups were found in choline/creatine (Ch/Cr), N-acetylaspartic acid/Cr, or hippocampal volumes. Ch/Cr was highly associated with CII across the sample. Conclusions: This is the first study to correlate cognitive impairment with an increase in Ch/Cr ratio among patients with SLE. These results, although preliminary, suggest that changes in cerebral white matter may be important in determining the subtle cognitive impairment that may occur in patients with SLE, even in the absence of neuropsychiatric symptoms. C1 ABPP, CN, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA. Univ Colorado, Ctr Hlth Sci, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kozora, E (reprint author), ABPP, CN, Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA. EM Kozorae@njc.org RI Arciniegas, David/A-3792-2009 NR 43 TC 39 Z9 45 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1543-3633 J9 COGN BEHAV NEUROL JI Cogn. Behav. Neurol. PD SEP PY 2005 VL 18 IS 3 BP 159 EP 162 DI 10.1097/01.wnn.0000181543.05064.4b PG 4 WC Behavioral Sciences; Clinical Neurology SC Behavioral Sciences; Neurosciences & Neurology GA 969LE UT WOS:000232234800004 PM 16175019 ER PT J AU Stanley, MA Veazey, C Hopko, D Diefenbach, G AF Stanley, Melinda A. Veazey, Connie Hopko, Derek Diefenbach, Gretchen TI Anxiety and-depression in chronic obstructive pulmonary disease: A new intervention and case report SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Article ID QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL TREATMENT; RANDOMIZED CONTROLLED-TRIAL; ELDERLY-PATIENTS; SUBTHRESHOLD DEPRESSION; PSYCHOMETRIC EVALUATION; CLINICAL-SIGNIFICANCE; GENDER-DIFFERENCES; COPD PATIENTS; OLDER-ADULTS AB Anxiety and depression coexist frequently in chronic obstructive pulmonary disease and compound the impact of the disease on quality of life and functional status. However, little attention has been given to the development of treatment strategies for this subset of patients. The current article describes the development of a new, multicomponent cognitive behavioral treatment for reducing anxiety and depression among patients with respiratory disease (CBT-RADAR). Outcome data from a group of 5 patients who participated in an ongoing clinical trial are reviewed to illustrate the strengths and limitations of this intervention. C1 Baylor Coll Med, Dept Psychiat & Behav Sci, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Univ Tennessee, Knoxville, TN USA. Baylor Coll Med, Inst Living, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Stanley, MA (reprint author), Baylor Coll Med, Dept Psychiat & Behav Sci, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM mstanley@bcm.tmc.edu NR 83 TC 16 Z9 16 U1 2 U2 7 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 1077-7229 J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD FAL PY 2005 VL 12 IS 4 BP 424 EP 436 DI 10.1016/S1077-7229(05)80070-7 PG 13 WC Psychology, Clinical SC Psychology GA 090SR UT WOS:000240972200007 ER PT J AU Graham, DP Kunik, ME Doody, R Snow, AL AF Graham, DP Kunik, ME Doody, R Snow, AL TI Self-reported awareness of performance in dementia SO COGNITIVE BRAIN RESEARCH LA English DT Article DE Alzheimer disease; awareness; psychometrics ID STAGE ALZHEIMERS-DISEASE; IMPAIRED AWARENESS; MEMORY IMPAIRMENT; COGNITIVE DEFICITS; CAREGIVER BURDEN; ASSESSMENT SCALE; ANOSOGNOSIA; DEPRESSION; INSIGHT; UNAWARENESS AB The purpose of this study was to test the theory that patients with dementia do not update their self-perceptions based on actual performance. This experiment compared differences between post-task perceptions of performance and actual performance in persons with dementia and normal controls on seven cognitive tasks. Participants included 35 volunteers (12 with dementia and 23 without) from the Houston Veterans Affairs nursing home and geropsychiatric inpatient unit and outpatient clinics and from the Baylor College of Medicine's Alzheimer's Disease Center. Measurements included 7 subtests of the Alzheimer Disease Assessment Scale-Cognitive Subscale and standardized interview questions assessing perceived performance on each of these subtests. Participants with dementia had similar perceptions of performance to normal controls yet evidenced much worse performance on all seven cognitive screening tasks. Thirty-one percent of normal controls over-estimated their performance, compared to 64% of those with mild-moderate dementia and 93% with moderate-severe dementia. Our study supports the theory that demented individuals do not update their self-perceptions of performance. However, a large portion of normal controls was also inaccurate evaluating their own performances. Thus, post-diction measures provide useful insight into the mechanisms of self-awareness but may not be appropriate assessment tools to identify clinically significant impaired self-awareness. (c) 2005 Elsevier B.V. All rights reserved. C1 Michael E DeBakey Vet Affairs Med Ctr, HSR&D 152, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, MHCL 116, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Mental Hlth Serv Lines, Houston, TX 77030 USA. RP Graham, DP (reprint author), Michael E DeBakey Vet Affairs Med Ctr, HSR&D 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM david.graham@med.va.gov NR 57 TC 29 Z9 29 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0926-6410 J9 COGNITIVE BRAIN RES JI Cognit. Brain Res. PD SEP PY 2005 VL 25 IS 1 BP 144 EP 152 DI 10.1016/j.cogbrainres.2005.05.001 PG 9 WC Computer Science, Artificial Intelligence; Neurosciences; Neuroimaging SC Computer Science; Neurosciences & Neurology GA 976CE UT WOS:000232709600013 ER PT J AU Wen, PH De Gasperi, R Sosa, MAG Rocher, AB Friedrich, VL Hof, PR Elder, GA AF Wen, PH De Gasperi, R Sosa, MAG Rocher, AB Friedrich, VL Hof, PR Elder, GA TI Selective expression of presenilin 1 in neural progenitor cells rescues the cerebral hemorrhages and cortical lamination defects in presenilin 1-null mutant mice SO DEVELOPMENT LA English DT Article DE cortical development; CNS hemorrhages; familial Alzheimer's disease; neural progenitor cells; presenilin 1 (PS1, Psen1); transgenic mice; vascular development ID CENTRAL-NERVOUS-SYSTEM; CAJAL-RETZIUS NEURONS; GFP TRANSGENIC MICE; CNS STEM-CELLS; ALZHEIMER-DISEASE; ADULT MICE; NESTIN; MOUSE; NEUROGENESIS; HIPPOCAMPUS AB Mice with a null mutation of the presenilin 1 gene (Pseu1(-/-)) die during late intrauterine life or shortly after birth and exhibit multiple CNS and non-CNS abnormalities, including cerebral hemorrhages and altered cortical development. The cellular and molecular basis for the developmental effects of Psen1 remain incompletely understood. Psen1 is expressed in neural progenitors in developing brain, as well as in postmitotic neurons. We crossed transgenic mice with either neuron-specific or neural progenitor-specific expression of Psen1 onto the Psen1(-/-) background. We show that neither neuron-specific nor neural progenitor-specific expression of Psen1 can rescue the embryonic lethality of the Psen1(-/-) embryo. Indeed neuron-specific expression rescued none of the abnormalities in Psen1(-/-) mice. However, Psen1 expression in neural progenitors rescued the cortical lamination defects, as well as the cerebral hemorrhages, and restored a normal vascular pattern in Psen1(-/-) embryos. Collectively, these studies demonstrate that Psen1 expression in neural progenitor cells is crucial for cortical development and reveal a novel role for neuroectodermal expression of Psen1 in development of the brain vasculature. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Psychiat Serv, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA. RP Elder, GA (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. EM gregory.elder@mssm.edu FU NIA NIH HHS [P01 AG002219, AG23599, R01 AG020139, AG20139, R03 AG021305, AG05138, R21 AG023599, AG21305, AG02219, P50 AG005138]; NIMH NIH HHS [R01 MH064673, R03 MH070603, MH70603] NR 50 TC 18 Z9 19 U1 0 U2 1 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0950-1991 J9 DEVELOPMENT JI Development PD SEP PY 2005 VL 132 IS 17 BP 3873 EP 3883 DI 10.1242/dev.01946 PG 11 WC Developmental Biology SC Developmental Biology GA 972CG UT WOS:000232430900008 PM 16079160 ER PT J AU Boyko, EJ AF Boyko, EJ TI Progress in the estimation of mortality due to diabetes SO DIABETES CARE LA English DT Editorial Material ID CORONARY-HEART-DISEASE; FOLLOW-UP; POPULATION; DEATHS; ADULTS; RISK C1 VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, S-152E,1660 S Columbian Way, Seattle, WA 98108 USA. EM eboyko@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X NR 11 TC 6 Z9 6 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2005 VL 28 IS 9 BP 2320 EP 2321 DI 10.2337/diacare.28.9.2320 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 959NV UT WOS:000231525700040 PM 16123511 ER PT J AU Rosengren, DB Baer, JS Hartzler, B Dunn, CW Wells, EA AF Rosengren, DB Baer, JS Hartzler, B Dunn, CW Wells, EA TI The video assessment of simulated encounters (VASE): Development and validation of a group-administered method for evaluating clinician skills in motivational interviewing SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE motivational interviewing; training evaluation; skill assessment AB The authors developed and evaluated a group-administered method for measuring motivational interviewing (MI) skills. The video assessment of simulated encounters (VASE) consists of three videotaped vignettes of actors playing substance abusers. Each vignette is followed by eight questions asking examinees to generate written responses consistent with MI principles. Twenty-two clinicians completed the VASE questionnaire and two other measures of MI skill: a paper-and-pencil measure that elicited responses to written scenarios and an audiotaped interaction with a standardized patient (SP), subsequently scored for MI skill by independent tape raters. Psychometric analyses of this original VASE scale evaluated: (1) scoring reliability of the 24 VASE items; (2) internal reliability of the VASE full-scale score, seven subscale scores and the three vignettes; and (3) concurrent validity with aforementioned indices of MI skill. Analyses informed the removal of two subscales, redesign of a third and revisions to a fourth. The resulting 18-item VASE-R scale retains its three-vignette format, and assesses overall MI skill as well as the following five MI "microskills": reflective listening, responding to resistance, summarizing, eliciting change talk and developing discrepancy. The VASE-R requires further analysis to evaluate these revisions, but shows promise as a cost-effective alternative for use in MI skill assessment in a variety of training and research contexts. (c) 2005 Elsevier Ireland Ltd. All rights reserved. C1 Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98195 USA. Univ Washington, Dept Psychol, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. Univ Washington, Sch Social Work, Seattle, WA 98195 USA. RP Rosengren, DB (reprint author), Univ Washington, Inst Alcohol & Drug Abuse, 1107 NE 45th St,Suite 120, Seattle, WA 98195 USA. EM dbr@u.washington.edu NR 25 TC 18 Z9 19 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD SEP 1 PY 2005 VL 79 IS 3 BP 321 EP 330 DI 10.1016/j.drugalcdep.2005.02.004 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 960YG UT WOS:000231628500005 PM 16102376 ER PT J AU Hind, JA Nicosia, MA Gangnon, R Robbins, J AF Hind, JA Nicosia, MA Gangnon, R Robbins, J TI The effects of intraoral pressure sensors on normal young and old swallowing patterns SO DYSPHAGIA LA English DT Article DE deglutition; lingual pressure; instrumentation; deglutition disorders ID PENETRATION-ASPIRATION SCALE; VOLUME; AGE AB Lingual pressure generation plays a crucial role in oropharyngeal swallowing. To more discretely study the dynamic oropharyngeal system, a 3-bulb array of pressure sensors was designed with the Kay Elemetrics Corporation (Lincoln Park, NJ). The influence of the device upon normal swallowing mechanics and boluses representative of flow relative to age and bolus condition was the focus of this study. Twelve healthy adults in two age groups (31 +/- 5 years, 2 males and 4 females, and 78 +/- 7 years, 2 males and 4 females) participated. Each subject was instructed to swallow four boluses representative of conditions with and without three pressure sensors affixed to the hard palate. Post-swallow residue at four locations, Penetration/Aspiration Scale scores, and three bolus flow timing measures were assessed videofluoroscopically with respect to age and bolus condition. The only statistically significant influences attributable to the presence of the pressure sensors were slight increases in residue in the oral cavity and upper esophageal sphincter with some bolus consistencies, 8% more frequent trace penetration of the laryngeal vestibule predominantly with effortful swallowing, and variances in oral clearance duration. We conclude that the presence of the pressure sensors does not significantly alter normal swallowing patterns of healthy individuals. C1 William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Madison, WI USA. Univ Minnesota, Dept Biomed Engn, Minneapolis, MN USA. Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. RP Hind, JA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, GRECC 11G,2500 Overlook Terrace, Madison, WI 53705 USA. EM jahind@wisc.edu FU NINDS NIH HHS [NS24427] NR 12 TC 14 Z9 15 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD FAL PY 2005 VL 20 IS 4 BP 249 EP 253 DI 10.1007/s00455-005-0020-2 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 024EV UT WOS:000236179200001 PM 16633867 ER PT J AU Antonescu, CN Huang, C Niu, W Liu, Z Eyers, PA Heidenreich, KA Bilan, PJ Klip, A AF Antonescu, CN Huang, C Niu, W Liu, Z Eyers, PA Heidenreich, KA Bilan, PJ Klip, A TI Reduction of insulin-stimulated glucose uptake in L6 myotubes by the protein kinase inhibitor SB203580 is independent of p38MAPK activity SO ENDOCRINOLOGY LA English DT Article ID TYPE-2 DIABETIC-PATIENTS; RAT SKELETAL-MUSCLE; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; P38 MAPK; CELLULAR STRESSES; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ECTOPIC EXPRESSION; MAMMALIAN-CELLS AB Insulin increases glucose uptake through translocation of the glucose transporter GLUT4 to the plasma membrane. We previously showed that insulin activates p38MAPK, and inhibitors of p38MAPK alpha and p38MAPK beta (e. g. SB203580) reduce insulin-stimulated glucose uptake without affecting GLUT4 translocation. This observation suggested that insulin may increase GLUT4 activity via p38 alpha and/or p38 beta. Here we further explore the possible participation of p38MAPK through a combination of molecular strategies. SB203580 reduced insulin stimulation of glucose uptake in L6 myotubes overexpressing an SB203580-resistant p38 alpha (drug-resistant p38 alpha) but barely affected phosphorylation of the p38 substrate MAPK-activated protein kinase-2. Expression of dominant-negative p38 alpha or p38 beta reduced p38MAPK phosphorylation by 70% but had no effect on insulin-stimulated glucose uptake. Gene silencing via isoform-specific small interfering RNAs reduced expression of p38 alpha or p38 beta by 60-70% without diminishing insulin-stimulated glucose uptake. SB203580 reduced photoaffinity labeling of GLUT4 by bio-LC-ATB-BMPA only in the insulin-stimulated state. Unless low levels of p38MAPK suffice to regulate glucose uptake, these results suggest that the inhibition of insulin-stimulated glucose transport by SB203580 is likely not mediated by p38MAPK. Instead, changes experienced by insulin-stimulated GLUT4 make it susceptible to inhibition by SB203580. C1 Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada. Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada. Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada. Univ Manchester, Sch Life Sci, Manchester M13 9PT, Lancs, England. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Klip, A (reprint author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM amira@sickkids.ca RI Antonescu, Costin/A-2353-2011; Huang, Carol/H-2248-2014 NR 58 TC 41 Z9 45 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2005 VL 146 IS 9 BP 3773 EP 3781 DI 10.1210/en.2005-0404 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 955RB UT WOS:000231243600015 PM 15947002 ER PT J AU McNabb, DS Reed, R Marciniak, RA AF McNabb, DS Reed, R Marciniak, RA TI Dual luciferase assay system for rapid assessment of gene expression in Saccharomyces cerevisiae SO EUKARYOTIC CELL LA English DT Article ID ESCHERICHIA-COLI; BETA-GALACTOSIDASE; 2-HYBRID SYSTEM; REPORTER ASSAY; CYC1 GENE; YEAST; PROTEIN; TERMINATION; TRANSFORMATION; CONSTRUCTION AB A new reporter system has been developed for quantifying gene expression in the yeast Saccharomyces cerevisiae. The system relies on two different reporter genes, Renilla and firefly luciferase, to evaluate regulated gene expression. The gene encoding Renilla luciferase is fused to a constitutive promoter (PGK1 or SPT15) and integrated into the yeast genome at the CAN1 locus as a control for normalizing the assay. The firefly luciferase gene is fused to the test promoter and integrated into the yeast genome at the ura3 or leu2 locus. The dual luciferase assay is performed by sequentially measuring the firefly and Renilla luciferase activities of the same sample, with the results expressed as the ratio of firefly to Renilla luciferase activity (Fluc/Rluc). The yeast dual luciferase reporter (DLR) was characterized and shown to be very efficient, requiring approximately I minute to complete each assay, and has proven to yield data that accurately and reproducibly reflect promoter activity. A series of integrating plasmids were generated that contain either the firefly or Renilla luciferase gene preceded by a multicloning region in two different orientations and the three reading frames to make possible the generation of translational fusions. Additionally, each set of plasmids contains either the URA3 or LEU2 marker for genetic selection in yeast. A series of S288C-based yeast strains, including a two-hybrid strain, were developed to facilitate the use of the yeast DLR assay. This assay can be readily adapted to a high-throughput platform for studies requiring numerous measurements. C1 Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Univ Arkansas, Dept Biol Sci, SCEN601, Fayetteville, AR 72701 USA. EM dmcnabb@uark.edu FU NIAID NIH HHS [AI51470, R01 AI051470] NR 36 TC 37 Z9 43 U1 0 U2 13 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1535-9778 EI 1535-9786 J9 EUKARYOT CELL JI Eukaryot. Cell PD SEP PY 2005 VL 4 IS 9 BP 1539 EP 1549 DI 10.1128/EC.4.9.1539-1549.2005 PG 11 WC Microbiology; Mycology SC Microbiology; Mycology GA 965HV UT WOS:000231942100004 PM 16151247 ER PT J AU Staszewsky, L Masson, S Carretta, E Amigoni, M Wong, M Anand, I Cohn, JN Latini, R AF Staszewsky, L. Masson, S. Carretta, E. Amigoni, M. Wong, M. Anand, I. Cohn, J. N. Latini, R. CA Val-HeFT investigators TI Prognostic value of chronic obstructive pulmonary disease in heart failure patients: data from the Val-HeFT trial SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT 27th Congress of the European-Society-of-Cardiology CY SEP 03-07, 2005 CL Stockholm, SWEDEN SP European Soc Cardiol C1 Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, Milan, Italy. VA Greater Healthcare Syst, Los Angeles, CA USA. Univ Minnesota, Sch Med, VA Med Ctr, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP PY 2005 VL 26 SU 1 MA P1782 BP 280 EP 280 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 993WO UT WOS:000233987102025 ER PT J AU Hatsukami, T Zhao, XQ Kraiss, LW Parker, DL Waterton, J Cain, V Raichlen, J Yuan, C AF Hatsukami, T. Zhao, X. Q. Kraiss, L. W. Parker, D. L. Waterton, J. Cain, V. Raichlen, J. Yuan, C. TI Assessment of rosuvastatin treatment on carotid atherosclerosis in moderately hypercholesterolemic subjects using high-resolution magnetic resonance imaging SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT 27th Congress of the European-Society-of-Cardiology CY SEP 03-07, 2005 CL Stockholm, SWEDEN SP European Soc Cardiol C1 Univ Washington, Sch Med, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Utah, Salt Lake City, UT USA. AstraZeneca, Alderley Pk, Cheshire, England. AstraZeneca, Wilmington, DE USA. RI Waterton, John/A-8565-2008 OI Waterton, John/0000-0002-7734-2290 NR 0 TC 9 Z9 9 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP PY 2005 VL 26 SU 1 BP 626 EP 627 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 993WO UT WOS:000233987104362 ER PT J AU Wolf, N Penn, P Pendergrass, W Van Remmen, H Bartke, A Rabinovitch, P Martin, GM AF Wolf, N Penn, P Pendergrass, W Van Remmen, H Bartke, A Rabinovitch, P Martin, GM TI Age-related cataract progression in five mouse models for anti-oxidant protection or hormonal influence SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE catarack; hormonal; hemizygous KO model; lens; mouse ID CELLULAR GLUTATHIONE-PEROXIDASE; MITOCHONDRIAL OXIDATIVE STRESS; RECEPTOR/BINDING PROTEIN GENE; SUPEROXIDE-DISMUTASE; NUCLEAR CATARACT; KNOCKOUT MICE; LIFE-SPAN; LIGHT EXPOSURE; LENS; DAMAGE AB Five mouse models with known alterations of resistance to oxidative damage were compared by slit lamp examination for the presence and degree of advancement of age-related cataract in young adult and old animals along with wild type controls. A group of young and old normal C57BL/6Jax mice were examined first to constitute a standard, and they were found to exhibit age-related cataract development. Following this, four models on the C57BL/6 background with imposed genetic alterations affecting anti-oxidant enzyme presence or activity, and one outbred model in which a deletion blocked the growth hormone/IGF-1 axis, were similarly examined. There was no evidence of foetal or juvenile cataract development in any of these models, and an age-related severity for lens opacities was shown between young adult and old mice in all groups. Model 1, mice null for the anti-oxidant gene glutathione peroxidase-1 (GPX1) had significantly advanced cataracts in older mice vs. same age controls. In mouse model 2 hemizygous knockout of SOD2 (MnSOD) did not affect age-related cataract development. In model 3 combining the GPX1 and SOD2 deficiencies in the same animal did not advance cataract development beyond that of the GPX1 null alone. In model 4 the addition of anti-oxidant protection in the lens by transfection of human catalase targeted only to the mitochondria resulted in a significant delay in cataract development. The 5th model, growth hormone receptor knockout (GHR-/-) mice, also demonstrated a significant reduction in age-related cataract development, as well as dwarfism. These findings, in general, support the oxidative theory of age-related cataract development. The exception, the partial deletion of SOD2 in the hemizygous KO model, probably did not represent a sufficiently severe deprivation of anti-oxidant protection to produce pathologic changes in the lens. (c) 2005 Elsevier Ltd. All rights reserved. C1 Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98195 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev Studies, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. So Illinois Univ, Sch Med, Dept Internal Med, Springfield, IL USA. RP Wolf, N (reprint author), Univ Washington, Dept Pathol, Sch Med, Box 3557470, Seattle, WA 98195 USA. EM normwolf@u.washington.edu RI Bartke, Andzej/D-6640-2017 OI Bartke, Andzej/0000-0002-2569-557X FU NEI NIH HHS [R01 EY11733]; NIA NIH HHS [R01 AG19899]; PHS HHS [P01 01751] NR 52 TC 40 Z9 42 U1 1 U2 4 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 J9 EXP EYE RES JI Exp. Eye Res. PD SEP PY 2005 VL 81 IS 3 BP 276 EP 285 DI 10.1016/j.exer.2005.01.024 PG 10 WC Ophthalmology SC Ophthalmology GA 965RG UT WOS:000231967400004 PM 16129095 ER PT J AU Chew, LD Nelson, KM Young, BA Bradley, KA AF Chew, LD Nelson, KM Young, BA Bradley, KA TI Association between alcohol consumption and diabetes preventive practices SO FAMILY MEDICINE LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med ID SELF-RATED HEALTH; RISK FACTOR SURVEILLANCE; PROBLEM DRINKING; CONTROLLED TRIAL; POPULATION; MELLITUS; MORTALITY; AUDIT; DISEASE; COMPLICATIONS AB Background and Objectives: Little is known about the effect of alcohol consumption on the quality of care among patients with diabetes. We evaluated the association between alcohol consumption and diabetes preventive practices. Methods: We analyzed data from the 2001 Behavioral Risk Factor Surveillance System. Based on self-reported alcohol consumption in the past 30 days, we categorized participants into the following groups: nondrinkers, moderate drinkers (average drinks/day: < one for women, < two for men), or heavy drinkers (average drinks/day: > one for women, > two for men). We then examined the association between alcohol consumption and participants' reports of diabetes preventive practices. Results: Of 10, 980 respondents with a self-reported diagnosis of diabetes, 70% were current nondrinkers, 28% moderate drinkers, and 2% heavy drinkers. Heavy drinkers compared with nondrinkers were more likely to report not performing daily glucose self monitoring and not having had an eye examination in the past year, adjusting for age, gender, race, education, income, marital status, health insurance, diabetes duration, health status, and insulin use. Moderate drinkers were more likely than nondrinkers to report not performing daily glucose self monitoring and not having had a provider visit for diabetes in the past year. Conclusions: Adults with diabetes who report moderate or heavy alcohol consumption may be at risk for adverse diabetes outcomes due to suboptimal preventive practices. C1 Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Chew, LD (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, 325 9Th Ave,Box 359780, Seattle, WA 98104 USA. EM lchew@u.washington.edu FU NIAAA NIH HHS [K23AA00313] NR 35 TC 13 Z9 13 U1 1 U2 2 PU SOC TEACHERS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA SN 0742-3225 J9 FAM MED JI Fam. Med. PD SEP PY 2005 VL 37 IS 8 BP 589 EP 594 PG 6 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 964DQ UT WOS:000231859300015 PM 16145630 ER PT J AU Paintlia, AS Paintlia, MK Khan, M Vollmer, T Singh, AK Singh, I AF Paintlia, AS Paintlia, MK Khan, M Vollmer, T Singh, AK Singh, I TI HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis SO FASEB JOURNAL LA English DT Article DE lovastatin; oligodendrocyte progenitors; spinal cord; encephalomyelitis; multiple sclerosis; remyelination ID CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DEMYELINATING DISEASES; CNS REMYELINATION; NITRIC-OXIDE; GLIAL-CELLS; RHO; ACTIVATION; EXPRESSION; LOVASTATIN AB Impaired remyelination due to degeneration of both postmitotic oligodendrocytes and oligodendrocyte progenitors (OPs) is the major hallmark of inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE). Here, we have demonstrated the potential of lovastatin, a HMG-CoA reductase inhibitor, for the restoration of impaired remyelination mediated through enhanced survival and differentiation of OPs in the spinal cord of treated EAE animals. Lovastatin treatment significantly increased the level of myelin lipids in the spinal cord of treated EAE animals, coinciding with the attenuation of disease severity and inflammatory demyelination as compared with untreated EAE animals. The increased expression of myelin proteins and transcription factors associated with differentiating oligodendrocytes along with the increase in number of NG2(+)/BrdU(-) and NG2(+)/BrdU(+) cells, and the expression of proliferating OP-specific proteins, demonstrated the restoration of remyelination in the spinal cord of lovastatin-treated EAE animals. Corresponding to this, in vitro studies further corroborated the increased survival and differentiation of OPs in lovastatin-treated activated mixed glial cells suggesting that lovastatin protects against the degeneration of OPs and enhances their differentiation through induction of a pro-remyelinating environment in the spinal cord of treated EAE animals. Together, these data demonstrate that lovastatin has the potential to augment remyelination in MS lesions and other neuroinflammatory diseases. C1 Med Univ S Carolina, Children Res Inst, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Barrow Neurol Inst, Phoenix, AZ 85013 USA. RP Singh, I (reprint author), Med Univ S Carolina, Children Res Inst, Dept Pediat, 173 Ashley Ave,509 CRI,POB 250515, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144] NR 48 TC 66 Z9 70 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD SEP PY 2005 VL 19 IS 11 BP 1407 EP 1421 DI 10.1096/fj.05-3861com PG 15 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 970NA UT WOS:000232315700034 PM 16126908 ER PT J AU Imam, SZ Jankovic, J Ali, SF Skinner, JT Xie, WJ Conneely, OM Lee, WD AF Imam, SZ Jankovic, J Ali, SF Skinner, JT Xie, WJ Conneely, OM Lee, WD TI Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice SO FASEB JOURNAL LA English DT Article DE nitric oxide; dopamine; 3-NT; caspase; transcription; apoptosis ID ORPHAN NUCLEAR RECEPTOR; ISCHEMIC BRAIN-INJURY; ALPHA-SYNUCLEIN; EXPRESSION INCREASES; TRANSCRIPTION FACTOR; NEURONAL APOPTOSIS; CELL-DEATH; METHAMPHETAMINE; NEUROTOXICITY; GENE AB Knocking out of Nurr1 gene, a member of nuclear receptor superfamily, causes selective agenesis of dopaminergic neurons in midbrain. Reduced expression of Nurr1 increases the vulnerability of mesencephalic dopamine neurons to dopaminergic toxins. We evaluated the role of nitric oxide as a possible mechanism for this increased susceptibility. Increased expression of neuronal nitric oxide synthase and increased 3-nitrotyrosine were observed in striatum of Nurr1 heterozygous (Nurr1 +/-) mice as compared with wild-type. Increased cytochrome C activation and consecutive release of Smac/DIABLO were also observed in Nurr1 +/- mice. An induction of active Caspase-3 and p53, cleavage of poly-ADP (RNase) polymerase and reduced expression of bcl-2 were observed in Nurr1 +/- mice. Methamphetamine significantly increased these markers in Nurr1 +/- mice as compared with wild-type. The present data therefore suggest that nitric oxide plays a role as a modulating factor for the increased susceptibility, but not the potentiation, of the dopaminergic terminals in Nurr1 +/- mice. We also report that this increased neuronal nitric oxide synthase expression and increased nitration in Nurr1 +/- mice led to the activation of apoptotic cascade via the differential alterations in the DNA binding activity of transcription factors responsible for the propagation of growth arrest as well as apoptosis. C1 Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. UT Hlth Sci, Dept Med, San Antonio, TX USA. US FDA, Neurochem Lab, Div Neurotoxicol, NCTR, Jefferson, AR USA. Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA. RP Lee, WD (reprint author), Baylor Coll Med, Dept Neurol, NB 205,6501 Fannin St, Houston, TX 77030 USA. EM simam@satx.rr.com; Weidongl@bcm.tmc.edu FU NINDS NIH HHS [NS40370, NS043567] NR 48 TC 18 Z9 18 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD SEP PY 2005 VL 19 IS 11 BP 1441 EP 1450 DI 10.1096/fj.04-3362com PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 970NA UT WOS:000232315700037 PM 16126911 ER PT J AU Zhao, Z Ho, L Wang, J Qin, WP Festa, ED Mobbs, C Hof, P Rocher, A Masur, S Haroutunian, V Pasinetti, GM AF Zhao, Z Ho, L Wang, J Qin, WP Festa, ED Mobbs, C Hof, P Rocher, A Masur, S Haroutunian, V Pasinetti, GM TI Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance-associated promotion of Alzheimer's disease beta-amyloid neuropathology SO FASEB JOURNAL LA English DT Article DE diabetes; IDE; secretase; IDE; AKT; MAPK ID GAMMA-SECRETASE ACTIVITY; HUMAN MESANGIAL CELLS; DEGRADING ENZYME; NEUROFIBRILLARY TANGLES; EXTRACELLULAR-MATRIX; STEREOLOGIC ANALYSIS; POTENTIAL MECHANISM; DIABETES-MELLITUS; PRECURSOR PROTEIN; NEURITIC PLAQUES AB The goal of this study was to further explore potential mechanisms through which diabetogenic dietary conditions that result in promotion of insulin resistance (IR), a feature of non-insulin dependant diabetes mellitus (type-2 diabetes), may influence Alzheimer's disease ( AD). Using genome-wide array technology, we found that connective tissue growth factor ( CTGF), a gene product described previously for its involvement in diabetic fibrosis, is elevated in brain tissue in an established mouse model of diet-induced IR. With this evidence we continued to explore the regulation of CTGF in postmortem AD brain tissue and found that CTGF expression correlated with the progression of AD clinical dementia and amyloid neuritic plaque (NP) neuropathology, but not neurofibrillary tangle (NFT) deposition. Consistent with this evidence, we also found that exposure of Tg2576 mice ( a model AD-type amyloid neuropathology) to a diabetogenic diet that promotes IR results in a similar to 2-fold elevation in CTGF steady-state levels in the brain, coincident with a commensurate promotion of AD-type amyloid plaque burden. Finally, using in vitro cellular models of amyloid precursor protein (APP)-processing and A beta generation/clearance, we confirmed that human recombinant (hr) CTGF may increase A beta(1-40) and A beta(1-42) peptide steady-state levels, possibly through a mechanism that involves gamma-secretase activation and decreased insulin-degrading enzyme (IDE) steady-state levels in a MAP kinase ( MAPK)/ phosphatidylinositol 3-kinase (PI-3K)/protein kinase-B (AKT) 1-dependent manner. The findings in this study tentatively suggest that increased CTGF expression in the brain might be a novel biological predicative factor of AD clinical progression and neuropathology in response to dietary regimens promoting IR conditions. C1 Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, GRECC, Translat Neurosci Labs, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU NIA NIH HHS [AG13799, AG02219] NR 59 TC 21 Z9 21 U1 1 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD SEP PY 2005 VL 19 IS 11 BP 2081 EP + DI 10.1096/fj.05-4359fje PG 25 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 970NA UT WOS:000232315700005 PM 16186174 ER PT J AU Chiappelli, F Alwan, J Prolo, P Christensen, R Fiala, M Cajulis, OS Bernard, G AF Chiappelli, F Alwan, J Prolo, P Christensen, R Fiala, M Cajulis, OS Bernard, G TI Neuro-immunity in stress-related oral ulcerations: A fractal analysis SO FRONTIERS IN BIOSCIENCE LA English DT Article DE oral lichen planus (OLP); recurrent aphthous stomatitis (RAS); oral mucosa CD3+T cells; vesicles of monoamines transport; vesicles of acetylcholine transport; fractal dimension; euclidean dimension ID LICHEN-PLANUS; LYMPHOCYTES; INTERFACE; DIMENSION; CELLS AB By testing archival paraffinized biopsy blocks obtained from the oral pathology library with immunohistochemistry, we tested the hypothesis that substantial alterations are demonstrable in the cross-talk between sympathetic (VMAT) and para-sympathetic innervation (VAchT), and resident CD3+ T cells in the mucosa from oral lichen planus (OLP), compared to recurrent aphthous stomatitis (RAS) and control biopsies. We quantified fractal dimension and Euclidean dimension of CD3+ cells between the two pathologies, and across the set of CD3+ cells proximal to the vesicles of monoamines transport (VMAT)+ or the vesicles of acetylcholine transport (VAchT)+ innervation, compared to cells relatively distal to the nerve endings. The data show exquisite organization of the punctuate sympathetic and para-sympathetic staining about the resident CD3+ T cells in the OLP lesions, but not in the aphthous lesions or in control mucosa. Fractal analysis reveals that aphthous lesions are characterized by CD3+ T cells of larger size (Euclidean dimensional map), compared to control mucosa. CD3+ T cells in OLP lesions are also found to be significantly larger than those found in control lesions, when they are not proximal to sympathetic or para-sympathetic vesicles. The membrane of CD3+ T cells is overall more complex (fractal dimension) in aphthous lesions, compared to control sections. A similar trend is apparent, albeit not statistically significant, in CD3+ T cells resident in OLP lesions, whether or not they are located proximal to nerve endings. An overall decrease in the ratio of fractal dimension-over-topological dimension was also observed across the pathological lesions, compared to control. Taken together, these data indicate that as CD3+ T cells grow larger in the pathological conditions, they, in effect, stretch their plasma membrane, and that the cells may be at different stage of the cell cycle, relative to their position vis a vis nerve endings. Because fractal analysis is performed on individual cells, it has the potential of being developed in a novel diagnostic test, as well as a prognostic tool for monitoring the etiology and the course of treatment at the individual cellular level. Our findings also open new frontiers of fundamental, clinical and translational biosciences of OLP. C1 Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. Loma Linda Univ, Sch Dent, Loma Linda, CA 92350 USA. RP Chiappelli, F (reprint author), Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, CHS 63-090, Los Angeles, CA 90095 USA. EM chiappelli@dent.ucla.edu NR 27 TC 3 Z9 6 U1 0 U2 0 PU FRONTIERS IN BIOSCIENCE INC PI MANHASSET PA C/O NORTH SHORE UNIV HOSPITAL, BIOMEDICAL RESEARCH CENTER, 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1093-9946 J9 FRONT BIOSCI JI Front. Biosci. PD SEP 1 PY 2005 VL 10 SU S BP 3034 EP 3041 DI 10.2741/1760 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 970OU UT WOS:000232320300087 PM 15970558 ER PT J AU Ku, NO Lim, JK Krams, SM Esquivel, CO Keeffe, EB Wright, TL Parry, DAD Omary, MB AF Ku, NO Lim, JK Krams, SM Esquivel, CO Keeffe, EB Wright, TL Parry, DAD Omary, MB TI Keratins as susceptibility genes for end-stage liver disease SO GASTROENTEROLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; INTERMEDIATE-FILAMENTS; INDUCED APOPTOSIS; G62C MUTATIONS; MICE; CYTOKERATINS; ASSOCIATION; RESISTANCE; HEPATITIS; INJURY AB Background & Aims: Keratins 8 and :18 protect the liver from stress. Keratin 8 and :18 variants in 17 of 467 liver disease explants and 2 of 349 blood bank controls were previously reported in 5 analyzed exonic regions. We asked whether mutations were present in the remaining 10 exons of keratins 8 and 18. Methods: Exonic regions were polymerase chain reaction-amplified from genomic DNA, isolated from the above-mentioned 2 cohorts, and analyzed for the presence of mutations. Mutant keratins were also studied biochemically. Results: We identified 10 novel keratin 8 and 18 heterozygous variants in 44 of 467 explants and 11 of 349 controls: keratin IS deletion (A64-71), a keratin 8 frameshift that truncates the last 14 amino acids; 8 missense keratin 8 and IS alterations; and several new polymorphisms. The most common variant, keratin 8 R340H, at the highly conserved R340 was found in 30 of 467 explants and 10 of 349 controls (P =.02) and was confirmed in the diseased livers by generation of an R3401-1-specific antibody. Germline transmission and variant protein expression were verified. The mutations involved a variety of liver diseases, and some variants had an ethnic background preponderance. Mutations that introduced disulfide bonds (keratin 8 G61C or R453C) decreased keratin solubility, particularly after oxidative stress, whereas others decreased keratin 8 phosphorylation (keratin 8 G433S). Conclusions: The overall frequency of keratin 8 and :18 variants was 12.4% in 467 liver disease explants and 3.7% in 349 blood bank controls (P < .0001). Variants can alter keratin solubility or phosphorylation and may render individuals susceptible to end-stage liver disease, depending on their genetic background and exposure to other insults, such as alcohol or viral infection. C1 Palo Alto VA Med Ctr, Dept Med, Palo Alto, CA 94304 USA. Palo Alto VA Med Ctr, Dept Surg, Palo Alto, CA 94304 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Massey Univ, Palmerston North, New Zealand. RP Ku, NO (reprint author), Palo Alto VA Med Ctr, Dept Med, Mail Code 154J,3801 Miranda Ave, Palo Alto, CA 94304 USA. FU NIDDK NIH HHS [DK47918, DK56339] NR 29 TC 49 Z9 52 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD SEP PY 2005 VL 129 IS 3 BP 885 EP 893 DI 10.1053/j.gastro.2005.06.065 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 963PO UT WOS:000231816500016 PM 16143128 ER PT J AU Simon, GE Katon, WJ Lin, EHB Ludman, E VonKorff, M Ciechanowski, P Young, BA AF Simon, GE Katon, WJ Lin, EHB Ludman, E VonKorff, M Ciechanowski, P Young, BA TI Diabetes complications and depression as predictors of health service costs SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE diabetes; depression; cost; complications; utilization ID PRIMARY-CARE; MEDICAL ILLNESS; MYOCARDIAL-INFARCTION; COMORBID DEPRESSION; MEXICAN-AMERICANS; MAJOR DEPRESSION; MENTAL-DISORDERS; SELF-CARE; SYMPTOMS; POPULATION AB Objective: The aim of this study was to assess the relative contributions of diabetes complications, depression and comorbid medical disorders to health service costs in adults with diabetes. Methods: A total of 4398 adult health plan members with diabetes completed a mailed survey. Depression was assessed using the nine-item PHQ. Health service costs, diabetes complications, glycohemoglobin levels and comorbid medical conditions were assessed using computerized health plan records. Results: Total health service costs were approximately 70% higher for individuals with major depression than for those without any depressive disorder US$5361 over 6 months vs. US$3120, P < .001); this difference was consistent across all categories of health service costs. Diabetes complications were the strongest predictor of total costs (US$6845 for those with three or more complications vs. US$1719 for those with none), but depression remained strongly associated with increased costs at all levels of diabetes severity. Conclusions: Among people with diabetes, depression is associated with 50-75% increases in health service costs. This proportional difference is similar to that in general population samples, but the absolute dollar difference is much greater. The effect of depression on health service use is undoubtedly complex and not limited to unexplained physical symptoms among the worried well. (c) 2005 Elsevier Inc. All rights reserved. C1 Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Primary & Epidemioil Res & Informat Ctr, Seattle, WA 98108 USA. RP Simon, GE (reprint author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. EM simon.g@ghc.org FU NIMH NIH HHS [R01 MH41739] NR 36 TC 117 Z9 119 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD SEP-OCT PY 2005 VL 27 IS 5 BP 344 EP 351 DI 10.1016/j.genhosppsych.2005.04.008 PG 8 WC Psychiatry SC Psychiatry GA 972JM UT WOS:000232450100007 PM 16168795 ER PT J AU Turnbull, J Lohi, H Kearney, JA Rouleau, GA Delgado-Escueta, AV Meisler, MH Cossette, P Minassian, BA AF Turnbull, J Lohi, H Kearney, JA Rouleau, GA Delgado-Escueta, AV Meisler, MH Cossette, P Minassian, BA TI Sacred disease secrets revealed: the genetics of human epilepsy SO HUMAN MOLECULAR GENETICS LA English DT Article ID IDIOPATHIC GENERALIZED EPILEPSY; CHILDHOOD ABSENCE EPILEPSY; POTASSIUM CHANNEL GENE; FRONTAL-LOBE EPILEPSY; JUVENILE MYOCLONIC EPILEPSY; NICOTINIC ACETYLCHOLINE-RECEPTOR; LATERAL TEMPORAL EPILEPSY; EPISODIC ATAXIA TYPE-2; FEBRILE SEIZURES PLUS; FAMILIAL NEONATAL CONVULSIONS AB Neurons throughout the brain suddenly discharging synchronously and recurrently cause primarily generalized seizures. Discharges localized awhile in one part of the brain cause focal-onset seizures. A genetically determined generalized hyperexcitability had been predicted in primarily generalized seizures, but surprisingly the first epilepsy gene discovered, CHRNA4, was in a focal (frontal lobe)-onset syndrome. Another surprise with CHRNA4 was its encoding of an ion channel present throughout the brain. The reason why CHRNA4 causes focal-onset seizures is unknown. Recently, the second focal (temporal lobe)-onset epilepsy gene, LGI1 (unknown function), was discovered. CHRNA4 led the way to mutation identifications in 15 ion channel genes, most causing primarily generalized epilepsies. Potassium channel mutations cause benign familial neonatal convulsions. Sodium channel mutations cause generalized epilepsy with febrile seizures plus or, if more severe, severe myoclonic epilepsy of infancy. Chloride and calcium channel mutations are found in rare families with the common syndromes childhood absence epilepsy and juvenile myoclonic epilepsy (JME). Mutations in the EFHC1 gene (unknown function) occur in other rare JME families, and yet in other families, associations are present between JME (or other generalized epilepsies) and single nucleotide polymorphisms in the BRD2 gene (unknown function) and the malic enzyme 2 (ME2) gene. Hippocrates predicted the genetic nature of the 'sacred' disease. Genes underlying the 'malevolent' forces seizing 1% of humans have now been revealed. These, however, still account for a mere fraction of the genetic contribution to epilepsy. Exciting years are ahead, in which the genetics of this extremely common, and debilitating, neurological disorder will be solved. C1 Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada. Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA. Ctr Hosp Univ Montreal, Notre Dame Hosp, Ctr Study Brain Dis, Montreal, PQ H2L 4M1, Canada. Greater Los Angeles VA Healthcare Syst, Epilepsy Ctr Excellence, Los Angeles, CA 90073 USA. RP Minassian, BA (reprint author), Hosp Sick Children, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM bminass@sickkids.ca OI Delgado-Escueta, Antonio V./0000-0002-1581-6999; Kearney, Jennifer/0000-0003-1726-4769 NR 95 TC 64 Z9 69 U1 3 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD SEP 1 PY 2005 VL 14 IS 17 BP 2491 EP 2500 DI 10.1093/hmg/ddi250 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 958UI UT WOS:000231473300004 PM 16278970 ER PT J AU DeLuca, AK Lenze, EJ Mulsant, BH Butters, MA Karp, JF Dew, MA Pollock, BG Shear, MK Houck, PR Reynolds, CR AF DeLuca, AK Lenze, EJ Mulsant, BH Butters, MA Karp, JF Dew, MA Pollock, BG Shear, MK Houck, PR Reynolds, CR TI Comorbid anxiety disorder in late life depression: association with memory decline over four years SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE depression; anxiety disorders; geriatrics; neuropsychological testing ID ELDERLY-PATIENTS; COGNITIVE DECLINE; ANXIOUS DEPRESSION; CONTROLLED-TRIAL; DOUBLE-BLIND; OLDER; NORTRIPTYLINE; QUESTIONNAIRE; PSYCHOTHERAPY; SYMPTOMS AB Objective In elderly persons with Major Depressive Disorder (MDD), coexisting Generalized Anxiety Disorder (GAD) or Panic Disorder (PD) is associated with more severe symptoms and poorer short-term treatment outcomes. The purpose of this study was to determine whether comorbid GAD or PD was associated with poorer long-term outcomes of late-life MDD, in terms of symptoms, functional disability, and cognitive status. Methods Seventy-nine older subjects with major depressive disorder who had responded to initial treatment in clinical trials were followed at yearly intervals for up to four years with assessment of their symptoms, cognitive status, and functional disability. For this analysis, subjects were divided into two groups, anxious and non-anxious, based on presence (n = 37) or absence (n = 42) of a lifetime diagnosis of GAD and/or PD. Results The anxious group showed a greater decline in memory, but not in other cognitive measures or measures of functional status. Depression recurrence was similar in the anxious and non-anxious groups. Among those in the anxious group, a later age of onset (> 55) of the anxiety disorder was associated with worse overall cognition at baseline, but a similar rate of decline in cognition over time, compared with early-onset anxiety disorder. Conclusion We found evidence that comorbid GAD or PD is associated with a greater decline in memory in late-life MDD. The data also suggest that anxiety disorders with an onset later in life may be associated with cognitive impairment, although further study is needed to confirm this finding. Copyright (c) 2005 John Wiley & Sons, Ltd. C1 Clin Room E835, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Intervent Res Ctr Late Life Mood Disorders, Pittsburgh, PA USA. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychol, Pittsburgh, PA USA. RP Lenze, EJ (reprint author), Western Psychiat Inst & Clin, 3811 O Hara St, Pittsburgh, PA 15213 USA. EM lenzeej@upmc.edu FU NIMH NIH HHS [K24 MH 65416, K01 MH 01613, K23 MH 64196, K01 MH 01684, P30 MH 52247, R01 MH 37869, R01 MH 43832] NR 36 TC 54 Z9 58 U1 1 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD SEP PY 2005 VL 20 IS 9 BP 848 EP 854 DI 10.1002/gps.1366 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 967JV UT WOS:000232088400007 PM 16116585 ER PT J AU Tran, A Wallner, K Merrick, G Seeberger, J Armstrong, J Mueller, A Cavanagh, W Lin, D Butler, W AF Tran, A Wallner, K Merrick, G Seeberger, J Armstrong, J Mueller, A Cavanagh, W Lin, D Butler, W TI Rectal fistulas after prostate brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate carcinoma; brachytherapy; rectum; morbidity ID RANDOMIZED MULTICENTER TRIAL; MORBIDITY OUTCOMES; I-125; RISK; COMPLICATIONS; CANCER; PD-103 AB Purpose: To compare the rectal and prostatic radiation doses for a prospective series of 503 patients, 44 of whom developed persistent rectal bleeding, and 2 of whom developed rectal-prostatic fistulas. Methods and Materials: The 503 patients were randomized and treated by implantation with I-125 vs. Pd-103 alone (n = 290) or to Pd with 20 Gy vs. 44 Gy supplemental external beam radiotherapy (n = 213) and treated at the Puget Sound Veterans Affairs Medical Center (n = 227), Schiffler Cancer Center (n = 242) or University of Washington (n = 34). Patients were treated between September 1998 and October 2001 and had a minimum of 24 months of follow-up. The patient groups were treated concurrently. Treatment-related morbidity was monitored by mailed questionnaires, using standard American Urological Association and Radiation Therapy Oncology Group criteria, at 1, 3, 6, 12, 18, and 24 months. Patients who reported Grade 1 or greater Radiation Therapy Oncology Group rectal morbidity were interviewed by telephone to clarify details regarding their rectal bleeding. Those who reported persistent bleeding, lasting for > 1 month were included as having Grade 2 toxicity. Three of the patients with rectal bleeding required a colostomy, two of whom developed a fistula. No patient was lost to follow-up. The rectal doses were defined as the rectal volume in cubic centimeters that received > 50%, 100%, 200%, or 300% of the prescription dose. The rectum was considered as a solid structure defined by the outer wall, without attempting to differentiate the inner wall or contents. Results: Persistent rectal bleeding occurred in 44 of the 502 patients, 32 of whom (73%) underwent confirmatory endoscopy. In univariate analysis, multiple parameters were associated with late rectal bleeding, including all rectal brachytherapy indexes. In multivariate analysis, however, only the rectal volume that received > 100% of the dose was significantly predictive of bleeding. Rectal fistulas occurred in 2 patients(0.4%), both of whom had received moderate rectal radiation doses and extensive intervention for rectal bleeding. Conclusion: Partly on the basis of data from others and data presented here, we believe that the incidence of rectal fistulas can be much lower than in our series. High rectal radiation doses should be avoided a priori, to minimize the likelihood of rectal bleeding, and hence the likelihood that invasive procedures will be performed. (c) 2005 Elsevier Inc. C1 US Dept Vet Affairs, Dept Radiat Oncol, Seattle, WA 98108 USA. Puget Sound Hlth Care Syst, Dept Radiat Oncol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA USA. Grp Hlth Cooperat Puget Sound, Dept Radiat Oncol, Seattle, WA 98121 USA. Schiffler Canc Ctr, Wheeling, WV USA. RP Wallner, K (reprint author), US Dept Vet Affairs, Dept Radiat Oncol, 174,1660 S Columbian Way, Seattle, WA 98108 USA. EM Kent.wallner@med.va.gov NR 23 TC 51 Z9 51 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2005 VL 63 IS 1 BP 150 EP 154 DI 10.1016/j.ijrobp.2005.01.021 PG 5 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 956TK UT WOS:000231322500018 PM 16111583 ER PT J AU Offner, H Vandenbark, AA AF Offner, H Vandenbark, AA TI Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS SO INTERNATIONAL REVIEWS OF IMMUNOLOGY LA English DT Review DE T cell receptor; estrogen; multiple sclerosis; experimental autoimmune encephalomyelitis; therapy; FoxP3 ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS PATIENTS; CENTRAL-NERVOUS-SYSTEM; BV8S2 TRANSGENIC MICE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; V-BETA-6.1 CDR2 PEPTIDES; DEMYELINATING DISEASES; SELF-TOLERANCE; TCR PEPTIDES; DOUBLE-BLIND AB Both estrogen (E2) and T-cell receptor (TCR) peptides have beneficial effects on the clinical course of experimental autoimmune encephalomyelitis (EAE) and possibly multiple sclerosis (MS) that involve distinct but congruent mechanisms. Of interest, these two approaches share an ability to enhance expression of the Fl gene and associated activity of regulatory T (Treg) cells. E2 increases the number and activity of FoxP3(+) T cells through Esr-1 signaling during TCR activation of CD4(+)CD25(-) T cells. In contrast, TCR peptide therapy appears to increase the frequency of regulatory FoxP3(+) T cells specific for self-TCR determinants expressed by targeted pathogenic T cells. The combined effects on Treg expansion and activation induced by these distinct immunoregulatory approaches may account for their potent effects on clinical EAE and argue for a similar combined therapeutic approach for MS. C1 Portland VA Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D 31, 3710 SW US Vet Hosp Rd,Bldg 101,Rm 408, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NINDS NIH HHS [NS49210, NS45445, NS23444, NS23221] NR 82 TC 15 Z9 16 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0883-0185 J9 INT REV IMMUNOL JI Int. Rev. Immunol. PD SEP-DEC PY 2005 VL 24 IS 5-6 BP 447 EP 477 DI 10.1080/08830180500371462 PG 31 WC Immunology SC Immunology GA 002NI UT WOS:000234617800009 PM 16318990 ER PT J AU Kaye, JA Moore, MM Dame, A Quinn, J Camicioli, R Howieson, D Corbridge, E Care, B Nesbit, G Sexton, G AF Kaye, JA Moore, MM Dame, A Quinn, J Camicioli, R Howieson, D Corbridge, E Care, B Nesbit, G Sexton, G TI Asynchronous regional brain volume losses in presymptomatic to moderate AD SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE aging; oldest-old; MRI; dementia; Alzheimer disease ID HEALTHY ELDERLY PERSONS; ALZHEIMERS-DISEASE; OLDEST-OLD; HIPPOCAMPAL ATROPHY; ENTORHINAL CORTEX; COGNITIVE DECLINE; TEMPORAL-LOBE; MRI; DEMENTIA AB To determine if rates and locations of brain volume loss associated with AD are phase-specific, occurring prior to clinical onset and at later stages, we performed longitudinal volumetric MRI analysis on 155 subjects enrolled ill a prospective study of aging and dementia. Subjects were divided by Clinical Dementia Rating (CDR) scale into stages of Normal (CDR 0 -> Very Mild (CDR 0 -> 0.5 and 0.5 -> 0.5), Mild (CDR 0.5 -> 1.0 and 1.0 -> 1.0) and Moderate (CDR 1.0 -> 2.0 and 2.0 -> 2.0) dementia. Rates of volume change in CSF spaces, lobar and medial temporal lobe regions were analyzed for group differences across stages. Annual rates of ventricular volume change differed between non-demented and very mild group (p < 0.01). In later severity stages, ventricular, temporal, basal ganglia-thalamic region and total volumes show change. Rates of volume loss increase as dementia progresses, but not uniformly in all regions. These regional and phase-specific volume changes form targets for monitoring disease-modifying therapies at clinically relevant, defined stages of dementia. C1 Oregon Hlth Sci Univ, Layton Aging & Alzheimers Dis Ctr, Dept Neurol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Layton Aging & Alzheimers Dis Ctr, Dept Med & Prevent Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Layton Aging & Alzheimers Dis Ctr, Dept Radiol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Univ Alberta, Edmonton, AB T6G 2M7, Canada. RP Kaye, JA (reprint author), Oregon Hlth Sci Univ, Layton Aging & Alzheimers Dis Ctr, Dept Neurol, CR-131,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM kaye@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478; Camicioli, Richard/0000-0003-2977-8660 FU NCCIH NIH HHS [P50 AT00066]; NCRR NIH HHS [M01 RR000334]; NIA NIH HHS [P30 AG08017] NR 29 TC 25 Z9 29 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD SEP PY 2005 VL 8 IS 1 BP 51 EP 56 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 039HT UT WOS:000237297300006 PM 16155349 ER PT J AU Giraud, GD Faber, JJ Jonker, S Davis, L Anderson, DF AF Giraud, GD Faber, JJ Jonker, S Davis, L Anderson, DF TI Intravascular infusions of plasma into fetal sheep cause arterial and venous hypertension SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE blood pressure; renin; angiotensin ID ANGIOTENSIN-II; BLOOD-PRESSURE; UMBILICAL CIRCULATION; PLACENTAL CIRCULATION; RENIN ACTIVITY; HEART-RATE; RESPONSES; LOSARTAN; SYSTEM; VOLUME AB Fetal volume control is driven by an equilibrium between fetal and maternal hydrostatic and oncotic pressures in the placenta. Renal contributions to blood volume regulation are minor because the fetal kidneys cannot excrete fluid from the fetal compartment. We hypothesized that an increase in fetal plasma protein would lead to an increase in plasma oncotic pressure, resulting in an increase in fetal arterial and venous pressures and decreased angiotensin levels. Plasma or lactated Ringer solution was infused into each of five, twin fetuses. After 7 days, fetal protein concentration was 71.2 +/- 4.2 g/l in the plasma-infused fetuses compared with 35.7 +/- 6.3 g/l in the lactated Ringer-solution-infused fetuses. Arterial pressure was 68.0 +/- 3.6 compared with 43.4 +/- 1.9 mmHg in the lactated Ringer solution-infused fetuses (P < 0.0003), whereas venous, pressure was 4.8 +/- 0.3 mmHg in the plasma-infused fetuses compared with 3.3 +/- 0.4. mmHg in the lactated Ringer solution-infused fetuses (P < 0.036). Six fetuses were studied on days 0, 7, and 14 of plasma protein infusion. Fetal protein concentration increased from 31.1 +/- 1.5 to 84.8 +/- 3.8 g/l after 14 days,(P < 0.01), and arterial pressure increased from 43.1 +/- 1.8 to 69.1 +/- 4.1 mmHg (P < 0.01). Venous pressure increased from 3.0 +/- 0.4 to 6.2 +/- 1.3 mmHg (P < 0.05). Fetal heart rate did not change. Angiotensin H concentration decreased, from 24.6 +/- 5.6 to 2.9 +/- 1.3 pg/l, after 14 days (P < 0.01). Fetal plasma infusions resulted in fetal arterial and venous hypertensions that could not be corrected by reductions in angiotensin II levels. C1 Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Heart Res Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Giraud, GD (reprint author), Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Heart Res Ctr, L334, Portland, OR 97239 USA. EM giraudg@ohsu.edu OI Jonker, Sonnet/0000-0002-1097-2562 FU NHLBI NIH HHS [HL-45043]; NICHD NIH HHS [HD-37376, 5PO1-HD-34430] NR 29 TC 11 Z9 11 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD SEP PY 2005 VL 99 IS 3 BP 884 EP 889 DI 10.1152/japplphysiol.01429.2004 PG 6 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 959RW UT WOS:000231538000014 PM 15879162 ER EF